

2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report

ALVIN C. BRONSTEIN, MD; DANIEL A. SPYKER, MD, PHD; LOUIS R. CANTILENA, JR, MD, PHD; JODY L. GREEN, PHD; BARRY H. RUMACK, MD, and RICHARD C. DART, MD, PHD



| Table of Contents | _ |
|--|-----|
| Abstract | |
| Introduction | |
| What's New in NPDS and the Annual Report | |
| The NPDS Application | |
| Limitations and Plans | |
| Methods | |
| Characterization of Participating Poison Centers and Population Served | |
| Call Management – Specialized Poison Exposure Emergency Providers | |
| NPDS – Near Real-time Data Capture | |
| Annual Report Case Inclusion Criteria | |
| Statistical Methods | |
| NPDS Surveillance | |
| Fatality Case Review and Abstract Selection | |
| Pediatric Fatality Case Review | |
| Results | |
| Information Calls to Poison Centers | 9 |
| Exposure Calls to Poison Centers | |
| Age and Gender Distributions | |
| Caller Site and Exposure Site | |
| Exposures in Pregnancy | |
| Chronicity | |
| Reason for Exposure | |
| Scenarios | |
| Reason by Age | |
| Route of Exposure | |
| Clinical Effects | |
| Case Management Site | |
| Medical Outcome | |
| Decontamination Procedures and Specific Antidotes | |
| Top Substances in Human Exposures | |
| Changes from Last Year | |
| Distribution of Suicides | |
| Plant Exposures | |
| Deaths and Exposure-related Fatalities | |
| All fatalities – all ages | |
| Pediatric fatalities – age ≤5 years | |
| Pediatric fatalities – ages 6–12 years | |
| Adolescent fatalities – ages 13–19 years | |
| Pregnancy and Fatalities | |
| AAPCC Surveillance Results | |
| 2010 Gulf of Mexico Oil Spill | |
| THC Homologs and Bath Salts | 31 |
| Discussion | 31 |
| Summary | 31 |
| References | 31 |
| Disclaimer | |
| Appendix A – Acknowledgments | 172 |
| NPDS Toxicology Quote of the Day | |
| Poison Centers (PCs) | |
| Fatality Review Team | |
| AAPCC Micromedex Joint Coding Group | |
| AAPCC Rapid Coding Team | |
| AAPCC Surveillance Team | |
| Regional Poison Center (PC) Fatality Awards | |



| Appendix B – Data Definitions | 170 |
|---|-----|
| Reason for Exposure | |
| Medical Outcome | |
| Relative Contribution to Fatality (RCF) | 177 |
| Appendix C – Abstracts of Selected Cases | |
| Selection of Abstracts for Publication | |
| Abstracts | |
| Abbreviations & Normal ranges for Abstracts | 20 |

| List of Figures and Tables | |
|--|-----|
| Figure 1. Human Exposure Calls, Information Calls and Animal Exposure Calls by Day since 1 January 2000 | 10 |
| Figure 2. All Drug Identification and Law Enforcement Drug Identification Calls by Day since 1 January 2000 | 12 |
| Figure 3. Health Care Facility (HCF) Exposure Calls and HCF Information Calls by Day since 1 January 2000 | 13 |
| Figure 4. Change in Encounters from 2009 to 2010 with Graphical Breakdown of Exposure Calls | |
| Figure 5. Gulf Oil Spill Encounters per Day | |
| Figure 6. Emerging Trends: Bath Salts and THC Homologs Exposures | |
| Figure 7. Human Exposure Calls By Year 2000–2010 – Top 4 Categories | |
| Table 1A. AAPCC Population Served and Reported Exposures (1983–2010) | 9 |
| Table 1B. Non-Human Exposures by Animal Type | |
| Table 1C. Distribution of Information Calls | |
| Table 2. Site of Call and Site of Exposure, Human Exposure Cases | |
| Table 3A. Age and Gender Distribution of Human Exposures | |
| Table 3B. Population-Adjusted Exposures by Age Group. | |
| Table 4. Distribution of Age ^a and Gender for Fatalities ^b | 15 |
| Table 5. Number of Substances Involved in Human Exposure Cases | 15 |
| Table 6A. Reason for Human Exposure Cases | |
| Table 6B. Scenarios for Therapeutic Errors ^a by Age ^b | |
| Table 7. Distribution of Reason for Exposure by Age | 17 |
| Table 8. Distribution of Reason for Exposure and Age for Fatalities ^a | |
| Table 9. Route of Exposure for Human Exposure Cases | |
| Table 10. Management Site of Human Exposures | |
| Table 11. Medical Outcome of Human Exposure Cases by Patient Age ^a | |
| Table 12. Medical Outcome by Reason for Exposure in Human Exposures ^a | |
| Table 13. Duration of Clinical Effects by Medical Outcome | 20 |
| Table 14. Decontamination and Therapeutic Interventions | |
| Table 15. Therapy Provided in Human Exposures by Age | |
| Table 16A. Decontamination Trends (1985–2009) | |
| Table 16B. Decontamination Trends: Total Human and Pediatric Exposures ≤5 Years (2010) ^a | |
| Table 17A. Substance Categories Most Frequently Involved in Human Exposures (Top 25) | |
| Table 17B. Substance Categories with the Greatest Rate of Exposure Increase (Top 25) | 26 |
| Table 17C. Substance Categories Most Frequently Involved in Pediatric (≤5 years) Exposures (Top 25) ^a | |
| Table 17D. Substance Categories Most Frequently Involved in Adult (≥20 years) Exposures (Top 25) ^a | |
| Table 17E. Substance Categories Most Frequently Involved in Pediatric (≤5 years) Deaths ^a | |
| Table 17F. Substance Categories Most Frequently Identified in Drug Identification Calls (Top 25) | |
| Table 17G. Substance Categories Most Frequently Involved in Pregnant Exposures ^a (Top 25) | |
| Table 18. Categories Associated with Largest Number of Fatalities (Top 25) ^a | |
| Table 19A. Comparisons of Death Data (1985–2010) ^a | 29 |
| Table 19B. Comparisons of Direct and Indirect Death Data (2000–2010) ^a | |
| Table 20. Frequency of Plant Exposures (Top 25) ^a | |
| Table 21. Listing of Fatal Nonpharmaceutical and Pharmaceutical Exposures | 33 |
| Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases | |
| by generic category | 130 |
| Table 22B. Demographic profile of SINGLE SUBSTANCE Pharmaceuticals exposure cases | |
| by generic category | 150 |



Abstract

Background: This is the 28th Annual Report of the American Association of Poison Control Centers' (AAPCC) National Poison Data System (NPDS). All US poison centers upload case data automatically with a median time interval of 19.0 [11.9, 40.6] (median [25%, 75%]) minutes, creating a near real-time national exposure and information database and surveillance system.

Methodology: We analyzed the case data tabulating specific indices from NPDS. The methodology was similar to that of previous years. Where changes were introduced, the differences are identified. Poison center cases with medical outcomes of death were evaluated by a team of 33 medical and clinical toxicologist reviewers using an ordinal scale of 1 (Undoubtedly responsible)–6 (Unknown) to determine Relative Contribution to Fatality (RCF) of the exposure to the death.

Results: In 2010, 3,952,772 closed encounters were logged by NPDS: 2,384,825, human exposures, 94,823 animal exposures, 1,466,253 information calls, 6537 human confirmed nonexposures, and 334 animal confirmed nonexposures. Total encounters showed a 7.7% decline from 2009 while health care facility calls increased by 2.7%. Human exposures with more serious outcomes (minor, moderate, major or death) increased 4.5% while those with less serious outcomes (all other medical outcome categories) decreased 5.9%. All information calls decreased 12.6% and health care facility (HCF) information calls decreased 13.6%, Drug ID calls decreased 10.9%, and human exposures decreased 3.8%. The top 5 substance classes most frequently involved in all human exposures were analgesics (11.5%), cosmetics/personal care products (7.7%), household cleaning substances (7.3%), sedatives/hypnotics/ antipsychotics (6.0%), and foreign bodies/toys/miscellaneous (4.2%). Analgesic exposures as a class increased the most rapidly by 32.8% over the last decade. The top five most common exposures in children age 5 years or less were cosmetics/personal care products (13.2%), analgesics (9.4%), household cleaning substances (9.2%), foreign bodies/toys/miscellaneous (7.2%), and topical preparations (6.8%). THC homolog and designer amphetamine ("Bath Salts") exposures were identified as emerging public health threats. Drug identification requests comprised 64.3% of all information calls. NPDS documented 1730 human exposures resulting in death with 1146 human fatalities judged related with an RCF of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory.

Conclusions: These data support the continued value of poison center expertise and need for specialized medical toxicology information to manage the more severe exposures, despite a decrease in calls involving less severe exposures. Unintentional and intentional exposures continue to be a significant cause of

WARNING: Comparison of exposure or outcome data from previous AAPCC Annual Reports is problematic. In particular, the identification of fatalities (attribution of a death to the exposure) differed from pre-2006 Annual Reports (see Fatality Case Review-Methods). Poison center death cases are described as all cases resulting in death and those determined to be exposure-related fatalities. Likewise, Table 22 (Exposure Cases by Generic Category) since year 2006 restricts the breakdown including deaths to single-substance cases to improve precision and avoid misinterpretation.

morbidity and mortality in the US. The near real-time, always current status of NPDS represents a national public health resource to collect and monitor US exposure cases and information calls. The continuing mission of NPDS is to provide a nationwide infrastructure for public health surveillance for all types of exposures, public health event identification, resilience response and situational awareness tracking. NPDS is a model system for the nation and global public health.

Introduction

This is the 28th Annual Report of the American Association of Poison Control Centers' (AAPCC; http://www.aapcc.org) National Poison Data System (NPDS). On 1 January 2010, sixty regional Poison Centers (PCs) serving the entire population of the 50 United States, American Samoa, District of Columbia, Federated States of Micronesia, Guam, Puerto Rico, and the US Virgin Islands submitted information and exposure case data collected during the course of providing telephonic patient tailored exposure management and poison information. On 17 December 2010, the Western New York Poison Center (Buffalo) serving Western New York ceased operations. The Ruth A. Lawrence Poison Center (Rochester) closed on 30 December 2010. The Long Island Regional Poison Control Center (Mineola) ceased operations on 31 December 2010. New York State is now served by two poison centers based in New York City and Syracuse. During this transition national coverage remained seamless.

NPDS is the data warehouse for the nation's poison centers. Poison Centers (PCs) place emphasis on exposure management, accurate data collection and coding, and the continuing need for poison related public and professional education. The PC's health care professionals are available free of charge to all, 24-hours a day, every day of the year. PCs respond to questions from the public, health care professionals, and public health agencies. The continuous staff dedication at the regional PCs is manifest as the number of exposure and information call encounters exceeds 3.9 million annually. PC encounters either involve an exposed human or animal (EXPOSURE CALL) or a request for information (INFORMATION CALL) with no exposed person or animal.

What's New in NPDS and the Annual Report

Several enhancements were made to the tables and figures for this report. Continuing goals of the writing team have been to remove inconsistencies, improve the reader's ability to clearly understand the data, and provide additional data where appropriate. Two new tables have been added to this year's report: Table 3B Population-Adjusted Exposures by Age Groups and Table 17G Substance Categories Most Frequently Involved in Pregnant Exposures (Top 25).

This year, the AAPCC Fatality Review team did not review death (indirect report) cases. Death (indirect report) cases are reports identified through other sources (news feeds, medical examiner data or other) about which no inquiry to the PC was made. In previous years, both death and death (indirect report) cases were reviewed and included in the tables. This year, all the tables related to fatalities contain only death cases with an AAPCC Relative Contribution of Fatality (RCF) of 1, 2, or 3, except Tables 11, 12, 19A, 19B, and 21 which also contain death (indirect report) cases—see list below:

| Table | Fatalities Included | RCF | Number of Deaths |
|-------|---|-------|------------------|
| 4 | Death only | 1,2,3 | 1,146 |
| 5 | Death only | 1,2,3 | 1,146 |
| 8 | Death only | 1,2,3 | 1,146 |
| 9 | Death only | 1,2,3 | 1,146 |
| 11 | Death and Death (indirect report) | All | 1,730 |
| 12 | Death and Death (indirect report) | All | 1,730 |
| 17E | Death and Death (indirect report) | All | 1,730 |
| 18 | Death only | 1,2,3 | 1,366 |
| 19A | Death and Death (indirect report) | All | 1,730 |
| 19B | Death and Death (indirect report) | All | 1,730 |
| 21 | Death and Death (indirect report) | 1,2,3 | 1,366 |
| 22 | Death and Death (indirect report) - Single substance deaths only | All | 764 |

Enhancements were added to the NPDS Fatality module to aid the fatality team in performing their review. The assignment of the Annual Report ID for the fatality cases included in Table 21 has now been automated. This will allow the cases in Table 21 to be easily identified when responding to Annual Report questions or comments.

Throughout the year the AAPCC Micromedex Joint Coding Group reviews the Generic Codes and responds to questions and requests for new generic codes. The group consists of AAPCC members and editorial and lexicon staff from Micromedex Poisindex® (Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Reuters [Healthcare] Inc.). New Product Codes and AAPCC Generic Codes were added to NPDS to address emerging products. In 2010, new generic codes were added for the following six product classes:

- **Electronic Cigarettes** 1.
- 2. **Energy Drinks**
- Hand sanitizers 3.
- 4. **Opioids**
- 5. Tetrahydrocannabinol (THC) Pharmaceuticals
- Tetrahydrocannabinol (THC) Homologs

At the time of this report, there were 965 active and 12 obsolete generic codes. The active codes are divided into Non-Pharmaceutical (541) and Pharmaceutical (424) groups. These two groups are further divided into Major (67) and Minor (167) categories. New products associated with these classes were also added by Micromedex. Addition of these generic codes provides enhanced report granularity as reflected in Table 22. Because the new codes were added at different times during the year, the numbers in Table 22 may not accurately reflect all of the cases in these categories, and for completeness certain categories require customized data retrieval until these categories have been in place for a minimum of a full year or more (2011 forward).

The NPDS Application

In 2010, numerous enhancements were introduced in the NPDS web-based application. Many of these focused on enhancing enterprise reports and surveillance functions. One hundred sixty-nine (169) enterprise reports now return multiyear results. The Case Log reports were expanded to support any combination of 24 separate search parameters and nine (9) different result formats. NPDS Case Log reports now support a variety of outputs including case line listing, daily and monthly counts, time series charts, and US maps. Case Log Counts Reports were added that stratify the results based on user defined classifications. To simplify product selection for reports, a new product selection function was added that displays products associated with a specific AAPCC Generic Code. Finally, a new National Case Log report was added that allows Regional Poison Centers to use the power of the Case Log (Generic Code) report to execute a national case listing without geographic or case identifiers.

New surveillance functions were added to support information call and animal call volume surveillance. To aid the AAPCC Surveillance Team anomaly review, a 'Pending' Status indicator was added for all anomalies to allow users to identify anomalies that are in the process of being analyzed. In addition, a new Case Classification parameter was added to the Case Based anomalies to allow users to classify the anomaly.

To provide centers with more information on public health events, a Special Projects report was added to the NPDS enterprise reporting system. This report provides geocentric reporting of AAPCC defined products for real time event monitoring. For example, the NPDS report was utilized by regional poison centers to access national cases related to the Gulf of Mexico Oil spill in real-time.

NPDS aggregate and case detail web services operate continuously, allowing external systems or viewers to analyze NPDS data in ways not otherwise possible in the NPDS application. The aggregate web service provides total call volume, human exposure call volume, or clinical effects counts allowing an external system such as RODS (Realtime Outbreak and Disease Surveillance, University of Pittsburgh, Department of Biomedical Informatics) to create time-series or GIS displays. Unique to NPDS, the aggregate case count web service is not only accessible by external computer systems but also directly by system users to create their own time series without the need for external system software. Two state health departments utilize the case detail web service to analyze data from their PCs. Four state health departments access the aggregate count web service for data. The web services allow NPDS data to be provisioned in a federated manner where the data is always current in NPDS and can be readily accessed as needed without the need for costly cloning and warehousing.²

Limitations and Plans

As outlined above, the encounters (exposure reports and information questions) which comprise NPDS are collected from spontaneous, self-reported calls made to US PCs. Exposures



in NPDS comprise a portion of the total number of incidents that occurred. These reflect the limitations of this type of passive reporting system (see DISCLAIMER).

Most of the 390,000 proprietary and non-proprietary drugs, chemicals, and biological agents including food poisoning agents in the NPDS products data base are classified by their primary active ingredient into one of 965 AAPCC generic codes. Some multiple ingredient products are coded to multiple product generic codes (e.g., acetaminophen with hydrocodone). Table 22 and other tables reporting information by generic category are organized by this system. Thus our current review and reporting methods do not necessarily distinguish between the individual components of a combination product.

Nonetheless, the scope and immediacy of these data have much to offer. In particular, the 28-years history offers a unique opportunity to assess the long term (secular) trends in exposures and information calls.

There are a number of plans to improve the data system and reporting for 2010 and beyond including:

- Enhancements to NPDS real-time geographic information system (GIS) with more data display options for appropriate data analyses;
- Enhancements to case-based surveillance systems;
- Continued improvements in data quality edits;
- Implement security paradigm enhancements to support specific product access for reports and surveillance;
- Enterprise report enhancements;
- New auto-upload requirements and improved solution;
- Lexicon based analysis of the current generic code system to better meet current exposure tracking and surveillance needs;
- Review and analysis of NPDS clinical effect coding terminology.

These and other initiatives are under continuous review by the AAPCC Board, NPDS Steering Committee, and CDC.

Methods

Characterization of Participating Poison Centers and Population Served

Sixty participating centers submitted data to AAPCC through 17 December 2010, 59 participating centers submitted data to AAPCC through 30 December 2010, 58 participating centers submitted data to AAPCC through 31 December 2010, with the total center count decreasing to 57 for the remainder of 2010. Fifty-seven centers (95%) were accredited by AAPCC as of 1 July 2010. The entire population of the 50 states, American Samoa, the District of Columbia, Federated States of Micronesia, Guam, Puerto Rico, and the US Virgin Islands was served by the US PC network in 2010.^{3,4}

The average number of human exposure cases managed per day by all US PCs was 6,534. Similar to other years, higher volumes were observed in the warmer months, with a mean of 6,950 cases per day in June compared with 6,305 per day in January. On average, US PCs received a call about an actual human exposure every 13.2 sec.

Call Management - Specialized Poison **Exposure Emergency Providers**

Most PC operations management, clinical education, and instruction are directed by Managing Directors (most are PharmDs and RNs with American Board of Applied Toxicology [ABAT] board certification). Medical direction is provided by Medical Directors who are board-certified physician medical toxicologists. At some PCs, the Managing and Medical Director positions are held by the same person.

Calls received at US PCs are managed by healthcare professionals who have received specialized training in toxicology and managing exposure emergencies. These providers include medical and clinical toxicologists, registered nurses, doctors of pharmacy, pharmacists, chemists, hazardous materials specialists, and epidemiologists. Specialists in Poison Information (SPIs) are primarily registered nurses, PharmDs, and pharmacists. They work under the supervision of a Certified Specialist in Poison Information (CSPI). SPIs must log a minimum of 2,000 calls over a 12-month period to become eligible to take the CSPI examination for certification in poison information. Poison Information Providers (PIPs) are allied healthcare professionals. They manage information-type and low acuity (non-hospital) calls and work under the supervision of a CSPI. Of note is the fact that no nursing or pharmacy school offers a toxicology curriculum designed for PC work and SPIs must be trained in programs offered by their respective PC. Centers are accredited by the AAPCC meeting strict standards and must be reaccredited every 5 years.

NPDS – Near Real-time Data Capture

Launched on 12 April 2006, NPDS is the data repository for all of the US regional PCs. In 2010, all 60 of the 60 US PCs uploaded case data automatically to NPDS through 17 December 2010. The center count decreased to 59 as of 17 December 2010, to 58 as of 30 December 2010 and to 57 as of 31 December 2010. All centers submitted data in near real-time making NPDS one of the few operational systems of its kind. PC staff record calls contemporaneously in 1 of 4 case management systems. Each center uploads case data periodically as it is entered. The time to upload data for all PCs is 19.9 [9.7, 58.7] (median [25%, 75%]) minutes creating a real-time national exposure database and surveillance system.

The web-based NPDS software facilitates detection, analysis, and reporting of NPDS surveillance anomalies. System software offers a myriad of surveillance uses allowing AAPCC, its member centers and public health agencies to utilize NPDS US exposure data. Users are able to access local and regional data for their own areas and view national aggregate data. The application allows for increased "drilldown" capability and mapping via a geographic information system (GIS). Custom surveillance definitions are available along with ad hoc reporting tools. Information in the NPDS database is dynamic. Each year the database is locked prior to extraction of annual report data to prevent inadvertent changes and ensure consistent, reproducible reports. The 2010 database was locked on 9 October 2011 at 0930 hr EDT.

Annual Report Case Inclusion Criteria

The information in this report reflects only those cases that are not duplicates and classified by the regional PC as CLOSED. A case is closed when the PC has determined that no further follow-up/recommendations are required or no further information is available. Exposure cases are followed to obtain the most precise medical outcome possible. Depending on the case specifics, most calls are "closed" within the first hours of the initial call. Some calls regarding complex hospitalized patients or cases resulting in death may remain open for weeks or months while data continues to be collected. Follow-up calls provide a proven mechanism for monitoring the appropriateness of management recommendations, augmenting patient guidelines, and providing poison prevention education, enabling continual updates of case information as well as obtaining final/known medical outcome status to make the data collected as accurate and complete as possible.

Statistical Methods

All tables except Tables 3B and 17B were generated directly by the NPDS web-based application and can thus be reproduced by each center. The figures and statistics in Tables 3B and 17B were created using SAS JMP version 9.0.0 (SAS Institute, Cary, NC) on summary counts generated by the NPDS web-based application.

NPDS Surveillance

As previously noted, all of the active US PCs upload case data automatically to NPDS. This unique near real-time upload is the foundation of the NPDS surveillance system. This makes possible both spatial and temporal case volume and case based surveillance. NPDS software allows creation of volume and case based definitions. Definitions can be applied to national, regional, state, or ZIP code coverage areas. Geocentric definitions can also be created. This functionality is available not only to the AAPCC surveillance team, but to every regional PC. PCs also have the ability to share NPDS real-time surveillance technology with external organizations such as their state and local health departments or other regulatory agencies. Another NPDS feature is the ability to generate system alerts on adverse drug events and other products of public health interest like contaminated food or product recalls. NPDS can thus provide real-time adverse event monitoring and surveillance for resilience response and situational awareness.

Surveillance definitions can be created to monitor a variety of volume parameters, any desired substance or commercial product in the Micromedex Poisindex products database. The database contains over 390,000 entries. Surveillance definitions may be constructed using volume or case based definitions with a variety of mathematical options and historical baseline periods from 1 to 11 years. NPDS surveillance tools include the following:

- Volume Alerts Surveillance Definitions
- Total Call Volume
- Human Exposure Call Volume
- Animal Exposure Call Volume
- Information Call Volume
- Clinical Effects Volume (signs and symptoms, or laboratory abnormalities)
- Case Based Surveillance Definitions utilizing various NPDS data fields linked in Boolean expressions
 - Substance
 - 0 Clinical Effects
 - Species
 - Medical Outcome and others

Incoming data is monitored continuously and anomalous signals generate an automated email alert to the AAPCC's surveillance team or designated regional PC or public health agency. These anomaly alerts are reviewed daily by the AAPCC surveillance team and/or the regional PC that created the surveillance definition. When reports of potential public health significance are detected, additional information is obtained via the NPDS surveillance correspondence system or phone as appropriate from reporting PCs. The regional PC then alerts their respective state or local health departments. Public health issues are brought to the attention of the Health Studies Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC). This unique near real-time tracking ability is a unique feature offered by NPDS and the regional PCs.

AAPCC Surveillance Team clinical and medical toxicologists review surveillance definitions on a regular basis to fine-tune the queries. CDC, as well as State and local health departments with NPDS access as granted by their respective regional PCs, also have the ability to create surveillance definitions for routine surveillance tasks or to respond to emerging public health events.

Fatality Case Review and Abstract Selection

NPDS fatality cases can be recorded as DEATH or DEATH (INDIRECT REPORT). Medical outcome of death is by direct report. Death (indirect reports) are deaths that the PC acquired from medical examiners or media, but did not manage nor answer any questions related specifically to that death.

Although PCs may report death as an outcome, the death may not be the direct result of the exposure. We define exposure-related fatality as a death judged by the AAPCC Fatality Review Team to be at least contributory to the exposure. The definitions used for the Relative Contribution to Fatality (RCF) classification are defined in Appendix B and the methods to select abstracts for publications is described in Appendix C. For details of the AAPCC fatality review process, see the 2008 annual report.¹



Pediatric Fatality Case Review

A focused Pediatric Fatality Review team, comprised of 3 pediatric toxicologists, was assembled this year to evaluate cases in patients under 18 years of age. The panel reviewed the documentation of all such cases, with specific focus on the conditions behind the poisoning exposure and on finding commonality which might inform efforts at prevention. Seventy-one cases were reviewed and found to have a bimodal age distribution. Exposures causing death in children \leq age 5 years were mostly coded as "Unintentional-General" while those in ages over 12 years were mostly "Intentional". Often the Reason Code did not capture the complexities of the case. For example, there were few mentions of details such as the involvement of law enforcement or child protective services. While there were some complete and informative reports, in many narratives the circumstances which preceded the exposure thought responsible for the death was unclear or absent. In response to these findings, the pediatric fatality review team will develop Pediatric Narrative Guidelines for the upcoming year, with specific attention to the root cause of these cases. As a result, poison centers will be requested to implement guidelines recommending the most in-depth "causality" investigation possible.

Results

In 2010, the participating PCs logged 3,952,772 total encounters including 2,384,825 closed human exposure cases (Table 1A), 94,823 animal exposures (Table 1B), 1,466,253 information calls (Table 1C), 6,537 human confirmed nonexposures, and 334 animal confirmed non-exposures. An additional 449 calls were still open at the time of database lock. The cumulative AAPCC database now contains nearly 51 million human exposure case records (Table 1A). A total of 13,357,650 information calls have been logged by NPDS since the year 2001.

Figure 1 shows the human exposures, information calls and animal exposures by day since 2001. Second order (quadratic) least squares regression for 2000-2010 has shown a statistically significant departure from linearity (declining rate of calls since mid-2007) for Human Exposure Calls. Information Calls are declining more rapidly than the quadratic regression this year, and Animal Exposure Calls have likewise been declining since mid-2005.

A hallmark of PC case management is the use of follow-up calls to monitor case progress and medical outcome. US PCs made 2,841,477 follow-up calls in 2010. Follow-up calls were done in 46.0% of human exposure cases. One follow-up call was made in 22.4% of human exposure cases, and multiple follow-up calls (range 2-666) were placed in 23.6% of cases.

Information Calls to Poison Centers

Data from 1,466,253 information calls to PCs in 2010 (Table 1C) was transmitted to NPDS, including calls in optional reporting categories such as prevention/safety/education (31,656), administrative (23,546) and caller referral (65,652).

Table 1A. AAPCC Population Served and Reported Exposures (1983-2010)

| Year | No. of participating centers | Population served (in millions) | Human exposures | Exposures per thousand population |
|-------|------------------------------|---------------------------------------|--------------------|--|
| 1983 | 16 | 43.1 | 251,012 | 5.8 |
| 1984 | 47 | 99.8 | 730,224 | 7.3 |
| 1985 | 56 | 113.6 | 900,513 | 7.9 |
| 1986 | 57 | 132.1 | 1,098,894 | 8.3 |
| 1987 | 63 | 137.5 | 1,166,940 | 8.5 |
| 1988 | 64 | 155.7 | 1,368,748 | 8.8 |
| 1989 | 70 | 182.4 | 1,581,540 | 8.7 |
| 1990 | 72 | 191.7 | 1,713,462 | 8.9 |
| 1991 | 73 | 200.7 | 1,837,939 | 9.2 |
| 1992 | 68 | 196.7 | 1,864,188 | 9.5 |
| 1993 | 64 | 181.3 | 1,751,476 | 9.7 |
| 1994 | 65 | 215.9 | 1,926,438 | 8.9 |
| 1995 | 67 | 218.5 | 2,023,089 | 9.3 |
| 1996 | 67 | 232.3 | 2,155,952 | 9.3 |
| 1997 | 66 | 250.1 | 2,192,088 | 8.8 |
| 1998 | 65 | 257.5 | 2,241,082 | 8.7 |
| 1999 | 64 | 260.9 | 2,201,156 | 8.4 |
| 2000 | 63 | 270.6 | 2,168,248 | 8.0 |
| 2001 | 64 | 281.3 | 2,267,979 | 8.1 |
| 2002 | 64 | 291.6 | 2,380,028 | 8.2 |
| 2003 | 64 | 294.7 | 2,395,582 | 8.1 |
| 2004 | 62 | 293.7 | 2,438,643 | 8.3 |
| 2005 | 61 | 296.4 | 2,424,180 | 8.2 |
| 2006 | 61 | 299.4 | 2,403,539 | 8.0 |
| 2007 | 61 | 305.6 | 2,482,041 | 8.1 |
| 2008 | 61 | 308.5 ^b | 2,491,049 | 8.1 |
| 2009 | 60 | 310.9 ^b | 2,479,355 | 8.0 |
| 2010 | 60^{a} | 313.3 ^b | 2,384,825 | 7.6 |
| Total | | | 50,935,385 | |

^aAs of 1 July 2010 there were 60 Participating Centers.

^bAs of 1 July Mid Year US Census (50 United States, American Samoa, District of Columbia, Federated States of Micronesia, Guam, Puerto Rico, and the US Virgin Islands).3,4

Figure 2 shows that All Drug ID calls decreased dramatically in mid-2009, and again in late-2010 (no regression was fit to these data). Enforcement Drug ID Calls showed a declining rate of increase. The most frequent information call was for Drug ID, comprising 942,614 calls to PCs during the year. Of these, 566,543 (60.1%) were identified as drugs with known abuse potential; however, these cases were categorized based on the drug's abuse potential without knowledge of whether abuse was actually intended.

While the number of Drug Information calls decreased 9.4% from 2009 (239,943 calls) to 2010 (217,286), the Drug Information calls as a percentage of all information calls was 14.3% and 14.8%, respectively. Of these, the most common requests were in regards to therapeutic use and indications, followed by drug-drug interactions, questions about dosage and inquiries of adverse effects. Environmental inquiries comprised 1.6% of all information calls. Of these environmental inquiries, questions related to cleanup of mercury (thermometers and other) remained the most common followed by questions involving pesticides.




Fig. 1. Human Exposure Calls, Information Calls and Animal Exposure Calls by Day since 1 January 2000. Black lines show least-squares second order regression - both linear and second order (quadratic) terms were statistically significant for each of the 3 regressions. (See colour version of this figure online).

Of all the information calls, poison information comprised 4.8% of the requests with inquiries involving general toxicity the most common followed by questions involving food preparation practices, plant toxicity, and safe use of household products.

Exposure Calls to Poison Centers

Figure 3 shows a graphic summary and analyses of Health Care Facility (HCF) Exposure and HCF Information calls. HCF Exposure Calls did not depart from linearity (continued to increase at a steady rate) while the rate of HCF Information Calls has been declining since early 2005. This linearly increasing use of the PCs for the more serious exposures (HCF calls) is important in the face of the declining growth of all exposure and information calls. The 2 May 2006, exposure data spike on the figure was the result of 602 children in a Midwest school reporting a noxious odor which caused anxiety, but resolved without sequelae.

Tables 22A (Nonpharmaceuticals) and 22B (Pharmaceuticals) provide summary demographic data on patient age, reason for exposure, medical outcome, and use of a health care facility for all 2,384,825 human exposure cases, presented by substance categories.

Table 1B. Non-Human Exposures by Animal Type

| Animal | N | % |
|------------------|--------|--------|
| Dog | 85,804 | 90.49 |
| Cat | 7,936 | 8.37 |
| Horse | 259 | 0.27 |
| Bird | 238 | 0.25 |
| Rodent/lagomorph | 185 | 0.20 |
| Cow | 70 | 0.07 |
| Sheep/goat | 64 | 0.07 |
| Aquatic | 30 | 0.03 |
| Other | 237 | 0.25 |
| Total | 94,823 | 100.00 |

Table 1C. Distribution of Information Calls

| Information call type | N | % of Info. calls |
|---|---------|------------------------|
| Drug identification | | |
| Public inquiry: Drug sometimes | 462,128 | 31.52 |
| involved in abuse | | |
| Public inquiry: Drug not known to be abused | 192,972 | 13.16 |
| Public inquiry: Unknown abuse potential | 5,416 | 0.37 |
| Public inquiry: Unable to identify | 86,201 | 5.88 |
| HCP inquiry: Drug sometimes | 6,819 | 0.47 |
| involved in abuse | -, | |
| HCP inquiry: Drug not known to be abused | 12,317 | 0.84 |
| HCP inquiry: Unknown abuse potential | 458 | 0.03 |
| HCP inquiry: Unable to identify | 5,056 | 0.34 |
| Law Enf. Inquiry: Drug | 97,596 | 6.66 |
| sometimes involved in abuse | , | |
| Law Enf. Inquiry: Drug not known to be abused | 51,007 | 3.48 |
| Law Enf. Inquiry: Unknown abuse potential | 1,726 | 0.12 |
| Law Enf. Inquiry: Unable to identify | 14,121 | 0.96 |
| Other drug ID | 6,797 | 0.46 |
| Subtotal | 942,614 | 64.29 |
| Drug information | 742,014 | 04.27 |
| Adverse effects (no known | 13,893 | 0.95 |
| exposure) Brand/generic name clarifications | 3,710 | 0.25 |
| Calculations | 213 | 0.23 |
| Compatibility of parenteral | 309 | 0.01 |
| medications | 509 | 0.02 |
| Compounding | 617 | 0.04 |
| Contraindications | 1,824 | 0.12 |
| Dietary supplement, herbal, and | 792 | 0.05 |
| homeopathic | | |
| Dosage | 13,506 | 0.92 |
| Dosage form/formulation | 2,865 | 0.20 |
| - | | (Continued) |



Table 1C. (Continued)

| Table 1C. (Continued) | | |
|---|-----------------|----------------|
| | | % of |
| Information call type | N | Info. calls |
| Information call type | | |
| Drug use during breast-feeding | 4,644 | 0.32 |
| Drug-drug interactions | 29,050 | 1.98 |
| Drug-food interactions | 1,659 | 0.11 |
| Foreign drug | 638 | 0.04 |
| Generic substitution Indications/therapeutic use | 1,108 71,864 | 0.08 4.90 |
| Medication administration | 5,383 | 0.37 |
| Medication availability | 2,209 | 0.15 |
| Medication disposal | 4,907 | 0.33 |
| Pharmacokinetics | 2,615 | 0.18 |
| Pharmacology | 2,044 | 0.14 |
| Regulatory | 13,808 | 0.94 |
| Stability/storage | 3,446 | 0.24 |
| Therapeutic drug monitoring | 938 | 0.06 |
| Other drug info | 35,244 | 2.40 |
| Subtotal | 217,286 | 14.82 |
| Environmental information | 1.005 | 0.14 |
| Air quality | 1,995 | 0.14 |
| Carbon monoxide - no known | 847 | 0.06 |
| patient(s) Carbon monoxide alarm use | 507 | 0.03 |
| Chem/bioterrorism/weapons | 22 | 0.00 |
| (suspected or confirmed) | 22 | 0.00 |
| Clarification of media reports of | 26 | 0.00 |
| environmental contamination | | |
| Clarification of substances | 104 | 0.01 |
| involved in a HAZMAT | | |
| incident - no known victim(s) | | |
| General questions about | 559 | 0.04 |
| contamination of air and/or soil | | |
| HAZMAT planning | 150 | 0.01 |
| Lead - no known patient(s) | 671 | 0.05 |
| Mercury thermometer cleanup | 2,453 | 0.17 |
| Mercury (excluding | 2,996 | 0.20 |
| thermometers) cleanup Notification of a HAZMAT | 357 | 0.02 |
| incident - no known patient(s) | 337 | 0.02 |
| Pesticide application by a | 680 | 0.05 |
| professional pest control operator | 000 | 0.03 |
| Pesticides (other) | 3,017 | 0.21 |
| Potential toxicity of chemicals in | 1,352 | 0.09 |
| the environment | , | |
| Radiation | 70 | 0.00 |
| Safe disposal of chemicals | 1,740 | 0.12 |
| Water purity/contamination | 945 | 0.06 |
| Other environmental | 5,251 | 0.36 |
| Subtotal | 23,742 | 1.62 |
| Medical information | 132 | 0.01 |
| Dental questions Diagnostic or treatment recom- | 9,633 | 0.66 |
| mendations for diseases or | 7,033 | 0.00 |
| conditions - non-toxicology | | |
| Disease prevention | 742 | 0.05 |
| Explanation of disease states | 1,448 | 0.10 |
| General first-aid | 1,418 | 0.10 |
| Interpretation of non-toxicology | 185 | 0.01 |
| laboratory reports | | |
| Medical terminology questions | 72 | 0.00 |
| Rabies – no known patient(s) | 373 | 0.03 |
| Sunburn management | 119 | 0.01 |
| Other medical | 17,502 | 1.19 |
| Subtotal | 31,624 | 2.16 |
| | | (Carations 1) |

Table 1C (Continued)

| March Marc | Table 1C. (Continued) | | |
|--|----------------------------------|-------------------------|-------|
| Information call type | | | % of |
| Occupational Information | | | Info. |
| Occupational treatment/first-aid guidelines - no known patient(s) | Information call type | N | calls |
| Occupational treatment/first-aid guidelines - no known patient(s) | Occupational information | | |
| Information on chemicals in the workplace WSDS interpretation 71 0.00 | Occupational treatment/first-aid | 39 | 0.00 |
| workplace MSDS interpretation 71 0.00 Occupational MSDS requests 1,359 0.00 Routine toxicity monitoring 30 0.00 Safe handling of workplace chemicals 117 0.01 Other occupational 216 0.01 Subtotal 1,982 0.14 Poison information 40 0.01 Analytical toxicology 805 0.05 Carcinogenicity 94 0.01 Food poisoning - no known patient(s) 2,815 0.19 Food preparation/handling patient(s) 7,374 0.50 Food preparation/handling practices 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) Safe use of household products 3,743 0.26 Toxicology information for legal 213 0.01 | | 1.50 | 0.01 |
| MSDS interpretation 71 0.00 Occupational MSDS requests 1,359 0.09 Routine toxicity monitoring 30 0.00 Safe handling of workplace chemicals 117 0.01 Other occupational 216 0.01 Subtotal 1,982 0.14 Poison information | | 150 | 0.01 |
| Occupational MSDS requests 1,359 0.09 Routine toxicity monitoring 30 0.00 Safe handling of workplace 117 0.01 | | 71 | 0.00 |
| Routine toxicity monitoring 30 0.00 | Occupational MSDS requests | | |
| chemicals Other occupational 216 0.01 Subtotal 1,982 0.14 Poison information 4nalytical toxicology 805 0.05 Carcinogenicity 94 0.01 Food poisoning - no known patient(s) 2,815 0.19 Food preparation/handling patient(s) 7,374 0.50 Food preparation/handling practices 6 0.6 General toxicity 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) Safe use of household products 3,743 0.26 Toxicology information for legal use/litigation 213 0.01 Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 70,456 4.81 Prevention/Safety/Education 677 0.05 Prevention requests 390 0.03 Media requests 390 0.03 <td>Routine toxicity monitoring</td> <td></td> <td></td> | Routine toxicity monitoring | | |
| Other occupational Subtotal 1,982 0.14 Poison information 0.05 0.05 Analytical toxicology 805 0.05 Carcinogenicity 94 0.01 Food poisoning - no known patient(s) 2,815 0.19 Food preparation/handling pratient(s) 7,374 0.50 Food preparation/handling practices 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) 3,743 0.26 Safe use of household products 3,743 0.26 Toxicology information for legal use/litigation 213 0.01 Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 15,051 1.03 Confirmation of poison center 15,051 1.03 number General (non-poison) injury 677 0.05 prevention requests Media requests 390 0.03 | | 117 | 0.01 |
| Subtotal 1,982 0.14 Poison information | | 216 | 0.01 |
| Poison information | | | |
| Analytical toxicology Carcinogenicity 94 0.01 Food poisoning - no known patient(s) Food preparation/handling 7,374 0.50 practices General toxicity 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) Safe use of household products 3,743 0.26 Toxicology information for legal use/litigation Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education Confirmation of poison center 15,051 1.03 number General (non-poison) injury 677 0.05 prevention requests Media requests 390 0.03 Poison prevention material 13,046 0.89 requests Poison prevention week date 59 0.00 inquiries Professional education 407 0.03 presentation requests Public education presentation 567 0.04 requests Other prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity 1,508 0.21 Subtotal 3,058 0.21 Other information Other 45,538 3.11 Subtance Abuse Drug screen information 7,165 0.49 Effects of illicit substances - no 335 0.02 known patient(s) New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 Subtotal 9,099 0.62 Administrative | | 1,902 | 0.14 |
| Carcinogenicity | | 805 | 0.05 |
| Food poisoning - no known patient(s) Food preparation/handling 7,374 0.50 practices General toxicity 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products (including food) Safe use of household products 3,743 0.26 Toxicology information for legal use/litigation Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education Confirmation of poison center 15,051 1.03 number General (non-poison) injury 677 0.05 prevention requests 390 0.03 Poison prevention material 13,046 0.89 requests Poison prevention week date inquiries Professional education presentation requests Public education presentation 567 0.04 requests Other prevention 31,656 2.16 Teratogenicity information Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Other information 0.145,538 3.11 Subtotal 45,538 3.11 Substance Abuse Drug screen information 7,165 0.49 Effects of illicit substances - no 335 0.02 known patient(s) New trend information 386 0.03 Withdrawal from illicit substances - no known patient(s) 0.04 Administrative | | | |
| Food preparation/handling practices General toxicity 31,765 2.17 | Food poisoning - no known | 2,815 | 0.19 |
| Practices General toxicity 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) 3,743 0.26 Toxicology information for legal 213 0.01 use/litigation 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 25,051 1.03 number General (non-poison) injury 677 0.05 prevention requests 390 0.03 Poison prevention material 13,046 0.89 requests Poison prevention week date 59 0.00 inquiries Professional education 407 0.03 presentation requests Public education presentation 567 0.04 requests Other prevention 3,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Subtotal 45,538 3.11 Substance Abuse Drug screen information 7,165 0.49 Effects of illicit substances - no known patient(s) New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 Subtotal 9,099 0.62 Administrative Administrative 3,099 0.62 | | | |
| General toxicity 31,765 2.17 Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) 3,743 0.26 Safe use of household products 3,743 0.26 Toxicology information for legal 213 0.01 use/litigation 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 15,051 1.03 Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date inquiries 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 567 0.04 Public education presentation 567 0.04 requests 0.10 0.04 | | 7,374 | 0.50 |
| Mutagenicity 46 0.00 Plant toxicity 4,105 0.28 Recalls of non-drug products 856 0.06 (including food) 3,743 0.26 Safe use of household products 3,743 0.26 Toxicology information for legal use/litigation 213 0.01 Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 200 200 Confirmation of poison center number 15,051 1.03 number 677 0.05 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date sequests 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 0.04 1,459 0.10 Subtotal 31,656 2.16 2.16 Teratogenicity information 3,058 | | 21 765 | 2 17 |
| Plant toxicity Recalls of non-drug products (including food) | | | |
| Recalls of non-drug products (including food) 856 0.06 (including food) Safe use of household products 3,743 0.26 Toxicology information for legal use/litigation 213 0.01 Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 15,051 1.03 Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date inquiries 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 567 0.04 Public education presentation 567 0.04 requests 0.10 0.10 Other prevention 1,459 0.10 Subtotal 3,058 0.21 Teratogenicity information 3,058 0.21 Teratogenicity information | | | |
| (including food) 3,743 0.26 Toxicology information for legal use/litigation 213 0.01 Other poison 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 15,051 1.03 Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date inquiries 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 567 0.04 Public education presentation 567 0.04 requests 0ther prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Teratogenicity information 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 | | | |
| Toxicology information for legal use/litigation | | | |
| use/litigation 18,640 1.27 Subtotal 70,456 4.81 Prevention/Safety/Education 15,051 1.03 Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date requests 59 0.00 Poison prevention week date requests 59 0.00 Professional education presentation requests 67 0.04 Public education presentation requests 567 0.04 Other prevention subtotal 31,656 2.16 Teratogenicity information 1,459 0.10 Subtotal 3,058 0.21 Other information 30,58 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 0.02 0.02 Drug screen information 7,165 0.49 <td< td=""><td></td><td></td><td></td></td<> | | | |
| Other poison Subtotal 18,640 70,456 4.81 Prevention/Safety/Education Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date requests 59 0.00 Professional education presentation requests 567 0.04 Public education presentation requests 567 0.04 Public education presentation requests 567 0.04 Other prevention subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Teratogenicity information 3,058 0.21 Other information 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse Drug screen information Annum patient(s) 7,165 0.49 Effects of illicit substances - no known patient(s) 335 0.02 New trend information Annum patient(s) Other substance abuse - no known patient(s) 0.01 - 0.07 Other substance abuse - no known patient(s) 0.062 Administrative 0.062 | | 213 | 0.01 |
| Subtotal 70,456 4.81 Prevention/Safety/Education 15,051 1.03 Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date inquiries 59 0.00 Professional education presentation requests 567 0.04 Public education presentation requests 567 0.04 Other prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 1,459 0.21 Subtotal 3,058 0.21 Subtotal 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Subtotal 45,538 3.11 Subtotal 7,165 0.49 Effects of illicit substances – no known patient(s) 335 0.02 New trend information in m | | 19.640 | 1.27 |
| Prevention/Safety/Education Confirmation of poison center number 15,051 1.03 General (non-poison) injury prevention requests 677 0.05 Media requests 390 0.03 Poison prevention material requests 13,046 0.89 Poison prevention week date requests 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 567 0.04 Other prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Subtotal 45,538 3.11 Subtotal 7,165 0.49 Effects of illicit substances – no known patient(s) 335 0.02 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) | | 18,040 70.456 | |
| Confirmation of poison center number General (non-poison) injury 677 0.05 | | 70,430 | 7.01 |
| number General (non-poison) injury 677 0.05 prevention requests 390 0.03 Poison prevention material 13,046 0.89 requests 70 0.00 0.00 presentation prevention week date 59 0.00 inquiries 0.03 0.03 Professional education presentation requests 567 0.04 Public education presentation requests 567 0.04 Other prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Subtotal 45,538 3.11 Subtotal 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.02 0.01 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 | | 15,051 | 1.03 |
| prevention requests Media requests Media requests Poison prevention material requests Poison prevention week date inquiries Professional education presentation requests Public education presentation requests Other prevention Teratogenicity information Teratogenicity Subtotal Other information Other Other 45,538 Subtotal Substance Abuse Drug screen information Fiffects of illicit substances – no known patient(s) New trend information To known patient(s) Other substance abuse Other substance abuse 1,006 Other Subtotal Administrative | | | |
| Media requests 390 0.03 Poison prevention material 13,046 0.89 requests 13,046 0.89 Poison prevention week date inquiries 59 0.00 Professional education presentation presentation requests 407 0.03 Public education presentation requests 567 0.04 Other prevention subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Subtance Abuse 0.49 Effects of illicit substances – no assistance information 7,165 0.49 Effects of illicit substances – no known patient(s) 386 0.03 Withdrawal from illicit substances – no known patient(s) 207 0.01 Other substance abuse – no known patient(s) 1,006 0.07 Subtotal 9,099 0.62 | | 677 | 0.05 |
| Poison prevention material requests 13,046 0.89 Poison prevention week date inquiries 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 567 0.04 Public education presentation requests 567 0.04 Other prevention subtotal 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 7,165 0.49 Effects of illicit substances – no known patient(s) 335 0.02 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 | | 200 | 0.02 |
| Poison prevention week date 59 0.00 | | | |
| Poison prevention week date inquiries 59 0.00 Professional education presentation requests 407 0.03 Public education presentation requests 567 0.04 Public education presentation requests 567 0.04 Other prevention subtotal 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 000 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 0.49 0.49 Effects of illicit substances – no associated information 335 0.02 known patient(s) 0.02 0.01 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 | | 13,040 | 0.09 |
| inquiries Professional education 407 0.03 presentation requests Public education presentation 567 0.04 requests Other prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Subtotal 3,058 0.21 Other information Other 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 59 | 0.00 |
| Professional education presentation requests 407 0.03 presentation requests Public education presentation requests 567 0.04 requests Other prevention Subtotal 31,656 2.16 Teratogenicity information Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Subtotal 3,058 0.21 0.21 Subtotal 3,058 0.21 Subtotal 45,538 3.11 Subtotal 45,538 3.11 Subtotal 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.02 known patient(s) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0. | | | |
| Public education presentation 567 0.04 requests 0 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Other information 00 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.02 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 0.07 Subtotal 9,099 0.62 Administrative | | 407 | 0.03 |
| requests Other prevention Subtotal 31,656 2.16 Teratogenicity information Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Other information Other 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse Drug screen information Effects of illicit substances – no known patient(s) New trend information - no known patient(s) Other substance abuse Other substance abuse - no known patient(s) Other substance abuse - 1,006 Subtotal 9,099 0.62 Administrative | | | |
| Other prevention 1,459 0.10 Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 5 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.02 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 0.07 Subtotal 9,099 0.62 Administrative | _ | 567 | 0.04 |
| Subtotal 31,656 2.16 Teratogenicity information 3,058 0.21 Subtotal 3,058 0.21 Other information 0ther 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 50.49 0.49 Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.02 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 1 450 | 0.10 |
| Teratogenicity information Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Other information 0ther 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 0ther 0.49 0.49 Effects of illicit substances – no 335 0.02 0.02 known patient(s) 0ther substances 207 0.01 0.07 - no known patient(s) 0ther substance abuse 1,006 0.07 0.07 Subtotal 9,099 0.62 Administrative | | | |
| Teratogenicity 3,058 0.21 Subtotal 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 538 3.11 Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.02 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 31,030 | 2.10 |
| Subtotal 3,058 0.21 Other information 3,058 0.21 Other information 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse 5 3.11 Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 3,058 | 0.21 |
| Other 45,538 3.11 Subtotal 45,538 3.11 Substance Abuse Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 3,058 | 0.21 |
| Subtotal 45,538 3.11 Substance Abuse 7,165 0.49 Drug screen information 7,165 0.02 Effects of illicit substances – no 335 0.02 known patient(s) 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 000 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 45.520 | 0.11 |
| Substance Abuse Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.03 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | | |
| Drug screen information 7,165 0.49 Effects of illicit substances – no 335 0.02 known patient(s) 0.03 New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 0.07 Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 45,556 | 3.11 |
| Effects of illicit substances – no known patient(s) New trend information Withdrawal from illicit substances - no known patient(s) Other substance abuse Subtotal Administrative 335 0.02 0.03 0.03 0.01 - 1,006 0.07 0.07 0.07 0.07 0.06 0.07 | | 7,165 | 0.49 |
| New trend information 386 0.03 Withdrawal from illicit substances 207 0.01 - no known patient(s) 1,006 0.07 Subtotal 9,099 0.62 Administrative | | | |
| Withdrawal from illicit substances 207 0.01 - no known patient(s) Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | | |
| - no known patient(s) Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | | |
| Other substance abuse 1,006 0.07 Subtotal 9,099 0.62 Administrative | | 207 | 0.01 |
| Subtotal 9,099 0.62 Administrative | | 1 006 | 0.07 |
| Administrative | | | |
| | | 2,022 | V.U. |
| | Expert witness requests | 37 | 0.00 |

(Continued)

Table 1C. (Continued)

| Table IC. (Continued) | | |
|--|-----------|--------|
| | | % of |
| | | Info. |
| Information call type | N | calls |
| Faculty activities | 51 | 0.00 |
| Funding | 47 | 0.00 |
| Personnel issues | 462 | 0.03 |
| Poison center record request | 211 | 0.01 |
| Product replacement/malfunction (issues intended for the manufacturer) | 2,350 | 0.16 |
| Scheduling of poison center rotations | 143 | 0.01 |
| Other administration | 20,245 | 1.38 |
| Subtotal | 23,546 | 1.61 |
| Caller Referred | 20,010 | 101 |
| Immediate referral - animal poison center or veterinarian | 16,083 | 1.10 |
| Immediate referral - drug | 15,704 | 1.07 |
| Immediate referral - drug information | 931 | 0.06 |
| Immediate referral - health department | 5,958 | 0.41 |
| Immediate referral - medical advice line | 1,117 | 0.08 |
| Immediate referral - pediatric triage service | 60 | 0.00 |
| Immediate referral - pesticide hotline | 319 | 0.02 |
| Immediate referral - pharmacy | 2,620 | 0.18 |
| Immediate referral - poison center | 3,550 | 0.24 |
| Immediate referral - private physician | 2,442 | 0.17 |
| Immediate referral - psychiatric crisis line | 167 | 0.01 |
| Immediate referral - teratology information program | 162 | 0.01 |
| Other call referral | 16,539 | 1.13 |
| Subtotal | 65,652 | 4.48 |
| Total | 1,466,253 | 100.00 |
| | _,100,200 | 100,00 |
| | | |

Column 1: Name of the major, minor generic categories and their associated generic codes.

Column 2: No. of Case Mentions (all exposures) in grey shading and displays the number of times the specific generic code was reported in all human exposure cases. If a human exposure case has multiple instances of a specific generic code it is only counted once.

Column 3: No. of Single Exposures-this column was previously named "No. of 'Single Exposures'" and was renamed in the 2009 report for clarity. This column displays the number of human exposure cases that identified only one substance (one case, one substance).

The succeeding columns (Age, Reason, Treatment Site, and Outcome) show selected detail from these singlesubstance exposure cases. Death cases include both cases that have the outcome of Death or Death, (indirect report). These death cases are not limited by the relative contribution to fatality.

Tables 22A and 22B restrict the breakdown columns to single-substance cases. Prior to 2007, when multi-substance exposures were included, a relatively innocuous substance could be mentioned in a death column when, for example, the death was attributed to an antidepressant, opioid, or cyanide. This subtlety was not always appreciated by the user of this table. The restriction of the breakdowns to singlesubstance exposures should increase precision and reduce misrepresentation of the results in this unique by-substance table. Single substance cases reflect the majority (90%) of all exposures yet 41% of fatalities (Table 5).

Tables 22A and 22B tabulate 2,759,287 substanceexposures, of which 2,147,248 were single-substance exposures, including 1,125,336 (52.4%) nonpharmaceuticals and 1,021,909 (47.6%) pharmaceuticals. The remaining 4 exposure cases (3 single exposures cases) did not specify if the substance was pharmaceutical or nonpharmaceutical (invalid generic codes).




Fig. 2. All Drug Identification and Law Enforcement Drug Identification Calls by Day since 1 January 2000.

Black line shows least-squares second order regression - both linear and second order (quadratic) terms were statistically significant for the Law Enforcement Drug ID Calls. (See colour version of this figure online).






Fig. 3. Health Care Facility (HCF) Exposure Calls and HCF Information Calls by Day since 1 January 2000.

Black lines show least-squares first and second order regressions - linear regression for HCF Exposure Calls (second order term was not statistically significant) and second order regression for HCF Information Calls. All terms shown were statistically significant for each of the 2 regressions. (See colour version of this figure online).

In 17.6% of single-substance exposures that involved pharmaceutical substances, the reason for exposure was intentional, compared to only 3.5% when the exposure involved a nonpharmaceutical substance. Correspondingly, treatment in a health care facility was provided in a higher percentage of exposures that involved pharmaceutical substances (27.5%) compared with nonpharmaceutical substances (14.7%). Exposures to pharmaceuticals also had more severe outcomes. Of single-substance exposure-related fatal cases, 521 (0.05%) were pharmaceuticals compared with 242 (0.02%) nonpharmaceuticals.

Age and Gender Distributions

The age and gender distribution of human exposures is outlined in Table 3A. Children younger than 3 years of age were involved in 37.7% of exposures and children younger than 6 years accounted for approximately half of all human exposures (50.5%). A male predominance was found among cases involving children younger than 13 years, but this gender distribution was reversed in teenagers and adults, with females comprising the majority of reported exposures. Table 3B shows population-adjusted exposures for the same age groups.

Caller Site and Exposure Site

As shown in Table 2, of the 2,384,825 human exposures reported, 74.6% of calls originated from a residence (own or other) but 93.7% actually occurred at a residence (own or other). Another 17.5% of calls were made from a health care facility. Beyond residences, exposures occurred in the workplace in 1.6% of cases, schools (1.2%), health care facilities (0.3%), and restaurants or food services (0.2%).

Exposures in Pregnancy

Exposure during pregnancy occurred in 7,849 women (0.33% of all human exposures). Of those with known pregnancy duration (n = 7,193), 31.6% occurred in the first trimester, 37.5% in the second trimester, and 30.9% in the third trimester. Most (72.2%) were unintentional exposures and 20.4% were intentional exposures. Medical outcome was No effect in 16.9%, Minor effect in 20.3%, Moderate effect in 5.76%, and Major Effect in 0.542%. There was one death in a pregnant female in 2010.

Chronicity

Most human exposures, 2,136,572 (89.6%) were acute cases (single, repeated, or continuous exposure occurring over 8 hr or less) compared to 869 acute cases of 1730 fatalities (50.2%). Chronic exposures (continuous or repeated exposures occurring over >8 hr) comprised 2% (47,700) of all human exposures. Acute-on-chronic exposures (single exposure that was preceded by a continuous, repeated, or intermittent exposure occurring over a period greater than 8 hr) numbered 174,777 (7.3%).

Reason for Exposure

The reason category for most human exposures was unintentional (81.4%) with unintentional general (57.3%),

Table 2. Site of Call and Site of Exposure, Human Exposure Cases

| | Site of c | aller | Site of exposure | | |
|-------------------------|-----------|-------|------------------|-------|--|
| Site | N | % | N | % | |
| Residence | | | | | |
| Own | 1,736,145 | 72.80 | 2,172,987 | 91.12 | |
| Other | 42,813 | 1.80 | 61,635 | 2.58 | |
| Workplace | 28,429 | 1.19 | 37,707 | 1.58 | |
| Health care facility | 418,412 | 17.54 | 7,381 | 0.31 | |
| School | 10,901 | 0.46 | 29,568 | 1.24 | |
| Restaurant/food service | 566 | 0.02 | 5,741 | 0.24 | |
| Public area | 8,166 | 0.34 | 22,793 | 0.96 | |
| Other | 131,067 | 5.50 | 26,020 | 1.09 | |
| Unknown | 8,326 | 0.35 | 20,993 | 0.88 | |

Table 3A. Age and Gender Distribution of Human Exposures

| | Ma | Male Female Unknown gender Total | | Male | | Cumulativ | e total | | | |
|----------------------|-----------|----------------------------------|-----------|----------------------------|--------|----------------------------|-----------|----------------------|-----------|--------|
| Age (y) | N | % of age group total | N | % of age group total | N | % of age group total | N | % of total exposures | N | % |
| Children (< 20) | | | | | | | | | | |
| < 1 | 61,837 | 51.96 | 56,779 | 47.71 | 401 | 0.34 | 119,017 | 4.99 | 119,017 | 4.99 |
| 1 | 196,460 | 51.83 | 182,070 | 48.03 | 539 | 0.14 | 379,069 | 15.90 | 498,086 | 20.89 |
| 2 3 | 209,515 | 52.29 | 190,541 | 47.55 | 629 | 0.16 | 400,685 | 16.80 | 898,771 | 37.69 |
| 3 | 96,889 | 54.90 | 79,231 | 44.90 | 358 | 0.20 | 176,478 | 7.40 | 1,075,249 | 45.09 |
| 4 | 46,270 | 55.91 | 36,300 | 43.86 | 187 | 0.23 | 82,757 | 3.47 | 1,158,006 | 48.56 |
| 5 | 26,281 | 56.46 | 20,098 | 43.18 | 167 | 0.36 | 46,546 | 1.95 | 1,204,552 | 50.51 |
| Unknown ≤ 5 | 1,414 | 46.77 | 1,290 | 42.67 | 319 | 10.55 | 3,023 | 0.13 | 1,207,575 | 50.64 |
| Child 6-12 | 83,114 | 57.95 | 59,525 | 41.50 | 785 | 0.55 | 143,424 | 6.01 | 1,350,999 | 56.65 |
| Teen 13-19 | 72,506 | 46.43 | 83,122 | 53.23 | 536 | 0.34 | 156,164 | 6.55 | 1,507,163 | 63.20 |
| Unknown Child | 2,054 | 39.36 | 1,991 | 38.16 | 1,173 | 22.48 | 5,218 | 0.22 | 1,512,381 | 63.42 |
| Subtotal | 796,340 | 52.65 | 710,947 | 47.01 | 5,094 | 0.34 | 1,512,381 | 63.42 | 1,512,381 | 63.42 |
| Adults (≥ 20) | | | | | | | | | | |
| 20-29 | 90,853 | 46.19 | 105,622 | 53.70 | 198 | 0.10 | 196,673 | 8.25 | 1,709,054 | 71.66 |
| 30-39 | 65,446 | 43.03 | 86,511 | 56.88 | 135 | 0.09 | 152,092 | 6.38 | 1,861,146 | 78.04 |
| 40–49 | 58,233 | 41.49 | 82,024 | 58.45 | 85 | 0.06 | 140,342 | 5.88 | 2,001,488 | 83.93 |
| 50-59 | 46,214 | 39.83 | 69,769 | 60.13 | 51 | 0.04 | 116,034 | 4.87 | 2,117,522 | 88.79 |
| 60–69 | 27,166 | 37.60 | 45,046 | 62.35 | 34 | 0.05 | 72,246 | 3.03 | 2,189,768 | 91.82 |
| 70–79 | 15,075 | 34.97 | 28,022 | 65.00 | 17 | 0.04 | 43,114 | 1.81 | 2,232,882 | 93.63 |
| 80-89 | 9,110 | 32.96 | 18,515 | 66.99 | 12 | 0.04 | 27,637 | 1.16 | 2,260,519 | 94.79 |
| ≥ 90 | 1,530 | 28.60 | 3,816 | 71.34 | 3 | 0.06 | 5,349 | 0.22 | 2,265,868 | 95.01 |
| Unknown adult | 41,761 | 39.59 | 61,333 | 58.14 | 2,401 | 2.28 | 105,495 | 4.42 | 2,371,363 | 99.44 |
| Subtotal | 355,388 | 41.37 | 500,658 | 58.29 | 2,936 | 0.34 | 858,982 | 36.02 | 2,371,363 | 99.44 |
| Other | | | | | | | | | | |
| Unknown age | 4,718 | 35.05 | 5,954 | 44.23 | 2,790 | 20.73 | 13,462 | 0.56 | 2,384,825 | 100.00 |
| Total | 1,156,446 | 48.49 | 1,217,559 | 51.05 | 10,820 | 0.45 | 2,384,825 | 100.00 | 2,384,825 | 100.00 |

therapeutic error (11.3%) and unintentional misuse (5.4%) of all exposures (Table 6A).

Scenarios

Of the total 285,277 therapeutic errors, the most common scenarios for all ages included: inadvertent double-dosing (29.1%), wrong medication taken or give (14.7%), other incorrect dose (12.9%), doses given/taken too close together (9.5%), and inadvertent exposure to someone else's medication (9.0%). The types of therapeutic errors observed are different for each age group and are summarized in Table 6B.

Reason by Age

Intentional exposures accounted for 14.7% of human exposures. Suicidal intent was suspected in 9.2% of cases, intentional misuse in 2.5% and intentional abuse in 2.2%. Unintentional exposures outnumbered intentional exposures in all age groups with the exception of ages 13–19 years (Table 7). Intentional exposures were more frequently reported than unintentional exposures in patients aged 13–19 years. In contrast, of the 1,146 reported fatalities with RCF 1–3, the majority reason reported for children ≤ 5 years was unintentional while most fatalities in adults (≥ 20 years) were intentional (Table 8).

Table 3B. Population-Adjusted Exposures by Age Group

| Age Group | Exposures/100k population | Number of Exposures ^a | Population ^b |
|----------------------|---------------------------|----------------------------------|-------------------------|
| Children (< 20) | | | |
| <1 | 2,760 | 119,017 | 4,312,097 |
| 1 | 8,858 | 379,069 | 4,278,394 |
| 2 | 9,287 | 400,685 | 4,313,444 |
| 3 | 4,057 | 176,478 | 4,349,133 |
| 4 | 1,953 | 82,757 | 4,236,333 |
| 5 | 1,110 | 46,546 | 4,193,338 |
| Child 6–12 | 502 | 143,424 | 28,575,574 |
| Teen 13-19 | 533 | 156,164 | 29,262,563 |
| Subtotal | 1,813 | 1,512,381 | 83,520,876 |
| Adults (≥ 20) | | | |
| 20-29 | 451 | 196,673 | 43,608,697 |
| 30–39 | 753 | 152,092 | 20,183,872 |
| 40–49 | 220 | 140,342 | 63,820,032 |
| 50-59 | 279 | 116,034 | 41,553,408 |
| 60–69 | 251 | 72,246 | 28,800,304 |
| 70–79 | 261 | 43,114 | 16,502,508 |
| 80–89 | 288 | 27,637 | 9,580,266 |
| ≥90 | 260 | 5,349 | 2,059,452 |
| Subtotal | 380 | 858,982 | 226,108,539 |
| Overall Total | 761 | 2,384,825 | 313,306,729 |

^aNumber of Exposures excludes UNKNOWN ages from the individual age categories, but includes them in the Subtotals and Overall Total (see Table 3A). ^bAs of 1 July Mid Year US Census (50 United States, American Samoa, District of Columbia, Federated States of Micronesia, Guam, Puerto Rico, and the US Virgin Islands).3,4



Table 4. Distribution of Agea and Gender for Fatalities^b

| Age (y) | Male | Female | Unknown | Total (%) | Cumulative total (%) |
|------------------|------|--------|---------|----------------|----------------------|
| <1 year | 1 | 2 | 0 | 3 (0.3%) | 3 (0.3%) |
| 1 year | 4 | 5 | 0 | 9 (0.8%) | 12 (1.1%) |
| 2 years | 1 | 5 | 0 | 6 (0.5%) | 18 (1.6%) |
| 3 years | 4 | 2 | 0 | 6 (0.5%) | 24 (2.1%) |
| 4 years | 2 | 3 | 0 | 5 (0.4%) | 29 (2.5%) |
| 5 years | 1 | 2 | 0 | 3 (0.3%) | 32 (2.8%) |
| Child 6–12 years | 2 | 1 | 0 | 3 (0.3%) | 35 (3.1%) |
| Teen 13–19 years | 30 | 26 | 0 | 56 (4.9%) | 91 (7.9%) |
| 20–29 years | 95 | 77 | 0 | 172 (15.0%) | 263 (23.0%) |
| 30–39 years | 80 | 104 | 0 | 184 (16.1%) | 447 (39.0%) |
| 40–49 years | 103 | 134 | 0 | 237 (20.7%) | 684 (59.7%) |
| 50–59 years | 113 | 110 | 1 | 224 (19.6%) | 908 (79.2%) |
| 60–69 years | 61 | 58 | 0 | 119 (10.4%) | 1,027 (89.6%) |
| 70–79 years | 25 | 29 | 0 | 54 (4.7%) | 1,081 (94.3%) |
| 80–89 years | 23 | 27 | 0 | 50 (4.4%) | 1,131 (98.7%) |
| ≥90 years | 4 | 5 | 0 | 9 (0.8%) | 1,140 (99.5%) |
| Unknown adult | 1 | 2 | 0 | 3 (0.3%) | 1,143 (99.7%) |
| Unknown age | 2 | 0 | 1 | 3 (0.3%) | 1,146 (100.0%) |
| Total | 552 | 592 | 2 | 1,146 (100.0%) | 1,146 (100.0%) |

^aAge includes cases with both actual and estimated ages as shown in Table 21.

Route of Exposure

Ingestion was the route of exposure in 83.5% of cases (Table 9), followed in frequency by dermal (7.2%), inhalation/nasal (5.7%), and ocular routes (4.5%). For the 1,146 exposure-related fatalities, ingestion (87.5%), inhalation/nasal (7.7%), and parenteral (3.1%) were the predominant exposure routes. Each exposure case may have more than one route.

Clinical Effects

The NPDS database allows for the coding of up to 131 different clinical effects (signs, symptoms, or laboratory

Table 5. Number of Substances Involved in Human Exposure Cases

| | Human ex | posures | Fatal ex | aposures ^a |
|-------------------|-----------|---------|----------|-----------------------|
| No. of Substances | N | % | N | % |
| 1 | 2,147,248 | 90.04 | 474 | 41.36 |
| 2 | 151,642 | 6.36 | 270 | 23.56 |
| 3 | 48,575 | 2.04 | 159 | 13.87 |
| 4 | 19,666 | 0.82 | 97 | 8.46 |
| 5 | 8,773 | 0.37 | 67 | 5.85 |
| 6 | 3,913 | 0.16 | 31 | 2.71 |
| 7 | 2,130 | 0.09 | 20 | 1.75 |
| 8 | 1,152 | 0.05 | 12 | 1.05 |
| ≥9 | 1,726 | 0.07 | 16 | 1.40 |
| Total | 2,384,825 | 100.00 | 1,146 | 100.00 |

^aIncludes cases with relative contribution to fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory. This excludes reports with outcome of Death INDIRECT.

Table 6A. Reason for Human Exposure Cases

| Reason | N | % Human exposures |
|-----------------------------------|-----------|-------------------|
| - Teason | 11 | caposures |
| Unintentional | | |
| Unintentional - General | 1,367,682 | 57.3 |
| Unintentional - Therapeutic error | 269,889 | 11.3 |
| Unintentional - Misuse | 128,923 | 5.4 |
| Unintentional - Bite/sting | 61,584 | 2.6 |
| Unintentional - Environmental | 57,384 | 2.4 |
| Unintentional - Food poisoning | 26,221 | 1.1 |
| Unintentional - Occupational | 24,546 | 1.0 |
| Unintentional - Unknown | 4,619 | 0.2 |
| Subtotal | 1,940,848 | 81.4 |
| Intentional | | |
| Intentional - Suspected suicide | 219,934 | 9.2 |
| Intentional - Misuse | 58,568 | 2.5 |
| Intentional - Abuse | 51,715 | 2.2 |
| Intentional - Unknown | 19,837 | 0.8 |
| Subtotal | 350,054 | 14.7 |
| Adverse Reaction | | |
| Adverse reaction - Drug | 42,201 | 1.8 |
| Adverse reaction - Other | 13,612 | 0.6 |
| Adverse reaction - Food | 5,775 | 0.2 |
| Subtotal | 61,588 | 2.6 |
| Unknown | | |
| Unknown reason | 14,332 | 0.6 |
| Subtotal | 14,332 | 0.6 |
| Other | , | |
| Other - Malicious | 8,351 | 0.4 |
| Other - Contamination/tampering | 8,191 | 0.3 |
| Other - Withdrawal | 1,461 | 0.1 |
| Subtotal | 18,003 | 0.8 |
| Total | 2,384,825 | 100.0 |

bIncludes cases with relative contribution to fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory. This excludes reports with outcome of Death INDIRECT.

Table 6B. Scenarios for Therapeutic Errors^a by Age^b

| Scenario | N | ≤ 5 y (Row %) | 6–12 y (Row %) | 13–19 y (Row %) | ≥ 20 y (Row %) | Unknown child (Row %) | Unknown adult (Row %) | Unknown age (Row %) |
|---|--------|------------------|-------------------|--------------------|-------------------|-----------------------------|-----------------------------|---------------------------|
| Inadvertently took/given medication twice | 83,140 | 20.11 | 12.49 | 5.88 | 55.04 | 0.08 | 6.13 | 0.26 |
| Wrong medication taken/given | 41,794 | 16.20 | 12.01 | 6.52 | 58.69 | 0.07 | 6.19 | 0.33 |
| Other incorrect dose | 36,942 | 31.76 | 11.83 | 6.94 | 44.62 | 0.09 | 4.53 | 0.23 |
| Medication doses given/taken too close together | 27,233 | 19.53 | 10.15 | 7.12 | 56.66 | 0.06 | 6.29 | 0.18 |
| Inadvertently took/given someone else's medication | 25,542 | 20.48 | 18.80 | 6.94 | 49.03 | 0.07 | 4.54 | 0.13 |
| Other/unknown therapeutic error | 16,361 | 21.26 | 10.70 | 7.26 | 53.85 | 0.20 | 6.19 | 0.54 |
| Incorrect dosing route | 16,056 | 8.84 | 4.02 | 3.10 | 72.14 | 0.14 | 11.02 | 0.74 |
| Confused units of measure | 10,496 | 56.98 | 17.24 | 4.89 | 18.90 | 0.06 | 1.82 | 0.11 |
| Incorrect formulation or concentration given | 6,135 | 46.36 | 16.45 | 4.74 | 29.54 | 0.10 | 2.62 | 0.20 |
| Health professional/iatrogenic error (pharmacist/nurse/physician) | 5,684 | 28.20 | 10.38 | 6.33 | 47.59 | 0.48 | 5.96 | 1.06 |
| More than 1 product containing same ingredient | 5,589 | 15.80 | 14.96 | 14.17 | 48.77 | 0.05 | 6.07 | 0.18 |
| Dispensing cup error | 5,395 | 62.65 | 18.78 | 4.54 | 13.01 | 0.11 | 0.83 | 0.07 |
| Drug interaction | 1,701 | 8.47 | 7.94 | 6.88 | 66.67 | 0.06 | 9.64 | 0.35 |
| Incorrect formulation or concentration dispensed | 1,656 | 43.90 | 15.16 | 4.95 | 31.28 | 0.30 | 4.17 | 0.24 |
| 10-fold dosing error | 1,444 | 55.89 | 7.62 | 4.36 | 29.36 | 0.14 | 2.35 | 0.28 |
| Exposure through breast milk | 109 | 88.99 | 0.92 | 0.00 | 5.50 | 2.75 | 1.83 | 0.00 |

^aAll cases with a scenario category of therapeutic error regardless of reason.

abnormalities) for each case. Each clinical effect can be further defined as related, not related, or unknown if related. Clinical effects were coded in 849,516 (35.6%) cases. (17.9%) had 1 effect, 9.3% had 2 effects, 4.9% had 3 effects, 2% had 4 effects, 0.8% had 5 effects, and 0.9% had >5 effects coded). Of clinical effects coded, 79.2% were deemed related to the exposure(s), 9.3% were considered not related, and 11.5% were coded as unknown if related.

The duration of effect is required for all cases that report at least one clinical effect and have a medical outcome of minor, moderate, or major effect (n = 514,203; 21.6% of exposures). Table 13 demonstrates an increasing duration of the clinical effects observed with more severe outcomes.

Case Management Site

The majority of cases reported to PCs were managed in a non-health care facility (71.3%), usually at the site of exposure, primarily the patient's own residence (Table 10). 1.8% of cases were referred to a health care facility but refused referral. Treatment in a health care facility was rendered in 25.2% of cases.

Of the 601,197 cases managed in a health care facility, 292,289 (48.6%) were treated and released, 97,650 (16.2%) were admitted for critical care (intensive care or monitored unit), and 62,346 (10.4%) were admitted to a noncritical unit.

The percentage of patients treated in a health care facility varied considerably with age. Only 11.1% of children ≤5 years or younger and only 12.7% of children between 6 and

12 years were managed in a health care facility compared to 48.6% of teenagers (13-19 years) and 40.1% of adults (age \geq 20 years).

Medical Outcome

Table 11 displays the medical outcome of human exposure cases distributed by age. A greater number of severe medical outcomes is observed in the older age groups. Table 12 compares medical outcome and reason for exposure and shows a greater frequency of serious outcomes in intentional exposures.

Decontamination Procedures and Specific Antidotes

Tables 14 and 15 outline the use of decontamination procedures, specific antidotes, and measures to enhance elimination in the treatment of patients reported in the NPDS database. These must be interpreted as minimum frequencies because of the limitations of telephone data gathering.

Ipecac-induced emesis for poisoning continues to decline as shown in Tables 16A and 16B. Ipecac was administered in only 163 (0.01%) pediatric exposures in 2010. The continued decrease in ipecac syrup use over the last two decades was likely a result of ipecac use guidelines issued in 1997 by the American Academy of Clinical Toxicology, European Association of Poisons Centres, and Clinical Toxicologists and updated in 2004.^{5,6} In a separate report, the American Academy of Pediatrics concluded not only that ipecac should no longer be used routinely as a home treatment strategy,



^bOf the human exposure cases reported to U.S. Poison Centers in 2010, 425,655 (17.8%) were coded to 1 or more of 54 scenarios.

Table 7. Distribution of Reason for Exposure by Age

| | ≤ 5 y | y | 6–12 y | 2 y | 13–19 y | 9 y | N | $\geq 20 \text{ y}$ | Unkno | Jnknown child | Unknown | n adult | Unknc | Unknown age | Total | |
|--|--|--|--|---------------------------------------|--|--|---|---|--|---|--|---|---|--------------------------------------|---|--|
| Reason | z | Row % | z | Row % | z | Row % | z | Row % | z | Row % | z | Row % | z | Row % | Z | % |
| Unintentional Intentional Adverse reaction Other Unknown | 1,198,972 1,014 4,543 2,248 798 1,207,575 | 64.55 0.30 8.39 14.44 6.23 | 127,612 9,999 3,102 1,885 826 143,424 | 6.87 2.99 5.73 12.11 6.45 | 67,487 80,139 4,632 2,039 1,867 156,164 | 3.63 23.99 8.55 13.10 14.57 6.87 | 455,897 239,151 40,833 9,109 8,497 753,487 | 24.54 71.58 75.40 58.53 66.32 | 4,577 276 162 149 54 5.218 | 0.25 0.08 0.30 0.96 0.42 0.23 | 78,768 15,696 7,274 2,291 1,466 105,495 | 4.24 4.70 13.43 14.72 11.44 | 7,535 3,779 1,042 282 824 13,462 | 0.41 1.13 1.92 1.81 6.43 | 1,940,848 350,054 61,588 18,003 14,332 2,384,825 | 81.38 14.68 2.58 0.75 0.60 |

but also recommended disposal of home ipecac stocks.⁷ A decline was also observed since the early 1990s for reported use of activated charcoal. While not as dramatic as the decline in use of ipecac, reported use of activated charcoal decreased from 3.7% of pediatric cases in 1993 to just 1.4% in 2010.

Top Substances in Human Exposures

Table 17A presents the most common 25 substance categories, listed by frequency of human exposure. This ranking provides an indication where prevention efforts might be focused, as well as the types of exposures PCs regularly manage. It is relevant to know whether exposures to these substances are increasing or decreasing.

To better understand these relationships, we examined exposures per year over the last 11 years for the change over time for each of the 67 major generic categories via least squares linear regression. Despite an overall decrease in human exposure calls (3.8%) for this year, the calls per year increased for 42 and decreased for 25 of the 67 major categories. The change over time for the 11-yearly values was statistically significant (p < 0.05) for 49 of the 67 categories. Table 17B shows the 25 categories which were increasing the most rapidly. Statistical significance of the 25 regressions can be verified by noting the 95% confidence interval on the rate of increase excludes zero. Figure 7 shows the linear regressions for the top 4 increasing categories in Table 17B. Tables 17C and 17D present exposure results for children and adults, respectively, and show the differences between substance categories involved in pediatric and adult

Table 17E reports the 25 categories of substances most frequently involved in pediatric (≤5 years) fatalities in 2010.

Table 17F reports the 25 Drug ID categories most frequently identified in 2010. The most often identified drug category is miscellaneous and unknown; this category includes medications which could not be identified. Drug ID information is of value to AAPCC, public health, public safety, and regulatory agencies. Internet based resources do not allow data capture nor do they afford the caller the ability to speak with a specialist in poison information if the inquiry is more than a drug identification question. Proper resources to continue this vital public service are essential, especially since the top 10 substance categories include antibiotics as well as drugs with widespread use and abuse potential such as opioids and benzodiazepines.

Table 17G (new this year) reports the 25 substance categories most frequently reported in exposures involving pregnant patients.

Changes from Last Year

Figure 4 shows the year-to-year changes for 2009–2010 for all encounters and for several major categories.

The graphic breaks down the change in exposure calls by outcome category. Although overall exposure calls have decreased by 94,530 calls (-3.8%), there is a consistent increase in the exposures with a more serious outcome

Table 8. Distribution of Reason for Exposure and Age for Fatalities^a

| Reason | ≤5 y | 6–12 y | 13–19 y | ≥20 y | Unknown child | Unknown adult | Unknown age | Total |
|-----------------------------------|------|--------|---------|-------|---------------|------------------|----------------|-------|
| Unintentional | | | | | | | | |
| Unintentional - General | 15 | 0 | 0 | 24 | 0 | 0 | 0 | 39 |
| Unintentional - Environmental | 6 | 0 | 2 | 21 | 0 | 0 | 0 | 29 |
| Unintentional - Occupational | 0 | 0 | 2 | 11 | 0 | 0 | 0 | 13 |
| Unintentional - Therapeutic error | 3 | 0 | 1 | 22 | 0 | 0 | 0 | 26 |
| Unintentional - Misuse | 0 | 1 | 0 | 16 | 0 | 0 | 0 | 17 |
| Unintentional - Bite/sting | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 5 |
| Unintentional - Food poisoning | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unintentional - Unknown | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 4 |
| Subtotal | 26 | 1 | 5 | 102 | 0 | 0 | 0 | 134 |
| Intentional | | | | | | | | |
| Intentional - Suspected suicide | 0 | 0 | 31 | 603 | 0 | 3 | 0 | 637 |
| Intentional - Misuse | 1 | 0 | 1 | 44 | 0 | 0 | 0 | 46 |
| Intentional - Abuse | 0 | 1 | 9 | 88 | 0 | 0 | 1 | 99 |
| Intentional - Unknown | 0 | 0 | 5 | 93 | 0 | 0 | 0 | 98 |
| Subtotal | 1 | 1 | 46 | 828 | 0 | 3 | 1 | 880 |
| Other | | | | | | | | |
| Other - Contamination/tampering | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Other - Malicious | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 6 |
| Other - Withdrawal | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Subtotal | 2 | 0 | 2 | 5 | 0 | 0 | 0 | 9 |
| Adverse reaction | | | | | | | | |
| Adverse reaction - Drug | 1 | 0 | 0 | 25 | 0 | 0 | 0 | 26 |
| Adverse reaction - Other | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Subtotal | 1 | 0 | 0 | 27 | 0 | 0 | 0 | 28 |
| Unknown | | | | | | | | |
| Unknown reason | 2 | 1 | 3 | 87 | 0 | 0 | 2 | 95 |
| Subtotal | 2 | 1 | 3 | 87 | 0 | 0 | 2 | 95 |
| Total | 32 | 3 | 56 | 1,049 | 0 | 3 | 3 | 1,146 |

^aIncludes cases with relative contribution to fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory. This excludes reports with outcome of Death INDIRECT.

(minor, moderate, major or death) and as a group increased by 22,175 encounters (4.5%).

Thus we see a consistent increase in exposure calls from HCFs and for the more severe exposures, despite a decrease in calls involving less severe exposures.

Distribution of Suicides

Table 19A shows the modest variation in the distribution of suicides and pediatric deaths over the past two decades as reported to the NPDS national database. Within the last decade, the percent of exposures determined to be suspected

Table 9. Route of Exposure for Human Exposure Cases

| |] | Human exposures | | | Fatal exposures | a |
|-------------------------------|-----------|--------------------|-------------------|-------|--------------------|---------------------|
| Route | N | % of All Routes | % of All Cases | N | % of All Routes | % of All Cases |
| Ingestion | 1,990,244 | 79.51 | 83.45 | 1,003 | 80.82 | 87.52 |
| Dermal | 172,318 | 6.88 | 7.23 | 18 | 1.45 | 1.57 |
| Inhalation/nasal | 136,799 | 5.47 | 5.74 | 88 | 7.09 | 7.68 |
| Ocular | 107,374 | 4.29 | 4.50 | 0 | 0.0 | 0 |
| Bite/sting | 61,606 | 2.46 | 2.58 | 5 | 0.40 | 0.44 |
| Parenteral | 16,865 | 0.67 | 0.71 | 35 | 2.82 | 3.05 |
| Unknown | 8,944 | 0.36 | 0.38 | 69 | 5.56 | 6.02 |
| Other | 3,016 | 0.12 | 0.13 | 4 | 0.32 | 0.35 |
| Otic | 2,519 | 0.10 | 0.11 | 0 | 0.0 | 0 |
| Aspiration (with ingestion) | 1,624 | 0.06 | 0.07 | 19 | 1.53 | 1.66 |
| Vaginal | 1,106 | 0.04 | 0.05 | 0 | 0.0 | 0 |
| Rectal | 736 | 0.03 | 0.03 | 0 | 0.0 | 0 |
| Total Number of Routes | 2,503,151 | 100.00 | 104.96 | 1,241 | 100.00 | 108.29 ^b |

^aIncludes cases with relative contribution to fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory. This excludes reports with outcome of Death INDIRECT.



^bEach exposure case may have more than one route.

Table 10. Management Site of Human Exposures

| | - | |
|--|-----------|-------|
| Site of management | N | % |
| Managed on site, nonhealth care facility | 1,700,736 | 71.3 |
| Managed in healthcare facility | | |
| Treated/evaluated and released | 292,289 | 12.3 |
| Admitted to critical care unit | 97,650 | 4.1 |
| Patient lost to follow-up/left AMA | 96,226 | 4.0 |
| Admitted to noncritical care unit | 62,346 | 2.6 |
| Admitted to psychiatric facility | 52,686 | 2.2 |
| Subtotal (managed in HCF) | 601,197 | 25.2 |
| Other | 29,417 | 1.2 |
| Refused referral | 42,497 | 1.8 |
| Unknown | 10,978 | 0.5 |
| Total | 2,384,825 | 100.0 |
| | | |

suicides ranged from 45.0 to 54.3% and the percent of pediatric cases has ranged from 2.2% to 3.2%.

Plant Exposures

Table 20 provides the number of times the specific plant was reported to NPDS (N = 53,526). The 25 most commonly involved plant species and categories account for 40% of all plant exposures reported. The top 3 categories in the table are essentially synonymous for unknown plant and comprise 13.2% (7,076/53,526) of all plant exposures. For a variety of reasons it was not possible to make a precise identification in these three groups. The top most frequent plant exposures where a positive plant identification was made were (descending order): Phytolacca americana (L.), Spathiphyllum spp. Not otherwise specified (NOS), Ilex spp. (NOS), *Philodendron* spp. (NOS), and plants-pokeweed.

Deaths and Exposure-related Fatalities

A listing of cases (Table 21) and summary of cases (Tables 4, 5, 8, 9, 18, and 22) are provided for fatal cases for which there exists reasonable confidence that the death was a result of that exposure (exposure-related fatalities). Tables 11, 12, 17E and 19 list all deaths, irrespective of the RCF. Beginning in 2010, cases with outcome of death, indirect were not reviewed and the Relative Contribution to Fatality (RCF) was determined by the individual poison center team.

| Table | Fatalities Included | RCF | Number of Deaths |
|-------|--|-------|---------------------|
| 4 | Death only | 1,2,3 | 1,146 |
| 5 | Death only | 1,2,3 | 1,146 |
| 8 | Death only | 1,2,3 | 1,146 |
| 9 | Death only | 1,2,3 | 1,146 |
| 11 | Death and Death (indirect report) | All | 1,730 |
| 12 | Death and Death (indirect report) | All | 1,730 |
| 17E | Death and Death (indirect report) | All | 1,730 |
| 18 | Death and Death (indirect report) | 1,2,3 | 1,366 |
| 19A | Death and Death (indirect report) | All | 1,730 |
| 19B | Death and Death (indirect report) | All | 1,730 |
| 21 | Death and Death (indirect report) | 1,2,3 | 1,366 |
| 22 | Death and Death (indirect report) - Single substance deaths only | All | 764 |

 Table 11. Medical Outcome of Human Exposure Cases by Patient Age^a

| | ≤5 y | > | 6–12 y | χ | 13–19 y |) y | $\geq 20 \text{ y}$ | y 0 | Unknowr child | own Id | Unknown adul | ı adult | Unknow | nwc | Total | |
|--|-----------------------------|--------|------------|-----------|------------|-------------|---------------------|------------|------------------|------------|--------------|-------------|-------------|-----------|---------------|---------|
| Outcome | Z | % | z | % | z | % | z | % | z | % | z | % | z | % | z | % |
| No effect | 302,659 | 25.06 | 25,660 | 17.89 | 25,014 | 16.02 | 93,311 | 12.38 | 1,018 | 19.51 | 10,418 | 9.88 | 1,199 | 8.9 | 459,279 | 19.26 |
| Minor effect | 95,105 | 7.88 | 22,015 | 15.35 | 40,125 | 25.69 | 179,640 | 23.84 | 519 | 9.95 | 15,444 | 14.64 | 1,930 | 14.3 | 354,778 | 14.88 |
| Moderate effect | 10,757 | 0.89 | 4,090 | 2.85 | 20,655 | 13.23 | 99,504 | 13.21 | 24 | 1.86 | 4,038 | 3.83 | 482 | 3.6 | 139,623 | 5.85 |
| Major effect | 833 | 0.07 | 177 | 0.12 | 2,069 | 1.32 | 16,385 | 2.17 | 2 | 0.04 | 267 | 0.25 | 69 | 0.5 | 19,802 | 0.83 |
| Death | 47 | 0.00 | 3 | 0.00 | 99 | 0.04 | 1,314 | 0.17 | 0 | 0.00 | 14 | 0.01 | 11 | 0.1 | 1,455 | 90.0 |
| No follow-up, nontoxic | 232,671 | 19.27 | 21,810 | 15.21 | 8,698 | 5.57 | 44,926 | 5.96 | 647 | 12.40 | 10,775 | 10.21 | 837 | 6.2 | 320,364 | 13.43 |
| No follow-up, minimal toxicity | 528,424 | 43.76 | 62,824 | 43.80 | 41,710 | 26.71 | 236,547 | 31.39 | 2,166 | 41.51 | 45,309 | 42.95 | 3,777 | 28.1 | 920,757 | 38.61 |
| No follow-up, potentially toxic | 20,916 | 1.73 | 3,494 | 2.44 | 13,706 | 8.78 | 51,417 | 6.82 | 648 | 12.42 | 14,879 | 14.10 | 4,784 | 35.5 | 109,844 | 4.61 |
| Unrelated effect | 16,155 | 1.34 | 3,349 | 2.34 | 4,108 | 2.63 | 30,203 | 4.01 | 121 | 2.32 | 4,341 | 4.11 | 371 | 2.8 | 58,648 | 2.46 |
| Death, indirect report | 8 | 0.00 | 2 | 0.00 | 13 | 0.01 | 240 | 0.03 | 0 | 0.00 | 10 | 0.01 | 2 | 0.0 | 275 | 0.01 |
| Total | 1,207,575 100.00 143,424 10 | 100.00 | 143,424 | 100.0 | 156,164 | 100.00 | 753,487 | 100.00 | 5,218 | 100.00 | 105,495 | 100.00 | 13,462 | 100.00 | 2,384,825 | 100.00 |
| Trich number of cocce whose Death was an outcome of 1165 1 775) is amorted than the number of fortalities (1 116) induced to be assessed and about another properties of 1 Industrial assessment of the second of th | acotic do som | 1000 | 275) is am | otor thon | the mumber | of fotoliti | 00 (1 146); | ndand to b | 110004.40 | pototos os | (reletive oc | acitaniha a | to fotolity | of 1 IInc | and the other | oldiono |

"Iotal number of cases where Death was an outcome (1,455 + 2/5) is greater than the number of tatalities (1,146) judged to be exposure-related (relative contribution to tatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory

Table 12. Medical Outcome by Reason for Exposure in Human Exposures^a

| | Unintent | ional | Intenti | onal | Otl | her | Adv reac | | Unk | nown | Tota | al |
|---------------------------------|-----------|--------|---------|--------|--------|--------|-------------|--------|--------|--------|-----------|--------|
| Outcome | N | % | N | % | N | % | N | % | N | % | N | % |
| No effect | 398,439 | 20.53 | 55,812 | 15.94 | 2,295 | 12.75 | 1,522 | 2.47 | 1,211 | 8.45 | 459,279 | 19.26 |
| Minor effect | 234,875 | 12.10 | 98,991 | 28.28 | 3,356 | 18.64 | 15,329 | 24.89 | 2,227 | 15.54 | 354,778 | 14.88 |
| Moderate effect | 46,532 | 2.40 | 80,998 | 23.14 | 1,265 | 7.03 | 7,914 | 12.85 | 2,914 | 20.33 | 139,623 | 5.85 |
| Major effect | 2,756 | 0.14 | 15,203 | 4.34 | 158 | 0.88 | 714 | 1.16 | 971 | 6.78 | 19,802 | 0.83 |
| Death | 172 | 0.01 | 1,023 | 0.29 | 14 | 0.08 | 62 | 0.10 | 184 | 1.28 | 1,455 | 0.06 |
| No follow-up, nontoxic | 313,047 | 16.13 | 4,926 | 1.41 | 1,228 | 6.82 | 891 | 1.45 | 272 | 1.90 | 320,364 | 13.43 |
| No follow-up, minimal toxicity | 853,887 | 44.00 | 36,708 | 10.49 | 6,547 | 36.37 | 21,727 | 35.28 | 1,888 | 13.17 | 920,757 | 38.61 |
| No follow-up, potentially toxic | 51,189 | 2.64 | 49,196 | 14.05 | 1,821 | 10.11 | 4,426 | 7.19 | 3,212 | 22.41 | 109,844 | 4.61 |
| Unrelated effect | 39,921 | 2.06 | 6,996 | 2.00 | 1,316 | 7.31 | 9,001 | 14.61 | 1,414 | 9.87 | 58,648 | 2.46 |
| Death, indirect report | 30 | 0.00 | 201 | 0.06 | 3 | 0.02 | 2 | 0.00 | 39 | 0.27 | 275 | 0.01 |
| Total | 1,940,848 | 100.00 | 350,054 | 100.00 | 18,003 | 100.00 | 61,588 | 100.00 | 14,332 | 100.00 | 2,384,825 | 100.00 |

^aTotal number of cases where Death was an outcome (1,455 + 275) is greater than the number of fatalities (1,146) judged to be exposure-related (relative contribution to fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory).

There were 275 death, indirect and 1,455 deaths. Of these 1,730 cases, 1,366 were judged exposure-related fatalities (RCF = 1, Undoubtedly responsible; 2, Probably responsible;or 3, Contributory). The remaining 364 cases were judged as follows: 73 as RCF = 4, Probably not responsible; 27 as 5, Clearly not responsible; and 264 as RCF = 6, Unknown.

Deaths are sorted in Table 21 according to the category, substance deemed most likely responsible for the death (Cause Rank), and then by patient age. The Cause Rank permits the PC to judge two or more substances as indistinguishable in terms of cause, e.g., two substances which appear equally likely to have caused the death could have Substance Rank of 1, 2 and Cause Rank of 1, 1. Additional agents implicated are listed below the primary agent in the order of their contribution to the fatality.

As shown in Table 5, a single substance was implicated in 90.0% of reported human exposures, and 6.4% of patients were exposed to two or more drugs or products. The exposure-related fatalities involved a single substance in 474 cases (41.4%), 2 substances in 270 cases (23.6%), 3 in 159 cases (13.9%) and 4 or more in the balance of the cases.

In Table 21, the Annual Report ID number [bracketed] indicates that the abstract for that case is included in Appendix C. The letters following the Annual Report ID number indicate: i = Death, Indirect report (occurred in 220, 16.1% of cases), p = prehospital cardiac and/or respiratory arrest (occurred in 666 of 1,366, 44.4% of cases), h = hospitalrecords reviewed (occurred in 53, 3.9% of cases), a = autopsyreport reviewed (occurred in 356, 26.1% of cases). The distribution of NPDS RCF was: 1 = Undoubtedly responsible in 559 cases (40.9%), 2 = Probably responsible in 599 cases (43.9%), 3 = Contributory in 208 cases (15.2%). The denominator for these Table 21 percentages is 1,366.

All fatalities – all ages

Table 4 presents the age and gender distribution for these 1,146 exposure-related fatalities (excluding death, indirect). The age distribution of reported fatalities is similar to that in past years with 91 (7.9%) of the fatalities in children (< 20years old), 1,052 of 1,146 (92.1%) of fatal cases occurring in adults (age \geq 20 years) and 3 (0.3%) of fatalities occurring in Unknown Age patients. Although children ≤5 years old were involved in the majority of exposures, the 32 fatalities comprised just 2.8% of the exposure-related fatalities. Most (71.4%) of the fatalities occurred in 20-to 59-year-old individuals.

Table 21 lists each of the 1,366 human fatalities (including death, indirect report) along with all of the substances

Table 13. Duration of Clinical Effects by Medical Outcome

| | Minor | Minor effect | | e effect | Major effect | |
|---------------------------|---------|--------------|---------|----------|--------------|--------|
| Duration of effect | N | % | N | % | N | % |
| ≤2 hours | 122,045 | 34.40 | 8,186 | 5.86 | 443 | 2.24 |
| >2 hours, ≤8 hours | 94,233 | 26.56 | 30,472 | 21.82 | 1,242 | 6.27 |
| >8 hours, ≤24 hours | 64,672 | 18.23 | 46,587 | 33.37 | 4,826 | 24.37 |
| >24 hours, ≤3 days | 24,525 | 6.91 | 26,536 | 19.01 | 6,294 | 31.78 |
| >3 days, ≤1 week | 5,473 | 1.54 | 7,783 | 5.57 | 3,550 | 17.93 |
| >1 week, ≤ 1 month | 1,484 | 0.42 | 1,799 | 1.29 | 1,160 | 5.86 |
| >1 month | 568 | 0.16 | 465 | 0.33 | 170 | 0.86 |
| Anticipated permanent | 331 | 0.09 | 167 | 0.12 | 345 | 1.74 |
| Unknown | 41,447 | 11.68 | 17,628 | 12.63 | 1,772 | 8.95 |
| Total | 354,778 | 100.00 | 139,623 | 100.00 | 19,802 | 100.00 |



Table 14. Decontamination and Therapeutic Interventions

| Therapy | N | % |
|-------------------------------|-----------|-------|
| Decontamination Only | 960,389 | 40.3 |
| Therapeutic Intervention Only | 237,057 | 9.9 |
| Decontamination and | 405,953 | 17.0 |
| Therapeutic Intervention | | |
| Not Coded | 781,426 | 32.8 |
| Total | 2,384,825 | 100.0 |

involved. Please note: the substance listed in column 3 of Table 21 (alternate name) was chosen to be the most specific generic name based upon analysis of the Micromedex Poisindex product name and generic code. Alternate names are maintained in the NPDS for each substance involved in a fatality. The cross-references at the end of each major category section in Table 21 list all cases that identify this substance as other than the primary substance. This Alternate name may not agree with the AAPCC generic categories used in the summary tables (including Table 22).

Table 18 lists the top 25 minor generic substance categories associated with reported fatalities and the number of single substance exposure fatalities for that category miscellaneous sedative/hypnotics/antipsychotics, miscellaneous cardiovascular drugs, opioids, and acetaminophen combination products, lead this list followed by miscellaneous antidepressants, miscellaneous alcohols, acetaminophen alone, miscellaneous anticonvulsants, and miscellaneous

Table 15. Therapy Provided in Human Exposures by Age.

| Therapy | ≤5 y | 6–12 y | 13–19 у | ≥ 20 y | Unknown child | Unknown adult | Unknown age | Total |
|----------------------------------|---------|--------|---------|---------|---------------|---------------|-------------|---------|
| Decontamination | | | | | | | | |
| Cathartic | 2,426 | 249 | 3,388 | 11,544 | 2 | 221 | 12 | 17,842 |
| Charcoal, multiple doses | 141 | 21 | 397 | 1,446 | 0 | 15 | 4 | 2,024 |
| Charcoal, single dose | 16,440 | 1,104 | 13,221 | 40,965 | 6 | 602 | 69 | 72,407 |
| Dilute/irrigate/wash | 592,610 | 59,422 | 35,531 | 202,957 | 1,704 | 34,815 | 2,535 | 929,574 |
| Food/snack | 145,624 | 11,454 | 5,911 | 29,105 | 192 | 4,289 | 183 | 196,758 |
| Fresh air | 6,873 | 5,141 | 4,844 | 41,151 | 600 | 11,456 | 1,042 | 71,107 |
| Ipecac | 163 | 24 | 55 | 109 | 0 | 9 | 0 | 360 |
| Lavage | 180 | 27 | 872 | 3,746 | 0 | 52 | 6 | 4,883 |
| Other emetic | 5,323 | 473 | 845 | 4,213 | 9 | 362 | 39 | 11,264 |
| Whole bowel irrigation | 115 | 22 | 331 | 1,484 | 0 | 18 | 2 | 1,972 |
| Other Therapies | | | | , - | | | | , |
| 2-PAM | 6 | 1 | 4 | 66 | 0 | 0 | 0 | 77 |
| Alkalinization | 127 | 69 | 1,586 | 8,396 | 0 | 70 | 12 | 10,260 |
| Amyl nitrite | 0 | 0 | 2 | 7 | 0 | 2 | 0 | 11 |
| Antiarrhythmic | 5 | 1 | 57 | 555 | 0 | 3 | 0 | 621 |
| Antibiotics | 2,025 | 919 | 1,245 | 12,084 | 21 | 925 | 84 | 17,303 |
| Anticonvulsants ^a | 47 | 19 | 116 | 665 | 0 | 7 | 1 | 855 |
| Antiemetics | 917 | 335 | 3,734 | 9,878 | 0 | 149 | 12 | 15,025 |
| Antihistamines | 2,664 | 1,702 | 1,945 | 10,710 | 20 | 1,418 | 103 | 18,562 |
| Antihypertensives | 12 | 10 | 114 | 1,879 | 0 | 25 | 1 | 2,041 |
| Antivenin (fab fragment) | 418 | 257 | 170 | 1,326 | 2 | 26 | 6 | 2,205 |
| Antivenin/antitoxin ^b | 34 | 34 | 27 | 246 | 0 | 5 | 0 | 346 |
| Atropine | 96 | 17 | 78 | 1,054 | 0 | 8 | ĺ | 1,254 |
| BAL | 11 | 1 | 6 | 20 | 0 | 0 | 0 | 38 |
| Benzodiazepines | 871 | 359 | 4,212 | 20,459 | 4 | 233 | 34 | 26,172 |
| Bronchodilators | 533 | 312 | 405 | 4,340 | 29 | 259 | 18 | 5,896 |
| Calcium | 9,571 | 572 | 242 | 2,062 | 19 | 62 | 5 | 12,533 |
| Cardioversion | 3 | 2 | 26 | 203 | 0 | 0 | 0 | 234 |
| CPR | 31 | 7 | 75 | 707 | 0 | 5 | 2 | 827 |
| Deferoxamine | 2 | 1 | 29 | 28 | 0 | 1 | 0 | 61 |
| ECMO | 7 | 0 | 2 | 5 | 0 | 0 | 0 | 14 |
| EDTA | 46 | 2 | 1 | 12 | 0 | 0 | 0 | 61 |
| Ethanol | 2 | 1 | 5 | 100 | 0 | 1 | 2 | 111 |
| Extracorp. procedure (other) | 1 | 1 | 2 | 14 | 0 | 0 | 0 | 18 |
| Fab fragments | 39 | 23 | 19 | 570 | 0 | 4 | 2 | 657 |
| Fluids, IV | 6,687 | 1,609 | 21,596 | 102,505 | 8 | 1,126 | 123 | 133,654 |
| Flumazenil | 122 | 22 | 183 | 1,737 | 0 | 24 | 5 | 2,093 |
| Folate | 18 | 1 | 26 | 929 | 0 | 6 | 1 | 981 |
| Fomepizole | 132 | 17 | 106 | 1,668 | 0 | 15 | 3 | 1,941 |
| Glucagon | 31 | 6 | 57 | 1,436 | 0 | 16 | 2 | 1,548 |
| Glucose, > 5% | 346 | 24 | 186 | 2,586 | 0 | 29 | 3 | 3,174 |
| Hemodialysis | 12 | 4 | 107 | 2,162 | 0 | 12 | 1 | 2,298 |
| Hemoperfusion | 0 | 0 | 1 | 22 | 0 | 0 | 0 | 23 |
| Hydroxocobalamin | 5 | 0 | 5 | 37 | ő | 6 | 0 | 53 |
| | | | | | | | | |

Table 15. (Continued)

| Therapy | ≤5 y | 6–12 y | 13–19 y | ≥ 20 y | Unknown child | Unknown adult | Unknown age | Total |
|-----------------------|--------|--------|---------|--------|---------------|---------------|-------------|---------|
| Hyperbaric oxygen | 32 | 37 | 35 | 302 | 1 | 14 | 0 | 421 |
| Insulin | 9 | 7 | 77 | 1,419 | 0 | 5 | 0 | 1,517 |
| Intubation | 502 | 73 | 1,509 | 16,996 | 0 | 188 | 40 | 19,308 |
| Methylene blue | 11 | 2 | 7 | 80 | 0 | 0 | 0 | 100 |
| NAC, IV | 210 | 91 | 3,341 | 13,169 | 0 | 128 | 22 | 16,961 |
| NAC, PO | 118 | 53 | 1,730 | 6,374 | 0 | 68 | 19 | 8,362 |
| Nalmefene | 0 | 0 | 4 | 20 | 0 | 0 | 0 | 24 |
| Naloxone | 1,152 | 131 | 1,603 | 15,509 | 1 | 197 | 28 | 18,621 |
| Neuromuscular blocker | 32 | 8 | 117 | 963 | 0 | 6 | 1 | 1,127 |
| Octreotide | 66 | 2 | 25 | 237 | 0 | 1 | 0 | 331 |
| Other | 51,470 | 9,878 | 13,882 | 86,302 | 203 | 6,606 | 712 | 169,053 |
| Oxygen | 1,659 | 618 | 3,406 | 38,675 | 78 | 710 | 104 | 45,250 |
| Pacemaker | 2 | 0 | 4 | 168 | 0 | 0 | 0 | 174 |
| Penicillamine | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 4 |
| Physostigmine | 3 | 5 | 87 | 150 | 0 | 0 | 0 | 245 |
| Phytonadione | 28 | 6 | 57 | 686 | 0 | 7 | 2 | 786 |
| Pyridoxine | 14 | 2 | 68 | 404 | 0 | 1 | 2 | 491 |
| Sedation (other) | 304 | 67 | 1,121 | 11,122 | 0 | 96 | 15 | 12,725 |
| Sodium nitrite | 0 | 0 | 2 | 32 | 0 | 1 | 0 | 35 |
| Sodium thiosulfate | 4 | 0 | 5 | 51 | 0 | 3 | 1 | 64 |
| Steroids | 765 | 409 | 543 | 4,771 | 15 | 442 | 38 | 6,983 |
| Succimer | 117 | 3 | 7 | 65 | 0 | 2 | 0 | 194 |
| Transplantation | 0 | 0 | 1 | 21 | 0 | 0 | 0 | 22 |
| Vasopressors | 88 | 26 | 268 | 4,699 | 0 | 35 | 3 | 5,119 |
| Ventilator | 447 | 70 | 1,322 | 15,300 | 0 | 165 | 33 | 17,337 |

^aExcludes benzodiazepines.

Table 16A. Decontamination Trends (1985–2009)

| Year | Human exposures | Ipecac administered (% of all exposures) | Activated charcoal administered (% of all exposures) | Exposures involving children ≤ 5 y (% of all exposures) | Ipecac adminis- tered (% of child exposures) | Activated charcoal administered (% of child exposures) |
|------|-----------------|--|--|--|--|--|
| 1985 | 886,389 | 132,947 (14.999) | 41,063 (4.6) | 568,691 (64.2) | 94,919 (16.6908) | 14,718 (2.59) |
| 1986 | 1,095,228 | 145,516 (13.286) | 56,481 (5.2) | 690,137 (63.0) | 99,688 (14.4447) | 18,191 (2.64) |
| 1987 | 1,164,648 | 117,840 (10.118) | 60,310 (5.2) | 730,228 (62.7) | 83,443 (11.427) | 18,507 (2.53) |
| 1988 | 1,364,113 | 114,654 (8.4050) | 88,876 (6.5) | 843,106 (61.8) | 80,749 (9.5776) | 26,118 (3.10) |
| 1989 | 1,578,968 | 110,545 (7.0011) | 101,368 (6.4) | 963,924 (61.0) | 79,192 (8.2156) | 30,345 (3.15) |
| 1990 | 1,646,946 | 98,986 (6.0103) | 108,341 (6.6) | 999,751 (60.7) | 73,469 (7.3487) | 31,579 (3.16) |
| 1991 | 1,836,364 | 94,877 (5.1666) | 129,092 (7.0) | 1,099,179 (59.9) | 73,069 (6.6476) | 36,177 (3.29) |
| 1992 | 1,862,796 | 79,493 (4.2674) | 135,625 (7.3) | 1,094,256 (58.7) | 63,486 (5.8018) | 38,937 (3.56) |
| 1993 | 1,747,147 | 65,078 (3.7248) | 127,893 (7.3) | 978,560 (56.0) | 50,834 (5.1948) | 35,791 (3.66) |
| 1994 | 1,926,992 | 51,356 (2.6651) | 138,247 (7.2) | 1,042,651 (54.1) | 41,489 (3.9792) | 35,670 (3.42) |
| 1995 | 2,023,089 | 47,359 (2.3409) | 155,880 (7.7) | 1,070,472 (52.9) | 38,372 (3.5846) | 38,095 (3.56) |
| 1996 | 2,155,952 | 39,376 (1.8264) | 157,331 (7.3) | 1,137,263 (52.7) | 32,622 (2.8685) | 37,986 (3.34) |
| 1997 | 2,192,088 | 32,098 (1.4643) | 156,213 (7.1) | 1,150,931 (52.5) | 26,536 (2.3056) | 35,856 (3.12) |
| 1998 | 2,241,082 | 26,653 (1.1893) | 152,134 (6.8) | 1,180,989 (52.7) | 22,247 (1.8838) | 34,302 (2.90) |
| 1999 | 2,201,156 | 21,942 (0.9968) | 145,853 (6.6) | 1,154,799 (52.5) | 18,326 (1.5869) | 33,812 (2.93) |
| 2000 | 2,168,248 | 18,177 (0.8383) | 145,911 (6.7) | 1,142,796 (52.7) | 15,239 (1.3335) | 31,554 (2.76) |
| 2001 | 2,267,979 | 16,058 (0.7080) | 149,442 (6.6) | 1,169,478 (51.6) | 13,389 (1.1449) | 30,367 (2.60) |
| 2002 | 2,380,028 | 13,555 (0.5695) | 149,527 (6.3) | 1,227,381 (51.6) | 11,163 (0.9095) | 30,340 (2.47) |
| 2003 | 2,395,582 | 9,284 (0.3875) | 140,412 (5.9) | 1,245,584 (52.0) | 7,310 (0.5869) | 28,888 (2.32) |
| 2004 | 2,438,643 | 4,701 (0.1928) | 135,969 (5.6) | 1,250,536 (51.3) | 3,366 (0.2692) | 28,335 (2.27) |
| 2005 | 2,424,180 | 3,027 (0.1249) | 123,263 (5.1) | 1,233,695 (50.9) | 1,999 (0.1620) | 26,338 (2.13) |
| 2006 | 2,403,539 | 2,176 (0.0905) | 111,351 (4.6) | 1,223,815 (50.9) | 1,337 (0.1092) | 23,843 (1.95) |
| 2007 | 2,482,041 | 1,740 (0.0701) | 106,010 (4.3) | 1,271,595 (51.2) | 1,052 (0.0827) | 22,829 (1.80) |
| 2008 | 2,491,049 | 1,205 (0.0484) | 97,297 (3.9) | 1,292,754 (51.9) | 641 (0.0496) | 21,286 (1.65) |
| 2009 | 2,479,355 | 658 (0.0265) | 84,805 (3.4) | 1,290,784 (52.1) | 330 (0.0256) | 19,168 (1.48) |
| 2010 | 2,384,825 | 360 (0.0200) | 74,431 (3.1) | 1,207,575 (50.6) | 163 (0.0100) | 16,581 (1.37) |



^bExcludes Fab fragments.

Table 16B. Decontamination Trends: Total Human and Pediatric Exposures ≤ 5 Years $(2010)^a$.

| | Human exposures | | Exposures children ≤5 y | |
|---------------------------------|-----------------|------|-------------------------|------|
| Therapy | N | % | N | % |
| Activated charcoal administered | 74,431 | 3.12 | 16,581 | 1.37 |
| Cathartic | 17,842 | 0.75 | 2,426 | 0.20 |
| Ipecac administered | 360 | 0.02 | 163 | 0.01 |
| Lavage | 4,883 | 0.20 | 180 | 0.01 |
| Other Emetic | 11,264 | 0.47 | 5,323 | 0.44 |
| Whole Bowel Irrigation | 1,972 | 0.08 | 115 | 0.01 |
| Total | 110,752 | 4.64 | 24,788 | 2.05 |


^aHuman exposures = 2,384,825; Pediatric exposures = 1,207,575.

stimulants and street drugs. Note that Table 18 is sorted by all substances to which a patient was exposed (i.e., a patient exposed to an opioid may have also been exposed to 1 or more other products) and shows single substance exposures in the right hand column.

The first ranked substance (Table 21) was a pharmaceutical in 1,104 (80.8%) of the 1,366 fatalities. These 1,104 first ranked pharmaceuticals included:

526 analgesics (92 acetaminophen, 89 acetaminophen/ hydrocodone, 67 methadone, 53 oxycodone, 36 salicylate, 27 morphine, 20 acetaminophen/oxycodone, 17 fentanyl, 16 acetaminophen/diphenhydramine, 16 acetaminophen/propoxyphene, 14 tramadol, 12

| Encounter Type | 2009 | 2010 | Increase | %Increase | % of Total |
|-------------------------------|-----------|-----------|-----------|-----------|------------|
| All Encounters | 4,280,391 | 3,952,772 | (327,619) | -7.7% | 100% |
| Human Exposure Calls | 2,479,355 | 2,384,825 | (94,530) | -3.8% | 29% |
| Information Calls | 1,677,403 | 1,466,253 | (211,150) | -12.6% | 64% |
| All Drug Identification Calls | 1,057,632 | 942,614 | (115,018) | -10.9% | 35% |
| Animal Exposure Calls | 116,408 | 94,823 | (21,585) | -18.5% | 7% |
| Law Enforcement Drug ID Calls | 180,036 | 171,247 | (8,789) | -4.9% | 3% |
| HCF Information Calls | 33,558 | 29,009 | (4,549) | -13.6% | 1% |
| HCF Exposure Calls | 407,446 | 418,412 | 10,966 | 2.7% | -3% |



| Outcome | 2009 | 2010 | Increase | % Increase | % of Total |
|---|-------------------------------|-------------------------------|---------------------------------|-----------------------------|---------------------------|
| Human Exposure Calls | 2,479,355 | 2,384,825 | (94,530) | -3.8% | 100% |
| Death | 1,452 | 1,455 | 3 | 0.2% | 0.0% |
| Major effect | 18,994 | 19,802 | 808 | 4.3% | 0.9% |
| Moderate effect | 132,816 | 139,623 | 6,807 | 5.1% | 7.2% |
| Minor effect | 340,221 | 354,778 | 14,557 | 4.3% | 15.4% |
| Total for More Serious Exposur | es | | 22,175 | 4.5% | 23.5% |
| | | | | | |
| No effect | 482,202 | 459,279 | (22,923) | -4.8% | -24.2% |
| No effect Not followed, nontoxic | 482,202 338,635 | 459,279 320,364 | (22,923) (18,271) | -4.8% -5.4% | -24.2% -19.3% |
| | | , | | -5.4% | |
| Not followed, nontoxic | 338,635 | 320,364 | (18,271) | -5.4% | -19.3% |
| Not followed, nontoxic Not followed, minor | 338,635 991,851 | 320,364 920,757 | (18,271) a(71,094 | -5.4% 4)a -7.2% | -19.3% -75.2% |
| Not followed, nontoxic Not followed, minor Unable to follow | 338,635 991,851 115,244 | 320,364 920,757 109,844 | (18,271) a(71,094 (5,400) | -5.4% 4)a -7.2% -4.7% | -19.3% -75.2% -5.7% |

Fig. 4. Change in Encounters from 2009 to 2010 with Graphical Breakdown of Exposure Calls.

The figure shows how the decrease of 94,530 in Human Exposure Calls divides among the 10 Medical Outcomes. The More Serious Exposures (Minor, Moderate, Major and Death) all increased and their combined increase was 22,175 calls (23.5% of the 94,530 total decrease). The Less Serious Exposures (the other 6 outcome groups) decreased by 116,705 (-123.5% of the 94,530 total decrease). (See colour version of this figure online).





Fig. 5. Gulf Oil Spill Encounters per Day.

Black line for Gulf Oil Spill Encounters (human and animal exposure and information calls) shows a spline smoothing fit (lambda v 0.0000117, rsquare v 0.710). Map shows number of calls per day. (See colour version of this figure online).



methylenedioxypyrovalerone Ivory Wave, Purple Wave, impaired perception, reduced motor control, disorientation, Clinical Effects tachycardia, hypertension, extreme paranoia, violent vomiting, disorientation episodes DEA Emergency Scheduled 1-Mar-2011 7-Sep-2011 First NPDS Exposure Report 3-Oct-2009 24-Feb-2010 Number of Exposures 8,264 5,624 Number of information calls 1,087 Total Encounters 9,159 8,479

Fig. 6. Emerging Trends: Bath Salts and THC Homologs Exposures.

Black line for Bath Salt Exposures shows a spline smoothing fit (lambda = 0.01, rsquare = 0.829).

Black line for THC Homolog Exposures shows s show least-squares second order regressions: THC Exposures = -26,223 + 13.0*Year -3.83* $(\text{Year-2011})^2$ (requare = 0.708). All 3 terms in this regression were statistically significant (p < 0.05). (See colour version of this figure online).






Fig. 7. Human Exposure Calls By Year 2000-2010 - Top 4 Categories.

Solid lines show least-squares linear regressions for the Human Exposure Calls per year for that category (

). Broken lines show 95% confidence interval on the regression. (See colour version of this figure online).

- fentanyl (transdermal), 11 colchicine, 11 opioid, 7 propoxyphene)
- 128 cardiovascular drugs (24 amlodipine, 17 cardiac glycoside, 13 verapamil, 7 atenolol, 7 beta blocker, 7 diltiazem, 7 diltiazem (extended release), 7 metoprolol)
- 112 antidepressants (29 amitriptyline, 12 doxepin, 9 citalopram, 9 venlafaxine, 8 trazodone, 7 tricyclic antidepressant,
- 6 bupropion, 6 bupropion (extended release), 5 venlafaxine (extended release))
- 106 sedative/hypnotic/antipsychotics (31 quetiapine, 16 alprazolam, 8 clonazepam, 7 diazepam, 6 lorazepam), 86 stimulants/street drugs (28 methamphetamine, 20 heroin, 20 cocaine, 10 methylenedioxymethamphetamine (MDMA))

Table 17A. Substance Categories Most Frequently Involved in Human Exposures (Top 25)

| Substance (Major Conorio Catagory) | All | % ^a | Single substance | %b |
|------------------------------------|------------|----------------|------------------|------|
| Substance (Major Generic Category) | substances | 70 | exposures | 70 |
| Analgesics | 319,622 | 11.48 | 208,222 | 9.70 |
| Cosmetics/Personal Care Products | 215,387 | 7.73 | 208,321 | 9.70 |
| Cleaning Substances (Household) | 202,056 | 7.26 | 180,493 | 8.41 |
| Sedative/Hypnotics/Antipsychotics | 168,030 | 6.03 | 66,897 | 3.12 |
| Foreign Bodies/Toys/Miscellaneous | 116,659 | 4.19 | 113,877 | 5.30 |
| Topical Preparations | 110,033 | 3.95 | 107,874 | 5.02 |
| Antidepressants | 103,041 | 3.70 | 43,675 | 2.03 |
| Cardiovascular Drugs | 98,386 | 3.53 | 48,460 | 2.26 |
| Antihistamines | 95,880 | 3.44 | 69,291 | 3.23 |
| Pesticides | 91,940 | 3.30 | 86,419 | 4.02 |
| Alcohols | 85,205 | 3.06 | 39,404 | 1.84 |
| Cold and Cough Preparations | 77,899 | 2.80 | 57,793 | 2.69 |
| Vitamins | 71,545 | 2.57 | 62,743 | 2.92 |
| Bites and Envenomations | 67,692 | 2.43 | 66,944 | 3.12 |
| Antimicrobials | 66,021 | 2.37 | 55,139 | 2.57 |
| Hormones and Hormone Antagonists | 58,890 | 2.11 | 40,410 | 1.88 |
| Plants | 53,526 | 1.92 | 50,759 | 2.36 |
| Gastrointestinal Preparations | 53,388 | 1.92 | 42,797 | 1.99 |
| Stimulants and Street Drugs | 51,641 | 1.85 | 30,654 | 1.43 |
| Anticonvulsants | 48,005 | 1.72 | 21,064 | 0.98 |
| Hydrocarbons | 42,663 | 1.53 | 40,402 | 1.88 |
| Chemicals | 39,908 | 1.43 | 34,393 | 1.60 |
| Arts/Crafts/Office Supplies | 33,502 | 1.20 | 32,493 | 1.51 |
| Fumes/Gases/Vapors | 32,797 | 1.18 | 30,468 | 1.42 |
| Electrolytes and Minerals | 32,505 | 1.17 | 27,172 | 1.27 |

^aPercentages are based on the total number of substances reported in all exposures (N = 2,784,907).

^bPercentages are based on the total number of single substance exposures (N = 2,147,248).

Table 17B. Substance Categories with the Greatest Rate of Exposure Increase (Top 25)

| | Increase | | |
|---|----------|---------------------|------------------------|
| Substance (Major Generic Category) | Mean | 95% CI ^a | All substances in 2010 |
| Analgesics | 11,240 | [9034, 13446] | 319,622 |
| Sedative/Hypnotics/Antipsychotics | 8,605 | [7682, 9529] | 168,030 |
| Cardiovascular Drugs | 4,897 | [4579, 5216] | 98,386 |
| Antihistamines | 3,700 | [3055, 4346] | 95,880 |
| Alcohols | 2,831 | [2217, 3445] | 85,205 |
| Vitamins | 2,337 | [2005, 2668] | 71,545 |
| Gastrointestinal Preparations | 2,256 | [1706, 2807] | 53,388 |
| Hormones and Hormone Antagonists | 1,948 | [1633, 2264] | 58,890 |
| Anticonvulsants | 1,898 | [1557, 2240] | 48,005 |
| Topical Preparations | 1,849 | [611, 3088] | 110,033 |
| Other/Unknown Nondrug Substances | 1,823 | [1264, 2383] | 32,102 |
| Cosmetics/Personal Care Products | 1,654 | [56, 3252] | 215,387 |
| Cleaning Substances (Household) | 1,560 | [-295, 3415] | 202,056 |
| Antidepressants | 1,475 | [453, 2496] | 103,041 |
| Muscle Relaxants | 1,241 | [1074, 1407] | 28,489 |
| Miscellaneous Drugs | 1,228 | [781, 1676] | 24,558 |
| Anticholinergic Drugs | 1,137 | [852, 1422] | 11,436 |
| Foreign Bodies/Toys/Miscellaneous | 1,093 | [-142, 2329] | 116,659 |
| Antimicrobials | 971 | [533, 1409] | 66,021 |
| Dietary Supplements/Herbals/Homeopathic | 900 | [448, 1351] | 32,052 |
| Unknown Drug | 784 | [662, 905] | 20,471 |
| Deodorizers | 684 | [424, 944] | 25,619 |
| Essential Oils | 646 | [578, 715] | 10,720 |
| Eye/Ear/Nose/Throat Preparations | 599 | [471, 727] | 21,172 |
| Asthma Therapies | 585 | [22, 1149] | 21,123 |

^aIncrease and confidence intervals are based on least squares linear regression of the number of calls per year for 2000–2010.

Table 17C. Substance Categories Most Frequently Involved in Pediatric (≤ 5 years) Exposures (Top 25)^a

| Substance (Major Generic Category) | All substances | % ^b | Single substance exposures | %с |
|---|----------------|----------------|----------------------------|-------|
| Cosmetics/Personal Care Products | 165,719 | 13.18 | 162,208 | 13.83 |
| Analgesics | 117,586 | 9.35 | 106,743 | 9.10 |
| Cleaning Substances (Household) | 116,203 | 9.24 | 111,817 | 9.53 |
| Foreign Bodies/Toys/Miscellaneous | 86,426 | 6.88 | 84,580 | 7.21 |
| Topical Preparations | 85,384 | 6.79 | 84,129 | 7.17 |
| Vitamins | 52,254 | 4.16 | 47,758 | 4.07 |
| Antihistamines | 47,674 | 3.79 | 42,690 | 3.64 |
| Pesticides | 40,418 | 3.22 | 39,333 | 3.35 |
| Cold and Cough Preparations | 38,410 | 3.06 | 34,865 | 2.97 |
| Gastrointestinal Preparations | 35,680 | 2.84 | 32,749 | 2.79 |
| Plants | 35,674 | 2.84 | 34,363 | 2.93 |
| Antimicrobials | 34,769 | 2.77 | 32,729 | 2.79 |
| Cardiovascular Drugs | 26,253 | 2.09 | 17,246 | 1.47 |
| Arts/Crafts/Office Supplies | 24,600 | 1.96 | 23,982 | 2.04 |
| Hormones and Hormone Antagonists | 24,593 | 1.96 | 19,013 | 1.62 |
| Electrolytes and Minerals | 22,891 | 1.82 | 20,854 | 1.78 |
| Dietary Supplements/Herbals/Homeopathic | 22,017 | 1.75 | 20,240 | 1.73 |
| Alcohols | 21,860 | 1.74 | 21,512 | 1.83 |
| Deodorizers | 21,799 | 1.73 | 21,571 | 1.84 |
| Sedative/Hypnotics/Antipsychotics | 15,746 | 1.25 | 12,314 | 1.05 |
| Other/Unknown Nondrug Substances | 14,258 | 1.13 | 13,790 | 1.18 |
| Hydrocarbons | 13,503 | 1.07 | 13,094 | 1.12 |
| Asthma Therapies | 13,436 | 1.07 | 12,279 | 1.05 |
| Antidepressants | 13,433 | 1.07 | 9,829 | 0.84 |
| Information Calls | 11,963 | 0.95 | 11,383 | 0.97 |

aIncludes all children with actual or estimated ages ≤5 years old. Results do not include "Unknown Child" or "Unknown Age".



 $^{^{}b}$ Percentages are based on the total number of substances reported in pediatric exposures (N = 1,257,025).

^cPercentages are based on the total number of single substance pediatric exposures (N = 1,173,168).

Table 17D. Substance Categories Most Frequently Involved in Adult (≥ 20 years) Exposures (Top 25)^a

| Substance (Major Generic Category) | All substances | %b | Single substance exposures | %с |
|---------------------------------------|----------------|-------|----------------------------------|-------|
| Analgesics | 149,532 | 12.96 | 69,333 | 10.01 |
| Sedative/Hypnotics/ Antipsychotics | 128,982 | 11.18 | 42,540 | 6.14 |
| Antidepressants | 71,367 | 6.19 | 24,389 | 3.52 |
| Cleaning Substances (Household) | 69,376 | 6.01 | 54,666 | 7.89 |
| Cardiovascular Drugs | 63,229 | 5.48 | 25,556 | 3.69 |
| Alcohols | 54,128 | 4.69 | 12,829 | 1.85 |
| Bites and Envenomations | 44,580 | 3.86 | 44,133 | 6.37 |
| Pesticides | 42,737 | 3.70 | 38,861 | 5.61 |
| Anticonvulsants | 33,720 | 2.92 | 12,391 | 1.79 |
| Cosmetics/Personal Care Products | 33,009 | 2.86 | 30,516 | 4.41 |
| Antihistamines | 29,962 | 2.60 | 14,557 | 2.10 |
| Hormones and Hormone Antagonists | 29,317 | 2.54 | 17,780 | 2.57 |
| Stimulants and Street Drugs | 25,559 | 2.22 | 12,065 | 1.74 |
| Chemicals | 23,504 | 2.04 | 19,552 | 2.82 |
| Hydrocarbons | 23,001 | 1.99 | 21,512 | 3.11 |
| Fumes/Gases/Vapors | 22,977 | 1.99 | 21,190 | 3.06 |
| Antimicrobials | 22,905 | 1.99 | 16,212 | 2.34 |
| Muscle Relaxants | 22,242 | 1.93 | 7,970 | 1.15 |
| Cold and Cough Preparations | 20,121 | 1.74 | 10,591 | 1.53 |
| Topical Preparations | 18,324 | 1.59 | 17,663 | 2.55 |
| Food Products/Food Poisoning | 17,228 | 1.49 | 16,728 | 2.42 |
| Gastrointestinal Preparations | 13,942 | 1.21 | 7,381 | 1.07 |
| Information Calls | 13,076 | 1.13 | 12,027 | 1.74 |
| Miscellaneous Drugs | 13,057 | 1.13 | 6,821 | 0.98 |
| Other/Unknown Nondrug Substances | 12,644 | 1.10 | 11,070 | 1.60 |

^aIncludes all adults with actual or estimated ages ≥20 years old. Results also include "Unknown Adult" but do not include "Unknown Age".

The exposure was acute in 706 (51.7%), A/C = acute on chronic in 266 (19.5%), C = chronic exposure in 86 (6.3%)and U = unknown in 308 (22.6%).

A total of 1,639 tissue concentrations for 1 or more related analytes were reported in 692 cases. Most of these (1,537) are listed in Table 21, while all tissue concentrations are available to the member centers through the NPDS Enterprise Reports. These 125 analytes included: 231 acetaminophen, 153 ethanol, 76 hydrocodone, 67 oxycodone, 60 alprazolam, 60 methadone, 54 salicylate, 33 diphenhydramine, 28 morphine.

Route of exposure was: Ingestion only in 1057 cases (77.4%), inhalation/nasal only in 89 cases (6.5%), parenteral in 23 cases (1.7%). Most other routes were combination routes or unknown.

Table 17E. Substance Categories Most Frequently Involved in Pediatric (≤5 years) Deaths^a

| | | | Single | |
|---|------------|--------|-----------|--------|
| Substance (Major | All | | substance | |
| Generic Category) | substances | %b | exposures | %с |
| Analgesics | 11 | 15.71 | 7 | 14.89 |
| Antihistamines | 6 | 8.57 | 3 | 6.38 |
| Sedative/Hypnotics/ Antipsychotics | 6 | 8.57 | 3 | 6.38 |
| Fumes/Gases/Vapors | 5 | 7.14 | 5 | 10.64 |
| Chemicals | 4 | 5.71 | 2 | 4.26 |
| Cold and Cough Preparations | 4 | 5.71 | 2 | 4.26 |
| Food Products/Food Poisoning | 4 | 5.71 | 4 | 8.51 |
| Pesticides | 4 | 5.71 | 2 | 4.26 |
| Alcohols | 3 | 4.29 | 1 | 2.13 |
| Cardiovascular Drugs | 3 | 4.29 | 3 | 6.38 |
| Hydrocarbons | 3 | 4.29 | 3 | 6.38 |
| Unknown Drug | 3 | 4.29 | 2 | 4.26 |
| Automotive/Aircraft/ Boat Products | 2 | 2.86 | 1 | 2.13 |
| Batteries | 2 | 2.86 | 2 | 4.26 |
| Bites and Envenomations | 2 2 | 2.86 | 2 2 | 4.26 |
| Other/Unknown Nondrug Substances | 2 | 2.86 | 1 | 2.13 |
| Cleaning Substances (Household) | 1 | 1.43 | 1 | 2.13 |
| Dietary Supplements/ Herbals/ Homeopathic | 1 | 1.43 | 1 | 2.13 |
| Electrolytes and Minerals | 1 | 1.43 | 1 | 2.13 |
| Foreign Bodies/Toys/ Miscellaneous | 1 | 1.43 | 0 | 0.00 |
| Hormones and Hor- mone Antagonists | 1 | 1.43 | 1 | 2.13 |
| Information Calls | 1 | 1.43 | 0 | 0.00 |
| Total | 70 | 100.00 | 47 | 100.00 |

^aIncludes all children with actual or estimated ages ≤5 years old. Results do not include "Unknown Child" or "Unknown Age". Includes death and death, indirect regardless of Relative Contribution to Fatality.

The Intentional exposure reason was: Suspected suicide in 673 cases (49.3%), Abuse in 230 cases (16.8%), and Misuse in 49 cases (3.6%). Unintentional exposure reason was: Environmental in 36 cases (2.6%), Therapeutic error in 29 cases (2.1%), and Misuse in 21 cases 1.5%), and Occupational in 15 (1.1%). Adverse drug reaction was the reason in 27 (2.0%).

Pediatric fatalities – age ≤ 5 years

Although children younger than 6 years were involved in the majority of exposures, they comprised 55 of 1,730 (3.2%) of fatalities. These numbers are similar to those reported since 1985 (Table 19A). The percentage fatalities in children ≤5 years related to total pediatric

^bPercentages are based on the total number of substances reported in adult exposures (N = 1,153,827).

^cPercentages are based on the total number of single substance adult exposures (N = 692,666).

^bPercentages are based on the total number of substances reported in pediatric fatalities (N = 70).

^cPercentages are based on the total number of single substance pediatric fatalities (N = 47).

Table 17F. Substance Categories Most Frequently Identified in **Drug Identification Calls (Top 25)**

| Substance (Major Generic Category) | All substances | %ª |
|---------------------------------------|----------------|-------|
| Analgesics | 506,838 | 35.05 |
| Sedative/Hypnotics/Antipsychotics | 180,009 | 12.45 |
| Information Calls | 139,789 | 9.67 |
| Unknown Drug | 77,584 | 5.37 |
| Muscle Relaxants | 69,595 | 4.81 |
| Antidepressants | 63,202 | 4.37 |
| Cardiovascular Drugs | 57,682 | 3.99 |
| Antihistamines | 50,922 | 3.52 |
| Antimicrobials | 48,779 | 3.37 |
| Stimulants and Street Drugs | 31,795 | 2.20 |
| Anticonvulsants | 28,709 | 1.99 |
| Hormones and Hormone Antagonists | 26,667 | 1.84 |
| Gastrointestinal Preparations | 25,151 | 1.74 |
| Cold and Cough Preparations | 14,326 | 0.99 |
| Diuretics | 14,201 | 0.98 |
| Miscellaneous Drugs | 13,757 | 0.95 |
| Pesticides | 9,939 | 0.69 |
| Foreign Bodies/Toys/ | 7,074 | 0.49 |
| Miscellaneous | | |
| Other/Unknown Nondrug Substances | 6,324 | 0.44 |
| Plants | 5,945 | 0.41 |
| Cleaning Substances (Household) | 5,603 | 0.39 |
| Electrolytes and Minerals | 4,303 | 0.30 |
| Chemicals | 4,191 | 0.29 |
| Vitamins | 4,186 | 0.29 |
| Bites and Envenomations | 4,107 | 0.28 |

^aPercentages are based on the total number of substances reported in all drug identification calls (N = 1,446,038).

exposures was 32/1,207,575 = 0.00265%. By comparison, 1,052/858,982 = 0.122% of all adult exposures involved a fatality. Of these 32 pediatric fatalities, 18 (81.3%) were reported as unintentional and 2 (6.3%) were coded as resulting from malicious intent (Table 8).

The 37 fatalities in children ≤5 years old in Table 21 (includes death, indirect reports, and RCF 1-3) included 16 pharmaceuticals and 21 nonpharmaceuticals. The first ranked substances associated with these fatalities included: carbon monoxide in 3 cases, aluminum phosphide, hydrofluoric acid, lamp oil, smoke, diphenhydramine, flecainide in 2 cases each, and 22 other substances (1 each).

Pediatric fatalities – ages 6–12 years

In the age range 6-12 years, there were 3 reported fatalities, 1 of which was unintentional misuse, 1 was intentional abuse, and 1 unknown reason (Table 8). The 4 fatalities listed in Table 21 (includes death, indirect reports, and RCF 1–3) included: 2 fluorinated hydrocarbons, 1 carbon monoxide, and 1 oxycodone.

Adolescent fatalities - ages 13-19 years

In the age range 13–19 years, there were 56 reported fatalities including 46 intentional and 4 unintentional (Table 8). The 67 fatalities listed in Table 21 (includes death, indirect

Table 17G. Substance Categories Most Frequently Involved in Pregnant Exposures^a (Top 25)

| Substance (Major Generic Category) | All substances | %b | Single substance exposures | % |
|---------------------------------------|----------------|-------|----------------------------------|------|
| Analgesics | 1,121 | 12.42 | 685 | 9.75 |
| Cleaning Substances (Household) | 796 | 8.82 | 593 | 8.44 |
| Pesticides | 629 | 6.97 | 576 | 8.20 |
| Bites and Envenomations | 523 | 5.79 | 521 | 7.41 |
| Fumes/Gases/Vapors | 506 | 5.61 | 471 | 6.70 |
| Sedative/Hypnotics/ | 434 | 4.81 | 198 | 2.82 |
| Antipsychotics | 737 | 7.01 | 170 | 2.02 |
| Vitamins | 372 | 4.12 | 305 | 4.34 |
| Antihistamines | 303 | 3.36 | 186 | 2.65 |
| Foreign Bodies/Toys/ | 278 | 3.08 | 260 | 3.70 |
| Miscellaneous | 276 | 3.00 | 200 | 3.70 |
| Antidepressants | 262 | 2.90 | 131 | 1.86 |
| Information Calls | 249 | 2.76 | 233 | 3.32 |
| Cosmetics/Personal Care | 247 | 2.74 | 227 | 3.23 |
| Products | 247 | 2.74 | 221 | 3.23 |
| Antimicrobials | 219 | 2.43 | 158 | 2.25 |
| Chemicals | 194 | 2.15 | 169 | 2.40 |
| Hydrocarbons | 192 | 2.13 | 178 | 2.53 |
| Cold and Cough | 180 | 1.99 | 107 | 1.52 |
| Preparations | | | | |
| Food Products/Food | 149 | 1.65 | 146 | 2.08 |
| Poisoning | | | | |
| Cardiovascular Drugs | 144 | 1.60 | 97 | 1.38 |
| Hormones and Hormone | 142 | 1.57 | 120 | 1.71 |
| Antagonists | | | | |
| Alcohols | 136 | 1.51 | 57 | 0.81 |
| Electrolytes and Minerals | 136 | 1.51 | 116 | 1.65 |
| Gastrointestinal | 132 | 1.46 | 105 | 1.49 |
| Preparations | | | | |
| Stimulants and Street | 130 | 1.44 | 84 | 1.20 |
| Drugs | | | | |
| Other/Unknown Nondrug | 122 | 1.35 | 104 | 1.48 |
| Substances | | | | |
| Paints and Stripping Agents | 121 | 1.34 | 111 | 1.58 |

^aIncludes all patient classified as pregnant and all female patients with a 'duration of pregnancy' greater than 0.

reports, and RCF 1-3) included 53 pharmaceuticals and 14 nonpharmaceuticals. The first ranked pharmaceuticals associated with these fatalities included: acetaminophen/ hydrocodone, methylenedioxymethamphetamine (MDMA), oxycodone, and salicylate (3 cases each); acetaminophen, acetaminophen/diphenhydramine, clonazepam, colchicine, diphenhydramine, methadone, morphine (2 cases each); and the balance 1 substance each. The first ranked nonpharmaceuticals associated with these fatalities included: ethanol in 3 cases, cyanide, and ethylene glycol (2 cases each); and the balance 1 substance each.

Pregnancy and Fatalities

A total of 25 deaths of pregnant women have been reported from the years 2000 through 2010. The majority (21 of 25)



^bPercentages are based on the total number of substances reported in pregnant exposures (N = 9,027).

^cPercentages are based on the total number of single substance pregnant exposures (N = 7,028).

Table 18. Categories Associated with Largest Number of Fatalities (Top 25)a

| Substance (Minor Generic Category) | All substances | %b | Single substance exposures | %с |
|---------------------------------------|----------------|-------|----------------------------------|------|
| Miscellaneous Sedative/ | 445 | 15.82 | 29 | 3.80 |
| Hypnotics/ | | | | |
| Antipsychotics | | | | |
| Miscellaneous | 265 | 9.42 | 53 | 6.94 |
| Cardiovascular Drugs | | | | |
| Opioids | 265 | 9.42 | 59 | 7.72 |
| Acetaminophen | 240 | 8.53 | 65 | 8.51 |
| Combinations | | | | |
| Miscellaneous | 212 | 7.54 | 16 | 2.09 |
| Antidepressants | | | | |
| Miscellaneous Alcohols | 171 | 6.08 | 38 | 4.97 |
| Acetaminophen Alone | 130 | 4.62 | 60 | 7.85 |
| Miscellaneous | 121 | 4.30 | 11 | 1.44 |
| Anticonvulsants | | | | |
| Miscellaneous Stimulants | 117 | 4.16 | 45 | 5.89 |
| and Street Drugs | | | | |
| Cyclic Antidepressants | 88 | 3.13 | 21 | 2.75 |
| Miscellaneous Muscle | 78 | 2.77 | 6 | 0.79 |
| Relaxants | | | | |
| Miscellaneous | 66 | 2.35 | 12 | 1.57 |
| Antihistamines | | | | |
| Acetylsalicylic Acid Alone | 62 | 2.20 | 21 | 2.75 |
| Nonsteroidal | 58 | 2.06 | 5 | 0.65 |
| Antiinflammatory Drugs | | | | |
| Miscellaneous Fumes/ | 50 | 1.78 | 52 | 6.81 |
| Gases/Vapors | | | | |
| Miscellaneous Unknown | 41 | 1.46 | 57 | 7.46 |
| Drug | | | | |
| Miscellaneous Chemicals | 34 | 1.21 | 29 | 3.80 |
| Oral Hypoglycemic | 28 | 1.00 | 6 | 0.79 |
| Miscellaneous Hormones | 23 | 0.82 | 8 | 1.05 |
| and Hormone Antagonists | | | | |
| Other Miscellaneous Drugs | 18 | 0.64 | 4 | 0.52 |
| Miscellaneous | 17 | 0.60 | 16 | 2.09 |
| Hydrocarbons | | | | |
| Acids | 16 | 0.57 | 11 | 1.44 |
| Miscellaneous | 13 | 0.46 | 3 | 0.39 |
| Anticoagulants | | | | |
| Antacids | 12 | 0.43 | 0 | 0.00 |
| Automotive Products | 12 | 0.43 | 10 | 1.31 |

^aNumbers represent total exposures associated with 1,366 fatalities (with relative contribution to fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory); each fatality may have had exposure to more than one substance.

were intentional exposures (misuse, abuse, or suspected suicide). There was 1 death in a pregnant women reported to NPDS in 2010. A 25 year-old female at 27 weeks gestation presented to the maternity ward with fetal demise. The patient was acidotic and in fulminate hepatic failure following an intentional ingestion of acetaminophen and aspirin. She expired on the afternoon of hospital day 3. The fatality was judged undoubtedly responsible to the acetaminophen and salicylate.

Table 19A. Comparisons of Death Data (1985-2010)^a

| | Total | fatalities | S | uicides | Ped | iatric deaths ^b |
|------|-------|------------|-----|-------------|-----|----------------------------|
| Year | N | % of cases | N | % of deaths | N | % of deaths |
| 1985 | 328 | 0.036 | 174 | (53.0) | 20 | (6.1) |
| 1986 | 406 | 0.037 | 223 | (54.9) | 15 | (3.7) |
| 1987 | 398 | 0.034 | 227 | (57.0) | 22 | (5.5) |
| 1988 | 544 | 0.040 | 296 | (54.4) | 30 | (5.5) |
| 1989 | 590 | 0.037 | 323 | (54.7) | 24 | (4.1) |
| 1990 | 553 | 0.032 | 320 | (57.9) | 21 | (3.8) |
| 1991 | 764 | 0.042 | 408 | (53.4) | 44 | (5.8) |
| 1992 | 705 | 0.038 | 395 | (56.0) | 29 | (4.1) |
| 1993 | 626 | 0.036 | 338 | (54.0) | 27 | (4.3) |
| 1994 | 766 | 0.040 | 410 | (53.5) | 26 | (3.4) |
| 1995 | 724 | 0.036 | 405 | (55.9) | 20 | (2.8) |
| 1996 | 726 | 0.034 | 358 | (49.3) | 29 | (4.0) |
| 1997 | 786 | 0.036 | 418 | (53.2) | 25 | (3.2) |
| 1998 | 775 | 0.035 | 421 | (54.3) | 16 | (2.1) |
| 1999 | 873 | 0.040 | 472 | (54.1) | 24 | (2.7) |
| 2000 | 921 | 0.042 | 477 | (51.8) | 20 | (2.2) |
| 2001 | 1,085 | 0.048 | 553 | (51.0) | 27 | (2.5) |
| 2002 | 1,170 | 0.049 | 635 | (54.3) | 27 | (2.3) |
| 2003 | 1,109 | 0.046 | 592 | (53.4) | 35 | (3.2) |
| 2004 | 1,190 | 0.049 | 642 | (53.9) | 27 | (2.3) |
| 2005 | 1,438 | 0.059 | 674 | (46.9) | 32 | (2.2) |
| 2006 | 1,515 | 0.063 | 705 | (46.5) | 39 | (2.6) |
| 2007 | 1,597 | 0.064 | 737 | (46.1) | 47 | (2.9) |
| 2008 | 1,756 | 0.070 | 797 | (45.4) | 39 | (2.2) |
| 2009 | 1,544 | 0.062 | 779 | (50.5) | 37 | (2.4) |
| 2010 | 1,730 | 0.072 | 779 | (45.0) | 55 | (3.2) |

^aHuman exposures with medical outcome of death or death, indirect regardless of Relative Contribution to Fatality.

AAPCC Surveillance Results

A key component of the NPDS surveillance system is the variety of monitoring tools available to the NPDS user community. In addition to AAPCC national surveillance definitions, 38 regional PCs utilize NPDS as part of their surveillance programs. Five state health departments plus CDC run surveillance definitions in NPDS. Since Surveillance Anomaly 1, generated at 2:00 pm EDT on 17 September 2006, over 177,000 anomalies have been detected. More than 600 were confirmed as being of public health significance with regional PCs working collaboratively with their local and state health departments and in some instances CDC on the public health issues identified.

At the time of this report, 375 surveillance definitions run continuously, monitoring case and clinical effects volume and a variety of case based definitions from food poisoning to nerve agents. These definitions represent the surveillance work by many regional PCs, state health departments, the AAPCC, and the Health Studies Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control, and Prevention (CDC).

In 2010, the NPDS surveillance application module underwent incremental improvements. Information call

bPercentages are based on the total number of substances reported in fatal exposures (N = 2.813).

^cPercentages are based on the total number of single substance fatal exposures (N = 764).

bIncludes all children with actual or estimated ages ≤ 5 years old. Results do not include "Unknown Child" or "Unknown Age". Includes death and death, indirect regardless of Relative Contribution to Fatality.

Table 19B. Comparisons of Direct and Indirect Death Data (2000-2010)^a

| | | All death | ns | Suicides | | | | | | Pediatric deaths | | | | | |
|------|-------|-----------|----------|----------|-------------|--------|-------------|----------|-------|------------------|--------|-------------|----------|--|--|
| Year | Total | Direct | Indirect | Total | % of deaths | Direct | % of direct | Indirect | Total | % of deaths | Direct | % of direct | Indirect | | |
| 2000 | 864 | 845 | 19 | 448 | 51.85 | 443 | 52.43 | 5 | 18 | 2.08 | 18 | 2.13 | 0 | | |
| 2001 | 1066 | 952 | 114 | 542 | 50.84 | 503 | 52.84 | 39 | 26 | 2.44 | 24 | 2.52 | 2 | | |
| 2002 | 850 | 739 | 111 | 455 | 53.53 | 436 | 59.00 | 19 | 24 | 2.82 | 15 | 2.03 | 9 | | |
| 2003 | 867 | 826 | 41 | 464 | 53.52 | 454 | 54.96 | 10 | 29 | 3.34 | 22 | 2.66 | 7 | | |
| 2004 | 955 | 898 | 57 | 516 | 54.03 | 501 | 55.79 | 15 | 25 | 2.62 | 21 | 2.34 | 4 | | |
| 2005 | 1423 | 1332 | 91 | 666 | 46.80 | 656 | 49.25 | 10 | 32 | 2.25 | 26 | 1.95 | 6 | | |
| 2006 | 1515 | 1415 | 100 | 705 | 46.53 | 687 | 48.55 | 18 | 39 | 2.57 | 32 | 2.26 | 7 | | |
| 2007 | 1597 | 1502 | 95 | 737 | 46.15 | 712 | 47.40 | 25 | 47 | 2.94 | 41 | 2.73 | 6 | | |
| 2008 | 1756 | 1535 | 221 | 797 | 45.39 | 750 | 48.86 | 47 | 39 | 2.22 | 32 | 2.08 | 7 | | |
| 2009 | 1544 | 1452 | 92 | 779 | 50.45 | 748 | 51.52 | 31 | 37 | 2.40 | 31 | 2.13 | 6 | | |
| 2010 | 1730 | 1455 | 275 | 779 | 45.03 | 732 | 50.31 | 47 | 55 | 3.18 | 47 | 3.23 | 8 | | |

^aHuman exposures with medical outcome of death or death, indirect regardless of Relative Contribution to Fatality.

surveillance tools were enhanced with the activation of animal exposure call surveillance for volume definitions. Analysis process improvements included the addition of anomaly status tracking and case based time series reports.

Automated surveillance continues to remain controversial as a viable methodology to detect the index case of a public health event. Uniform evaluation algorithms are not available to determine the optimal methodologies. Less controversial is the benefit to situational awareness that NPDS can provide. Typical NPDS surveillance data detects a response to an event rather than event prediction. This aids in situational awareness and resilience during and after a public health event.

2010 Gulf of Mexico Oil Spill

On Tuesday, 20 April 2010, an explosion aboard the Deepwater Horizon drilling rig working on a well one mile below the surface of the Gulf of Mexico created the largest unintentional oil spill in history. The human, animal, and environmental impact spanned thousands of miles across the Gulf Coast and the coastal states of Alabama, Florida, Louisiana, Texas, and Mississippi. US Poison Centers began receiving calls related to the spill. In order to better track these calls to aid state and CDC public health response, the AAPCC Rapid Coding Team in concert with Micromedex Poisindex staff activated a Gulf Oil Spill surveillance code. Product codes were also initiated for the two dispersants used (Corexit EC

Table 20. Frequency of Plant Exposures (Top 25)^a

| | Botanical name or Category | AAPCC Generic Code Name | N |
|----|--|--|-------|
| 1 | Plants-general-unknown | Unknown Toxic Types or Unknown if Toxic | 2,761 |
| 2 | Botanical terms | Unknown Toxic Types or Unknown if Toxic | 2,201 |
| 3 | Unknown Botanical Name | Unknown Toxic Types or Unknown if Toxic | 2,114 |
| 4 | Phytolacca americana (L.) | Gastrointestinal Irritants (Excluding Oxalate Containing Plants) | 1,933 |
| 5 | Spathiphyllum spp. | Oxalates | 1,550 |
| 6 | <i>Ilex</i> spp. (not otherwise specified) | Gastrointestinal Irritants (Excluding Oxalate Containing Plants) | 877 |
| 7 | Philodendron spp. | Oxalates | 852 |
| 8 | Plants-pokeweed | Other Toxic Types | 823 |
| 9 | Euphorbia pulcherrima (Willd.) | Gastrointestinal Irritants (Excluding Oxalate Containing Plants) | 750 |
| 10 | Toxicodendron radicans (L.) | Skin Irritants (Excluding Oxalate Containing Plants) | 690 |
| 11 | Plants-cardiac glycosides | Cardiac Glycosides (Excluding Drugs) | 637 |
| 12 | Cherry (<i>Prunus</i> spp.) | Amygdalin and/or Cyanogenic Glycosides | 556 |
| 13 | Plants-cyanogenic glycosides | Amygdalin and/or Cyanogenic Glycosides | 537 |
| 14 | Zantedeschia aethiopica | Oxalates | 497 |
| 15 | Malus species | Amygdalin and/or Cyanogenic Glycosides | 495 |
| 16 | Berry (not otherwise specified) | Unknown Toxic Types or Unknown if Toxic | 495 |
| 17 | Caladium spp. | Oxalates | 461 |
| 18 | Mold (not otherwise specified) | Unknown Toxic Types or Unknown if Toxic | 451 |
| 19 | Narcissus pseudonarcissus (L.) | Gastrointestinal Irritants (Excluding Oxalate Containing Plants) | 424 |
| 20 | Taraxacum officinale | Non-Toxic | 409 |
| 21 | Epipremnum areum | Oxalates | 409 |
| 22 | Solanum dulcamara | Solanine | 406 |
| 23 | Nandina domestica (Thumb) | Unknown Toxic Types or Unknown if Toxic | 384 |
| 24 | Schlumbergera bridgesii | Non-Toxic | 384 |
| 25 | Plants-oxalates | Oxalates | 375 |

aNumber of substances related to a human exposure with a Major Generic Category of Plant. Unknown Botanical Name represents substances with a Major Generic Category of Plant and a NULL substance code. Total = 53, 526.



9500A and EC 9527A, Nalco Company, Naperville, IL). As the disaster progressed, another product code was implemented for Contaminated Seafood so seafood questions could be tabulated. This code allowed the tracking of these calls in NPDS. US poison centers received 1932 calls (1222 exposure calls and 710 information calls). Figure 5 shows the distribution of calls received as of 1 July 2010 over space and time.

This data demonstrates how the public utilizes PCs in times of crisis. This unique system can be supported and enhanced to serve as a national public health hotline providing information and management beyond traditional poison exposure calls. PCs represent the only 24/7 system that is always open in the US and requires no membership or preregistration where the public can speak to a health care professional at no charge. This data demonstrates how the public utilizes PCs in times of crisis. This unique system can be supported and enhanced to serve as a national public health hotline providing information and management beyond traditional poison exposure calls.

THC Homologs and Bath Salts

In 2009 US poison centers began receiving an increased number of calls about THC homologs and Bath Salts. Several PCs worked with their state governments to ban sales of these products. On 1 March 2011, the US Drug Enforcement Administration used its emergency scheduling authority to place 5 THC homologs into controlled substances Schedule I.9 Likewise on 7 September 2011, the DEA placed 3 synthetic stimulants into Schedule I.¹⁰ This action makes possessing and selling these chemicals or the products that contain them illegal in the US for at least one year while the DEA and the Department of Health and Human Services decide whether these chemicals should be permanently controlled.

Figure 6 shows these emerging trends for each substance along with the time of the DEA action. The continuation of the graphics through October 2011 illustrates the real-time nature of NPDS.

Discussion

The exposure cases and information requests reported by PCs in 2010 do not reflect the full extent of PC efforts which also include poison prevention activities and public and health care professional education programs.

NPDS exposure data may be considered as providing "numerator data", in the absence of a true denominator, that is, we do not know the number of actual exposures that occur in the population. NPDS data covers only those exposures which are reported to PCs.

NPDS regression analyses indicate that all reported analgesic exposures including opioids and sedatives are increasing year after year. This trend is shown in Table 17B and Figure 7. NPDS data mirrors CDC data that demonstrates similar findings. 11 Thus NPDS provides a real-time view of these public health issues without the need for data source extrapolations.

One of the limitations of NPDS data has been the perceived lack of fatality case volume compared to other reporting sources. Although NPDS fatality volumes are less than those reported by CDC for prior years, the immediacy of NPDS data offers a current window not readily available with other US surveillance systems.

Overall, NPDS encounter volume is larger than similar reporting systems for pharmaceutical exposures, adverse events, or food borne cases. Perceived limitations in NPDS volume are due in part to the fact that electronic surveillance systems seldom follow a federated approach with common output streams. This is particularly apparent with the various electronic medical record systems available. It is important to build a federated approach similar to the one modeled by NPDS to allow data sharing, for example, between hospital emergency departments and other medical record systems including medical examiner offices nationwide. Enhancements to NPDS can promote interoperability between NPDS and electronic medical records systems to better trend poisonrelated morbidity and mortality in the US and internationally.

Summary

Unintentional and intentional exposures continue to be a significant cause of morbidity and mortality in the US. The near real-time, always current status of NPDS represents a national public health resource to collect and monitor US exposure cases and information calls.

Changes in encounters in 2010 compared to 2009 shown in Figure 4 include:

- Total encounters (all exposure and information calls) decreased by 7.7%;
- All information calls decreased 12.6%, Drug ID calls decreased 10.9%, and human exposures decreased 3.8%;
- Health care facility (HCF) information calls decreased 13.6% while HCF exposures increased 2.7%;
- Human exposures with less serious outcomes decreased 5.9% while those with more serious outcomes (minor, moderate, major, or death) increased 4.5%;

These data support the continued value of poison center expertise and need for specialized medical toxicology information to manage the more severe exposures, despite a decrease in calls involving less severe exposures.

The continuing mission of NPDS is to provide a nationwide infrastructure for public health surveillance for all types of exposures, public health event identification, resilience response, and situational awareness tracking. NPDS is a model system for the nation and global public health.

References

- 1. National Poison Data System: Annual reports 1983–2009 [Internet]. Alexandria (VA): American Association of Poison Control Centers; http://www.aapcc.org/dnn/NPDSPoisonData/ from: AnnualReports/tabid/125/Default.aspx
- 2. Savel TG, Bronstein A, Duck, M, Rhodes MB, Lee, B, Stinn J, Worthen K. Using Secure Web Services to Visualize Poison Center Data for

- Nationwide Biosurveillance: A Case Study [Internet]. Online Journal of Public Health Informatics. 2010;2:1–9; [cited 2010 Nov 1] http://ojphi. org/htbin/cgiwrap/bin/ojs/index.php/ojphi/article/view/2920/2505
- 3. US Census Bureau. Table 1. Preliminary Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2010 [downloaded 2011 Oct 9] www. census.gov/popest/states/tables/NST-PEST2010-01.xls
- US Census Bureau: International Data Base (IDB) Demographic Indicators for: American Samoa, Federated States of Micronesia, Guam, Virgin Islands, [downloaded 2011 Oct 9]: http://www.census. gov/ipc/www/idb/country.php
- 5. Position statement: ipecac syrup. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35:699–709
- American Academy of Clinical Toxicology European Association of Poisons Centres and Clinical Toxicologists. Position Paper: Ipecac Syrup. J Toxicol Clin Toxicol. 2004;42:133-143
- American Academy of Pediatrics Policy Statement. Poison treatment in the home. Pediatrics. 2003;112:1182-1185.
- 8. Sosin DM, DeThomasis J. Evaluation challenges for syndromic surveillance-making incremental progress. MMWR Morb Mortal Wkly Rep. 2004;53 Suppl:125-129.
- 9. US Drug Enforcement Administration, Chemicals Used in "Spice" and "K2" Type Products Now Under Federal Control and Regulation. News Release, 1-Mar-2011, [downloaded 2011 Oct 9] http://www. justice.gov/dea/pubs/pressrel/pr030111p.html
- 10. US Drug Enforcement Administration, DEA Moves to Emergency Control Synthetic Stimulants - Agency Will Study Whether To Permanently Control Three Substances. News Release, 7-Sep-2011, [downloaded 2011 Oct 9] http://www.justice.gov/dea/pubs/pressrel/pr090711.html
- 11. Centers for Disease Control and Prevention. QuickStats: Number of Poisoning Deaths* Involving Opioid Analgesics and Other Drugs or

- Substances United States, 1999-2007. MMWR Morb Mortal Wkly Rep. 2010;59:1026
- 12. McGraw-Hill's AccessMedicine, Laboratory Values of Clinical Importance (Appendix), Harrison's Principles of Internal Medicine 17e. McGraw-Hill Professional, 2008[cited 2010 Nov 1]. Available from: http://www.accessmedicine.com/.
- 13. Goldfrank's Toxicologic Emergencies, Ninth Edition. New York, NY, McGraw-Hill Companies, 2010.
- 14. Dart RC, editor. Medical Toxicology, Third Edition. Philadelphia, Lippincott, Williams & Wilkins, 2004.

Disclaimer

The American Association of Poison Control Centers (AAPCC; http://www.aapcc.org) maintains the national database of information logged by the country's regional Poison Centers (PCs) serving all 50 United States, Puerto Rico, and the District of Columbia. Case records in this database are from self-reported calls: they reflect only information provided when the public or healthcare professionals report an actual or potential exposure to a substance (e.g., an ingestion, inhalation, or topical exposure, etc.), or request information/educational materials. Exposures do not necessarily represent a poisoning or overdose. The AAPCC is not able to completely verify the accuracy of every report made to member centers. Additional exposures may go unreported to PCs and data referenced from the AAPCC should not be construed to represent the complete incidence of national exposures to any substance(s).

Appendix Materials are available online

Table 21 Table 22 A and B **Appendices**



Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|------------------------|-------------|-------------------------------------|-------------------|---------------|------------|--------------|----------|-----|--|---|
| Non-Pharma | aceutical E | xposures | | | | | | | | |
| Alcohols 1pa | 4 y M | | | | U | Unk | Oth-M | 3 | | |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.015 g/dL In Blood (unspecified) @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 0.016 mcg/mL In Blood (unspecified) @ Autopsy |
| | | isopropanol | 3 | 3 | | | | | isopropanol | 3.5 mg/dL In Blood (unspecified) @ |
| | | isopropanol | 3 | 3 | | | | | acetone | Autopsy 4.2 mg/dL In Blood (unspecified) @ |
| | | chlorpheniramine | 4 | 4 | | | | | chlorpheniramine | Autopsy 0.11 mcg/mL In Blood (unspecified |
| | | diphenhydramine | 5 | 5 | | | | | diphenhydramine | @ Autopsy0.66 mcg/mL In Blood (unspecified |
| | | dextromethorphan | 6 | 6 | | | | | dextromethorphan | @ Autopsy 0.012 mcg/mL In Blood |
| 2p | 16 y M | • | | | A | Ingst+ Unk | Int-A | 1 | , and the second | (unspecified) @ Autopsy |
| -p | 10 y 141 | ethanol* | 3 | 1 | 71 | mgst onk | 1111-71 | 1 | | |
| | | fentanyl | 1 | 1 | | | | | | |
| | | (transdermal)* dextromethorphan* | 2 | 2 | | | | | | |
| | | marijuana* | 4 | 2 | | | | | | |
| 3pi | 16 y F | | | | U | Ingst+ Inhal | Unk | 2 | | |
| | | ethanol marijuana | 1 2 | 1 2 | | | | | | |
| | | cyclobenzaprine | 3 | 3 | | | | | | |
| 4i | 17 y M | | | | A | Ingst | Int-A | 2 | | |
| 5nh | 21 y M | ethanol | 1 | 1 | A/C | Inget | Int-U | 2 | | |
| 5ph | 21 y IVI | ethanol* | 3 | 1 | A/C | Ingst | IIII-U | 2 | | |
| | | morphine* | 1 | 1 | | | | | | |
| | | benzodiazepine* | 2 | 2 | | | | | | |
| | | clonazepam* | 4 | 2 | | | | | | |
| <i>c</i> | 21 E | marijuana | 5 | 5 | C | Toront | Int C | 1 | | |
| 6 | 21 y F | methanol | 1 | 1 | С | Ingst | Int-S | 1 | | |
| | | ibuprofen | 2 | 2 | | | | | | |
| 7pa | 22 y M | | | | C | Ingst | Int-A | 1 | | |
| | | ethanol | 1 | 1 | | | | | | |
| | | alprazolam | 2 | 2 | | | | | | |
| | | acetaminophen/hy- drocodone | 3 | 3 | | | | | | |
| | | drug, unknown | 4 | 4 | | | | | | |
| 8pa | 22 y M | | | | A | Ingst+ Unk | Int-S | 1 | | |
| | | drug, unknown* | 4 | 1 | | | | | | |
| | | ethanol* | 1 | 1 | | | | | ethanol | 0.1 g/dL In Blood (unspecified) @ Unknown |
| | | ethanol* | 1 | 1 | | | | | ethanol | 118 mg/dL In Blood (unspecified) @ Unknown |
| | | oxycodone | 2 | 2 | | | | | oxymorphone (total) | 0.1 mg/L In Blood (unspecified) @ Unknown |
| | | oxycodone | 2 | 2 | | | | | oxycodone (free) | 0.12 mg/L |
| | | | | | | | | | | In Blood (unspecified) @ Unknown |
| 9pai | 23 y M | benzodiazepine | 3 | 3 | U | Ingst | Int-A | 2 | | |
|)pui | 23 y 1VI | ethanol | 1 | 1 | O | nigst | 111t-7 t | 2 | ethanol | 0.22% |
| | | | | | | | | | | (wt/Vol) In Whole Blood @ |
| | | -4h1 | 1 | 1 | | | | | -4h 1 | Autopsy |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.3% (wt/Vol) In Vitreous @ Autopsy |
| 10a | 31 y F | meperidine | 2 | 2 | A | Ingst | Int-S | 2 | | |
| | 2. , 1 | ethanol | 2 | 1 | 2.1 | | 0 | - | ethanol | 0.044 g/dL In Blood (unspecified) @ Unknown |
| | | ethanol | 2 | 1 | | | | | ethanol | 58 mg/dL In Blood (unspecified) @ |
| | | butalbital* | 3 | 3 | | | | | butalbital | Unknown 0.104 mg/L In Blood (unspecified) |
| | | nondrug, unknown* temazepam | 4 | 3 4 | | | | | temazepam | @ Unknown 2.247 mg/L In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|----------------------------------|-------------------|---------------|------------|------------|--------|-----|-------------|---|
| 11 | 32 y F | | | | С | Ingst | Int-M | 3 | | |
| | | ethanol | 2 1 | 1 2 | | | | | | |
| 12 | 32 y F | acetaminophen | 1 | 2 | U | Ingst | Unk | 2 | | |
| | | methanol | 1 | 1 | | | | | methanol | 13 mg/dL In Blood (unspecified) @ 18 d (pe) |
| 13pa | 34 y M | ath an al | 1 | 1 | A/C | Ingst | Int-S | 1 | -4h1 | 0.15% (author) In Dinad (annual) |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.15% (wt/wt) In Blood (unspeci- fied) @ Unknown |
| | | quetiapine | 3 | 2 | | | | | quetiapine | 0.65 mg/L In Blood (unspecified) @ Unknown |
| | | lithium | 4 | 3 | | | | | lithium | 1.5 mmol/L In Blood (unspecified) @ Unknown |
| | | citalopram | 2 | 4 | | | | | citalopram | 0.54 mg/L In Blood (unspecified) @ Unknown |
| 14a | 39 y M | | 1 | 1 | A | Ingst | Int-S | 1 | | O MARIO WI |
| 15p | 39 y M | methanol | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | • | ethanol | 1 | 1 | | C | | | | |
| | | zolpidem trazodone | 2 3 | 2 3 | | | | | | |
| 16pai | 39 y M | trazodone | 3 | 3 | U | Ingst | Int-S | 2 | | |
| • | | ethanol | 1 | 1 | | | | | ethanol | 0.55% (wt/Vol) In Vitreous @ |
| | | ethanol | 1 | 1 | | | | | ethanol | Autopsy 0.72% (wt/Vol) In Whole Blood @ Autopsy |
| | | diphenhydramine | 2 | 2 | | | | | | |
| | | chlorpheniramine cyclobenzaprine | 3 4 | 3 4 | | | | | | |
| 17 | 40 y F | сустовендартне | + | 4 | U | Ingst+ Unk | Int-A | 2 | | |
| | , | isopropanol | 1 | 1 | | 8 | | | | |
| | | mouthwash | 2 | 2 | | | | | | |
| | | (ethanol) heroin | 3 | 3 | | | | | | |
| 18 | 40 y M | | | | A | Ingst | Int-S | 2 | | |
| | | ethanol benzodiazepine | 1 2 | 1 2 | | | | | | |
| 19pai | 40 y M | benzodiazepine | 2 | 2 | A | Ingst | Int-A | 3 | | |
| | | isopropanol | 1 | 1 | | | | | acetone | 100% (wt/Vol) In Whole Blood @ |
| | | isopropanol | 1 | 1 | | | | | acetone | Autopsy 105% (wt/Vol) In Vitreous @ |
| | | isopropanol | 1 | 1 | | | | | isopropanol | Autopsy 191% (wt/Vol) In Whole Blood @ |
| | | isopropanol | 1 | 1 | | | | | isopropanol | Autopsy 199% (wt/Vol) In Vitreous @ |
| | | ethanol | 2 | 2 | | | | | | Autopsy |
| 20 | 41 y M | ethanol | 1 | 1 | A | Ingst | Int-S | 2 | ethanol | 436 mg/dL In Blood (unspecified) |
| | | ethanoi | 1 | 1 | | | | | ethanoi | @ Unknown |
| 21a | 42 y F | | 1 | 1 | A | Ingst | Oth-M | 1 | | 154 / W. L. C @ U.l |
| 22a | 44 y M | methanol | 1 | 1 | A | Ingst | Unk | 1 | methanol | 154 mg/dL In Serum @ Unknown |
| | • | methanol | 1 | 1 | | | | | methanol | 79 mg/dL In Serum @ Unknown |
| 23p | 44 y F | methanol | 1 | 1 | A | Ingst | Unk | 2 | | |
| | | ethanol | 2 | 2 | | | | | | |
| 24pai | 44 y M | | | | A/C | Ingst | Int-A | 3 | | 0.24% |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.34% (wt/Vol) In Whole |
| | | ethanol | 1 | 1 | | | | | ethanol | Blood @ Autopsy 0.4% (wt/Vol) In Vitreous @ |
| 25 | 45 y F | | | | A | Ingst | Int-U | 3 | | Autopsy |
| | 15 y 1 | ethanol | 1 | 1 | 2.1 | 111501 | IIIO | 5 | | |
| 26 | 45 y F | mother =1 | 1 | 1 | A | Ingst | Unt-G | 1 | | |
| 27h | 45 y M | methanol | 1 | 1 | U | Ingst | Int-U | 3 | | |
| | • | ethanol | 1 | 1 | | | | | | |
| 28 | 46 y M | methanol | 1 | 1 | A | Ingst | Int-A | 1 | methanol | 378 mg/dL In Blood (unspecified) @ 1 d (pe) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------------|-------------------|---------------|------------|--------------|---------|-----|-----------------|--|
| 29pa | 46 y F | | | | A | Ingst | Int-S | 2 | | |
| | | ethanol | 2 | 1 | | | | | ethanol | 76 mg/dL In Blood (unspecified) @ Unknown |
| | | ethanol | 2 | 1 | | | | | ethanol | 85 mg/dL In Blood (unspecified) @ Unknown |
| | | diazepam acetaminophen | 3 | 2 3 | | | | | acetaminophen | 20 mcg/mL In Blood (unspecified) |
| | | diphenhydramine | 4 | 4 | | | | | diphenhydramine | @ Unknown 1200 ng/mL In Blood (unspecified) |
| | | fluoxetine | 5 | 5 | | | | | fluoxetine | @ Autopsy 61 ng/mL In Blood (unspecified) @ |
| 30a | 47 y M | | | | A | Inget | Int-S | 1 | | Autopsy |
| 30a | 47 y IVI | antifreeze (ethylene glycol)* | 1 | 1 | А | Ingst | III-5 | 1 | ethylene glycol | 130 mg/dL In Other @ Unknown |
| | | methanol* | 2 | 1 | | | | | | |
| 31a | 48 y M | | 1 | 1 | A | Ingst | Unk | 1 | | 12/dI In Comme @ Halanana |
| 32a | 48 y F | methanol | 1 | 1 | U | Ingst | Unk | 1 | methanol | 13 mg/dL In Serum @ Unknown |
| 33pai | 48 y F | methanol | 1 | 1 | A | Ingst | Int-A | 2 | methanol | 102 mg/dL In Serum @ 4 h (pe) |
| Зэраг | 40 y 1 | ethanol | 1 | 1 | A | nigst | III-A | 2 | ethanol | 0.38% (wt/Vol) In Vitreous @ |
| | | ethanol | 1 | 1 | | | | | ethanol | Autopsy 0.38% (wt/Vol) In Whole Blood @ |
| 34 | 49 y M | | | | A/C | Ingst | Int-A | 3 | | Autopsy |
| 54 | 42 y 1v1 | ethanol | 1 | 1 | 700 | mgst | 1111-71 | 3 | | |
| 35 | 49 y M | isopropanol | 2 | 2 | U | Ingst | Int-U | 2 | | |
| | • | methanol | 1 | 1 | | | | | | |
| 36a | 50 y M | methanol | 1 | 1 | U | Ingst | Int-S | 1 | methanol | 163 mg/dL In Blood (unspecified) |
| | | | | | | | | | | @ Unknown |
| | | methanol | 1 | 1 | | | | | methanol | 26 mg/dL In Blood (unspecified) @ Unknown |
| 37 | 50 y M | ethanol | 1 | 1 | A | Ingst | Int-S | 3 | | |
| 38 | 50 y M | | | | C | Ingst+ Inhal | Int-A | 1 | | 77 (YY Y D) 1 () () () () |
| | | methanol | 1 | 1 | | | | | methanol | 75 mg/dL In Blood (unspecified) @ 1 d (pe) |
| | | acetaminophen/ hydrocodone | 2 | 3 | | | | | acetaminophen | 68 mcg/mL In Blood (unspecified) @ Unknown |
| 39pai | 50 y F | • | | | U | Ingst | Int-A | 3 | | |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.32% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.37% (wt/Vol) In Vitreous @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 106 ng/mL In Whole Blood @ |
| 40i | 51 y M | | | | A/C | Ingst | Int-S | 2 | | Autopsy |
| 411 | | ethanol | 1 | 1 | | | | 2 | ethanol | 320 mg/dL In Serum @ 1 h (pe) |
| 41h | 51 y F | ethanol | 1 | 1 | A/C | Ingst | Int-S | 2 | ethanol | 259 mg/dL In Blood (unspecified) |
| | | bupropion | 2 | 2 | | | | | | @ Unknown |
| | | (extended release) propranolol | 3 | 3 | | | | | | |
| | | cyclobenzaprine | 4 | 4 | | | | | | |
| | | lorazepam | 5 | 5 | | | | | | |
| | | hydrochlorothiazide | 6 | 6 | | | | | | |
| | | paroxetine | 7 | 7 | | | | | | |
| | | ondansetron simvastatin | 8 9 | 8 9 | | | | | | |
| 42 | 51 y M | ethanol | 1 | 1 | A | Ingst | Int-A | 2 | ethanol | 200 mg/dL In Blood (unspecified) |
| | | alcohol, unknown | 2 | 2 | | | | | | @ Unknown |
| 43 | 51 y M | | | | A | Ingst | Int-U | 3 | a | 100 /# 7 75 1/ |
| | | ethanol | 1 | 1 | | | | | ethanol | 190 mg/dL In Blood (unspecified) @ 1 h (pe) |
| 44 | 52 y F | methanol | 1 | 1 | U | Ingst | Unk | 1 | | - · · |
| 45 | 52 y F | | | | A/C | Ingst | Int-A | 3 | | |
| | | isopropanol | 1 | 1 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|---------------------------|-------------------|---------------|------------|---------|---------|-----|-----------------|--|
| 46pa | 52 y M | | | _ | A | Ingst | Int-S | 1 | | |
| | | ethanol* | 1 | 1 | | | | | | |
| | | oxycodone (extended | 2 | 1 | | | | | oxycodone | 502 ng/mL In Whole Blood @ |
| 47pa | 57 y M | release)* | | | U | Inhal | Int-A | 1 | | Autopsy |
| +1 pa | 37 y 1VI | butanol* | 1 | 1 | O | IIIIIai | 1111-71 | 1 | | |
| | | heavy metal fumes* | 2 | 1 | | | | | | |
| 48a | 58 y F | • | | | C | Ingst | Int-A | 3 | | |
| | | ethanol | 1 | 1 | | | | | | |
| | | phenobarbital | 2 | 2 | | | | | phenobarbital | 8.6 mg/L In Blood (unspecified) @ |
| | | cyclobenzaprine | 3 | 3 | | | | | cyclobenzaprine | Unknown 0.03 mg/L In Blood (unspecified) @ Unknown |
| 49 | 59 y F | | | | A/C | Ingst | Oth-W | 2 | | Clikilowii |
| ., | 07) 1 | ethanol | 1 | 1 | 120 | Ings. | 0111 | _ | | |
| 50a | 60 y M | | | | A/C | Ingst | Int-U | 3 | | |
| | | ethanol | 1 | 1 | | | | | ethanol | 114 mg/dL In Serum @ Unknown |
| | | ethanol | 1 | 1 | | | | | ethanol | 30 mg/dL In Blood (unspecified) @ |
| | | isopropanol | 2 | 2 | | | | | acetone | Autopsy 14 mg/dL In Blood (unspecified) @ |
| | | isopropanol | 2 | 2 | | | | | isopropanol | Autopsy 8 mg/dL In Blood (unspecified) @ |
| 51p | 62 y F | | | | A | Ingst | Unk | 3 | | Autopsy |
| ЭТР | 02 9 1 | ethanol | 1 | 1 | 7.1 | mgst | Ome | 5 | ethanol | 38 mg/dL In Serum @ 0 h (pe) |
| | | acetaminophen | 2 | 2 | | | | | | 4 / |
| 52 | 62 y M | • | | | A/C | Ingst | Int-A | 2 | | |
| | | ethanol | 1 | 1 | | _ | | | ethanol | 100 mg/dL In Serum @ Unknown |
| 53pai | 62 y F | -4h1 | 1 | 1 | U | Ingst | Int-A | 1 | | 0.220/ (mt/Mal) In Whale Black @ |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.33% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.41% (wt/Vol) In Vitreous @ Autopsy |
| 54pa | 64 y M | | | | C | Ingst | Unk | 1 | | |
| • | | ethanol | 1 | 1 | | | | | ethanol | 0.14% (wt/Vol) In Blood (unspeci- |
| | | | | 2 | | | | | | fied) @ Autopsy |
| | | acetaminophen/ codeine | 2 | 2 | | | | | codeine | 1.6 mg/L In Blood (unspecified) @ |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | Autopsy 57 mg/L In Blood (unspecified) @ |
| | | codeine | - | - | | | | | uccummopnen | Autopsy |
| 55pai | 65 y F | | | | U | Ingst | Int-A | 3 | | |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.39% (wt/Vol) In Whole Blood @ |
| | | 4 1 | | | | | | | a 1 | Autopsy |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.45% (wt/Vol) In Vitreous @ Autopsy |
| | | paroxetine | 2 | 2 | | | | | | Autopsy |
| 56pai | 72 y F | r | | | U | Ingst | Int-A | 2 | | |
| _ | | ethanol | 1 | 1 | | | | | ethanol | 0.35% (wt/Vol) In Whole Blood @ |
| | | | | | | | | | | Autopsy |
| | | ethanol | 1 | 1 | | | | | ethanol | 0.39% (wt/Vol) In Vitreous @ |
| 57 | 78 y F | | | | U | Ingst | Int-A | 2 | | Autopsy |
| | , o y 1 | ethanol | 1 | 1 | O | 111500 | 1110-71 | _ | | |
| 58 | 7 m M | | | | A | Oth | Unt-T | 1 | | |
| | | isopropanol | 1 | 1 | | | | | | |

See also case 88, 100, 155, 174, 187, 188, 194, 217, 246, 261, 290, 296, 301, 306, 313, 321, 323, 325, 331, 351, 359, 366, 369, 370, 373, 375, 390, 391, 397, 410, 423, 435, 448, 454, 461, 467, 480, 486, 492, 512, 518, 528, 535, 549, 553, 556, 558, 564, 568, 570, 572, 575, 578, 582, 588, 589, 592, 596, 599, 601, 616, 617, 619, 625, 629, 630, 631, 640, 655, 656, 673, 680, 681, 692, 706, 707, 719, 731, 761, 771, 805, 807, 813, 815, 816, 832, 833, 837, 839, 854, 857, 869, 890, 893, 898, 909, 911, 913, 918, 931, 936, 951, 952, 960, 977, 988, 989, 992, 998, 1001, 1004, 1005, 1006, 1007, 1019, 1020, 1027, 1030, 1057, 1101, 1109, 1114, 1141, 1156, 1170, 1177, 1178, 1181, 1187, 1189, 1197, 1203, 1209, 1214, 1216, 1218, 1221, 1224, 1228, 1229, 1237, 1272, 1276, 1288, 1300, 1309, 1310, 1311, 1313, 1338, 1340, 1345, 1346, 1347, 1350

| Automoti 59 | ive/Aircraft/B 16 y M | oat Products | | | A | Ingst | Int-S | 1 | | |
|----------------|--------------------------|-----------------------------------|---|---|---|-------|-------|---|-----------------|--|
| | · | antifreeze (ethylene glycol) | 1 | 1 | | Ü | | | | |
| 60 | 18 y M | | | | A | Ingst | Int-S | 2 | | |
| | · | antifreeze (ethylene glycol) | 1 | 1 | | | | | | |
| | | amino acids/ caffeine/vitamins | 2 | 2 | | | | | | |
| 61a | 31 y M | | | | U | Ingst | Int-S | 1 | | |
| | • | antifreeze (ethylene glycol) | 1 | 1 | | - | | | ethylene glycol | 203 mg/dL In Blood (unspecified) @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|--------------------------|---------------------|---|-------------------|---------------|------------|-------------|--------|-----|-----------------|--|
| 52a | 36 y F | methanol | 1 | 1 | A | Ingst | Oth-M | 1 | methanol | 140 mg/dL In Blood (unspecified @ Unknown |
| 53 | 43 y M | antifreeze (ethylene glycol) | 1 | 1 | A | Ingst | Int-S | 1 | ethylene glycol | 57 mg/dL In Blood (unspecified) @ 1-h (pe) |
| 54a | 44 y F | methanol | 1 | 1 | A | Ingst | Int-A | 1 | methanol | 510 mg/dL In Blood (unspecified |
| 55 | 45 y M | methanol | 1 | 1 | U | Ingst | Int-U | 1 | methanol | @ Autopsy180 mg/dL In Blood (unspecified@ 6 h (pe) |
| 66a | 49 y M | antifreeze (ethylene | 1 | 1 | A | Ingst | Int-S | 1 | ethylene glycol | 1282 mg/dL In Serum @ 30 m (pe |
| | | glycol) antifreeze (ethylene glycol) | 1 | 1 | | | | | ethylene glycol | 554 mg/dL In Serum @ 18 h (pe) |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | ethylene glycol | 770 mg/dL In Serum @ 12 h (pe) |
| 57 | 55 y M | antifreeze (ethylene glycol) | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 58a See also case | 13 m M | antifreeze (ethylene glycol) | 1 | 1 | U | Ingst | Unt-G | 1 | | |
| Batteries | 77, 129, 1 | 79, 1213 | | | | | | | | |
| 59 | 2 y F | disc battery, lithium | 1 | 1 | A | Ingst | Unt-G | 1 | | |
| '0a | 47 y F | battery morphine (extended release) | 1 2 | 1 2 | A | Ingst | Int-S | 2 | | |
| 71ai | 13 m M | hydromorphone drug, unknown | 3 4 | 3 4 | A | Ingst | Unt-G | 1 | | |
| | | disc battery | 1 | 1 | | | | | | |
| Bites and En 72 | venomatio 82 y M | ns | | | A | B-S | Unt-B | 3 | | |
| 73 | 84 y M | hymenoptera sting | 1 | 1 | A | B-S | Unt-B | 3 | | |
| 74a | 23 m F | hymenoptera sting | 1 | 1 | A | B-S | Unt-B | 1 | | |
| 75 | 5 d F | envenomation, crotalid | 1 | 1 | A | B-S | Unt-B | 1 | | |
| See also case | | bite (canine) | 1 | 1 | | | | | | |
| C hemicals 76p | 3 y M | | | | A | Ingst | Unt-G | 1 | | |
| 77a | 4 y F | hydrofluoric acid | 1 | 1 | A | Ingst | Unt-G | 1 | | |
| / / a | 4 y 1 | hydrofluoric acid automotive-aircraft- boat product | 1 3 | 1 3 | A | nigst | Ont-G | 1 | | |
| 78p | 17 y M | hydrocarbons | 1 | 1 | A | Inhal+ Derm | Unt-O | 1 | | |
| 79 | 19 y F | cyanide carbon monoxide | 2 1 | 1 2 | A | Inhal | Unt-E | 1 | | |
| 30p | 19 y M | smoke cyanide | 3 | 3 | A | Ingst | Int-S | 1 | cyanide | 11300 ng/mL In Whole Blood |
| 31pa | 22 y M | chemical, | 1 | 1 | A | Inhal | Int-A | 2 | • | @ 5 h (pe) |
| 32 | 24 y M | unknown antifreeze (ethylene | | 1 | A | Ingst | Int-U | 1 | | |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|---------------------------------|-------------------|---------------|------------|-------|--------|-----|------------------|--|
| 83p | 24 y M | | | | A | Inhal | Int-S | 2 | | |
| | , | sulfur | 1 | 1 | | | | | | |
| | | toilet bowl cleaner (acid) | 2 | 2 | | | | | | |
| 84pa | 33 y F | (acid) | | | A | Ingst | Int-M | 1 | | |
| • | | cyanide | 1 | 1 | | | | | cyanide | 15 mg/L In Blood (unspecified) @ |
| | | venlafaxine | 2 | 2 | | | | | | Unknown |
| | | lorazepam | 3 | 3 | | | | | | |
| 85 | 35 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | | |
| 86pai | 35 y M | gijeoi) | | | U | Ingst | Int-S | 1 | | |
| | | antifreeze (ethylene | 1 | 1 | | | | | ethylene glycol | 6100 mcg/mL In Whole Blood @ |
| 87i | 42 y M | glycol) | | | A | Ingst | Int-S | 2 | | Autopsy |
| 071 | 12) 111 | hydrochloric acid | 1 | 1 | 71 | mgst | III 5 | - | | |
| 88 | 42 y M | | | | A | Ingst | Int-S | 2 | | |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 54 mg/dL In Blood (unspecified) @ |
| | | | | | | | | | | Unknown |
| 89p | 47 y F | antifreeze (ethylene | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | glycol) | 1 | 1 | | | | | | |
| 90 | 49 y M | | | | A | Ingst | Int-S | 2 | | |
| 01 | 50 v M | hydrochloric acid | 1 | 1 | ٨ | Inact | Int C | 1 | | |
| 91 | 50 y M | antifreeze (ethylene | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | glycol) | | | | | | | | |
| 92pa | 50 y F | | 1 | 1 | A | Unk | Unk | 2 | | |
| 93a | 51 y F | cyanide | 1 | 1 | U | Ingst | Int-S | 1 | | |
| | , - | antifreeze (ethylene | 4 | 1 | | | | | ethylene glycol | 1073 mg/L In Serum @ Unknown |
| | | glycol) | 4 | | | | | | .d. 111 | 200 |
| | | antifreeze (ethylene glycol) | 4 | 1 | | | | | ethylene glycol | 200 mg/L In Serum @ Autopsy |
| | | zolpidem | 1 | 2 | | | | | zolpidem | 0.11 mg/L In Serum @ Unknown |
| | | acetaminophen/ | 3 | 3 | | | | | hydrocodone | 0.01 mg/L In Serum @ Unknown |
| | | hydrocodone* clonazepam* | 2 | 3 | | | | | | |
| | | tramadol | 5 | 5 | | | | | tramadol | 3.9 mg/L In Serum @ Unknown |
| 0.4 | F | propoxyphene | 6 | 6 | | | | | propoxyphene | 0.11 mg/L In Serum @ Unknown |
| 94 | 51 y F | antifreeze (ethylene | 1 | 1 | A | Ingst | Int-U | 1 | ethylene glycol | 125 mg/dL In Serum @ 1 h (pe) |
| | | glycol) | 1 | 1 | | | | | emylene grycor | 125 mg/d2 m Serum @ 1 m (pc) |
| | | antifreeze (ethylene | 1 | 1 | | | | | ethylene glycol | 34 mg/dL In Serum @ 2 d (pe) |
| | | glycol) antifreeze (ethylene | 1 | 1 | | | | | ethylene glycol | 75 mg/dL In Serum @ 1 d (pe) |
| | | glycol) | 1 | 1 | | | | | cury tene grycor | 75 mg/d2 m Serdin e 1 d (pe) |
| 95 | 53 y M | | | | A | Ingst | Int-U | 2 | | |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | | |
| 96 | 55 y F | (empleme gipeon) | | | A | Ingst | Int-S | 1 | | |
| | | hydrochloric acid | 1 | 1 | | | | | | |
| 97a | 57 y M | antifreeze (ethylene | 1 | 1 | A | Unk | Int-S | 1 | | |
| | | glycol) | 1 | 1 | | | | | | |
| 98pa | 59 y M | | | | A | Ingst | Int-S | 1 | | |
| | | cyanide | 1 | 1 | | | | | citralopram | 0.061 mg/L In Blood (unspecified) @ Unknown |
| | | cyanide | 1 | 1 | | | | | cyanide | 13.3 mg/L In Blood (unspecified) @ |
| | | | | | | | | | | Autopsy |
| | | cyanide | 1 | 1 | | | | | cyanide | 4.7 mg/L In Blood (unspecified) @ 30 m (pe) |
| 99 | 59 y M | | | | A | Ingst | Int-S | 1 | | 50 m (pc) |
| | | hydrochloric acid | 1 | 1 | | | | | | |
| 100a | 60 y F | hydrochloria said | 1 | 1 | A | Ingst | Int-S | 1 | hydromorphone | 14.1 ng/ml. In Pland (unenceif-4) |
| | | hydrochloric acid | 1 | 1 | | | | | hydromorphone | 14.1 ng/mL In Blood (unspecified) @ Autopsy |
| | | hydrochloric acid | 1 | 1 | | | | | diazepam | 211 ng/mL In Blood (unspecified) |
| | | hudroohlorio: 4 | 1 | 1 | | | | | lorozenom | @ Autopsy |
| | | hydrochloric acid | 1 | 1 | | | | | lorazepam | 267 ng/mL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------------|------------------------------------|-------------------|---------------|------------|----------------|--------|-----|-----------------|---|
| | | hydrochloric acid | 1 | 1 | | | | | morphine | 78.7 ng/mL In Blood (unspecified) |
| | | hydrochloric acid | 1 | 1 | | | | | nordiazepam | @ Autopsy 847 ng/mL In Blood (unspecified) |
| | | ethanol | 2 | 2 | | | | | ethanol | @ Autopsy 0.03% In Urine (quantitative only) |
| | | ethanol | 2 | 2 | | | | | ethanol | @ Autopsy 24 mg/dL In Blood (unspecified) @ Unknown |
| 101 | 61 y M | | | | A | Ingst | Int-S | 2 | | Chkhown |
| 102 | 61 y M | hydrochloric acid | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | | |
| 103 | 62 y M | hydrochloric acid | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 104a | 63 y M | • | | | A | Ingst+ Unk | Int-S | 1 | 4 1 1 1 | 474 (IV. I. DI |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | ethylene glycol | 474 mg/dL In Plasma @ 0 h (pe) |
| 105p | 63 y M | hydrochloric acid | 1 | 1 | A | Ingst | Unt-M | 1 | | |
| 106 | 64 y F | potassium | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 107 | 65 34 | hydroxide | 1 | 1 | A | Inhali Dire | II | 2 | | |
| 107pa | 65 y M | drain cleaner (alkali) | 1 | 1 | A | Inhal+ Derm | Unt-O | 3 | | |
| 108 | 65 y F | ethylene glycol | 1 | 1 | A | Ingst | Int-S | 1 | ethylene glycol | 643 mg/dL In Blood (unspecified) |
| 109p | 66 y M | | | | A | Ingst | Int-S | 1 | | @ Unknown |
| • | | cyanide | 1 | 1 | | _ | | | | |
| 110p | 66 y F | hydrochloric acid | 1 | 1 | U | Unk | Unt-G | 2 | | |
| 111p | 68 y F | antifreeze (ethylene | 2 | 1 | A | Unk | Unk | 1 | ethylene glycol | 29 mg/dL In Blood (unspecified) @ |
| | | glycol) substance (non- | 1 | 2 | | | | | , ,, | 1 d (pe) |
| 1101 | (0.)/ | drug), unknown | 1 | 2 | | . | T . C | | | |
| 112h | 69 y M | sulfuric acid | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 113pa | 76 y M | cyanide | 1 | 1 | A | Ingst | Int-S | 1 | cyanide | 3.9 mg/L In Blood (unspecified) @ Autopsy |
| 114a | 76 y M | | | | A | Ingst | Int-S | 1 | | |
| | | antifreeze (ethylene glycol) | 1 | 1 | | | | | ethylene glycol | 100 mg/dL In Serum @ Unknown |
| 115 | 89 y M | brodifacoum | 2 | 2 | A | Ingst | Unt-M | 2 | | |
| 116a | 89 y M | chemical, unknown | 1 | 1 | A | Ingst | Unk | 1 | | |
| 110a | 69 y WI | antifreeze (ethylene glycol) | 1 | 1 | А | nigst | Olik | 1 | ethylene glycol | 420 mg/dL In Blood (unspecified) @ Unknown |
| 117 | 40+ y M | | | | A | Ingst | Int-S | 1 | | |
| 118 | 50+ y | drain cleaner (acid) | 1 | 1 | A | Inhal+ Derm | Unt-G | 3 | | |
| 110 | M | | | | A | IIIIai+ Deiiii | Ont-G | 3 | | |
| See also case | 2 30, 119, 1 | cyanide 53, 172, 199, 387, 780, | 1 1108, 1231, | 1 1298 | | | | | | |
| Cleaning Su | | Household) | | | | | | | | |
| 119p | 21 y F | THC homolog | 1 | 1 | A | Inhal | Int-S | 1 | | |
| 120a | 25 y F | sulfur | 2 | 2 | A | Ingst | Int-S | 1 | | |
| 1204 | 23 y 1 | toilet bowl cleaner | 1 | 1 | А | mgot | IIID | 1 | | |
| 121 | 28 y M | (acid) | | | A | Ingst+ Aspir | Int-S | 1 | | |
| | | drain opener (sulfuric acid) | 1 | 1 | | | | | | |
| 122a | 32 y M | hypochlorite | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 123 | 36 y F | пуростопис | 1 | 1 | A | Ingst | Int-S | 1 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|-------------------|------------------------------|-------------------|---------------|------------|--------------|----------|-----|--------------|-------------------------------|
| | | drain cleaner (alkali) | 1 | 1 | | | | | | |
| 24 | 40 y F | | | | A | Ingst | Int-U | 1 | | |
| 27 | 40 y 1 | drain cleaner (alkali) | 1 | 1 | 7 % | nigst | IIIt-O | 1 | | |
| 25a | 44 y F | dram eleuner (umum) | • | • | A | Ingst | Int-S | 1 | | |
| | • | toilet bowl cleaner | 1 | 1 | | C | | | | |
| | | (acid) | | | | | | | | |
| 26a | 46 y M | | | | A | Ingst+ Aspir | Int-S | 1 | | |
| | | drain cleaner (alkali) | 1 | 1 | | | | | | |
| 27 | 51 y M | | | | A | Ingst | Int-S | 2 | | |
| 20 | 50 F | drain cleaner (alkali) | 1 | 1 | | | ** | 2 | | |
| 128 | 53 y F | 1 1 1 | | | Α | Ingst | Unt-G | 3 | | |
| | | laundry detergent, liquid | 1 | 1 | | | | | | |
| 29a | 54 y M | nquiu | | | A | Ingst | Int-S | 1 | | |
| 2)u | 34 y 1 v 1 | cleaner (acid) | 1 | 1 | 7.1 | mgst | IIIt-5 | 1 | | |
| | | ethylene glycol/ | 2 | 2 | | | | | | |
| | | diethylene glycol | _ | _ | | | | | | |
| | | hydrochloric acid | 3 | 3 | | | | | | |
| | | xylene | 4 | 4 | | | | | | |
| | | hydrocarbons | 5 | 5 | | | | | | |
| | | cleaner (anionic/ | 6 | 6 | | | | | | |
| | | nonionic) | | | | | | | | |
| | | acetone/toluene/pro- | 7 | 7 | | | | | | |
| | | pellants | | | | | | | | |
| 30 | 56 y M | 1 11 1 | | _ | U | Ingst | Int-S | 1 | | |
| 21 | (0.)/ | hypochlorite | 1 | 1 | | T A | T . C | | | |
| 131 | 60 y M | drain cleaner (acid) | 1 | 1 | A | Ingst+ Aspir | Int-S | 1 | | |
| 132 | 61 y F | drain cleaner (acid) | 1 | 1 | A | Inact | Int C | 1 | | |
| 132 | огуг | drain cleaner | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 133 | 65 y F | diani cicanci | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 133 | 03 y 1 | THC homolog | 1 | 1 | А | nigst | IIIt-5 | 1 | | |
| 134 | 73 y F | Tire nomoreg | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | toilet bowl cleaner | 1 | 1 | | 8 | | - | | |
| | | (acid) | | | | | | | | |
| 135 | 75 y M | , , | | | A | Ingst | Unt-G | 2 | | |
| | | cleaner (ammonia) | 1 | 1 | | | | | | |
| 136 | 87 y F | | | | A | Ingst+ Aspir | Unt-U | 2 | | |
| | | laundry deternent, | 1 | 1 | | | | | | |
| | | liquid | | | | _ | | | | |
| 137 | 88 y F | 1 1 1 (11 11) | | | Α | Ingst | Unt-G | 2 | | |
| 120 | 90 M | drain cleaner (alkali) | 1 | 1 | 4 | Toront | T T., 1. | 2 | | |
| 138p | 89 y M | 1:.: | 1 | 1 | A | Ingst | Unk | 2 | | |
| | | disinfectants (pine oil) | 1 | 1 | | | | | | |
| See also case | 83 210 1 | | | | | | | | | |
| | | re Products | | | | | | | | |
| 139 | 82 y F | | | | U | Ingst+ Aspir | Int-M | 1 | | |
| | <i>y</i> - | hydrogen peroxide | 1 | 1 | - | 2 F | | | | |
| See also case | 17, 281 | | | | | | | | | |
| Deodorizers | | | | | | | | | | |
| 140 | 84 y F | | | | A | Ingst | Unt-G | 2 | | |
| | | air freshener | 1 | 1 | | | | | | |
| | | (liquid) | | | | | | | | |
| Essential Oi | | | | | | Towns A | The 25 | 1 | | |
| 41 | 91 y M | augalymtus ail | 1 | 1 | A | Ingst+ Aspir | Unt-M | 1 | | |
| Food Produc | ote/Food D | eucalyptus oil | 1 | 1 | | | | | | |
| 142 | 54 y M | naviilig | | | A | Ingst | Unt-F | 2 | | |
| . 14 | J → y 1v1 | tetrodotoxin | 1 | 1 | Α | 111531 | Om-1 | _ | | |
| 43i | 77 y M | CHOGOLOAIII | 1 | 1 | A | Ingst | Unt-F | 1 | | |
| | . , , 141 | botulism | 1 | 1 | 4.1 | | J 111 1 | | | |
| 44 | 88 y F | | • | • | A/C | Unk | Unt-G | 2 | | |
| | , - | botulism | 1 | 1 | | - | 0 | _ | | |
| | | azacitidine | 2 | 2 | | | | | | |
| umes/Gase | s/Vapors | | | | | | | | | |
| 45pa | 3 y M | | | | A | Inhal | Unt-E | 1 | | |
| | | carbon monoxide | 1 | 1 | | | | | | |
| 146p | 3 y M | | | | A | Inhal | Unt-E | 1 | | |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- | 56% In Blood (unspecified) @ |
| 47 | 5 F | | | | | Y. 1 1 | TI - F | 4 | globin | Unknown |
| 47p | 5 y F | | | _ | Α | Inhal | Unt-E | 1 | | |
| | | carbon monoxide | 1 | 1 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|----------------------------|-------------------|---------------|------------|--------------|----------|-----|------------------------|--|
| 48pi | 9 y M | | | | A | Inhal | Unt-E | 1 | | |
| 49p | 16 y F | carbon monoxide | 1 | 1 | A | Inhal | Unt-E | 2 | | |
| • | | carbon monoxide | 1 | 1 | | | | | | |
| 50p | 18 y M | propane | 1 | 1 | A | Inhal | Int-A | 1 | | |
| 51pi | 18 y M | carbon monoxide | 1 | 1 | С | Inhal | Unt-M | 1 | | |
| 52pai | 18 y M | | | | A | Inhal | Oth-M | 1 | | 777 J. D. 17 (10.1) |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | 77% In Blood (unspecified) @ Autopsy |
| .53p | 19 y M | hydrogen sulfide | 1 | 1 | A | Inhal | Unt-O | 1 | | |
| | | hydrochloric acid | 2 | 2 | | | | | | |
| 54pi | 20 y M | carbon monoxide | 1 | 1 | С | Inhal | Unt-M | 1 | | |
| 55pai | 21 y M | | | | A | Inhal | Int-S | 1 | | |
| | | hydrogen sulfide ethanol | 1 2 | 1 2 | | | | | | |
| 56pi | 21 y M | | 1 | | C | Inhal | Unt-M | 1 | | |
| 57pa | 26 y M | carbon monoxide | 1 | 1 | A | Inhal | Unt-O | 2 | | |
| 58p | 27 y M | nitrogen oxides | 1 | 1 | A | Inhal | Unt-E | 2 | | |
| • | | carbon monoxide | 1 | 1 | | | | | | |
| 59p | 27 y M | methane | 1 | 1 | A | Inhal | Unt-O | 2 | | |
| 60p | 29 y M | | | | A | Inhal | Unt-E | 2 | | |
| 61p | 30 y M | hydrogen sulfide | 1 | 1 | A | Inhal | Unt-O | 1 | | |
| 60mi | | nitrogen gas | 1 | 1 | Δ. | Inhal | Unt-E | 1 | | |
| 62pi | 30 y M | carbon monoxide | 1 | 1 | A | Inhal | | 1 | | |
| 63pai | 33 y F | carbon monoxide | 1 | 1 | A | Inhal | Int-S | 1 | carboxyhemo- | 84% In Blood (unspecified) @ |
| ć. | 24 5 | caroon monoxide | • | • | | | ** | 2 | globin | Autopsy |
| 64pa | 34 y F | fume-gas-vapor, | 1 | 1 | Α | Inhal | Unt-E | 2 | | |
| 65 | 35 y M | unknown | | | A | Inhal | Unt-M | 1 | | |
| 03 | | carbon monoxide | 1 | 1 | A | IIIIai | CIII-IVI | 1 | | |
| 66p | 35 y M | hydrogen sulfide | 1 | 1 | A | Inhal | Unt-O | 1 | | |
| 67pa | 35 y M | | | | A | Inhal | Unt-E | 2 | | |
| | | fume-gas-vapor, unknown | 1 | 1 | | | | | | |
| 68pa | 35 y M | | 1 | 1 | A | Inhal | Unt-E | 2 | | |
| 69a | 38 y F | smoke | 1 | 1 | A | Inhal | Unt-G | 1 | | |
| | - | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | 36.4% In Blood (unspecified) @ Autopsy |
| 70pai | 38 y M | | | | A | Inhal | Unt-M | 1 | 5100III | лиюрзу |
| 71pi | 39 y M | chlorine gas | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| • | | carbon monoxide | 1 | 1 | | | | | | |
| 72p | 40 y M | hydrogen sulfide | 1 | 1 | Α | Inhal | Unt-O | 1 | | |
| 73 | /1 v M | hydrochloric acid | 2 | 2 | Α. | Inhal | Unt-M | 1 | | |
| 73 | 41 y M | chlorine gas | 1 | 1 | A | | | | | |
| 74pa | 42 y M | smoke | 1 | 1 | A | Ingst+ Inhal | Unt-E | 1 | carboxyhemo- | 16.5% In Serum @ Autopsy |
| | | | | | | | | | globin | • • |
| 75p | 43 y M | ethanol | 2 | 3 | U | Ingst | Int-S | 1 | ethanol | 54 mg/dL In Serum @ Autopsy |
| | , - | carbon monoxide | 1 | 1 | - | C | | | | |
| 76i | 44 y F | brodifacoum | 2 | 2 | A | Inhal | Unt-E | 1 | | |
| | 45 y M | carbon monoxide | 1 | 1 | A | Inhal | Int-S | 2 | | |
| 77 | • | carbon monoxide | 1 | 1 | | | | | | |
| 78pai | 46 y F | carbon monoxide | 1 | 1 | A | Inhal | Int-S | 1 | carboxyhemo- | 77% In Blood (unspecified) @ |
| | | Carbon monoxide | 1 | 1 | | | | | globin | Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|---|-------------------|---------------|------------|----------------|--------|-----|------------------------|--|
| 179pai | 49 y M | carbon monoxide | 1 | 1 | A | Ingst+ Inhal | Int-S | 2 | carboxyhemo- | 12% In Unknown @ Autopsy |
| | | methanol | 2 | 2 | | | | | globin | |
| 80pa | 50 y F | carbon monoxide | 1 | 1 | A | Inhal | Unt-E | 1 | carboxyhemo- globin | 37% In Whole Blood @ Autopsy |
| 81pa | 52 y M | | | | A | Inhal | Unt-E | 1 | giooni | |
| 82pi | 53 y M | smoke | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| .83p | 54 y M | carbon monoxide | 1 | 1 | A | Inhal | Unt-O | 1 | | |
| 84i | 54 y M | hydrogen sulfide | 1 | 1 | С | Inhal | Unt-E | 2 | | |
| | | carbon monoxide | 1 | 1 | | | | 3 | | |
| 185ai | 57 y M | chlorine gas | 1 | 1 | U | Inhal | Unt-O | | | |
| .86ha | 59 y F | smoke | 1 | 1 | A | Inhal | Unt-E | 1 | carboxyhemo- globin | 33% In Blood (unspecified) @ Unknown |
| .87 | 60 y M | drug unknown* | 1 | 1 | A | Ingst+ Inhal | Int-S | 2 | C | |
| | | drug, unknown* natural gas* | 1 2 | 1 1 | | | | | | |
| | | oxygen | 3 | 2 | | | | | | |
| 188pai | 60 y F | ethanol | 4 | 3 | A | Inhal | Int-S | 1 | | |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- | 63% In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | globin ethanol | 0.04% (wt/Vol) In Whole Blood @ Autopsy |
| 89pa | 60 y M | carbon monoxide | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| .90p | 62 y M | smoke | 1 | 1 | A | Inhal | Unt-E | 3 | carboxyhemo- globin | 31.2% In Blood (unspecified) @ 1 h (pe) |
| 191ph | 63 y M | | 1 | 1 | A | Inhal | Unt-G | 1 | groom | (pe) |
| 192pa | 64 y F | smoke | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | 45.9% In Blood (unspecified) @ Unknown |
| 193pa | 64 y F | carbon monoxide | 1 | 1 | A | Inhal | Unt-E | 1 | | 41% In Blood (unspecified) @ |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | Autopsy |
| 194pai | 64 y M | carbon monoxide | 1 | 1 | U | Ingst+ Inhal | Int-S | 1 | carboxyhemo- globin | 53% In Whole Blood @ Unknown |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.24% (wt/Vol) In Whole Blood @ Unknown |
| 195p | 65 y M | hadaa 101 | 1 | 1 | A | Inhal | Unt-O | 1 | | C.III.IO. |
| 196p | 65 y F | hydrogen sulfide | 1 | 1 | A | Inhal | Unt-E | 2 | | |
| 197pa | 67 y M | smoke | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| 198 | 71 y M | smoke | 1 | 1 | U | Inhal | Int-U | 2 | | |
| | | natural gas | 1 | 1 | | | | | | |
| 199p | 71 y M | carbon monoxide | 1 | 1 | Α | Inhal | Unt-E | 1 | | |
| 200a | 72 y F | cyanide | 2 | 2 | A | Inhal+ Derm | Unt-E | 1 | | |
| -30 u | , 2 y 1 | carbon monoxide | 1 | 1 | 11 | IIIIIII Deliil | One | 1 | carboxyhemo- globin | 35% In Blood (unspecified) @ |
| 201p | 74 y F | | | | A | Inhal | Unt-G | 1 | giooni | Autopsy |
| | | carbon monoxide fume-gas-vapor, unknown | 1 2 | 1 2 | | | | | | |
| 202 | 75 y M | | | 4 | A | Inhal | Unt-E | 3 | 1 1 | 120/ L. D1 1 / |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | 13% In Blood (unspecified) @ Unknown |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | 40% In Blood (unspecified) @ Unknown |
| 203pai | 82 y M | carbon monovido | 1 | 1 | U | Inhal | Int-S | 1 | carbovyhamo | 81% In Whole Pland @ Autonov |
| | | carbon monoxide | 1 | 1 | | | | | carboxyhemo- globin | 81% In Whole Blood @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|------------------------------------|-------------|---|-------------------|---------------|------------|--------------|--------|-----|--------------------|---------------------------------|
| | | diazepam | 2 | 2 | | | | | | |
| | | carbamazepine laxative (stimulant) | 3 4 | 3 4 | | | | | sertraline | 0.21 mcg/mL In Whole Blood @ |
| 0.4 | | , | | | | T. 1 1 | ш., г | 1 | | Autopsy |
| 204 | 92 y F | carbon monoxide | 1 | 1 | С | Inhal | Unt-E | 1 | | |
| 205pi | 15 m F | amala | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| 206 | 18 m F | smoke | 1 | 1 | A | Inhal | Unt-E | 3 | | |
| 207p | 50+ y | smoke | 1 | 1 | A | Inhal | Int-S | 1 | | |
| .07р | M | | | | A | IIIIai | IIIt-3 | 1 | | |
| 208p | 80+ y F | carbon monoxide | 1 | 1 | U | Inhal | Unt-E | 2 | | |
| • | • | carbon monoxide | 1 | 1 | C | | | | | |
| 209p | Unknown | adult (>=20 yrs) M hydrogen sulfide | 1 | 1 | A | Inhal | Int-S | 1 | | |
| 210i | Unknown | adult (>=20 yrs) M | | | A | Inhal | Int-S | 1 | | |
| | | hydrogen sulfide toilet bowl cleaner | 2 1 | 1 2 | | | | | | |
| | | (alkali) | • | - | | | | | | |
| See also case | | | | | | | | | | |
| H <mark>eavy Metals</mark> 211a | 44 y M | | | | A | Ingst | Int-S | 1 | | |
| | • | arsenic | 1 | 1 | | 800 | 0 | 1 | | |
| See also case | 47, 778, 11 | 31 | | | | | | | | |
| Hydrocarbon 212 | 3 y F | | | | A | Ingst+ Aspir | Unt-G | 1 | | |
| .12 | | lamp oil | 1 | 1 | A | підзіт Азріі | OIII-G | 1 | | |
| 13 | 3 y M | lamp oil | 1 | 1 | A | Ingst+ Aspir | Unt-G | 1 | | |
| 214p | 12 y M | iamp on | 1 | 1 | A | Inhal | Int-A | 1 | | |
| | | fluorinated hydrocarbons | 1 | 1 | | | | | | |
| 215p | 12 y F | nydrocarbons | | | A | Inhal | Unk | 1 | | |
| | | fluorinated hydrocarbons | 1 | 1 | | | | | | |
| 216pai | 21 y M | • | | | A | Inhal | Int-A | 2 | | |
| | | toluene-xylene alprazolam | 1 2 | 1 2 | | | | | | |
| | | diazepam | 3 | 3 | | | | | | |
| 217pai | 21 y F | diflunisal | 1 | 1 | U | Inhal | Int-A | 2 | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.11% (wt/Vol) In Whole Blood @ |
| 218p | 23 y M | | | | A | Inhal | Int-A | 2 | | Autopsy |
| | J | fluorochlorocarbon/ | 1 | 1 | | | | | | |
| 219 | 25 y M | propellant | | | U | Inhal | Int-A | 2 | | |
| | • | tetrafluoroethane | 1 | 1 | | | | | | |
| 220 | 27 y M | fluorinated | 1 | 1 | A | Inhal | Int-A | 2 | | |
| 221pa | 28 y M | hydrocarbons | | | A | Inhal | Int-A | 1 | | |
| -21pa | 20 y IVI | fluorochlorocarbon/ | 1 | 1 | Α | ıımal | mt-A | 1 | | |
| 222 | 31 y F | propellant | | | A | Inhal | Int-A | 1 | | |
| | | freon | 1 | 1 | | | | | | |
| 223a | 42 y M | gasoline | 1 | 1 | A | Inhal+ Derm | Int-S | 1 | | |
| 224p | 45 y F | | | | A | Inhal | Int-A | 2 | | |
| | | fluorochlorocarbon/ propellant | 1 | 1 | | | | | | |
| 225 | 45 y M | • • | | | A | Ingst | Int-S | 1 | | |
| 226pa | 50 y F | mineral spirits | 1 | 1 | U | Inhal | Int-A | 1 | | |
| 2P. | 20,1 | fluorochlorocarbon/ | 1 | 1 | ٥ | | / 1 | 1 | 1,1-difluoroethane | 32 mcg/mL In Blood (unspecified |
| | | propellant | | | A | Ingst | Unt-G | 1 | | @ Autopsy |
| 227 | 94 y F | | | | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Report ID | Age | Substances | Substance Rank | | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|--|--|---|---|--|-----------------------|---|---|--------------------------------------|---------------|-------------------------------|
| 228pa | 18 m F | | | | A | Ingst | Unt-G | 1 | | |
| 229pi | 40.1 | mineral spirits | 1 | 1 | Α. | Inhal | Unt-O | 2 | | |
| .29pi | 40+ y M | | | | A | mnai | Unt-O | 2 | | |
| | | toluene | 1 | 1 | | | | | | |
| | 20 227 0 | xylene | 2 | 2 | | | | | | |
| See also case | 38, 237, 8 | 11 | | | | | | | | |
| ndustrial C | | | | | | D | 11 . 0 | 2 | | |
| 230ha | 31 y M | cleaner (alkali) | 1 | 1 | A | Derm | Unt-O | 3 | | |
| See also case | 129 | ereuner (umum) | - | • | | | | | | |
| nformation | Calls | | | | | | | | | |
| 231pa | 4 y M | | | | A | Unk | Unk | 2 | | |
| | | water | 1 | 1 | | | | | | |
| | | coin (quarter) | 2 | 2 | | | | | | |
| Mushrooms | 60 F | | | | | | * | | | |
| 232 | 68 y F | Amanita pantherina | 1 | 1 | A/C | Ingst | Int-M | 2 | | |
| | | Russula fragilis | 2 | 2 | | | | | | |
| | | Gymnopilus | 3 | 3 | | | | | | |
| | | spectabilis | | | | | | | | |
| | | rug Substances | | | | | | | | |
| 233a | 21 y M | THC homolog | 1 | 1 | A | Inhal | Int-A | 3 | | |
| | | guaifenesin | 2 | 2 | | | | | | |
| 234p | 35 y F | | | | A | Ingst | Int-S | 3 | | |
| | | substance (non- | 1 | 1 | | | | | | |
| 235 | 50 y M | drug), unknown | | | U | Ingst+ Unk | Unk | 2 | | |
| | 3 | substance (non- | 1 | 1 | | 8 | | | | |
| | | drug), unknown | 2 | 2 | | | | | | 272 / 1. 5 |
| 236a | 55 y F | acetaminophen | 2 | 2 | A | Ingst | Unt-M | 2 | acetaminophen | 273 mcg/mL In Serum @ Unkno |
| 2304 | 33 y I | disinfectant (alkyldimethyl- benzyl ammonium chloride/nonionic) | 1 | 1 | 71 | ingst | OIK W | - | | |
| See also case | 10, 111, 9 | 35 | | | | | | | | |
| Paints and S | tripping A | gents | | | | | | | | |
| 237pa | 31 y M | | | | A | Inhal | Unt-E | 2 | | |
| | | methylene chloride hydrocarbons | 1 2 | 1 2 | | | | | | |
| See also case | 129 | nydrocarbons | 2 | _ | | | | | | |
| | | | | | | | | | | |
| Doctioidos | | | | | | | | | | |
| | 4 v F | | | | A | Inhal | Unt-E | 1 | | |
| 238a | 4 y F | aluminum phosphide | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| 238a | 4 y F 17 y M | | | | A A | Inhal Ingst | Unt-E Int-S | 1 2 | | |
| 238a 239p | 17 y M | aluminum phosphide | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 238a 239p | | | | | | | | | | |
| 238a 239p 240 | 17 y M | paraquat carbamate | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 238a 239p 240 241a | 17 y M 41 y M 46 y M | paraquat | 1 | 1 | A A A | Ingst Ingst Ingst | Int-S Int-S Unt-M | 2 2 1 | | |
| 238a 239p 240 241a 242pa | 17 y M 41 y M 46 y M 47 y M | paraquat carbamate | 1 | 1 | A A A U | Ingst Ingst Ingst Ingst | Int-S Int-S Unt-M Int-S | 2 2 1 2 | | |
| 238a 239p 240 241a 242pa | 17 y M 41 y M 46 y M | paraquat carbamate chlorfenapyr methomyl | 1 1 1 | 1 1 1 | A A A | Ingst Ingst Ingst | Int-S Int-S Unt-M | 2 2 1 | | |
| 238a 239p 240 241a 242pa | 17 y M 41 y M 46 y M 47 y M | paraquat carbamate chlorfenapyr methomyl glyphosate | 1 1 1 1 | 1 1 1 1 | A A A U | Ingst Ingst Ingst Ingst | Int-S Int-S Unt-M Int-S | 2 2 1 2 | | |
| 238a 239p 240 241a 242pa | 17 y M 41 y M 46 y M 47 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana | 1 1 1 1 1 2 | 1 1 1 1 1 2 | A A A U | Ingst Ingst Ingst Ingst | Int-S Int-S Unt-M Int-S | 2 2 1 2 | | |
| 238a 239p 240 241a 242pa 243 | 17 y M 41 y M 46 y M 47 y M 49 y M | paraquat carbamate chlorfenapyr methomyl glyphosate | 1 1 1 1 | 1 1 1 1 | A A U A | Ingst Ingst Ingst Ingst Ingst Ingst+Unk | Int-S Int-S Unt-M Int-S Int-S Unt-M | 2 2 1 2 3 | | |
| 238a 239p 240 241a 242pa 243 | 17 y M 41 y M 46 y M 47 y M 49 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana paraquat | 1 1 1 1 1 2 | 1 1 1 1 2 | A A A U A | Ingst Ingst Ingst Ingst Ingst Unk | Int-S Int-S Unt-M Int-S Int-S | 2 2 1 2 3 | | |
| 238a 239p 240 241a 242pa 243 244 | 17 y M 41 y M 46 y M 47 y M 49 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana | 1 1 1 1 1 2 | 1 1 1 1 1 2 | A A U A | Ingst Ingst Ingst Ingst Ingst Ingst+Unk | Int-S Int-S Unt-M Int-S Int-S Unt-M | 2 2 1 2 3 | | |
| 238a 239p 240 241a 242pa 243 244 | 17 y M 41 y M 46 y M 47 y M 49 y M 50 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana paraquat aldicarb organophosphate | 1 1 1 1 2 1 1 | 1 1 1 1 1 2 1 1 | A A U A A | Ingst Ingst Ingst Ingst Ingst+ Unk Ingst | Int-S Int-S Unt-M Int-S Int-S Unt-M Int-S | 2 2 1 2 3 | | |
| 238a 239p 240 241a 242pa 243 244 245 | 17 y M 41 y M 46 y M 47 y M 49 y M 50 y M 50 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana paraquat aldicarb | 1 1 1 1 1 2 1 | 1 1 1 1 1 2 1 | A A U A A A A | Ingst Ingst Ingst Ingst Ingst+Unk Ingst Ingst Ingst | Int-S Int-S Unt-M Int-S Int-S Int-S Int-S | 2 2 1 2 3 1 1 2 | | |
| 238a 239p 240 241a 242pa 243 244 245 | 17 y M 41 y M 46 y M 47 y M 49 y M 50 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana paraquat aldicarb organophosphate ethanol | 1 1 1 1 2 1 1 | 1 1 1 1 1 2 1 1 | A A U A A | Ingst Ingst Ingst Ingst Ingst+ Unk Ingst | Int-S Int-S Unt-M Int-S Int-S Unt-M Int-S | 2 2 1 2 3 | | |
| Pesticides 238a 239p 240 241a 242pa 243 244 245 246 | 17 y M 41 y M 46 y M 47 y M 49 y M 50 y M 50 y M | paraquat carbamate chlorfenapyr methomyl glyphosate marijuana paraquat aldicarb organophosphate | 1 1 1 1 2 1 1 1 2 | 1 1 1 1 1 2 1 1 1 2 | A A U A A A A | Ingst Ingst Ingst Ingst Ingst+Unk Ingst Ingst Ingst | Int-S Int-S Unt-M Int-S Int-S Int-S Int-S | 2 2 1 2 3 1 1 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|--------------------------|----------------------|---|-------------------|---------------|------------|-------------|--------|-----|--|---|
| 249 | 59 y F | -lamba a seta | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 250p | 61 y F | glyphosate | 1 1 | 1 | A | Ingst | Int-S | 1 | | |
| 251p | 64 y M | organophosphate | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 252a | 65 y M | ropinirole | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | oxcabazepine lorazepam | 2 3 | 2 3 | | | | | | |
| 253 | 70 y M | carbamate | 1 | 1 | A | Ingst | Int-S | 3 | | |
| 254 | 72 y M | paraquat | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 255a | 88 y M | malathion | 1 | 1 | A | Ingst | Unt-M | 2 | | |
| 256 | 92 y M | pyrethroids | 1 | 1 | A | Inhal | Unt-M | 3 | | |
| 257a | 15 m F | aluminum phosphide | 1 | 1 | A | Inhal | Unt-E | 1 | | |
| 258 | 2 d F | brodifacoum* rodenticide (antocoagulant)* | 2 | 1 1 | A | Oth | Oth-M | 1 | | |
| 259p See also case | 50+ y U 114, 175, | strychnine | 1 | 1 | A | Ingst | Int-S | 1 | | |
| Plants 260pai | 30 y U | Brugmansia suaveolens (Datura | 1 | 1 | A | Ingst | Int-M | 1 | | |
| 261h | 55 y F | suaveolens) Allium sativum ethanol | 1 2 | 1 2 | A | Ingst | Unt-M | 2 | | |
| Weapons of 262 | Mass Dest 58 y M | ruction phosgene | 1 | 1 | A | Inhal+ Derm | Unt-O | 1 | | |
| Pharmaceut Analgesics | | ures | | | | | | | | |
| 263pi | 2 y M | oxycodone | 1 | 1 | A | Ingst | Unk | 2 | | |
| 264pa | 2 y M | methadone | 1 | 1 | A | Ingst | Unt-G | 1 | eddp (2- ethylidene-1- ,5-dimethyl-3- ,3-diphenyl pyrrolidine) | 33.5 ng/mL In Blood (unspecified @ Autopsy |
| | | methadone | 1 | 1 | | | | | methadone | 514 ng/mL In Blood (unspecified) @ Autopsy |
| 265pa | 2 y F | acetaminophen/hy- drocodone | 1 | 1 | A | Ingst | Unt-G | 2 | | |
| | | clonazepam buprenorphine (sub- lingual) | 2 3 | 2 3 | | | | | | |
| 266 | 4 y F | morphine acetaminophen/oxy- codone | 1 2 | 1 2 | A | Ingst | Unt-G | 1 | | |
| 267pa | 5 y M | alprazolam | 3 | 3 | A | Unk | AR-D | 1 | | |
| 268pa | 7 y M | fentanyl | 1 | 1 | A | Ingst | Unt-M | 1 | | |
| 269pai | 13 y M | oxycodone oxycodone | 1 1 1 | 1 1 1 | U | Ingst | Int-A | 1 | oxycodone (total) oxycodone (total) | 1956 ng/mL In Serum @ Autopsy 5000 ng/mL In Urine (quantitative only) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--------------------------------------|-------------------|---------------|------------|-------|--------|-----|-------------------------|--|
| 270pa | 14 y M | | | | A/C | Ingst | Unk | 3 | | |
| | | codeine | 1 | 1 | | | | | codeine | 10000 ng/mL In Urine (quantitative only) @ Autopsy |
| | | codeine | 1 | 1 | | | | | morphine | 11.8 ng/mL In Blood (unspecified) @ Autopsy |
| | | codeine | 1 | 1 | | | | | codeine | 117 ng/mL In Blood (unspecified) @ Autopsy |
| | | codeine | 1 | 1 | | | | | morphine | 5069 ng/mL In Urine (quantitative only) @ Autopsy |
| | | codeine | 1 | 1 | | | | | hydrocodone | 57 ng/mL In Urine (quantitative only) @ Autopsy |
| | | laxative (stimulant) | 2 | 2 | | | | | sertraline | 274 ng/mL In Blood (unspecified) @ Autopsy |
| | | laxative (stimulant) | 2 | 2 | | | | | norsertraline | 526 ng/mL In Blood (unspecified) @ Autopsy |
| | | quetiapine | 3 | 3 | | | | | quetiapine | 190 ng/mL In Blood (unspecified) @ Autopsy |
| | | aripiprazole | 4 | 4 | | | | | aripiprazole | 190 ng/mL In Blood (unspecified) @ Autopsy |
| | | valproic acid | 5 | 5 | | | | | valproic acid | 19.6 mcg/mL In Blood (unspecified @ Autopsy |
| | | lisdexamfetamine | 6 | 6 | | | | | amphetamine | 93 ng/mL In Blood (unspecified) @ Autopsy |
| | | diphenhydramine | 7 | 7 | | | | | diphenhydramine | 138 ng/mL In Blood (unspecified) @ Autopsy |
| | | penicillin | 8 | 8 | | | | | | Crutopsy |
| | | meloxicam clonidine | 9 10 | 9 10 | | | | | | |
| 271 | 14 y F | | | | A | Ingst | Int-U | 3 | | |
| 272ph | 15 y M | acetaminophen | 1 | 1 | A | Ingst | Int-U | 1 | | |
| | | morphine | 1 | 1 | | | T A | 2 | | |
| 273pa | 15 y M | oxycodone | 1 | 1 | A | Ingst | Int-A | 2 | oxycodone (total) | 0.14 mcg/mL In Blood (unspecified @ Unknown |
| 274p | 16 y F | | | | A | Ingst | Int-S | 2 | | @ Unknown |
| | | morphine lisdexamfetamine | 1 2 | 1 2 | | | | | | |
| | | laxative (stimulant) | 3 | 3 | | | | | | |
| 275pai | 16 y M | acetaminophen/hy- | 1 | 1 | U | Ingst | Int-A | 2 | hydrocodone | 0.23 mcg/mL In Whole Blood @ |
| | | drocodone | | | | | | | nydrocodone | Autopsy |
| | | alprazolam | 2 3 | 2 3 | | | | | | |
| | | chlorpheniramine dextromethorphan | 4 | 4 | | | | | | |
| 276pai | 16 y M | de.iii oineinoi piidii | | · | U | Ingst | Int-A | 1 | | |
| | | acetaminophen/hy- drocodone | 1 | 1 | | | | | hydrocodone | 0.11 mcg/mL In Whole Blood @ Autopsy |
| 277pai | 17 y M | arocouone | | | U | Unk | Unk | 1 | | Tutopoy |
| | | methadone | 1 | 1 | | | | | alpha-oh- alprazolam | 0 mcg/mL In Whole Blood @ Autopsy |
| | | methadone | 1 | 1 | | | | | alprazolam | 0 Other (see abst) In Urine (quanti- tative only) @ Autopsy |
| | | methadone | 1 | 1 | | | | | methadone | 0.12 mcg/mL In Whole Blood @ Autopsy |
| | | methadone | 1 | 1 | | | | | alprazolam | 0.175 mcg/mL In Whole Blood @ Autopsy |
| | | methadone | 1 | 1 | | | | | methadone | 1.1 Other (see abst) In Liver @ Autopsy |
| | | methadone | 1 | 1 | | | | | meprobamate | 3.5 mcg/mL In Whole Blood @ Autopsy |
| 278a | 17 y M | | _ | | A | Ingst | Int-S | 1 | | * * |
| | | acetaminophen* | 2 1 | 1 1 | | | | | | |
| | | acetaminophen/di- phenhydramine* | 1 | 1 | | | | | | |
| 279ai | 17 y M | | _ | | A | Ingst | Int-S | 2 | | |
| | | colchicine | 1 | 1 | | | | | | |
| | | atenolol amlodipine | 2 3 | 2 3 | | | | | | |
| 280a | 17 y F | amoupine | J | 5 | U | Ingst | Int-U | 1 | | |
| | J | acetaminophen/ diphenhydramine | 1 | 1 | - | Č | - | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|-------|----------|-----|---------------|---|
| 281a | 17 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | • | acetaminophen/ | 1 | 1 | | | | | hydrocodone | 0.46 mcg/mL In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 1 | 1 | | | | | acetaminophen | @ Unknown 160 mcg/mL In Blood (unspecified) |
| | | hydrocodone | 1 | 1 | | | | | acetammophen | @ 6 h (pe) |
| | | mouthwash | 2 | 2 | | | | | | |
| | | (ethanol) ibuprofen | 3 | 3 | | | | | | |
| | | naproxen | 4 | 4 | | | | | | |
| | | citalopram | 5 | 5 | | | | | | |
| | | magnesium methylphenidate | 6 7 | 6 7 | | | | | | |
| | | dextromethorphan | 8 | 8 | | | | | | |
| | | pseudoephedrine | 9 | 9 | | | | | | |
| | | fluoxetine guaifenesin | 10 11 | 10 11 | | | | | | |
| | | loperamide | 12 | 12 | | | | | | |
| | | phenol | 13 | 13 | | | | | | |
| | | haloperidol hyoscyamine | 14 15 | 14 15 | | | | | | |
| | | rosuvastatin | 16 | 16 | | | | | | |
| | | montelukast | 17 | 17 | | | | | | |
| | | laxative, unknown | 18 | 18 | | | | | | |
| 282a | 18 y M | | | | A | Ingst | Int-S | 1 | | |
| | | salicylate | 1 | 1 | | | | | salicylate | 85.5 mg/dL In Serum @ 6 h (pe) |
| | | salicylate loratadine | 1 2 | 1 2 | | | | | salicylate | 98.2 mg/dL In Serum @ Autopsy |
| 283ph | 18 y M | Torutuanie | 2 | - | A/C | Ingst | Int-S | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 120 mcg/mL In Blood (unspecified) |
| | | propoxyphene trazodone | 2 | 2 | | | | | | @ Unknown |
| 284 | 18 y M | uzodone | 2 | - | A | Ingst | Int-A | 1 | | |
| 205 : | 10. 34 | colchicine | 1 | 1 | | τ | T . A | | | |
| 285pi | 18 y M | methadone | 1 | 1 | A | Ingst | Int-A | 1 | | |
| 286 | 18 y M | memadone | • | 1 | A | Ingst | Int-S | 1 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| | | diphenhydramine acetaminophen/ | 2 | 2 | | | | | | |
| | | dextromethorphan/ | | | | | | | | |
| | | doxylamine/ pseudoephedrine | | | | | | | | |
| | | heroin | 3 | 3 | | | | | | |
| 287 | 19 y F | | | | A | Ingst | Int-S | 1 | | |
| | | acetaminophen/butal- bital/caffeine | 1 | 1 | | | | | | |
| | | propoxyphene | 2 | 2 | | | | | | |
| 288pa | 19 y M | | | | U | Ingst | Int-S | 1 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 364 ng/mL In Blood (unspecified) @ Autopsy |
| | | morphine | 2 | 2 | | | | | morphine | 84.2 ng/mL In Whole Blood @ |
| | | | 2 | 2 | | | | | | Autopsy |
| | | alprazolam | 3 | 3 | | | | | alprazolam | 23.6 ng/mL In Blood (unspecified) @ Autopsy |
| 289a | 19 y F | | | | A | Ingst | Int-S | 1 | | Criatopsy |
| | | ibuprofen | 1 | 1 | | | | | ibuprofen | 410 mcg/mL In Blood (unspecified) |
| | | salicylate | 2 | 2 | | | | | salicylate | @ 4 d (pe) 29 mg/dL In Blood (unspecified) @ |
| | | sancylate | 2 | 2 | | | | | sarreylate | 4 h (pe) |
| | | acetaminophen/ | 3 | 3 | | | | | acetaminophen | 10.3 mcg/mL In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 3 | 3 | | | | | hydrocodone | @ 4 h (pe) 1576 ng/mL In Urine (quantitative |
| | | hydrocodone | 3 | 3 | | | | | nyurocodone | only) @ 4 h (pe) |
| | | acetaminophen/ | 3 | 3 | | | | | hydromorphone | 298 ng/mL In Urine (quantitative |
| 290p | 19 y F | hydrocodone | | | A | Ingst | Int-M | 2 | | only) @ 4 h (pe) |
| 2>0p | 17 1 | acetaminophen/ | 1 | 1 | 71 | mgst | 1111 111 | - | | |
| | | opioid | | | | | | | | |
| | | | | | | | | | | |
| 291p | 19 v F | ethanol | 2 | 2 | A | Unk | Int-S | 3 | | |
| 291p | 19 y F | ethanol salicylate | 1 | 1 | A | Unk | Int-S | 3 | salicylate | 25 mg/dL In Blood (unspecified) @ |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---|-------------------|---------------|------------|------------|--------|-----|------------------------|--|
| 292p | 19 y F | salicylate | 3 | 1 | A | Ingst | Int-S | 1 | salicylate | 47 mg/dL In Blood (unspecified) @ |
| | | atenolol | 2 | 2 | | | | | | Unknown |
| | | amlodipine | 1 | 3 | | | | | | |
| | | diazepam | 6 | 4 | | | | | | |
| | | hydroxyzine | 4 | 5 | | | | | | |
| | | diphenhydramine acetaminophen/hy- drocodone | 5 7 | 6 7 | | | | | | |
| | | hydrochlorothiazide/ triamterene | 8 | 8 | | | | | | |
| 293pa | 20 y F | | | | A | Inhal+ Unk | Int-A | 1 | | |
| | | fentanyl | 1 | 1 | | | | | fentanyl | 4.5 mcg/L In Blood (unspecified) |
| | | (transdermal) cocaine | 2 | 2 | | | | | cocaine | Autopsy 1.3 mg/L In Blood (unspecified) @ Autopsy |
| | | diazepam | 3 | 3 | | | | | | Ашорзу |
| 294pa | 20 y F | morphine | 1 | 1 | A | Ingst | Int-U | 1 | morphine (total) | 10000 ng/mL In Urine (quantitative |
| | | morphine | 1 | 1 | | | | | morphine (total) | only) @ Autopsy 502 ng/mL In Blood (unspecified) @ Autopsy |
| | | diazepam | 2 | 2 | | | | | nordiazepam | 229 ng/mL In Urine (quantitative only) @ Autopsy |
| | | diazepam | 2 | 2 | | | | | diazepam | 64.7 ng/mL In Blood (unspecified) @ Autopsy |
| | | diazepam | 2 | 2 | | | | | nordiazepam | 71.2 ng/mL In Blood (unspecified) @ Autopsy |
| | | venlafaxine | 3 | 3 | | | | | norvenlafaxine | 364 ng/mL In Blood (unspecified) @ Autopsy |
| | | benzodiazepine | 4 | 4 | | | | | temazepam | 364 ng/mL In Urine (quantitative only) @ Autopsy |
| | | benzodiazepine | 4 | 4 | | | | | 7-aminoclonaze- pam | 45 ng/mL In Blood (unspecified) @ Autopsy |
| 295 | 20 y M | marijuana | 5 | 5 | A | Inget | Int-S | 1 | r | |
| 293 | 20 y W | colchicine | 1 | 1 | A | Ingst | 1111-5 | 1 | | |
| 296 | 20 y F | acetaminophen/hy- | 1 | 1 | A/C | Ingst | Int-S | 1 | acetaminophen | 25 mcg/mL In Serum @ Unknown |
| | | drocodone ethanol | 2 | 2 | | | | | ethanol | 260 mg/dL In Blood (unspecified) @ Unknown |
| 297p | 20 y F | tramadol | 1 | 1 | A/C | Ingst | Int-S | 2 | tramadol | 3600 ng/mL In Blood (unspecified) |
| | | alprazolam | 2 | 2 | | | | | alprazolam | @ Unknown 38 ng/mL In Blood (unspecified) @ |
| 298p | 20 y M | | | | A/C | Ingst | Int-U | 2 | | Unknown |
| | , | oxycodone | 1 | 1 | | Ü | | | | |
| 299p | 20 y M | | | | A | Ingst | Unk | 2 | | |
| | | methadone | 1 | 1 | | | | | | |
| 300a | 21 y F | benzodiazepine | 2 | 2 | A | Ingst | Int-S | 1 | | |
| 300a | 21 y 1 | tramadol | 1 | 1 | A | nigst | IIIt-3 | 1 | tramadol | 2.8 mg/L In Blood (unspecified) @ Autopsy |
| | | cyclobenzaprine | 2 | 2 | | | | | | - - |
| | | ibuprofen | 3 | 3 | | | | | | |
| 301pai | 21 v M | amoxicillin | 4 | 4 | U | Ingst+ Unk | Int-A | 1 | | |
| 301 pai | 21 y M | oxycodone | 1 | 1 | O | nigst+ Onk | III-A | 1 | oxycodone | 0.98 mg/L In Blood (unspecified) @ Autopsy |
| | | cocaine | 2 | 2 | | | | | cocaine | 0.1 mg/L In Blood (unspecified) @ Autopsy |
| | | cocaine | 2 | 2 | | | | | cocaethylene | 0.18 mg/L In Blood (unspecified) @ Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.13% In Blood (unspecified) @ Autopsy |
| | | citalopram | 4 | 4 | | | | | citalopram | 0.15 mg/L In Blood (unspecified) @ Autopsy |
| 302p | 21 y M | | | | A | Ingst | Int-A | 2 | | - Autopoj |
| • | - | oxymorphone (extended release) | 1 | 1 | | - | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|-------------|---------|-----|--|--|
| 303pai | 21 y M | fentanyl | 1 | 1 | A | Ingst | Int-A | 2 | fentanyl | 6.5 ng/mL In Whole Blood @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 70 ng/mL In Whole Blood @ |
| | | amphetamine | 3 | 3 | | | | | amphetamine | Autopsy 0.07 mcg/mL In Whole Blood @ Autopsy |
| 304a | 22 y F | acetaminophen/ hydrocodone | 1 | 1 | С | Ingst | Int-A | 2 | | Autopsy |
| 305 | 22 y M | methadone | 1 | 1 | A | Ingst | Unk | 2 | | |
| 206 | 22 F | benzodiazepine | 2 | 2 | | T 4 | T A | 1 | | |
| 306ра | 22 y F | methadone | 1 | 1 | A | Ingst | Int-A | 1 | methadone | 350 ng/mL In Blood (unspecified) @ Autopsy |
| | | methadone | 1 | 1 | | | | | eddp (2- ethylidene-1, 5-dimethyl-3, 3-diphenyl pyrrolidine) | 69 ng/mL In Blood (unspecified) @ Autopsy |
| 207 | 22 M | ethanol | 2 | 2 | A | To and | Int C | 1 | | |
| 307 | 22 y M | acetaminophen | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 400 mcg/mL In Blood (unspecified) @ Unknown |
| 308 | 22 y M | | | | A | Ingst | Int-S | 2 | | |
| 309 | 22 y M | acetaminophen | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 29.3 mcg/mL In Serum @ Unknown |
| 210 | 22 F | salicylate | 1 | 1 | | ** 1 | T . TT | | salicylate | 110 mg/dL In Serum @ 15 m (pe) |
| 310pa | 22 y F | methadone | 1 | 1 | A | Unk | Int-U | 1 | methadone | 0.5 mg/L In Serum @ Autopsy |
| 311pai | 22 y M | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 0.21 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/hy- drocodone | 2 | 2 | | | | | hydrocodone | 0.11 mcg/mL In Whole Blood @ Autopsy |
| 312a | 23 y F | | | | A | Ingst | Int-M | 1 | | |
| | | acetaminophen/hy- drocodone | 1 | 1 | | | | | | 7(|
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 76 mcg/mL In Blood (unspecified) @ Unknown |
| 313pai | 23 y F | acetaminophen/hy- | 1 | 1 | U | Ingst | Int-A | 1 | hydrocodone | 0.14 mcg/mL In Whole Blood @ |
| | | drocodone alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 46 ng/mL In Whole Blood @ |
| | | methylene- dioxymethamphet- amine (MDMA) | 3 | 3 | | | | | mdma (3,4- methylene dioxymetham- phetamine) | Autopsy 0.15 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 4 | 4 | | | | | ethanol | 0.11% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 4 | 4 | | | | | ethanol | 0.14% (wt/Vol) In Vitreous @ Autopsy |
| 314p | 23 y F | | | | A/C | Ingst | Int-S | 2 | | * • |
| | | oxycodone | 1 | 1 | | | | | | |
| | | trazodone | 2 | 2 | | | | | | |
| | | alprazolam gabapentin | 3 4 | 3 4 | | | | | | |
| 315 | 23 y F | Sacapentin | 7 | 7 | A | Ingst | Int-M | 2 | | |
| | - , - | acetaminophen/hy- drocodone | 1 | 1 | | U ** | | | acetaminophen | 16 mcg/mL In Serum @ Unknown |
| 216 | 22 35 | acetaminophen/hy- drocodone | 1 | 1 | | * | * . * - | | acetaminophen | 25.6 mcg/mL In Serum @ Unknown |
| 316 | 23 y M | acetaminophen | 1 | 1 | Α | Ingst | Int-M | 1 | acetaminophen | 67.3 mcg/mL In Blood (unspecified) @ Unknown |
| 317pi | 24 y F | | | | A | Ingst | Int-S | 2 | | e Ulikilowii |
| · Ľ. | , , . | acetaminophen | 1 | 1 | | | | - | | |
| | | opioid | 2 | 2 | | | | | | |
| | | benzodiazepine | 3 | 3 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|---|-------------------|---------------|------------|--------------|--------|-----|-----------------|--|
| 318 | 24 y F | acetaminophen | 1 | 1 | U | Ingst | Int-S | 2 | acetaminophen | 58.4 mcg/mL In Blood (unspecified |
| | | salicylate | 2 | 2 | | | | | salicylate | @ 3 d (pe) 0.6 mg/dL In Blood (unspecified) @ Unknown |
| 319 | 24 y F | cocaine | 3 | 3 | U | Ingst | Int-S | 2 | | |
| 320pai | 24 y M | acetaminophen methadone | 1 | 1 | U | Ingst | Int-A | 3 | methadone | 1.7 mcg/mL In Whole Blood @ |
| 321pai | 24 y M | mediadone | • | • | U | Ingst | Int-A | 2 | mediadone | Autopsy |
| | | methadone | 1 | 1 | | | | | methadone | 0.13 mcg/mL In Whole Blood @ Autopsy |
| | | diphenhydramine | 2 | 2 | | | | | diphenhydramine | 0.71 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol ethanol | 3 | 3 | | | | | ethanol ethanol | 0.07% (wt/Vol) In Whole Blood @ Autopsy 0.09% (wt/Vol) In Vitreous @ |
| 322pai | 24 y M | | 5 | J | A | Ingst+ Unk | Int-A | 2 | Culturor | Autopsy |
| | | morphine | 1 | 1 | | | | | morphine | 0.15 mcg/mL In Whole Blood @ Autopsy |
| | | oxycodone acetaminophen/ hydrocodone | 2 3 | 2 3 | | | | | | |
| 323pai | 24 y M | fluoxetine | 4 | 4 | A | Ingst | Int-A | 2 | | |
| | Ž | acetaminophen/ hydrocodone | 1 | 1 | | J | | | hydrocodone | 0.17 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.19% (wt/Vol) In Vitreous @ Autopsy |
| | | ethanol mirtazapine | 2 | 2 | | | | | ethanol | 0.22% (wt/Vol) In Blood (unspecified) @ Autopsy |
| | | citalopram | 4 | 4 | | | | | | |
| 324p | 25 y F | methadone | 1 2 | 1 | A | Ingst | Unk | 2 | | |
| 325i | 25 y F | carbamazepine acetaminophen/ | 1 | 2 | С | Ingst+ Inhal | Int-S | 1 | | |
| | | diphenhydramine ethanol morphine | 2 3 | 2 3 | | | | | | |
| | | cocaine | 4 | 4 | | | | | | |
| | | diazepam | 5 | 5 | | | | | | |
| 326a | 25 y F | opiod/salicylate | 6 | 6 | U | Ingst | Int-S | 1 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 22 mcg/mL In Serum @ Unknown |
| | | acetaminophen/ hydrocodone acetaminophen/ | 1 2 | 1 2 | | | | | hydrocodone | 26 ng/mL In Blood (unspecified) @ Autopsy |
| | | hydrocodone acetaminophen | 3 | 3 | | | | | | |
| | | alprazolam | 4 | 4 | | | | | | |
| | | lorazepam | 5 | 5 | | | | | | |
| | | hydromorphone skeletal muscle relaxant | 6 7 | 6 7 | | | | | | |
| 327 | 25 y M | | | | A | Ingst | Int-S | 1 | | |
| 220n=: | 25 17 | salicylate | 1 | 1 | A | Inact | Int M | 1 | salicylate | 108.1 mg/dL In Serum @ 0 h (pe) |
| 328pai | 25 y F | methadone | 1 | 1 | A | Ingst | Int-M | 1 | | |
| | | citalopram | 2 | 2 | | | | | | |
| 329p | 25 y F | • | | | A | Ingst | Unk | 2 | | |
| | | methadone | 1 | 1 | | | | | | |
| | | opioid | 2 | 2 | | | | | | |
| 330 | 25 y F-P | benzodiazepine regnant acetaminophen | 3 | 3 | U | Ingst | Int-S | 1 | acetaminophen | 14 mcg/mL In Blood (unspecified) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 11 h (pe) 43 mcg/mL In Blood (unspecified) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------------|-------------------|---------------|------------|--------|---------|-----|--------------------------------|--|
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 8 mcg/mL In Blood (unspecified) @ 2 d (pe) |
| | | salicylate | 2 | 2 | | | | | salicylate | 40 mcg/mL In Blood (unspecified) @ Unknown |
| | | salicylate | 2 | 2 | | | | | salicylate | 43 mcg/mL In Blood (unspecified) |
| | | salicylate | 2 | 2 | | | | | salicylate | @ 2 d (pe) 90 mcg/mL In Blood (unspecified) |
| | | acetaminophen/ oxycodone | 3 | 3 | | | | | | @ 9 h (pe) |
| 331pa | 25 y M | methadone | 1 | 1 | A | Ingst | Int-U | 2 | methadone | 0.2 mg/L In Whole Blood @ |
| 332 | 25 y M | ethanol | 2 | 2 | A | Ingst | Int-S | 1 | | Autopsy |
| 332 | 23 y 141 | salicylate | 1 | 1 | 71 | mgst | IIID | 1 | salicylate | 102 mg/dL In Serum @ Unknown |
| 222- | 25 M | ibuprofen | 2 | 2 | Α. | Toront | I4 C | 1 | | |
| 333a | 25 y M | acetaminophen/ diphenhydramine | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 692 mcg/mL In Plasma @ 0 h (pe) |
| 334 | 26 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 335p | 26 y F | diphenhydramine | | | U | Ingst | Int-U | 2 | | |
| эээр | 20) 1 | tramadol acetaminophen/ | 1 3 | 1 2 | C | 111890 | mi c | - | | |
| | | hydrocodone tricyclic | 2 | 4 | | | | | | |
| 336 | 26 y F | antidepressant | | | U | Ingst | Int-U | 1 | | |
| | | acetaminophen* | 1 | 1 | | 8 | | | | |
| 337 | 26 y F | drug, unknown* | 2 | 1 | A | Ingst | Int-S | 1 | | |
| 337 | 20 y 1 | acetaminophen | 1 | 1 | Α | nigst | 1111-13 | 1 | acetaminophen | 148 mcg/mL In Plasma @ Unknow |
| 338pa | 26 y M | | 1 | 1 | A | Ingst | Int-S | 2 | | 100 / I I- S @ II-l |
| | | acetaminophen acetaminophen | 1 1 | 1 1 | | | | | acetaminophen acetaminophen | 100 mcg/mL In Serum @ Unknown 72 mcg/mL In Serum @ Unknown |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 751 mg/L In Gastric (stomach content) @ Autopsy |
| | | oxycodone | 2 | 2 | | | | | | |
| | | benzodiazepine acetaminophen/ | 3 4 | 3 4 | | | | | alprazolam hydrocodone | 0.01 mg/L In Serum @ Autopsy 0.02 mg/L In Blood (unspecified) @ |
| | | hydrocodone acetaminophen/ | 4 | 4 | | | | | hydrocodone | Autopsy 4 mg/L In Gastric (stomach content |
| | | hydrocodone carisoprodol | 5 | 5 | | | | | carisoprodol | @ Autopsy 16 mg/L In Blood (unspecified) @ |
| | | carisoprodol | 5 | 5 | | | | | carisoprodol | Autopsy 17500 mg/L In Gastric (stomach |
| 339pai | 26 y M | | | | U | Ingst | Int-A | 2 | | content) @ Autopsy |
| | J | methadone | 1 | 1 | | C | | | methadone | 0.4 mcg/L In Whole Blood @ Autopsy |
| 340pha | 27 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 1 | hydrocodone | 543 ng/mL In Urine (quantitative |
| | | hydrocodone acetaminophen/ | 1 | 1 | | | | | acetaminophen | only) @ 1 h (pe) 97 mcg/mL In Serum @ 1 h (pe) |
| | | hydrocodone cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | 0.28 mg/L In Blood (unspecified) |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | @ 1 h (pe) 136 mg/kg In Gastric (stomach |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | content) @ Autopsy 2.4 mg/kg In Liver @ Autopsy |
| | | lamotrigine | 3 | 3 | | | | | , | 0 0ray |
| 341pai | 27 y F | oxycodone | 1 | 1 | U | Ingst | Int-A | 3 | oxycodone | 1260 ng/mL In Blood (unspecified) @ Autopsy |
| | | oxycodone | 1 | 1 | | | | | oxymorphone | 20.1 ng/mL In Blood (unspecified) @ Autopsy |
| | | oxycodone diazepam | 2 5 | 2 5 | | | | | diazepam | 66 ng/mL In Blood (unspecified) @ |
| | | diazepam | 5 | 5 | | | | | nordiazepam | Autopsy 96.2 ng/mL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------------|-------------------|---------------|------------|--------------|---------|-----|-----------------------------|---|
| 342p | 27 y M | | | | A | Ingst | Int-A | 3 | | |
| _ | • | methadone | 1 | 1 | | | | | | |
| | | alprazolam | 2 | 2 | | | | | | |
| 343p | 27 y F | | | | A | Ingst | Int-S | 2 | | |
| | | acetaminophen/ diphenhydramine | 1 | 1 | | | | | | |
| 344a | 27 y M | diphennydrannne | | | A | Ingst | Int-S | 1 | | |
| 5114 | 27 9 111 | salicylate | 1 | 1 | 11 | mgst | III S | • | | |
| 345 | 27 y F | • | | | A | Ingst | Int-S | 1 | | |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 15 mcg/mL In Blood (unspecified) |
| | | hydrocodone | • | | | | | | | @ Unknown |
| | | methadone | 2 3 | 2 3 | | | | | | |
| 346a | 27 y M | benzodiazepine | 3 | 3 | A | Ingst | Int-S | 1 | | |
| J-10a | 27 y 141 | salicylate | 1 | 1 | 71 | mgst | IIIt-5 | 1 | salicylate | 80 mg/dL In Plasma @ Unknown |
| 347p | 27 y M | | | | U | Ingst+ Aspir | Unk | 2 | | |
| * | • | methadone | 1 | 1 | | | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | oxycodone | 2 | 2 | | | | | | |
| | | carisoprodol | 3 4 | 3 | | | | | | |
| 348 | 27 y F | alprazolam | 4 | 4 | A | Ingst | Int-S | 1 | | |
| 510 | 27 9 1 | acetaminophen/ | 2 | 1 | 11 | mgst | III S | • | acetaminophen | 76 mcg/mL In Blood (unspecified) |
| | | oxycodone | | | | | | | | @ Unknown |
| | | phenobarbital | 1 | 2 | | | | | phenobarbital | 50.6 mg/L In Blood (unspecified) @ |
| | | | | | | | | | | Unknown |
| 349 | 27 y M | | 1 | 1 | A | Ingst | Int-S | 1 | | 91 |
| | | salicylate acetaminophen | 1 2 | 1 2 | | | | | salicylate acetaminophen | 81 mg/dL In Serum @ 5 h (pe) 32 mcg/mL In Serum @ 5 h (pe) |
| | | acetaminophen/ | 3 | 3 | | | | | acctammophen | 32 meg/m2 m serum @ 3 n (pc) |
| | | diphenhydramine | | | | | | | | |
| 350p | 27 y M | | | | A | Ingst | Int-S | 2 | | |
| | | tramadol | 1 | 1 | | | | | | |
| | | methamphetamine | 2 | 2 | | | | | | |
| 351 | 27 - F | cocaine | 3 | 3 | С | Turnet | Total M | 3 | | |
| 331 | 27 y F | acetaminophen | 1 | 1 | C | Ingst | Int-M | 3 | acetaminophen | 42 mg/L In Plasma @ Unknown |
| | | ibuprofen | 2 | 2 | | | | | шескиннориен | .2 mg/2 m r monm e emmown |
| | | ethanol | 3 | 3 | | | | | | |
| 352p | 27 y F | | | | U | Ingst | Int-S | 2 | | |
| | | fentanyl | 1 | 1 | | | | | | |
| | | alprazolam | 2 3 | 2 3 | | | | | | |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | | |
| 353pai | 27 y F | nydrocodone | | | A | Ingst+ Par | Int-A | 1 | | |
| | | morphine | 1 | 1 | | 6 | | | morphine (free) | 0.17 mcg/mL In Vitreous @ |
| | | • | | | | | | | | Autopsy |
| | | morphine | 1 | 1 | | | | | morphine (free) | 0.48 mcg/mL In Blood (unspecified) |
| | | 1. 1 1 1 . | 2 | 2 | | | | | | @ Autopsy |
| | | diphenhydramine citalopram | 2 3 | 2 | | | | | | |
| 354pa | 28 y M | Citalopiani | 3 | 3 | U | Unk | Int-A | 2 | | |
| 55 ipu | 20) 111 | drug, unknown* | 2 | 1 | O | Olik | 1111 71 | - | | |
| | | methadone* | 1 | 1 | | | | | methadone | 320 ng/mL In Urine (quantitative |
| | | | | | | | | | metabolite | only) @ Autopsy |
| | | methadone* | 1 | 1 | | | | | morphine (free) | 40 ng/mL In Bile @ Autopsy |
| | | methadone* | 1 | 1 | | | | | methadone | 510 ng/mL In Blood (unspecified) |
| | | methadone* | 1 | 1 | | | | | methadone | @ Autopsy 55 ng/mL In Blood (unspecified) @ |
| | | . Tie ti tudo i te | 1 | 1 | | | | | metabolite | Autopsy |
| | | methadone* | 1 | 1 | | | | | methadone | 6800 ng/mL In Bile @ Autopsy |
| | | methadone* | 1 | 1 | | | | | methadone | 720 ng/mL In Urine (quantitative |
| | | | | | | | | | | only) @ Autopsy |
| | | methadone* | 1 | 1 | | | | | methadone | 9400 ng/mL In Bile @ Autopsy |
| 2550 | 20 E | | | | II | Unle | Link | 2 | metabolite | |
| 355a | 28 y F | fentanyl | 1 | 1 | U | Unk | Unk | 2 | norfentanyl | 3.6 ng/mL In Blood (unspecified) @ |
| | | (transdermal) | 1 | 1 | | | | | noncinanyi | Autopsy |
| | | fentanyl (| 1 | 1 | | | | | fentanyl | 5 ng/mL In Blood (unspecified) @ |
| | | transdermal) | | | | | | | - | Autopsy |
| 256 | 20 - | mirtazapine | 2 | 2 | ~ | | | _ | | |
| 356a | 28 y F | | 1 | 1 | С | Ingst | Int-M | 2 | | |
| | | acetaminophen | 1 | 1 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|--------------|--------|-----|--------------------------------|--|
| 357 | 28 y M | | | | С | Ingst | Int-A | 3 | | |
| | Ĭ | acetaminophen/ | 1 | 1 | | Ü | | | | |
| | | hydrocodone oxymorphone (extended release) | 2 | 2 | | | | | | |
| | | ketamine | 3 | 3 | | | | | | |
| | | clonidine | 4 | 4 | | | | | | |
| 358pi | 28 y M | gabapentin | 5 | 5 | U | Inhal+ Unk | Int-A | 1 | | |
| эорг | 20 y W | oxycodone | 1 | 1 | U | Illiai+ Ulik | IIIt-A | 1 | | |
| | | THC homolog | 2 | 2 | | | | | | |
| 359a | 28 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | hydrocodone | | | | | | | | |
| | | trazodone | 2 | 2 | | | | | trazodone | 4.05 mg/L In Blood (unspecified) (Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 20 mg/dL In Vitreous @ Autopsy |
| | | clonazepam | 4 | 4 | | | | | clonazepam | 53 ng/mL In Blood (unspecified) @ Autopsy |
| 360a | 28 y F | | | | U | Ingst | Int-A | 1 | | 1.7 |
| | | methadone | 1 | 1 | | | | | methadone | 0.46 mcg/mL In Whole Blood @ Autopsy |
| | | methadone | 1 | 1 | | | | | methadone | 1.9 Other (see abst) In Liver @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.18 mcg/mL In Whole Blood @ Autopsy |
| 361 | 28 y M | acetaminophen | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 29 mcg/mL In Blood (unspecified) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 29 h (pe) 33 mcg/mL In Blood (unspecified) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 48 h (pe) 58 mcg/mL In Blood (unspecified) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 39 h (pe) 63 mcg/mL In Blood (unspecified) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 34 h (pe) 99 mcg/mL In Blood (unspecified) |
| | | ueeummopmen | • | • | | | | | шесиннориен | @ 23.5 h (pe) |
| 362 | 28 y F | | 1 | 1 | A/C | Ingst | Int-S | 1 | | 97 / L. C @ Lini |
| | | acetaminophen acetaminophen/ | 1 2 | 1 2 | | | | | acetaminophen acetaminophen | 87 mcg/mL In Serum @ Unknown 16 mcg/mL In Serum @ Unknown |
| | | hydrocodone acetaminophen/ | 2 | 2 | | | | | acetaminophen | 34 mcg/mL In Serum @ Unknown |
| | | hydrocodone | | | | | | | | S |
| 363pa | 28 y F | | 1 | 1 | U | Par | Int-A | 1 | | |
| | | opioid amphetamine | 1 2 | 1 2 | | | | | | |
| 364a | 28 y F | шприсшине | - | - | A | Ingst | Int-A | 3 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.4 mg/L In Blood (unspecified) @ |
| | | cocaine | 2 | 2 | | | | | benzoylecognine | Autopsy 0.1 mg/L In Blood (unspecified) @ |
| | | cocame | 2 | 2 | | | | | benzoyiecoginne | Autopsy |
| 365 | 28 y F | | 2 | 1 | A | Ingst | Int-S | 1 | | 52 / I I C @ III |
| | | acetaminophen salicylate | 2 1 | 1 2 | | | | | acetaminophen salicylate | 52 mcg/mL In Serum @ Unknown 5 mg/dL In Serum @ Unknown |
| 366pai | 28 y M | propoxyphene | 1 | 1 | U | Ingst | Int-A | 1 | norpropoxyphene | 2 mcg/mL In Whole Blood @ |
| | | | | | | | | | | Autopsy |
| | | propoxyphene | 1 | 1 | | | | | propoxyphene | 2.6 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.09% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.13% (wt/Vol) In Vitreous @ Autopsy |
| 367pai | 28 y F | acetaminophen/ hydrocodone | 1 | 1 | A | Ingst | Int-A | 2 | hydrocodone | 0.16 mcg/mL In Whole Blood @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 114 ng/mL In Whole Blood @ |
| | | amitriptyline | 3 | 3 | | | | _ | | Autopsy |
| 368pai | 28 y M | methadone | 1 | 1 | A | Ingst | Int-A | 2 | methadone | 0.18 Other (see abst) In Liver @ |
| | | methadone | 1 | 1 | | | | | methadone | Autopsy 0.46 mcg/mL In Whole Blood @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--|-------------------|---------------|------------|--------------|----------|-----|------------------|--|
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.18 mcg/mL In Whole Blood @ Autopsy |
| 369pai | 28 y M | diazepam | 3 | 3 | U | Ingst+ Unk | Int-A | 2 | | |
| зоэрш | 20 9 111 | morphine | 1 | 1 | C | ingst v Olik | 1111 | 2 | morphine (free) | 0.16 mcg/mL In Whole Blood @ Autopsy |
| | | tramadol | 2 | 2 | | | | | tramadol | 0.5 mcg/mL In Whole Blood @ |
| | | ethanol | 3 | 3 | | | | | ethanol | Autopsy 0.2% (wt/Vol) In Whole Blood @ |
| | | ethanol | 3 | 3 | | | | | ethanol | Autopsy 0.27% (wt/Vol) In Vitreous @ Autopsy |
| | | diazepam chlordiazepoxide | 4 5 | 4 5 | | | | | | лиюрзу |
| 370pai | 28 y M | propoxyphene | 1 | 1 | U | Ingst | Int-A | 2 | norpropoxyphene | 2 mcg/mL In Whole Blood @ |
| | | propoxyphene | 1 | 1 | | | | | propoxyphene | Autopsy 2.6 mcg/mL In Whole Blood @ |
| | | ethanol | 2 | 2 | | | | | ethanol | Autopsy 0.09% (wt/Vol) In Whole Blood @ |
| | | ethanol | 2 | 2 | | | | | ethanol | Autopsy 0.13% (wt/Vol) In Vitreous @ |
| 371p | 28 y F | | 4 | | A | Ingst | Int-U | 2 | | Autopsy |
| 372pai | 28 y F | acetaminophen | 1 | 1 | A | Ingst | Int-A | 2 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.25 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 75 ng/mL In Whole Blood @ Autopsy |
| 373pa | 29 y M | oxymorphone | 1 | 1 | U | Ingst | Int-U | 1 | oxymorphone | 0.044 mg/L In Blood (unspecified) |
| | | (extended release) oxymorphone | 1 | 1 | | | | | oxymorphone | @ Autopsy 0.069 mg/L In Blood (unspecified) |
| | | (extended release) ethanol | 2 | 2 | | | | | ethanol | @ Autopsy 110 mg/dL In Blood (unspecified) |
| | | acetaminophen/ | 3 | 3 | | | | | | @ Autopsy |
| 374pai | 29 y M | hydrocodone | | | U | Ingst | Int-A | 2 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.3 mcg/mL In Whole Blood @ Autopsy |
| | | codeine | 2 | 2 | | | | | codeine | 0.26 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | | |
| | | alprazolam | 4 | 4 | | | | | alprazolam | 64 ng/mL In Whole Blood @ Autopsy |
| 375pa | 29 y M | morphine | 1 | 1 | A | Ingst+ Par | Unk | 1 | morphine | 167 ng/mL In Plasma @ Unknown |
| 376pa | 29 y M | ethanol | 2 | 2 | A/C | Ingst | Int-A | 1 | ethanol | 240 mg/dL In Serum @ Unknown |
| - · · · · · · | | methadone | 1 | 1 | | 8. | | | methadone | 0.1 mg/L In Blood (unspecified) @ Autopsy |
| | | alprazolam* cocaine* | 3 2 | 2 2 | | | | | | 1 3 |
| 377pai | 29 y M | oxycodone | 1 | 1 | A | Ingst | Int-A | 2 | oxycodone | 0.25 mcg/mL In Whole Blood @ |
| | | oxycodone | 1 | 1 | | | | | oxymorphone | Autopsy 39 ng/mL In Whole Blood @ |
| 378 | 30 y F | on code one | - | • | A/C | Ingst | Int-M | 1 | on in or priorie | Autopsy |
| 376 | 30 y 1 | acetaminophen/ | 1 | 1 | AC | mgst | 1111-141 | 1 | acetaminophen | 140 mcg/mL In Serum @ 9.65 h |
| | | diphenhydramine acetaminophen/ | 1 | 1 | | | | | acetaminophen | (pe) 185.5 mcg/mL In Serum @ 6 h (pe) |
| | | diphenhydramine acetaminophen/ | 1 | 1 | | | | | acetaminophen | 25 mcg/mL In Serum @ 54 h (pe) |
| | | diphenhydramine acetaminophen/ | 1 | 1 | | | | | acetaminophen | 36 mcg/mL In Serum @ 43.67 h |
| | | diphenhydramine acetaminophen/ | 1 | 1 | | | | | acetaminophen | (pe) 52 mcg/mL In Serum @ 30 h (pe) |
| | | diphenhydramine acetaminophen/ diphenhydramine | 1 | 1 | | | | | acetaminophen | 97 mcg/mL In Serum @ 17.83 h (pe) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---------------------------------|-------------------|---------------|------------|------------|---------|-----|------------------|--|
| 379pa | 30 y M | codeine* | 1 | 1 | A | Par | Int-S | 2 | morphine | 1.7 Other (see abst) In Liver @ |
| | | insulin* | 2 | 1 | | | | | | Autopsy |
| 380pa | 30 y F | oxycodone | 1 | 1 | U | Ingst | Unk | 1 | oxycodone | 0.61 mcg/mL In Blood (unspecified) |
| | | diphenhydramine | 2 | 2 | | | | | diphenhydramine | @ Autopsy 0.47 mcg/mL In Blood (unspecified) @ Autopsy |
| | | temazepam | 3 | 3 | | | | | | |
| | | mirtazapine gabapentin | 4 5 | 4 5 | | | | | | |
| 381 | 30 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | acetaminophen acetaminophen/ | 1 2 | 1 2 | | | | | | |
| | | diphenhydramine carisoprodol | 3 | 3 | | | | | | |
| 382pai | 30 y F | fentanyl | 1 | 1 | U | Ingst | Int-A | 2 | fentanyl | 7.1 ng/mL In Whole Blood @ |
| | | (transdermal) diazepam | 2 | 2 | | | | | nordiazepam | Unknown 1.4 mcg/mL In Whole Blood @ |
| | | diazepam | 2 | 2 | | | | | diazepam | Unknown 1.7 mcg/mL In Whole Blood @ |
| 383p | 30 y F | | | | A | Ingst | Int-S | 2 | | Unknown |
| 363р | 30 y 1 | acetaminophen/ hydrocodone | 1 | 1 | A | nigst | IIIC-S | 2 | acetaminophen | 41.9 mcg/mL In Serum @ Unknown |
| 384pai | 30 y F | salicylate | 2 | 2 | A | Ingst | Int-A | 2 | salicylate | 10 mg/dL In Serum @ Unknown |
| 30-траі | 30 y 1 | methadone | 1 | 1 | A | mgst | IIIt-A | 2 | methadone | 0.65 mcg/mL In Whole Blood @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 41 ng/mL In Whole Blood @ |
| 385pai | 30 y F | | | | U | Ingst+ Unk | Int-A | 2 | | Autopsy |
| | | fentanyl | 1 | 1 | | | | | fentanyl | 7.1 ng/mL In Whole Blood @ Unknown |
| | | diazepam | 2 | 2 | | | | | nordiazepam | 1.4 mcg/mL In Whole Blood @ Unknown |
| | | diazepam | 2 | 2 | | | | | diazepam | 1.7 mcg/mL In Whole Blood @ Unknown |
| 386pai | 30 y F | / | 1 | 1 | U | Ingst | Int-A | 2 | hadaa aadaa a | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.09 mcg/mL In Whole Blood @ Autopsy |
| | | tramadol | 2 | 2 | | | | | tramadol | 1.1 mcg/mL In Whole Blood @ Autopsy |
| 207 | 20 E | cyclobenzaprine | 3 | 3 | A (C) | Torres | Total C | 2 | | 1 2 |
| 387 | 30 y F | acetaminophen/ hydrocodone | 1 | 1 | A/C | Ingst | Int-S | 3 | | |
| 388 | 30 y M | buprenorphine/ | 1 | 1 | A | Ingst | Int-U | 2 | | |
| | | naloxone (sublingual) | • | • | | | | | | |
| 200 : | 20 - E | benzodiazepine | 2 | 2 | ** | ** 1 | ** 1 | | | |
| 389ai | 30 y F | oxycodone | 1 | 1 | U | Unk | Unk | 1 | oxycodone | 0.58 mg/L In Blood (unspecified) @ |
| | | oxycodone | 1 | 1 | | | | | oxycodone | Autopsy 0.7 mg/L In Blood (unspecified) @ |
| | | antihistamine | 2 | 2 | | | | | diphenhydramine | Autopsy 0.72 mg/L In Blood (unspecified) @ |
| | | antihistamine | 2 | 2 | | | | | diphenhydramine | Autopsy 1.1 mg/L In Blood (unspecified) @ |
| | | antihistamine | 2 | 2 | | | | | diphenhydramine | Autopsy 4.3 mg/kg In Liver @ Autopsy |
| 390pai | 30 y M | morphine | 1 | 1 | A | Ingst | Int-S | 3 | morphine (free) | 1.7 Other (see abst) In Liver @ |
| | | ethanol | 2 | 2 | | | | | ethanol | Autopsy 0.03% (wt/Vol) In Urine (quantita- |
| | | ethanol | 2 | 2 | | | | | ethanol | tive only) @ Autopsy 0.1% (wt/Vol) In Whole Blood @ |
| | | dextromethorphan | 3 | 3 | | | | | dextromethorphan | Autopsy 74 Other (see abst) In Liver @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|------------------------------|-------------------|---------------|------------|--------------|--------|-----|---|---|
| 391pa | 31 y F | methadone | 1 | 1 | A | Ingst | Unk | 2 | methadone | 0.13 mg/L In Blood (unspecified) @ |
| | | methadone | 1 | 1 | | | | | methadone | Autopsy 0.25 mg/L In Blood (unspecified) @ |
| | | alprazolam | 3 | 2 | | | | | alprazolam | Unknown 0.073 mg/L In Blood (unspecified) @ |
| | | trazodone cyclobenzaprine | 2 4 | 3 4 | | | | | cyclobenzaprine | Unknown 0.05 mg/L In Blood (unspecified) @ |
| | | ethanol | 5 | 5 | | | | | ethanol | Autopsy 9 mg/dL In Blood (unspecified) @ |
| 392pa | 31 y M | | | | A | Ingst+ Aspir | Int-U | 1 | | Unknown |
| _ | | fentanyl | 1 | 1 | | | | | | |
| 393 | 31 y M | salicylate | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | doxylamine | 2 | 2 | | | | | | |
| | | famotidine | 3 | 3 | | | | | | |
| | | diphenhydramine | 4 | 4 | | | | | | |
| 394p | 31 y F | | | | A | Ingst+ Unk | Int-S | 3 | | |
| | | methadone | 1 | 1 | | | | | | |
| | | alprazolam | 2 3 | 2 3 | | | | | | |
| 395p | 31 y F | opioid | 3 | 3 | A/C | Ingst | Int-U | 2 | | |
| 373р | 31 y 1 | benzodiazepine | 1 | 8 | 740 | mgst | IIIt-O | _ | | |
| | | alprazolam | 2 | 9 | | | | | | |
| 396pai | 31 y M | | | | A | Ingst | Int-S | 2 | | |
| | | propoxyphene | 1 | 1 | | | | | norpropoxyphene | 5.3 Other (see abst) In Liver @ Autopsy |
| | | propranolol | 2 | 2 | | | | | propranolol | 1.4 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 3 | 3 | | | | | alprazolam | 111 ng/mL In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant | 4 | 4 | | | | | carisoprodol | 19 mcg/mL In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant | 4 | 4 | | | | | meprobamate | 5.9 mcg/mL In Whole Blood @ Autopsy |
| | | lamotrigine | 5 | 5 | | | | | | |
| 397p | 32 y F | d d | 4 | 4 | A/C | Ingst | Int-A | 2 | | |
| | | methadone ethanol | 1 2 | 1 2 | | | | | | |
| 398pa | 32 y M | Culation | 2 | 2 | С | Ingst | Unk | 2 | | |
| элори | 32 y 111 | oxycodone | 1 | 1 | C | 111551 | CHK | - | oxycodone | 171 ng/mL In Blood (unspecified) |
| | | , , , , , , | | | | | | | , | @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 44.2 ng/mL In Blood (unspecified) @ Autopsy |
| 399p | 32 y M | | | | A | Ingst | Int-S | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| | | hydrocodone | 2 | 2 | | | | | | |
| 400pa | 32 y M | carisoprodol | 2 | 2 | U | Ingst | Int-U | 1 | | |
| тоори | 32 y 111 | fentanyl (transdermal) | 1 | 1 | C | 111551 | III C | 1 | | |
| | | oxycodone | 2 | 2 | | | | | | |
| | | cyclobenzaprine | 3 | 3 | | | | | | |
| | | fluphenazine | 4 | 4 | | | | | | |
| 401pai | 32 y F | oxycodone | 1 | 1 | A/C | Ingst | Int-U | 3 | oxycodone | 0.38 mcg/mL In Whole Blood @ |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | Autopsy 0.12 mcg/mL In Whole Blood @ |
| | | venlafaxine | 3 | 3 | | | | | venlafaxine | Autopsy 1.4 mcg/mL In Whole Blood @ |
| | | amitriptyline | 4 | 4 | | | | | nortriptyline | Autopsy 0.37 mcg/mL In Whole Blood @ |
| 402p | 32 y M | | | | U | Ingst+ Derm | Int-U | 1 | | Autopsy |
| 402p | 32 y IVI | acetaminophen/ | 2 | 1 | U | nigst+ Denn | IIII-U | 1 | | |
| | | hydrocodone | - | • | | | | | | |
| | | fentanyl (transdermal) | 1 | 2 | | | | | norfentanyl | 1.6 ng/mL In Blood (unspecified) @ 10 m (pe) |
| | | fentanyl (transdermal) | 1 | 2 | | | | | fentanyl | 2.3 ng/mL In Blood (unspecified) @ 15 m (pe) |
| | | diazepam | 3 | 3 | | | | | nordiazepam | 190 ng/mL In Blood (unspecified) @ 10 m (pe) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|----------------------------------|-------------------|---------------|------------|-------|---------|-----|--------------------------------|--|
| | | diazepam | 3 | 3 | | | | | diazepam | 430 ng/mL In Blood (unspecified) @ 10 m (pe) |
| | | carisoprodol | 4 | 4 | | | | | | @ 10 m (pc) |
| 403pai | 32 y M | methadone | 1 | 1 | U | Ingst | Int-A | 2 | methadone | 1 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | | |
| 404pai | 32 y F | oxycodone | 1 | 1 | A | Ingst | Int-U | 2 | oxycodone | 0.38 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.12 mcg/mL In Whole Blood @ Autopsy |
| | | amitriptyline | 3 | 3 | | | | | nortriptyline | 0.37 mcg/mL In Whole Blood @ Autopsy |
| | | venlafaxine | 4 | 4 | | | | | venlafaxine | 1.4 mcg/mL In Whole Blood |
| 405ai | 32 y M | | | | U | Ingst | Int-A | 2 | | @ Autopsy |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 0.37 mcg/mL In Whole Blood @ Unknown |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 149 mcg/mL In Whole Blood @ Unknown |
| 406pai | 32 y F | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 0.24 mcg/mL In Whole Blood |
| | | skeletal muscle | 2 | 2 | | | | | meprobamate | @ Autopsy 11.1 mcg/mL In Whole Blood @ |
| | | relaxant | | | | | | | • | Autopsy |
| | | skeletal muscle relaxant | 2 | 2 | | | | | carisoprodol | 11.5 mcg/mL In Whole Blood @ Autopsy |
| | | diphenhydramine valproic acid | 3 4 | 3 4 | | | | | | |
| 407pai | 32 y M | varprote acid | 7 | 7 | U | Ingst | Unk | 2 | | |
| | | acetaminophen/ oxycodone* | 1 | 1 | | | | | oxycodone | 255 ng/mL In Blood (unspecified) @ Autopsy |
| | | alprazolam* | 3 | 1 | | | | | alprazolam | 52.3 ng/mL In Blood (unspecified) @ Autopsy |
| | | fentanyl* | 2 | 1 | | | | | fentanyl | 5 ng/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 4 | 2 | | | | | 7-aminoclonaze- pam | 49.5 ng/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 4 | 2 | | | | | clonazepam | 6.4 ng/mL In Blood (unspecified) @ Autopsy |
| | | carisoprodol | 5 6 | 3 4 | | | | | the (tetrohydrogen | 6.2 ng/mL In Blood (unspecified) @ |
| | | marijuana | Ü | 4 | | | | | nabinol) | Autopsy |
| 408pa | 32 y F | morphine | 1 | 1 | A | Ingst | Unt-U | 2 | morphine | 1.1 mg/L In Blood (unspecified) @ |
| 400 | 22 F | • | | | ** | T 4 | Total C | | Î | Autopsy |
| 409 | 33 y F | acetaminophen/ hydrocodone | 1 | 1 | U | Ingst | Int-S | 1 | acetaminophen | 435 mcg/mL In Blood (unspecified) @ Unknown |
| | | fluoxetine | 2 | 2 | | | | | | |
| 410 | 22 v. E | ibuprofen | 3 | 3 | U | Inact | Int II | 1 | | |
| 410 | 33 y F | acetaminophen/ hydrocodone | 1 | 1 | U | Ingst | Int-U | 1 | acetaminophen | 11.1 mcg/mL In Blood (unspecified @ Unknown |
| | | ethanol | 2 | 2 | | | | | ethanol | 77 mg/dL In Blood (unspecified) @ Unknown |
| 411a | 33 y F | | | | A | Ingst | Int-S | 1 | | |
| | | acetaminophen* acetaminophen* | 2 2 | 1 1 | | | | | acetaminophen acetaminophen | 75 mcg/mL In Serum @ Unknown 82.4 mg/mL In Blood (unspecified) @ Unknown |
| | | diphenhydramine* lorazepam | 1 3 | 1 2 | | | | | lorazepam | 755 ng/mL In Blood (unspecified) |
| | | codeine | 4 | 3 | | | | | codeine | @ Autopsy 540 ng/mL In Blood (unspecified) |
| | | mirtazapine | 5 | 5 | | | | | | @ Autopsy |
| 412pa | 33 y F | • | | | A | Ingst | Int-U | 3 | | |
| | | methadone | 1 | 1 | | | | | methadone | 110 ng/mL In Whole Blood @ Unknown |
| | | paroxetine | 2 | 2 | | | | | paroxetine | 190 ng/mL In Whole Blood @ Unknown |
| | | alprazolam | 3 | 3 | | | | | alprazolam | 16 ng/mL In Whole Blood @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|------------|------------------------------------|-------------------|---------------|------------|--------------|---------|-----|-----------------|---|
| 413pa | 33 y M | | | | U | Unk | Unk | 2 | | |
| • | • | buprenorphine | 1 | 1 | | | | | | |
| | | cocaine | 2 | 2 | | | | | | |
| 114 | 33 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | acetaminophen | 4 | 1 | | | | | acetaminophen | 0 mcg/mL In Blood (unspecified) @ Unknown |
| | | quetiapine lithium | 2 | 2 3 | | | | | lithium | 2.4 mEq/L In Blood (unspecified) @ |
| | | | | | | | | | | Unknown |
| | | lamotrigine | 5 | 4 | | | | | | |
| | | topiramate | 6 | 5 | | | | | | |
| | | paroxetine | 7 | 6 | | | | | | |
| | | loratadine | 8 | 7 | | | | | | |
| | | diphenhydramine | 3 | 8 | | | | | | |
| | | acetaminophe/ dextromethorphan/ | 9 | 9 | | | | | | |
| | | decongestant | | | | | | | | |
| 415pai | 33 y M | | | | U | Derm | Int-A | 3 | | |
| | | fentanyl (transdermal) | 1 | 1 | | | | | fentanyl | 19.6 ng/mL In Whole Blood @ Autopsy |
| 416a | 33 y F | | | | A/C | Ingst | Int-U | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 55.7 mcg/mL In Blood (unspecified) |
| | | hydrocodone | | | | | | | | @ Unknown |
| 417p | 33 y M | | | | A | Ingst | Unt-G | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 17 mcg/mL In Blood (unspecified) |
| | | oxycodone | | | | | | | | @ Unknown |
| 418pai | 33 y M | | | | U | Derm | Int-A | 2 | | |
| | | fentanyl | 1 | 1 | | | | | fentanyl | 19.6 ng/mL In Whole Blood @ |
| 440 | 22 5 | | | | | | ** . | | | Autopsy |
| 419 | 33 y F | | 1 | | A/C | Ingst | Unk | 2 | | 50 / I I DI 1/ (C.1) |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 52 mcg/mL In Blood (unspecified) |
| 120 | 22 14 | opioid | | | | T TT. 1 | Total A | 2 | | @ Unknown |
| 420pai | 33 y M | mamhina | 1 | 1 | A | Ingst+ Unk | Int-A | 2 | marnhina (fraa) | 0.21 mag/mL In Whala Blood @ |
| | | morphine | 1 | 1 | | | | | morphine (free) | 0.21 mcg/mL In Whole Blood @ Autopsy |
| | | trazodone | 2 | 2 | | | | | | Autopsy |
| | | citalopram | 3 | 3 | | | | | | |
| | | diphenhydramine | 4 | 4 | | | | | | |
| 421p | 34 y M | | | | U | Ingst | Int-U | 2 | | |
| ı | - 3 | buprenorphine/ naloxone | 1 | 1 | | 6 | | | | |
| | | (sublingual) | | | | | | | | |
| | | alprazolam | 2 | 2 | | | | | | |
| | | marijuana | 3 | 3 | | | | | | |
| 422p | 34 y F | • | | | A | Derm | Int-U | 2 | | |
| _ | | fentanyl (transdermal) | 1 | 1 | | | | | | |
| 423h | 34 y F | | | | A | Ingst | Int-U | 1 | | |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 110 mcg/mL In Serum @ Unknown |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 127 mcg/mL In Serum @ Unknown |
| | | quetiapine | 2 | 2 | | | | | | |
| | | ethanol | 3 | 3 | | | | | ethanol | 161 mg/dL In Blood (unspecified) |
| 10.1 | 24 35 | | | | | T . | T . C | | | @ Unknown |
| 424 | 34 y M | colinylata | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 425 | 24 - F | salicylate | 1 | 1 | | Toront | Total C | 2 | | |
| 423 | 34 y F | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 2 | acataminanhan | 44 mcg/mL In Blood (unspecified) |
| | | propoxyphene | 1 | 1 | | | | | acetaminophen | @ 16 h (pe) |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 552 mcg/mL In Blood (unspecified) |
| | | propoxyphene | 1 | 1 | | | | | acctammophen | @ 1 h (pe) |
| 426pa | 34 y F | ргорохурнене | | | U | Ingst+ Derm+ | Unk | 2 | | C In (pc) |
| ¥ | <i>y</i> - | | | | - | Par | | | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 0.53 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| | | carisoprodol | 2 | 2 | | | | | meprobamate | 12 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| | | carisoprodol | 2 | 2 | | | | | carisoprodol | 4.9 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| | | fentanyl (transdermal) | 3 | 3 | | | | | | |
| | | lidocaine | 4 | 4 | | | | | | |
| | | buprenorphine/ | 5 | 5 | | | | | | |
| | | naloxone | | | | | | | | |
| | | (sublingual) | 7 | 7 | | | | | | |
| | | alprazolam | | | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--|-------------------|---------------|------------|--------------|--------|-----|--------------------------|--|
| 427pa | 34 y M | | | | U | Ingst+ Inhal | Int-U | 2 | | |
| | | opioid cocaine | 1 2 | 1 2 | | | | | | |
| 428p | 34 y F | | | | U | Ingst+ Unk | Int-U | 2 | | |
| 429 | 34 y F | fentanyl | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | acetaminophen | 16 mcg/mL In Serum @ Unknown |
| 430a | 34 y M | carisoprodol | 2 | 2 | U | Ingst | Int-S | 1 | | |
| | , | salicylate salicylate | 1 1 | 1 1 | | 6 | | | salicylate salicylate | 110 mg/dL In Serum @ Unknown 66 mg/dL In Blood (unspecified) @ Autopsy |
| 431pai | 34 y M | buprenorphine/ naloxone (sublingual) | 1 | 1 | U | Ingst | Unk | 1 | | Ликороу |
| | | amitriptyline | 2 | 2 | | | | | amitriptyline | 100 ng/mL In Blood (unspecified) |
| | | amitriptyline | 2 | 2 | | | | | nortriptyline | @ Autopsy 59 ng/mL In Blood (unspecified) @ Autopsy |
| | | morphine | 3 | 3 | | | | | morphine (free) | 200 ng/mL In Blood (unspecified) @ Autopsy |
| 432pai | 34 y F | | 1 | 1 | U | Ingst | Int-A | 2 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.13 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 34 ng/mL In Whole Blood @ Autopsy |
| 433p | 34 y F | butalbital | 3 | 3 | A/C | Ingst+ Unk | Int-S | 1 | | |
| • | • | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 57.5 mcg/mL In Blood (unspecified @ Unknown |
| | | eszopiclone carisoprodol | 2 3 | 2 3 | | | | | | |
| 434 | 35 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 2 | acetaminophen | 30.4 mcg/mL In Unknown @ |
| 435pa | 35 y M | hydrocodone | | | U | Ingst+ | Int-S | 1 | • | Unknown |
| | 55 J 1.1 | avvaadana | 1 | 1 | C | Aspir+ Unk | III 0 | • | avvandana | 2862 ng/ml. In Pland (unemonified) |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 2862 ng/mL In Blood (unspecified) @ Autopsy |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 353 ng/mL In Urine (quantitative only) @ Autopsy |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 4371 ng/mL In Blood (unspecified) @ Autopsy |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | 102 ng/mL In Urine (quantitative only) @ Autopsy |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | 1362 ng/mL In Blood (unspecified) |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | @ Autopsy 962 ng/mL In Blood (unspecified) |
| | | diphenhydramine | 3 | 3 | | | | | diphenhydramine | @ Autopsy14567 ng/mL In Blood (unspecified |
| | | propoxyphene | 4 | 4 | | | | | propoxyphene | @ Autopsy 391 ng/mL In Blood (unspecified) |
| | | diazepam | 5 | 5 | | | | | nordiazepam | @ Autopsy 234 ng/mL In Urine (quantitative |
| | | diazepam | 5 | 5 | | | | | nordiazepam | only) @ Autopsy 5176 ng/mL In Blood (unspecified) |
| | | Î | 5 | 5 | | | | | • | @ Autopsy |
| | | diazepam | | | | | | | nordiazepam | 7477 ng/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen | 6 | 6 | | | | | acetaminophen | 98.6 mcg/mL In Blood (unspecified @ Autopsy |
| | | ethanol | 7 | 7 | | | | | ethanol | 0.023% In Urine (quantitative only) @ Autopsy |
| | | ethanol chloazepate | 7 8 | 7 8 | | | | | ethanol | 0.033% In Vitreous @ Autopsy |
| 436 | 35 y F | • | | | A/C | Ingst | Unk | 1 | | |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 148 mcg/mL In Blood (unspecified @ Unknown |
| 437pa | 35 y F | methadone | 1 | 1 | A | Ingst | Int-M | 1 | | |
| | | cyclobenzaprine alprazolam | 2 3 | 2 3 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|-----------------------------------|-------------------|---------------|------------|------------|--------|-----|--------------------------------|--|
| 438 | 35 y M | opioid | 1 | 1 | С | Ingst | Int-S | 1 | | |
| 439 | 35 y F | • | | | A | Ingst | Int-S | 1 | | |
| 440pai | 35 y F | acetaminophen | 1 | 1 | U | Ingst | Int-S | 2 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.37 mcg/mL In Whole Blood @ Autopsy |
| | | antihistamine | 2 | 2 | | | | | diphenhydramine | 1.3 mcg/mL In Whole Blood @ Autopsy |
| | | propoxyphene | 3 | 3 | | | | | propoxyphene | 1 mcg/mL In Whole Blood @ Autopsy |
| | | propoxyphene | 3 | 3 | | | | | norpropoxyphene | 2.5 mcg/mL In Whole Blood @ Autopsy |
| | | citalopram | 4 | 4 | | | | | citalopram | 1.6 mcg/mL In Whole Blood @ Autopsy |
| | | zolpidem | 5 | 5 | | | | | zolpidem | 0.34 mcg/mL In Whole Blood @ Autopsy |
| 441 | 35 y M | acetaminophen | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 442pa | 36 y F | acetaminophen | 1 | 1 | U | Ingst+ Unk | Unk | 2 | acetaminophen | 42.3 ng/mL In Blood (unspecified) |
| | | salicylate | 2 | 2 | | | | | acctammophen | @ Unknown |
| | | opioid | 3 | 4 | | | | | | |
| 443 | 36 y F | benzodiazepine | 4 | 5 | U | Ingst | Int-A | 3 | | |
| 773 | 30 y 1 | acetaminophen/ diphenhydramine | 1 | 1 | O | nigst | III-A | 3 | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 197 mcg/mL In Serum @ Unknown |
| | | acetaminophen acetaminophen | 2 2 | 2 2 | | | | | acetaminophen acetaminophen | 225 mcg/mL In Serum @ Unknowr 351 mcg/mL In Serum @ Unknowr |
| | | ibuprofen | 3 | 3 | | | | | | |
| 444p | 36 y M | acetaminophen/ propoxyphene | 1 | 1 | U | Ingst | Int-S | 1 | | |
| 445a | 36 y F | acetaminophen | 1 | 1 | U | Ingst | Int-S | 3 | acetaminophen | 20.9 mcg/mL In Blood (unspecified |
| 446pai | 36 y M | | | | A | Ingst | Int-A | 2 | | @ Unknown |
| - | | methadone | 1 | 1 | | | | | methadone | 0.18 mcg/mL In Whole Blood @ Autopsy |
| 447pai | 36 y F | propoxyphene | 1 | 1 | U | Ingst | Int-A | 2 | propoxyphene | 1.6 mcg/mL In Whole Blood @ |
| | | propoxyphene | 1 | 1 | | | | | norpropoxyphene | Autopsy 2.7 mcg/mL In Whole Blood @ |
| | | tramadol | 2 | 2 | | | | | | Autopsy |
| 448pai | 36 y M | diazepam | 3 | 3 | A | Ingst+ Unk | Int-A | 2 | | |
| ттораг | 30 y W | morphine | 1 | 1 | Α | mgst+ Onk | IIIt-A | 2 | morphine (free) | 0.55 mcg/mL In Whole Blood @ Autopsy |
| | | diphenhydramine | 4 | 2 | | | | | diphenhydramine | 0.71 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 5 | 3 | | | | | ethanol | 0.07% (wt/Vol) In Whole Blood @ Autopsy |
| | | alprazolam | 3 | 4 | | | | | alprazolam | 38 ng/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 5 | | | | | hydrocodone | 0.05 mcg/mL In Whole Blood @ Autopsy |
| 449 | 37 y F | acetaminophen/ propoxyphene | 1 | 1 | A | Ingst | Int-S | 3 | acetaminophen | 181 mcg/mL In Blood (unspecified) @ Unknown |
| 450pa | 37 y F | acetaminophen/ hydrocodone | 1 | 1 | A | Ingst | Int-U | 2 | | |
| | | clonazepam | 2 | 2 | | | | | | |
| 451 | 37 y F | acetaminophen | 1 | 1 | U | Ingst | Unk | 1 | | |
| 452pa | 37 y F | opioid | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | paroxetine | 2 | 2 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|--|-------------------|---------------|------------|--------------|---------|-----|------------------|--|
| 453 | 37 y M | acetaminophen | 1 | 1 | A/C | Ingst | Int-M | 1 | acetaminophen | 131 mcg/mL In Blood (unspecified |
| 454pa | 37 y F | | | | A | Ingst | Int-S | 1 | | @ 24 h (pe) |
| 1 | , | morphine | 1 | 1 | | J | | | morphine (free) | 112 ng/mL In Serum @ Autopsy |
| | | cyclobenzaprine* | 2 3 | 2 | | | | | cyclobenzaprine | 11 mcg/L In Plasma @ Autopsy |
| 455p | 37 y F | ethanol* | 3 | 2 | A | Ingst | Int-A | 2 | ethanol | 109 mg/dL In Plasma @ 2 h (pe) |
| | | methadone | 1 | 1 | | 8 | | | | |
| 150 | 27 14 | clonazepam | 2 | 2 | *** | T | Total C | 2 | | |
| 456p | 37 y M | buprenorphine/nalox- one (sublingual) | 1 | 1 | U | Ingst | Int-S | 2 | | |
| | | lamotrigine | 3 | 2 | | | | | | |
| 157no | 27 v E | venlafaxine | 2 | 3 | A/C | Ingst+ Derm | Int-U | 1 | | |
| 457pa | 37 y F | fentanyl | 1 | 1 | A/C | nigst+ Denn | III-U | 1 | fentanyl | 0.6 mcg/L In Blood (unspecified) @ 2 d (pe) |
| | | fentanyl | 1 | 1 | | | | | norfentanyl | 0.8 mcg/L In Blood (unspecified) @ 2 d (pe) |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.014 mg/L In Blood (unspecified) @ 1 d (pe) |
| 458 | 37 y F | gabapentin | 3 | 3 | A | Ingst | Int-S | 1 | | |
| 430 | 37 y 1 | acetaminophen | 1 | 1 | Α | nigst | IIIt-3 | 1 | | |
| | | drug, unknown | 2 | 2 | | | | | | |
| 459 | 37 y M | acataminonhan* | 1 | 1 | U | Unk | Int-S | 3 | acetaminonhan | 72 mag/ml. In Sarum @ Unknown |
| | | acetaminophen* drug, unknown* | 2 | 1 1 | | | | | acetaminophen | 73 mcg/mL In Serum @ Unknown |
| 460pai | 37 y F | | | | U | Ingst | Int-A | 2 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.16 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 51 ng/mL In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant | 3 | 3 | | | | | meprobamate | 20.1 mcg/mL In Whole Blood @ Autopsy |
| | | diltiazem quetiapine | 4 5 | 4 5 | | | | | | |
| 461pa | 37 y F | quettapine | 5 | 5 | A | Ingst | Int-S | 2 | | |
| * | • | acetaminophen/ oxycodone | 1 | 1 | | | | | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| | | fluoxetine | 3 | 3 | | | | | | |
| 462 | 37 y M | ethanol | 4 | 4 | A/C | Ingst | Int-S | 3 | | |
| 402 | 37 y W1 | acetaminophen | 1 | 1 | AC | nigst | IIIC-S | 3 | acetaminophen | 92 mcg/mL In Serum @ 16 h (pe) |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| 163noi | 27 v M | hydrocodone | | | ٨ | Inget Dorm | Int A | 2 | | |
| 463pai | 37 y M | fentanyl | 1 | 1 | A | Ingst+ Derm | Int-A | 2 | fentanyl | 10.4 ng/mL In Whole Blood @ |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | Unknown 0.07 mcg/mL In Whole Blood @ Unknown |
| 464pha | 38 y F | oxycodone | 1 | 1 | A | Ingst | Int-S | 1 | oxycodone (free) | 0.22 mg/L In Blood (unspecified) @ |
| | | lorazepam | 2 | 2 | | | | | lorazepam | Autopsy 47 mcg/mL In Blood (unspecified) |
| | | temazepam | 3 | 3 | | | | | temazepam | @ Autopsy 111 ng/mL In Blood (unspecified) |
| 465 | 38 y F | • | | | U | Unk | Unk | 2 | • | @ Autopsy |
| | • | oxycodone | 1 | 1 | | | | | | |
| 466pa | 38 y M | methadone | 1 | 1 | С | Ingst | Int-A | 1 | methadone | 200 ng/mL In Blood (unspecified) |
| | | alprazolam | 3 | 2 | | | | | alprazolam | @ Autopsy 73.2 ng/mL In Blood (unspecified) |
| | | oxycodone | 2 | 3 | | | | | oxycodone | @ Autopsy 64.2 ng/mL In Blood (unspecified) |
| | | acetaminophen | 4 | 4 | | | | | acetaminophen | @ Autopsy 4 mcg/mL In Blood (unspecified) @ |
| | | citalopram | 5 | 5 | | | | | citalopram | Autopsy 970 ng/mL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|--|-------------------|---------------|------------|-------------|--------|-----|--------------------------------|--|
| 467a | 38 y F | | | | U | Ingst | Int-M | 1 | | |
| | - | acetaminophen acetaminophen/ hydrocodone | 1 2 | 1 2 | | | | | acetaminophen | 57.5 mcg/mL In Serum @ Unknown |
| | | ethanol | 3 | 3 | | | | | | |
| 468a | 38 y F | acetaminophen/ diphenhydramine | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 107 mcg/mL In Serum @ 48 h (pe) |
| 469pa | 38 y F | oxycodone | 1 | 1 | A/C | Unk | Unk | 1 | morphine (total) | 19 ng/mL In Blood (unspecified) @ |
| | | oxycodone | 1 | 1 | | | | | oxycodone (free) | Autopsy 2500 ng/mL In Blood (unspecified) @ Autopsy |
| | | diazepam | 2 | 2 | | | | | diazepam | 140 ng/mL In Blood (unspecified) @ Autopsy |
| 470p | 38 y M | fentanyl | 1 | 1 | A | Ingst+ Derm | Int-A | 2 | | @ Autopsy |
| | | (transdermal) propoxyphene | 2 | 2 | | | | | | |
| 471pa | 38 y M | ргорохурнене | 2 | 2 | A/C | Ingst | Int-U | 2 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 274 ng/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 30.3 mcg/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | dihydrocodeine | 40 ng/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydromorphone | 6 ng/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | trazodone | 822 ng/mL In Blood (unspecified) @ Autopsy |
| 450 : | 20 5 | trazodone | 2 | 2 | | | | 2 | | |
| 472pai | 38 y F | methadone | 1 | 1 | A | Ingst | Int-U | 3 | methadone | 0.61 mcg/mL In Whole Blood @ Autopsy |
| | | venlafaxine | 2 | 2 | | | | | venlafaxine | 1.8 mcg/mL In Whole Blood @ Autopsy |
| | | amitriptyline | 3 | 3 | | | | | | |
| | | diazepam fluoxetine | 4 5 | 4 5 | | | | | | |
| 473pai | 38 y M | | | | A | Ingst | Int-U | 2 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 1.9 mcg/mL In Whole Blood @ Autopsy |
| | | laxative (stimulant) olanzapine | 2 3 | 2 3 | | | | | | |
| 474 | 38 y F | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 475 | 38 y F | butalbital/caffeine | | | A | Ingst | Int-S | 2 | | |
| 473 | 36 y 1 | acetaminophen/ hydrocodone | 1 | 1 | A | Iligst | IIIt-S | 2 | acetaminophen | 19 mcg/mL In Serum @ Unknown |
| | | valproic acid | 2 | 2 | | | | | valproic acid | 20 mcg/mL In Serum @ Unknown |
| 476 | 38 y M | salicylate | 1 | 1 | A | Ingst | Int-S | 1 | salicylate | 99.3 mg/dL In Blood (unspecified) |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | @ 1 m (pe) 35 mcg/dL In Blood (unspecified) |
| 477p | 39 y M | diphenhydramine | | | A/C | Ingst | Unk | 1 | | @ 1 m (pe) |
| +//p | 37 y WI | morphine | 1 | 1 | NC | Ingst | Olik | 1 | morphine | 0.03 mg/L In Blood (unspecified) @ Autopsy |
| | | dextromethorphan* | 2 | 2 | | | | | dextromethorphan | 0.48 mg/L In Blood (unspecified) @ Autopsy |
| | | methadone* | 3 | 2 | | | | | methadone | 0.32 mg/L In Blood (unspecified) @ Autopsy |
| | | diazepam | 4 | 3 | | | | | temazepam | 0.01 mg/L In Blood (unspecified) @ |
| | | diazepam | 4 | 3 | | | | | nordiazepam | Autopsy 0.12 mg/L In Blood (unspecified) @ |
| | | diazepam | 4 | 3 | | | | | diazepam | Autopsy 0.15 mg/L In Blood (unspecified) @ Autopsy |
| 478h | 39 y F | | | | A | Ingst | Unk | 1 | | |
| | | acetaminophen acetaminophen | 1 1 | 1 1 | | | | | acetaminophen acetaminophen | 35 mcg/mL In Serum @ Unknown 66 mcg/mL In Serum @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---|-------------------|---------------|------------|--------------|--------|-----|--|---|
| 479a | 39 y F | acetaminophen | 1 | 1 | A | Ingst | Int-S | 2 | acetaminophen | 176 mcg/mL In Blood (unspecified) |
| 480pa | 39 y F | acetaminophen/ | 1 | 1 | U | Ingst | Unk | 2 | hydrocodone | @ Unknown 0.23 mcg/mL In Blood (unspecified |
| | | hydrocodone ethanol cyclobenzaprine | 2 3 | 2 3 | | | | | ethanol cyclobenzaprine | @ Autopsy 0.18 g/dL In Vitreous @ Autopsy 0.92 mcg/mL In Blood (unspecified |
| | | diazepam | 4 | 4 | | | | | | @ Autopsy |
| 481p | 39 y F | acetaminophen/ propoxyphene | 3 | 1 | A | Ingst | Int-S | 1 | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 205 mcg/mL In Serum @ Unknown |
| | | quetiapine | 1 | 3 | | | | | | |
| 482pa | 39 y F | alprazolam | 4 | 4 | U | Ingst | Unk | 1 | | |
| | | hydrocodone* | 1 | 1 | | | | | hydrocodone | 0.23 mg/L In Blood (unspecified) @ Unknown |
| | | quetiapine* alprazolam | 3 2 | 1 2 | | | | | alprazolam | 0.051 mg/L In Blood (unspecified) @ Unknown |
| 483a | 39 y F | salicylate | 1 | 1 | U | Ingst | Int-S | 1 | salicylate | 104.8 mg/dL In Blood (unspecified) |
| | | salicylate | 1 | 1 | | | | | salicylate | @ Unknown 909 mg/L In Blood (unspecified) @ |
| | | | | | | _ | | | | Autopsy |
| 484a | 39 y F | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 3 | diphenhydramine | 1 mg/L In Blood (unspecified) @ |
| | | diphenhydramine acetaminophen/ | 2 | 2 | | | | | | Autopsy |
| | | diphenhydramine quetiapine | 3 | 3 | | | | | quetiapine | 210 ng/mL In Blood (unspecified) |
| 485 | 39 y F | | | | A | Ingst | Int-S | 1 | | @ Autopsy |
| 403 | 37 y 1 | acetaminophen/ hydrocodone | 1 | 1 | 71 | mgst | IIIC-O | | | |
| 486a | 39 y F | , | | | A/C | Ingst | Int-S | 1 | | |
| | | acetaminophen/ diphenhydramine | 1 | 1 | | | | | acetaminophen | 12.8 mg/L In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ diphenhydramine | 1 | 1 | | | | | acetaminophen | 19.7 mcg/mL In Blood (unspecified) @ Unknown |
| | | venlafaxine | 2 | 2 | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| 107no: | 20 v M | ethanol | 4 | 4 | Α. | Unk | Int A | 2 | | |
| 487pai | 39 y M | oxycodone | 1 | 1 | A | Ulik | Int-A | 2 | oxycodone | 0.24 mcg/L In Whole Blood @ Autopsy |
| 488pa | 40 y F | quetiapine* | 6 | 1 | A/C | Ingst | Int-S | 2 | quetiapine | 7000 ng/mL In Blood (unspecified) |
| | | salicylate* | 1 | 1 | | | | | salicylate | @ Autopsy 350 mcg/mL In Blood (unspecified) |
| | | citalopram* | 7 | 2 | | | | | citalopram | @ Autopsy 1200 ng/mL In Blood (unspecified) |
| | | midazolam* | 2 | 2 | | | | | midazolam | @ Autopsy 5.3 ng/mL In Blood (unspecified) @ |
| | | diphenhydramine | 3 | 3 | | | | | diphenhydramine | Autopsy 460 ng/mL In Blood (unspecified) |
| | | carbamazepine | 4 | 4 | | | | | carbamazepine | @ Autopsy1 mcg/mL In Blood (unspecified) @ Autopsy |
| | | venlafaxine | 5 | 5 | | | | | venlafaxine | 560 ng/mL In Blood (unspecified) |
| 489a | 40 y F | acetaminophen/ | 1 | 1 | U | Ingst+ Aspir | Int-S | 1 | hydrocodone | @ Autopsy 0.15 mg/L In Blood (unspecified) @ |
| | | hydrocodone* acetaminophen/ | 1 | 1 | | | | | acetaminophen | Unknown 14.7 mg/L In Blood (unspecified) @ |
| | | hydrocodone* carisoprodol* | 2 | 1 | | | | | carisoprodol | Unknown 0.03 mg/L In Blood (unspecified) @ |
| | | Ŷ | | | | | | | (n-isopropyl meprobamate) | Unknown |
| | | carisoprodol* | 2 | 1 | | | | | carisoprodol (n-isopropyl meprobamate) | 16.8 mg/L In Blood (unspecified) @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|-------------|--------|-----|-----------------|--|
| | | ibuprofen | 3 | 3 | | | | | ibuprofen | 3.2 mg/L In Blood (unspecified) @ Unknown |
| | | hydromorphone | 4 | 4 | | | | | hydromorphone | 0.05 mg/L In Blood (unspecified) @ Unknown |
| 490p | 40 y F | acetaminophen/ hydrocodone | 1 | 1 | A/C | Ingst | Int-A | 1 | acetaminophen | 105.6 mcg/mL In Serum @ Unknown |
| 491 | 40 y F | acetaminophen/ | 1 | 1 | U | Ingst | Int-M | 3 | acetaminophen | 29 mcg/mL In Plasma @ 4 d (pe) |
| 492pha | 40 y M | oxycodone acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 3 | acetaminophen | 37 mcg/mL In Serum @ Unknown |
| | | hydrocodone alprazolam | 2 | 2 | | | | | - | |
| 493 | 40 y F | ethanol | 3 | 3 | A | Ingst | Int-S | 3 | | |
| 194 | 40 y M | acetaminophen | 1 | 1 | A | Unk | Unk | 3 | | |
| 4051 | 40 E | opioid salicylate | 1 2 | 1 2 | | T | T . G | | salicylate | 6.9 mg/dL In Serum @ Unknown |
| 495ha | 40 y F | acetaminophen/ oxycodone | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 23.6 mcg/mL In Blood (unspecified @ Unknown |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | acetaminophen | 28.3 mcg/mL In Blood (unspecified @ Unknown |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | acetaminophen | 32.9 mg/L In Blood (unspecified) @ Autopsy |
| | | salicylate | 2 | 2 | | | | | salicylate | 11.2 mg/dL In Blood (unspecified) @ Unknown |
| | | salicylate | 2 | 2 | | | | | salicylate | 453.7 mg/L In Blood (unspecified) @ Autopsy |
| | | salicylate | 2 | 2 | | | | | salicylate | 46 mg/dL In Blood (unspecified) @ Unknown |
| | | oxymorphone (extended release) | 3 | 3 | | | | | oxymorphone | 0.25 mg/L In Urine (quantitative only) @ Autopsy |
| | | oxymorphone (extended release) | 3 | 3 | | | | | oxycodone | 0.33 mg/L In Blood (unspecified) @ Autopsy |
| | | oxymorphone (extended release) | 3 | 3 | | | | | oxymorphone | 0.63 mg/L In Blood (unspecified) @ Autopsy |
| | | doxylamine pregabalin | 4 5 | 4 5 | | | | | | |
| 496pa | 40 y M | oxycodone | 1 | 1 | U | Ingst+ Unk | Int-U | 1 | oxycodone | 135 ng/mL In Whole Blood @ |
| | | clonazepam | 2 | 2 | | | | | 7-aminoclonaze- | Autopsy 8.1 ng/mL In Blood (unspecified) @ |
| 497 | 40 y F | cronazopam | _ | 2 | A | Ingst | Int-U | 3 | pam | Autopsy |
| 498pai | 40 y F | methadone | 1 | 1 | U | Ingst | Int-A | 3 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 0.61 mcg/mL In Whole Blood @ Autopsy |
| | | oxycodone | 1 | 1 | | | | | oxymorphone | 16 ng/mL In Whole Blood @ Autopsy |
| 499i | 40 y M | acetaminophen/ | 1 | 1 | С | Ingst | Int-M | 3 | | |
| | | oxycodone acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| 500hi | 41 y F | Ť | | | A/C | Ingst | Int-S | 1 | | |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| | | tricyclic antidepressant | 3 | 3 | | | | | | |
| 504 | | benzodiazepine | 4 | 4 | | | | _ | | |
| 501pa | 41 y F | fentanyl (transdermal)* | 3 | 1 | U | Ingst+ Derm | Unk | 1 | fentanyl | 0.001 mg/L In Blood (unspecified) @ Autopsy |
| | | oxycodone* | 1 | 1 | | | | | oxycodone | 0.49 mg/L In Blood (unspecified) @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 0.081 mg/L In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--------------------------------|-------------------|---------------|------------|--------------|--------|-----|-----------------|---|
| | | acetaminophen/ | 4 | 4 | | | | | | |
| | | oxycodone diazepam | 5 | 5 | | | | | diazepam | 0.092 mg/L In Blood (unspecified) |
| | | uiazepaiii | 3 | | | | | | urazepani | @ Autopsy |
| | | diazepam | 5 | 5 | | | | | | nordiazepam 0.43 mg/L In Blood (unspecified) @ Autopsy |
| 502p | 41 y M | | | | A/C | Unk | Int-U | 2 | | (unspecifica) & Autopsy |
| | | opioid heroin | 1 2 | 1 2 | | | | | | |
| 503 | 41 y F | nerom | 2 | 2 | A | Ingst | Unt-T | 1 | | |
| | | colchicine | 1 2 | 1 2 | | | | | | |
| 504pa | 41 y F | cocaine | 2 | 2 | A | Ingst+ Unk | Int-S | 2 | | |
| • | | methadone | 1 | 1 | | | | | methadone | 0.12 mg/L In Whole Blood @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Unknown 0.015 mg/L In Whole Blood @ |
| 505 | 41 14 | • | | | *** | T | T. C | 2 | • | Unknown |
| 505 | 41 y M | opioid | 1 | 1 | U | Ingst+ Unk | Int-S | 2 | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 112 mcg/mL In Unknown @ |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | Unknown 120 mcg/mL In Unknown @ |
| | | • | | | | | | | | Unknown |
| | | acetaminophen | 2 | 2 | | | | | | 48.6 mcg/mL In Unknown @ 1 d (pe) |
| 506pa | 41 y F | | | | A | Ingst | Int-S | 2 | | _ |
| | | tramadol | 1 | 1 | | | | | tramadol | 2500 ng/mL In Blood (unspecified) @ Autopsy |
| 507 | 41 y F | | | | A | Ingst | Int-S | 1 | | 1 7 |
| 508pa | 41 y F | acetaminophen | 1 | 1 | A | Ingst | Int-S | 1 | | |
| F | , - | carisoprodol* | 3 | 1 | | 8 | | | | |
| | | fentanyl* clonazepam | 1 2 | 1 2 | | | | | | |
| 509pai | 41 y M | cionazepani | 2 | 2 | A | Ingst | Int-A | 2 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 1.9 mcg/mL In Whole Blood @ Autopsy |
| | | citalopram | 2 | 2 | | | | | | Tutopsy |
| 510pai | 41 y F | tramadol | 1 | 1 | U | Ingst | Int-A | 2 | tramadol | 3.6 mcg/mL In Whole Blood @ |
| | | u amadoi | | | | | | | tramador | Autopsy |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | 0.26 mcg/mL In Whole Blood @ Autopsy |
| 511a | 42 y M | | | | A | Ingst | Int-S | 3 | | rutopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 123 mcg/mL In Blood (unspecified) @ Unknown |
| 512 | 42 y F | • | | | A/C | Ingst | Int-S | 2 | | © Chridwii |
| | | oxycodone | 1 | 1 | | | | | | |
| | | clonazepam ethanol | 2 3 | 2 3 | | | | | | |
| 513 | 42 y F | | | | U | Ingst | Unk | 2 | | |
| 514pa | 42 y M | acetaminophen | 1 | 1 | A | Ingst | Int-U | 2 | acetaminophen | 10.2 mcg/mL In Serum @ Unknown |
| • | | opioid | 1 | 1 | | - | | | | |
| 515h | 42 y F | acetaminophen/ | 1 | 1 | U | Ingst+ Aspir | Int-S | 2 | acetaminophen | 500.9 mcg/mL In Blood |
| | | hydrocodone | 1 | 1 | | | | | acctanimophen | (unspecified) @ Unknown |
| 516 | 42 y F | acetaminophen | 1 | 1 | A | Unk | Unt-G | 2 | acetaminophen | 45 mcg/mL In Blood (unspecified) |
| | | ассиннюрнен | 1 | 1 | | | | | ассыппорнен | @ 1 h (pe) |
| 517 | 42 y F | acetaminophen | 1 | 1 | A | Ingst | Int-S | 2 | acetaminophen | 10 mcg/mL In Serum @ 1 d (pe) |
| 518p | 42 y M | ассаниюриен | | | A | Ingst | Int-S | 1 | асстаннорнен | ro megame in ocium @ 1 u (pe) |
| | - | acetaminophen/ propoxyphene | 2 | 1 | | | | | | |
| | | acetaminophen/ | 1 | 2 | | | | | acetaminophen | 23 mcg/mL In Serum @ Unknown |
| | | diphenhydramine | 3 | 3 | | | | | • | - |
| | | ethanol | 3 | 3 | | | | | ethanol | 79 mg/dL In Blood (unspecified) @ 1 h (pe) |
| 519pai | 42 y F | methadone | 1 | 1 | U | Ingst | Unk | 2 | methadone | 0.21 mag/ml In Whata Diand G |
| | | шешаиопе | 1 | 1 | | | | | шешацопе | 0.21 mcg/mL In Whole Blood @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------------|-------------------|---------------|------------|-------------|---------|-----|--|--|
| 520pai | 42 y M | oxycodone | 1 | 1 | A | Ingst | Int-A | 3 | oxycodone | 1.1 mcg/mL In Whole Blood @ |
| | | oxycodone | 1 | 1 | | | | | oxymorphone | Autopsy 40 ng/mL In Whole Blood @ Autopsy |
| | | promethazine | 2 | 2 | | | | | | Ашорзу |
| 521ha | 43 y M | citalopram | 3 | 3 | A | Ingst | Int-S | 1 | | |
| ,2111d | 15 y 111 | morphine (extended release) | 1 | 1 | 71 | mgst | III S | 1 | | |
| | 42 M | diazepam | 2 | 2 | | I D | Total A | 2 | | |
| 522pai | 43 y M | fentanyl (transdermal) | 1 | 1 | A | Ingst+ Derm | Int-A | 2 | fentanyl | 12.4 ng/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 91.3 ng/mL In Whole Blood @ Autopsy |
| | | oxycodone | 3 | 3 | | | | | oxycodone | 0.32 mcg/mL In Whole Blood @ Autopsy |
| 523pa | 43 y F | methadone | 1 | 1 | A | Ingst | Unk | 1 | methadone | 1000 ng/mL In Blood (unspecified) |
| | | tramadol | 2 | 2 | | | | | eddp (2- ethylidene- 1,5-dimethyl- 3,3-diphenyl pyrrolidine) | @ 30 m (pe) 0 Other (see abst) In Blood (unspecified) @ 30 m (pe)" |
| | | tramadol | 2 | 2 | | | | | tramadol | 200 ng/mL In Blood (unspecified) @ 30 m (pe) |
| | | diazepam | 3 | 3 | | | | | diazepam | 120 ng/mL In Blood (unspecified) @ 30 m (pe) |
| | | diazepam | 3 | 3 | | | | | nordiazepam | 260 ng/mL In Blood (unspecified) @ 30 m (pe) |
| 524p | 43 y F | acetaminophen/ propoxyphene | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 390 mcg/mL In Blood (unspecified @ Unknown |
| 525a | 43 y M | | 1 | | A/C | Ingst | Int-M | 2 | | |
| 526p | 43 y F | colchicine | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | | |
| | | paroxetine aripiprazole | 3 4 | 3 4 | | | | | | |
| | | zolpidem | 5 | 5 | | | | | | |
| | | eszopiclone | 6 | 6 | | | | | | |
| | | bupropion (extended release) | 7 | 7 | | | | | | |
| 527a | 43 y F | / | 1 | 1 | A/C | Ingst | Int-U | 2 | | 0.022// In Disad (|
| | | acetaminophen/ oxycodone | | 1 | | | | | oxymorphone | 0.033 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | oxycodone | 0.16 mg/L In Blood (unspecified) (Unknown |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | acetaminophen | 98 mcg/mL In Blood (unspecified) @ Unknown |
| 528 | 43 y M | oxycodone | | | U | Ingst | Int-U | 3 | | @ Chkhown |
| | · | acetaminophen ethanol | 1 2 | 1 2 | | | | | acetaminophen ethanol | 60 mcg/mL In Serum @ Unknown 72 mg/dL In Blood (unspecified) @ |
| 529 | 43 y F | | | | U | Ingst | Unk | 1 | | Unknown |
| | Ĭ | acetaminophen | 1 | 1 | | C | | | acetaminophen | 20 mcg/mL In Blood (unspecified) @ Unknown |
| 530pa | 43 y M | morphine | 1 | 1 | A | Ingst | Int-S | 1 | morphine | 0.77 mg/L In Blood (unspecified) (|
| | | diltiazem | 2 | 2 | | | | | diltiazem | Unknown 3.3 mg/L In Blood (unspecified) @ |
| 5210 | 12 E | | | | Α. | Inget | Int C | 1 | | Unknown |
| 531a | 43 y F | acetaminophen/ diphenhydramine | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 229 mcg/mL In Serum @ Unknow |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| -20- | 44 37 | dextromethorphan | | | * * | T 4 | T C | 2 | | |
| 532a | 44 y M | acetaminophen/ hydrocodone | 1 | 1 | U | Ingst | Int-S | 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---------------------------------------|-------------------|---------------|------------|--------------|----------|-----|--------------------------|--|
| 533a | 44 y F | salicylate | 1 | 1 | A/C | Ingst | Int-S | 2 | hydrocodone | 0.02 mg/L In Blood (unspecified) @ |
| | | salicylate | 1 | 1 | | | | | ecgonine methyl | Unknown 0.07 mg/L In Blood (unspecified) @ |
| | | salicylate | 1 | 1 | | | | | ester benzoylecognine | Unknown 0.33 mg/L In Blood (unspecified) @ Unknown |
| | | salicylate | 1 | 1 | | | | | salicylate | 100 mg/dL In Blood (unspecified) @ Unknown |
| | | valproic acid | 2 | 2 | | | | | | e chikhown |
| | | gabapentin alendronate | 3 4 | 3 4 | | | | | | |
| | | cocaine | 5 | 5 | | | | | benzoylecognine | 0.33 mg/L In Blood (unspecified) @ Unknown |
| | | cocaine | 5 | 5 | | | | | ecgonine methyl ester | 0.7 mg/L In Blood (unspecified) @ Unknown |
| | | hydrocodone | 6 | 6 | | | | | hydrocodone | 0.2 mg/L In Blood (unspecified) @ Unknown |
| 534a | 44 y M | | | | A | Ingst | Int-S | 1 | | Chkhown |
| | , | acetaminophen/ diphenhydramine | 1 | 1 | | Ü | | | | |
| 535 | 44 y M | | 2 | 1 | A | Ingst+ Unk | Int-S | 2 | tih | 00 |
| | | acetaminophen | 2 | 1 | | | | | acetaminophen | 90 mcg/mL In Unknown @ Unknown |
| | | salicylate | 1 | 2 | | | | | salicylate | 11 mg/dL In Unknown @ Unknown |
| | | methamphetamine diphenhydramine | 4 3 | 3 4 | | | | | | |
| | | ethanol | 5 | 5 | | | | | ethanol | 345 mg/dL In Unknown @ Unknown |
| 536h | 44 y F | | | | A | Ingst+ Inhal | Int-S | 1 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 35 mcg/mL In Serum @ Unknown |
| | | oxycodone (extended release) | 2 | 2 | | | | | | |
| | | acetaminophen/ butalbital/caffeine | 3 | 3 | | | | | | |
| | | clonidine | 4 | 4 | | | | | | |
| 525 | 44 34 | lithium | 5 | 5 | A (C) | . | 7 . 34 | 2 | | |
| 537 | 44 y M | acetaminophen/ | 1 | 1 | A/C | Ingst | Int-M | 2 | | |
| 538 | 44 y F | hydrocodone | | | A | Ingst | Int-S | 1 | | |
| | , | acetaminophen | 1 | 1 | | 8 | | | acetaminophen | 405 mcg/mL In Serum @ Unknown |
| | 44.34 | acetaminophen | 1 | 1 | ** | | * | | acetaminophen | 686 mcg/mL In Serum @ Unknown |
| 539pai | 44 y M | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 0.22 mcg/mL In Whole Blood @ |
| | | mirtazapine | 2 | 2 | | | | | mirtazapine | Autopsy 0.15 mcg/mL In Whole Blood @ |
| | | trazodone | 3 | 3 | | | | | trazodone | Autopsy 0.92 mcg/mL In Whole Blood @ |
| | | hydroxyzine | 4 | 4 | | | | | | Autopsy |
| 540 | 44 y M | salicylate | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | tricyclic | 2 | 2 | | | | | | |
| | | antidepressant acetaminophen | 3 | 3 | | | | | | |
| 541pai | 44 y M | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 0.22 mcg/mL In Whole Blood @ |
| | | mirtazapine* | 3 | 2 | | | | | mirtazapine | Autopsy 0.15 mcg/mL In Whole Blood @ |
| | | • | | | | | | | • | Autopsy |
| | | trazodone* | 2 | 2 | | | | | trazodone | 0.92 mcg/mL In Whole Blood @ Autopsy |
| 5.40 · | 44 35 | hydroxyzine paroxetine | 4 5 | 4 5 | | * . | T | 2 | | |
| 542pai | 44 y M | methadone | 1 | 1 | A | Ingst | Int-A | 2 | methadone | 0.09 mcg/mL In Whole Blood @ |
| | | propoxyphene | 2 | 2 | | | | | propoxyphene | Autopsy 0.5 mcg/mL In Whole Blood @ |
| | | propoxyphene | 2 | 2 | | | | | norpropoxyphene | Autopsy 1.2 mcg/mL In Whole Blood @ |
| | | | | | | | | | | Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---------------------------------|-------------------|---------------|------------|-------------|--------|-----|-----------------|---|
| 543pa | 45 y F | morphine | 1 | 1 | U | Ingst | Unk | 2 | morphine | 54 ng/mL In Blood (unspecified) @ |
| | | amitriptyline | 2 | 2 | | | | | amitriptyline | Autopsy 109 ng/mL In Blood (unspecified) |
| | | amitriptyline | 2 | 2 | | | | | nortriptyline | @ Autopsy 130 ng/mL In Blood (unspecified) |
| | | alprazolam | 3 | 3 | | | | | alprazolam | @ Autopsy68.9 ng/mL In Blood (unspecified)@ Autopsy |
| 544p | 45 y M | cetirizine | 4 | 4 | С | Inget | Int-A | 3 | | e rutopsy |
| 3 44 р | | oxycodone (extended release) | 1 | 1 | C | Ingst | IIIt-A | | | |
| 545 | 45 y M | acetaminophen | 1 | 1 | A/C | Ingst | Int-M | 3 | acetaminophen | 69 mcg/mL In Serum @ Unknown |
| 546a | 45 y M | salicylate | 1 | 1 | A | Ingst | Int-S | 1 | salicylate | 61.1 mg/dL In Blood (unspecified) |
| | | salicylate | 1 | 1 | | | | | salicylate | @ Autopsy 92.9 mg/dL In Serum @ Unknown |
| 547p | 45 y F | acetaminophen/ hydrocodone | 1 | 1 | A/C | Ingst | Int-S | 1 | acetaminophen | 103 mcg/mL In Blood (unspecified) @ 1 h (pe) |
| 548p | 45 y F | oxycodone | 1 | 1 | A | Ingst+ Derm | Int-S | 1 | | |
| | | (extended release) opioid | 2 | 2 | | | | | | |
| 549 | 45 y F | acetaminophen | 1 | 1 | A | Ingst | Unt-G | 1 | acetaminophen | 136.6 mcg/mL In Blood |
| | | ethanol | 2 | 2 | | | | | ethanol | (unspecified) @ Unknown 83 mg/dL In Blood (unspecified) @ Unknown |
| | | lorazepam alprazolam | 3 4 | 3 4 | | | | | | |
| 550a | 45 y F | fentanyl | 1 | 1 | A | Ingst | Int-S | 2 | fentanyl | 6.5 ng/mL In Whole Blood @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 473 ng/mL In Whole Blood @ |
| | | acetaminophen/ | 3 | 3 | | | | | hydromorphone | Autopsy 176 ng/mL In Whole Blood @ |
| | | hydrocodone acetaminophen/ | 3 | 3 | | | | | hydrocodone | Autopsy 3 mcg/mL In Whole Blood @ |
| | | hydrocodone acetaminophen | 4 | 4 | | | | | acetaminophen | Autopsy 962 mcg/mL In Whole Blood @ |
| 551a | 45 y F | | | | A | Ingst | Int-S | 1 | | Autopsy |
| 552a | 45 y F | acetaminophen | 1 | 1 | A | Ingst | Int-S | 1 | acetaminophen | 77.6 mcg/mL In Serum @ 2 d (pe) |
| 553pai | 45 y M | salicylate | 1 | 1 | U | Ingst | Int-A | 2 | salicylate | 121 mg/dL In Serum @ 5.5 h (pe) |
| | , | oxycodone | 3 | 1 | | 8 | | _ | oxycodone | 1.3 Other (see abst) In Liver @ Autopsy |
| | | oxycodone | 3 | 1 | | | | | oxymorphone | 56 Other (see abst) In Liver @ Autopsy |
| | | ethanol* | 1 | 2 | | | | | ethanol | 0.09% (wt/Vol) In Vitreous @ Autopsy |
| | | ethanol* | 1 | 2 | | | | | ethanol | 0.17% (wt/Vol) In Whole Blood @ Autopsy |
| | | paroxetine* | 2 | 2 | | | | | paroxetine | 20.8 Other (see abst) In Liver @ Autopsy |
| 554pai | 45 y F | propoxyphene | 1 | 1 | U | Ingst | Int-A | 2 | propoxyphene | 0.75 mcg/mL In Whole Blood @ |
| | | propoxyphene | 1 | 1 | | | | | norpropoxyphene | Autopsy 2.2 mcg/mL In Whole Blood @ |
| | | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 86 ng/mL In Whole Blood @ |
| | | diphenhydramine | 3 | 3 | | | | | diphenhydramine | Autopsy 1.2 mg/mL In Whole Blood @ Autopsy |
| 555n | 45 v E | fluoxetine | 4 | 4 | C | Inget | Int A | 2 | | Λιιορεγ |
| 555p | 45 y F | acetaminophen/ hydrocodone | 1 | 1 | С | Ingst | Int-A | 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--------------------------------|-------------------|---------------|------------|--------|---------|-----|--------------------------|---|
| 556 | 46 y F | | | | A/C | Ingst | Int-M | 3 | | |
| | • | acetaminophen | 1 | 1 | | C | | | | |
| | | ethanol | 2 | 2 | | | | | | |
| 557 | 46 y F | | | 1 | С | Ingst | Int-M | 1 | | 124 / 1 1 12 0 0 11 1 |
| 558ha | 46 y F | acetaminophen | 1 | 1 | A | Ingst | Int-S | 2 | acetaminophen | 134 mcg/mL In Plasma @ Unknown |
| 33611a | 40 y 1 | acetaminophen | 1 | 1 | А | nigst | IIIC-S | 2 | acetaminophen | 29 mg/L In Blood (unspecified) @ Unknown |
| | | salicylate | 2 | 2 | | | | | | |
| | | ethanol | 3 | 3 | | | | | | |
| 559p | 46 y M | | | | A/C | Ingst | Int-U | 2 | | |
| | | opioid benzodiazepine | 1 2 | 1 2 | | | | | | |
| 560p | 46 y M | belizodiazepilie | 2 | 2 | A | Par | Int-S | 1 | | |
| Зоор | 10 9 111 | oxycodone (extended release) | 1 | 1 | 11 | T tu | int 5 | • | | |
| 561ha | 46 y M | | | | U | Unk | Unk | 3 | | |
| | | salicylate | 1 | 1 | | | | | salicylate | 17.8 mg/dL In Serum @ Unknown |
| | | opioid | 2 | 2 | | | | | | |
| 5.00 | 46 M | cocaine | 3 | 3 | | T | Total C | | | |
| 562pa | 46 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 1 | dihydrocodeine/ | 100 ng/mL In Blood (unspecified) |
| | | hydrocodone | 1 | 1 | | | | | hydrocodol (free) | @ Autopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 43 mcg/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone (free) | 440 ng/mL In Blood (unspecified) @ Autopsy |
| | | methadone | 2 | 2 | | | | | , | * 2 |
| 563 | 46 y F | acetaminophen | 1 | 1 | С | Ingst | Int-M | 1 | acetaminophen | 9 mcg/mL In Blood (unspecified) @ |
| 564no | 16 v. E | | | | ٨ | Inact | Int A | 1 | | Unknown |
| 564pa | 46 y F | acetaminophen/ hydrocodone* | 2 | 1 | A | Ingst | Int-A | 1 | hydrocodone | 467 ng/mL In Urine (quantitative only) @ Autopsy |
| | | acetaminophen/ hydrocodone* | 2 | 1 | | | | | hydrocodone | 69.2 ng/mL In Blood (unspecified) @ Autopsy |
| | | methadone* | 1 | 1 | | | | | methadone | 1440 ng/mL In Urine (quantitative only) @ Autopsy |
| | | methadone* | 1 | 1 | | | | | methadone | 300 ng/mL In Blood (unspecified) @ Autopsy |
| | | carisoprodol | 3 | 2 | | | | | | |
| | | alprazolam | 4 | 3 | | | | | 7-aminoclonaze- pam | 10.8 ng/mL In Blood (unspecified) @ Autopsy |
| | | alprazolam | 4 | 3 | | | | | 7-aminoclonaze- pam | 133 ng/mL In Urine (quantitative only) @ Autopsy |
| | | alprazolam | 4 | 3 | | | | | alpha-oh-alpra- zolam | 192 ng/mL In Urine (quantitative only) @ Autopsy |
| | | alprazolam | 4 | 3 | | | | | alprazolam | 198 ng/mL In Urine (quantitative only) @ Autopsy |
| | | alprazolam | 4 | 3 | | | | | alprazolam | 25.7 ng/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 5 | 4 | | | | | | |
| 565 | 46 v E | ethanol | 6 | 5 | ٨ | Inget | Int-U | 2 | | |
| 303 | 46 y F | acetaminophen | 1 | 1 | A | Ingst | IIII-U | ۷ | acetaminophen | 52.5 mcg/mL In Blood (unspecified) @ Unknown |
| 566pai | 46 y F | | | | U | Ingst | Int-A | 2 | | © Chillown |
| F | , - | oxycodone | 1 | 1 | | 8 | | | oxycodone | 0.21 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 70 ng/mL In Whole Blood @ |
| | | clonazepam | 3 | 3 | | | | | clonazepam | Autopsy 33 ng/mL In Whole Blood @ |
| 5.67 | 46.35 | quetiapine | 4 | 4 | A 10 | Torres | TT1 | 2 | | Autopsy |
| 567 | 46 y M | acetaminophen/ | 1 | 1 | A/C | Ingst | Unk | 3 | | |
| 568 | 47 y F | hydrocodone | | | A | Ingst | Int-S | 1 | | |
| | ., , 1 | salicylate | 1 | 1 | 4.1 | | 0 | | | |
| | | ethanol | 3 | 2 | | | | | | |
| | | ibuprofen | 2 | 3 | | | | | | |
| 569a | 47 y M | ющрготен | _ | | C | Ingst | Int-M | 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|-----------|----------------------------------|-------------------|---------------|------------|------------|----------|-----|---------------|---|
| 570 | 47 y M | | | | A/C | Ingst | Unt-M | 1 | | |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 13 mcg/mL In Serum @ 48 h (pe) |
| | | ethanol | 2 | 2 | | | | | | |
| | | acetaminophen/ propoxyphene | 3 | 3 | | | | | | |
| 571p | 47 y F | propoxypnene | | | A | Ingst | Int-U | 2 | | |
| • | • | caffeine/ | 1 | 1 | | | | | | |
| | | salicylamide/ | | | | | | | | |
| 572pai | 47 y M | salicylate | | | A | Ingst | Int-U | 2 | | |
| . | ., , 1.1 | acetaminophen/ | 1 | 1 | • • | mgs. | | _ | hydrocodone | 0.32 mcg/mL In Whole Blood @ |
| | | hydrocodone | | 2 | | | | | | Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxycodone | 0.56 mcg/mL In Whole Blood @ Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxymorphone | 212 ng/mL In Whole Blood @ |
| | | • | | | | | | | | Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.02% (wt/Vol) In Whole Blood @ |
| | | quetiapine | 4 | 4 | | | | | | Autopsy |
| 573pai | 47 y M | 1 | | | A | Ingst | Int-A | 2 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.54 mcg/mL In Whole Blood @ |
| 574 | 47 y M | | | | U | Ingst+ Unk | Int-A | 2 | | Autopsy |
| 314 | 47 y 141 | fentanyl (transdermal) | 1 | 1 | O | mgst onk | 1111-71 | _ | | |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | 2 mcg/mL In Serum @ 1 h (pe) |
| | | hydrocodone | 3 | 3 | | | | | | |
| | | amitriptyline methamphetamine | 4 | 4 | | | | | | |
| | | clonazepam | 5 | 5 | | | | | | |
| 575pa | 47 y M | | | | A | Ingst | Int-S | 1 | | |
| | | acetaminophen/ propoxyphene | 1 | 1 | | | | | acetaminophen | 184 mcg/mL In Serum @ Unknown |
| | | ethanol | 2 | 2 | | | | | | ethanol 0.23 g/dL In Serum @ |
| | | | | | | | | | | Unknown |
| 576pai | 47 y M | methadone | 1 | 1 | U | Ingst | Int-A | 2 | methadone | 0.77 mag/ml. In Whala Pland @ |
| | | memadone | 1 | 1 | | | | | methadone | 0.77 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 115 ng/mL In Whole Blood @ |
| | | harden on done | 3 | 3 | | | | | | Autopsy |
| 577pai | 47 y F | hydrocodone | 3 | 3 | U | Ingst | Int-A | 2 | | |
| 577 pti | 17 9 1 | methadone | 1 | 1 | C | 111550 | 1111 71 | _ | methadone | 0.2 mcg/mL In Whole Blood @ |
| | | | | 2 | | | | | | Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 186 ng/mL In Whole Blood @ Autopsy |
| 578pai | 47 y M | | | | A | Ingst | Int-A | 2 | | Autopsy |
| - · · · I · · · | , , | oxycodone | 1 | 1 | | 8 | | | oxycodone | 0.8 mcg/mL In Whole Blood @ |
| | | 1 | 2 | 2 | | | | | | Autopsy |
| | | diazepam ethanol | 2 3 | 2 3 | | | | | ethanol | 0.22% (wt/Vol) In Whole Blood @ |
| | | outairo i | | | | | | | Cilianor | Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.27% (wt/Vol) In Vitreous @ |
| 579 | 47 y F | | | | С | Ingst | Int-M | 2 | | Autopsy |
| 517 | +/ y 1 | acetaminophen/ | 1 | 1 | C | 111501 | 1111-141 | - | | |
| | | oxycodone | _ | | | | | | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| 580pa | 48 y M | nyurocouone | | | A | Ingst | Int-S | 2 | | |
| * | • | salicylate | 1 | 1 | | Č | | | salicylate | 301 mcg/mL In Blood (unspecified) |
| | | caliavlata | 1 | 1 | | | | | caliavlat- | @ Autopsy |
| 581 | 48 y M | salicylate | 1 | 1 | A/C | Ingst | Int-M | 3 | salicylate | 82 mg/dL In Plasma @ Unknown |
| • | - , | tramadol | 1 | 1 | | o · | | - | | |
| | | hydrocodone/ | 2 | 2 | | | | | | |
| 582pai | 48 y M | ibuprofen | | | U | Ingst | Int-A | 1 | | |
| 702pai | -10 y IVI | oxycodone | 1 | 1 | U | nigot | IIII-A | 1 | oxycodone | 0.33 mcg/mL In Whole Blood @ |
| | | • | | | | | | | | Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.12% (wt/Vol) In Whole Blood @ |
| | | ethanol | 2 | 2 | | | | | ethanol | Autopsy 0.17% (wt/Vol) In Vitreous @ |
| | | | - | - | | | | | | Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|--------|--|---|--|---|--|---|--|--|---|
| 48 v F | | | | U | Ingst+ Unk | Int-S | 2 | | |
| | acetaminophen* | 2 | 1 | | 8 | | | acetaminophen | 218.3 mcg/mL In Plasma @ 8 h (pe) |
| | acetaminophen* opioid* | 2 1 | 1 1 | | | | | acetaminophen fentanyl | 264 mcg/mL In Plasma @ 0 h (pe) 100 ng/mL In Blood (unspecified) |
| | opioid* | 1 | 1 | | | | | norfentanyl | @ Autopsy 6.7 ng/mL In Blood (unspecified) @ |
| 18 v M | | | | Δ | Inget | Int_S | 2 | | Autopsy |
| 40 y W | salicylate | 1 | 1 | Α | nigst | III-5 | 2 | salicylate | 86.2 mg/dL In Blood (unspecified) @ 1 h (pe) |
| 48 y F | | | | U | Ingst | Unk | 2 | | (4-) |
| • | acetaminophen/ oxycodone | 1 | 1 | | | | | acetaminophen | 45 mcg/mL In Blood (unspecified) @ Unknown |
| 48 y F | | | | A/C | Ingst | Int-U | 2 | | |
| | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 13 mcg/mL In Serum @ Unknown |
| | carisoprodol | 2 | 2 | | | | | | |
| | zolpidem | | | | | | | | |
| | | | | | | | | | |
| 48 v F | gabapentin | 3 | 3 | Δ | Inget | Int_S | 1 | | |
| 40 y 1 | acetaminophen/ hvdrocodone | 1 | 1 | A | nigst | III-5 | 1 | | |
| 48 y M | , | | | A/C | Ingst | Int-S | 1 | | |
| | colchicine ethanol | 1 2 | 1 2 | | | | | ethanol | 0.08% In Blood (unspecified) @ |
| 40 E | | | | * * | T . | T . A | 2 | | Unknown |
| 48 y F | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 0.23 mcg/mL In Whole Blood @ Autopsy |
| | diphenhydramine | 2 | 2 | | | | | diphenhydramine | 1.7 mcg/mL In Whole Blood @ Autopsy |
| | tapentadol citalopram | 3 4 | 3 4 | | | | | citalopram | 1.1 mcg/mL In Whole Blood @ |
| | hydrocodone | 5 | 5 | | | | | | Autopsy |
| | ethanol | 6 | 6 | | | | | ethanol | 0.02% (wt/Vol) In Whole Blood @ Autopsy |
| 48 y M | | | | A/C | Ingst | Unk | 3 | | |
| | buprenorphine/ naloxone | 1 | 1 | | | | | | |
| | | 2 | 2 | | | | | | |
| | acetaminophen/ | 3 | 3 | | | | | | |
| 48 y M | • | | | A | Ingst | Unk | 3 | | |
| | oxycodone | 1 | 1 | | | | | oxycodone | 0.19 mcg/mL In Whole Blood @ Autopsy |
| | alprazolam | 2 | 2 | | | | | alprazolam | 94 ng/mL In Whole Blood @ Autopsy |
| 49 y F | diazepam | 3 | 3 | A | Ingst | Unk | 1 | | |
| | oxycodone | 1 | 1 | | | | | mirtazapine | 0.05 mg/L In Serum @ Autopsy |
| | • | | | | | | | | 0.16 mcg/mL In Serum @ Autopsy |
| | • | | | | | | | | 1.7 mg/L In Serum @ Autopsy 46 mcg/mL In Serum @ Autopsy |
| | | | | | | | | | 8 mg/L In Serum @ Autopsy |
| | ethanol | 2 | 2 | | | | | ethanol | 0.07% (wt/Vol) In Serum @ Autopsy |
| | ethanol | 2 | 2 | | | | | ethanol | 0.08% (wt/Vol) In Vitreous @ Autopsy |
| 49 y M | acetaminophen* | 3 | 1 | U | Ingst | Unk | 2 | acetaminophen | 0 Other (see abst) In Unknown @ |
| | methadone* | 1 | 1 | | | | | methadone | Unknown 0.22 mg/L In Blood (unspecified) @ |
| | alprazolam | 2 | 2 | | | | | alprazolam | Autopsy 0.03 mg/L In Blood (unspecified) @ Autopsy |
| 49 y M | | | | A | Ingst | Int-S | 1 | | ···· k · J |
| - | salicylate | 1 | 1 | | - | | | salicylate | 123 mg/dL In Blood (unspecified) @ Unknown |
| | | | | | | | | | e chikhown |
| | lamotrigine | 2 | 2 | | | | | | e Ulkilowii |
| | lamotrigine gabapentin zolpidem | 2 3 4 | 2 3 4 | | | | | | e onklowii |
| | 48 y F 48 y M 48 y F | 48 y F acetaminophen* acetaminophen* opioid* 48 y M salicylate 48 y F acetaminophen/ oxycodone 48 y F acetaminophen/ hydrocodone carisoprodol zolpidem ondansetron gabapentin 48 y F acetaminophen/ hydrocodone carisoprodol zolpidem ondansetron gabapentin 48 y F acetaminophen/ hydrocodone diphenhydramine tapentadol citalopram hydrocodone ethanol 48 y M buprenorphine/ naloxone (sublingual) escitalopram acetaminophen/ hydrocodone 48 y M oxycodone | Age Substances Rank 48 y F acetaminophen* 2 opioid* 1 48 y M salicylate 48 y F acetaminophen/ oxycodone 48 y F acetaminophen/ hydrocodone carisoprodol zolpidem ondansetron gabapentin 48 y M colchicine ethanol 48 y F oxycodone 48 y F oxycodone 48 y M colchicine ethanol 2 48 y F oxycodone 48 y M colchicine ethanol 2 48 y F oxycodone 48 y M buprenorphine/ naloxone (sublingual) escitalopram acetaminophen/ hydrocodone 48 y M oxycodone 1 diphenhydramine 2 tapentadol citalopram 4 hydrocodone ethanol 6 48 y M oxycodone diaprazolam 2 diazepam 3 49 y F oxycodone | Age Substances Rank Rank 48 y F acetaminophen* acetaminophen* 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Age Substances Rank Rank chronicity 48 y F | Age Substances Rank Rank Chronicity Route 48 y F acetaminophen* opioid* 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Age Substances Rank Rank Chronicity Route Reason 48 y F acetaminophen* opioid* 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Age Substances Rank Rank Chronicity Route Reason RCF 48 y F acetaminophen* opioid* 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Substances |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--------------------------------|-------------------|---------------|------------|------------|--------|-----|------------------|---|
| 595p | 49 y M | | | | A/C | Ingst | Int-S | 2 | | |
| • | • | methadone | 1 | 1 | | | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | hydrocodone | 2 | 2 | | | | | | |
| 196 | 49 y F | diazepam | 3 | 3 | U | Ingst | Int-S | 2 | | |
| 90 | 49 y 1 | acetaminophen/ | 1 | 1 | U | nigst | 1111-5 | 2 | acetaminophen | 159 mcg/mL In Serum @ Unknown |
| | | propoxyphene | - | • | | | | | ueciaiiiiopiioii | 107 meg/m2 m gerum e emmow. |
| | | ethanol | 2 | 2 | | | | | | |
| 97p | 49 y F | | | | U | Ingst | Int-U | 2 | | |
| | | methadone | 1 | 1 | | | | | | |
| | | clonazepam acetaminophen/ | 2 3 | 2 | | | | | | |
| | | hydrocodone | 3 | 3 | | | | | | |
| 98pa | 49 y F | , | | | C | Ingst | Int-U | 3 | | |
| • | • | acetaminophen/ | 1 | 1 | | | | | hydrocodone | 0.26 mg/L In Blood (unspecified) @ |
| | | hydrocodone | | | | | | | | Unknown |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 1.6 mg/L In Blood (unspecified) @ |
| | | hydrocodone phenytoin | 2 | 2 | | | | | | Unknown |
| | | alprazolam | 3 | 3 | | | | | | |
| | | topiramate | 4 | 4 | | | | | | |
| 99pai | 49 y M | r | | | U | Ingst | Int-A | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | hydrocodone | 0.23 mcg/mL In Whole Blood @ |
| | | hydrocodone | | | | | | | | Autopsy |
| | | carisoprodol | 2 | 2 | | | | | carisoprodol | 10.1 mcg/mL In Whole Blood @ |
| | | carisoprodol | 2 | 2 | | | | | meprobamate | Autopsy 13.9 mcg/mL In Whole Blood @ |
| | | carisoprodor | 2 | 2 | | | | | тергование | Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.02% (wt/Vol) In Whole Blood @ |
| | | | | | | | | | | Autopsy |
| 00pai | 49 y F | | | | A | Ingst+ Par | Int-A | 3 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 0.33 mcg/mL In Whole Blood @ |
| | | butalbital | 2 | 3 | | | | | | Autopsy |
| | | diphenhydramine | 3 | 4 | | | | | diphenhydramine | 1.7 mcg/mL In Whole Blood @ |
| | | | | | | | | | | Autopsy |
| | | citalopram | 4 | 5 | | | | | | |
| 601pai | 49 y M | | | | U | Ingst | Int-A | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | hydrocodone | 0.23 mcg/mL In Whole Blood @ |
| | | hydrocodone skeletal muscle | 2 | 2 | | | | | carisoprodol | Autopsy 10.1 mcg/mL In Whole Blood @ |
| | | relaxant | 2 | 2 | | | | | carisoprodor | Autopsy |
| | | skeletal muscle | 2 | 2 | | | | | meprobamate | 13.9 mcg/mL In Whole Blood @ |
| | | relaxant | | | | | | | • | Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.02% (wt/Vol) In Whole Blood @ |
| :02 | 40 M | | | | A | Toront | Int C | 1 | | Autopsy |
| 502 | 49 y M | salicylate | 1 | 1 | A | Ingst | Int-S | 1 | salicylate | 126 mg/dL In Blood (unspecified) |
| | | sancylate | 1 | 1 | | | | | sancylate | @ Unknown |
| 503 | 49 y F | | | | U | Ingst | Unk | 1 | | |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 6 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ 5 d (pe) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 9 mcg/mL In Blood (unspecified) |
| 504 | 50 y M | | | | U | Ingst | Int-S | 1 | | @ 4 d (pe) |
| JU -1 | 30 y 1v1 | methadone | 1 | 1 | O | nigst | 1111-5 | 1 | | |
| 605pai | 50 y M | memadone | - | • | A | Derm | Unk | 3 | | |
| • | • | opioid | 1 | 1 | | | | | fentanyl | 7.1 ng/mL |
| | | | | | | | | | | In Whole Blood @ Autopsy |
| | | valproic acid | 2 | 2 | | | | | valproic acid | 22 mcg/mL |
| 606pa | 50 y F | | | | A/C | Inget | Int-S | 1 | | In Whole Blood @ Autopsy |
| юора | 30 y 1 | acetaminophen | 1 | 1 | A/C | Ingst | 1111-5 | 1 | acetaminophen | 192.8 mg/L In Blood (unspecified) |
| | | | | • | | | | | piion | @ Autopsy |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 212 mg/L In Plasma @ 0 h (pe) |
| | | alprazolam | 2 | 2 | | | | | _ | _ : |
| | | eszopiclone | 3 | 3 | | | | | | |
| | | ibuprofen | 4 | 4 | | | | | ibuprofen | 26 mg/L In Blood (unspecified) @ |
| | | oxycodone | 5 | 5 | | | | | oxycodone | Autopsy 0.02 mg/L In Blood (unspecified) @ |
| | | | | | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-------------------------------|-------------------|---------------|------------|------------|--------|-----|-----------------------------|---|
| | | oxycodone | 5 | 5 | | | | | oxycodone | 0.03 mg/L In Vitreous @ Autopsy |
| | | morphine | 6 | 6 | | | | | morphine | 0.02 mg/L In Vitreous @ Autopsy |
| | | morphine | 6 | 6 | | | | | morphine | 0.12 mg/L In Blood (unspecified) @ Autopsy |
| | | fluoxetine | 7 | 7 | | | | | fluoxetine | 0.44 mg/L In Blood (unspecified) @ Autopsy |
| | | fluoxetine | 7 | 7 | | | | | norfluoxetine | 0.89 mg/L In Blood (unspecified) @ Autopsy |
| | 50. 34 | naproxen | 8 | 8 | ** | τ | T . A | 2 | | |
| 607pai | 50 y M | oxycodone | 1 | 1 | U | Ingst | Int-A | 3 | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| | | methamphetamine | 3 | 3 | | | | | | |
| .00 | 50 M | carisoprodol | 4 | 4 | *** | T | TT1 | 2 | | |
| 08pa | 50 y M | tramadol | 1 | 1 | U | Ingst | Unk | 2 | tramadol | 1613 ng/mL In Unknown @ |
| | | uamadoi | 1 | 1 | | | | | tramador | Autopsy |
| 609a | 50 y M | | | | A | Ingst | Int-S | 3 | | |
| | | tramadol | 1 | 1 | | | | | | |
| | | clonazepam tricyclic | 2 3 | 2 3 | | | | | | |
| | | antidepressant | 3 | 3 | | | | | | |
| 10a | 50 y F | Ŷ | | | U | Ingst | Int-S | 1 | | |
| | | acetaminophen | 1 | 1 | | | | | | |
| | | citalopram* citalopram* | 2 2 | 2 2 | | | | | citalopram citalopram | 0.29 mcg/mL In Serum @ Autopsy 8.4 Other (see abst) In Liver @ |
| | | Citalopiani | 2 | 2 | | | | | citaiopiani | Autopsy |
| 11a | 50 v M | drug, unknown* | 3 | 2 | Δ. | Inact | Int-S | 3 | | 1 7 |
| 114 | 50 y M | acetaminophen | 1 | 1 | A | Ingst | 1111-5 | 3 | acetaminophen | 179.1 mcg/mL In Whole Blood @ Unknown |
| | | etodolac | 2 | 2 | | | | | | |
| | | hydrocodone | 3 | 3 | | | | | hydrocodone | 1 mcg/mL In Whole Blood @ Unknown |
| 10 | 50 N | cyclobenzaprine | 4 | 4 | A (C) | T . | T . C | | | |
| 12 | 50 y M | colchicine | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | alprazolam | 2 | 2 | | | | | | |
| 13pai | 50 y M | • | | | A | Unk | Int-A | 2 | | |
| | | morphine | 1 | 1 | | | | | morphine (free) | 0.37 mcg/mL In Vitreous @ |
| | | morphine | 1 | 1 | | | | | morphine (free) | Autopsy 1.7 mcg/mL In Whole Blood @ |
| | | тогрине | 1 | • | | | | | morphine (rec) | Autopsy |
| 14pai | 50 y M | tramadol | 2 | 1 | A | Ingst | Int-A | 2 | tramadol | 4.4 mcg/mL In Whole Blood @ |
| | | tramador | 2 | 1 | | | | | tramador | Autopsy |
| | | acetaminophen/ | 1 | 2 | | | | | hydrocodone | 0.06 mcg/mL In Whole Blood @ |
| | | hydrocodone | 2 | 2 | | | | | | Autopsy |
| | | alprazolam diazepam | 3 4 | 3 4 | | | | | | |
| 15pai | 50 y M | unazepani | 7 | 7 | A | Ingst | Int-A | 2 | | |
| | , i | methadone | 1 | 1 | | C | | | methadone | 0.5 mcg/mL In Whole Blood @ |
| 1600 | 51 y F | | | | U | Inget | Int M | 1 | | Autopsy |
| 16pa | 51 y F | fentanyl (transdermal) | 1 | 1 | U | Ingst | Int-M | 1 | fentanyl | 7.3 ng/mL In Blood (unspecified) @ |
| | | | | | | | | | | Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 206 mg/dL In Blood (unspecified) @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 248 mg/dL In Urine (quantitative |
| 617pa | 51 y M | | | | A | Ingst | Int-S | 1 | | only) @ Autopsy |
| 17 pu | 31 y 1VI | oxycodone | 2 | 1 | 7.1 | 111551 | III 5 | • | oxymorphone | 32 ng/mL In Blood (unspecified) @ |
| | | oxycodone | 2 | 1 | | | | | oxycodone (free) | Autopsy 50000 ng/mL In Blood (unspecified) |
| | | • | | | | | | | | @ Autopsy |
| | | venlafaxine | 3 | 2 | | | | | o-desmethylvenla- faxine | @ Autopsy |
| | | venlafaxine | 3 | 2 | | | | | venlafaxine | 46000 ng/mL In Blood (unspecified) @ Autopsy |
| | | diazepam | 4 | 3 | | | | | diazepam | 11000 ng/mL In Blood (unspecified) |
| | | diazepam | 4 | 3 | | | | | nordiazepam | @ Autopsy 39 ng/mL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|------------------------------------|-------------------|---------------|------------|------------|--------|-----|-----------------|--|
| | | ethanol | 1 | 4 | | | | | ethanol | 193 mg/dL In Blood (unspecified) @ Autopsy |
| | | allopurinol | 5 | 5 | | | | | | @ Autopsy |
| | | diflunisal | 6 | 6 | | | | | | |
| 518 | 51 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 3 | | |
| | | propoxyphene baclofen | 2 | 2 | | | | | | |
| | | trazodone | 3 | 3 | | | | | | |
| | | sertraline | 4 | 4 | | | | | | |
| 619 | 51 y F | | | | A | Ingst | Int-U | 2 | | |
| | | acetaminophen | 1 2 | 1 2 | | | | | acetaminophen | 5.6 mcg/mL In Serum @ 24 h (pe) |
| 620a | 51 y M | ethanol | 2 | 2 | A | Ingst | Int-A | 2 | | |
| 0204 | 31 y 111 | methadone | 1 | 1 | 71 | mgst | III 11 | - | methadone | 0.27 mg/L In Blood (unspecified) (Unknown |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 0.57 mg/L In Blood (unspecified) (Unknown |
| | | diphenhydramine | 3 | 3 | | | | | diphenhydramine | 2.664 mg/L In Blood (unspecified) @ Unknown |
| 621a | 51 y F | acatamin l | 1 | 1 | A | Ingst | Int-A | 2 | hudrosadar | 0.16 mag/ml. In Diag 17 mag 16 |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.16 mcg/mL In Blood (unspecified @ Unknown |
| | | acetaminophen/ | 2 | 2 | | | | | propoxyphene | 0.2 mcg/mL In Whole Blood @ |
| | | propoxyphene | | | | | | | | Autopsy |
| | | acetaminophen/ | 2 | 2 | | | | | norpropoxyphene | 0.79 mcg/mL In Whole Blood @ |
| 622pa | 51 y F | propoxyphene | | | A | Ingst | Int-S | 1 | | Autopsy |
| 022pa | 31 y 1 | morphine | 1 | 1 | 7. | nigst | IIIC-S | 1 | | |
| | | hydromorphone | 2 | 2 | | | | | | |
| | | fluoxetine | 3 | 3 | | | | | | |
| | | alprazolam promethazine | 4 5 | 4 5 | | | | | | |
| 623 | 51 y F | promemazme | 3 | 3 | A | Ingst | Unk | 2 | | |
| |) - | acetaminophen | 1 | 1 | | 8 | | | | |
| | | tramadol | 2 | 2 | | | | | | |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | | |
| 624p | 51 y M | nydrocodone | | | A/C | Ingst | Int-A | 2 | | |
| | , | fentanyl | 1 | 1 | | Ü | | | | |
| 625a | 51 y F | | | | C | Ingst | Int-M | 2 | | |
| | | acetaminophen | 1 2 | 1 2 | | | | | | |
| | | acetaminophen/ dextromethorphan | 2 | 2 | | | | | | |
| | | ethanol | 3 | 3 | | | | | | |
| | | cocaine | 4 | 4 | | | | | | |
| 626pai | 51 y M | | | | U | Ingst | Int-A | 2 | | 0.00 |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.86 mcg/mL In Whole Blood @ Autopsy |
| | | diazepam | 2 | 2 | | | | | | rutopsy |
| | | lorazepam | 3 | 3 | | | | | | |
| 627pai | 51 y F | propoxyphene | 1 | 1 | U | Ingst | Int-A | 2 | propoxyphene | 0.2 mcg/mL In Whole Blood @ |
| | | propoxyphene | 1 | 1 | | | | | propoxyphene | Unknown 0.26 mcg/mL In Whole Blood @ Autopsy |
| | | propoxyphene | 1 | 1 | | | | | norpropoxyphene | 0.76 mcg/mL In Whole Blood @ Unknown |
| | | propoxyphene | 1 | 1 | | | | | norpropoxyphene | 0.79 mcg/mL In Whole Blood @ Autopsy |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | 0.16 mcg/mL In Whole Blood @ Unknown |
| 628 | 51 y F | | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 629pai | 51 v M | acetaminophen | 1 | 1 | A | Ingst+ Unk | Int-A | 1 | | |
| 029pai | 51 y M | morphine | 1 | 1 | А | mgst+ Ulik | mt-A | 1 | morphine (free) | 0.09 mcg/mL In Whole Blood @ |
| | | • | | | | | | | | Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.34% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.39% (wt/Vol) In Vitreous @ Autopsy |
| | | lamotrigine | 3 | 3 | | | | | | Lutopay |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------------|--------------------------------|-------------------|---------------|------------|----------|--------|-----|------------------------|---|
| 630pa | 52 y F | | | | A/C | Ingst | Int-S | 1 | | |
| _ | • | amitriptyline* | 1 | 1 | | - | | | | |
| | | cyclobenzaprine* | 3 | 1 | | | | | | |
| | | morphine (extended release)* | 2 | 1 | | | | | | |
| | | propranolol | 4 | 4 | | | | | | |
| | | metoclopramide | 5 | 5 | | | | | | |
| | | gabapentin | 6 | 6 | | | | | | |
| | | gemfibrozil | 7 | 7 | | | | | | |
| | | ethanol | 8 | 8 | | | | | ethanol | 20 mg/dL In Whole Blood @ |
| | | amphetamine | 9 | 9 | _ | | | | | Autopsy |
| 631h | 52 y F | acetaminophen/ | 1 | 1 | С | Ingst | Int-U | 1 | acetaminophen | 35.2 mg/L In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 1 | 1 | | | | | acetaminophen | Autopsy 37.5 mg/mL In Blood (unspecified) |
| | | hydrocodone | | | | | | | Î | @ Unknown |
| | | ethanol | 2 | 2 | | | | | ethanol | 300 mg/dL In Blood (unspecified) @ Unknown |
| 632 | 52 y F | | | | U | Ingst | Int-S | 1 | | |
| | · | acetaminophen/ propoxyphene | 1 | 1 | | | | | | |
| 633 | 52 y F | Y Y . JE | | | A | Ingst | Int-S | 1 | | |
| | , * | acetaminophen/ oxycodone | 1 | 1 | | <i>5</i> | | - | | |
| 634 | 52 y M | oxycodolic | | | A | Ingst | Int-S | 2 | | |
| 034 | 32 y IVI | acetaminophen/ hydrocodone | 1 | 1 | A | mgst | III-3 | 2 | acetaminophen | 106 mcg/mL In Blood (unspecified @ Unknown |
| 635pa | 52 y M | nyurocodone | | | A | Inact | Unk | 2 | | @ Chkhown |
| 335ра | 32 y IVI | oxycodone | 1 | 1 | A | Ingst | Olik | 2 | oxycodone | 376 ng/mL In Blood (unspecified) |
| | | lorazepam | 2 | 2 | | | | | 7-aminoclonaze- pam | @ Autopsy22.4 ng/mL In Blood (unspecified)@ Autopsy |
| 636a | 52 y F | | | | A | Ingst | Int-S | 2 | pam | @ Autopsy |
| 030a | 32 y 1 | acetaminophen/ | 1 | 1 | A | nigst | III-3 | 2 | acetaminophen | 58.9 mcg/mL In Plasma @ 6 h (pe) |
| | | hydrocodone ibuprofen | 2 | 2 | | | | | | |
| 637 | 52 y F | | | | A | Ingst | Int-S | 2 | | |
| | | acetaminophen | 1 | 1 | | | | | | |
| 638 | 52 y F | _ | | | A | Ingst | Int-S | 1 | | |
| | | acetaminophen/ opioid | 1 | 1 | | | | | acetaminophen | 125 mcg/mL In Serum @ Unknown |
| 639 | 52 y M | • | | | U | Ingst | Int-S | 1 | | |
| | • | acetaminophen | 1 | 1 | | C | | | | |
| 640 | 52 y F | acetaminophen | 1 | 1 | U | Ingst | Unk | 2 | | |
| | | higher alcohols | 2 | 2 | | | | | | |
| 541a | 52 v E | mgner arconors | 2 | _ | A | Ingst | Int-S | 3 | | |
| 5 4 14 | 52 y F | methadone | 1 | 1 | A | nigst | IIIt-3 | 3 | methadone | 0.77 mg/L In Blood (unspecified) |
| | | propoxyphene | 2 | 2 | | | | | propoxyphene | Unknown 0.64 mg/L In Blood (unspecified) |
| | | alprazolam | 3 | 3 | | | | | alprazolam | Autopsy 0.17 mg/L In Blood (unspecified) @ |
| | | acetaminophen/ | 4 | 4 | | | | | | Unknown |
| | | hydrocodone | | | | | | | | |
| 642pai | 52 y M | trazodone | 5 | 5 | U | Ingst | Int-A | 2 | | |
| r *** | , 111 | acetaminophen/ | 1 | 1 | Č | | | - | hydrocodone | 0.25 mcg/mL In Whole Blood @ |
| | | hydrocodone | - | • | | | | | , | Autopsy |
| | | alprazolam | 2 | 2 | | | | | | · · · · · · · · · · · · · · · · · · · |
| | | skeletal muscle | 3 | 3 | | | | | | |
| (42 | <i>5</i> 2 - | relaxant | 3 | 5 | | ¥ . | T . ~ | _ | | |
| 643 | 52 y F | | | | A | Ingst | Int-S | 2 | | |
| | | hydromorphone | 1 | 1 | | | | | | |
| | | amitriptyline | 2 | 2 | | | | | | |
| 544 | 52 y M | colchicine | 1 | 1 | A/C | Ingst | Unt-T | 2 | | |
| 645 | 53 y F | • | | | A/C | Ingst | Int-U | 2 | | |
| - | J - | acetaminophen | 1 | 1 | | o | | _ | | |
| | | | | 2 | | | | | | |
| | | acetaminophen/ | 2 | | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--------------------------------|-------------------|---------------|------------|-------------|---------|-----|-----------------|--|
| 646 | 53 y F | | | | A | Ingst | Int-S | 2 | | |
| | 3 | acetaminophen/ | 1 | 1 | | 8 | | | acetaminophen | 58 mcg/mL In Plasma @ Unknown |
| | | hydrocodone | 2 | 2 | | | | | | |
| 647 | 53 y F | carisoprodol | 2 | 2 | С | Ingst | Int-A | 3 | | |
| 0+7 | 33 y 1 | acetaminophen/ | 1 | 1 | C | nigst | IIIt-71 | 3 | acetaminophen | 148 mcg/mL In Blood (unspecified) |
| | | hydrocodone | | | | | | | • | @ 4.5 h (pe) |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 188 mcg/mL In Blood (unspecified) @ Unknown |
| 648a | 53 y M | hydrocodone | | | U | Par+ Unk | Int-M | 1 | | @ Clikilowii |
| | 3 | oxycodone | 1 | 1 | | | | | oxycodone | 309 ng/mL In Blood (unspecified) |
| | | | 1 | | | | | | 1 | @ Unknown |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 327 ng/mL In Blood (unspecified) @ Autopsy |
| | | cocaine | 2 | 2 | | | | | benzoylecognine | 1082 ng/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| | | cocaine | 2 | 2 | | | | | benzoylecognine | 1288 ng/mL In Blood (unspecified) @ Unknown |
| 649 | 53 y F | | | | A/C | Ingst+ Derm | Int-S | 1 | | e Chillown |
| | | fentanyl (transdermal) | 1 | 1 | | | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | 0 mcg/mL In Serum @ Unknown |
| | | oxycodone acetaminophen/ | 3 | 3 | | | | | acetaminophen | 0 mcg/mL In Serum @ Unknown |
| | | hydrocodone | - | | | | | | | B |
| | | alprazolam | 4 | 4 | | | | | | |
| | | zolpidem carisoprodol | 5 6 | 5 6 | | | | | | |
| | | levothyroxine | 7 | 7 | | | | | | |
| | | tolterodine | 8 | 8 | _ | | | | | |
| 650 | 53 y F | acetaminophen/ | 1 | 1 | С | Ingst | Int-S | 3 | aastaminanhan | 82 mag/ml. In Samum @ Unknown |
| | | hydrocodone | 1 | 1 | | | | | acetaminophen | 82 mcg/mL In Serum @ Unknown |
| 651pai | 53 y F | • | | | U | Ingst+ Unk | Int-A | 2 | | |
| | | fentanyl | 1 | 1 | | | | | fentanyl | 19.5 ng/mL In Whole Blood @ |
| | | citalopram | 2 | 2 | | | | | | Autopsy |
| 552pai | 53 y M | onaroprami | - | _ | U | Ingst | Int-U | 2 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 0.54 mcg/mL In Whole Blood @ |
| | | propoxyphene | 2 | 2 | | | | | propoxyphene | Autopsy 0.36 mcg/mL In Whole Blood @ |
| | | ргорохурнене | 2 | - | | | | | propoxyphene | Autopsy |
| | | propoxyphene | 2 | 2 | | | | | norpropoxyphene | 0.48 mcg/mL In Whole Blood @ |
| | | fluoxetine | 3 | 3 | | | | | | Autopsy |
| | | metoprolol | 4 | 4 | | | | | | |
| 653 | 54 y M | 1 | | | A | Ingst | Int-S | 1 | | |
| C = 1 | 54 M | acetaminophen | 1 | 1 | | T | Total A | 2 | | |
| 654 | 54 y M | oxycodone | 1 | 1 | A | Ingst | Int-A | 2 | | |
| 555 | 54 y F | onyeodone | • | • | A/C | Ingst | Int-S | 1 | | |
| | | methadone | 1 | 1 | | | | | | |
| 656p | 54 y M | ethanol | 2 | 2 | A | Ingst | Int-S | 1 | | |
| ээор | 34 y IVI | oxycodone | 1 | 1 | Λ | nigst | III-5 | 1 | | |
| | | ethanol | 2 | 2 | | | | | | |
| 657 | 54 y M | | 1 | 1 | С | Ingst | Int-M | 3 | | 5 mag/ml In Dland (managified) |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 5 mcg/mL In Blood (unspecified) @ 8 h (pe) |
| 658a | 54 y M | | | | A/C | Ingst | Int-S | 1 | | 2 2 2 4 2) |
| | | acetaminophen/ | 1 | 1 | | | | | norpropoxyphene | 1.3 mg/L In Blood (unspecified) @ |
| | | propoxyphene acetaminophen/ | 1 | 1 | | | | | propoxyphene | Unknown 2 mg/L In Blood (unspecified) @ |
| | | propoxyphene | • | • | | | | | proponypneme | Unknown |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 735 mcg/mL In Serum @ Unknown |
| | | propoxyphene lorazepam | 2 | 2 | | | | | | |
| 659p | 54 y M | тогагерані | 2 | 4 | A | Unk | Int-U | 2 | | |
| | - | methadone | 1 | 1 | | | | | | |
| 560a | 54 y F | diazepam | 2 | 2 | A | Inget | Int-S | 1 | | |
| oooa | э+уГ | acetaminophen/ | 1 | 1 | А | Ingst | IIII-3 | 1 | acetaminophen | 260 mcg/mL In Blood (unspecified) |
| | | diphenhydramine | | | | | | | | @ 3 h (pe) |
| | | melatonin | 2 | 2 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|---------------------------------|-------------------|---------------|------------|------------|--------|-----|---------------|---|
| 61 | 54 y F | | | | A/C | Unk | Unk | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| | | butalbital/caffeine opioid | 2 | 2 | | | | | | |
| | | tricyclic | 3 | 3 | | | | | | |
| | | antidepressant | 5 | 3 | | | | | | |
| 52ai | 54 y M | • | | | A/C | Ingst | Int-S | 3 | | |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | | |
| 63p | 54 y M | oxycodone | | | A/C | Ingst | Int-S | 2 | | |
| | , | methadone | 1 | 1 | | Ü | | | | |
| | | nadolol | 2 | 2 | | | | | | |
| | | oxycodone | 5 | 3 | | | | | | |
| | | acetaminophen/ oxycodone | 4 | 4 | | | | | | |
| | | ibuprofen | 3 | 5 | | | | | | |
| 64pai | 54 y M | | | | A | Ingst | Int-A | 2 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.2 mcg/mL In Whole Blood @ Autopsy |
| | | diazepam | 2 | 2 | | | | | nordiazepam | 0.49 mcg/mL In Whole Blood @ |
| | | diazepam | 2 | 2 | | | | | diazepam | Autopsy 1.1 mcg/mL In Whole Blood @ |
| | | шагераш | | | | | | | diazepani | Autopsy |
| | | laxative (stimulant) | 3 | 3 | | | | | sertraline | 1.2 mcg/mL In Whole Blood @ Autopsy |
| 65p | 54 y M | | | | U | Unk | Int-U | 2 | | rutopsy |
| | | oxymorphone | 1 | 1 | | | | | | |
| | | (extended release) methadone | 2 | 2 | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| 66pai | 54 y F | • | | | U | Ingst+ Unk | Unk | 2 | | |
| | | oxycodone | 1 | 1 | | | | | oxycodone | 0.19 mcg/mL In Whole Blood @ Unknown |
| | | methamphetamine | 2 | 2 | | | | | amphetamine | 1.2 mcg/mL In Whole Blood @ |
| | | diphenhydramine | 3 | 3 | | | | | | Unknown |
| 67pai | 54 y F | dipitetitiyaramine | 3 | 3 | U | Ingst | Int-A | 2 | | |
| • | | oxycodone | 1 | 1 | | C | | | oxycodone | 0.96 mcg/mL In Whole Blood @ |
| | | citalopram | 2 | 2 | | | | | citalopram | Autopsy 2 mcg/mL In Whole Blood @ Autopsy |
| | | diazepam | 3 | 3 | | | | | | |
| | | bupropion | 4 | 4 | | | | | | |
| | | cyclobenzaprine | 5 | 5 | | | | | | |
| 68 | 54 v. M | doxylamine | 6 | 6 | A/C | Inact | Int-S | 2 | | |
| 08 | 54 y M | acetaminophen/ | 1 | 1 | A/C | Ingst | IIII-3 | 2 | acetaminophen | 57 mcg/mL In Unknown @ |
| | | hydrocodone | | | | | | | | Unknown |
| | | cyclobenzaprine | 2 | 2 | | | | | | |
| 60 | 54 F | ropinirole | 3 | 3 | A /C | T . | T . C | 2 | | |
| 69p | 54 y F | fentanyl | 6 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | fentanyl clonazepam | 2 | 2 | | | | | | |
| | | acetaminophen/ | 7 | 3 | | | | | | |
| | | hydrocodone | 4 | 4 | | | | | | |
| | | acetaminophen/ oxycodone | 4 | 4 | | | | | | |
| | | quetiapine | 5 | 5 | | | | | | |
| | | pregabalin | 3 | 6 | | | | | | |
| 70 | 54 35 | duloxetine | 1 | 7 | A | Innet | T A | 1 | | |
| 70pai | 54 y M | methadone | 1 | 1 | A | Ingst | Int-A | 1 | methadone | 0.62 mcg/mL In Whole Blood @ |
| | | desipramine | 2 | 2 | | | | | desipramine | Autopsy 9.6 mcg/mL In Whole Blood @ |
| 71p | 54 14 | | | | A /C | Inget | Int IT | 2 | | Autopsy |
| 71p | 54 y M | methadone | 1 | 1 | A/C | Ingst | Int-U | 2 | | |
| | | alprazolam | 2 | 2 | | | | | | |
| | | cyclobenzaprine | 3 | 3 | | | | | | |
| | | sulindac | 4 | 4 | | | | | | |
| | | duloxetine | 5 | 5 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|--------------|--------|-----|-----------------|--|
| 672 | 55 y M | acetaminophen | 1 | 1 | U | Ingst | Int-S | 1 | acetaminophen | 300 mcg/mL In Blood (unspecified |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 2 d (pe) 683 mcg/mL In Blood (unspecified |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | @ 1 d (pe) 852 mcg/mL In Blood (unspecified |
| | | trazodone | 2 | 2 | | | | | trazodone | @ Unknown 0 mcg/mL In Blood (unspecified) |
| 673 | 55 y M | | | | С | Ingst+ Aspir | Unk | 2 | | Unknown |
| | | acetaminophen ethanol | 1 2 | 1 2 | | | | | acetaminophen | 15 mcg/mL In Serum @ Unknown |
| 674 | 55 y F | emanor | 2 | 2 | C | Ingst | Int-S | 3 | | |
| | | hydromorphone | 1 | 1 | | | | | | |
| | | lorazepam trazodone | 2 3 | 2 3 | | | | | | |
| 675a | 55 y F | | | | C | Ingst | Int-M | 1 | | |
| | | acetaminophen acetaminophen/ hydrocodone | 1 2 | 1 2 | | | | | acetaminophen | 34 mcg/mL In Serum @ Unknown |
| | | acetaminophen/ codeine | 3 | 3 | | | | | | |
| 676 | 55 y F | acetaminophen/ | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | caffeine/salicylate gabapentin | 2 | 2 | | | | | | |
| | | fluoxetine | 3 | 3 | | | | | | |
| 677a | 55 y F | morphine | 1 | 1 | A | Ingst | Int-U | 2 | morphine (free) | 36 mcg/L In Serum @ Unknown |
| | | cocaine | 2 | 2 | | | | | morphine (free) | 30 meg/2 m serum e emanown |
| | | cyclobenzaprine | 3 | 3 | | | | | | |
| | | alprazolam | 4 | 4 | | | | | | |
| | | oxycodone | 5 | 5 | | | | | | |
| | | hydrocodone | 6 | 6 | | | | | | |
| | | gabapentin lisinopril | 7 8 | 7 8 | | | | | | |
| | | montelukast | 9 | 9 | | | | | | |
| | | naproxen | 10 | 10 | | | | | | |
| | | cimetidine | 11 | 11 | | | | | | |
| | | ezetimibe/simvastatin | 12 | 12 | | | | | | |
| | | pravastatin | 13 | 13 | | | | | | |
| 678ai | 55 y M | tramadol | 1 | 1 | U | Ingst | Int-A | 2 | tramadol | 2.3 mcg/mL In Blood (unspecified) @ Unknown |
| | | doxepin | 2 | 2 | | | | | nordoxepin | 0.75 mcg/mL In Blood (unspecified @ Unknown |
| | | doxepin | 2 | 2 | | | | | doxepin | 3.1 mcg/mL In Blood (unspecified) @ Unknown |
| 679pai | 55 y M | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 0.38 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 173 ng/mL In Whole Blood @ Autopsy |
| (00 : | 55) 4 | diazepam | 3 | 3 | ** | T . | T . A | 2 | | |
| 680pai | 55 y M | morphine | 1 | 1 | U | Ingst | Int-A | 2 | morphine (free) | 2.1 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.17 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.07% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.1% (wt/Vol) In Vitreous @ Autopsy |
| | | skeletal muscle relaxant | 4 | 4 | | | | | meprobamate | 5.8 mcg/mL In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant phenobarbital | 4 5 | 4 5 | | | | | carisoprodol | 7.3 mcg/mL In Whole Blood @ Autopsy |
| | | amitriptyline | 6 | 6 | | | | | | |
| 681pai | 55 y M | | ~ | | U | Ingst | Int-A | 2 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.12 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.02% (wt/Vol) In Vitreous @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|-----------------------------------|-------------------|---------------|------------|------------|--------|-----|-----------------|--|
| | | ethanol | 2 | 2 | | | | | ethanol | 0.14% (wt/Vol) In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant | 3 | 3 | | | | | carisoprodol | 2 mcg/mL In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant | 3 | 3 | | | | | meprobamate | 6.5 mcg/mL In Whole Blood @ Autopsy |
| | | morphine | 4 | 4 | | | | | morphine (free) | 0.13 mcg/mL In Whole Blood @ Autopsy |
| 682pai | 55 y M | oxycodone | 1 | 1 | U | Ingst | Int-A | 2 | oxycodone | 1.1 mcg/mL In Whole Blood @ |
| | | oxycodone | 1 | 1 | | | | | oxymorphone | Autopsy 69 ng/mL In Whole Blood @ |
| | | • | | | | | | | | Autopsy |
| | | skeletal muscle relaxant | 2 | 2 | | | | | meprobamate | 35.2 mcg/mL In Whole Blood @ Autopsy |
| | | skeletal muscle relaxant | 2 | 2 | | | | | carisoprodol | 9.7 mcg/mL In Whole Blood @ Autopsy |
| 683pa | 55 y M | diazepam | 3 | 3 | U | Unk | Int-U | 2 | | |
| • | • | hydrocodone | 1 | 1 | | | | | hydromorphone | 7 ng/mL In Blood (unspecified) @ Autopsy |
| | | hydrocodone | 1 | 1 | | | | | hydrocodone | 729 ng/mL In Blood (unspecified) |
| | | alprazolam | 2 | 2 | | | | | alprazolam | @ Autopsy 125 ng/mL In Blood (unspecified) @ Autopsy |
| 684pai | 55 y F | morphine | 1 | 1 | A | Ingst+ Unk | Int-S | 1 | morphine (free) | 0.07 mcg/mL In Whole Blood @ |
| | | acetaminophen/ | 2 | 2 | | | | | hydrocodone | Autopsy 0.12 mcg/mL In Whole Blood @ |
| | | hydrocodone fluoxetine | 3 | 3 | | | | | norfluoxetine | Autopsy 0.74 mcg/mL In Whole Blood @ |
| | | fluoxetine | 3 | 3 | | | | | fluoxetine | Autopsy 1.2 mcg/mL In Whole Blood @ |
| | | quetiapine | 4 | 4 | | | | | | Autopsy |
| 685 | 56 y F | acetaminophen | 1 | 1 | С | Ingst | Int-M | 1 | acetaminophen | 97 mcg/mL In Serum @ Unknown |
| 686pa | 56 y F | acetaminophen/ | 2 | 1 | U | Ingst | Int-S | 1 | acetaminophen | 105.2 mcg/mL In Serum @ Un- |
| | | hydrocodone acetaminophen/ | 2 | 1 | | | | | hydrocodone | known 124 ng/mL In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 3 | 2 | | | | | norpropoxyphene | @ Unknown 490 ng/mL In Blood (unspecified) |
| | | propoxyphene | | | | | | | | @ Unknown |
| | | acetaminophen/ diphenhydramine | 1 | 3 | | | | | diphenhydramine | 774 ng/mL In Blood (unspecified) @ Unknown |
| | | carisoprodol/ salicylate | 4 | 4 | | | | | | |
| 687pa | 56 y F | caffeine/salicylate | 1 | 1 | С | Ingst | Unk | 1 | salicylate | 30 mg/dL In Serum @ Unknown |
| 688 | 56 y F | acetaminophen/ | 1 | 1 | A/C | Ingst | Int-S | 1 | · | C |
| | | propoxyphene | 2 | 2 | | | | | | |
| 689a | 56 y F | alprazolam | | | A/C | Ingst | Int-S | 1 | | |
| | | salicylate | 1 | 1 | | | | | salicylate | @ Autopsy |
| | | buprenorphine* | 2 | 2 | | | | | buprenorphine | 46 ng/mL In Blood (unspecified) @ Autopsy |
| | | zolpidem* lamotrigine | 3 4 | 2 3 | | | | | lamotrigine | 3 mcg/mL In Blood (unspecified) @ Autopsy |
| 600 | 56 F | naproxen | 5 | 4 | A /C | Toront | Int C | 2 | | rucopsy |
| 690pa | 56 y F | acetaminophen/ oxycodone | 1 | 1 | A/C | Ingst | Int-S | 3 | | |
| 691a | 56 y F | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 692pai | 56 y M | diphenhydramine | | | A | Ingst+ Unk | Int-A | 2 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.22 mcg/mL In Whole Blood @ Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxycodone | 0.45 mcg/L In Whole Blood @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-------------------------------|-------------------|---------------|------------|----------|---------|-----|-----------------|--|
| | | ketamine | 3 | 3 | | | | | | |
| | | diazepam | 4 | 4 | | | | | | |
| | | amitriptyline | 5 | 5 | | | | | | |
| | | citalopram | 6 | 6 | | | | | | |
| | | memantine ethanol | 7 8 | 7 8 | | | | | | |
| 593pa | 57 y F | Cinanoi | 0 | 0 | A/C | Ingst | Int-A | 2 | | |
| F- | 2. , 2 | methadone | 1 | 1 | | 6 | | | methadone | 0.693 mg/L In Blood (unspecified) @ Unknown |
| 694pa | 57 y F | | | | A | Ingst | Int-S | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| 595 | 57 y M | hydrocodone | | | U | Ingst | Int-S | 1 | | |
| 373 | 37 y 1VI | salicylate | 1 | 1 | O | nigst | 1111-5 | 1 | | |
| | | ibuprofen | 2 | 2 | | | | | | |
| | | naproxen | 3 | 3 | | | | | | |
| 696p | 57 y F | | | | U | Ingst | Int-S | 2 | | |
| | | codeine | 1 | 1 | | | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | hydrocodone acetaminophen/ | 5 | 4 | | | | | | |
| | | diphenhydramine | 3 | r | | | | | | |
| | | lorazepam | 4 | 5 | | | | | | |
| | | alprazolam | 6 | 6 | | | | | | |
| 697pa | 57 y F | .1 1 | | | U | Ingst | Unk | 1 | | |
| | | methadone | 1 2 | 1 2 | | | | | budraaadana | 0.112 mg/dL In Pland (unemonified |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | 0.113 mg/dL In Blood (unspecified @ Autopsy |
| 698a | 57 y F | | | | A/C | Ingst | Unt-G | 1 | | e rutopsy |
| | | acetaminophen/ | 3 | 1 | | 8 | | | oxycodone | 0.57 mg/L In Blood (unspecified) |
| | | oxycodone* | | | | | | | | Autopsy |
| | | amitriptyline* | 1 | 1 | | | | | amitriptyline | 13.1 mg/L In Blood (unspecified) (|
| | | bangadiaganina | 2 | 2 | | | | | alprozalam | Autopsy |
| | | benzodiazepine | 2 | 2 | | | | | alprazolam | 12 ng/mL In Blood (unspecified) @ Autopsy |
| 699p | 57 y M | | | | A | Ingst | Int-U | 2 | | Tutopsy |
| | , | acetaminophen/ | 1 | 1 | | C | | | | |
| | | hydrocodone | | | | | | | | |
| 700 : | 67 E | carisoprodol | 2 | 2 | * * | . | T . A | 2 | | |
| 700ai | 57 y F | methadone | 1 | 1 | U | Ingst | Int-A | 2 | methadone | 0.70 mag/mL In Whole Blood @ |
| | | memadone | 1 | 1 | | | | | meuladone | 0.79 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ | 2 | 2 | | | | | hydrocodone | 0.16 mcg/mL In Whole Blood @ |
| | | hydrocodone | | | | | | | • | Autopsy |
| | | quetiapine | 3 | 3 | | | | | | |
| 701 | 57 F | fluoxetine | 4 | 4 | | T 4 | T., 4 A | 2 | | |
| 701pai | 57 y F | morphine | 1 | 1 | Α | Ingst | Int-A | 2 | morphine (free) | 0.52 mcg/mL In Whole Blood @ |
| | | шогрише | 1 | 1 | | | | | morphine (nee) | Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxycodone | 0.21 mcg/mL In Whole Blood @ |
| | | • | | | | | | | Ž | Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxymorphone | 21 ng/mL In Whole Blood @ |
| | | 1 | 2 | 2 | | | | | | Autopsy |
| 702noi | 57 v M | diazepam | 3 | 3 | U | Inget | Int-A | 2 | | |
| 702pai | 57 y M | acetaminophen/ | 1 | 1 | U | Ingst | IIIt-A | 2 | hydrocodone | 0.49 mcg/mL In Whole Blood @ |
| | | hydrocodone | | | | | | | , ar ocodone | Autopsy |
| | | skeletal muscle | 2 | 2 | | | | | carisoprodol | 2.9 mcg/mL In Whole Blood @ |
| | | relaxant | 2 | 2 | | | | | | Autopsy |
| | | skeletal muscle relaxant | 2 | 2 | | | | | meprobamate | 5.5 mcg/mL In Whole Blood @ |
| | | pseudoephedrine | 3 | 3 | | | | | | Autopsy |
| | | amitriptyline | 4 | 4 | | | | | | |
| | | laxative (stimulant) | 5 | 5 | | | | | | |
| 703pai | 57 y M | | | | U | Ingst | Int-A | 2 | | |
| | | methadone | 1 | 1 | | | | | methadone | 0.74 mcg/mL In Whole Blood @ |
| | | alnrazolom | 2 | 2 | | | | | alnrazolom | Autopsy |
| | | alprazolam | 2 | 7 | | | | | alprazolam | 217 ng/mL In Whole Blood @ Autopsy |
| 704pai | 57 y F | | | | U | Derm | Int-A | 2 | | Mulopsy |
| | - · J - | fentanyl | 1 | 1 | - | | | _ | fentanyl | 9.4 mcg/mL In Whole Blood @ |
| | | | | | | | | | | Autopsy |
| | | lamotrigine | 2 | 2 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---|-------------------|---------------|------------|--------------|--------|-----|------------------|--|
| 705pa | 57 y M | fentanyl | 1 | 1 | U | Ingst | Unk | 2 | fentanyl | 14.9 ng/mL In Blood (unspecified) |
| | | diazepam | 2 | 2 | | | | | nordiazepam | @ Autopsy 501 ng/mL In Blood (unspecified) |
| | | diazepam | 2 | 2 | | | | | diltiazem | @ Autopsy516 ng/mL In Blood (unspecified)@ Autopsy |
| 706pa | 58 y M | hydrocodone | 3 | 3 | U | Ingst | Int-S | 1 | | Criatopsy |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | oxymorphone | 0.042 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | oxycodone | 0.291 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.047 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | acetaminophen | 108 mg/L In Blood (unspecified) @ Unknown |
| | | ethanol | 3 | 3 | | | | | ethanol | 118 mg/dL In Blood (unspecified) @ Unknown |
| 707 | 58 y M | acetaminophen | 1 | 1 | С | Ingst+ Aspir | Int-S | 1 | acetaminophen | 13 mcg/mL In Blood (unspecified) |
| | | ethanol | 2 | 2 | | | | | ethanol | @ Unknown 48% (wt/Vol) In Blood (unspecified |
| 708ph | 58 y F | | | | A | Ingst | Int-S | 2 | | @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 1 | | | | | | |
| | | colchicine hydrochlorothia-zide/ lisinopril | 1 3 | 2 3 | | | | | | |
| 709p | 58 y F | simvastatin | 4 | 4 | A/C | Ingst | Int-S | 2 | | |
| 705p | 30 y 1 | acetaminophen/ oxycodone | 1 | 1 | 700 | mgst | int 5 | - | | |
| | | prednisone alprazolam | 2 3 | 2 3 | | | | | | |
| 710pa | 58 y F | acetaminophen/ | 1 | 1 | A/C | Ingst | Int-S | 1 | hydrocodone | 1 mg/L In Blood (unspecified) @ |
| | | hydrocodone acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | Unknown 281.2 mcg/mL In Blood (unspecified) @ 11 h (pe) |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 290.9 mcg/mL In Blood (unspecified) @ Unknown |
| | | zolpidem | 2 | 2 | | | | | zolpidem | 1.8 mg/L In Blood (unspecified) @ Unknown |
| | | fluoxetine | 3 | 3 | | | | | norfluoxetine | 0.79 mg/L In Blood (unspecified) @ Autopsy |
| | | fluoxetine | 3 | 3 | | | | | fluoxetine | 1.3 mg/L In Blood (unspecified) @ Autopsy |
| | | doxylamine | 4 | 4 | | | | | doxylamine | 0.16 mg/L In Blood (unspecified) @ Autopsy |
| | | dextromethorphan | 5 | 5 | | | | | dextromethorphan | 0.17 mg/L In Blood (unspecified) @ Autopsy |
| | | alprazolam | 6 | 6 | | | | | alprazolam | 0.13 mg/L In Blood (unspecified) @ Autopsy |
| 711p | 58 y F | morphine | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | metoprolol | 2 | 2 | | | | | | |
| 712 | 58 y M | benzodiazepine | 3 | 3 | A/C | Ingst | Int-S | 3 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 117 mcg/mL In Serum @ Unknown |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 97 mcg/mL In Serum @ Unknown |
| 712 | 50 F | fentanyl (transdermal) | 2 | 2 | | Total | T., C | 2 | | |
| 713 | 58 y F | acetaminophen/ hydrocodone | 1 | 1 | Α | Ingst | Int-S | 2 | acetaminophen | 216 mcg/mL In Serum @ Unknown |
| 714p | 50 v M | duloxetine | 2 | 2 | A/C | Inget | Int IT | 2 | | |
| | 58 y M | propoxyphene | 1 | 1 | A/C | Ingst | Int-U | 4 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|---------------------------------------|-------------------|---------------|------------|------------|--------|-----|-----------------|--|
| 715pa | 59 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | methadone | 1 | 1 | | _ | | | | |
| 716pi | 59 y F | | 2 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | acetaminophen | 3 | 1 2 | | | | | | |
| | | clozapine lithium | 2 1 | 3 | | | | | | |
| | | lorazepam | 4 | 4 | | | | | | |
| | | omeprazole | 5 | 5 | | | | | | |
| 717a | 59 y F | V | | | C | Ingst | Int-S | 3 | | |
| | , | acetaminophen | 1 | 1 | | C | | | acetaminophen | 60 mcg/mL In Serum @ Unknown |
| | | diphenhydramine | 2 | 2 | | | | | diphenhydramine | 558 ng/mL In Blood (unspecified) @ Autopsy |
| | | droperidol/fentanyl | 3 | 3 | | | | | fentanyl | 11.9 ng/mL In Blood (unspecified) @ Autopsy |
| | | prochlorperazine | 4 | 4 | | | | | promethazine | 68 ng/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 5 | 5 | | | | | hydrocodone | 95 ng/mL In Urine (quantitative only) @ Autopsy |
| | | methadone | 6 | 6 | | | | | methadone | 362 ng/mL In Urine (quantitative only) @ Autopsy |
| 718 | 59 y F | | | _ | U | Ingst | Int-S | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 9 mcg/mL In Blood (unspecified) @ |
| | | hydrocodone carbamazepine | 2 | 2 | | | | | carbamazepine | Unknown 28.8 mcg/mL In Blood (unspecified) @ Unknown |
| | | atenolol | 3 | 3 | | | | | | @ Ulkilowii |
| | | enalapril | 4 | 4 | | | | | | |
| | | hydroxychloroquine | 5 | 5 | | | | | | |
| | | buspirone | 6 | 6 | | | | | | |
| | | alprazolam | 7 | 7 | | | | | | |
| | | prednisone | 8 | 8 | | | | | | |
| 719p | 60 y F | omeprazole | 9 | 9 | U | Ingst | Int-S | 1 | | |
| | | methadone | 1 | 1 | | | | | | |
| | | duloxetine | 2 | 2 | | | | | | |
| | | zolpidem (extended release) | 3 | 3 | | | | | ath an al | 24 /- II |
| | | ethanol pantoprazole | 5 4 | 4 5 | | | | | ethanol | 34 mg/dL In Serum @ 0 h (pe) |
| 720h | 60 y M | pantoprazoie | 4 | 3 | A | Ingst | Int-S | 3 | | |
| 72011 | 00) 1.1 | morphine (extended release) | 2 | 1 | | mgot | 5 | | | |
| | | acetaminophen | 1 | 2 | | | | | acetaminophen | 5.1 ng/mL In Serum @ Unknown |
| 721a | 60 y M | Î | | | U | Ingst | Int-S | 1 | Î | - |
| | | salicylate | 1 | 1 | | | | | salicylate | 124 mg/dL In Serum @ 1 h (pe) |
| 722 | 60 y F | | | | A/C | Ingst+ Par | Int-S | 1 | | |
| | | tramadol | 1 | 1 | | | | | | |
| | | insulin muscle relaxant, | 2 3 | 2 3 | | | | | | |
| | | unknown | 3 | 3 | | | | | | |
| 723 | 60 y F | unknown | | | U | Ingst | Unk | 2 | | |
| | | acetaminophen | 1 | 1 | | 6 | | | acetaminophen | 17.1 mcg/mL In Blood (unspecified) |
| 724 | (0 M | | | | | T | T C | 2 | | @ Unknown |
| 724 | 60 y M | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 3 | | |
| | | hydrocodone acetaminophen | 2 | 2 | | | | | acetaminophen | 30.8 mg/mL In Blood (unspecified) |
| 725pai | 60 y M | | | | A | Unk | Int-A | 2 | | @ Unknown |
| 723pai | 00 y WI | fentanyl | 1 | 1 | A | Olik | IIIt-A | 2 | fentanyl | 13.5 ng/mL In Whole Blood @ |
| | | diazepam | 2 | 2 | | | | | | Autopsy |
| 726 | 61 y F | - | | | A/C | Ingst | Unt-T | 3 | | |
| | | acetaminophen/ butalbital/caffeine | 1 | 1 | | | | | acetaminophen | 43 mcg/mL In Blood (unspecified) @ Unknown |
| 727 | 61 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | acetaminophen/ propoxyphene | 1 | 1 | | | | | | |
| 728 | 61 y F | ** | | | U | Ingst | Int-M | 2 | | |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | | |
| | | amphetamine | 2 | 2 | | | | | | |
| | | benzodiazepine | 3 | 3 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------------|-------------------|---------------|------------|--------------|--------|-----|---------------|------------------------------------|
| 729a | 61 y M | | | | U | Ingst | Int-S | 1 | | |
| | • | salicylate | 1 | 1 | | C | | | salicylate | 340 mcg/mL In Serum @ Autopsy |
| | | salicylate | 1 | 1 | | | | | salicylate | 85 mg/dL In Serum @ 1 h (pe) |
| 730 | 61 y M | | | | A | Ingst | Int-S | 2 | | |
| | | methadone | 1 | 1 | | | | | | |
| | | diazepam | 2 | 2 | | | | | | |
| | | naproxen | 3 | 3 | | _ | | | | |
| 731 | 61 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| | | hydrocodone ethanol | 2 | 2 | | | | | | |
| 732 | 61 y M | emanor | 2 | 2 | A | Ingst | Int-S | 3 | | |
| 132 | OI y IVI | acetaminophen/ | 1 | 1 | Α | nigst | 1111-3 | 3 | acetaminophen | 0 mcg/mL In Serum @ Unknown |
| | | hydrocodone | 1 | 1 | | | | | acctammophen | o meg/me in octum @ Chknown |
| | | atenolol | 2 | 2 | | | | | | |
| | | oxycodone (extended | 3 | 3 | | | | | | |
| | | release) | | | | | | | | |
| 733 | 61 y F | , | | | U | Ingst | Int-M | 1 | | |
| | - 5 | acetaminophen | 1 | 1 | | 8 | | | acetaminophen | 91 mg/dL In Blood (unspecified) @ |
| | | 1 | | | | | | | | Unknown |
| 734 | 62 y F | | | | A | Ingst+ Inhal | Int-S | 1 | | |
| | | salicylate | 1 | 1 | | | | | salicylate | 125 mg/dL In Serum @ 1 h (pe) |
| | | cocaine | 2 | 2 | | | | | | * ' |
| 735a | 62 y F | | | | U | Ingst | Int-S | 2 | | |
| | | acetaminophen/ | 2 | 1 | | | | | acetaminophen | 45.3 mcg/mL In Blood (unspecified) |
| | | hydrocodone* | | | | | | | | @ Unknown |
| | | diltiazem (extended | 1 | 1 | | | | | | |
| | | release)* | | | ~ | _ | | _ | | |
| 736p | 62 y F | | | | C | Ingst | Int-A | 2 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| | | hydrocodone | 2 | 2 | | | | | | 121 / 1 6 6 6 |
| 737 | 62 y M | acetaminophen | 2 | 2 | A/C | Ingst | Int-S | 2 | acetaminophen | 121 mcg/mL In Serum @ Unknown |
| 131 | 02 y WI | colchicine | 1 | 1 | A/C | nigst | 1111-3 | 2 | | |
| | | venlafaxine | 2 | 2 | | | | | | |
| | | (extended release) | 2 | 2 | | | | | | |
| | | carvedilol | 3 | 3 | | | | | | |
| | | naltrexone | 4 | 4 | | | | | | |
| 738 | 62 y M | | | | C | Ingst | Int-U | 3 | | |
| | , | acetaminophen/ | 1 | 1 | | C | | | acetaminophen | 48 mcg/mL In Blood (unspecified) |
| | | hydrocodone | | | | | | | Î | @ Unknown |
| 739 | 63 y F | | | | A | Ingst | Int-S | 2 | | |
| | | meperidine | 1 | 1 | | | | | | |
| | | promethazine | 2 | 2 | | | | | | |
| | | zolpidem | 3 | 3 | | | | | | |
| 740 | 63 y F | | | | A | Ingst | Int-U | 3 | | |
| | | acetaminophen/ | 1 | 1 | | | | | | |
| | | diphenhydramine | | | | _ | | _ | | |
| 741p | 63 y M | | | | A/C | Ingst | Int-S | 2 | | 10 / 7 7 71 1/ 10 10 |
| | | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 42 mcg/mL In Blood (unspecified) |
| | | hydrocodone morphine (extended | 2 | 2 | | | | | | @ 4 d (pe) |
| | | 1 ' | 2 | 2 | | | | | | |
| | | release) diazepam | 3 | 3 | | | | | | |
| 742 | 63 y M | uiazepaiii | 3 | 3 | A/C | Ingst | Int-U | 3 | | |
| 742 | 03 y IVI | morphine | 1 | 1 | A/C | nigst | IIIt-U | 3 | | |
| 743pai | 63 y F | погрине | 1 | 1 | U | Ingst+ Derm | Unk | 2 | | |
| 7 15ptii | 03 y 1 | fentanyl | 1 | 1 | C | mgst Deim | Olik | _ | fentanyl | 140 ng/mL In Whole Blood @ |
| | | Temanyi | 1 | 1 | | | | | Temany i | Autopsy |
| | | doxepin | 2 | 2 | | | | | nordoxepin | 0.87 mcg/mL In Whole Blood @ |
| | | | | | | | | | | Autopsy |
| | | doxepin | 2 | 2 | | | | | doxepin | 1.1 mcg/mL In Whole Blood @ |
| | | fluoratina | 2 | 2 | | | | | | Autopsy |
| | | fluoxetine | 3 | 3 | | | | | | |
| | 62 F | diazepam | 4 | 4 | A | Inget | Int-S | 1 | | |
| 744 | | | | | A | Ingst | 1111-3 | 1 | | 120/ |
| 744 | 63 y F | acetaminophan | 1 | - 1 | | | | | acetaminonhan | |
| 744 745 | - | acetaminophen | 1 | 1 | Λ | Inget | ∐nt_T | 3 | acetaminophen | 128 mcg/mL In Serum @ Unknown |
| 744 745 | 63 y F | acetaminophen acetaminophen | 1 | 1 | A | Ingst | Unt-T | 3 | acetaminophen | 15.4 mcg/mL In Blood (unspecified) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| 746a 747a 748a 749 | 64 y F 64 y F 65 y M | acetaminophen/ hydrocodone acetaminophen/ hydrocodone acetaminophen/ hydrocodone acetaminophen/ hydrocodone | 1 1 1 | 1 1 | A/C | Ingst | Int-M | 1 | alprazolam | 0.05 mg/L In Dlood (|
|-----------------------------|----------------------------|--|-------------|--------|-----|-------|----------|---|--------------------------|--|
| 748a | · | hydrocodone acetaminophen/ hydrocodone acetaminophen/ hydrocodone acetaminophen/ | 1 | 1 | | | | | alprazolam | 0.05 mg/L In Dlood (|
| 748a | · | acetaminophen/ hydrocodone acetaminophen/ hydrocodone acetaminophen/ | 1 | | | | | | arprazolam | 0.05 mg/L In Blood (unspecified) @ Unknown |
| 748a | · | acetaminophen/ hydrocodone acetaminophen/ | | 4 | | | | | hydrocodone | 0.08 mg/L In Blood (unspecified) @ |
| 748a | · | hydrocodone acetaminophen/ | | | | | | | (free) | Unknown |
| 748a | · | acetaminophen/ | 1 | 1 | | | | | acetaminophen | 160.7 mcg/mL In Blood (unspeci- fied) @ Unknown |
| 748a | · | | | 1 | | | | | acetaminophen | 412.6 mcg/mL In Blood (unspecified) @ Unknown |
| | 65 y M | salicylate | 1 | 1 | A | Ingst | Int-S | 1 | salicylate | 155 mg/dL In Blood (unspecified) @ |
| | 65 y M | sancylate | 1 | 1 | | | | | sancylate | 4 h (pe) |
| 749 | | | 1 | 1 | U | Ingst | Int-U | 3 | | |
| 749 | | methadone diazepam | 1 2 | 1 2 | | | | | | |
| | 65 y F | • | | | C | Ingst | Unt-T | 2 | | |
| | | acetaminophen/ oxycodone | 1 | 1 | | | | | acetaminophen | 57 mcg/mL In Serum @ Unknown |
| | | acetaminophen | 2 | 2 | | | | | | |
| 750 | 65 y M | aaataminanhan | 1 | 1 | С | Ingst | Int-U | 3 | aaataminanhan | 22.0 mag/ml. In Pland (unappointed |
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 32.9 mcg/mL In Blood (unspecified) @ Unknown |
| | 65 P | salicylate | 2 | 2 | | | * | • | salicylate | 15.9 mg/dL In Serum @ Unknown |
| 751p | 65 y F | acetaminophen/ | 1 | 1 | Α | Ingst | Int-S | 2 | acetaminophen | 199 mcg/mL In Serum @ Unknown |
| | | hydrocodone | | | | | | | шесинторнен | 199 meg me serum e emmonii |
| 752noi | 65 M | metformin | 2 | 2 | U | Inact | Int-A | 2 | | |
| 752pai | 65 y M | methadone | 1 | 1 | U | Ingst | IIIt-A | 2 | methadone | 0.35 mcg/mL In Whole Blood @ |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | Autopsy 0.1 mcg/mL In Whole Blood @ |
| | | diazepam | 3 | 3 | | | | | | Autopsy |
| 753 | 65 y M | шигорин | 5 | 3 | A | Ingst | Int-S | 1 | | |
| | | methadone | 1 | 1 | | | | | | |
| | | acetaminophen/ opioid | 2 | 2 | | | | | | |
| | | carisoprodol | 3 | 3 | | | | | | |
| 754 | 66 y M | benzodiazepine | 4 | 4 | A/C | Ingst | Int-M | 1 | | |
| 754 | 00 y 1v1 | acetaminophen | 1 | 1 | 700 | nigst | 1111-141 | 1 | | |
| 755 | 66 y F | | 1 | 1 | С | Ingst | Int-M | 1 | | 50 / I In Dland (|
| | | acetaminophen | 1 | 1 | | | | | acetaminophen | 50 mcg/mL In Blood (unspecified) @ Unknown |
| 756a | 66 y M | | | | C | Ingst | Int-M | 1 | | |
| 757 | 66 y F | acetaminophen | 1 | 1 | A/C | Ingst | Int-S | 3 | | |
| | • | methadone | 1 | 1 | | | | | | |
| 758pai | 66 y F | tramadol | 1 | 1 | U | Ingst | Int-S | 2 | | |
| | | propoxyphene | 2 | 2 | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| | | doxepin chlorpheniramine | 4 5 | 4 5 | | | | | | |
| 759a | 67 y M | Chiorphennannie | 3 | 3 | A/C | Ingst | Int-S | 3 | | |
| | • | salicylate | 1 | 1 | _ | | | | | |
| 760 | 67 y F | acetaminophen | 1 | 1 | С | Ingst | Unt-M | 3 | acetaminophen | 148 mcg/mL In Unknown @ Unknown |
| | | magnesium oxide/zinc | 2 | 2 | | | | | | Chanown |
| 761 | 67 y M | | | | C | Ingst | Int-M | 1 | | |
| | | acetaminophen ethanol | 1 2 | 1 2 | | | | | | |
| | | acetaminophen/ | 3 | 3 | | | | | | |
| | | oxycodone | 4 | 4 | | | | | | |
| 762pi | 67 y F | drug, unknown | 4 | 4 | U | Ingst | Unk | 1 | | |
| p- | J I | acetaminophen | 1 | 1 | Ü | | J | - | | |
| | | glipizide | 2 | 2 | | | | | | |
| 763 | 67 y F | quinine | 3 | 3 | A | Ingst | Int-S | 1 | | |
| . 55 | J. J. | salicylate | 1 | 1 | 11 | 630 | 5 | 1 | salicylate | 62 mg/dL In Serum @ 3 h (pe) |
| | | salicylate salicylate | 1 1 | 1 1 | | | | | salicylate salicylate | 82 mg/dL In Serum @ 8 h (pe) 99 mg/dL In Serum @ 5.5 h (pe) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|------------|-----------|-----|---------------|--|
| 764 | 69 y M | acetaminophen | 1 | 1 | С | Ingst | Int-U | 2 | acetaminophen | 26 mcg/mL In Blood (unspecified) |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | @ 1 d (pe) |
| 765p | 69 y F | | 1 | 1 | A | Ingst | Int-A | 3 | | |
| 766 | 69 y M | methadone | 1 | 1 | C | Ingst | Unt-M | 3 | | |
| | 70 F | caffeine/salicylam- ide/salicylate | 1 | 1 | | . | II . T | | | |
| 767i | 70 y F | acetaminophen/ propoxyphene | 1 | 1 | С | Ingst | Unt-T | 1 | | |
| 768 | 71 y F | | | | A | Ingst | Unt-G | 1 | | |
| | | caffeine/salicylate salicylate | 1 2 | 1 2 | | | | | | |
| 69 | 71 y F | • | | | U | Ingst | Int-S | 1 | | |
| | | hydrocodone | 2 | 1 2 | | | | | | |
| 70a | 71 y M | pregabalin | 2 | 2 | A | Ingst | Int-S | 1 | | |
| | - | colchicine | 1 | 1 | | | | | | |
| 771p | 71 y M | acetaminophen/ tramadol | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | acetaminophen/ oxycodone | 2 | 2 | | | | | acetaminophen | 45 mcg/mL In Blood (unspecified) @ 8 h (pe) |
| | | acetaminophen/ hydrocodone cyclobenzaprine | 3 | 3 | | | | | | |
| | | ethanol | 4 5 | 5 | | | | | ethanol | 280 mg/dL In Blood (unspecified) @ |
| 72 | 71 y F | | | | A | Ingst | Int-S | 2 | | 8 h (pe) |
| | ,,,, | acetaminophen/ hydrocodone | 1 | 1 | | got | 5 | _ | | |
| 73a | 72 y F | quetiapine | 2 | 2 | U | Ingst+ Unk | Int-S | 2 | | |
| | | acetaminophen drug, unknown | 1 2 | 1 2 | | | | | | |
| 74 | 72 y F | salicylate | 1 | 1 | C | Ingst | Unt-T | 2 | salicylate | 60 mg/dL In Blood (unspecified) @ |
| | | same y lace | • | • | _ | | | | Sarreyrane | Unknown |
| 775 | 73 y M | salicylate | 1 | 1 | С | Ingst | Int-M | 1 | salicylate | 37.1 mg/dL In Blood (unspecified) @ Unknown |
| | | ibuprofen | 2 | 2 | | | | | | e emme |
| 776 | 74 y F | acetaminophen/ | 1 | 1 | A | Ingst | Int-S | 2 | acetaminophen | 432 mcg/mL In Serum @ Unknown |
| 777a | 75 y M | acetaminophen/ | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | hydrocodone skeletal muscle relaxant | 2 | 2 | | | | | | |
| 778p | 77 y M | Totaxair | | | A | Ingst | Int-S | 3 | | |
| | | oxycodone | 1 | 1 | | | | | | |
| | | potassium chloride acetaminophen | 2 3 | 2 3 | | | | | carbamazepine | 12.6 mg/L In Serum @ 30 h (pe) |
| | | acetaminophen | 3 | 3 | | | | | carbamazepine | 22 mg/L In Serum @ Unknown |
| | | acetaminophen | 3 | 3 | | | | | acetaminophen | 77 mcg/mL In Serum @ Unknown |
| 79 | 79 y F | carbamazepine | 4 | 4 | A/C | Ingst | Int-U | 3 | | |
| | ý | acetaminophen/ oxycodone | 1 | 1 | | ٥ | - | | acetaminophen | 15.3 mcg/mL In Serum @ Unknow |
| | | alprazolam | 2 | 2 | | | | | | |
| | | theophylline warfarin | 3 4 | 3 4 | | | | | | |
| 780pa | 79 y F | | | | A | Ingst | Int-S | 2 | | |
| 781p | 79 y M | acetaminophen | 1 | 1 | A | Ingst | Unk | 3 | | |
| | | morphine | 2 | 1 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---|-------------------|---------------|------------|----------|---------|-----|-----------------------------|--|
| 782a | 80 y M | acetaminophen/ | 1 | 1 | A/C | Ingst | Int-S | 3 | acetaminophen | 46 mcg/mL In Serum @ 12 h (pe) |
| | | hydrocodone | 1 | 1 | | | | | acctammophen | 40 meg/mil in Serum @ 12 ii (pc) |
| 783 | 80 y M | , | | | A | Ingst | Int-S | 2 | | |
| | | tramadol | 1 | 1 | | | | | | |
| 784a | 84 y F | | 1 | | A | Ingst | Oth-M | 1 | | 50000 /- I I II II / |
| | | morphine | 1 | 1 | | | | | morphine | 50000 ng/mL In Urine (quantitative only) @ Unknown |
| 785 | 84 y F | | | | C | Ingst | Unk | 2 | | omy) e emmown |
| | • | acetaminophen/ | 1 | 1 | | Ü | | | acetaminophen | 44.1 mcg/mL In Blood (unspecified) |
| 706 | 05 14 | codeine | | | | . | 4 D. D. | 2 | | @ Unknown |
| 786 | 85 y M | methadone | 1 | 1 | A | Ingst | AR-D | 3 | | |
| | | acetaminophen/ | 1 2 | 1 2 | | | | | | |
| | | oxycodone | 2 | 2 | | | | | | |
| 787a | 86 y M | onyeodone | | | A/C | Ingst | Int-S | 1 | | |
| | , | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.011 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | hydrocodone | 0.024 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 1 | 1 | | | | | acetaminophen | 378 mcg/mL In Blood (unspecified) @ Unknown |
| 788 | 86 y F | | | | A | Ingst | Unt-T | 1 | | |
| | | colchicine | 1 | 1 | | _ | | | | |
| 789a | 86 y M | | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 790a | 86 y F | salicylate | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| 190a | 00 y 1 | salicylate | 3 | 1 | AC | nigst | 1111-5 | 1 | | |
| | | venlafaxine | 2 | 2 | | | | | venlafaxine | 19000 mcg/mL In Blood (unspecified) @ Autopsy |
| | | venlafaxine | 2 | 2 | | | | | o-desmethylvenla- faxine | |
| | | nateglinide | 4 | 3 | | | | | | |
| | | insulin | 1 | 4 | | | | | | |
| 791p | 87 y M | | | | A | Ingst | Int-S | 2 | | |
| | | acetaminophen/ propoxyphene | 1 | 1 | | | | | acetaminophen | 60 mcg/mL In Blood (unspecified) @ 1 h (pe) |
| | | diazepam | 2 | 2 | | _ | | | | |
| 792pa | 15 m F | | | | A | Ingst | Unt-G | 2 | | |
| 793 | Unknow | opioid n adult (>=20 yrs) F acetaminophen | 1 | 1 | U | Ingst | Int-S | 1 | | |

See also case 2, 5, 6, 7, 8, 9, 11, 29, 38, 46, 51, 54, 70, 93, 235, 794, 796, 797, 799, 802, 812, 813, 824, 827, 831, 832, 836, 839, 840, 843, 849, 856, 857, 860, 862, 863, 867, 868, 870, 876, 880, 882, 884, 888, 891, 895, 896, 902, 912, 913, 916, 918, 919, 922, 923, 924, 927, 930, 955, 957, 958, 964, 975, 977, 980, 981, 983, 985, 987, 988, 989, 993, 995, 1001, 1004, 1006, 1007, 1013, 1020, 1022, 1023, 1026, 1028, 1031, 1032, 1042, 1054, 1057, 1060, 1061, 1067, 1073, 1079, 1090, 1100, 1102, 1109, 1126, 1130, 1136, 1137, 1138, 1139, 1140, 1141, 1145, 1147, 1150, 1151, 1153, 1154, 1157, 1158, 1163, 1164, 1165, 1172, 1173, 1174, 1182, 1183, 1184, 1192, 1193, 1197, 1198, 1200, 1201, 1204, 1208, 1210, 1220, 1221, 1222, 1226, 1232, 1233, 1235, 1237, 1238, 1239, 1247, 1255, 1258, 1260, 1261, 1266, 1267, 1268, 1282, 1284, 1285, 1288, 1292, 1294, 1295, 1297, 1302, 1309, 1313, 1316, 1317, 1322, 1323, 1334, 1338, 1342, 1343, 1352

| 1297, 1302, | 1309, 1313 | , 1316, 1317, 1322, 1323, | 1334, 133 | 38, 1342, 13 | 343, 1352 | | | |
|---------------|------------|---------------------------|-----------|--------------|-----------|-------------|-------|---|
| Anesthetics | | | | | | | | |
| 794 | 49 y M | | | | C | Ingst+ Derm | Unk | 2 |
| | | lidocaine | 1 | 1 | | | | |
| | | fentanyl (transdermal) | 2 | 2 3 | | | | |
| | | oxycodone | 3 | 3 | | | | |
| 795pi | Unknow | n adult (>=20 yrs) M | | | A | Inhal | Int-S | 1 |
| | | isoflurane | 1 | 1 | | | | |
| See also case | 357, 426, | 692 | | | | | | |
| Anticoagula | nts | | | | | | | |
| 796 | 23 y M | | | | A | Ingst | Int-S | 2 |
| | - 3 | verapami1* | 2 | 1 | | 8 | | |
| | | warfarin* | 1 | 1 | | | | |
| | | skeletal muscle | 3 | 3 | | | | |
| | | relaxant | | | | | | |
| | | ibuprofen | 4 | 4 | | | | |
| | | benztropine | 5 | 5 | | | | |
| | | bupropion | 6 | 6 | | | | |
| | | fexofenadine | 7 | 7 | | | | |
| | | metoprolol | 8 | 8 | | | | |
| | | clindamycin | 9 | 9 | | | | |
| | | haloperidol | 10 | 10 | | | | |
| | | cephalexin | 11 | 11 | | | | |
| | | antihyperlipidemic | 12 | 12 | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|-----------|--------------------------------------|-------------------|---------------|------------|-------|---------|-----|--------------------------------|--|
| 797 | 46 y M | | | | A | Ingst | AR-D | 3 | | |
| | | clopidogrel | 1 | 1 | | | | | | |
| | | salicylate | 2 | 2 | | _ | | | | |
| 798 | 82 y M | ation outside at a con- | 1 | 1 | A | Par | AR-D | 2 | | |
| See also case | 779, 941, | thrombolytics 978, 1015, 1029, 1032, | 1 1081, 1082, | 1 1111, 11 | 58 | | | | | |
| Anticonvuls | ants | | | | | | | | | |
| 799p | 20 y M | | | | A | Ingst | Int-S | 2 | | |
| • | • | levetiracetam | 1 | 1 | | | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | hydrocodone | 2 | 2 | | | | | | |
| 800p | 21 y F | valproic acid | 3 | 3 | A/C | Ingst | Int-U | 2 | | |
| воор | 21 y 1 | gabapentin | 1 | 1 | A/C | nigst | IIII-U | 2 | | |
| 801pa | 25 y F | guoupenun | • | • | A/C | Ingst | Int-S | 2 | | |
| | , | alprazolam* | 2 | 1 | | C | | | alprazolam | 89 ng/mL In Blood (unspecified) @ |
| | | 1 | | | | | | | | Autopsy |
| | | carbamazepine* | 1 | 1 | | | | | carbamazepine | 38 mcg/mL In Blood (unspecified) @ Autopsy |
| | | escitalopram | 3 | 3 | | | | | escitalopram | 1200 ng/mL In Blood (unspecified) |
| | | озениюргин | | | | | | | oseranoprani | @ Autopsy |
| | | lamotrigine | 4 | 4 | | | | | lamotrigine | 9.3 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| 802p | 27 y M | | | 4 | Α | Ingst | Int-S | 2 | | 242 / 1 1 5 0 2 1 /) |
| | | carbamazepine carbamazepine | 1 1 | 1 1 | | | | | carbamazepine carbamazepine | 24.3 mcg/mL In Serum @ 3 d (pe) 31.8 mcg/mL In Serum @ 2 d (pe) |
| | | carbamazepine | 1 | 1 | | | | | carbamazepine | 37 mcg/mL In Serum @ 2 d (pe) |
| | | carbamazepine | 1 | 1 | | | | | carbamazepine | 48 mcg/mL In Serum @ Unknown |
| | | carbamazepine | 1 | 1 | | | | | carbamazepine | 62 mcg/mL In Serum @ Unknown |
| | | carbamazepine | 1 | 1 | | | | | carbamazepine | 8.3 mcg/mL In Serum @ 3 d (pe) |
| | | methocarbamol | 2 | 2 | | | | | | |
| 002 | 20 E | oxycodone | 3 | 3 | A /C | T | Total C | 1 | | |
| 803pa | 28 y F | valproic acid | 1 | 1 | A/C | Ingst | Int-S | 1 | valproic acid | 1000 mcg/mL In Serum @ |
| | | (extended release) | 1 | 1 | | | | | varprote actu | Unknown |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 1072 mcg/mL In Serum @ |
| | | (extended release) | | | | | | | _ | Unknown |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 1073.1 mcg/mL In Serum @ |
| | | (extended release) valproic acid | 1 | 1 | | | | | valercia said | Unknown |
| | | (extended release) | 1 | 1 | | | | | valproic acid | 987.1 mcg/mL In Serum @ Unknown |
| | | ziprasidone | 2 | 2 | | | | | | Challown |
| 804a | 28 y M | 1 | | | A/C | Ingst | Int-S | 3 | | |
| | | phenytoin | 1 | 1 | | | | | phenytoin | 52.1 mcg/mL In Serum @ Unknow |
| 805p | 29 y M | | | | A | Ingst | Int-S | 2 | | |
| | | gabapentin | 1 | 1 | | | | | | |
| | | ethanol | 2 3 | 2 3 | | | | | ethanol | 240 mg/dL In Blood (unspecified) |
| | | Culturor | 5 | 3 | | | | | Cultuloi | @ Unknown |
| 806pa | 33 y F | | | | U | Ingst | Int-S | 2 | | |
| | | lamotrigine | 1 | 1 | | | | | | |
| 005 | 24 5 | drug, unknown | 2 | 2 | | | * | • | | |
| 807 | 34 y F | valproic acid | 1 | 1 | A/C | Ingst | Int-S | 2 | valproic acid | 225 mcg/mL In Serum @ 0.5 d (pe |
| | | (extended release) | 1 | 1 | | | | | varproic acid | 223 mcg/mll in Serum @ 0.3 d (pe |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 25.3 mcg/mL In Serum @ 4 d (pe) |
| | | (extended release) | | | | | | | * | |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 43.5 mcg/mL In Serum @ 24 h (pe) |
| | | (extended release) | 1 | 1 | | | | | valnrois acid | 57.8 mcg/mL In Serum @ 3 d (pe) |
| | | valproic acid (extended release) | 1 | 1 | | | | | valproic acid | 57.6 mcg/mL in Serum @ 5 d (pe) |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 94.9 mcg/mL In Serum @ Unknow |
| | | (extended release) | | | | | | | | |
| | | ethanol | 2 | 2 | | | | | | |
| 000 | 25 - | activated charcoal | 3 | 3 | | | ¥ . ~ | | | |
| 808p | 35 y F | lamatriain - | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | lamotrigine propranolol | 1 2 | 1 2 | | | | | | |
| | | | 4 | ~ | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---|-------------------|---------------|------------|-------------|---------|-----|--------------------------------|---|
| 809a | 37 y M | | | | A | Ingst | Int-S | 1 | | |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 1286 mcg/mL In Blood (unspeci- fied) @ 2 h (pe) |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 1399 mcg/mL In Blood |
| | | valproic acid | 1 | 1 | | | | | valproic acid | (unspecified) @ 6 h (pe) 1548 mcg/mL In Blood (unspeci- fied) @ 2 d (pe) |
| | | valproic acid valproic acid | 1 1 | 1 1 | | | | | valproic acid valproic acid | 414 mg/L In Serum @ Unknown 532 mcg/mL In Blood (unspecified) @ 3 d (pe) |
| | | methamphetamine | 2 | 2 | | | | | methamphetamine | 0.11 mg/L In Serum @ Unknown |
| 810 | 38 y F | | | | A | Ingst | Int-S | 3 | _ | |
| | | anticonvulsant drug, unknown | 1 2 | 1 2 | | | | | | |
| 811 | 40 y F | | | | U | Ingst+ Derm | Int-S | 3 | | |
| | | lamotrigine | 1 | 1 | | | | | | |
| | | diazepam duloxetine | 2 3 | 2 3 | | | | | | |
| | | gasoline | 4 | 4 | | | | | | |
| 812pa | 43 y F | C | | | A/C | Ingst | Unk | 3 | | |
| | | oxcabazepine | 1 | 1 | | | | | oxcarbazepine | 21.1 mcg/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 2 | 2 | | | | | clonazepam | 10.9 ng/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 2 | 2 | | | | | 7-aminoclonaze- pam | 188 ng/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 2 | 2 | | | | | 7-aminoclonaze- pam | 2500 ng/mL In Urine (quantitative only) @ Autopsy |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | hydromorphone | 1094 ng/mL In Urine (quantitative only) @ Autopsy |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | hydrocodone | 20.1 ng/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone duloxetine | 3 | 3 | | | | | hydrocodone duloxetine | 3321 ng/mL In Urine (quantitative only) @ Autopsy 98.4 ng/mL In Blood (unspecified) |
| | | trazodone | 5 | 5 | | | | | trazodone | @ Autopsy 1 mcg/mL In Blood (unspecified) @ |
| | | quetiapine | 6 | 6 | | | | | quetiapine | Autopsy 523 ng/mL In Blood (unspecified) |
| 813p | 44 y F | quettapine | Ü | 0 | С | Ingst | Int-A | 2 | quettapine | @ Autopsy |
| 015р | ,1 | gabapentin | 1 | 1 | C | mgst | 1111 71 | - | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| | | quetiapine | 3 | 3 | | | | | | |
| | | fluoxetine | 4 | 4 | | | | | | |
| 814 | 45 y F | ethanol | 5 | 5 | U | Ingst | AR-D | 3 | | |
| 014 | 43 y 1 | valproic acid | 1 | 1 | O | nigst | AIK-D | 3 | | |
| 815pa | 49 y F | lamotrigine* | 1 | 1 | U | Ingst | Int-S | 1 | lamotrigine | 32 mg/L In Blood (unspecified) @ |
| | | quetiapine (extended | 2 | 1 | | | | | | Unknown |
| | | release)* ethanol | 5 | 2 | | | | | ethanol | 256 mg/dL In Blood (unspecified) |
| | | clonazepam | 3 | 3 | | | | | clonazepam | @ Unknown 19 mcg/L In Blood (unspecified) @ |
| | | venlafaxine | 4 | 4 | | | | | venlafaxine | Unknown 14 mg/L In Blood (unspecified) @ |
| 816 | 49 y F | | | | A/C | Ingst+ Unk | Int-S | 2 | | Unknown |
| 610 | 49 y 1 | valproic acid | 1 | 1 | A/C | nigst+ Olik | III-3 | 2 | valproic acid | 1088 mcg/mL In Unknown @ 10 h (pe) |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 223 mcg/mL In Unknown @ 53 h (pe) |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 225 mcg/mL In Unknown @ 30 h (pe) |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 300 mcg/mL In Unknown @ Unknown |
| | | valproic acid | 1 | 1 | | | | | valproic acid | 869 mcg/mL In Unknown @ 18 h (pe) |
| | | diazepam | 2 | 2 | | | | | | |
| | | zolpidem ethanol | 3 4 | 3 4 | | | | | ethanol | 64 mg/dL In Serum @ Unknown |
| | | methamphetamine | 5 | 5 | | | | | Culation | 04 mg/ul in Sciuli @ Ulkilowii |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|-------------------------------|-------------------|---------------|------------|--------|---------|-----|-----------------------------|---|
| 817p | 50 y F | | | | U | Ingst | Int-S | 2 | | |
| ^ | • | oxcabazepine | 1 | 1 | | - | | | | |
| | | bupropion (extended | 2 | 2 | | | | | | |
| | | release) | | | | | | | | |
| | | lorazepam | 3 | 3 | | | | | | |
| | | escitalopram | 4 | 4 | | | | | | |
| | | zolpidem quetiapine (extended | 5 6 | 5 6 | | | | | | |
| | | release) | O | O | | | | | | |
| 818 | 50 y M | , | | | A/C | Ingst | Int-S | 1 | | |
| | | oxcabazepine | 1 | 1 | | | | | | |
| | | bupropion (extended release) | 2 | 2 | | | | | | |
| | | diltiazem (extended | 3 | 3 | | | | | | |
| | | release) | | | ~ | _ | | | | |
| 819a | 52 y M | 1 2 | 1 | 1 | С | Ingst | AR-D | 3 | 1 | 21 # 1 1/ :0 1/ 0 |
| | | levetiracetam | 1 | 1 | | | | | levetiracetam | 21 mg/L In Blood (unspecified) @ Unknown |
| | | levetiracetam | 1 | 1 | | | | | levetiracetam | 2500 mg/L In Urine (quantitative only) @ Autopsy |
| | | levetiracetam | 1 | 1 | | | | | levetiracetam | 94 mg/L In Blood (unspecified) @ Autopsy |
| | | phenytoin | 2 | 2 | | | | | | |
| | | barbiturate | 3 | 3 | | _ | | | | |
| 820 | 55 y F | | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | valproic acid | 1 2 | 1 2 | | | | | | |
| | | ziprasidone benztropine | 3 | 3 | | | | | | |
| | | cyclobenzaprine | 4 | 4 | | | | | | |
| 821a | 57 y F | ., | | | A/C | Ingst | Int-S | 2 | | |
| | • | carbamazepine | 1 | 1 | | - | | | carbamazepine | 16.7 mcg/mL In Serum @ Unknow |
| | | carbamazepine carbamazepine | 1 1 | 1 1 | | | | | carbamazepine carbamazepine | 32.2 mcg/mL In Serum @ Unknow 9.6 mcg/mL In Whole Blood @ |
| | | thorazine | 2 | 2 | | | | | chlorpromazine | Autopsy 0.27 mcg/mL In Whole Blood @ |
| 822 | 57 M | | | | A /C | Toront | Uma T | 2 | | Autopsy |
| 022 | 57 y M | phenytoin | 1 | 1 | A/C | Ingst | Unt-T | 3 | phenytoin | 38.2 mg/L In Serum @ 8 h (pe) |
| | | phenytoin | 1 | 1 | | | | | phenytoin | 57 mg/L In Serum @ 4 h (pe) |
| 823 | 57 y M | r · J·· | | | A/C | Ingst | Int-S | 3 | 1 - 2 | Q , |
| | | phenytoin | 1 | 1 | | | | | phenytoin | 36 mcg/mL In Serum @ Unknown |
| | | topiramate | 2 | 2 | | | | | | |
| 824a | 58 y F | | | | A | Ingst | Int-S | 2 | | |
| | | carbamazepine | 1 | 1 | | | | | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| | | hydromorphone | 3 | 3 | | | | | | |
| | | antihistamine | 4 | 4 | | | | | | |
| 825 | 60 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | oxcabazepine | 1 | 1 | | | | | | |
| | | clonazepam | 2 | 2 | | | | | | |
| 926 | 60 34 | bupropion | 3 | 3 | A | Toront | Total C | 2 | | |
| 826 | 60 y M | carbamazepine | 1 | 1 | A | Ingst | Int-S | 3 | | |
| | | levetiracetam | 2 | 2 | | | | | | |
| 827 | 66 y M | / curacounii | - | - | A | Ingst | Int-S | 2 | | |
| | , | valproic acid | 2 | 1 | | | | | valproic acid | 364 mg/L In Blood (unspecified) @ Unknown |
| | | losartan | 3 | 2 | | | | | | |
| | | naproxen | 4 | 3 | | | | | | |
| | | citalopram | 1 | 4 | | _ | | _ | | |
| 828a | 66 y M | phenytoin | 1 | 1 | U | Ingst | Unk | 3 | phenytoin | 40 mcg/mL In Blood (unspecified) |
| 820 | 94 v E | | | | A /C | Inact | Int C | 2 | | @ Unknown |
| 829 | 84 y F | carbamazepine | 1 | 1 | A/C | Ingst | Int-S | 2 | carbamazepine | 35 mcg/mL In Blood (unspecified) |
| | | • | | | | | | | • | @ Unknown |
| | | carbamazepine | 1 | 1 | | | | | carbamazepine | 39 mcg/mL In Blood (unspecified) @ Unknown |
| | | carbamazepine | 1 | 1 | | | | | carbamazepine | 48 mcg/mL In Blood (unspecified) @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|----------------|-------------|-----------------------------------|-------------------|---------------|---------------|-----------------|---------------|-----|------------------------|--|
| 830 | 86 y F | | | | A/C | Ingst | Unt-T | 2 | | |
| 778, 849, 850, | , 854, 855, | | 4, 895, 904, 9 | 910, 931 | , 937, 953, 9 | 66, 974, 976, 9 | 980, 993, 994 | | | 0, 669, 676, 677, 689, 704, 718, 769, 037, 1043, 1059, 1068, 1097, 1109, |
| Antidepressa | | | | | Δ | Inact | Int-S | 1 | | |
| 831pa | 16 y F | tricyclic | 1 | 1 | A | Ingst | IIIt-S | 1 | nortriptyline | 1 Other (see abst) In Serum @ |
| | | antidepressant tricyclic | 1 | 1 | | | | | amitriptyline | Autopsy 6000 ng/mL In Serum @ Autopsy |
| | | antidepressant acetaminophen/ | 2 | 2 | | | | | | 0.13 mcg/mL In Serum @ Autopsy |
| | | codeine | 2 | 2 | | | | | morphine | |
| | | acetaminophen/ codeine | | | | | | | oxycodone | 0.22 mcg/mL In Serum @ Autopsy |
| | | acetaminophen/ codeine | 2 | 2 | | | | | oxymorphone | 0.37 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | acetaminophen/ codeine | 2 | 2 | | | | | oxycodone | 0.4 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | acetaminophen/ codeine | 2 | 2 | | | | | hydrocodone | 0.8 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | acetaminophen/ codeine | 2 | 2 | | | | | acetaminophen | 110 mcg/mL In Serum @ 30 m (pe) |
| | | acetaminophen/ codeine | 2 | 2 | | | | | acetaminophen | 122 mcg/mL In Serum @ Autopsy |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | 181 mcg/mL In Urine (quantitative |
| | | codeine acetaminophen/ | 2 | 2 | | | | | morphine | only) @ Autopsy 2.5 mcg/mL In Urine (quantitative |
| | | codeine acetaminophen/ | 2 | 2 | | | | | codeine | only) @ Autopsy 3.3 mcg/mL In Serum @ Autopsy |
| | | codeine metoprolol | 3 | 3 | | | | | | |
| | | phenazopyridine | 4 | 4 | | | | | | |
| | | ciprofloxacin | 5 | 5 | | | | | | |
| 832p | 19 y M | | 1 | 1 | A | Ingst | Int-U | 2 | | |
| | | desvenlafaxine olanzapine | 1 2 | 1 2 | | | | | | |
| | | ethanol | 3 | 3 | | | | | ethanol | 9.2 mg/dL In Blood (unspecified) @ |
| | | acetaminophen | 4 | 4 | | | | | acetaminophen | 30 h (pe) 10 mcg/mL In Blood (unspecified) @ Unknown |
| 833a | 19 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | citalopram ethanol | 1 2 | 1 2 | | | | | citralopram ethanol | 6600 ng/mL In Serum @ 1 h (pe) 0.16 g/dL In Serum @ 1 h (pe) |
| 834pa | 19 y F | emanor | 2 | 2 | U | Ingst | Int-S | 1 | emanor | 0.10 g/dL iii Setulii @ 1 ii (pe) |
| | | venlafaxine | 1 | 1 | | | | | venlafaxine | 25000 ng/mL In Blood (unspecified) @ Unknown |
| | | venlafaxine | 1 | 1 | | | | | norvenlafaxine | 3825 ng/mL In Blood (unspecified) @ Unknown |
| | | temazepam | 2 | 2 | | | | | temazepam | 507 ng/mL In Blood (unspecified) @ Unknown |
| | | olanzapine | 3 | 3 | | | | | olanzapine | 49.2 ng/mL In Blood (unspecified) @ Unknown |
| 835pa | 19 y F | | | | U | Ingst | Int-S | 1 | | @ Chkhown |
| | | venlafaxine (extended release) | 1 | 1 | | | | | venlafaxine | 45000 ng/mL In Blood (unspecified) @ Autopsy |
| | | bupropion* diphenhydramine* | 3 2 | 2 2 | | | | | diphenhydramine | 4400 ng/mL In Blood (unspecified) |
| | | minocycline | 4 | 3 | | | | | arphenny aranine | @ Autopsy |
| 836pa | 19 y F | mmocycinie | 4 | 3 | A | Ingst | Int-S | 1 | | |
| | , | amitriptyline | 1 | 1 | | C | | | nortriptyline | 2200 ng/mL In Serum @ Autopsy |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | 690 ng/mL In Serum @ Autopsy |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | 45 ng/mL In Serum @ Autopsy |
| | | alprazolam naproxen | 3 4 | 3 4 | | | | | naproxen | 6 mcg/mL In Serum @ Autopsy |
| 837a | 20 y M | партолоп | -7 | -7 | A/C | Ingst | Int-S | 3 | партолен | o megnine in serum w Autopsy |
| | , | venlafaxine | 1 | 1 | | Ü | | | o-desmethylvenla- | 12000 ng/mL In Blood (unspecified) |
| | | (extended release) | _ | | | | | | faxine | @ Autopsy |
| | | venlafaxine (extended release) | 1 | 1 | | | | | venlafaxine | 20000 ng/mL In Blood (unspecified) @ Autopsy |
| | | ethanol | 2 3 | 2 3 | | | | | | |
| | | aripiprazole atomoxetine | 3 4 | 3 4 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|------------|--------|-----|----------------------------------|---|
| 838 | 20 y M | bupropion (extended | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | release) | 1 | 1 | | | | | | |
| 839a | 21 y M | paroxetine | 1 | 1 | A | Ingst | Int-S | 1 | paroxetine | 140 mcg/mL In Blood (unspecified) |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | @ Unknown 19 mcg/mL In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 2 | 2 | | | | | dihydrocodeine/ | @ Unknown 33 mcg/mL In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 2 | 2 | | | | | hydrocodol (free) hydrocodone | @ Unknown 410 mcg/mL In Blood (unspecified) |
| | | hydrocodone ethanol | 3 | 3 | | | | | (free) | @ Unknown |
| 840pa | 21 y M | amitriptyline | 1 | 1 | A | Ingst+ Par | Unk | 3 | nortriptyline | 0.35 mcg/mL In Blood (unspecified) |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | @ Autopsy 0.77 mcg/mL In Blood (unspecified) |
| | | alprazolam | 2 | 2 | | | | | alprazolam | @ Autopsy 0.075 mcg/mL In Blood (unspeci- |
| | | morphine | 3 | 3 | | | | | morphine | fied) @ Autopsy 12 mcg/mL In Urine (quantitative |
| | | diazepam | 4 | 4 | | | | | | only) @ Autopsy |
| 841a | 21 y M | 1:41-: | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | lithium risperidone | 1 2 | 1 2 | | | | | | |
| | | methylphenidate | 3 | 3 | | | | | | |
| | | alprazolam | 4 | 4 | | | | | | |
| 842p | 22 y F | • | | | A | Ingst | Int-S | 1 | | |
| 843pa | 23 y F | amitriptyline | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | • | mirtazapine | 1 | 1 | | C | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| 0.4.4 | 24 E | hydrocodone | | | A | Toront | Int C | 2 | | |
| 844pa | 24 y F | trazodone | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | escitalopram | 2 | 2 | | | | | | |
| | | bupropion (extended | 3 | 3 | | | | | | |
| | | release) | | | | | | | | |
| | | clonazepam | 4 | 4 | | | | | | |
| 845a | 24 v.M | lorazepam | 5 | 5 | ٨ | Inact | Int C | 1 | | |
| 04Ja | 24 y M | nortriptyline | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | diphenoxylate/ atropine | 2 | 2 | | | | | | |
| | | paroxetine | 3 | 3 | | | | | | |
| | | thorazine | 4 | 4 | | | | | | |
| | | metronidazole | 5 | 5 | | | | | | |
| | | citalopram antacid | 6 7 | 6 7 | | | | | | |
| 846a | 24 y F | antaciu | / | , | A | Ingst | Int-U | 1 | | |
| 0.100 | 2171 | benzodiazepine* | 2 | 1 | 11 | 111551 | III C | • | | |
| | | tricyclic | 1 | 1 | | | | | desipramine | 1.15 mg/L In Blood (unspecified) @ |
| 0.45 | 26.36 | antidepressant* | | | | | * | | | Autopsy |
| 847a | 26 y M | bupropion | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 848ph | 26 y M | bupropion | 1 | 1 | U | Ingst | Int-U | 2 | | |
| • | • | trazodone | 1 | 1 | | | | | | |
| 849p | 26 y F | and that are 10 are | | | U | Ingst | Int-S | 1 | | |
| | | amitriptyline propranolol | 6 1 | 1 2 | | | | | | |
| | | mirtazapine | 2 | 3 | | | | | | |
| | | ziprasidone | 3 | 4 | | | | | | |
| | | lamotrigine | 4 | 5 | | | | | | |
| 050 | 26 35 | naproxen | 5 | 6 | | T | T 3.5 | 4 | | |
| 850 | 26 y M | aitalonrom* | 1 | 1 | A | Ingst | Int-M | 1 | | |
| | | citalopram* drug, unknown* | 1 2 | 1 1 | | | | | | |
| | | anticonvulsant | 4 | 2 | | | | | | |
| | | (pyrrolidinone) dihydroergocornine/ | 3 | 3 | | | | | | |
| | | dihydroergocristine | | | | | | | | |
| | | caffeine | 5 | 4 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|-------------------------------|-------------------|---------------|------------|--------|---------|-----|------------------------|--|
| 851 | 26 y M | | | | A/C | Ingst | Int-S | 2 | | |
| 052 | 27 - F | amitriptyline | 1 | 1 | | Toront | Int C | 2 | | |
| 852p | 27 y F | citalopram | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | aripiprazole | 2 | 2 | | | | | | |
| 853p | 27 y F | | | | A | Ingst | Int-S | 1 | | |
| | | citalopram | 1 | 1 | | | | | | |
| 854a | 28 y M | bupropion | 1 | 1 | A/C | Ingst | Int-S | 1 | bupropion | 20000 ng/mL In Gastric (stomach |
| | | bupropion | 1 | 1 | | | | | bupropion | content) @ Autopsy 2929 ng/mL In Blood (unspecified) @ Autopsy |
| | | bupropion | 1 | 1 | | | | | hydroxybupropion | 1 2 |
| | | bupropion | 1 | 1 | | | | | hydroxybupropion | 69640 ng/mL In Gastric (stomach content) @ Autopsy |
| | | ethanol | 3 | 2 | | | | | ethanol | 100 mg/dL In Plasma @ 4 h (pe) |
| | | gabapentin | 2 | 3 | | | | | | 2 |
| | | diphenhydramine | 4 | 4 | | | | | | |
| 855 | 29 y F | | | | A | Ingst | Int-U | 1 | | |
| | | venlafaxine | 1 | 1 | | | | | | |
| | | buspirone | 2 | 2 | | | | | | |
| | | gabapentin | 3 | 3 | | | | | | |
| | | heroin | 4 5 | 4 | | | | | | |
| 856 | 29 y F | cocaine | 3 | 5 | A | Ingst | Int-S | 2 | | |
| 330 | 29 y 1 | desvenlafaxine | 1 | 1 | А | nigst | 1111-5 | 2 | | |
| | | quetiapine | 2 | 2 | | | | | | |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | acetaminophen | 32 mcg/mL In Serum @ Unknown |
| | | alprazolam | 4 | 4 | | | | | | |
| | | valproic acid | 5 | 5 | | | | | valproic acid | 53 mcg/mL In Serum @ Unknown |
| 857p | 29 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | amitriptyline | 1 | 1 | | | | | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 110 mg/dL In Serum @ 30 m (pe) |
| 050. | 20 14 | acetaminophen | 3 | 3 | ** | T | Total C | 1 | acetaminophen | 3.9 mcg/mL In Serum @ 30 m (pe) |
| 858a | 30 y M | amoxapine* | 1 | 1 | U | Ingst | Int-S | 1 | | |
| | | propranolol* | 2 | 1 | | | | | | |
| | | fluoxetine | 3 | 2 | | | | | | |
| | | diazepam | 4 | 3 | | | | | | |
| | | alprazolam | 5 | 4 | | | | | | |
| | | fexofenadine | 6 | 5 | | | | | | |
| 859a | 30 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | venlafaxine | 1 | 1 | | | | | venlafaxine | 96.54 mg/L In Blood (unspecified) @ Unknown |
| | | trazodone | 2 | 2 | | | | | | |
| 860p | 31 y M | | | | A | Ingst | Int-S | 2 | | |
| | | trazodone | 2 | 1 | | | | | | |
| | | methadone | 1 | 2 | | | | | | |
| | | hydroxyzine alprazolam | 4 3 | 3 4 | | | | | | |
| 861a | 31 y M | aiprazoiaiii | 3 | 4 | A | Ingst | Int-S | 1 | | |
| 0014 | 31 y W1 | bupropion (extended release) | 1 | 1 | А | nigst | III-5 | 1 | | |
| 862a | 31 y F | | | | A | Ingst | Int-S | 2 | | |
| | | trazodone | 1 | 1 | | | | | trazodone | 14.8 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Unknown |
| | | methamphetamine | 2 3 | 2 3 | | | | | methamphetamine | 0.12 mcg/mL In Serum @ Unknown |
| | | bupropion duloxetine | 4 | 4 | | | | | | |
| | | cyclobenzaprine | 5 | 5 | | | | | | |
| | | alprazolam | 6 | 6 | | | | | | |
| | | acetaminophen | 7 | 7 | | | | | acetaminophen | 22 mcg/mL In Blood (unspecified) @ |
| 062-1- | 22 🗜 | | | | A /C | Toront | T4 C | 2 | | Unknown |
| 863pha | 33 y F | diltiazem* | 1 | 1 | A/C | Ingst | Int-S | 2 | diltiazem | 1100 ng/mL In Blood (unspecified) |
| | | GIITIGECIII | 1 | 1 | | | | | GIITIGZCIII | @ Autopsy |
| | | lithium* | 4 | 1 | | | | | | y-J |
| | | tramadol | 2 | 4 | | | | | tramadol | 560 ng/mL In Blood (unspecified) @ Autopsy |
| | | tramadol | 2 | 4 | | | | | o-demethyl tramadol | 920 ng/mL In Blood (unspecified) @ Autopsy |
| | | clonazepam | 3 | 6 | | | | | 7-aminoclonaze- pam | 230 ng/mL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|-----------------|---|-------------------|---------------|------------|--------|---------|-----|-----------------|---|
| 864 | 33 y M | | | | A | Ingst | Int-S | 3 | | |
| | • | amitriptyline | 1 | 1 | | | | | | |
| | | fluoxetine | 2 | 2 | | | | | | |
| | | trazodone | 3 | 3 | | | | | | |
| 2650 | 22 v E | mirtazapine | 4 | 4 | A/C | Inact | Int-S | 2 | | |
| 865a | 33 y F | venlafaxine | 1 | 1 | A/C | Ingst | III-S | 2 | venlafaxine | 73 mg/L In Blood (unspecified) @ |
| | | aripiprazole | 2 | 2 | | | | | aripiprazole | Unknown 310 ng/mL In Blood (unspecified) |
| 866 | 34 y M | | | | A | Ingst | Int-S | 2 | | @ Unknown |
| | - | doxepin | 1 | 1 | | | | | | |
| 867 | 35 y F | h | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | bupropion (extended release) | 1 | 1 | | | | | | |
| | | tramadol | 2 | 2 | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| 868pai | 36 y F | and the track of the control of the | 1 | | U | Ingst | Unk | 2 | and the Paris | 0.51 |
| | | amitriptyline | 1 | 1 | | | | | nortriptyline | 0.51 mcg/mL In Whole Blood @ Autopsy |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | 0.63 mcg/mL In Whole Blood @ Autopsy |
| | | propoxyphene | 2 | 2 | | | | | propoxyphene | 1.3 mcg/mL In Whole Blood @ |
| | | propoxyphene | 2 | 2 | | | | | norpropoxyphene | Autopsy 2.7 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 3 | 3 | | | | | | rutopsy |
| | | laxative (stimulant) | 4 | 4 | | | | | | |
| 869a | 38 y M | | | | A | Ingst | Int-S | 1 | | |
| | | imipramine | 1 | 1 | | | | | | 400 (17 7 77) |
| | | ethanol | 2 | 2 | | | | | ethanol | 100 mg/dL In Vitreous @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 200 mg/dL In Blood (unspecified) @ Autopsy |
| | | amlodipine | 5 | 3 | | | | | | |
| | | atenolol | 4 3 | 4 5 | | | | | | |
| 870pai | 38 y F | lisinopril | 3 | 3 | U | Ingst | Int-S | 1 | | |
| o. op | ,- | fluoxetine | 2 | 1 | | 8 | | | | |
| | | lorazepam | 1 | 2 | | | | | | |
| | | fluoxetine | 3 | 3 | | | | | norfluoxetine | 110 ng/mL In Blood (unspecified) @ Autopsy |
| | | naproxen | 4 | 4 | | | | | | |
| | | cetirizine | 5 | 5 | | | | | | |
| | | methadone | 6 | 6 | | | | | methadone | 570 ng/mL In Blood (unspecified) @ Autopsy |
| | | citalopram | 7 | 7 | | | | | norfluoxetine | 110 ng/mL In Blood (unspecified) @ Autopsy |
| | | citalopram | 7 | 7 | | | | | citalopram | 650 ng/mL In Blood (unspecified) |
| 871 | 39 y M | | | | A/C | Ingst | Int-S | 2 | | @ Autopsy |
| 0,1 | <i>57</i> J 111 | doxepin | 1 | 1 | 120 | 111850 | III O | _ | | |
| 872pa | 39 y M | • | | | U | Ingst | Int-S | 1 | | |
| | | imipramine | 1 | 1 | | | | | | |
| | | zolpidem (extended | 2 | 2 | | | | | | |
| 873pai | 39 y F | release) | | | U | Ingst | Int-A | 3 | | |
| о гориг | <i>37</i> y 1 | trazodone | 1 | 1 | C | mgst | 1111 71 | 5 | trazodone | 2 mcg/mL In Whole Blood @ |
| | | trazodone | 1 | 1 | | | | | trazodone | Autopsy 5.2 mcg/mL In Whole Blood @ |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | Autopsy 0.28 mcg/mL In Whole Blood @ |
| | | citalopram | 3 | 3 | | | | | citalopram | Autopsy 2.2 mcg/mL In Whole Blood @ |
| | | citalopram | 3 | 3 | | | | | citalopram | Autopsy 2.6 mcg/mL In Whole Blood @ |
| | | hydroxyzine | 4 | 4 | | | | | | Autopsy |
| 874p | 39 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | bupropion (extended release) | 1 | 1 | | | | | | |
| | | trazodone | 2 | 2 | | | | | | |

(Continued)

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------------|-------------------|---------------|------------|------------|--------|-----|------------------------------|---|
| 875ha | 40 y F | doxepin | 1 | 1 | A | Ingst | Int-S | 1 | zolpidem | 340 ng/mL In Blood (unspecified) |
| | | doxepin | 1 | 1 | | | | | cyclobenzaprine | @ Autopsy 55 ng/mL In Blood (unspecified) @ |
| | | doxepin | 1 | 1 | | | | | doxepin | Autopsy 6632 ng/mL In Blood (unspecified) |
| | | doxepin | 1 | 1 | | | | | nordoxepin | @ Autopsy 726 ng/mL In Blood (unspecified) |
| | | zolpidem | 2 | 2 | | | | | | @ Autopsy |
| 876p | 40 y M | • | | | U | Ingst | Int-S | 2 | | |
| | | bupropion | 1 | 1 | | | | | | |
| | | citalopram ibuprofen | 2 3 | 2 3 | | | | | | |
| 877pa | 40 y F | louptoteti | 3 | 3 | A/C | Ingst | Int-S | 1 | | |
| 677pa | 40 y 1 | bupropion | 1 | 1 | A/C | nigst | 1111-5 | 1 | | |
| | | hydroxyzine | 2 | 2 | | | | | | |
| | | disulfiram | 3 | 3 | | | | | | |
| | | sumatriptan | 4 | 4 | | | | | | |
| | | lorazepam | 5 | 5 | | | | | | |
| 878 | 40 y F | 1 | | | A/C | Ingst | Int-S | 2 | | |
| | • | citalopram | 1 | 1 | | | | | | |
| 879 | 40 y F | bupropion (extended | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | release) | • | • | | | | | | |
| | | clonazepam | 2 | 2 | | | | | | |
| | | quetiapine | 3 | 3 | | | | | | |
| | | clozapine | 4 | 4 | | | | | | |
| | | gabapentin | 5 | 5 | | | | | | |
| | | amphetamine/ dextroamphetamine | 6 | 6 | | | | | | |
| | | omeprazole | 7 | 7 | | | | | | |
| | | desvenlafaxine | 8 | 8 | | | | | | |
| | | clonidine | 9 | 9 | | | | | | |
| | | cyclobenzaprine | 10 | 10 | | | | | | |
| 880pa | 41 y F | 4. 4 44 | | | A | Ingst | Int-S | 2 | | 250 / 7 7 0 0 10 /) |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | 250 ng/mL In Serum @ 10 m (pe) |
| | | amitriptyline | 1 | 1 | | | | | nortriptyline | 518 ng/mL In Serum @ 10 m (pe) |
| | | methadone | 2 | 2 | | | | | methadone | 54 ng/mL In Serum @ 10 m (pe) |
| | | alprazolam venlafaxine | 3 4 | 3 4 | | | | | alprazolam norvenlafaxine | 29.4 ng/mL In Serum @ 10 m (pe) 385 ng/mL In Serum @ 10 m (pe) |
| | | gabapentin | 5 | 5 | | | | | gabapentin | 3.1 mcg/mL In Serum @ 10 m (pe) |
| 881 | 41 y M | gaoapentin | 3 | 3 | A | Ingst | Int-S | 2 | gaoapentin | 3.1 meg/mil in Serum @ 10 m (pc) |
| 001 | 41 y 1V1 | nortriptyline | 1 | 1 | 7 % | nigst | IIIt-5 | 2 | | |
| 882 | 41 y F | norunpty mile | • | • | A | Ingst | Unk | 2 | | |
| | , - | paroxetine | 1 | 1 | | 8 | | _ | | |
| | | colesevelam | 2 | 2 | | | | | | |
| | | pseudoephedrine | 3 | 3 | | | | | | |
| | | propranolol | 4 | 4 | | | | | | |
| | | loperamide | 5 | 5 | | | | | | |
| | | vitamins-multiple | 6 | 6 | | | | | | |
| | | naproxen | 7 | 7 | | | | | | |
| 883 | 42 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | venlafaxine | 1 | 1 | | | | | | |
| | | (extended release) | | | | _ | | _ | | |
| 884 | 42 y M | 1 | 1 | 1 | Α | Ingst | Int-S | 3 | | |
| | | bupropion | 1 | 1 | | | | | | |
| | | fluvoxamine | 2 3 | 2 | | | | | | |
| 885 | 43 y F | naproxen | 3 | 3 | A | Ingst | Int-S | 2 | | |
| 003 | 43 y F | amitriptyline | 1 | 1 | А | nigst | 1111-3 | 2 | | |
| 886p | 43 y F | amurptymic | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| - 30P | , 1 | venlafaxine | 1 | 1 | | | 0 | - | | |
| | | fluoxetine | 2 | 2 | | | | | | |
| | | clozapine | 3 | 3 | | | | | | |
| | | clonazepam | 4 | 4 | | | | | | |
| | 43 y M | * | | | A | Ingst | Int-S | 1 | | |
| 887 | | venlafaxine | 1 | 1 | | = | | | | |
| 887 | | | | | | | | | | |
| 887 888pa | 43 y M | (extended release) | | | A/C | Ingst+ Oth | Int-S | 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|-----------------------------------|-------------------|---------------|------------|-------|--------|-----|-----------------------------|--|
| | | imipramine | 1 | 1 | | | | | imipramine | 3.8 mg/L In Blood (unspecified) @ |
| | | quetiapine | 2 | 2 | | | | | quetiapine | Autopsy 26 mg/L In Blood (unspecified) @ Autopsy |
| | | alprazolam | 3 | 3 | | | | | | Тисорзу |
| | | methadone | 4 | 4 | | | | | | |
| | | benzodiazepine | 5 | 5 | | | | | | |
| 889 | 44 y F | · · | | | A/C | Ingst | Int-S | 1 | | |
| | | trazodone | 1 | 1 | | | | | | |
| | | lorazepam | 2 | 2 | | | | | | |
| 890pa | 45 y F | venlafaxine | 1 | 1 | A/C | Ingst | Int-U | 1 | venlafaxine | 150 mcg/mL In Whole Blood @ |
| | | venlafaxine | 1 | 1 | | | | | o-desmethylvenla- faxine | Autopsy 3600 ng/mL In Whole Blood @ |
| | | clonazepam | 2 | 2 | | | | | 7-aminoclonaze- pam | Autopsy 140 ng/mL In Whole Blood @ Autopsy |
| | | clonazepam | 2 | 2 | | | | | clonazepam | 2.2 ng/mL In Whole Blood @ Autopsy |
| | | alprazolam | 3 | 3 | | | | | alprazolam | 21 ng/mL In Whole Blood @ Autopsy |
| | | ethanol | 4 | 4 | | | | | ethanol | 64 mg/dL In Whole Blood @ Autopsy |
| 891 | 45 y F | | | | U | Ingst | Unk | 2 | | |
| | | diphenhydramine* | 1 | 1 | | | | | | |
| | | fluoxetine* | 2 | 1 | | | | | | |
| | | pramipexole | 4 | 2 | | | | | | |
| | | topiramate | 10 | 3 | | | | | | |
| | | lamotrigine | 3 | 4 | | | | | | |
| | | pregabalin clonazepam | 5 6 | 5 6 | | | | | | |
| | | acetaminophen/ propoxyphene | 7 | 7 | | | | | | |
| | | acetaminophen/ hydrocodone | 8 | 8 | | | | | | |
| | | acetaminophen/ diphenhydramine | 9 | 9 | | | | | | |
| 892p | 45 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | tricyclic antidepressant | 1 | 1 | | | | | | |
| | | lorazepam | 2 | 2 | | | | | | |
| 002 | 46 8 | zolpidem | 3 | 3 | | | * | | | |
| 893p | 46 y F | | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | escitalopram | 1 2 | 1 2 | | | | | | |
| | | lorazepam ethanol | 3 | 3 | | | | | ethanol | 0.03 mg/dL In Serum @ 1 h (pe) |
| 894 | 47 y F | Culation | 3 | 3 | A | Ingst | Int-S | 2 | etilalioi | 0.03 mg/dL m Serum @ 1 m (pe) |
| 0) 1 | 17 9 1 | venlafaxine | 1 | 1 | 21 | nigst | III 5 | _ | | |
| | | lamotrigine | 2 | 2 | | | | | | |
| 895 | 48 y M | C | | | A/C | Ingst | Int-U | 1 | | |
| | | tricyclic antidepressant | 1 | 1 | | | | | amitriptyline | 1360 ng/mL In Serum @ Unknown |
| | | bupropion | 2 | 2 | | | | | | |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | | |
| | | gabapentin | 4 | 4 | | | | | | |
| | | methylprednisolone | 5 | 5 | | | | | | |
| 896 | 49 y F | tiotropiumtiotropium | 6 | 6 | U | Ingst | Int-S | 1 | | |
| | | amitriptyline | 1 | 1 | | | | | | |
| | | escitalopram | 3 4 | 3 | | | | | | |
| | | cyclobenzaprine salicylate | 5 | 4 5 | | | | | | |
| | | laxative, stimulant | 5 6 | 6 | | | | | | |
| 897p | 49 y F | ianauve, sumulam | U | U | A | Ingst | Int-S | 2 | | |
| 071P | 72 y 1 | tricyclic | 1 | 1 | Α | mgət | 1111-3 | 4 | | |
| | | antidepressant | 1 | 1 | | | | | | |
| 898pa | 49 y F | | | | U | Ingst | Int-S | 2 | | |
| - I | . , - | doxepin | 1 | 1 | - | 8 | | - | doxepin | 177 mg/kg In Liver @ Autopsy |
| | | doxepin | 1 | 1 | | | | | desmethyldoxepin | 42 mg/kg In Liver @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.154 g/dL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|-------|-------------|--|-------------------|---------------|------------|--------------|--------|-----|----------------------------|---|
| 899 | 49 y F | | | | U | Ingst | Int-S | 1 | | |
| | | doxepin doxepin | 1 1 | 1 1 | | | | | doxepin nordoxepin | 1133 ng/mL In Serum @ 1 d (pe) 514 ng/mL In Serum @ 1 d (pe) |
| 900a | 49 y F | Î | | | A/C | Ingst | Int-S | 2 | погаохери | 314 lig/lile lil setulii @ 1 u (pe) |
| 901 | 50 y M | amitriptyline | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 902ai | 50 y F | venlafaxine (extended release) | 1 | 1 | A | | Int-S | 2 | | |
| 902ai | 30 y 1 | amitriptyline | 1 | 1 | A | Ingst | III-3 | 2 | amitriptyline | 0.17 mcg/mL In Urine (quantitative |
| | | tramadol | 2 | 2 | | | | | tramadol | only) @ Unknown 0.69 mcg/mL In Whole Blood @ Unknown |
| | | naproxen | 3 | 3 | | | | | naproxen | 79 mcg/mL In Whole Blood @ Unknown |
| | | citalopram | 4 | 4 | | | | | citalopram | 0.13 mcg/mL In Whole Blood @ Unknown |
| 903pa | 51 y F | desipramine | 1 | 1 | A | Ingst | Int-S | 1 | desipramine | 6600 ng/mL In Blood (unspecified) |
| | | • | | | | | | | • | @ Autopsy |
| | | bupropion | 2 | 2 | | | | | hydroxybupropion | 380 ng/mL In Blood (unspecified) @ Autopsy |
| | | venlafaxine | 3 | 3 | | | | | venlafaxine | 710 ng/mL In Blood (unspecified) @ Autopsy |
| 004 | 51 E | clonazepam | 4 | 4 | | | T . G | | clonazepam | 21 ng/mL In Blood (unspecified) @ Autopsy |
| 904pa | 51 y F | doxepin | 1 | 1 | A | Ingst | Int-S | 1 | doxepin | 3100 ng/mL In Blood (unspecified) |
| | | doxepin | 1 | 1 | | | | | desmethyldoxepin | @ Unknown 540 ng/mL In Blood (unspecified) @ Unknown |
| | | carbamazepine | 2 | 2 | | | | | carbamazepine | 143 mcg/mL In Blood (unspecified) |
| | | zolpidem | 3 | 3 | | | | | zolpidem | @ Unknown 1200 ng/mL In Blood (unspecified) |
| | | clonazepam | 4 | 4 | | | | | clonazepam | @ Unknown 63 ng/mL In Blood (unspecified) @ Unknown |
| | | clonazepam | 4 | 4 | | | | | 7-aminoclonaze- | 69 ng/mL In Blood (unspecified) @ |
| 905a | 51 y F | | | | A | Ingst+ Inhal | Int-S | 1 | pam | Unknown |
| | | bupropion (extended release) cocaine | 1 2 | 1 2 | | | | | bupropion | 0.77 mg/L In Blood (unspecified) @ Unknown 0.11 mg/L In Blood (unspecified) @ |
| | | cocame | | | | | | | cocame | Unknown |
| | | cocaine | 2 | 2 | | | | | benzoylecognine | 4.79 mg/L In Blood (unspecified) @ Unknown |
| | | benzodiazepine | 3 | | | | | | diazepam | 0.21 mg/L In Blood (unspecified) @ Unknown |
| | | benzodiazepine | 3 | 3 | | | | | nordiazepam | 0.29 mg/L In Blood (unspecified) @ Unknown |
| 906p | 51 y M | d | 1 | 1 | U | Ingst | Int-S | 1 | | |
| 907a | 52 y M | doxepin | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | venlafaxine paroxetine | 1 2 | 1 2 | | | | | venlafaxine | 28 mg/L In Whole Blood @ 0 h (pe |
| 908 | 52 y F | 1 | | | U | Ingst | Int-S | 1 | | |
| 909p | 52 y F | nortriptyline | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | citalopram | 1 | 1 | | 3 | | | | |
| 910p | 53 y F | ethanol | 2 | 2 | A | Ingst | Int-S | 3 | | |
| | | doxepin lithium | 1 2 | 1 2 | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| | | duloxetine | 4 | 4 | | | | | | |
| | | topiramate citalopram | 5 6 | 5 6 | | | | | | |
| 911ha | 55 y F | Î | | | A | Ingst | Int-U | 3 | | |
| | | amitriptyline lorazepam | 1 | 1 2 | | | | | amitriptyline lorazepam | 1300 ng/mL In Serum @ 15 m (pe) 0.24 mcg/mL In Serum @ 15 m (pe |
| | | zolpidem | 2 3 | 3 | | | | | zolpidem | 0.52 mcg/mL In Serum @ 15 m (pe |
| | | ethanol venlafaxine | 4 5 | 4 5 | | | | | ethanol norvenlafaxine | 0.069% (wt/Vol) In Serum @ 15 m (pe 0.11 mcg/mL In Serum @ 15 m (pe |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|----------------------------------|-------------------|---------------|------------|-------------|--------|-----|---------------|--|
| 912pai | 55 y M | doxepin | 1 | 1 | U | Ingst | Int-A | 2 | doxepin | 3.1 mcg/mL In Whole Blood @ |
| | | tramadol | 2 | 2 | | | | | tramadol | Unknown 2.3 mcg/mL In Whole Blood @ |
| 913pai | 55 y F | amitriptyline | 1 | 1 | U | Ingst | Int-A | 2 | nortriptyline | Unknown 0.18 mcg/mL In Whole Blood @ |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | Autopsy 0.67 mcg/mL In Whole Blood @ |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | Autopsy 0.16 mcg/mL In Whole Blood @ Autopsy |
| | | alprazolam | 3 | 3 | | | | | alprazolam | 104 ng/mL In Whole Blood @ Autopsy |
| | | ethanol | 4 | 4 | | | | | ethanol | 0.05% (wt/Vol) In Whole Blood @ Autopsy |
| 914 | 56 y M | | | | A | Ingst | Int-S | 3 | | |
| | | bupropion | 3 | 1 | | | | | | |
| | | benztropine | 4 | 2 | | | | | | |
| | | clozapine | 1 | 3 | | | | | | |
| | | sertraline | 2 | 4 | | | | | | |
| 015 | 56 M | ezetimibe | 5 | 5 | A /C | T | T.,, C | 2 | | |
| 915 | 56 y M | lithium | 1 | 1 | A/C | Ingst | Int-S | 2 | lithium | 1.8 mEq/L In Blood (unspecified) @ 23 h (pe) |
| | | lithium | 1 | 1 | | | | | lithium | 1.8 mEq/L In Blood (unspecified) @ 28 h (pe) |
| | | lithium | 1 | 1 | | | | | lithium | 10 mEq/L In Blood (unspecified) @ 60 m (pe) |
| | | lithium escitalopram | 1 2 | 1 2 | | | | | lithium | 4.2 mEq/L In Blood (unspecified) @ 18 h (pe) |
| 916 | 56 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | - | amitriptyline | 1 | 1 | | | | | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| 917 | 57 y M | cyclobenzaprine nortriptyline | 3 | 3 | A | Ingst | Int-S | 3 | | |
| 918pa | 57 y M | noruiptynne | 1 | 1 | C | Ingst | Int-S | 1 | | |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | 3494 ng/mL In Blood (unspecified) @ Autopsy |
| | | amitriptyline amitriptyline | 1 2 | 1 2 | | | | | nortriptyline | 444 ng/mL In Blood (unspecified) @ Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.147 g/dL In Blood (unspecified) @ Autopsy |
| | | hydrocodone | 4 | 4 | | | | | | |
| | | citalopram | 5 | 5 | | | | | | |
| 919a | 58 y F | tricyclic antidepressant | 1 | 1 | A/C | Ingst+ Derm | Int-S | 2 | | |
| | | phencyclidine | 2 | 2 | | | | | | |
| | | acetaminophen/ propoxyphene | 3 | 3 | | | | | | |
| | | promethazine | 4 | 4 | | | | | | |
| | | fentanyl (transdermal) | 5 | 5 | | | | | | |
| | | zolpidem | 7 | 7 | | | | | | |
| | | salicylate | 8 | 8 | | | | | | |
| 920 | 58 y M | | _ | _ | A/C | Ingst | Int-S | 1 | | |
| 021 | 50 31 | amitriptyline | 1 | 1 | ** | T | T. C | 2 | | |
| 921 | 58 y M | .5.1 | 4 | 4 | U | Ingst | Int-S | 2 | | |
| | | citalopram | 1 | 1 | | | | | | |
| | | diazepam | 2 | 2 | | | | | | |
| | | buspirone | 3 4 | 3 4 | | | | | | |
| | | aripiprazole | 5 | 5 | | | | | | |
| | | bupropion bisoprolol/hydro- | 6 | 6 | | | | | | |
| | | chlorothiazide | U | U | | | | | | |
| 922p | 59 y F | omorounazide | | | A/C | Ingst | Int-S | 2 | | |
| |) - | amitriptyline | 1 | 1 | | 0 | . ~ | - | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--|-------------------|---------------|------------|------------|---------------------|-----|--------------------------------|--|
| 923 | 59 y F | tricyclic | 1 | 1 | U | Ingst | Int-S | 2 | | |
| | | antidepressant opioid | 2 | 2 | | | | | | |
| 924p | 59 y F | • | | | U | Ingst+ Unk | Unk | 2 | | |
| | | tricyclic antidepressant opioid | 2 | 1 2 | | | | | | |
| 925pai | 59 y M | doxepin | 1 | 1 | A | Ingst | Unk | 2 | doxepin | 7.2 mcg/mL In Whole Blood @ Autopsy |
| 926 | 60 y F | | | | U | Ingst | Int-S | 2 | | Autopsy |
| | | amitriptyline | 1 | 1 | | | | | | |
| 927p | 61 y M | clonidine | 2 | 2 | U | Ingst | Int-S | 3 | | |
| /=/P | 01) 1.1 | doxepin | 1 | 1 | Ü | mgs. | | | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| | | meclizine alprazolam | 3 4 | 3 4 | | | | | | |
| 928pai | 61 y M | • | | | U | Ingst | Int-U | 2 | | |
| | | amitriptyline | 1 | 1 | | | | | nortriptyline | 2.3 mcg/mL In Whole Blood @ Autopsy |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | 5.8 mcg/mL In Whole Blood @ Autopsy |
| 929pai | 61 y M | fluoxetine | 2 | 2 | A | Inget | Int-A | 2 | | |
| 929pai | OI y MI | citalopram | 1 | 1 | A | Ingst | IIIt-A | 2 | citalopram | 20.3 Other (see abst) In Liver @ Autopsy |
| 930a | 61 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | trazodone acetaminophen/ hydrocodone | 3 2 | 1 2 | | | | | acetaminophen | 209 mcg/mL In Serum @ Unknow |
| | | amlodipine/ benazepril | 1 | 3 | | | | | | |
| 021 | (2 F | lorazepam | 4 | 4 | A /C | T | L. C | 2 | | |
| 931 | 62 y F | trazodone | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | topiramate | 2 | 2 | | | | | | |
| | | drug, unknown | 3 | 3 | | | | | | |
| 932a | 62 y M | ethanol | 4 | 4 | A | Inget | Int-S | 1 | | |
| 932a | 02 y WI | amitriptyline | 1 | 1 | А | Ingst | 1111-53 | 1 | nortriptyline | 0.019 mg/L In Blood (unspecified) @ 1 h (pe) |
| | (2 F | amitriptyline | 1 | 1 | ** | * . | ** 1 | 2 | amitriptyline | 0.102 mg/L In Blood (unspecified) @ 1 h (pe) |
| 933pai | 62 y F | imipramine | 1 | 1 | U | Ingst | Unk | 2 | imipramine | 5.8 mcg/mL In Whole Blood @ Autopsy |
| | | diphenhydramine | 2 | 2 | | | | | diphenhydramine | 1.4 mcg/mL In Whole Blood @ Autopsy |
| | | laxative (stimulant) | 3 | 3 | | | | | | |
| | | bupropion trazodone | 4 5 | 4 5 | | | | | | |
| | | temazepam | 6 | 6 | | | | | | |
| 024 | 62 F | skeletal muscle relaxant | 7 | 7 | | | T . G | 2 | | |
| 934p | 63 y F | lithium | 1 | 1 | A | Ingst | Int-S | 3 | lithium | 3.36 mEq/L In Serum @ Unknown |
| | | sertraline | 2 | 2 | | | | | munuill | 5.50 mbqrb in Scrum & Unkilowii |
| | | clonazepam | 3 | 3 | | | | | | |
| 935a | 66 y M | amitriatedia | 1 | 1 | A | Ingst | Int-S | 2 | nontriestalia | 0.22 mg/L I- C 🖨 11 () |
| | | amitriptyline amitriptyline | 1 1 | 1 1 | | | | | nortriptyline amitriptyline | 0.33 mg/L In Serum @ 1 h (pe) 1.97 mg/L In Serum @ 1 h (pe) |
| | | carvedilol | 2 | 2 | | | | | annurptynne | 1.77 mg/L m scrum @ 1 m (pe) |
| | | metformin | 3 | 3 | | | | | | |
| | | pioglitazone | 4 | 4 | | | | | | |
| 026: | 60 F | nondrug, unknown | 5 | 5 | ** | In out | T 4 | 2 | | |
| 936pai | 68 y F | amitriptyline | 1 | 1 | U | Ingst | Int-A | 2 | amitriptyline | 11.7 mcg/mL In Whole Blood @ Autopsy |
| | | amitriptyline | 1 | 1 | | | | | nortriptyline | 3.3 mcg/mL In Whole Blood @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---------------|-------------------|---------------|------------|-------|--------|-----|---------------|---|
| | | fluoxetine | 2 | 2 | | | | | | |
| | | diazepam | 3 | 3 | | | | | | |
| | | ethanol | 4 | 4 | | | | | ethanol | 0.02% (wt/Vol) In Whole Blood @ Autopsy |
| 937 | 70 y M | | | | A | Ingst | Int-S | 2 | | |
| | | venlafaxine | 1 | 1 | | | | | | |
| | | gabapentin | 2 | 2 | | | | | | |
| 938 | 72 y M | | | | A | Ingst | Unt-G | 1 | | |
| | | amitriptyline | 1 | 1 | | | | | | |
| 939 | 75 y M | | | | A/C | Ingst | Unt-T | 3 | | |
| | | lithium | 1 | 1 | | | | | lithium | 1.76 mEq/L In Blood (unspecified) @ 2 d (pe) |
| | | lithium | 1 | 1 | | | | | lithium | 2.37 mEq/L In Blood (unspecified) @ 1 d (pe) |
| 940pai | 76 y M | | | | U | Ingst | Int-S | 2 | | 0 1 2 (4 1) |
| | | doxepin | 1 | 1 | | 8 | | | nordoxepin | 0.22 mcg/mL In Whole Blood @ Autopsy |
| | | doxepin | 1 | 1 | | | | | doxepin | 1.9 mcg/mL In Whole Blood @ Autopsy |
| | | trazodone | 2 | 2 | | | | | | 1 2 |
| 941 | 79 y M | | | | A | Ingst | Int-S | 2 | | |
| | • | amitriptyline | 1 | 1 | | C | | | | |
| | | warfarin | 2 | 2 | | | | | | |
| 942 | 81 y M | | | | C | Ingst | AR-D | 3 | | |
| | • | citalopram | 1 | 1 | | - | | | | |
| 943a | 92 y M | î. | | | A | Ingst | Int-S | 3 | | |
| | - | amitriptyline | 1 | 1 | | - | | | | |
| | | nadolol | 2 | 2 | | | | | | |
| | | trazodone | 3 | 3 | | | | | | |
| 944 | 95 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | amitriptyline | 1 | 1 | | | | | amitriptyline | 1596 ng/mL In Unknown @ |

Unknown See also case 13, 15, 29, 41, 55, 84, 203, 270, 274, 281, 283, 294, 301, 314, 322, 323, 328, 335, 344, 353, 355, 359, 367, 380, 391, 395, 401, 404, 409, 411, 412, 414, 364 a80 case 15, 15, 25, 41, 35, 41, 35, 41, 31, 42, 421, 431, 440, 452, 456, 461, 466, 471, 472, 473, 486, 488, 500, 509, 520, 526, 536, 539, 540, 541, 543, 553, 554, 574, 589, 590, 600, 606, 609, 610, 617, 618, 622, 630, 641, 643, 651, 652, 661, 664, 667, 669, 670, 671, 672, 674, 676, 678, 680, 684, 692, 698, 700, 702, 710, 713, 716, 719, 737, 743, 758, 790, 796, 801, 808, 811, 812, 813, 815, 817, 818, 825, 827, 959, 967, 971, 976, 977, 980, 987, 993, 994, 1001, 1002, 1013, 1016, 1017, 1019, 1023, 1025, 1030, 1037, 1053, 1054, 1056, 1058, 1061, 1067, 1068, 1073, 1076, 1109, 1117, 1123, 1126, 1131, 1144, 1149, 1151, 1152, 1157, 1161, 1165, 1167, 1181, 1183, 1186, 1190, 1192, 1195, 1196, 1197, 1199, 1205, 1206, 1207, 1209, 1212, 1213, 1215, 1219, 1225, 1235, 1236, 1250, 1270, 1292, 1309, 1317, 1333, 1340, 1342, 1354

| Antihistami | nes | | | | | | | | | |
|-------------|--------|-----------------------------|-----|-----|---|-------|--------|---|-----------------|---|
| 945pa | 2 y F | diphenhydramine | 1 | 1 | A | Ingst | Int-M | 1 | diphenhydramine | 0.71 mcg/mL In Whole Blood @ Autopsy |
| 946pa | 13 y F | | | | A | Ingst | Int-S | 1 | | Autopsy |
| • | • | diphenhydramine | 1 | 1 | | C | | | diphenhydramine | 17000 ng/mL In Blood (unspecified) @ Autopsy |
| | | antifungal drug, unknown | 2 | 2 | | | | | | |
| 947 | 17 y F | | | | A | Ingst | Int-S | 1 | | |
| | | diphenhydramine | 1 | 1 | | | | | diphenhydramine | 2000 ng/mL In Serum @ Unknown |
| | | theophylline | 2 3 | 2 3 | | | | | | |
| | | caffeine | 3 | 3 | | | | | | |
| 948p | 22 y F | | | | A | Ingst | Int-S | 2 | | |
| | | diphenhydramine | 1 | 1 | | | | | | |
| 949 | 27 y F | | | | A | Ingst | Int-S | 1 | | |
| | | diphenhydramine | 1 | 1 | | | | | | |
| 950pa | 29 y F | | | | A | Ingst | Int-S | 2 | | |
| | | diphenhydramine | 1 | 1 | | | | | | |
| 951pa | 31 y M | | | | A | Ingst | Int-S | 1 | | |
| | | diphenhydramine | 1 | 1 | | | | | diphenhydramine | 20000 ng/mL In Blood (unspecified) @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.07% (wt/Vol) In Blood (unspecified) @ Autopsy |
| 952pai | 33 y F | | | | U | Ingst | Int-A | 2 | | |
| | | doxylamine | 1 | 1 | | | | | doxylamine | 0.19 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.1% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.13% (wt/Vol) In Vitreous @ Autopsy |
| 953p | 36 y F | dextromethorphan | 3 | 3 | A | Ingst | Int-S | 2 | | F -5 |
| эээр | 30 y F | diphenhydramine | 1 | 1 | Α | nigst | 1111-3 | 4 | | |
| | | quetiapine | 2 | 2 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|-----------------------------|--------------|-----------------------------------|-------------------|---------------|------------|------------|---------|-----|-----------------|--|
| | | valproic acid | 3 | 3 | | | | | | |
| | | topiramate | 4 | 4 | | | | | | |
| | | clonazepam | 5 | 5 | | | | | | |
| | | risperidone | 6 | 6 | | | | | | |
| 954a | 40 y M | diphenhydramine | 1 | 1 | Α | Ingst | Int-U | 1 | diphenhydramine | 5.9 mg/L In Blood (unspecified) @ |
| | 41 37 | | | | | * . | T . C | 2 | | Autopsy |
| 55pai | 41 y M | diphenhydramine | 1 | 1 | A | Ingst | Int-S | 2 | diphenhydramine | 5.4 mcg/mL In Whole Blood @ Autopsy |
| | | doxylamine | 2 | 2 | | | | | doxylamine | 0.27 mcg/mL In Whole Blood @ Autopsy |
| | | codeine | 3 | 3 | | | | | codeine | 0.26 mcg/mL In Whole Blood @ Autopsy |
| 956p | 41 y F | | | | A | Ingst | Int-S | 2 | | |
| 957a | 49 y M | diphenhydramine | 1 | 1 | A | Ingst | Int-S | 3 | | |
| | | diphenhydramine | 1 | 1 | | | | | | |
| | | ibuprofen | 2 | 2 | | | | | | |
| 958 | 52 y M | | _ | _ | A | Ingst | Int-S | 1 | | |
| | | diphenhydramine | 2 | 1 | | | | | | |
| | | salicylate | 1 | 2 | | | | | | |
| | | acetaminophen/ | 3 | 3 | | | | | | |
|)50: | 60 E | dextromethorphan | | | ** | Terrort | Test TT | 2 | | |
| 959pai | 62 y F | diphenhydramine | 1 | 1 | U | Ingst | Int-U | 2 | diphenhydramine | 1.4 mcg/mL In Blood (unspecified) @ Autopsy |
| | | imipramine | 2 | 2 | | | | | | Critiopsy |
| | | laxative (stimulant) | 3 | 3 | | | | | | |
| | | bupropion | 4 | 4 | | | | | | |
| | | trazodone | 5 | 5 | | | | | | |
| | | skeletal muscle relaxant | 6 | 6 | | | | | | |
| 960 | 67 y M | | | | A | Ingst | Int-S | 3 | | |
| | | promethazine | 1 | 1 | | | | | | |
| | | ethanol | 2 | 2 | | | | | | |
| | | antacid (proton pump inhibitor) | 3 | 3 | | | | | | |
| 961pa | 84 y F | | | | A | Ingst | Int-S | 1 | | |
| | | diphenhydramine | 1 | 1 | | | | | diphenhydramine | 2.5 mg/L In Whole Blood @ Unknown |
| 962pa | 16 m M | | | | A | Ingst | Unt-G | 1 | | |
| 1 | | diphenhydramine | 1 | 1 | | | | | diphenhydramine | 16.1 mg/L In Blood (unspecified) @ 20 m (pe) |
| | | diphenhydramine | 1 | 1 | | | | | diphenhydramine | 39 mg/L In Whole Blood @ Autopsy |
| 963 | 30+ y F | | | | A | Ingst | Int-S | 2 | | |
| 758, 796, 835 | 5, 854, 858, | | | | | | | | | , 600, 620, 622, 666, 677, 717, 739, , 1209, 1220, 1232, 1250, 1315, 1317 |
| Antimicrobi 964ha | 38 y F | | | | A | Ingst | Int-S | 2 | | |
|) TIIA | 30 y 1 | quetiapine* | 2 | 1 | Λ | 111531 | 1111-D | _ | | |
| | | quinine* | 1 | 1 | | | | | quinine | 49 mcg/mL In Serum @ Autopsy |
| | | acetaminophen/ diphenhydramine | 3 | 2 | | | | | acetaminophen | 29 mcg/mL In Blood (unspecified) @ 2 h (pe) |
| | | acetaminophen/ diphenhydramine | 3 | 2 | | | | | hydromorphone | 33 ng/mL In Serum @ Autopsy |
| 965a | 57 y F | carprofen | 4 | 3 | A | Inhal | AR-D | 2 | | |
| | - · J - | levamisole | 1 | 1 | | | | _ | | |
| | | cocaine | 2 | 2 | | | | | benzoylecognine | 0.26 mg/L In Blood (unspecified) @ 1 h (pe) |
| 966a | 61 y F | | | | A/C | Ingst | Int-S | 1 | | 4 / |
| | , | hydroxychloroquine | 2 | 1 | | - | | | | |
| | | phenytoin | 1 | 2 | | | | | phenytoin | 21 mg/L In Blood (unspecified) @ Autopsy |
| 967h | 67 y F | phenytoin | 1 | 2 | A/C | Ingst | Unt-T | 3 | phenytoin | 38.1 mg/L In Serum @ Unknown |
| | - | linezolid | 1 | 1 | | - | | | | |
| | | | | | | | | | | |
| | | drug, unknown | 2 | 2 | | | | | | |
| | | drug, unknown fluoxetine | 2 3 | 2 3 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|-----------------------------|--------------------|---|-------------------|---------------|--------------|-----------------|------------|-----|-----------------|---|
| 968pi | 82 y F | | | | A | Ingst | AR-D | 1 | | |
| See also case | 270, 300, 3 | chloroquine 718, 762, 796, 831, 835, | 1 845 946 9 | 1 76 1018 | 1037 1069 | 1079 1131 1 | 142 1158 | | | |
| Antineoplast | | 710, 702, 770, 031, 033, | 013, 710, 7 | 70, 1010 | , 1037, 1007 | , 1079, 1131, 1 | 1112, 1130 | | | |
| 969 | 19 y F | | | | C | Ingst | Unk | 3 | | |
| | | methotrexate | 1 2 | 1 | | | | | | |
| 970a | 75 y M | prednisone | 2 | 2 | С | Ingst | Unt-T | 1 | | |
| See also case | 144 1027 | methotrexate | 1 | 1 | | | | | | |
| | | , 1009 | | | | | | | | |
| Asthma The 971h | 55 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | • | theophylline | 1 | 1 | | | | | theophylline | 13 mcg/mL In Serum @ Autopsy |
| | | laxative (stimulant) | 2 | 2 | | | | | sertraline | 359 ng/mL In Serum @ Autopsy |
| | | metformin | 3 | 3 | | | | | metformin | 47 mg/mL |
| | | venlafaxine | 4 | 4 | | | | | venlafaxine | In Serum @ Autopsy 96 ng/mL |
| | | (extended release) | | | | | | | | In Serum @ Autopsy |
| See also case | 281, 677, | 779, 947, 1126, 1210 | | | | | | | | |
| Cardiovascu 972ph | lar Drugs 2 y F | | | | A | Par | Unt-T | 1 | | |
| 972pii | 2 y 1 | cholestyramine | 1 | 1 | А | 1 ai | Ont-1 | 1 | | |
| 973p | 16 y F | flagginida | 1 | 1 | A | Ingst | Int-S | 1 | flaccinida | 12.29 mag/mL In Placed (unencoi |
| | | flecainide | 1 | 1 | | | | | flecainide | 13.28 mcg/mL In Blood (unspeci- fied) @ Autopsy |
| | | cyclobenzaprine | 2 | 2 | | | | | cyclobenzaprine | 206 ng/mL In Blood (unspecified) |
| 974a | 18 y F | | | | A | Ingst | Int-S | 1 | | @ Autopsy |
| | | diltiazem (extended | 1 | 1 | | | | | diltiazem | 36000 ng/mL In Blood (unspecified |
| | | release) metformin | 2 | 2 | | | | | metformin | @ Autopsy 23 mcg/mL In Blood (unspecified) |
| | | | 2 | 2 | | | | | | @ Unknown |
| | | pregabalin | 3 | 3 | | | | | pregabalin | 2.9 mcg/mL In Blood (unspecified)@ Unknown |
| | | esomeprazole | 4 | 4 | | | | | pregabalin | 2.9 mcg/mL In Blood (unspecified) |
| | | esomeprazole | 4 | 4 | | | | | metformin | @ Unknown 23 mcg/mL In Blood (unspecified) |
| | | • | 4 | 4 | | | | | 196 | @ Unknown |
| | | esomeprazole | 4 | 4 | | | | | diltiazem | 36000 ng/mL In Blood (unspecified @ Autopsy |
| 975 | 18 y F | | | | A | Ingst | Int-S | 2 | | |
| | | beta blocker tramadol | 1 2 | 1 2 | | | | | | |
| 976pa | 19 y M | | | | A/C | Ingst | Int-S | 1 | | |
| | | propranolol lithium* | 1 3 | 1 2 | | | | | | |
| | | trazodone* | 2 | 2 | | | | | | |
| | | neurontin | 5 | 3 | | | | | | |
| | | fluvoxamine* | 4 | 4 | | | | | | |
| 977 | 20 y M | valacyclovir* | 6 | 4 | A/C | Ingst | Int-S | 2 | | |
| | 20) 1.1 | amlodipine | 1 | 1 | | IIIgot | III O | _ | | |
| | | amitriptyline | 3 | 2 | | | | | | |
| | | salicylate | 2 | 3 | | | | | | |
| | | venlafaxine ethanol | 4 5 | 4 5 | | | | | | |
| 978 | 23 y M | Culation | 3 | J | A/C | Ingst | AR-D | 2 | | |
| | , 111 | cardiac glycoside | 1 | 1 | | | | - | digoxin | 4.4 ng/mL In Serum @ 1 h (pe) |
| 070 | 22 37 | warfarin | 2 | 2 | | T | T C | 4 | | |
| 979p | 23 y M | propafenone | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 980 | 26 y F | | 1 | 1 | A/C | Ingst | Int-S | 3 | | |
| | - | verapamil (extended | 1 | 1 | | - | | | | |
| | | release) nisoldipine | 2 | 2 | | | | | | |
| | | gabapentin | 3 | 3 | | | | | | |
| | | tricyclic | 4 | 4 | | | | | | |
| | | antidepressant | - | _ | | | | | | |
| | | acetaminophen/ butalbital/caffeine | 5 | 5 | | | | | | |
| | | clonazepam | 6 | 6 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|---|-------------------|---------------|------------|------------|--------|-----|---------------------------------|--|
| 981p | 27 y M | | | | A | Ingst | Int-S | 1 | | |
| _ | | atenolol | 2 | 1 | | | | | | |
| | | amlodipine | 3 | 2 | | | | | | |
| | | morphine (extended release) | 4 | 3 | | | | | | |
| | | alprazolam | 5 | 4 | | | | | | |
| 202 | 27. 5 | acetaminophen/ hydrocodone | 1 | 5 | | * . | 4 B B | 2 | | |
| 982 | 27 y F | cardina alvancida | 1 | 1 | С | Ingst | AR-D | 3 | | |
| 983 | 29 y F | cardiac glycoside | 1 | 1 | A | Ingst | Int-S | 3 | | |
| 763 | 2) y 1 | angiotensin- converting enzyme inhibitor metformin | 2 | 1 2 | A | nigst | III3 | 3 | | |
| | | acetaminophen | 3 | 3 | | | | | | |
| 984i | 30 y M | accammophen | | | A | Ingst | Int-S | 3 | | |
| | 3 | amlodipine | 1 | 1 | | 8 | | | | |
| 985pai | 31 y M | | | | U | Ingst | Int-S | 1 | | |
| | | propranolol | 1 | 1 | | | | | propranolol | 1.4 mcg/mL In Whole Blood @ Autopsy |
| | | propoxyphene skeletal muscle | 2 3 | 2 3 | | | | | norpropoxyphene carisoprodol | 5.3 mg/kg In Liver @ Autopsy 19 mcg/mL In Whole Blood @ |
| | | relaxant skeletal muscle relaxant | 3 | 3 | | | | | meprobamate | Autopsy 5.9 mcg/mL In Whole Blood @ |
| | | alprazolam | 4 | 4 | | | | | alprazolam | Autopsy 111 ng/mL In Whole Blood @ Autopsy |
| 986a | 31 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | , | diltiazem | 1 | 1 | | C | | | diltiazem | 4500 ng/mL In Serum @ Autopsy |
| | | amiodarone | 2 | 2 | | | | | | |
| | | metoprolol | 3 | 3 | | | | | metoprolol | 162 ng/mL In Serum @ Autopsy |
| | | lisinopril | 4 | 4 | | | | | | |
| 987 | 31 y F | 1. | 1 | | A | Ingst | Int-S | 2 | | |
| | | calcium antagonist acetaminophen/ opioid | 1 2 | 1 2 | | | | | | |
| | | metoprolol (extended release) | 3 | 3 | | | | | | |
| | | metformin | 4 | 4 | | | | | | |
| | | escitalopram | 5 | 5 | | | | | | |
| 000 | 22 F | esomeprazole | 6 | 6 | | Torred | T C | 2 | | |
| 988p | 33 y F | clonidine | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | promethazine | 1 2 | 2 | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| | | lorazepam | 4 | 4 | | | | | | |
| | | codeine | 5 | 5 | | | | | | |
| | | ethanol | 6 | 6 | | | | | ethanol | 216 mg/dL In Blood (unspecified) @ Unknown |
| 989a | 36 y M | propranolol | 1 | 1 | U | Ingst+ Unk | Int-S | 2 | propranolol | 840 ng/mL In Blood (unspecified) |
| | | cocaine | 2 | 2 | | | | | ecgonine methyl | @ Unknown 0.2 mg/L In Blood (unspecified) @ |
| | | cocaine | 2 | 2 | | | | | ester benzoylecognine | Unknown 0.878 mg/L In Blood (unspecified) @ Unknown |
| | | ethanol | 3 | 3 | | | | | ethanol | 195 mg/dL In Blood (unspecified) @ Unknown |
| | | amlodipine | 4 | 4 | | | | | | _ C |
| | | acetaminophen | 5 | 5 | | | | | | |
| 990 | 37 y M | atenolol | 2 | 1 | A | Ingst | Int-S | 2 | | |
| | | lisinopril | 1 | 2 | | | | | | |
| | | diazepam | 3 | 3 | | | | | | |
| 991 | 38 y M | | | | A/C | Ingst | Int-S | 1 | | |
| | | verapamil | 1 | 1 | | _ | | | | |
| 992a | 38 y F | ** | | _ | A | Ingst | Int-S | 1 | •• | 0.0 # 1 50 |
| | | verapamil | 1 | 1 | | | | | verapamil | 0.8 mg/L In Plasma @ Unknown |
| | | lorazepam ethanol | 2 3 | 2 3 | | | | | lorazepam ethanol | 0.04 mg/L In Plasma @ Unknown 0.02% (wt/Vol) In Plasma @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|-----------------------------|-------------------|---------------|------------|-------------|--------|-----|---------------|----------------------------------|
| 993 | 38 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | • | amlodipine | 1 | 1 | | C | | | | |
| | | acetaminophen | 2 | 2 | | | | | | |
| | | citalopram | 3 | 3 | | | | | | |
| | | carbamazepine | 4 | 4 | | | | | | |
| | | valproic acid | 5 | 5 | | | | | | |
| 994 | 41 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | metoprolol | 2 | 2 | | | | | | |
| | | valproic acid | 3 | 3 | | | | | | |
| | | ziprasidone | 4 | 4 | | | | | | |
| 995p | 41 y M | paroxetine | 5 | 5 | A | Ingst+ Unk | Int-S | 1 | | |
| 993p | 41 y WI | clonidine | 1 | 1 | А | nigst+ Ulik | 1111-3 | 1 | | |
| | | benzodiazepine | 2 | 2 | | | | | | |
| | | methadone | 3 | 3 | | | | | | |
| 996p | 41 y F | memadone | | | A | Ingst | Int-S | 2 | | |
| F | , - | verapamil | 1 | 1 | | 8 | | | | |
| | | alprazolam | 2 | 2 | | | | | | |
| 997p | 42 y F | • | | | A | Ingst | Int-S | 2 | | |
| _ | | amlodipine | 1 | 1 | | | | | | |
| | | ropinirole | 2 | 2 | | | | | | |
| 998 | 42 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | clonazepam | 2 | 2 | | | | | | |
| | 44 5 | ethanol | 3 | 3 | | | * | 2 | | |
| 999 | 44 y F | .1 1.11 | 1 | 1 | A | Ingst | Int-S | 3 | | |
| 1000 | 44 - F | clonidine | 1 | 1 | | Toront | Int C | 1 | | |
| 1000 | 44 y F | amlodipine | 1 | 1 | A | Ingst | Int-S | 1 | | |
| | | metoprolol (extended | 2 | 2 | | | | | | |
| | | release) | 2 | 2 | | | | | | |
| 1001 | 44 y F | release) | | | A/C | Ingst | Int-S | 2 | | |
| 1001 | , 1 | amlodipine | 6 | 1 | 140 | 111500 | 1111 0 | _ | | |
| | | propranolol | 1 | 2 | | | | | | |
| | | bupropion | 7 | 3 | | | | | | |
| | | quetiapine* | 8 | 4 | | | | | | |
| | | risperidone* | 3 | 4 | | | | | | |
| | | acetaminophen/ | 5 | 5 | | | | | | |
| | | opioid | | | | | | | | |
| | | diphenhydramine | 2 | 6 | | | | | | |
| 1000 | 45 35 | ethanol | 4 | 7 | •• | | * | • | | |
| 1002 | 45 y M | are tarater | 1 | 1 | U | Ingst | Int-S | 2 | | |
| | | atorvistatin/ | 1 | 1 | | | | | | |
| | | amlodipine valproic acid | 2 | 2 | | | | | | |
| | | duloxetine | 3 | 3 | | | | | | |
| | | lisinopril | 4 | 4 | | | | | | |
| | | quetiapine | 5 | 5 | | | | | | |
| | | diazepam | 6 | 6 | | | | | | |
| | | esomeprazole | 7 | 7 | | | | | | |
| 1003 | 46 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | • | verapamil | 1 | 1 | | C | | | | |
| | | clonidine | 2 | 2 | | | | | | |
| 1004a | 46 y F | | | | A | Ingst | Int-S | 1 | | |
| | | digoxin | 1 | 1 | | | | | digoxin | 44 ng/mL In Serum @ 1 h (pe) |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | 140 mcg/mL In Serum @ 1 h (pe) |
| | | codeine | 2 | | | | | | | 100 (17.7.0 |
| 1005 | 46 5 | ethanol | 3 | 3 | | | * | | ethanol | 180 mg/dL In Serum @ 1 h (pe) |
| 1005 | 46 y F | | 1 | | A | Ingst | Int-S | 1 | | |
| | | verapamil ethanol | 1 2 | 1 2 | | | | | | |
| 1006pa | 16 v M | emanor | 2 | 2 | A/C | Inget | Int-S | 1 | | |
| тооора | 46 y M | atenolol | 1 | 1 | AC | Ingst | 1111-3 | 1 | atenolol | 3900 mg/mL In Blood (unspecified |
| | | | 1 | 1 | | | | | ate110101 | @ Unknown |
| | | acetaminophen/ | 2 | 2 | | | | | acetaminophen | 169 mcg/mL In Serum @ 1 h (pe) |
| | | hydrocodone | - | - | | | | | | |
| | | clonazepam | 3 | 3 | | | | | | |
| | | ethanol | 4 | 4 | | | | | ethanol | 80 mg/dL In Serum @ 1 h (pe) |
| 1007 | 47 y F | | | | A | Ingst | Int-S | 1 | | * ' |
| | | nadolol | 1 | 1 | | | | | | |
| | | quinapril | 2 | 2 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|---|-------------------|---------------|------------|--------------|---------|-----|------------------|--|
| | | sildenafil | 3 | 3 | | | | | | |
| | | ethanol | 4 | 4 | | | | | | |
| | | acetaminophen | 5 | 5 | | | | | acetaminophen | 100 mcg/mL In Serum @ Unknown |
| 1008 | 47 y M | | | | A | Ingst | Int-S | 2 | | |
| | | calcium antagonist | 1 | 1 | | | | | | |
| | | doxazosin | 2 3 | 2 3 | | | | | | |
| | | angiotensin- converting enzyme | 3 | 3 | | | | | | |
| | | inhibitor | | | | | | | | |
| | | metformin | 5 | 5 | | | | | | |
| | | antihyperlipidemic | 6 | 6 | | | | | | |
| 1009 | 48 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | diltiazem (extended release) | 1 | 1 | | | | | | |
| | | metoprolol | 2 | 2 | | | | | | |
| 1010 | 48 y M | петоргогог | 2 | 2 | A | Ingst | Int-S | 2 | | |
| | | metoprolol (extended | 1 | 1 | | 8 | | | | |
| | | release) | | | | | | | | |
| | | amlodipine/valsartan | 2 | 2 | | | | | | |
| 1011 | 40 14 | metformin | 3 | 3 | ** | T4 | Total C | | | |
| 1011 | 48 y M | amlodipine | 1 | 1 | U | Ingst | Int-S | 1 | | |
| | | metformin/sitagliptin | 2 | 2 | | | | | | |
| 1012p | 48 y F | metroriiii, stagriptii | - | _ | A | Ingst | Int-S | 2 | | |
| 1 | , | diltiazem (extended release) | 1 | 1 | | Ü | | | | |
| | | eszopiclone | 2 | 2 | | | | | | |
| 1013p | 48 y F | | | | U | Ingst | Int-S | 1 | | |
| | | diltiazem (extended | 1 | 1 | | | | | dihydrocodone | 5300 ng/mL In Blood (unspecified) |
| | | release) naproxen | 2 | 2 | | | | | (free) | @ Autopsy |
| | | bupropion | 3 | 3 | | | | | | |
| | | meclizine | 4 | 4 | | | | | | |
| 1014 | 49 y M | | | | A | Ingst | Int-S | 2 | | |
| | | calcium antagonist | 1 | 1 | | | | | | |
| 1015a | 49 y F | 111.1 | | | A | Ingst | Int-S | 3 | | |
| | | diltiazem | 1 | 1 | | | | | | |
| | | valproic acid warfarin | 2 3 | 2 3 | | | | | | |
| | | gabapentin | 4 | 4 | | | | | | |
| | | lisinopril | 5 | 5 | | | | | | |
| | | hydrochlorothiazide | 6 | 6 | | | | | | |
| 1016a | 50 y F | | | | A/C | Ingst+ Inhal | Int-S | 1 | | |
| | | beta blocker | 1 2 | 1 2 | | | | | | |
| | | bupropion (extended release) | 2 | 2 | | | | | | |
| | | cocaine* | 3 | 4 | | | | | | |
| | | fenofibrate* | 4 | 4 | | | | | | |
| 1017a | 51 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | beta blocker | 1 | 1 | | | | | | |
| | | bupropion | 2 | 2 | | | | | hydroxybupropion | |
| | | (extended release) bupropion (extended | 2 | 2 | | | | | bupropion | @ Unknown 78 ng/mL In Blood (unspecified) @ |
| | | release) | 2 | 2 | | | | | oupropion | Unknown |
| | | benzodiazepine | 3 | 3 | | | | | clonazepam | 61 ng/mL In Blood (unspecified) @ Unknown |
| | | levothyroxine | 4 | 4 | | | | | | Ommown |
| 1018 | 51 y M | | | | A/C | Ingst | Int-S | 1 | | |
| | | verapamil | 1 | 1 | | | | | | |
| | | prednisone | 2 | 2 | | | | | | |
| 1019 | 51 y M | azithromycin | 3 | 3 | U | Ingst | Int-S | 2 | | |
| 1017 | 51 y IVI | diltiazem | 1 | 1 | U | ingst | 111t-O | _ | | |
| | | citalopram | 2 | 2 | | | | | | |
| | | clonazepam | 3 | 3 | | | | | | |
| | | quetiapine | 4 | 4 | | | | | | |
| | | ethanol | 5 | 5 | | | | | ethanol | 193 mg/dL In Serum @ Unknown |
| 1020 | 51 y M | 1.7.11.1 | 4 | 4 | A | Ingst | Int-S | 1 | | |
| | | beta blocker oxycodone | 1 2 | 1 2 | | | | | | |
| | | (extended release) | 2 | 2 | | | | | | |
| | | ethanol | 3 | 3 | | | | | | |
| | | alprazolam | 4 | 4 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|----------------------------|-------------------|---------------|------------|--------------|--------|-----|---------------|----------------------------------|
| 1021 | 51 y F | | | | U | Ingst | Int-S | 1 | | |
| | • | amlodipine | 1 | 1 | | | | | | |
| | | atenolol/ | 2 | 2 | | | | | | |
| | 50 F | chlorthalidone | | | | | * | • | | |
| 1022 | 52 y F | amladinina | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine lotensin | 1 2 | 1 2 | | | | | | |
| | | tramadol | 3 | 3 | | | | | | |
| | | progestins | 4 | 4 | | | | | | |
| 1023p | 52 y F | | | | A/C | Ingst | Int-S | 1 | | |
| | | beta blocker | 1 | 1 | | | | | | |
| | | propoxyphene | 2 | 2 | | | | | | |
| | | acetaminophen | 3 | 3 | | | | | acetaminophen | 247.7 mcg/mL In Serum @ 1 h (pe) |
| | | acetaminophen escitalopram | 3 4 | 3 4 | | | | | acetaminophen | 3.7 mcg/mL In Serum @ 3 d (pe) |
| 1024 | 52 y M | escitaiopiani | 7 | - | A/C | Ingst | Int-S | 1 | | |
| |) | diltiazem | 1 | 1 | | 8 | | - | | |
| | | drug, unknown | 2 | 2 | | | | | | |
| 1025h | 53 y M | | | | A/C | Ingst | Int-S | 1 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | bisoprolol | 2 3 | 2 | | | | | | |
| | | bupropion venlafaxine | 3 4 | 3 4 | | | | | | |
| | | (extended release) | 7 | 7 | | | | | | |
| | | hydrochlorothiazide | 6 | 6 | | | | | | |
| | | atorvastatin | 7 | 7 | | | | | | |
| 1026p | 53 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | beta blocker lovastatin | 2 3 | 2 | | | | | | |
| | | acetaminophen/ | 4 | 4 | | | | | | |
| | | propoxyphene | • | • | | | | | | |
| | | modafinil | 5 | 5 | | | | | | |
| 1027 | 54 y F | | | | A | Ingst | Int-S | 2 | | |
| | | metoprolol | 1 | 1 | | | | | | |
| 1028 | 55 y M | ethanol | 2 | 2 | A/C | Ingst | Int-S | 1 | | |
| 1026 | 33 y IVI | beta blocker | 1 | 1 | A/C | nigst | IIII-3 | 1 | | |
| | | gabapentin | 2 | 2 | | | | | | |
| | | methadone | 3 | 3 | | | | | | |
| 1029h | 56 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | ranolazine | 4 | 1 | | | | | | |
| | | carvedilol clopidogrel | 1 2 | 2 | | | | | | |
| | | lisinopril | 3 | 4 | | | | | | |
| 1030ph | 56 y F | пэшортт | 5 | · | A/C | Ingst | Int-S | 1 | | |
| | | atenolol | 1 | 1 | | 8 | | | | |
| | | escitalopram | 2 | 2 | | | | | | |
| | | citalopram | 3 | 3 | | | | | | |
| | | lamotrigine | 4 5 | 4 5 | | | | | | |
| | | venlafaxine hydroxyzine | 6 | 6 | | | | | | |
| | | ethanol | 7 | 7 | | | | | | |
| 1031 | 56 y M | | | | A | Ingst+ Aspir | Int-S | 1 | | |
| | - | propranolol | 1 | 1 | | _ | | | | |
| | | opioid | 2 | 2 | | | | | | |
| | | benzodiazepine | 3 | 3 | | | | | | |
| 1032 | 56 y M | rodenticide, unknown | 4 | 4 | A | Ingst | Int-S | 1 | | |
| 1032 | 30 y 1v1 | metoprolol | 1 | 1 | Α | nigst | 1111-5 | 1 | | |
| | | ranolazine | 2 | 2 | | | | | | |
| | | nitroglycerin | 3 | 3 | | | | | | |
| | | clopidogrel | 4 | 4 | | | | | | |
| 1022 | 56 35 | salicylate | 5 | 5 | A /C | To and | Int C | 1 | | |
| 1033 | 56 y M | diltiazem (extended | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | release) | 1 | 1 | | | | | | |
| | | potassium chloride | 2 | 2 | | | | | | |
| | 56 y M | • | | | A/C | Ingst | Int-S | 2 | | |
| 1034 | 30 y 111 | | | | | | | | | |
| 1034 | 50 y 111 | verapamil | 1 | 1 | | | | | | |
| 1034 1035 | 56 y M | verapamil drug, unknown | 1 2 | 1 2 | A | Ingst | Int-S | 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|-------------------|---|-------------------|---------------|------------|----------|--------|-----|-----------------|--|
| | | angiotensin- converting enzyme | 2 | 2 | | | | | | |
| | | inhibitor | | | | | | | | |
| 1026 | 56 34 | clonidine | 3 | 3 | | . | T . C | 2 | | |
| .036pa | 56 y M | varanamil | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | verapamil alprazolam | 1 2 | 1 2 | | | | | | |
| | | eszopiclone | 3 | 3 | | | | | | |
| | | hydrochlorothiazide/ | 4 | 4 | | | | | | |
| | | olmesartan | | | | | | | | |
| | | clonidine | 5 | 5 | | | | | | |
| 1037 | 57 y F | | | | U | Ingst | Int-S | 2 | | |
| | | diltiazem | 1 | 1 | | | | | | |
| | | antimalarials | 2 | 2 | | | | | | |
| | | (chloroquine type) | 2 | 2 | | | | | | |
| | | venlafaxine | 3 | 3 | | | | | | |
| | | methotrexate clonazepam | 4 5 | 4 5 | | | | | | |
| | | baclofen | 6 | 6 | | | | | | |
| | | fluoxetine | 7 | 7 | | | | | | |
| | | diphenhydramine | 8 | 8 | | | | | | |
| | | gabapentin | 9 | 9 | | | | | | |
| 1038 | 57 y M | C 1 | | | A | Ingst | Int-S | 1 | | |
| | | verapamil | 1 | 1 | | | | | | |
| | | lisinopril | 2 | 2 | | | | | | |
| 1039a | 57 y M | | | | A | Ingst | Int-S | 1 | | |
| | | cocaine* | 1 | 1 | | | | | cocaine | 0.05 mg/L In Blood (unspecified) @ |
| | | • 44 | | | | | | | | Autopsy |
| | | cocaine* | 1 1 | 1 1 | | | | | benzoylecognine | 1.8 mg/L In Vitreous @ Autopsy |
| | | cocame | 1 | 1 | | | | | benzoylecognine | 2 mg/L In Blood (unspecified) @ Autopsy |
| | | lisinopril* | 3 | 1 | | | | | | Autopsy |
| | | phencyclidine | 2 | 2 | | | | | | |
| 1040p | 57 y F | phoneyename | - | - | A | Ingst | Int-S | 2 | | |
| 1 | | verapamil | 1 | 1 | | 8 | | | | |
| 1041 | 57 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | carvedilol | 2 | 2 | | | | | | |
| | | hydrochlorothiazide/ | 3 | 3 | | | | | | |
| 10.42 | 50 F | olmesartan | | | | . | T . C | 2 | | |
| 1042p | 58 y F | cardiac glycoside | 1 | 1 | A | Ingst | Int-S | 3 | | |
| | | cardiac grycoside calcium antagonist | 1 2 | 1 2 | | | | | | |
| | | levothyroxine | 3 | 3 | | | | | | |
| | | diphenhydramine | 4 | 4 | | | | | | |
| | | carprofen | 5 | 5 | | | | | | |
| | | benzodiazepine | 6 | 6 | | | | | | |
| | | antihyperlipidemic | 7 | 7 | | | | | | |
| 1043 | 58 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | atenolol | 2 | 2 | | | | | | |
| | | phenytoin | 3 | 3 | | | | | phenytoin | 29.9 mcg/mL In Blood (unspecified |
| 1044 | 50 M | | | | | Toront | II T | 2 | | @ Unknown |
| 1044p | 58 y M | verapamil (extended | 1 | 1 | A | Ingst | Unt-T | 3 | | |
| | | release) | 1 | 1 | | | | | | |
| | | digoxin | 2 | 2 | | | | | | |
| | | carvedilol | 3 | 3 | | | | | | |
| 1045 | 59 y M | | | _ | A | Ingst | Unt-G | 1 | | |
| | | atenolol | 1 | 1 | | | | | | |
| 1046 | 59 y F | clonazepam | 2 | 2 | A/C | Ingst | Unt-T | 3 | | |
| | J J 1 | metoprolol | 1 | 1 | 1110 | 551 | J11. 1 | J | | |
| 1047 | 59 y M | | | | A/C | Ingst | AR-D | 3 | | |
| | | digoxin | 1 | 1 | | | | | digoxin | 3.3 ng/mL In Blood (unspecified) |
| | | | | | | | | | | @ 9 h (pe) |
| | | digoxin | 1 | 1 | | | | | digoxin | 3.5 ng/mL In Blood (unspecified) @ |
| 1048 | 60 y M | | | | A | Ingst | Int-S | 2 | | Unknown |
| | 50 y 1 v 1 | amlodipine | 1 | 1 | 11 | 111531 | mi-O | - | | |
| 1049a | 60 y F | • | | | A | Ingst | Int-S | 1 | | |
| | • | amlodipine/ | 1 | 1 | | - | | | verapamil | 2.3 mg/L In Blood (unspecified) @ |
| | | olmesartan | | _ | | | | | 1 1' ' | Autopsy |
| | | amlodipine/ | 1 | 1 | | | | | amlodipine | 970 ng/mL In Blood (unspecified) |
| | | olmesartan | | | | | | | | @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|--------------|--------|---|-------------------|---------------|------------|-------|---------|-----|------------------|--|
| 1050 | 60 y M | | | | A | Ingst | Int-S | 2 | | |
| 051 | (O M | verapamil | 1 | 1 | | T | Total C | 2 | | |
| 051 | 60 y M | verapamil | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | (extended release) | 1 | 1 | | | | | | |
| | | lisinopril | 2 | 2 | | | | | | |
| 052 | 61 y M | _ | | | A | Ingst | Int-S | 2 | | |
| | | atenolol | 1 | 1 | | | | | | |
| | | metoprolol (extended release) | 2 | 2 | | | | | | |
| | | diltiazem (extended | 3 | 3 | | | | | | |
| | | release) | | | | | | | | |
| 1053 | 62 y M | | | | A/C | Ingst | Int-S | 1 | | |
| | | carvedilol | 1 | 1 | | | | | | |
| | | diltiazem (extended release) | 2 | 2 | | | | | | |
| | | lisinopril | 3 | 3 | | | | | | |
| | | escitalopram | 4 | 4 | | | | | | |
| | | diazepam | 5 | 5 | | | | | | |
| 054 | 64 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | metoprolol | 1 | 1 | | | | | | |
| | | nitroglycerin venlafaxine | 2 3 | 2 3 | | | | | | |
| | | salicylate | 3 4 | 4 | | | | | | |
| | | ranitidine | 5 | 5 | | | | | | |
| 055 | 65 y M | | | | A/C | Ingst | Int-S | 1 | | |
| | | propafenone | 1 | 1 | | | | | | |
| | | (extended release) | | | | _ | | | | |
| 056a | 65 y M | 1. 4: | 2 | 1 | A | Ingst | Int-S | 2 | | |
| | | amlodipine atenolol | 2 1 | 1 2 | | | | | atenolol | 1900 ng/mL In Serum @ Unkno |
| | | lisinopril | 3 | 3 | | | | | atcholor | 1900 lightie in Scruit & Chkho |
| | | atorvastatin | 4 | 4 | | | | | | |
| | | paroxetine | 5 | 5 | | | | | | |
| 057 | 65 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | propafenone | 1 | 1 | | | | | propafenone | 245 ng/mL In Blood (unspecified |
| | | (extended release) propranolol | 2 | 2 | | | | | | @ Autopsy |
| | | ibuprofen | 3 | 3 | | | | | ibuprofen | 100 mcg/mL In Blood (unspecifi |
| | | | | | | | | | | @ Unknown |
| | | omeprazole | 6 | 4 | | | | | | |
| | | chlordiazepoxide* | 5 | 5 | | | | | chlordiazepoxide | 383 ng/mL In Blood (unspecified |
| | | ablardiazanavida* | 5 | 5 | | | | | damayanam | @ Unknown 575 ng/mL In Blood (unspecified |
| | | chlordiazepoxide* | 3 | 3 | | | | | demoxepam | @ Unknown |
| | | ethanol* | 4 | 5 | | | | | ethanol | 0.15% (wt/Vol) In Blood |
| | | | | | | | | | | (unspecified) @ Unknown |
| 1058p | 67 y F | | | | A/C | Ingst | Unk | 2 | | |
| | | metoprolol | 1 | 1 | | | | | | |
| | | escitalopram amphetamine/dextro- | 2 3 | 2 3 | | | | | | |
| | | amphetamine | 3 | 3 | | | | | | |
| | | clozapine | 4 | 4 | | | | | | |
| | | memantine | 6 | 5 | | | | | | |
| | | solifenacin | 5 | 6 | | | | | | |
| 050 | (0 F | simvastatin | 7 | 7 | | T | T C | 2 | | |
| 1059 | 68 y F | amladinina | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | amlodipine losartan | 1 2 | 1 2 | | | | | | |
| | | diazepam | 3 | 3 | | | | | | |
| | | carbamazepine | 4 | 4 | | | | | carbamazepine | 18.4 mg/L In Plasma @ Unknow |
| | 68 y M | Î | | | A/C | Ingst | Int-S | 2 | | - |
| 060p | | verapamil | 1 | 1 | | | | | | |
| 060p | | benzodiazepine | 2 3 | 2 | | | | | | |
| 060p | | .1 | | 3 | | | | | | |
| 060p | | alprazolam | | | | | | | | |
| 060р | | acetaminophen/ | 4 | 4 | | | | | | |
| • | 68 v F | | | | A/C | Ingst | Int-S | 1 | | |
| Î | 68 y F | acetaminophen/ | | | A/C | Ingst | Int-S | 1 | | |
| Î | 68 y F | acetaminophen/ hydrocodone | 1 3 | 4 1 2 | A/C | Ingst | Int-S | 1 | | |
| 060p 061p | 68 y F | acetaminophen/ hydrocodone amlodipine lorazepam eszopiclone | 1 3 4 | 1 2 3 | A/C | Ingst | Int-S | 1 | | |
| · | 68 y F | acetaminophen/ hydrocodone amlodipine lorazepam | 1 3 | 4 1 2 | A/C | Ingst | Int-S | 1 | acetaminophen | 124 mcg/mL In Blood (unspecifi @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------------|---------------------------------|-------------------|---------------|------------|----------|------------|-----|------------|---|
| 1062 | 70 y M | | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| 1063 | 70 y F | sotalol | 1 | 1 | C | Ingst | AR-D | 2 | at a set a | 47/ 1. 1. 0 |
| 1064 | 70 y M | cardiac glycoside | 1 | 1 | A/C | Ingst | Int-S | 2 | digoxin | 4.7 ng/mL In Serum @ Unknown |
| 1065pa | 71 y M | propafenone | 1 | 1 | A/C | Ingst | AR-D | 3 | | |
| 1066 | 72 y F | lisinopril | 1 | 1 | A | Ingst | AR-O | 1 | | |
| | | atenolol | 1 | 1 | | | | | | |
| 1067a | 72 y F | amlodipine | 2 | 2 | A | Ingst | Int-S | 2 | | |
| | | amlodipine venlafaxine | 1 3 | 1 2 | | | | | | |
| | | | 2 | 3 | | | | | | |
| 1068 | 73 y F | salicylate | 2 | 3 | U | Ingst | Int-U | 1 | | |
| 1008 | 7.5 y 1 | metoprolol | 1 | 1 | O | nigst | IIII-O | 1 | | |
| | | gabapentin | 2 | 2 | | | | | | |
| | | sertraline | 3 | 3 | | | | | | |
| | | hydroxyzine | 4 | 4 | | | | | | |
| | | phenytoin | 5 | 5 | | | | | phenytoin | 13 mcg/mL In Serum @ Unknown |
| | | omeprazole | 6 | 6 | | | | | phenytom | 13 meg/m2 m serum e emanown |
| | | antihyperlipidemic | 7 | 7 | | | | | | |
| 1069ра | 73 y F | diltiazem (extended | 1 | 1 | U | Ingst | Unt-T | 3 | | |
| | | release) | 2 | 2 | | | | | | |
| | | atenolol | 3 | 2 | | | | | | |
| | | methotrexate | 4 | 3 | | | | | | |
| | | hydroxychloroquine | 2 | 4 | | | | | | |
| 070 | 72 F | lotensin | 5 | 5 | | . | T.T. (ID) | 2 | | |
| 070p | 73 y F | 1. 1 .1 | | | C | Ingst | Unt-T | 3 | 1 | 22 / 11 0 011 |
| 1071 | 50. 3.6 | cardiac glycoside | 1 | 1 | | | ** . ** | 2 | digoxin | 3.2 ng/mL In Serum @ Unknown |
| 1071 | 73 y M | 1112 | 1 | | A/C | Ingst | Unt-U | 3 | | |
| 072 | 76 E | diltiazem | 1 | 1 | 0 | T | TT1 | 2 | | |
| .072 | 76 y F | | | | C | Ingst | Unk | 3 | | |
| 1072 | 77 F | cardiac glycoside | 1 | 1 | 4.10 | . | T . C | 2 | | |
| .073 | 77 y F | 111 1 | | | A/C | Ingst | Int-S | 3 | | |
| | | carvedilol | 1 | 1 | | | | | | |
| | | nitroglycerin | 2 | 2 | | | | | | |
| | | citalopram | 3 | 3 | | | | | | |
| | | oxybutynin | 4 | 4 | | | | | | |
| | | alprazolam | 5 | 5 | | | | | | |
| | | alendronate | 6 | 6 | | | | | | |
| | | salicylate | 7 | 7 | ~ | _ | | | | |
| 1074 | 78 y F | nifedipine (extended release) | 1 | 1 | С | Ingst | Int-S | 1 | | |
| | | hydrochlorothiazide/ | 2 | 2 | | | | | | |
| | | irbesartan | | | ~ | | | | | |
| 1075 | 79 y F | | | | C | Ingst | AR-D | 3 | | |
| 1076 | 00 14 | cardiac glycoside | 1 | 1 | 4.10 | . | T . C | 2 | | |
| 1076 | 80 y M | 1 . 40 . 5 | 1 | | A/C | Ingst | Int-S | 2 | | |
| | | amlodipine | 1 | 1 | | | | | | |
| | | carvedilol | 2 | 2 | | | | | | |
| | | amitriptyline | 3 | 3 | | | | | | |
| | | lisinopril | 4 | 4 | | | | | | |
| .055 | 00 - | trazodone | 5 | 5 | | | | | | |
| 1077a | 80 y F | 1. 1 .1 | | | A/C | Ingst | AR-D | 1 | 1 | 22.1 |
| | | cardiac glycoside | 1 | 1 | | | | | digoxin | 33.1 mcg/mL In Serum @ Autopsy |
| 0701- | 00 F | cardiac glycoside | 1 | 1 | C | Toront | AD D | 2 | digoxin | 7.5 ng/mL In Serum @ Unknown |
| 078h | 80 y F | condice almostide | 1 | 1 | С | Ingst | AR-D | 2 | | |
| 070- | 01 37 | cardiac glycoside | 1 | 1 | A /C | Toront | Int C | 1 | | |
| 1079a | 81 y M | verapamil (extended release) | 1 | 1 | A/C | Ingst | Int-S | 1 | verapamil | 190 ng/mL In Blood (unspecified) @ Autopsy |
| | | hydralazine | 2 | 2 | | | | | | x - 2 |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | | |
| | | diazepam | 4 | 4 | | | | | diazepam | 0.14 mg/L In Blood (unspecified) 6 Autopsy |
| | | | 5 | 5 | | | | | | · ·······poj |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------------|------------------------------------|-------------------|---------------|-------------|----------------|---------------|---------|--------------------|--|
| 1080a | 82 y F | | | | С | Ingst | AR-D | 3 | | |
| | | cardiac glycoside | 1 | 1 | | | | | digoxin | 11.1 ng/mL In Blood (unspecified) |
| 081 | 82 y F | | | | A/C | Ingst | Int-S | 1 | | @ Unknown |
| 001 | 02) 1 | diltiazem (extended release) | 1 | 1 | | mgs. | 5 | • | | |
| | | chlorpromazine | 2 | 2 | | | | | | |
| | | metformin/ sitagliptin | 3 | 3 | | | | | | |
| | | clopidogrel | 4 | 4 | | | | | | |
| 082 | 83 y F | | | | A/C | Ingst | Unt-T | 3 | | |
| | | cardiac glycoside warfarin | 1 2 | 1 2 | | | | | | |
| 083 | 83 y M | warrariii | 2 | 2 | C | Ingst | Unk | 3 | | |
| 000 | 00 J 1.1 | cardiac glycoside | 1 | 1 | C | 111800 | O IIII | | digoxin | 2.6 ng/mL In Blood (unspecified) |
| | | | | | | | | | C | Unknown |
| 084 | 84 y M | | | | U | Ingst | Unk | 1 | | |
| | | calcium antagonist | 1 2 | 1 2 | | | | | | |
| 085 | 84 y F | zolpidem | 2 | 2 | С | Ingst | AR-D | 3 | | |
| .005 | 0.71 | digoxin | 1 | 1 | C | mgst | int D | 5 | digoxin | 4.7 mcg/mL In Serum @ Unknown |
| 086 | 85 y F | C | | | A/C | Ingst | Unt-T | 2 | C | S |
| | | nifedipine | 1 | 1 | | | | | | |
| 1087 | 86 y F | 1. 1 .1 | 1 | 1 | C | Ingst | AR-D | 3 | | |
| 1088 | 86 y F | cardiac glycoside | 1 | 1 | A/C | Ingst | Unt-T | 3 | | |
| 1000 | 60 y 1 | cardiac glycoside | 1 | 1 | AC | nigst | Ont-1 | 3 | digoxin | 4.3 ng/mL In Blood (unspecified) |
| | | 8-7 | - | | | | | | 8 | @ 6 h (pe) |
| 1089 | 87 y F | | | | C | Ingst | AR-D | 3 | | |
| | | cardiac glycoside | 1 | 1 | | | | | digoxin | 3.7 ng/mL In Blood (unspecified) @ |
| 1090 | 87 y F | | | | A | Ingst | Int-S | 2 | | Unknown |
| .090 | 67 y 1 | metoprolol | 1 | 1 | Λ | nigst | 1111-5 | | | |
| | | (extended release) | | | | | | | | |
| | | colchicine | 2 | 2 | | | | | | |
| | | alprazolam | 4 | 3 | | | | | | |
| | | acetaminophen/ propoxyphene | 3 | 4 | | | | | | |
| | | zolpidem | 5 | 5 | | | | | | |
| | | hydralazine | 6 | 6 | | | | | | |
| | | nitroglycerin | 7 | 7 | | | | | | |
| | | levothyroxine | 8 | 8 | | _ | | | | |
| 1091 | 89 y M | | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 1092 | 90 y F | amlodipine | 1 | 1 | С | Ingst | Unt-T | 3 | | |
| 1072 | <i>70 y</i> 1 | metoprolol | 1 | 1 | C | mgst | Ont 1 | 5 | | |
| | | timolol | 2 | 2 | | | | | | |
| 1093 | 93 y M | | | | A | Ingst | Unt-G | 3 | | |
| 1004 | 05 17 | cardiac glycoside | 1 | 1 | AIC | Inact | Unle | 2 | | |
| 1094 | 95 y F | cardiac glycoside | 1 | 1 | A/C | Ingst | Unk | 2 | digoxin | 2.9 ng/mL In Blood (unspecified) @ |
| | | cardiae grycoside | 1 | 1 | | | | | aigoniii | Unknown |
| | | beta blocker | 2 | 2 | | | | | | |
| 1095pa | 18 m M | | | | A/C | Ingst | Unt-G | 1 | | |
| | | flecainide | 1 | 1 | | | | | flecainide | 104 Other (see abst) In Liver @ |
| | | flecainide | 1 | 1 | | | | | flecainide | Autopsy 54 mcg/mL In Blood (unspecified) |
| | | necumae | 1 | 1 | | | | | needinae | @ Autopsy |
| 1096р | 19 m M | | | | A/C | Ingst | Unt-T | 1 | | |
| | | flecainide | 1 | 1 | | · | | _ | | |
| 1097i | Unknow | n adult (>=20 yrs) M amlodipine | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | gabapentin | 1 2 | 1 2 | | | | | | |
| .098p | Unknow | n adult (>=20 yrs) F | 2 | 4 | U | Ingst | Int-S | 1 | | |
| • | | beta blocker | 1 | 1 | | - | | | | |
| | | | | | | | | | | 31, 849, 858, 863, 869, 879, 882, 914, |
| 21, 926, 930 | 0, 935, 943, | 1110, 1111, 1117, 112 | 2, 1126, 112 | 9, 1130, | 1142, 1143, | 1157, 1158, 11 | 189, 1197, 12 | 209, 12 | 37, 1248, 1274, 12 | 277 |
| Cold and Co | ough Prepa | rations | | | | | | | | |
| 099pai | 5 y M | | | | U | Ingst | Oth-M | 2 | | |
| | | chlorpheniramine/ | 1 | 1 | | | | | | |
| 100 | 19 v F | hydrocodone | | | C | Ingst | Unt-T | 2. | | |
| 1100 | | | | | . | | UIII-1 | /. | | |

C

Ingst

2

Unt-T

(Continued)

19 y F

1100

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|-----------------------------|--------------------|---|-------------------|---------------|---------------|------------------|--------------|---------|------------------|---|
| | | acetaminophen/ dextromethorphan | 1 | 1 | | | | | | |
| 101pa | 21 y F | acetaminophen | 2 | 2 | A | Ingst | Int-A | 1 | | |
| 1 | J | dextromethorphan/ guaifenesin | 1 | 1 | | Ü | | | dextromethorphan | 1200 ng/mL In Serum @ Autopsy |
| 102 | 24 y M | ethanol | 2 | 2 | A | Ingst | Int-M | 2 | ethanol | 264 mcg/dL In Serum @ Autopsy |
| | | acetaminophen/ dextromethorphan | 1 | 1 | | | | | | |
| 103 | 25 y F | morphine | 2 | 2 | A | Ingst | Int-S | 2 | | |
| 104 | 78 y F | dextromethorphan chlorpheniramine/ | 1 | 1 | U | Ingst | Unk | 3 | | |
| See also case | 1, 2, 233, | hydrocodone 275, 281, 286, 389, 390 | | | 625, 667, 702 | 2, 710, 824, 882 | 2, 952, 955, | 958, 10 | 013, 1109 | |
| | | Ierbals/Homeopathic | | | | | | | • | |
| 1105 | 50 y M | dietary supplement | 1 | 1 | C | Ingst | AR-O | 3 | | |
| 1106 | 85 y M | laetrile | 1 | 1 | A | Ingst | AR-D | 2 | | |
| See also case | | le | | | | | | | | |
| Electrolytes 1107a | 5 y F | sodium chloride | 1 | 1 | U | Ingst | Unk | 3 | | |
| 1108a | 30 y M | selenium | 1 | 1 | A | Ingst+ Inhal | Unt-O | 2 | selenium | 11000 mcg/L In Blood (unspecified |
| | | citric acid | 2 | 2 | | | | | | @ Autopsy |
| 1109 | 39 y F | iron | 1 | 1 | A | Ingst | Int-S | 1 | iron | 13106 mcg/dL In Serum @ Un- |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | known acetaminophen 130 mcg/mL In Serum @ Unknown |
| | | chlorzoxazone | 3 | 3 | | | | | | berum e emmown |
| | | benzonatate | 4 | 4 | | | | | | |
| | | fluoxetine | 5 | 5 | | | | | | |
| | | ethanol | 6 | 6 | | | | | ethanol | 62 mg/dL In Serum @ Unknown |
| | | gabapentin omeprazole | 7 8 | 7 8 | | | | | | |
| | | tramadol | 9 | 9 | | | | | | |
| | | vitamin D | 10 | 10 | | | | | | |
| 110ai | 46 y F | vitaliiii B | 10 | 10 | A/C | Ingst | Int-S | 1 | | |
| | , | magnesium sulfate | 2 | 1 | | C | | | | |
| | | simvastatin | 3 | 2 | | | | | | |
| | | paliperidone | 1 | 3 | | | | | | |
| 111 | 74 y F | | 1 | 1 | C | Ingst | Int-S | 1 | | |
| | | potassium chloride carvedilol | 1 2 | 1 2 | | | | | | |
| | | risperidone | 3 | 3 | | | | | | |
| | | temazepam | 4 | 4 | | | | | | |
| | | lisinopril | 5 | 5 | | | | | | |
| | | bumetanide | 6 | 6 | | | | | | |
| | | clopidogrel | 7 | 7 | | | | | | |
| | | levothyroxine | 8 | 8 | | | | | | |
| \l | 201 760 | simvastatin hypochlorite 1033, 1126, 1168 | 9 10 | 9 10 | | | | | | |
| | | | | | | | | | | |
| Hormones a 1112ai | nd Hormo 24 y M | ne Antagonists | | | A | Par | Int-S | 1 | | |
| 1113 | 24 y F | insulin | 1 | 1 | U | Ingst | Int-S | 1 | | |
| 1114 | 27 y F | metformin | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | metformin | 1 | 1 | | | | | | |
| | | alprazolam benztropine | 2 3 | 2 3 | | | | | | |
| | | risperidone | 3 4 | 3 4 | | | | | | |
| | | ethanol | 5 | 5 | | | | | ethanol | 266 mg/dL In Blood (unspecified) @ Unknown |
| | | | | | A | Ingst+ Par | Int-S | 1 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--|-------------------|---------------|------------|------------|--------|-----|-------------|---|
| | | insulin glulisine quetiapine | 1 2 | 1 2 | | | | | | |
| 1116ph | 35 y F | insulin | 1 | 1 | U | Ingst | Unk | 1 | | |
| 1117a | 36 y M | metformin | 1 | 1 | A | Ingst | Int-S | 1 | metformin | 100 mcg/mL In Blood (unspecified) |
| | | lisinopril | 2 | 2 | | | | | | @ 1 h (pe) |
| 1118 | 39 y M | fluoxetine | 3 | 3 | A | Ingst | Int-S | 1 | | ((|
| 1119a | 45 y F | metformin | 1 | 1 | U | Par | Unk | 3 | metformin | 66 mcg/mL In Blood (unspecified) @ 24 h (pe) |
| 1119a 1120pha | 53 y M | insulin | 1 | 1 | A | Ingst | Int-S | 1 | | |
| 1120рна | 33 y IVI | metformin | 1 | 1 | A | nigst | IIIt-S | 1 | metformin | 150 mg/L In Blood (unspecified) @ Unknown |
| 1121 | 54 y M | metformin | 1 | 1 | C | Ingst | AR-D | 3 | | Chkhown |
| 1122 | 54 y M | metformin | 1 | 1 | A/C | Ingst | Int-S | 1 | | |
| | | metformin/ sitagliptin lisinopril | 2 | 2 | | | | | | |
| 1123 | 59 y M | glipizide | 4 | 4 | A/C | Ingst | Int-S | 1 | | |
| | , | metformin | 1 | 1 | | C | | | | |
| | | risperidone trazodone | 2 4 | 2 3 | | | | | | |
| | | citalopram | 3 | 4 | | | | | | |
| 1124p | 59 y F | • | | | A | Ingst+ Par | Int-S | 3 | | |
| | | insulin | 1 | 1 | | | | | | |
| | | drug, unknown zolpidem | 2 3 | 2 3 | | | | | | |
| 1125p | 62 y F | zoipideili | 3 | 3 | A | Par | Int-S | 2 | | |
| r | v= | insulin | 1 | 1 | | | | _ | | |
| | | drug, unknown | 2 | 2 | | | | | | |
| 1126 | 62 y F | | , | | U | Unk | Unk | 3 | | |
| | | metformin amlodipine | 6 1 | 1 2 | | | | | | |
| | | metoprolol | 2 | 3 | | | | | | |
| | | (extended release) | 2 | 3 | | | | | | |
| | | clonidine | 3 | 4 | | | | | | |
| | | insulin | 4 | 5 | | | | | | |
| | | salicylate | 5 | 6 | | | | | | |
| | | iron | 7 | 7 | | | | | | |
| | | gabapentin angiotensin- converting enzyme inhibitor | 8 9 | 8 | | | | | | |
| | | citalopram | 10 | 10 | | | | | | |
| | | metolazone furosemide | 11 12 | 11 12 | | | | | | |
| | | omeprazole | 13 | 13 | | | | | | |
| | | famotidine | 14 | 14 | | | | | | |
| | | lovastatin | 15 | 15 | | | | | | |
| | | albuterol/ | 16 | 16 | | | | | | |
| | | ipatropium fluticasone/ salmeterol | 17 | 17 | | | | | | |
| | | docusate | 18 | 18 | | | | | | |
| 1127a | 62 y F | metformin* | 2 | 1 | A | Ingst | Int-S | 2 | | |
| | | phenothiazine* | 1 | 1 | | | | | thiothixene | 819 ng/mL In Serum @ 7 h (pe) |
| 1128h | 63 y M | insulin | 1 | 1 | С | Par | Unt-T | 3 | | |
| 1129 | 75 y F | metformin | 1 | 1 | С | Ingst | AR-D | 2 | | |
| | | glipizide | 2 | 2 | | | | | | |
| | | atenolol | 3 | 3 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|----------------------|---------------|----------------------------------|-------------------|---------------|------------------------------------|-----------------|------------|---------|---------------------|---|
| 1130ha | 86 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | metformin | 1 | 1 | | | | | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 530 mg/L In Blood (unspecified) @ Autopsy |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 910 mg/kg In Gastric (stomach |
| | | amlodipine | 3 | 3 | | | | | | content) @ Autopsy |
| | | atenolol | 4 | 4 | | | | | | |
| | | hydrochlorothiazide/ | 5 | 5 | | | | | | |
| See also case | 379 649 | valsartan 709 718 722 751 762 | 790 895 9 | 35 969 | 971 974 98 | 3 987 1008 1 | 010 1011 | 1017 10 | 018 1022 1042 10 | 081, 1090, 1111, 1142, 1210 |
| Miscellaneou | | 705, 710, 722, 751, 702 | , 770, 075, 7 | 55, 767, | <i>></i> 71, <i>></i> 71, >0 | 5, 707, 1000, 1 | 010, 1011, | 1017, 1 | 910, 1022, 1012, 10 | 501, 1050, 1111, 1112, 1210 |
| viiscenameot 1131 | 32 y M | | | | A | Ingst | Int-S | 2 | | |
| | · | ropinirole | 2 | 1 | | | | | | |
| | | alprazolam hydroxychloroquine | 3 1 | 2 3 | | | | | | |
| | | duloxetine | 4 | 4 | | | | | | |
| | | zolpidem | 5 | 5 | | | | | | |
| | | gabapentin potassium chloride | 6 7 | 6 7 | | | | | | |
| | | lorazepam | 8 | 8 | | | | | | |
| 132 | 45 y M | | | | A | Ingst | Int-S | 1 | | |
| 1133 | 47 y F | dalfampridine | 1 | 1 | A | Par | AR-D | 3 | | |
| 1133 | ., , 1 | succinylcholine | 1 | 1 | 71 | | | 5 | | |
| 1134a | 57 y M | epinephrine | 1 | 1 | A | Par | Unt-T | 1 | | |
| See also case | 41, 533, 5 | 86, 617, 668, 692, 837, | - | | 026, 1058, 1 | 073, 1366 | | | | |
| Muscle Rela | xants | | | | | | | | | |
| 1135 | 19 y M | | | | A | Par | Oth-W | 1 | | |
| 1126- | 27 E | baclofen | 1 | 1 | A /C | In cot : I Inla | Int C | 1 | | |
| 1136a | 27 y F | carisoprodol | 1 | 1 | A/C | Ingst+ Unk | Int-S | 1 | meprobamate | 36 mcg/mL In Serum @ 2.5 h (pe) |
| | | carisoprodol | 1 | 1 | | | | | carisoprodol | 4.4 mcg/mL In Serum @ 2.5 h (pe) |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 24.5 mcg/mL In Blood (unspecified @ Unknown |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 43 mcg/mL In Blood (unspecified) |
| | | 1 | | | | _ | | | 1 | @ Unknown |
| 1137 | 33 y F | carisoprodol | 2 | 1 | A | Ingst | Int-S | 2 | | |
| | | acetaminophen | 1 | 2 | | | | | acetaminophen | 19.2 mcg/mL In Serum @ Unknown |
| 1138a | 33 y M | | | | A | Ingst | Int-S | 2 | | |
| | | carisoprodol acetaminophen/ | 1 2 | 1 2 | | | | | | |
| | | hydrocodone | 2 | - | | | | | | |
| | | methadone | 3 | 3 | | | | | | |
| 1139p | 35 y F | cocaine | 4 | 4 | A | Ingst | Int-S | 2 | | |
| . 10 УР | <i>55</i> y 1 | carisoprodol | 1 | 1 | • • | 111850 | III D | _ | | |
| | | zolpidem | 2 3 | 2 | | | | | | |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | | |
| 1140a | 36 y F | • | | | U | Ingst | Int-S | 1 | | |
| | | carisoprodol | 2 | 1 | | | | | carisoprodol | 10 mcg/mL In Blood (unspecified) @ Unknown |
| | | carisoprodol | 2 | 1 | | | | | meprobamate | 64 mcg/mL In Blood (unspecified) |
| | | | 2 | 2 | | | | | | @ Unknown |
| | | oxycodone acetaminophen | 3 1 | 2 | | | | | acetaminophen | 32.4 mcg/mL In Blood (unspecified |
| | | • | | | | | | | | @ Unknown |
| 1141pa | 37 y F | cocaine | 4 | 4 | U | Ingst | Int-U | 1 | | |
| 1141ра | 37 y 1 | carisoprodol | 1 | 1 | U | nigst | IIIt-U | 1 | meprobamate | 10 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Unknown |
| | | carisoprodol | 1 | 1 | | | | | carisoprodol | 5.7 mcg/mL In Blood (unspecified) @ Unknown |
| | | alprazolam | 2 | 2 | | | | | alprazolam | 51 ng/mL In Blood (unspecified) @ Unknown |
| | | ethanol | 3 | 3 | | | | | | |
| | | acetaminophen/ | 4 | 4 | | | | | acetaminophen | 6.6 mcg/mL In Blood (unspecified) |
| | | hydrocodone acetaminophen/ | 4 | 4 | | | | | hydrocodone | @ Unknown (free) 72 ng/mL In Blood (unspeci- |
| | | hydrocodone | • | • | | | | | , | fied) @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|---|-------------------|---------------|------------|-----------------|---------|-----|-----------------|---|
| 1142p | 37 y F | | | | A/C | Ingst | Int-S | 1 | | |
| 1 | • | cyclobenzaprine | 1 | 1 | | C | | | | |
| | | lamotrigine | 2 | 2 | | | | | | |
| | | clozapine | 3 | 3 | | | | | | |
| | | atenolol | 4 | 4 | | | | | | |
| | | carbamazepine | 5 | 5 | | | | | | |
| | | glibenclamide | 6 | 6 | | | | | | |
| | | clindamycin | 7 | 7 | | | | | | |
| 1143p | 38 y M | ominating om | , | , | U | Ingst | Int-S | 3 | | |
| 11.0p | 50) 1.1 | carisoprodol | 1 | 1 | C | 111,500 | 1111 5 | | | |
| | | clonazepam | 2 | 2 | | | | | | |
| | | promethazine | 3 | 3 | | | | | | |
| | | clonidine | 4 | 4 | | | | | | |
| 1144a | 39 y M | cioniune | 7 | 7 | A | Ingst | Int-S | 1 | | |
| 11114 | 37 y 111 | cyclobenzaprine | 2 | 1 | 11 | mgst | Int 5 | 1 | | |
| | | clonazepam | 1 | 3 | | | | | | |
| | | scopolamine | 4 | 4 | | | | | | |
| | | mirtazapine | 3 | 5 | | | | | | |
| 1145 | 41 y M | mintazapine | 3 | 3 | A | Inact | Int-S | 2 | | |
| 1143 | 41 y 1v1 | carisoprodol | 1 | 1 | Α | Ingst | 1111-5 | 2 | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | | 2 | 2 | | | | | | |
| 1116n | 43 y F | hydrocodone | | | A | Inact | Int C | 3 | | |
| 1146p | 43 y F | | 1 | 1 | A | Ingst | Int-S | 3 | | |
| 1147 | 42 14 | carisoprodol | 1 | 1 | A (C) | T | Total C | | | |
| 1147 | 43 y M | 1 10 | | | A/C | Ingst | Int-S | 1 | | |
| | | baclofen | 1 | 1 | | | | | | 214 / 1 1 9 9 11 1 |
| 1140 | 45 E | acetaminophen | 2 | 2 | | * | T . C | 2 | acetaminophen | 214 mcg/mL In Serum @ Unknown |
| 1148a | 45 y F | benzodiazepine* | 1 | 1 | A/C | Ingst | Int-S | 2 | clonazepam | 65 ng/mL In Blood (unspecified) @ |
| | | tizanidine* | 4 | 1 | | | | | | Unknown |
| | | | 4 5 | 2 | | | | | | |
| | | carisoprodol barbiturate* | 3 | 3 | | | | | phenobarbital | 0.54 mcg/mL In Blood (unspecified |
| | | metoclopramide* | 6 | 3 | | | | | | @ Unknown |
| | | | | | | | | | | |
| | | laxative | 7 | 4 | | | | | 1 . 11 % 1 | 22 / 1 1 21 1/ :6 1 |
| | | butalbital | 2 | 6 | | | | | butalbital | 3.3 mcg/mL In Blood (unspecified) |
| 1140 | 46 - F | | | | A /C | In cot : I Inla | Total C | 1 | | @ Unknown |
| 1149pa | 46 y F | cocaine* | 1 | 1 | A/C | Ingst+ Unk | Int-S | 1 | cocaine | O / I I C @ At |
| | | cocaine* | 1 | | | | | | | 0 mg/mL In Serum @ Autopsy |
| | | | 1 | 1 | | | | | benzoylecognine | 2.44 mg/mL In Serum @ Autopsy |
| | | skeletal muscle | 3 | 1 | | | | | | |
| | | relaxant* | 2 | 2 | | | | | | 16 /- I I- C @ A + |
| | | quetiapine | 2 | 2 | | | | | quetiapine | 16 ng/mL In Serum @ Autopsy |
| 1150 | 40 - | duloxetine | 4 | 4 | | | ** | | | |
| 1150 | 48 y F | | | | C | Ingst | Unt-G | 2 | | |
| | | carisoprodol | 1 | 1 | | | | | | |
| | | alprazolam | 2 | 2 | | | | | | |
| | | acetaminophen/ | 3 | 3 | | | | | | |
| | | hydrocodone | | | | | | | | |
| 1151p | 49 y F | | | | C | Ingst | Int-S | 1 | | |
| | | baclofen | 1 | 1 | | | | | | |
| | | tramadol | 2 | 2 | | | | | | |
| | | amitriptyline | 3 | 3 | | | | | | |
| 1152 | 56 y F | muscle relaxant, | 3 | 1 | U | Ingst | Int-U | 2 | | |
| | | unknown | | | | | | | | |
| | | paroxetine | 2 | 2 | | | | | | |
| | | alprazolam | 1 | 3 | | | | | | |
| 1153p | 59 y F | | | | A | Ingst | Int-S | 2 | | |
| | - | carisoprodol | 1 | 1 | | | | | | |
| | | tramadol | 2 | 2 | | | | | | |
| | | clonazepam | 3 | 3 | | | | | | |
| 1154 | 60 y F | | | | A | Ingst | Int-S | 2 | | |
| | • | carisoprodol | 1 | 1 | | _ | | | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 25 mcg/mL In Blood (unspecified) |
| | | - I I I I I I I I I I I I I I I I I I I | ~ | - | | | | | | @ Unknown |
| 1155a | 61 y F | | | | A | Ingst | Int-S | 3 | | _ C |
| | , - | baclofen | 1 | 1 | •• | | | - | | |
| 1156a | 63 y F | -30101011 | | | A/C | Ingst | Int-S | 1 | | |
| 11000 | 03 y 1 | tizanidine | 1 | 1 | 11/0 | 111501 | III-O | 1 | tizanidine | 440 ng/mL In Blood (unspecified) |
| | | ethanol | 2 | 2 | | | | | ethanol | @ Autopsy 0.184 g/dL In Blood (unspecified) @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--------------------|-------------------|---------------|------------|-------|--------|-----|---------------|----------------------------------|
| 1157 | 71 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | • | baclofen | 1 | 1 | | | | | | |
| | | diphenhydramine | 2 | 2 | | | | | | |
| | | nabumetone | 3 | 3 | | | | | | |
| | | lisinopril | 4 | 4 | | | | | | |
| | | citalopram | 5 | 5 | | | | | | |
| | | ibuprofen | 6 | 6 | | | | | | |
| 1158 | 82 y M | 1 | | | A/C | Ingst | Int-S | 1 | | |
| | - , | cyclobenzaprine | 1 | 1 | | 8 | | | | |
| | | amlodipine | 2 | 2 | | | | | | |
| | | methadone | 3 | 3 | | | | | | |
| | | pregabalin | 4 | 4 | | | | | | |
| | | acetaminophen/ | 5 | 5 | | | | | acetaminophen | 23 mcg/mL In Blood (unspecified) |
| | | hydrocodone | - | - | | | | | | @ Unknown |
| | | warfarin | 6 | 6 | | | | | | |
| | | hydroxychloroquine | 7 | 7 | | | | | | 20 500 510 564 506 500 601 607 |

See also case 3, 16, 41, 48, 300, 326, 338, 340, 347, 381, 386, 391, 396, 399, 400, 402, 406, 407, 426, 429, 433, 437, 454, 460, 480, 489, 508, 510, 564, 586, 599, 601, 607, 611, 618, 630, 642, 646, 649, 667, 668, 671, 677, 680, 681, 682, 699, 702, 722, 752, 753, 771, 777, 796, 802, 820, 836, 862, 873, 879, 896, 916, 933, 959, 973, 985, 1037, 1109, 1184, 1206, 1208, 1226, 1247, 1307

| 1109, 1184, | 1206, 1208 | , 1226, 1247, 1307 | | | | | | | | |
|----------------------|------------|-----------------------------|-----|---|----|--------------|--------|---|------------------|--|
| Sedative/Hy 1159a | | ntipsychotics | | | A | Inact | Unt-G | 1 | | |
| 1139a | 2 y F | haloperidol | 1 | 1 | Α | Ingst | UIII-G | 1 | | |
| 1160pai | 4 y F | .1.1 | 1 | 1 | U | Ingst+ Aspir | Unk | 2 | .1.1 | 0.65 L. Wh. 1. Dl 1 @ |
| | | chlorpromazine | 1 | 1 | | | | | chlorpromazine | 0.65 mcg/mL In Whole Blood @ Autopsy |
| | | chlorpromazine | 1 | 1 | | | | | chlorpromazine | 5.2 Other (see abst) In Liver @ Autopsy |
| 1161pa | 13 y F | | | | A | Ingst | Oth-M | 1 | | Tutopoj |
| • | | olanzapine* | 1 | 1 | | | | | olanzapine | 0.46 mg/L In Whole Blood @ Autopsy |
| | | zolpidem* | 5 | 1 | | | | | zolpidem | 58 ng/mL In Whole Blood @ Autopsy |
| | | lorazepam | 2 | 2 | | | | | | 1 3 |
| | | oxcabazepine* | 6 | 3 | | | | | | |
| | | quetiapine* | 3 | 3 | | | | | | |
| | | fluoxetine* | 7 | 4 | | | | | | |
| | | temazepam* | 4 | 4 | | | | | | |
| | | trazodone | 8 | 7 | | | | | trazodone | 3.3 mg/L In Whole Blood @ Autopsy |
| 1162p | 17 y M | | | | A | Par | Unk | 3 | | |
| | | fluphenazine | 1 | 1 | | | | | | |
| 1163 | 17 y M | | | | A | Ingst | Int-U | 1 | | |
| | | zolpidem | 1 | 1 | | | | | | |
| | | clonazepam | 2 | 2 | | | | | | |
| | | acetaminophen/ oxycodone | 3 | 3 | | | | | morphine | 1.77 mg/L In Blood (unspecified) @ Autopsy |
| 1164 | 18 y M | | | | A | Ingst | Int-S | 3 | | |
| | | clonazepam | 1 | 1 | | | | | | |
| | | acetaminophen/ oxycodone | 2 | 2 | | | | | | |
| 1165p | 19 y M | | | | U | Ingst | Int-S | 2 | | |
| _ | | quetiapine | 2 | 1 | | | | | | |
| | | paroxetine | 1 | 2 | | | | | | |
| | | ibuprofen | 3 | 3 | | | | | | |
| 1166p | 19 y M | • | | | A | Ingst | Int-S | 2 | | |
| 1 | • | clonazepam | 1 | 1 | | C | | | | |
| 1167ha | 21 y M | | | | A | Ingst | Int-S | 1 | | |
| | , | antipsychotic (atypical) | 1 | 1 | | 8 | | | quetiapine | 9900 ng/mL In Blood (unspecified) @ Autopsy |
| | | antidepressant (SSRI) | 2 | 2 | | | | | citralopram | 1600 ng/mL In Blood (unspecified) @ Autopsy |
| | | antipsychotic (atypical) | 3 | 3 | | | | | | |
| | | anticonvulsant | 4 | 4 | | | | | 10-hydroxycarba- | 63 mcg/mL In Blood (unspecified) |
| 11600 | 21 5 | | | | Α. | Inact | Int C | 2 | zepine | @ Autopsy |
| 1168a | 21 y F | | 1 | 1 | Α | Ingst | Int-S | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| | | ziprasidone | 2 3 | 2 | | | | | | |
| 1160 | 21 37 | iron | 3 | 3 | | T . | T . C | 3 | | |
| 1169p | 21 y M | | | | Α | Ingst | Int-S | | | |
| | 21 9 111 | lorazepam | 1 | 1 | | 111851 | IIIt-5 | 3 | | |

(Continued)

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-----------------------------|-------------------|---------------|------------|------------|--------|-----|--------------------|---|
| 1170pa | 23 y M | | | | A | Ingst | Int-S | 1 | | |
| ттори | 23 y 111 | quetiapine | 1 | 1 | 7.1 | ngst | int 5 | • | quetiapine | 19.73 mg/L In Serum @ Autopsy |
| | | temazepam | 2 | 2 | | | | | temazepam | 84 ng/mL In Blood (unspecified) @ |
| | | | | | | | | | | Autopsy |
| | | ethanol ethanol | 3 | 4 4 | | | | | ethanol ethanol | 10 mg/dL In Vitreous @ Autopsy 30 mg/dL In Whole Blood @ |
| | | ethanoi | 3 | 4 | | | | | ethanoi | Autopsy |
| 1171hai | 24 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | chlorpromazine | 1 | 1 | | | | | | |
| 1172pa | 25 y M | 1 . 1 | 4 | | U | Ingst | Int-S | 2 | | |
| | | zolpidem ketorolac | 4 5 | 1 2 | | | | | | |
| | | acetaminophen | 3 | 3 | | | | | acetaminophen | 116.9 mg/L In Urine (quantitative |
| | | • | | | | | | | • | only) @ Autopsy |
| | | acetaminophen | 3 | 3 | | | | | acetaminophen | 39 mcg/mL In Blood (unspecified) |
| | | aaataminanhan | 3 | 3 | | | | | aaataminanhan | @ Unknown 59 mg/L In Blood (unspecified) @ |
| | | acetaminophen | 3 | 3 | | | | | acetaminophen | Autopsy |
| | | oxycodone | 2 | 4 | | | | | oxycodone | 0.41 mg/L In Blood (unspecified) @ |
| | | | | | | | | | | Autopsy |
| | | oxycodone | 2 | 4 | | | | | oxycodone | 0.9 mg/L In Urine (quantitative |
| | | oxymorphone | 1 | 5 | | | | | | only) @ Autopsy |
| 1173pa | 25 y F | oxymorphone | 1 | 5 | A | Ingst | Int-S | 3 | | |
| Î | | alprazolam | 1 | 1 | | | | | alprazolam | 47 ng/mL In Blood (unspecified) @ |
| | | 1 | 2 | 2 | | | | | | Autopsy |
| 1174 | 26 y F | analgesic, unknown | 2 | 2 | A | Ingst | Int-S | 2 | | |
| 11/4 | 20 y 1 | quetiapine | 3 | 1 | 71 | IIIgst | III-5 | _ | | |
| | | lorazepam | 2 | 2 | | | | | | |
| | | lamotrigine | 1 | 3 | | | | | | |
| | | zolpidem | 4 5 | 4 | | | | | | |
| 1175pa | 26 y M | naproxen | 3 | 5 | U | Ingst+ Unk | Int-A | 2 | | |
| 1170ри | 20) 1.1 | alprazolam* | 1 | 1 | Ü | ingst. Oim | ***** | _ | alprazolam | 10 ng/mL In Blood (unspecified) @ |
| | | | | | | | | | _ | Unknown |
| 1176 | 27 - F | drug, unknown* | 2 | 1 | A /C | Toront | Int C | 2 | | |
| 1176 | 27 y F | quetiapine | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| 1177p | 27 y F | 4F | | | A | Ingst | Int-S | 2 | | |
| | | clonazepam | 1 | 1 | | | | | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 102 mg/dL In Blood (unspecified) @ Unknown |
| 1178 | 28 y M | | | | U | Ingst | Int-S | 2 | | @ Ulkilowii |
| |) | olanzapine | 2 | 1 | - | 8 | | _ | | |
| | | carbamazepine | 3 | 2 | | | | | carbamazepine | 12 mcg/mL In Serum @ 1 h (pe) |
| | | ethanol | 1 | 3 | | | | | | |
| 1179p | 29 y M | buspirone | 4 | 4 | A | Ingst | Int-U | 2 | | |
| 1177р | 2) j 111 | alprazolam | 1 | 1 | 7.1 | ngst | int o | - | | |
| 1180 | 30 y F | • | | | A | Par | AR-D | 2 | | |
| 1101 | 20. 14 | haloperidol | 1 | 1 | | T . | T . C | 1 | | |
| 1181a | 30 y M | quetiapine | 1 | 1 | A | Ingst | Int-S | 1 | quetiapine | 3200 ng/mL In Blood (unspecified) |
| | | quettapffie | 1 | 1 | | | | | quettapine | @ Autopsy |
| | | citalopram* | 2 | 2 | | | | | citalopram | 650 ng/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| | | ethanol* | 3 | 2 | | | | | ethanol | 134 mg/dL In Blood (unspecified) @ Autopsy |
| | | ethanol* | 3 | 2 | | | | | ethanol | 171 mg/dL In Blood (unspecified) |
| | | Culturor | 3 | - | | | | | Cinarior | @ Unknown |
| | | cocaine | 4 | 3 | | | | | benzoylecognine | 146.65 ng/mL In Blood (unspeci- |
| | | morinese | 5 | 4 | | | | | | fied) @ Autopsy |
| 1182p | 30 y F | marijuana | 5 | 4 | U | Ingst | Int-S | 2 | | |
| P | 20 1 1 | alprazolam | 3 | 1 | J | 800 | 0 | - | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | hydrocodone | 4 | 2 | | | | | | |
| | | acetaminophen/ oxycodone | 1 | 3 | | | | | | |
| | | OXYCOUOTIC | | | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|------------------------------|-------------------|---------------|------------|------------|---------|-----|------------------|---|
| 1183p | 31 y M | | | | A/C | Ingst | Unk | 2 | | |
| | - 3 | diazepam | 1 | 1 | | 8 | | | | |
| | | lorazepam | 2 | 2 | | | | | | |
| | | acetaminophen/ | 3 | 3 | | | | | | |
| | | hydrocodone | | | | | | | | |
| | | citalopram | 4 | 4 | | | | | | |
| 184p | 31 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| | | clonazepam | 2 | 2 | | | | | | |
| | | acetaminophen/ | 3 | 3 | | | | | | |
| | | codeine | | | | | | | | |
| | | cyclobenzaprine | 4 | 4 | | | | | | |
| | | temazepam | 5 | 5 | | | | | | |
| l 185pha | 33 y M | | | | A | Ingst | Int-S | 1 | | |
| | | clonazepam | 1 | 1 | | | | | benzoylecognine | 251 mcg/L In Serum @ Autopsy |
| | | clonazepam | 1 | 1 | | | | | clonazepam | 30 mcg/L In Serum @ Autopsy |
| | | clonazepam | 1 | 1 | | | | | 7-aminoclonaze- | 39 mcg/L In Serum @ Autopsy |
| | | | | | | _ | | _ | pam | |
| 186p | 33 y M | | | | A | Ingst | Int-S | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| | | barbiturates | 2 | 2 | | | | | | |
| | | (extended release) | | 2 | | | | | | |
| | | benzodiazepine | 3 | 3 | | | | | | |
| | | laxative (stimulant) | 4 | 4 | | | | | | |
| 105 | 24 34 | trazodone | 5 | 5 | | | | | | |
| 1187p | 34 y M | | | | A/C | Ingst | Int-M | 2 | | |
| | | alprazolam | 1 | 1 | | | | | | |
| 1100 | 24 34 | ethanol | 2 | 2 | | | | | | |
| 1188 | 34 y M | | | | A/C | Ingst | Int-U | 1 | | |
| 100 | 25 15 | chloral hydrate | 1 | 1 | | T . | T . C | 2 | | |
| 1189a | 35 y M | | | | A | Ingst | Int-S | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| | | amlodipine | 2 | 2 | | | | | | |
| 1100 | 25 5 | ethanol | 3 | 3 | * * | T . | ** . ** | 2 | | |
| 1190 | 35 y F | | | | U | Ingst | Unt-U | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| | | escitalopram | 2 | 2 | | | | | | |
| 1101 | 25 5 | gabapentin | 3 | 3 | * * | T . | T . C | 2 | | |
| 1191p | 35 y F | | | | U | Ingst | Int-S | 2 | | |
| 1100 | 25 5 | quetiapine | 1 | 1 | | T . | T . TT | 1 | | |
| 1192pa | 35 y F | 1 | 2 | | A/C | Ingst | Int-U | 1 | | |
| | | lorazepam | 3 | 1 | | | | | | |
| | | antidepressant, unknown* | 2 | 2 | | | | | | |
| | | | 4 | 2 | | | | | | |
| | | zolpidem* clonazepam | 4 5 | 2 3 | | | | | | |
| | | | 1 | 4 | | | | | | |
| | | oxycodone (extended release) | 1 | 4 | | | | | | |
| 193 | 36 y F | release) | | | A | Inact | Int-S | 2 | | |
| 1193 | 30 y F | quetiapine | 1 | 1 | А | Ingst | 1111-3 | 2 | | |
| | | acetaminophen/ | 1 2 | 2 | | | | | | |
| | | hydrocodone | 2 | 4 | | | | | | |
| 1194p | 36 y F | nyarocouolic | | | A | Ingst | Int-S | 3 | | |
| тэтр | 30 y 1 | diazepam | 1 | 1 | А | nigot | 1111-3 | 5 | ethanol | 12 mg/dL In Serum @ 10 m (pe) |
| | | diazepam | 1 | 1 | | | | | salicylate | 9 mg/dL In Serum @ 10 m (pe) |
| 1195pa | 37 y F | шагераш | 1 | 1 | A | Ingst | Int-S | 1 | sancyrate | / mg/all in Scium @ 10 m (pe) |
| 1195pa | эт у г | diazepam | 1 | 1 | Α | mgst | 1111-3 | 1 | diazepam | 289 ng/mL In Blood (unspecified |
| | | шагераш | 1 | 1 | | | | | шагераш | @ Unknown |
| | | diazepam | 1 | 1 | | | | | nordiazepam | 450 ng/mL In Blood (unspecified |
| | | шалерані | 1 | 1 | | | | | потигалерані | @ Unknown |
| | | fluoxetine | 2 | 2 | | | | | fluoxetine | 2.3 mg/L In Serum @ Autopsy |
| | | paroxetine | 3 | 3 | | | | | | 0.25 mg/L In Serum @ Autopsy |
| | | | 3 4 | 3 4 | | | | | paroxetine | 0.23 mg/L m Serum @ Autopsy |
| 1106n | 27 v E | diphenhydramine | 4 | 4 | A | Unk | Int C | 2 | | |
| 1196р | 37 y F | rieneridona | 1 | 1 | A | Unk | Int-S | 2 | | |
| | | risperidone | 1 | 1 | | | | | | |
| | | citalopram | 2 | 2 | | | | | | |
| 1107. | 20 - | trazodone | 3 | 3 | A | Tenne | L. C | 1 | | |
| 1197pa | 38 y F | 4: | 1 | 1 | A | Ingst | Int-S | 1 | 4: | 1400 Other (1) * * * * * * |
| | | diazepam | 1 | 1 | | | | | diazepam | 1488 Other (see abst) In Liver @ |
| | | | | | | | | | | Autopsy |
| | | 4 | ~ | ^ | | | | | | 277 04 / 1 0 7 7 7 |
| | | codeine | 2 | 2 | | | | | morphine | 277 Other (see abst) In Liver @ |
| | | codeine | 2 | 2 | | | | | morphine codeine | 277 Other (see abst) In Liver @ Autopsy 918 Other (see abst) In Liver @ |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|--------------|--------|-----|--------------------------|---|
| | | methadone | 3 | 3 | | | | | methadone | 605 Other (see abst) In Liver @ Autopsy |
| | | propoxyphene | 4 | 4 | | | | | norpropoxyphene | 1679 Other (see abst) In Liver @ |
| | | hydrocodone | 5 | 5 | | | | | hydrocodone | Autopsy 25.5 Other (see abst) In Liver @ Autopsy |
| | | laxative (stimulant) | 6 | 6 | | | | | | Tutopoy |
| | | lisinopril ethanol | 7 8 | 7 8 | | | | | ethanol | 0.6 Other (see abst) In Liver @ Autopsy |
| 1198p | 39 y M | | | | A | Ingst | Int-A | 2 | | Autopsy |
| | | diazepam acetaminophen/ | 1 2 | 1 2 | | | | | acetaminophen | 39.5 mcg/mL In Blood (unspecified |
| 1199 | 39 y F | oxycodone | | | U | Unk | Int-S | 2 | | @ Unknown |
| ,, | 57) 1 | lorazepam | 1 | 1 | Ü | · · · · · · | 1111 5 | _ | | |
| | | ziprasidone | 3 | 2 | | | | | | |
| | | hydroxyzine | 4 | 3 | | | | | | |
| 1200 | 40 y F | venlafaxine | 2 | 4 | A | Inget | Int-S | 1 | | |
| 1200 | 40 y 1 | quetiapine | 1 | 1 | Α | Ingst | 1111-5 | 1 | | |
| | | zolpidem | 2 | 2 | | | | | | |
| | | acetaminophen/ | 3 | 3 | | | | | | |
| 1201 | 40.35 | hydrocodone | | | | | * | • | | |
| 1201p | 40 y M | quetiapine | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 162 mcg/mL In Blood (unspecified) |
| | | ······································ | | | | | | | ····· | @ Unknown |
| 1202p | 40 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | alprazolam | 1 | 1 | | | | | | |
| | | lorazepam zolpidem | 2 3 | 2 | | | | | | |
| 1203p | 42 y M | zoipidem | 3 | 3 | A | Ingst | Unk | 3 | | |
| | , | quetiapine | 1 | 1 | | U | | | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 110 mg/dL In Blood (unspecified) |
| 1204 | 42 y F | | | | A | Inget | Int-S | 2 | | @ Unknown |
| 1204 | 42 y 1 | clonazepam | 1 | 1 | Α | Ingst | 1111-5 | 2 | | |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | | |
| 1205a | 42 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | quetiapine | 1 | 1 | | | | | quetiapine | 8400 ng/mL In Blood (unspecified) @ Unknown |
| | | citalopram alprazolam | 2 | 2 | | | | | citalopram alprazolam | 12 ng/mL In Blood (unspecified) @ Unknown 31 ng/mL In Blood (unspecified) @ |
| | | aiprazoiaiii | 3 | 3 | | | | | aiprazoiaiii | Unknown |
| 1206a | 43 y F | | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | quetiapine diazepam | 1 5 | 1 2 | | | | | | |
| | | carisoprodol | 2 | 3 | | | | | | |
| | | metaxalone | 3 | 4 | | | | | | |
| | | citalopram | 6 | 5 | | | | | | |
| 1207 | 42 M | pregabalin | 4 | 6 | A /C | T T. 1 . 1 | II C | 2 | | |
| 1207 | 43 y M | quetiapine (extended release) | 1 | 1 | A/C | Ingst+ Inhal | Unt-G | 2 | | |
| | | fluoxetine | 2 | 2 | | | | | | |
| | | marijuana | 3 | 3 | | | | | | |
| 1208p | 44 y F | | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| | | quetiapine cyclobenzaprine | 1 2 | 1 2 | | | | | | |
| | | diazepam | 3 | 3 | | | | | | |
| | | acetaminophen/ | 4 | 4 | | | | | | |
| 1200 | | hydrocodone | | | ~ | | ¥ . ~ | _ | | |
| 1209 | 44 y F | quationing | 2 | 1 | A/C | Ingst | Int-S | 3 | | |
| | | quetiapine promethazine | 3 4 | 1 2 | | | | | | |
| | | citalopram | 5 | 3 | | | | | | |
| | | lotensin | 6 | 4 | | | | | | |
| | | clonazepam | 2 | 5 | | | | | | 210 |
| | | ethanol | 1 | 6 | | | | | ethanol | 210 mg/dL In Blood (unspecified) @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|----------------------|-------------------|---------------|------------|--------|---------|-----|-----------------|------------------------------------|
| 1210 | 45 y F | | | | A/C | Ingst | Int-S | 3 | | |
| | • | phenobarbital | 1 | 1 | | C | | | | |
| | | diazepam | 2 | 2 | | | | | | |
| | | topiramate | 3 | 3 | | | | | | |
| | | gabapentin | 4 | 4 | | | | | | |
| | | temazepam | 5 | 5 | | | | | | |
| | | clonazepam | 6 | 6 | | | | | | |
| | | naproxen | 7 | 7 | | | | | | |
| | | montelukast | 8 | 8 | | | | | | |
| | | | | | | | | | | |
| | | spironolactone | 9 | 9 | | | | | | |
| | | progestins | 10 | 10 | | | | | | |
| 1211a | 45 y F | | | | A | Ingst | Int-U | 1 | | |
| | | alprazolam | 1 | 1 | | | | | | |
| | | zolpidem | 2 | 2 | | | | | | |
| | | methamphetamine | 3 | 3 | | | | | methamphetamine | 0.13 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Autopsy |
| 1212a | 46 y F | | | | A/C | Ingst | Int-S | 3 | | |
| | | clonazepam | 1 | 1 | | | | | | |
| | | trazodone | 2 | 2 | | | | | | |
| 1213pa | 46 y M | | | | A/C | Ingst | Int-S | 3 | | |
| | • | alprazolam | 1 | 1 | | C | | | | |
| | | risperidone | 2 | 2 | | | | | | |
| | | lithium | 3 | 3 | | | | | | |
| | | antifreeze (ethylene | 4 | 4 | | | | | | |
| | | glycol) | • | | | | | | | |
| 1214p | 46 y F | 81,001) | | | A | Ingst | Int-A | 3 | | |
| 121-гр | 40 y 1 | benzodiazepine | 1 | 1 | 7 1 | mgst | 1111-71 | 3 | | |
| | | ethanol | 2 | 2 | | | | | | |
| 1215a | 16 v E | emanoi | 2 | 2 | A/C | Inact | Int-S | 1 | | |
| 1213a | 46 y F | | 2 | | A/C | Ingst | 1111-3 | 1 | | |
| | | quetiapine | 2 | 1 | | | | | | |
| | | paroxetine | 3 | 2 | | | | | | |
| | | gabapentin | 4 | 3 | | | | | | |
| | | amitriptyline | 1 | 4 | | _ | | | | |
| 1216p | 46 y F | | | | A | Ingst | Int-S | 1 | | |
| | | phenobarbital | 1 | 1 | | | | | phenobarbital | 48 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Unknown |
| | | phenobarbital | 1 | 1 | | | | | phenobarbital | 52.2 mcg/mL In Blood (unspecified) |
| | | | | | | | | | | @ Unknown |
| | | ethanol | 2 | 2 | | | | | ethanol | 317 mg/dL In Blood (unspecified) |
| | | | | | | | | | | @ Unknown |
| 1217p | 46 y M | | | | A | Ingst | Unt-G | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| 1218a | 46 y M | | | | A/C | Ingst | Int-S | 2 | | |
| | | alprazolam | 1 | 1 | | | | | | |
| | | cocaine | 2 | 2 | | | | | | |
| | | ethanol | 3 | 3 | | | | | | |
| 1219a | 47 y M | | | | U | Ingst | Int-S | 2 | | |
| | • | flurazepam | 1 | 1 | | C | | | | |
| | | trazodone | 2 | 2 | | | | | trazodone | 3.9 mcg/mL In Serum @ 2 h (pe) |
| | | mirtazapine | 3 | 3 | | | | | | g g (f) |
| | | chloral hydrate | 4 | 4 | | | | | | |
| | | buspirone | 5 | 5 | | | | | | |
| | | gabapentin | 6 | 6 | | | | | | |
| | | zolpidem | 7 | 7 | | | | | | |
| | | | 8 | | | | | | | |
| 1220 | 47 - E | venlafaxine | 0 | 8 | | Toront | Int C | 2 | | |
| 1220p | 47 y F | 1 41 1 | | | Α | Ingst | Int-S | 2 | | |
| | | phenothiazine | 1 | 1 | | | | | | |
| | | acetaminophen | 2 | 2 | | | | | | |
| | | ibuprofen | 3 | 3 | | | | | | |
| | | hydroxyzine | 4 | 4 | | | | | | |
| 1221p | 48 y F | | | | A | Ingst | Int-S | 2 | | |
| | | quetiapine | 1 | 1 | | | | | | |
| | | alprazolam | 2 | 2 | | | | | | |
| | | cocaine | 3 | 3 | | | | | | |
| | | ethanol | 4 | 4 | | | | | ethanol | 0.095% (wt/Vol) In Serum @ 15 |
| | | | | | | | | | | m (pe) |
| | | opioid | 5 | 5 | | | | | | |
| | | benzodiazepine | 6 | 6 | | | | | | |
| 1222 | 48 y M | | | | A | Ingst | Oth-C | 3 | | |
| | - | quetiapine | 1 | 1 | | _ | | | quetiapine | 14000 ng/mL In Serum @ Unknown |
| | | A A . | | | | | | | | |
| | | quetiapine | 1 | 1 | | | | | quetiapine | 32000 ng/mL In Whole Blood @ |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|------------|-------------------------------|-------------------|---------------|------------|--------------|--------|-----|------------------|---|
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | acetaminophen | 15.4 mg/mL In Blood (unspecified) @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 297 ng/mL In Serum @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 925 ng/mL In Blood (unspecified) @ Autopsy |
| 223a | 48 y M | , | | | A | Ingst | Int-S | 2 | | 2 company |
| | | quetiapine | 1 | 1 | | | | | | |
| | | temazepam | 2 | 2 | | | | | | |
| | | lorazepam alprazolam | 3 4 | 3 4 | | | | | | |
| 224p | 48 y M | aipiazoiaiii | 4 | 4 | A/C | Ingst | Int-M | 1 | | |
| ·r | | clonazepam | 1 | 1 | | 8 | | _ | | |
| | | ethanol | 2 | 2 | | | | | | |
| 225a | 49 y M | aripiprazole | 1 | 1 | A/C | Ingst | Int-U | 1 | aripiprazole | 730 ng/mL In Blood (unspecified) @ Autopsy |
| | | bupropion (extended release) | 2 | 2 | | | | | bupropion | 0.91 mcg/mL In Blood (unspecified @ Autopsy |
| | | bupropion (extended release) | 2 | 2 | | | | | hydroxybupropion | 3.9 mcg/mL In Blood (unspecified) @ Autopsy |
| | | cocaine | 3 | 3 | | | | | benzoylecognine | 0 Other (see abst) In Blood (unspecified) @ Autopsy |
| 226p | 49 y F | .1 | 4 | | A | Ingst | Int-A | 3 | | |
| | | alprazolam carisoprodol | 1 2 | 1 2 | | | | | | |
| | | tramadol | 3 | 3 | | | | | | |
| | | cocaine | 4 | 4 | | | | | | |
| | | marijuana | 5 | 5 | | | | | | |
| | | opioid | 6 | 6 | | | | | | 2.4 |
| | | acetaminophen | 7 8 | 7 8 | | | | | acetaminophen | 3.4 mcg/mL In Serum @ Unknown |
| 227p | 50 y M | salicylate | o | o | С | Ingst | Int-S | 2 | salicylate | 4.6 mg/dL In Serum @ Unknown |
| . K. | 5 | risperidone | 1 | 1 | - | 6 | | _ | | |
| 228p | 50 y F | | | | A/C | Ingst | Int-S | 2 | | |
| | | risperidone | 1 | 1 | | | | | | |
| | | quetiapine ethanol | 2 3 | 2 3 | | | | | | |
| 229p | 51 y F | Calulion | 5 | J | A | Ingst | Int-S | 2 | | |
| | <i>y</i> - | quetiapine | 1 | 1 | | | | | | |
| | | ethanol | 2 | 2 | | | | _ | | |
| 230 | 51 y M | auation: | 1 | 1 | A | Ingst | Int-S | 2 | | |
| | | quetiapine alprazolam | 1 2 | 1 2 | | | | | | |
| 231 | 51 y F | шртаготані | 4 | 4 | A | Ingst | Int-S | 2 | | |
| | -) - | clozapine | 1 | 1 | ·- | 8 | | - | | |
| | | carbon black | 2 | 2 | | | | | | |
| 232pa | 51 y M | lorazepam | 1 | 1 | A/C | Ingst | Int-S | 1 | lorazepam | 0.06 mg/L In Blood (unspecified) @ Unknown |
| | | oxycodone (extended release) | 2 | 2 | | | | | oxymorphone | 0.33 mg/L In Blood (unspecified) @ Unknown |
| | | oxycodone (extended release) | 2 | 2 | | | | | oxycodone | 0.7 mg/L In Blood (unspecified) @ Unknown |
| | | antihistamine* | 3 | 3 | | | | | diphenhydramine | 0.03 mg/L In Blood (unspecified) @ Unknown |
| 233a | 51 ·· E | clonazepam* | 4 | 3 | A/C | Ingst+ Aspir | Int II | 2 | clonazepam | 0.03 mg/L In Blood (unspecified) © Unknown |
| 233a | 51 y F | aripiprazole | 1 | 1 | A/C | mgst+ Aspir | Int-U | 2 | | |
| | | ibuprofen | 2 | 2 | | | | | | |
| | | methadone | 3 | 3 | | | | | | |
| 234 | 52 y F | quetiapine (extended release) | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| 235p | 52 y F | marijuana | 2 | 2 | A | Ingst | Int-S | 1 | | |
| K | , - | zolpidem | 1 | 1 | | 6 | | - | | |
| | | olanzapine | 2 | 2 | | | | | olanzapine | 0.18 mg/L In Blood (unspecified) @ Autopsy |
| | | oxcabazepine | 3 | 3 | | | | | | |
| | | fluoxetine sertraline | 4 5 | 4 5 | | | | | | |
| | | clonazepam | 6 | 6 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|-------------------------------|-------------------|---------------|------------|-------|---------------------|-----|-----------------------|---|
| | | trazodone | 7 | 7 | | | | | trazodone | 0.25 mg/L In Blood (unspecified) @ Autopsy |
| | | morphine | 8 | 8 | | | | | morphine | 0.13 mg/L In Blood (unspecified) @ Autopsy |
| | | temazepam | 9 | 9 | | | | | temazepam | 0.08 mg/L In Blood (unspecified) @ Autopsy |
| 1007 | 5.4 D | lorazepam | 10 | 10 | | | X . G | | lorazepam | 0.01 mg/L In Blood (unspecified) @ Autopsy |
| 1236a | 54 y F | olanzapine | 1 | 1 | U | Ingst | Int-S | 1 | olanzapine | 1.2 mcg/mL In Whole Blood @ Autopsy |
| | | fluoxetine | 2 | 2 | | | | | norfluoxetine | 0.25 mcg/mL In Whole Blood @ Autopsy |
| | | fluoxetine | 2 | 2 | | | | | fluoxetine | 0.35 mcg/mL In Whole Blood @ Autopsy |
| 1237a | 55 y F | lorazepam | 1 | 1 | A/C | Ingst | Int-S | 3 | benzodiazepines | 100 ng/mL In Urine (quantitative only) @ Unknown |
| | | lorazepam | 1 | 1 | | | | | lorazepam | 500 ng/mL In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | acetaminophen | 370 mcg/mL In Urine (quantitative only) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | propoxyphene | 50 ng/mL In Urine (quantitative only) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | acetaminophen | 51.1 mcg/mL In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone (free) | 61 ng/mL In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | acetaminophen | 72.3 mcg/mL In Blood (unspecified) @ Unknown |
| | | simvastatin ethanol | 3 4 | 3 4 | | | | | ethanol | 12% In Blood (unspecified) @ |
| | | ethanol | 4 | 4 | | | | | ethanol | Unknown 32 mg/dL In Urine (quantitative only) @ Unknown |
| 1238p | 56 y M | diazepam | 1 | 1 | A/C | Ingst | Int-S | 2 | | omy) c ommown |
| | | opioid | 2 | 2 | | | | | | |
| 1239pa | 56 y F | chlorpromazine* | 1 | 1 | A/C | Ingst | Int-S | 2 | chlorpromazine | 18 mcg/mL In Serum @ Autopsy |
| | | clonazepam* | 2 | 1 | | | | | propoxyphene | 0.18 mcg/mL In Serum @ Autopsy |
| 1240pai | 56 y F | propoxyphene | 3 | 3 | U | Ingst | Int-A | 2 | | |
| 1 | , | butalbital | 1 | 1 | | 8 | | | butalbital | 22.7 mcg/mL In Whole Blood @ Autopsy |
| 1241pha | 57 y M | quetiapine | 1 | 1 | A/C | Ingst | Int-S | 1 | quetiapine | 33800 ng/mL In Whole Blood @ |
| 1242pai | 59 y M | alamanalam | 1 | 1 | A | Ingst | Int-S | 2 | .11 | Autopsy |
| | | alprazolam | 1 | 1 | | | | | alprazolam | 2.2 mcg/mL In Whole Blood @ Autopsy |
| 1010 | 60 F | alprazolam | 1 | 1 | ** | | * | | alprazolam | 7.9 Other (see abst) In Liver @ Autopsy |
| 1243 | 60 y F | quetiapine | 1 | 1 | U | Ingst | Int-S | 3 | | |
| | | clonazepam | 2 | 2 | | | | | | |
| 1244a | 60 y F | quetiapine (extended release) | 1 | 1 | U | Ingst | Int-S | 2 | | |
| 1245 | 61 y F | clonazepam | 1 | 1 | A | Ingst | Int-S | 2 | | |
| 1246p | 63 y F | • | | | A | Ingst | Int-S | 2 | | |
| 1247 | 64 y F | quetiapine | 1 | 1 | A | Ingst | Int-A | 3 | | |
| | - | alprazolam | 1 | 1 | | - | | | | |
| | | oxycodone skeletal muscle | 2 3 | 2 | | | | | | |
| 1240- | 71 5 | relaxant | | | A IC | Innet | Let C | 1 | | |
| 1248a | 71 y F | zolpidem | 1 | 1 | A/C | Ingst | Int-S | 1 | zolpidem | 1800 ng/mL In Plasma @ Unknown |
| | | metoprolol | 2 | 2 | | | | | • | - |
| | | diltiazem (extended release) | 3 | 3 | | | | | diltiazem | 160 ng/mL In Plasma @ Unknown |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|--------------------|-------------------|---------------|------------|---------------|-----------|-----|-----------------|--|
| 1249 | 72 y F | | | | A/C | Ingst | Int-S | 3 | | |
| | | alprazolam | 1 | 1 | | | | | | |
| 1250 | 77 y M | | | | U | Ingst | Int-S | 3 | | |
| | | temazepam | 2 | 1 | | | | | | |
| | | hydroxyzine | 3 | 2 3 | | | | | | |
| | | escitalopram | 1 | 3 | | | | | | |
| 1251 | 78 y M | | | | A/C | Ingst | Unk | 3 | | |
| | | lorazepam | 1 | 1 | | | | | | |
| 1252 | 79 y F | _ | | | A/C | Ingst | Int-S | 2 | | |
| | | alprazolam | 1 | 1 | | | | | | |
| | | hypochlorite | 2 | 2 | | | | | | |
| 1253a | 83 y F | * * | | | A | Ingst | Int-S | 2 | | |
| | , | phenobarbital | 1 | 1 | | Ü | | | | |
| 1254 | 85 y F | 1 | | | A/C | Ingst+ Aspir | Int-S | 2 | | |
| | - | temazepam | 1 | 1 | | | | | | |
| | | activated charcoal | 2 | 2 | | | | | | |
| 1255 | 86 y M | | | | A | Ingst | Int-S | 3 | | |
| | 3 | chlordiazepoxide | 1 | 1 | | 8 | | | | |
| | | acetaminophen | 2 | 2 | | | | | acetaminophen | 134 mcg/mL In Blood (unspecified) @ 30 h (pe) |
| 1256a | Unknow | n age M | | | U | Ingst | Unk | 2 | | 4 1 |
| | | phenobarbital | 1 | 1 | | 8 | | | phenobarbital | 180 mcg/mL In Blood (unspecified) @ Autopsy |
| 1257pa | Unknow | n age U | | | U | Unk | Unk | 3 | | |
| | | alprazolam* | 1 | 1 | | | | | | |
| | | methylphenidate* | 2 | 1 | | | | | | |
| 1258pi | Unknow | | _ | _ | A/C | Ingst+ Derm | Unt-T | 2 | | |
| F- | | diazepam | 1 | 1 | | S = | | _ | | |
| | | oxazepam | 2 | 2 | | | | | | |
| | | temazepam | 3 | 3 | | | | | | |
| | | fentanyl | 4 | 4 | | | | | | |
| | | hydrocodone | 5 | 5 | | | | | | |
| See also case | 1 5 7 8 | • | | | 6 252 265 | 266 270 275 2 | 91 288 20 | 202 | 203 204 207 200 | 0, 303, 305, 313, 314, 317, 325, 326, |

523, 526, 542, 543, 549, 550, 554, 559, 564, 566, 572, 574, 576, 577, 578, 586, 591, 593, 594, 595, 597, 598, 600, 606, 609, 612, 614, 617, 620, 622, 626, 628, 635, 641, 642, 649, 658, 659, 664, 665, 667, 669, 671, 674, 677, 679, 680, 682, 683, 684, 688, 689, 692, 696, 698, 700, 701, 703, 705, 709, 710, 711, 716, 717, 718, 719, 725, 728, 730, 739, 741, 743, 748, 752, 753, 758, 772, 779, 781, 791, 796, 801, 803, 805, 811, 812, 813, 815, 816, 817, 819, 820, 821, 825, 832, 834, 836, 837, 840, 841, 844, 845, 846, 849, 852, 936, 953, 964, 980, 981, 985, 988, 990, 992, 994, 995, 996, 998, 1001, 1002, 1006, 1012, 1017, 1019, 1020, 1031, 1036, 1037, 1042, 1045, 1053, 1057, 1058, 1059, 1060,1061, 1073, 1079, 1081, 1084, 1090, 1110, 1111, 1114, 1115, 1123, 1124, 1127, 1131, 1139, 1141, 1142, 1143, 1144, 1148, 1149, 1150, 1152, 1153, 1261, 1266, 1268, 1273, 1261, 1262, 1263, 12641277, 1282, 1286, 1287, 1296, 1297, 1299, 1301, 1307, 1309, 1313, 1322, 1323, 1334, 1338, 1342, 1347

| 12//, 1202, | 1200, 1207 | , 1290, 1297, 1299, 1301, | 1307, 130 | 9, 1313, 13 | 022, 1323 | , 1334, 1336, 132 | +2, 1347 | | | |
|----------------------|----------------------|--|-----------|-------------|-----------|-------------------|----------|---|------------|--------------------------------|
| Serums, Tox 1259a | oids, Vacc 37 y M | ines | | | A | B-S | Unt-B | 1 | | |
| | | antivenin, Latrodectus | 1 | 1 | | | | | | |
| | | Latrodectus mactans bite | 2 | 2 | | | | | | |
| Stimulants a | and Street | Drugs | | | | | | | | |
| 1260pa | 16 y F | | | | U | Ingst+ Par | Int-A | 1 | | |
| | | methamphetamine | 1 | 1 | | | | | | |
| | | oxycodone | 2 | 2 | | | | | | |
| 1261 | 17 y M | • | | | A | Ingst+ Inhal | Int-S | 2 | | |
| | | marijuana | 2 | 1 | | | | | | |
| | | salicylate | 1 | 2 | | | | | salicylate | 46.6 mg/dL In Serum @ 4 h (pe) |
| | | salicylate | 1 | 2 2 | | | | | salicylate | 62 mg/dL In Serum @ Unknown |
| | | quetiapine | 3 | 3 | | | | | · | |
| 1262h | 18 y M | 1 1 | | | U | Ingst | Int-A | 2 | | |
| | | methylene- dioxymethamphet- amine (MDMA) | 1 | 1 | | | | | | |
| 1263 | 18 y M | | | | A | Ingst | Int-A | 1 | | |
| | | methylene- dioxymethamphet- amine (MDMA) | 1 | 1 | | | | | | |
| 1264 | 18 y M | | | | A | Ingst | Int-A | 1 | | |
| | | methylene- dioxymethamphet- amine (MDMA) | 1 | 1 | | - | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|--------------------------------|-------------------|---------------|------------|----------------------|---------|-----|--------------------------------|--|
| 1265pa | 19 y M | | | | U | Unk | Int-A | 1 | | |
| 1205pu | 17 9 111 | heroin | 1 | 1 | C | Ciik | 1110 21 | 1 | morphine | 0.087 mg/L In Serum @ Autopsy |
| | | heroin | 1 | 1 | | | | | codeine | 0.1 mg/L In Urine (quantitative |
| | | heroin | 1 | 1 | | | | | morphine | only) @ Autopsy 2 mg/L In Urine (quantitative only) |
| | | nerom | • | • | | | | | | @ Autopsy |
| 1266pai | 19 y F | • | 2 | | U | Ingst+ Inhal | Int-A | 2 | 1 | 0.26 |
| | | cocaine acetaminophen/ | 2 1 | 1 2 | | | | | benzoylecognine hydrocodone | 0.36 mcg/mL In Serum @ Unknown 0.06 mcg/mL In Serum @ Unknown |
| | | hydrocodone | • | _ | | | | | nyaroeodone | oloo megama m perum e emmow. |
| | | alprazolam | 3 | 3 | | | | | | |
| 1267p | 20 y F | lorazepam | 4 | 4 | U | Ingst+ Unk | Int-U | 2 | | |
| | | heroin | 1 | 1 | | 8 | | | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | hydrocodone pregabalin | 3 | 3 | | | | | | |
| 1268ha | 20 y M | | | | A | Par | Int-A | 2 | | |
| | | heroin | 1 2 | 1 2 | | | | | morphine | 0.08 mg/L In Serum @ Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxycodone | 0.14 mg/L In Blood (unspecified) @ Autopsy |
| | | lorazepam | 3 | 3 | | | | | lorazepam | 35 ng/mL In Blood (unspecified) @ |
| 1269p | 20 y M | | | | A | Par | Int-A | 1 | | Autopsy |
| 1209р | 20 y W | heroin | 1 | 1 | Α | rai | IIIt-A | 1 | | |
| 1270 | 20 y F | | | | A | Ingst+ Oth | Int-S | 2 | | |
| | | heroin bupropion | 1 2 | 1 2 | | | | | | |
| | | escitalopram | 3 | 3 | | | | | | |
| 1271h | 20 y M | Î | | | U | Ingst | Int-U | 2 | | |
| 1272pa | 20 y F | methamphetamine | 1 | 1 | A | Ingst+ Unk | Int-A | 1 | | |
| 12/2pa | 20 y 1 | heroin | 1 | 1 | А | nigst+ Olik | IIIt-A | 1 | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 0.097 g/dL In Blood (unspecified) |
| 1273 | 21 y F | | | | U | Ingst+ Par | Int-U | 2 | | @ 1 h (pe) |
| 12/0 | 21) 1 | heroin | 1 | 1 | C | ingst: 1 til | | _ | | |
| 1274 | 22 M | benzodiazepine | 2 | 2 | A | Toronto Torbalo | Total A | 1 | | |
| 1274 | 22 y M | | | | A | Ingst+ Inhal+ Par | IIIt-A | 1 | | |
| | | methamphetamine | 1 | 1 | | | | | | |
| 1275a | 22 y M | metoprolol | 2 | 2 | A | Ingst | Int-A | 1 | | |
| 12/34 | 22 y 141 | methylene- | 1 | 1 | 71 | nigst | 1111-71 | 1 | | |
| | | dioxymethamphet- | | | | | | | | |
| 1276 | 22 y M | amine (MDMA) | | | A | Ingst | Int-A | 1 | | |
| 1270 | 22) 111 | methylene- | 1 | 1 | 71 | mgst | 1111 71 | 1 | | |
| | | dioxymethamphet- | | | | | | | | |
| | | amine (MDMA) ethanol | 2 | 2 | | | | | | |
| 1277p | 23 y M | | | | A/C | Ingst+ Par | Int-A | 1 | | |
| | | heroin clonidine | 1 2 | 1 2 | | | | | | |
| | | clonazepam | 3 | 3 | | | | | | |
| 1278p | 23 y M | • | | | A/C | Par | Int-U | 1 | | |
| 1270n | 22 v.M | heroin | 1 | 1 | A/C | Unk | Int-A | 1 | | |
| 1279p | 23 y M | heroin | 1 | 1 | A/C | Olik | IIIt-A | 1 | | |
| 1280a | 23 y F | | | | U | Ingst | Int-A | 1 | | |
| | | methylene- dioxymethamphet- | 1 | 1 | | | | | mdma (3,4- methylene- | 0.22 mg/L In Blood (unspecified) @ Unknown |
| | | amine (MDMA) | | | | | | | dioxymethamphet- | CHKHUWH |
| 1201 | 24 - | . , | | | | * | ¥ . ¥* | | amine) | |
| 1281a | 24 y F | cocaine | 1 | 1 | A | Ingst | Int-U | 1 | benzoylecognine | 1.1 mg/L In Whole Blood @ |
| | | Cocume | 1 | 1 | | | | | conzo, recognine | Unknown |
| 1282ai | 24 y M | | | | A | Ingst | Int-A | 2 | | |
| | | methamphetamine morphine | 1 2 | 1 2 | | | | | morphine (free) | 0.04 mcg/mL In Whole Blood @ |
| | | · r | _ | _ | | | | | 1 (-100) | Autopsy |
| | | acetaminophen/ | 3 | 3 | | | | | | rutopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|---------|---|-------------------|---------------|------------|------------|--------|-----|---------------------------|--|
| | | diazepam | 4 | 4 | | | | | | |
| 1283 | 25 y M | alprazolam | 5 | 5 | A | Ingst | Int-A | 2 | | |
| | | methylene- dioxymethamphet- amine (MDMA) | 1 | 1 | | 8 | | | | |
| 1284pa | 25 y M | methamphetamine | 1 | 1 | U | Unk | Int-U | 3 | methamphetamine | 323 ng/mL In Blood (unspecified) @ Unknown |
| | | methamphetamine | 1 | 1 | | | | | amphetamine | 96 ng/mL In Blood (unspecified) @ Unknown |
| | | oxycodone | 2 | 2 | | | | | oxycodone | 40.3 ng/mL In Blood (unspecified) @ Unknown |
| | | oxycodone | 2 | 2 | | | | | oxymorphone | 558 ng/mL In Blood (unspecified) @ Unknown |
| 1285pi | 25 y F | | | | U | Par+ Unk | Int-U | 2 | | |
| | | heroin oxycodone (extended | 1 2 | 1 2 | | | | | | |
| | | release) | 2 | 2 | | | | | | |
| | | buprenorphine/nalox- one (sublingual) | 3 | 3 | | | | | | |
| 1286р | 25 y M | methylene- | 1 | 1 | A | Ingst | Unk | 2 | | |
| | | dioxymethamphet- amine (MDMA) | 1 | 1 | | | | | | |
| 1207 | 26 M | clonazepam | 2 | 2 | A | Toront | Tot A | 1 | | |
| 1287pa | 26 y M | heroin | 1 | 1 | A | Ingst | Int-A | 1 | morphine | 10000 ng/mL In Urine (quantitative only) @ Autopsy |
| | | heroin | 1 | 1 | | | | | 6-monoacetylmor- phine | 3.9 ng/mL In Blood (unspecified) @ Autopsy |
| | | heroin | 1 | 1 | | | | | morphine (total) | 35.5 ng/mL In Blood (unspecified) @ Autopsy |
| | | heroin | 1 | 1 | | | | | codeine | 641 ng/mL In Urine (quantitative only) @ Autopsy |
| | | heroin | 1 | 1 | | | | | 6-monoacetylmor- phine | 854 ng/mL In Urine (quantitative only) @ Autopsy |
| | | alprazolam* | 2 | 3 | | | | | alprazolam | 31.1 ng/mL In Blood (unspecified) @ Autopsy |
| | | alprazolam* | 2 | 3 | | | | | alprazolam | 315 ng/mL In Urine (quantitative only) @ Autopsy |
| | | alprazolam* | 2 | 3 | | | | | alpha-oh-alpra- zolam | 757 ng/mL In Urine (quantitative only) @ Autopsy |
| 1288pai | 26 y M | THC homolog* | 3 | 3 | U | Ingst+ Unk | Int-A | 1 | | |
| 1200pui | 20 y W | heroin | 1 | 1 | C | mgst onk | III7 X | 1 | morphine (free) | 0.06 mcg/mL In Whole Blood @ Autopsy |
| | | oxycodone | 2 | 2 | | | | | oxycodone | 0.5 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol codeine | 3 4 | 3 4 | | | | | | |
| 1289p | 27 y F | codellie | 4 | + | A/C | Par | Int-A | 1 | | |
| | | heroin | 1 | 1 | | | | | | |
| 1290 | 27 y M | drug, unknown | 1 | 1 | A | Ingst | Int-M | 2 | | |
| 1291a | 27 y F | cocaine | 1 | 1 | A | Inhal | Int-A | 1 | cocaine | 0.09 mg/L In Blood (unspecified) @ |
| | | cocaine | 1 | 1 | | | | | benzoylecognine | Autopsy 2.7 mg/L In Blood (unspecified) @ |
| 1292pai | 27 y M | | | | U | Unk | Int-U | 2 | | Autopsy |
| 1292pai | 27 y WI | methamphetamine | 1 | 1 | O | Olik | IIIt-O | 2 | methamphetamine | 0.41 mcg/mL In Whole Blood @ 1.5 h (pe) |
| | | morphine | 2 | 2 | | | | | morphine (free) | 0.15 mcg/mL In Whole Blood @ 1.5 h (pe) |
| | | citalopram | 3 | 3 | | | | | citalopram | 0.33 mcg/mL In Whole Blood @ 1.5 h (pe) |
| 1293p | 28 y F | methylene- dioxymethamphet- | 1 | 1 | A | Ingst | Int-A | 1 | | |
| | | amine (MDMA) lysergic acid diethyl- amide (LSD) | 2 | 2 | | | | | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|--|-------------------|---------------|------------|----------------------|--------|-----|--|--|
| 1294pai | 28 y F | methamphetamine | 1 | 1 | U | Ingst+ Unk | Int-A | 3 | methamphetamine | _ |
| | | tramadol | 2 | 2 | | | | | tramadol | Autopsy 1.3 mcg/mL In Whole Blood @ |
| 1295pa | 29 y M | | | | U | Ingst+ Inhal+ Par | Int-A | 1 | | Autopsy |
| | | cocaine | 1 | 1 | | 1 di | | | benzoylecognine | 1000 ng/mL In Blood (unspecified) @ Unknown |
| | | methamphetamine | 2 | 2 | | | | | methamphetamine | 780 ng/mL In Blood (unspecified) @ Unknown |
| | | opioid | 3 | 3 | | | | | oxycodone (free) | 160 ng/mL In Blood (unspecified) @ Unknown |
| | | hydrocodone | 4 | 4 | | | | | hydrocodone (free) | 48 ng/mL In Whole Blood @ Unknown |
| | | amphetamine | 5 | 5 | | | | | amphetamine | 21 ng/mL In Blood (unspecified) @ Unknown |
| | | methylene- dioxymethamphet- amine (MDMA) | 6 | 6 | | | | | mdma (3,4- methylene- dioxymethamphet- amine) | 200 ng/mL In Blood (unspecified) @ Unknown |
| | | methylene- dioxymethamphet- amine (MDMA) | 7 | 7 | | | | | | |
| 1296pha | 29 y M | heroin | 1 | 1 | U | Par | Int-A | 1 | morphine | 153 mcg/L In Vitreous @ Autopsy |
| | | heroin | 1 | 1 | | | | | 6-monoacetylmor- phine | 19 mcg/L In Serum @ Autopsy |
| | | heroin heroin | 1 1 | 1 1 | | | | | morphine 6-monoacetylmor- | 342 mcg/L In Serum @ Autopsy 52 mcg/L In Vitreous @ Autopsy |
| | | clonazepam | 2 | 2 | | | | | phine 7-aminoclonaze- | 22 mcg/mL In Serum @ Autopsy |
| | | clonazepam | 2 | 2 | | | | | pam clonazepam | 6.5 mcg/mL In Serum @ Autopsy |
| | | pregabalin | 3 | 3 | | | | | codeine | 28 mcg/L In Vitreous @ Autopsy |
| 1297pha | 29 y M | pregabalin | 3 | 3 | A | Ingst | Int-U | 2 | midazolam | 67 mcg/L In Serum @ Autopsy |
| | | cocaine | 1 | 1 | | | | | benzoylecognine | 0.523 mg/L In Blood (unspecified) @ Unknown |
| | | methadone | 2 | 2 | | | | | methadone | 0.04 mg/L In Blood (unspecified) @ Unknown |
| | | benzodiazepine | 3 | 3 | | | | | alpha-oh-alpra- zolam | 291 ng/mL In Urine (quantitative only) @ Unknown |
| 1298 | 29 y M | and the second of the second | 1 | | U | Ingst | Unk | 1 | | |
| | | methamphetamine chemical, unknown | 1 2 | 1 2 | | | | | | |
| 1299p | 29 y F | , | | | С | Ingst+ Inhal+ Par | Int-A | 2 | | |
| | | heroin | 1 | 1 | | | | | | |
| | | cocaine benzodiazepine | 2 3 | 2 3 | | | | | | |
| 1300pai | 29 y M | heroin | 1 | 1 | U | Ingst | Int-A | 2 | morphine (free) | 0.09 mcg/mL In Whole Blood @ |
| | | ethanol | 2 | 2 | | | | | ethanol | Autopsy 0.18% (wt/Vol) In Serum @ |
| 1301pa | 30 y F | | | | A/C | Ingst | Int-A | 1 | | Unknown |
| 1501pa | 30 y 1 | methylphenidate | 1 | 1 | A/C | nigst | IIIt-A | 1 | | |
| | | diazepam | 2 | 2 | | | | | diazepam | 88 ng/mL In Blood (unspecified) @ 1 h (pe) |
| 1302 | 31 y M | | 4 | | U | Unk | Unk | 1 | | |
| | | cocaine amphetamine/dextro- amphetamine | 1 2 | 1 2 | | | | | | |
| 1202 | 21 5 | opioid | 3 | 3 | | Torres | T A | 4 | | |
| 1303a | 31 y F | methylene- | 1 | 1 | A | Ingst | Int-A | 1 | | |
| | | dioxymethamphet- amine (MDMA) | | | | | | | | |
| 1304pai | 31 y M | methamphetamine | 1 | 1 | U | Unk | Int-A | 2 | methamphetamine | 2.6 mcg/mL In Whole Blood @ Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|------------------|-------------------------------|-------------------|---------------|------------|--------------|---------|-----|-----------------|--|
| 1305p | 32 y M | | | | A | Ingst | Int-M | 1 | | |
| 1306a | 22 v M | methamphetamine | 1 | 1 | A | Inget | Unk | 3 | | |
| 1300a | 32 y M | methamphetamine | 1 | 1 | А | Ingst | Ulik | 3 | | |
| 1307 | 33 y M | amphetamine | 1 | 1 | A | Ingst | Unt-G | 2 | | |
| | | carisoprodol | 2 | 2 | | | | | | |
| | | temazepam | 3 | 3 | | | | | | |
| | | heroin | 4 | 4 | | | | | | |
| 1308 | 34 y M | benzodiazepine | 5 | 5 | U | Unk | Unk | 2 | | |
| 1300 | 5+ y 1 v1 | cocaine | 1 | 1 | C | Olik | Olik | 2 | | |
| 1309pai | 35 y F | methamphetamine | 1 | 1 | A | Ingst+ Unk | Int-A | 2 | amphetamine | 0.07 mcg/mL In Whole Blood @ |
| | | methamphetamine | 1 | 1 | | | | | methamphetamine | Autopsy 0.21 mcg/mL In Whole Blood @ |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | Autopsy 0.11 mcg/mL In Whole Blood @ Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.07% (wt/Vol) In Whole Blood @ Autopsy |
| | | ethanol | 3 | 3 | | | | | ethanol | 0.1% (wt/Vol) In Vitreous @ Autopsy |
| | | diazepam | 4 | 4 | | | | | | |
| 1310ai | 36 y M | trazodone | 5 | 5 | U | Ingst+ Unk | Int-A | 2 | | |
| 1310ai | 30 y W | methamphetamine | 1 | 1 | U | nigst+ Onk | IIIt-A | 2 | methamphetamine | 0.19 mcg/mL In Serum @ 2 d (pe) |
| | | ethanol | 2 | 2 | | | | | | 2 |
| 1311p | 36 y M | | 1 | | A | Ingst+ Inhal | Int-A | 2 | | |
| | | cocaine ethanol | 1 2 | 1 2 | | | | | | |
| 1312 | 38 y M | Culturor | - | - | A | Ingst | Unt-M | 1 | | |
| 1212 | 20 11 | cocaine | 1 | 1 | | | * | | | |
| 1313pa | 38 y M | cocaine | 1 | 1 | A/C | Ingst+ Inhal | Int-S | 1 | benzoylecognine | 1643 ng/mL In Blood (unspecified) @ Unknown |
| | | tramadol | 2 | 2 | | | | | tramadol | 1.1 mg/L In Blood (unspecified) @ Unknown |
| | | acetaminophen/ hydrocodone | 3 | 3 | | | | | hydrocodone | 29 ng/mL In Blood (unspecified) @ Unknown |
| | | diazepam | 4 | 4 | | | | | diazepam | 0.23 mg/L In Blood (unspecified) @ Unknown |
| | | diazepam | 4 | 4 | | | | | nordiazepam | 0.28 mg/L In Blood (unspecified) @ Unknown |
| | | ethanol morphine | 5 6 | 5 6 | | | | | morphine (free) | 95 ng/mL In Blood (unspecified) @ Unknown |
| 1314ph | 39 y M | | | | A | Unk | Int-A | 1 | | Challewii |
| 1015 : | 20 F | methamphetamine | 1 | 1 | | ** 1 | T . A | 2 | | |
| 1315pai | 39 y F | methamphetamine | 1 | 1 | Α | Unk | Int-A | 2 | methamphetamine | 2.1 mcg/mL In Whole Blood @ Unknown |
| 1216 | 40 E | diphenhydramine | 2 | 2 | *** | To core TT-1 | Total A | 2 | | C.I.I.I.O.W.I. |
| 1316pai | 40 y F | methamphetamine | 1 | 1 | U | Ingst+ Unk | Int-A | 2 | methamphetamine | 0.14 mcg/mL In Whole Blood @ Autopsy |
| | | methadone | 2 | 2 | | | | | methadone | 0.38 mcg/mL In Whole Blood @ Autopsy |
| | | tramadol | 3 | 3 | | | | | tramadol | 1.2 mcg/mL In Whole Blood @ Autopsy |
| 1317pa | 41 y F | heroin | 1 | 1 | U | Ingst+ Par | Unk | 2 | morphine | 0.64 mg/L In Blood (unspecified) @ Autopsy |
| | | sertraline tramadol | 2 3 | 2 3 | | | | | tramadol | 0.14 mg/L In Blood (unspecified) @ Autopsy |
| | | diphenhydramine | 4 | 4 | | | | | diphenhydramine | O.17 mg/L In Blood (unspecified) @ Autopsy |
| 1318pai | 41 y F | methamphetamine | 1 | 1 | A | Unk | Int-A | 2 | methamphetamine | 0.61 mcg/mL In Whole Blood @ |
| | 42 y M | | | | U | Ingst | Int-S | 3 | | Autopsy |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|--------|-------------------------------|-------------------|---------------|------------|-------------|--------|-----|--------------------|--|
| 1320pai | 42 y M | | | | U | Ingst | Int-A | 3 | | |
| 1321 | 43 y M | methamphetamine | 1 | 1 | A | Ingst | Int-A | 2 | | |
| 1322ai | 12 M | methamphetamine | 1 | 1 | U | Inact | Int A | 2 | | |
| 132241 | 43 y M | methamphetamine | 1 | 1 | U | Ingst | Int-A | 2 | methamphetamine | 0.1 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.05 mcg/mL In Whole Blood @ Autopsy |
| | | diazepam | 3 4 | 3 4 | | | | | | |
| 1323pai | 43 y M | quetiapine | 4 | 4 | U | Unk | Int-A | 2 | | |
| | | methamphetamine | 1 | 1 | | | | | methamphetamine | 0.1 mcg/mL In Whole Blood @ Autopsy |
| | | hydrocodone | 2 | 2 | | | | | hydrocodone | 0.05 mcg/mL In Whole Blood @ Autopsy |
| | | diazepam | 3 | 3 | | | | | | |
| 1324ai | 44 y M | quetiapine | 4 | 4 | С | Unk | Int-A | 3 | | |
| | • | amphetamine | 1 | 1 | | | | | | |
| 1325pa | 44 y F | cocaine | 1 | 1 | A/C | Par | Int-A | 1 | benzoylecognine | 830 ng/mL In Blood (unspecified) @ Autopsy |
| 1326pai | 45 y F | | | | U | Unk | Int-A | 2 | | @ Autopsy |
| | | cocaine | 1 | 1 | | | | | cocaine | 0.21 mcg/mL In Whole Blood @ Autopsy |
| 1327pa | 46 y F | cocaine | 1 | 1 | A | Inhal | Int-A | 2 | cocaine | 0.07 mg/L In Blood (unspecified) |
| | | cocaine | 1 | 1 | | | | | cocaethylene | Autopsy 0.1 mg/L In Blood (unspecified) @ |
| | | cocaine | 1 | 1 | | | | | benzoylecognine | Autopsy 1.18 mg/L In Blood (unspecified) @ |
| 1328p | 46 y F | | | | U | Inhal | Int-A | 3 | | Autopsy |
| 1220-: | 47 - M | cocaine | 1 | 1 | ** | I Inda | T4 A | 2 | | |
| 1329ai | 47 y M | methamphetamine | 1 | 1 | U | Unk | Int-A | 2 | amphetamine | 0.07 mcg/mL In Whole Blood @ Autopsy |
| | | methamphetamine | 1 | 1 | | | | | methamphetamine | 0.4 mcg/mL In Whole Blood @ Autopsy |
| 1330ph | 48 y M | heroin | 1 | 1 | A/C | Par | Int-A | 1 | | Tutopoj |
| 1331pai | 48 y F | nerom | 1 | 1 | A | Unk | Int-A | 3 | | |
| | | cocaine | 1 | 1 | | | | | benzoylecognine | 0.07 mcg/mL In Blood (unspecified @ Unknown |
| 1332pai | 50 y F | benzylpiperazine | 1 | 1 | U | Inhal+ Derm | Int-A | 2 | n-benzylpiperazine | 0.64 mcg/mL In Whole Blood @ |
| | | benzylpiperazine | 1 | 1 | | | | | n-benzylpiperazine | Autopsy 1.7 Other (see abst) In Liver @ |
| 1333pai | 50 y M | | | | U | Ingst+ Unk | Int-A | 2 | | Autopsy |
| 1 | , | methamphetamine | 1 | 1 | | Ü | | | methamphetamine | 0.15 mcg/mL In Whole Blood @ Autopsy |
| 1334pai | 50 v M | trazodone | 2 | 2 | U | Unk | Int-A | 2 | | 1 7 |
| 1554pai | 50 y M | methamphetamine | 1 | 1 | U | Olik | IIIt-A | 2 | methamphetamine | 0.12 mcg/mL In Whole Blood @ Autopsy |
| | | morphine | 2 | 2 | | | | | morphine (free) | 0.1 mcg/mL In Whole Blood @ Autopsy |
| | | oxycodone | 3 | 4 | | | | | | 1 - |
| | | alprazolam diazepam | 4 5 | 5 6 | | | | | | |
| 1335pai | 50 y F | шахераш | 3 | U | U | Unk | Int-A | 2 | | |
| = | - | n-benzylpiperazine (BZP) | 1 | 1 | | | | | | |
| 1336ai | 51 y F | , , | _ | | U | Unk | Int-A | 2 | 4 | 177 / 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 |
| | | methamphetamine | 1 | 1 | | | | | methamphetamine | 1.7 mcg/mL In Whole Blood @ Autopsy |
| 1337pai | 51 y F | methamphetamine | 1 | 1 | U | Unk | Int-A | 2 | methamphetamine | 0.17 mcg/mL In Whole Blood @ |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|----------|-------------------------------|-------------------|---------------|------------|--------------|---------|-----|--|---|
| 1338a | 56 y F | | | | A/C | Unk | Int-A | 2 | | |
| 15504 | 30 y 1 | cocaine | 1 | 1 | 2.00 | Cinc | 1111 71 | - | | |
| | | acetaminophen/ | 2 | 2 | | | | | | |
| | | hydrocodone | 2 | | | | | | | |
| | | alprazolam | 3 | 3 | | | | | | |
| | | oxybutynin | 4 | 4 | | | | | | |
| | | ethanol | 5 | 5 | | | | | ethanol | 46 mg/dL In Serum @ Unknown |
| 1339pai | 57 y M | | | | U | Unk | Int-A | 2 | | |
| | | methamphetamine | 1 | 1 | | | | | methamphetamine | 0.33 mcg/mL In Whole Blood @ Autopsy |
| 1340p | 58 y M | | | | U | Ingst | Int-S | 3 | | * * |
| - | | cocaine | 1 | 1 | | | | | | |
| | | ethanol | 2 | 2 | | | | | ethanol | 87 mg/dL In Serum @ Unknown |
| | | laxative (stimulant) | 3 | 3 | | | | | | 8 |
| 1341 | 60 y M | | | | A/C | Unk | Int-U | 2 | | |
| | 3 | cocaine | 1 | 1 | | | | | | |
| | | drug, unknown | 2 | 2 | | | | | | |
| 1342pai | 66 y M | arag, ammown | _ | _ | A | Ingst+ Unk | Int-A | 2 | | |
| 15 12pui | 00 y 141 | methamphetamine | 1 | 1 | 71 | ingse i Olik | III 11 | - | methamphetamine | 0.22 mcg/mL In Whole Blood @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.19 mcg/mL In Vitreous @ Autopsy |
| | | acetaminophen/ hydrocodone | 2 | 2 | | | | | hydrocodone | 0.34 mcg/mL In Whole Blood @ Autopsy |
| | | oxymorphone | 3 | 3 | | | | | oxymorphone | 188 ng/mL In Vitreous @ Autopsy |
| | | | 4 | 4 | | | | | oxymorphone | 100 lig/lilL lil viticous @ Autopsy |
| | | diazepam | 5 | 5 | | | | | | |
| | | mirtazapine | 6 | 6 | | | | | | |
| 1242 | TT1 | trazodone | 0 | 0 | *** | TT1 | T. A | 2 | | |
| 1343pa | Unknow | heroin | 1 | 1 | U | Unk | Int-A | 2 | morphine | 10000 ng/mL In Urine (quantitativ |
| | | | | | | | | | | only) @ Autopsy |
| | | heroin | 1 | 1 | | | | | eddp (2-eth- ylidene-1,5-dime- thyl-3,3-diphenyl pyrrolidine) | 25 ng/mL In Blood (unspecified) (Autopsy |
| | | heroin | 1 | 1 | | | | | morphine | 32 ng/mL In Blood (unspecified) (Autopsy |
| | | heroin | 1 | 1 | | | | | codeine | 556 ng/mL In Urine (quantitative only) @ Autopsy |
| | | heroin | 1 | 1 | | | | | methadone | 5920 ng/mL In Urine (quantitative only) @ Autopsy |
| | | heroin | 1 | 1 | | | | | 6-monoacetylmor- phine | 617 ng/mL In Urine (quantitative only) @ Autopsy |
| | | heroin | 1 | 1 | | | | | methadone | 91 ng/mL In Blood (unspecified) (Autopsy |
| | | methadone | 2 | 2 | | | | | | 1 - 3 |
| | | morphine | 3 | 3 | | | | | | |
| | | codeine | 4 | 4 | | | | | | |

See also case 2, 3, 5, 17, 243, 270, 274, 281, 286, 293, 294, 301, 303, 313, 318, 325, 350, 358, 363, 364, 376, 407, 413, 421, 427, 502, 503, 533, 535, 561, 574, 607, 625, 630, 648, 666, 677, 714, 728, 734, 809, 816, 841, 850, 855, 862, 879, 905, 919, 947, 965, 989, 1016, 1039, 1058, 1138, 1140, 1149, 1181, 1207, 1211, 1218, 1221, 1225, 1226, 1234, 1257, 1351, 1358

| Unknown I | | | | | | _ | | | | |
|-----------|--------|----------------|---|---|---|-------|-------|---|--------------------------------------|---|
| 1344a | 3 y F | | | | A | Ingst | Unt-G | 2 | | |
| | | drug, unknown | 1 | 1 | | | | | | |
| 1345pha | 21 y F | | | | A | Unk | Int-U | 3 | | |
| _ | | drug, unknown | 1 | 1 | | | | | hydrocodone | 0.11 mcg/mL In Serum @ 41 m (pe) |
| | | drug, unknown | 1 | 1 | | | | | dihydrocodeine/ hydrocodol (free) | 0.22 mcg/mL In Urine (quantitative only) @ 1 h (pe) |
| | | drug, unknown | 1 | 1 | | | | | hydrocodone | 1.8 mcg/mL In Urine (quantitative only) @ 48 m (pe) |
| | | drug, unknown | 1 | 1 | | | | | fentanyl | 39 ng/mL In Urine (quantitative only) @ 48 m (pe) |
| | | ethanol | 2 | 2 | | | | | ethanol | 22 mg/dL In Urine (quantitative only) @ 41 m (pe) |
| | | ethanol | 2 | 2 | | | | | ethanol | 30 mg/dL In Serum @ 41 m (pe) |
| 1346pa | 21 y M | | | | A | Ingst | Int-A | 1 | | 2 |
| | , | drug, unknown | 1 | 1 | | 8 | | | | |
| | | ethanol | 2 | 2 | | | | | | |
| 1347pa | 22 y M | ctilatioi | _ | - | A | Unk | Unk | 2 | | |
| _ | | drug, unknown | 1 | 1 | | | | | | |
| | | benzodiazepine | 2 | 2 | | | | | | |
| | | anticonvulsant | 3 | 3 | | | | | | |
| | | ethanol | 4 | 4 | | | | | | |
| | | | | | | | | | | (Continued) |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|------------|---|---------------------|----------------|--------------|-----------------|------------|----------|--------------------------------|--|
| 1348pai | 24 y M | drug, unknown | 1 | 1 | U | Unk | Unk | 1 | oxymorphone | 0.05 mcg/mL In Serum @ Autopsy |
| | | drug, unknown | 1 | 1 | | | | | (total) alprazolam | 0.094 mcg/mL In Serum @ |
| | | drug, unknown | 1 | 1 | | | | | methadone | Autopsy 0.1 mcg/mL In Serum @ |
| | | drug, unknown | 1 | 1 | | | | | 6-monoacetylmor- phine | Autopsy 0.18 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | drug, unknown | 1 | 1 | | | | | codeine | 0.4 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | drug, unknown | 1 | 1 | | | | | methadone me- tabolite | 0.53 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | drug, unknown | 1 | 1 | | | | | oxymorphone (total) | 0.62 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | drug, unknown drug, unknown | 1 1 | 1 1 | | | | | oxycodone (total) methadone | 0.63 mcg/mL In Serum @ Autopsy 1 mcg/mL In Urine (quantitative only) @ Autopsy |
| | | drug, unknown | 1 | 1 | | | | | oxycodone | 2.9 mcg/mL In Urine (quantitative only) @ Autopsy |
| 1349p | 26 y M | | | | A | Ingst | Int-S | 2 | | |
| 1350p | 28 y M | drug, unknown | 1 | 1 | U | Ingst+ Aspir | Int-A | 3 | | |
| | | drug, unknown ethanol | 1 2 | 1 2 | | | | | ethanol | 200 mg/dL In Blood (unspecified) |
| 1351pi | 29 y F | drug, unknown | 1 | 1 | A | Ingst+ Inhal | Unk | 2 | | @ Unknown |
| | | THC homolog | 2 | 2 | | | | | | |
| 1352 | 32 y F | drug, unknown opioid | 1 2 | 1 2 | С | Ingst | Int-M | 2 | | |
| 1353pi | 39 y F | drug, unknown | 1 | 1 | A | Inhal | Int-A | 1 | | |
| 1354 | 41 y M | drug, unknown | 1 | 1 | U | Ingst | Int-S | 2 | | |
| | | tricyclic antidepressant | 2 | 2 | | | | | | |
| 1355p | 42 y F | • | | | A/C | Ingst | Int-S | 2 | | |
| 1356 | 45 y F | drug, unknown | 1 | 1 | A/C | Ingst | Int-S | 2 | | |
| 1357p | 50 y M | drug, unknown | 1 | 1 | A | Inget | Int-S | 1 | | |
| 1357p 1358 | 50 y M | drug, unknown | 1 | 1 | A | Ingst | Int-U | 1 | | |
| | 2 0 J 2.12 | drug, unknown cocaine | 2 1 | 1 2 | | | | | | |
| 1359 | 52 y M | | | | A/C | Ingst | Int-A | 2 | | |
| 1360 | 54 y M | drug, unknown | 1 | 1 | U | Ingst | Int-U | 3 | | |
| 1361pa | 62 y M | drug, unknown | 1 | 1 | U | Unk | Unk | 2 | | |
| 1362 | 65 y M | drug, unknown | 1 | 1 | A | Inhal | AR-D | 2 | | |
| 1363 | 88 y M | sevoflurane | 1 | 1 | A | Ingst | Unk | 2 | | |
| 1364p | 40+ y M | drug, unknown | 1 | 1 | A | Par | Int-A | 1 | | |
| See also case | | drug, unknown 0, 187, 336, 354, 458, | 1 459, 610, 761. | 1 , 773, 80 | 6, 810, 850. | 931, 967, 1024. | 1034, 1124 | l, 1125. | 1175, 1341 | |
| Veterinary D | rugs | ,,,, ,, | -,,, | , | | | | | | |
| 1365p | 15 y F | pentobarbital/ phenytoin | 1 | 1 | A | Ingst | Int-S | 2 | | |

Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures

| Annual Report ID | Age | Substances | Substance Rank | Cause Rank | Chronicity | Route | Reason | RCF | Analyte | Blood Concentration @ Time |
|---------------------|-------------|--|-------------------|---------------|------------|-------|--------|-----|---------|-------------------------------|
| Vitamins 1366i | 48 y M | | | | С | Par | Unt-T | 3 | | |
| | | nicotnamide adenine dinucleotide (TPN) | 1 | 1 | | | | | | |
| | | amino acid (dietary) | 2 | 2 | | | | | | |
| See also case | e 882, 1109 | | | | | | | | | |

Listing of 1,146 + 220 fatalities classified as Relative Contribution to Fatality category = 1-Undoubtedly responsible, 2-Probably responsible, or 3-Con-

Annual Report ID: Bracketed [case number] = Narrative provided for this case in Appendix C i = Indirect case; identified through other sources (news feeds, medical examiner data, or other) about which no inquiry to the PC was made, p = prehospital cardiac and/or respiratory arrest, h = hospital records reviewed, $\mathbf{a} = \text{autopsy report reviewed}$.

Age Gender: y = years, m = months, d = days, F = female, M = male, F-Pregnant = pregnant, U = unknown.

Chronicity: C = chronic exposure, A = acute exposure, A/C = acute on chronic, U = unknown.

Route: Aspir = Aspiration (with ingestion), B-S = Bite/sting, Derm = Dermal, Ingst = Ingestion, Inhal = Inhalation/nasal, Oc = Ocular, Ot = Otic, Oth = Other, Par = Parenteral, Rec = Rectal, Unk = Unknown, Vag = Vaginal.

Reason: AR-D = Adverse reaction – Drug, AR-F = AR – Food, AR-O = AR – Other, Int-A = Intentional – Abuse, Int-M = Int – Misuse, Int-S = Int - Suspected Suicide, Int-U = Int - Unknown, Oth-C = Other - Contamination/tampering, Oth-M = Oth - Malicious, Oth-W = Oth - Withdrawal, Unk = Unknown reason, Unt-B = Unintentional - Bite/sting, Unt-E = Unt - Environmental, Unt-F = Unt - Food poisoning, Unt-G = Unt - General, **Unt-M** = Unt – Misuse, **Unt-O** = Unt – Occupational, **Unt-T** = Unt - Therapeutic error, **Unt-U** = Unt – Unknown.

RCF (Relative Contribution to Fatality): 1 = Undoubtedly responsible, 2 = Probably responsible, 3 = Contributory. Provided by the RPC for Indirect cases and the AAPCC Fatality Review Team for the direct (non-Indirect cases).

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | Treated | | Ō | Outcome | | |
|---|----------------------------|-------------------------------|-------------|---|-------|--------|--------------------------------|-------|---------|--------|--------|-------|--------------|---------------------------------|-------|---------|---------|---------|-------|
| | No. of Case Mentions | No. of Single Exposures | > = 5 | 6–12 | 13–19 | >=20 | Unknown Unknown Child Adult | | Unknown | Unint | Int | Other | Adv in Rxn F | in Health – Care Facility | None | Minor I | te | Major I | Death |
| Nombouncooutions | | | | | | | | | | | | | | | | | | | |
| Adhesives/Glues | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Adhesives/Glues | | | | | | | | | | | | | | | | | | | |
| Cyanoacrylates (Superglues, etc) | 7,561 | 7 | 3,355 | 622 | 260 | 2,306 | 25 | 216 | 57 | 7,164 | 244 | 34 | 48 | 1,670 | 086 | 1,434 | 219 | 4 | 0 |
| Epoxy | 624 | | 214 | 6 | 19 | 251 | 2 | 29 | 3 | 543 | 13 | 2 | 7 | 152 | 102 | 101 | 38 | 1 | 0 |
| Non-Toxic Adhesives/Glues | 1,554 | 1,459 | 926 | 301 | 29 | 83 | 5 | 24 | 3 | 1,364 | 64 | 22 | 2 | 28 | 193 | 89 | S | 1 | 0 |
| (White Glue, Paper Glue, etc) | | | | | | | | | | | | | | | | | | | |
| Toluene/Xylene (Adhesives Only) | 425 | | 205 | 20 | 16 | 130 | 0 | 39 | 3 | 389 | 13 | 1 | 6 | 82 | 103 | 81 | 9 | 33 | 0 |
| Unknown Types of Adhesive, | 3,779 | 3,635 | 1,862 | 240 | 194 | 1,055 | 14 | 247 | 23 | 3,400 | 104 | 51 | 71 | 672 | 773 | 605 | 116 | 2 | 0 |
| Glue, Cement or Paste | | | | | | | | | | | | | | | | | | | |
| Category Total: | 13,943 | 13,573 | 6,612 | 1,192 | 928 | 3,825 | 46 | 953 | 80 | 12,860 | 438 | 110 | 140 | 2,634 | 2,151 | 2,289 | 384 | 14 | 0 |
| Alcohols | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Alcohols | | | | | | | | | | | | | | | | | | | |
| Ethanol (Beverages) | 51,549 | | 1,475 | 161 | 1,698 | 5,049 | 14 | 736 | 174 | 2,381 | 6,223 | 289 | 251 | 3,749 | 894 | 1,498 | 1,099 | 225 | 21 |
| Ethanol (Non-Beverage, Non- | 17,060 | 15,847 | 11,989 | 1,238 | 258 | 1,726 | 25 | 285 | 26 | 14,746 | 807 | 235 | 28 | 1,063 | 3,986 | 1,296 | 135 | 14 | 7 |
| Kubbing) | | | | | | | | | | | | | | | | | | | |
| Higher Alcohols (Butanol, Amyl Alcohol, Propanols, etc) | 139 | 114 | 09 | т | 4 | 36 | 7 | S | - | 110 | 4 | 0 | 0 | 21 | 78 | 19 | 4 | 0 | 0 |
| Isopropanol (Excluding Rubbing | 6,056 | 5,408 | 2,950 | 202 | 206 | 1,761 | S | 260 | 24 | 4,575 | 723 | 55 | 23 | 1,146 | 1,287 | 919 | 277 | 37 | 3 |
| Alcohols and Cleaning Agents) | | | | | | | | | | | | | | | | | | | |
| Methanol (Excluding Automotive Products and Cleaning Agents) | 719 | 575 | 129 | 15 | 48 | 332 | - | 47 | n | 470 | 92 | 12 | 7 | 288 | 142 | 104 | 46 | 6 | 12 |
| Other Types of Alcohol | 410 | 385 | 281 | 12 | 10 | 71 | _ | 6 | 1 | 371 | 10 | 2 | 2 | 35 | 112 | 33 | 9 | 2 | 0 |
| Unknown Types of Alcohol | 460 | | 49 | 3 | 25 | 87 | 2 | 19 | 1 | 100 | 75 | 3 | 9 | 65 | 27 | 30 | 19 | 6 | 0 |
| Kubbing Alcohols | ı | | • | c | c | | c | c | | i, | c | c | c | c | - | , | C | c | c |
| Kubbing Alcohols: Ethanol With Methyl Salicylate | O | n | 4 | 0 | 0 | - | 0 | 0 | 0 | n | 0 | 0 | 0 | 0 | - | S | 0 | 0 | 0 |
| Rubbing Alcohols: Ethanol with- | 243 | 230 | 155 | ======================================= | 5 | 55 | 0 | 4 | 0 | 217 | 11 | 2 | 0 | 15 | 82 | 36 | 1 | 0 | 0 |
| out Methyl Salicylate | | | | | | | | | | | | | | | | | 1 | | |
| Rubbing Alcohols: Isopropanol | 296 | 285 | 201 | 9 | 12 | 59 | _ | 9 | 0 | 263 | 22 | 0 | 0 | 63 | 123 | 48 | 5 | 7 | 0 |
| wim Memyi Sancyiate | i | | | 0 | i c | | * | i c | ò | 000 | 9 | Ç. | (| | | | 9 | ī | (|
| Kubbing Alcohols: Isopropanol | 7,514 | 6,995 | 4,191 | 253 | /87 | 1,952 | Π | 295 | 70 | 0,080 | 819 | 53 | 6 | 1,233 | 1,658 | 1,057 | 740 | 17 | 0 |
| William Alcohols: Unknown | 75 | 29 | 28 | 4 | 4 | 20 | 0 | 0 | 0 | 52 | 41 | - | C | 23 | 23 | 7 | œ | C | 0 |
| Category Total: | 84.526 | 39.4 | 21.512 | 1.888 | 2.857 | 11.161 | 62 | 1.668 | 256 | 29.376 | 8.773 | 652 | 321 | 7.701 | 8.363 | 5.058 | 1.840 | 325 | 38 |
| Arts/Crafts/Office Supplies | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Arts/Crafts/Office Supplies | pplies | | | | | | | | | | | | | | | | | | |
| Artist Paints (Non-Water Color) | 2,942 | 2,835 | 2,091 | 214 | 127 | 332 | 11 | 54 | 9 | 2,742 | 65 | 4 | 22 | 88 | 443 | 119 | 14 | 0 | 0 |
| Artist Paints (Water Color) | 1,031 | | 898 | 89 | 22 | 41 | 5 | 3 | 2 | 686 | 14 | 7 | 4 | 18 | 133 | 24 | 2 | 0 | 0 |
| Chalks | 1,526 | 1,492 | 1,377 | 71 | 23 | 15 | 2 | 4 | 0 | 1,472 | 18 | - | 0 | 41 | 221 | 49 | S | 0 | 0 |
| Clavs | 2,236 | | 1.842 | 169 | 75 | 100 | 4 | 16 | 3 | 2,153 | 32 | 9 | 4 | 72 | 249 | 74 | 5 | 0 | 0 |
| Cravons | 2,220 | | 1.876 | 139 | 89 | 62 | 7 | 6 | 5 | 2,135 | 27 | - | - | 32 | 246 | 50 | 2 | 0 | 0 |
| Glazes | 128 | | 42 | 28 | 15 | 24 | 0 | 11 | 2 | 106 | 13 | - | 2 | 15 | 16 | 11 | 2 | 0 | 0 |
| Office Supplies: Miscellaneous | 137 | 127 | 64 | ∞ | 10 | 36 | 0 | 7 | 2 | 118 | 9 | 1 | 1 | 18 | 29 | 13 | _ | 0 | 0 |
| Other Types of Arts/Crafts/ | 5,857 | 5 | 4,077 | 527 | 231 | 549 | 29 | 122 | 11 | 5,375 | 122 | 32 | 12 | 237 | 813 | 239 | 24 | - | _ |
| Writing Products | | | | | | | | | | | | | | | | | | | |
| Pencils | 2,035 | | 992 | 716 | 128 | 108 | 14 | 37 | 3 | 1,864 | 77 | 42 | 3 | 85 | 209 | 165 | 11 | - | 0 |
| Pens or Inks | 13,950 | _ | 9,732 | 2,133 | 1,081 | 487 | 29 | 118 | 20 | 13,042 | 464 | 4 | 92 | 327 | 1,838 | 347 | 23 | 0 | 0 |
| Typewriter Correction Fluids | 1,282 | 1,257 | 954 | 123 | 74 | 88 | 2 | 13 | 3 | 1,201 | 48 | 3 | - | 107 | 302 | 106 | ∞ | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | L | Treated | | Out | Outcome | | |
|--|----------------------------|-------------------------------|--------------|-----------|-------|-----------|--------------------------------|----------|----------------|--------|----------------|-------|--------------|---------------------------------|-------|------------|------------|---------|-------|
| | No. of Case Mentions | No. of Single Exposures | > = \$ | 6–12 | 13–19 | Ur | Unknown Unknown Child Adult | | Unknown Age | Unint | Int | Other | Adv Rxn F | in Health — Care Facility | None | Minor M | Moderate M | Major D | Death |
| Unknown Types of Arts/Crafts/ | 94 | 94 | 19 | 14 | 2 | ∞ | 0 | 2 | - | 88 | 5 | 0 | - | 7 | 21 | 5 | 0 | 0 | 0 |
| Writing Products Category Total: Automotive/Aircraft/Rost Products | 33,438 | 32,493 | 23,982 | 4,210 | 1,856 | 1,850 | 141 | 396 | 28 | 31,285 | 891 | 137 | 137 | 1,047 | 4,520 | 1,202 | 76 | 7 | Т |
| Automotive Products Automotive Products: Brake | 1,107 | 1,036 | 343 | 25 | 4 | 530 | 0 | 90 | 4 | 975 | 50 | 7 | 0 | 387 | 256 | 266 | 29 | 6 | 0 |
| Fluids Automotive Products: Ethylene | 6,222 | 5,725 | 528 | 145 | 479 | 3,827 | 4 | 629 | 73 | 4,749 | 800 | 95 | 6 | 2,165 | 1,056 | 926 | 452 | 151 | 7 |
| Glycol (Including Antifreeze) Automotive Products: Glycol and | 190 | 179 | 50 | 10 | 15 | 88 | 1 | 14 | 1 | 158 | 16 | 4 | 0 | 54 | 4 | 35 | 4 | 0 | 0 |
| Methanol Mixtures Automotive Products: Hydro- carbons (Transmission Fluids, | 2,607 | 2,448 | 1,003 | 66 | 142 | 1,001 | 33 | 177 | 23 | 2,294 | 112 | 19 | 15 | 742 | 995 | 632 | 133 | 10 | 0 |
| Automotive Products: Methanol (Clyr Gas, Windshield Washing | 1,254 | 1,177 | 212 | 36 | 92 | 869 | ю | 125 | 11 | 1,035 | 115 | 13 | 12 | 472 | 284 | 296 | 64 | 12 | 8 |
| Solutions, etc.) Automotive Products: Other Glycols | 213 | 203 | 85 | 6 | 6 | 78 | 7 | 14 | 1 | 181 | 11 | 9 | 2 | 4 | 53 | 26 | 'n | 0 | 0 |
| Miscellaneous Automotive/Aircraft/Boat Products Automotive/Aircraft/Boat 12 Products: Non-Troxic | Boat Produ | icts 12 | 9 | 1 | - | ю | 0 | 1 | 0 | 12 | 0 | 0 | 0 | 1 | - | 8 | 0 | 0 | 0 |
| Automotive/Aircraft/Boat Products: Other | 1,913 | 1,830 | 711 | 114 | 86 | 747 | 4 | 135 | 21 | 1,741 | 40 | 13 | 29 | 526 | 366 | 809 | 113 | 9 | 0 |
| Automotive/Aircraft/Boat Producte: Unknown | 200 | 181 | 49 | 6 | 11 | 87 | 0 | 23 | 2 | 167 | 4 | 4 | 4 | 82 | 33 | 99 | 16 | 0 | 0 |
| Category Total: Batteries | 13,718 | 12,791 | 2,987 | 448 | 891 | 7,059 | 62 | 1,208 | 136 | 11,312 | 1,148 | 161 | 71 | 4,476 | 2,662 | 2,848 | 854 | 188 | 10 |
| Disc Batteries Disc Batteries: Albeline (MMO2) | 250 | 756 | 177 | ę | 2 | , | c | ٧ | - | 240 | Ξ | - | r | 175 | 141 | 10 | 4 | 0 | C |
| Disc Batteries: Lithium | 169 | 123 | 56 | 21 | 17 | 32 | 0 | | | 92 | 18 | 0 | 12 | 107 | 49 | 01 | 31 | 2 | |
| Disc Batteries: Mercuric Oxide | 4 c | 4 c | | 0 0 | 0 0 | e - | 0 0 | 0 0 | 0 0 | 4 c | 0 0 | 0 0 | 0 0 | m C | e - | - 0 | 0 0 | 0 0 | 0 0 |
| Disc Batteries: Other | 1 W | 1 W | | - 0 | 0 | | 0 | 0 | 0 | ٦ | - 0 | - | 0 | - | 0 | - 0 | 0 | 0 | 0 |
| Disc Batteries: Silver Oxide | 37 | 36 | 20 | 3 | 0 | 13 | 0 | 0 | 0 | 36 | 0 | 0 | 0 | | 26 | 2 | 0 | 1 | 0 |
| Disc Batteries: Unknown Disc Batteries: ZincAir | 3,121 | 3,076 | 2,141 | 494 - | 70 | 320 39 | 11 | 32 | s c | 2,986 | - 68 | 6 C | ς C | 2,288 | 1,519 | 175 | 53 | ς c | - 0 |
| Miscellaneous Batteries | | | | - | | 9 | | 8 | | 60 | | | | 5 | : 3 | | Ţ | |) (|
| Automouve/Aircrat/Boat Batteries | /10 | 060 | 64 | <u> </u> | 5 | 490 | - | 66 | n | 600 | 7 | o | 7 | 177 | \$ | C12 | /0 | 7 |) |
| Other Types of Battery | 150 | 141 | 09 | 12 | 11 | 43 | - | 14 | 0 | 131 | ∞ | 2 | 0 | 22 | 31 | 21 | 9 | 0 | 0 |
| Penlight/Flashlight/Dry Cell Batteries | 5,240 | 5,143 | 2,979 | 582 | 352 | 946 | 10 | 255 | 19 | 4,746 | 327 | 32 | 16 | 887 | 1,379 | 618 | 110 | 0 | 0 |
| Unknown Types of Battery | 58 | 57 | 22 | 4 | 2 5 | 22 | - ; | \$ | - 9 | 51 | 5 | - 9 | 0 | 11 | 13 | 41 2 | 8 | 0 ; | 0 |
| Category Total: Bites and Envenomations | 9,830 | 9,608 | 5,531 | 1,172 | 203 | 1,933 | 24 | 415 | 30 | 9,040 | 8 4 | 49 | 38 | 3,776 | 3,293 | 1,081 | 276 | c1 | 7 |
| Fish Stings Jellyfish and Other Coelenterate Stings | 863 | 856 559 | 24 74 | 42 150 | 91 | 606 | 7 2 | 74 37 | 17 6 | 853 | 7 7 | 0 1 | 7 - | 303 127 | 9 % | 247 166 | 37 | 3 8 | 0 |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | 9 | 9 | | | | Age | | | | | Reason | | Tre | Treated | | Outcome | me | | |
|--|---------------|---------------------|-------|-------|-------|----------------|-------------------|------------------------------------|---------------|--------|--------|------------------|-----|---------------------------------|---------|-----------|-------------|-------------|---------|
| 4 | Case Mentions | Single Exposures | <=> | 6–12 | 13–19 | U ₁ | nknown U Child | Unknown Unknown Child Adult Age | nknown Age | Unint | Int Or | Adv Other Rxn | I | nn neann Care Facility No | None Mi | Minor Mod | Moderate Ma | Major Death | l H |
| Other or Unknown Marine Animal Bites and/or Envenomations | 370 | 359 | 199 | 20 | 22 | 76 | 1 | 16 | 4 | 328 | 16 | 7 | 7 | 61 | 36 | 36 | 15 | 1 | 0 |
| Exotic Snake: Unknown If | 1 | - | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | _ | 0 | 0 | 0 | 0 | 0 |
| Poisonous Exotic Snakes: Non-Poisonous | 64 | 64 | 3 | 7 | 13 | 36 | - | ю | - | 49 | 0 | 0 | 0 | 32 | - | 28 | 2 | 0 | 0 |
| Exotic Snakes: Poisonous | 40 | 38 | 2 | - | Э | 27 | 0 | 4 | - | 37 | - | 0 | 0 | 32 | 0 | 9 | 14 | 9 | 0 |
| Insects Ant or Fire Ant Bites | 1.236 | 1.184 | 397 | 107 | × × | 508 | ч. | 101 | 10 | 1.157 | 4 | 10 | 4 | 122 | 37 | 323 | 71 | C | 0 |
| Bee, Wasp, or Hornet Stings | 6,888 | 6,768 | 1,364 | 726 | 402 | 3,572 | 19 | 622 | 63 | 6,761 | - 2 | 5 2 | - 2 | 701 | 72 2 | 2,362 | 376 | 17 | 0 |
| Caterpillars | 1,249 | 1,242 | 353 | 189 | 123 | 460 | 5 | 26 | 15 | 1,210 | 21 | 5 | 9 | 140 | | 392 | 61 | 2 | 0 |
| Centipede or Millipede Bites | 1,149 | 1,146 | 172 | 83 | 101 | 662 | 3 | 119 | 9 | 1,137 | 9 | - | 2 | 122 | 40 | 349 | 36 | 0 | 0 |
| Mosquito Bites | 187 | 178 | 52 | 16 | 12 | 73 | 0 ; | 22 | e 3 | 177 | 0 8 | 0 9 | - : | 19 | | 39 | 4 6 | 0 ; | 0 |
| Other Insect Bites and/or Stings | 9,430 | 9,242 | 2,047 | 649 | 1 487 | 4,503 | 47. | 1,304 | 8 4 7 | 9,029 | 77. | 148 | | 1,385 | 292 2 | 2,010 | 540 | 13 | 0 |
| Scorpton Stings Tick Bites | 1,521 | 16,761 | 366 | 1,090 | 1,462 | 10,422 695 | 0 11 | 1,537 | 13 | 16,731 | n 0 | 0 | 7 0 | 297 | | 242 | 1,062 30 | ос 1 | 0 |
| Mammals | | | | | | | | | | | | | | | | | | | |
| Bat Bites | 699 | 654 | 85 | 64 | 99 | 309 | 7 | 93 | 40 | 649 | 0 | 0 | _ | 335 | 135 | 77 | 3 | 0 | 0 |
| Cat Bites | 814 | 804 | 92 | 71 | 65 | 468 | 3 | 115 | 17 | 803 | 0 | 0 | 0 | 485 | Π | 228 | 33 | 2 | 0 |
| Dog Bites | 2,292 | 2,285 | 367 | 451 | 238 | 986 | 15 | 206 | 22 | 2,284 | 0 | _ | 0 | 1,704 | 33 | 763 | 147 | 2 | - |
| Fox Bites | 56 | 26 | 0 | 7 | 7 | 18 | 0 | co | _ | 56 | 0 | 0 | 0 | 21 | 0 | 7 | 0 | 0 | 0 |
| Human Bites | 42 | 42 | S | 7 | 7 (| 21 | - - ; | ∞ (| e (| 34 | - ı | 7 | 0 | 22 | - ; | Ξ ; | 7 7 | 0 , | 0 |
| Other Mammal Bites | 926 | 920 | 119 | 120 | 69 | 470 | 10 | 66 | 33 | 887 | ۲, | 10 | m (| 516 | 61 | 199 | 26 o | - (| 0 |
| Raccoon Bites | 146 | 144 | 10 | 10 | 14 | 96 | _ | 16 | 33 | 143 | _ | 0 | 0 | 112 | 13 | 41 | ∞ | 7 | \circ |
| Rodent or Lagomorph Bites (Squirrels, Rats, Mice, Gerbils, | 1,397 | 1,377 | 269 | 255 | 126 | 498 | 38 | 156 | 32 | 1,330 | 6 | 27 | ∞ | 409 | 72 | 359 | 21 | - | 0 |
| Hamsters, Rabbits, etc) | ; | ; | • | • | • | • | 4 | , | , | ; | • | (| | 1 | , | , | 4 | 4 | |
| Skunk Bites | 12 | 12 | 0 | 2 | 0 | ∞ | 0 | - | 1 | 12 | 0 | 0 | 0 | S | _ | S | 0 | 0 | 0 |
| Other or Unknown Animal Rites | 356 356 | 340 | 52 | 7 | 31 | 168 | C | 47 | 7 | 337 | v | _ | - | 120 | 7 | 06 | 38 | 0 | 0 |
| Other or Unknown Reptile Bites | 550 | 545 | 192 | 4 4 | 24 | 154 | 1 — | 25 | ٠ ٧ | 516 | . 21 | | 10 | 88 | 36 | 149 | 16 | 0 | |
| Unknown Types of Insect or Spider | 3,345 | 3,307 | 465 | 236 | 305 | 2,001 | 17 | 261 | 22 | 3,286 | Š | | 7 | 512 | 31 1 | 1,168 | 131 | 4 | 0 |
| Bite and/or Envenomation | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Snake Bites and Envenomations | nomations | | | | į | 0 | • | | , | | , | , | , | | e I | į | | | |
| Unknown or Known Non- Poisonous Snake Bites | 1,256 | 1,248 | 87 | 202 | 172 | C89 | 7 | 56 | 10 | 1,240 | .n | - | 7 | 496 | 80 | 2/2 | 84 | 0 | 0 |
| Unknown Types of Snake | 1,562 | 1,544 | 86 | 176 | 198 | 996 | 1 | 79 | 26 | 1,536 | 0 | 7 | 0 | 1,142 | 41 | 849 | 385 | 21 | 0 |
| Envenomation Snakes | | | | | | | | | | | | | | | | | | | |
| Copperhead Envenomations | 1,366 | 1,356 | 74 | 146 | 137 | 944 | _ | 50 | 4 | 1,347 | 7 | 0 | 2 | 1,260 | 18 | 388 | 745 | 48 | 0 |
| Coral Envenomations | 75 | 73 | 1 | 5 | 6 | 55 | 0 | 3 | 0 | 71 | - | 0 | 1 | 99 | 5 | 29 | 19 | 4 | 0 |
| Cottonmouth Envenomations | 259 | 256 | 5 | 20 | 21 | 199 | 0 | 7 | 4 | 252 | 2 | 0 | 0 | 225 | 4 | 100 | 68 | 5 | 0 |
| Rattlesnake Envenomations | 1,192 | 1,158 | 20 | 65 | 80 | 806 | _ | 46 | S | 1,145 | 7 | 7 | 3 | 1,071 | 25 | 297 | 562 | 79 | _ |
| Unknown Crotalid Envenomations | 648 | 640 | 45 | 80 | 64 | 436 | 0 | 12 | 3 | 632 | 7 | - | с | 593 | 9 | 178 | 348 | 26 | 0 |
| Spiders Black Widow Spider Bites and/or | 2,168 | 2,156 | 189 | 105 | 162 | 1,514 | - | 177 | ∞ | 2,145 | 4 | 2 | 2 | 892 | 61 | 930 | 359 | 13 | 0 |
| Envenomations Decreis Declare Carida: Dites and/ | 1 405 | 1 476 | 130 | 09 | 122 | 020 | c | 700 | OC. | 1 473 | c | c | c | (95 | 36 | 230 | 960 | - | |
| or Envenomations | 0,47 | 1,470 | 001 | 8 | C71 | 676 | 4 | t 07 | 07 | 7/+,1 | | | | 705 | 0.7 | 000 | 007 | <u>+</u> | > |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | Treated | | no | Outcome | | |
|--|----------------------------|-------------------------------|----------------|-------|-------|--------|------------------------------------|------------------|----------------|--------|--------|-------|--------------|---------------------------------|-------|--------|------------|-------------|-------|
| | No. of Case Mentions | No. of Single Exposures | <= > | 6-12 | 13–19 |)==20 | Unknown Unknown Child Adult Age | Jnknown Adult | Unknown Age | Unint | Int | Other | Adv in Rxn F | in Health — Care Facility | None | Minor | Moderate] | Major Death | Death |
| Other Necrotizing Spider Bites | 213 | 209 | 26 | 23 | 10 | 126 | 1 | 20 | 3 | 208 | 0 | 0 | 0 | 46 | v | 54 | 22 | 0 | 0 |
| and/or Envenomations Other Spider Bites and/or Envenometions | 6,433 | 6,388 | 902 | 427 | 542 | 3,962 | 11 | 929 | 64 | 6,356 | 7 | 6 | 5 | 1,181 | 94 | 1,460 | 396 | S | 1 |
| Envenomations Tarantula Bites and/or Envenomations | 85 | 84 | ∞ | 11 | 14 | 40 | 1 | 6 | - | 77 | 2 | 1 | 4 | 23 | 2 | 27 | 9 | 0 | 0 |
| Category Total: Building and Construction Products Insulation | 67,675 | 66,944 | 9,839 | 6,577 | 5,562 | 37,805 | 198 | 6,328 | 635 | 66,339 | 155 | 269 | 66 | 17,046 | 1,458 | 23,528 | 6,036 | 308 | w |
| Asbestos | 363 | 317 | 43 | 18 | 16 | 171 | - | 9 | 4 | 309 | 2 | - | 8 | 29 | 37 | 23 | S | 0 | С |
| Fiberglass | 752 | 701 | 294 | 09 | 41 | 239 | 4 | 56 | | 673 | 10 | 9 | 12 | 80 | 73 | 160 | 21 | _ | 0 |
| Other Types of Insulation | 126 | 122 | 41 | 10 | 4 | 55 | 0 | 12 | 0 | 119 | 1 | - | 0 | 18 | 7 | 20 | 2 | 0 | 0 |
| Unknown Types of Insulation | 458 | 423 | 263 | 28 | 6 | 82 | 0 | 39 | 2 | 410 | 4 | 4 | 4 | 46 | 75 | 57 | 4 | 0 | 0 |
| Urea or Formaldehyde Insulations 9 Miscellaneous Building and Construction Products | 9 ofion Dr od | 6 Jucte | 7 | 0 | 0 | 7 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | _ | П | 0 | 0 | 0 | 0 |
| Caulking Compounds and | 2,737 | 2,670 | 1,968 | 68 | 57 | 429 | 9 | 105 | 16 | 2,598 | 38 | ∞ | 25 | 225 | 576 | 178 | 30 | 0 | 0 |
| Cement or Concrete (Excluding | 1,197 | 1,127 | 329 | 24 | 4 | 605 | 0 | 119 | 9 | 1,074 | 21 | 9 | 22 | 462 | 134 | 239 | 219 | 4 | 0 |
| Other Types of Building or Construction Products | 2,559 | 2,394 | 1,366 | 103 | 19 | 089 | 9 | 154 | 18 | 2,323 | 37 | 7 | 23 | 396 | 402 | 329 | 108 | 9 | 0 |
| Soldering Flux | 208 | 195 | 65 | 9 | 13 | 16 | 0 | 17 | с. | 189 | 2 | 0 | m | 99 | 34 | 48 | 22 | 0 | 0 |
| Unknown Types of Building or Construction Products | 113 | 108 | 25 | 4 | 7 | 50 | 0 | 21 | - | 105 | 7 | - | 0 | 35 | 22 | 28 | 7 | - | 0 |
| Category Total: | 8,522 | 8,066 | 4,401 | 342 | 258 | 2,404 | 17 | 587 | 57 | 7,809 | 1117 | 34 | 92 | 1,396 | 1,361 | 1,082 | 418 | 12 | 0 |
| Chemicals Acids | | | | | | | | | | | | | | | | | | | |
| Hydrochloric Acid | 2,130 | 1,772 | 115 | 49 | 233 | 1,173 | 0 | 167 | 20 | 1,668 | 48 | 22 | 27 | 718 | 149 | 632 | 203 | 12 | ∞ |
| Hydrofluoric Acid | 646 | 268 | 32 | 33 | 31 | 436 | 2 | 26 | ∞ | 548 | ∞ | 3 | 2 | 442 | 42 | 219 | 141 | 12 | 1 |
| Other Types of Acid | 5,005 | 4,419 | 613 | 275 | 369 | 2,539 | 16 | 557 | 50 | 4,215 | 98 | 40 | 20 | 1,640 | 441 | 1,400 | 562 | 23 | 00 |
| Unknown 1ypes of Acid Miscellaneous Chemicals | 183 | 143 | 1 | c | Ξ | 06 | o | 19 | n | 172 | 4 | 6 | 7 | 00 | 6 | 0+ | 17 | - | 0 |
| Acetone (Excluding Nail Polish Removers) | 1,161 | 1,004 | 364 | 4 | 65 | 429 | 7 | 88 | 12 | 915 | 47 | 13 | 14 | 271 | 185 | 232 | 39 | 0 | 0 |
| Alkalis (Excluding Cleaning Agents, Bleaches, Batteries, and Deteroents) | 3,699 | 3,244 | 592 | 121 | 305 | 1,851 | ∞ | 332 | 35 | 3,063 | 74 | 47 | 42 | 1,616 | 298 | 686 | 209 | 4 | 2 |
| Ammonia (Excluding Cleaning | 3,291 | 2,464 | 648 | 136 | 157 | 1,200 | 46 | 258 | 19 | 2,298 | 101 | 27 | 23 | 885 | 315 | 731 | 245 | 12 | 0 |
| Borates or Boric Acid (Excluding | 2,851 | 2,620 | 1,308 | 132 | 93 | 884 | 7 | 179 | 17 | 2,443 | 96 | 40 | 35 | 380 | 573 | 271 | 29 | 1 | 0 |
| Chlorates (Excluding Matches and | 46 | 35 | 9 | 6 | 12 | ∞ | 0 | 0 | 0 | 34 | - | 0 | 0 | 7 | 7 | 5 | 2 | 0 | 0 |
| Frieworks) Cyanides (Excluding Rodenticides) | 225 | 145 | 1 | 0 | 3 | 104 | 0 | 31 | 9 | 103 | 18 | 10 | 3 | 68 | 26 | 30 | 11 | 7 | ∞ |
| Dioxins | 10 | 6 | П | 0 | П | 7 | 0 | 0 | 0 | 9 | - | - | 0 | 4 | 2 | 2 | 2 | - | 0 |
| Ethylene Glycol (Excluding Automotive, Aircraft, or Boat Products) | 892 | 723 | 47 | 6 | 38 | 458 | 7 | 62 | 107 | 459 | 210 | 10 | 7 | 505 | 100 | 71 | 93 | 105 | 13 |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | I | Treated | | Out | Outcome | | |
|---|----------------------------|-------------------------------|-----------------------|-------------------|------------------|---------------------|---------------------|------------------------------|---------------|-------------------------|------------------|----------------|--------------|---------------------------------|---------------------|---------------------|----------------|-------------|-------|
| 2 | No. of Case Mentions | No. of Single Exposures | >=> =5 | 6–12 1 | 13–19 > | =20 | Unknown Ur Child | Unknown Unknown Adult Age | ! | Unint | Int O | A Other R | Adv in Rxn F | in Health — Care Facility | None] | Minor M | Moderate 1 | Major Death | eath |
| Formaldehyde or Formalin | 784 | 691 | 98 | 38 | 109 | 357 | 4 , | 98 | = , | 616 | 37 | 9, | 27 | 267 | 93 | 205 | 49 | 2 , | 0 0 |
| Ketones Methylene Chloride (Excluding | 391 196 | 324 169 | 101 | 7 | 9 13 | 170 94 | | 36 27 | | 314 161 | 4 4 | - 0 | 4 7 | 146 74 | 2/ ₂ | 116 46 | 29 | 0 | 0 0 |
| Paint Strippers) Nitrates and Nitrites (Excluding Medications and Substances of | 1,190 | 1,104 | 374 | 245 | 111 | 297 | 4 | <i>L</i> 9 | 9 | 946 | 127 | 21 | ∞ | 227 | 227 | 152 | 50 | 9 | _ |
| Abuse) Other Chemicals Other Chemicals-Unknown If | 11,115 | 9,729 48 | 3,815 44 | 768 | 576 | 3,584 | 37 | 837 | 112 | 8,894 | 321 0 | 156 | 320 | 2,120 | 1,604 | 1,735 | 484 | 31 0 | 2 0 |
| loxic Other Glycols (Excluding Automotive, Aircraft, or Boat | 893 | 710 | 321 | 65 | 25 | 215 | 0 | 43 | 14 | 581 | 18 | 71 | 38 | 214 | 189 | 139 | 32 | 7 | 0 |
| Frouncis) Phenol or Creosotes (Excluding Disinfectants) | 350 | 301 | 18 | 3 | 21 | 215 | 1 | 41 | 2 | 292 | 5 | - | 3 | 126 | 21 | 109 | 45 | 3 | 0 |
| Strychnine (Excluding Rodenti- | 38 | 28 | ∞ | 8 | 0 | 15 | 0 | 2 | 0 | 18 | 4 | 8 | 2 | 15 | 7 | 7 | 2 | - | 0 |
| Toluene Diisocyanate | 556 | 526 | 144 | 28 | 22 | 248 | 3 | 77 | 4 5 | 497 | 12 | 1 27 | 12 | 126 | 67 | 1113 | 29 | 2 5 | 0 |
| Unknown Chemicals Category Total: Cleaning Substances (Household) Automatic Dishwasher Deterpents | 39,583 | 34,393 | 9,542 | | | 16,086 | 155 | 3,466 | 499 | 31,082 | 1,376 | 824 824 | | 11,146 | 4,861 | 8,024 | 2,946 | 298 | o 9 |
| Automatic Dishwasher Determents: Granules | 3,041 | 2,997 | 2,454 | 44 | 39 | 373 | 9 | 77 | 4 | 2,954 | 14 | 24 | 4 | 119 | 720 | 344 | 21 | - | 0 |
| Automatic Dishwasher Deterrente: Liquide | 2,821 | 2,769 | 2,321 | 45 | 40 | 313 | 3 | 4 | 3 | 2,731 | 21 | 12 | 5 | 134 | 712 | 334 | 27 | 1 | 0 |
| Automatic Dishwasher Detergents: Tablets | 1,552 | 1,538 | 1,439 | 11 | 12 | 58 | 3 | 14 | 1 | 1,532 | 2 | 4 | 0 | 45 | 397 | 189 | 1 | 0 | 0 |
| Automatic Dishwasher Rinse | 805 | 784 | 289 | 6 | 9 | 70 | _ | 10 | - | 779 | 3 | 2 | 0 | 74 | 161 | 136 | 5 | 0 | 0 |
| Other or Unknown Types of Automatic Dishwasher Detergent | 7,496 | 7,452 | 6,941 | 49 | 51 | 308 | 7 | 87 | 6 | 7,405 | 16 | 26 | 4 | 238 | 1,795 | 1,028 | 24 | - | - |
| Bleaches: Borates Bleaches: Hypochlorite (Liquid | 224 36,933 | 193 31,922 | 98 13,969 | 4 1,173 | 7 | 63 12,666 | 0 54 | 18 2,002 | 3 245 | 178 29,670 | 9 | 1 416 | 5 269 | 32 6,427 | 35 5,018 | 46 8,420 | 7 987 | 0 22 | 3 |
| Bleaches: Non-Hypochlorite Bleaches: Other or Unknown (Household) | 447 379 | 379 | 191 | 10 | 21 18 | 130 | 0 1 | 23 | 4 % | 354 279 | 16 | 6 9 | 5 0 | 71 | 72 42 | 88 | 10 | 0 | 0 |
| Anionic or Nonionic Cleansers Other or Unknown Types of Household Cleanser | 1,935 | 1,768 | 1,400 | 34 | 28 | 249 479 | w w | 46 96 | 8 112 | 1,718 | 32 | 8 22 | 7 | 165 | 475 485 | 192 317 | 111 | | 0 |
| Disinfectants: Hypochlorite (Non-Rleach Products) | 15,998 | 13,250 | 5,024 | 563 | 837 | 5,471 | 54 | 1,173 | 128 | 12,124 | 619 | 259 | 188 | 2,949 | 1,840 | 3,236 | 510 | 6 | 0 |
| Disinfectants: Other or Unknown Disinfectants: Phenol Disinfectants: Phenol | 6,897 1,305 3,586 | 6,503 1,265 3,250 | 4,200 836 1,958 | 382 110 127 | 249 65 119 | 1,322 202 911 | 73 8 | 291 46 110 | 31 3 23 | 6,154 1,189 3,029 | 189 46 138 | 70 23 39 | 69 7 20 | 559 133 564 | 1,382 335 907 | 1,130 172 671 | 88 30 52 | 4 T E | 0 0 1 |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | V 400 | | | | | Dancon | | | Treated | | | Outcome | | |
|--|--------|---------------------|-------|------|-------|-------|-------------------|--|----------------|-------|--------|-------|------------|------------------|------|------------|--------------|-------|-------|
| | No. of | No. of | | | | Age | | | | | INCASO | | | in Health | | | aicoille | | |
| | so. | Single Exposures | <=5 | 6–12 | 13–19 |)==20 | nknown U Child | Unknown Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv Rxn | Care Facility | None | Minor | Moderate | Major | Death |
| Drain Cleaners | | | | | | | | | | | | | | | | | | | |
| Drain Cleaners: Acids | 46 | 36 | 7 | _ | 0 | 22 | 0 | 9 | 0 | 33 | 2 | 0 | 0 | 14 | 4 | 6 | 4 | 0 | 0 |
| Drain Cleaners: Alkalis | 3,221 | 2,703 | 425 | 71 | 94 | 1,754 | 0 | 325 | 34 | 2,452 | 171 | 23 | 45 | 815 | 332 | 693 | 281 | 47 | 9 |
| Drain Cleaners: Hydrochloric | 209 | 87 | 10 | 4 | 9 | 54 | 0 | 10 | 3 | 78 | 2 | 0 | 33 | 22 | 14 | 4 | 7 | 2 | 0 |
| Acid | i | ; | | | , | 1 | | | , | | ! | : | , | | i | | | | |
| Drain Cleaners: Other or | 794 | 614 | 103 | 13 | 36 | 356 | n | 88 | 15 | 537 | 45 | 11 | 15 | 162 | 71 | 132 | 42 | ∞ | - |
| Unknown Desin Classes: Sulfarrio Asid | 376 | 203 | 1 | 1 | 16 | 212 | 0 | 9 | - | 177 | 7 | - | " | 127 | 71 | 03 | 8 | c | - |
| Fabric Softeners/Antistatic Agents | 370 | 267 | 1 | _ | 10 | 717 | > | 0 | 1 | † | CI | 1 | C . | + 71 | 1 / | 66 | 00 | 1 | - |
| Fabric Softener/Antistatic Agent: | 18 | 16 | 11 | 1 | 2 | 2 | 0 | 0 | 0 | 15 | 1 | 0 | 0 | 2 | 5 | 2 | 1 | 0 | 0 |
| Other or Unknown | | ! | , | 1 | , | : | 1 | , | , | : | | | | , | : | , | , | 1 | 1 |
| Fabric Softeners/Antistatic | 153 | 147 | 128 | S | 3 | 10 | 0 | _ | 0 | 142 | 0 | 4 | _ | 33 | 4 | 15 | 1 | 0 | 0 |
| Agents: Aerosol or Spray Fabric Softeners/Antistatic | ∞ | 8 | S | 0 | 0 | 2 | 0 | - | 0 | ∞ | 0 | 0 | 0 | 1 | - | 1 | 0 | 0 | 0 |
| Agents: Dry or Powder | | | | | | | | | | | | | | | | | | | |
| Fabric Softeners/Antistatic | 905 | 848 | 289 | 11 | ∞ | 115 | 9 | 20 | 1 | 822 | 16 | 1 | 7 | 29 | 194 | 86 | 3 | 1 | 0 |
| Agents: Elquid Fabric Softeners/Antistatic | 537 | 510 | 426 | 24 | = | 46 | C | 7 | с, | 500 | V | ď | C | 10 | 105 | 24 | A | 0 | 0 |
| Agents: Solid or Sheet | | | P | † | 1 | P | 1 | | 'n | | , |) | 1 | 2 | 6 | 1 | ٢ | | |
| Glass Cleaners | | | | | | | | | | | | | | | | | | | |
| Glass Cleaners: Ammonia | 3,504 | 3,139 | 2,569 | 100 | 102 | 307 | 7 | 47 | 7 | 2,999 | 107 | 26 | 4 | 232 | 732 | 377 | 24 | | - |
| Glass Cleaners: Anionics or | 142 | 129 | 108 | 9 | 9 | 7 | 0 | 6 | O | 121 | 9 | - | C | 7 | 36 | 13 | 0 | 0 | 0 |
| Nonionics | ! | | 9 | |) | | , | ı | • | |) | • | | |) | | | | |
| Glass Cleaners: Isopropanol | 2,436 | 2,211 | 1,725 | 69 | 79 | 285 | 2 | 49 | 2 | 2,109 | 92 | 12 | 9 | 178 | 511 | 246 | 15 | 0 | 0 |
| Glass Cleaners: Other or | 1,664 | 1,529 | 1,171 | 69 | 53 | 188 | 2 | 42 | 4 | 1,461 | 48 | 6 | 10 | 148 | 345 | 157 | 18 | 0 | 0 |
| Unknown Types of Household | | | | | | | | | | | | | | | | | | | |
| Hand Dishwashing | 5005 | 7 833 | 2 135 | 900 | 110 | 1 101 | o | 171 | = | 1 632 | 83 | 77 | - | 308 | 309 | 800 | - | 0 | C |
| Dishwashing Detergents | 0,430 | 7,00,4 | 0,133 | 2007 | 011 | 1,191 | 0 | 1/1 | 1 | 4,032 | 70 | ţ | Ť | 300 | 020 | 600 | , | > | > |
| Other or Unknown Types of | 2,359 | 2,112 | 1,299 | 81 | 56 | 268 | 3 | 95 | 10 | 2,019 | 28 | 51 | 12 | 126 | 275 | 301 | 12 | 0 | 0 |
| Household Hand Dishwashing | | | | | | | | | | | | | | | | | | | |
| Detergent | | | | | | | | | | | | | | | | | | | |
| Laundry Additives | G | ř | 7 | c | - | 5 | - | | < | ī | • | c | , | 5 | 4 | 4 | | < | c |
| Enzyme and/or Microbiological Laundry Additives | 70 | 0/ | 40 | 0 | - | 77 | - | 0 | 0 | 4 | 0 | 0 | 7 | 71 | E | CI | 7 | 0 | 0 |
| Laundry Bluing and/or Brightening | 36 | 26 | 14 | 0 | 0 | 12 | 0 | 0 | 0 | 25 | 1 | 0 | 0 | 5 | 11 | 2 | 1 | 0 | 0 |
| Agents (without Detergent) | | | | | | | | | | | | | | | | | | | |
| Laundry Detergent Boosters | 126 | 117 | 61 | - ; | 7 | 34 | 2 | ∞ ; | 6 | 100 | - : | 0 ; | 16 | 17 | 22 | 41 | 2 | 0 | 0 |
| Other or Unknown Laundry Addi- | 2,355 | 2,240 | 1,828 | 104 | 52 | 219 | 4 | 32 | _ | 2,157 | 43 | 30 | S | 186 | 481 | 289 | 22 | 2 | 0 |
| Water Softeners | 44 | 4 | 24 | 4 | 0 | 7 | C | 4 | C | 40 | - | C | C | 6 | 00 | 9 | 0 | C | 0 |
| Laundry Detergents | : | : | 1 | | 1 | | | | | 2 | • | | | 1 | | | | | |
| Laundry Detergents: Granules | 3,966 | 3,784 | 3,022 | 92 | 100 | 447 | 6 | 107 | 7 | 3,651 | 63 | 40 | 23 | 457 | 289 | <i>116</i> | 52 | 2 | 0 |
| Laundry Detergents: Liquids | 4,723 | 4,497 | 3,285 | 100 | 128 | 841 | 2 | 133 | 8 | 4,351 | 76 | 27 | 18 | 537 | 758 | 668 | 9/ | 2 | 2 |
| Laundry Detergents: Other or | 341 | 325 | 265 | 4 | 4 | 39 | 0 | 12 | 1 | 313 | 9 | 1 | 2 | 29 | 70 | 45 | 5 | 0 | 0 |
| Unknown Types of Household | | | | | | | | | | | | | | | | | | | |
| Fabric Cleaner | | | | | | | | | | | | | | | | | | | |
| Laundry Detergents: Soaps | 88 | 79 | 50 | 2 | 9 | 14 | 0 | 9 | - | 74 | 2 | 0 | 3 | 7 | 12 | 15 | - | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | L | Treated | | | Outcome | | |
|--|----------------------------|-------------------------------|-------|------|-------|--------|-------------------|--|---------------|-------|--------|---------|--------------|---------------------------------|-------|-------|----------|---------|-------|
| | No. of Case Mentions | No. of Single Exposures | > = > | 6-12 | 13–19 |) ==20 | nknown U Child | Unknown Unknown Unknown Child Adult Age | nknown Age | Unint | Int Or | Other R | Adv in Rxn F | in Health — Care Facility | None | Minor | Moderate | Major I | Death |
| Laundry Prewash/Stain Removers: Laundry Prewash/Stain Removers: Aerosol or Spray Solvent | 335 | 318 | 280 | - | w | 29 | - | 4 | 0 | 311 | 2 | 2 | ю | 44 | 69 | 62 | 14 | 0 | 0 |
| Based Laundry Prewash/Stain Removers: Aerosol or Spray Surfactant | 186 | 175 | 150 | 2 | 2 | 20 | 0 | | 0 | 173 | - | 0 | - | 23 | 42 | 37 | 2 | 0 | 0 |
| Laundry Prewash/Stain Removers: | 5 | 5 | 4 | 0 | 0 | - | 0 | 0 | 0 | S | 0 | 0 | 0 | 1 | 2 | - | 0 | 0 | 0 |
| Dry Solvent based Laundry Prewash/Stain Removers: Dry Surfactant Based | 110 | 107 | 94 | 0 | - | 10 | 0 | 2 | 0 | 105 | 2 | 0 | 0 | 9 | 27 | 10 | 2 | 0 | 0 |
| Lionid Solvent Based Lionid Solvent Based | 1,005 | 970 | 771 | 27 | 13 | 124 | 0 | 35 | 0 | 953 | 10 | 2 | 4 | 156 | 323 | 139 | 13 | - | 0 |
| Liquid Sorvent Based Liquid Surfactant Based | 2,049 | 1,974 | 1,731 | 37 | 22 | 138 | ∞ | 27 | 11 | 1,926 | 12 | 6 | 26 | 222 | 387 | 332 | 42 | 0 | 0 |
| Laundry Prewash/Stain Removers: Other or Unknown | 2,551 | 2,442 | 1,951 | 79 | 35 | 321 | 2 | 53 | П | 2,385 | 20 | 18 | 17 | 241 | 496 | 505 | 26 | - | 0 |
| Laundry Prewash/Stain Removers: Other or Unknown Solvent Based | 85 | 82 | 89 | 8 | 1 | 7 | 0 | 7 | - | 81 | 0 | 0 | - | 12 | 17 | 12 | 1 | 0 | 0 |
| Laundry Prewash/Stain Removers: Other or Unknown Surfactant Based | 94 | 92 | 81 | | 0 | 7 | - | 7 | 0 | 91 | | 0 | 0 | ϵ | 13 | 4 | | 0 | 0 |
| Miscellaneous Cleaning Agents: | 1,694 | 1,481 | 854 | 4 | 48 | 439 | 2 | 85 | 6 | 1,411 | 35 | 20 | 13 | 292 | 326 | 302 | 55 | 3 | 0 |
| Miscellaneous Cleaning Agents: | 8,054 | 7,148 | 4,642 | 175 | 254 | 1,746 | 11 | 300 | 20 | 6,813 | 181 | 75 | 9 | 1,309 | 1,604 | 1,230 | 199 | ∞ | 1 |
| Miscellaneous Cleaning Agents: Anionics or Nonionics | 6,277 | 5,687 | 3,995 | 172 | 166 | 1,109 | 10 | 215 | 20 | 5,455 | 134 | 41 | 50 | 682 | 1,180 | 836 | 91 | 2 | - |
| Miscellaneous Cleaning Agents: | 2,290 | 2,139 | 1,174 | 88 | 108 | 651 | 1 | 106 | 11 | 1,980 | 113 | 20 | 23 | 420 | 454 | 404 | 81 | 5 | 0 |
| Miscellaneous Cleaning Agents: Ethanol (Excluding Automotive Products) | 782 | 742 | 571 | 31 | 22 | 66 | - | 18 | 0 | 716 | 14 | 7 | ∞ | 28 | 153 | 68 | 9 | 0 | 0 |
| Miscellaneous Cleaning Agents: Glycols (Excluding Automotive Products) | 717 | 629 | 425 | 42 | 23 | 136 | 8 | 27 | ю | 628 | 24 | ю | 4 | 91 | 152 | 118 | 17 | 0 | 0 |
| Miscellaneous Cleaning Agents: Isopropanol (Excluding Automotive Products and Glass) | 2,309 | 2,117 | 1,426 | 219 | 108 | 302 | 6 | 47 | 9 | 2,021 | 09 | 21 | 10 | 185 | 475 | 297 | 19 | 0 | 0 |
| Miscellaneous Cleaning Agents: Methanol (Excluding Automotive Products) | 46 | 42 | 25 | 2 | 0 | 11 | 0 | 4 | 0 | 37 | 2 | 0 | 2 | 17 | 12 | 6 | 0 | 2 | 0 |
| Miscellaneous Cleaning Agents: Other or Unknown Household Cleaning Agents | 4,416 | 3,965 | 2,401 | 266 | 183 | 968 | 17 | 175 | 27 | 3,707 | 136 | 64 | 38 | 707 | 850 | 811 | 113 | 2 | 0 |
| Miscellaneous Cleaning Agents: Phenol (Excluding Disinfectants) | 7 | 9 | 4 | 1 | 0 | 0 | 0 | 1 | 0 | ν. | 0 | 0 | 1 | 4 | 3 | 1 | 0 | 0 | 0 |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | Treated | | nO | Outcome | | |
|---|------------------|---------------------|-------|------|-------|----------------|-------------------|------------------------------------|---------------|-------|--------|--------------|--------------|------------------|-------|-------|------------|-------------|-------|
| | No. of | No. of | | | | 20. | | | | | | | 1 | in Health — | | | | | |
| | Case Mentions | Single Exposures | <=> | 6-12 | 13–19 | U ₁ | nknown U Child | Unknown Unknown Child Adult Age | ıknown Age | Unint | Int Ot | A Other R | Adv Rxn F | Care Facility | None | Minor | Moderate 1 | Major Death | Seath |
| Miscellaneous Cleaning Substances (Household) | (Household | | | 1 | | | | | | | | | , | | | | | , | |
| Ammonia Cleaners (All Purpose) | 1,202 | 881 | 314 | 50 | 4 8 | 396 | 4 0 | 70 | m | 818 | 36 | 4 6 | ∞ í | 191 | 149 | 205 | 45 | 7 0 | 0 |
| Carpet, Upholstery, Leather, or Vinyl Cleaners | 4,607 | 4,529 | 3,203 | 118 | 88 | C7/ | × | 119 | × | 4,197 | 66 | 70 | 4 | 240 | 891 | 137 | 99 | S | 0 |
| Hydrofluoric Acid or Bifluoride | 54 | 53 | 12 | - | 7 | 30 | 0 | 3 | 0 | 52 | _ | 0 | 0 | 36 | ∞ | 18 | ∞ | - | 0 |
| Starches, Fabric Finishes, or | 339 | 323 | 267 | 12 | 6 | 23 | 2 | 10 | 0 | 317 | 4 | 1 | - | 14 | 73 | 26 | 2 | 0 | 0 |
| Sizing Oven Cleaners | | | | | | | | | | | | | | | | | | | |
| Oven Cleaners: Acids | 4 | 4 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | - | 3 | 0 | 0 | 0 | 0 |
| Oven Cleaners: Alkalis | 2,159 | 2,082 | 432 | 92 | 159 | 1,108 | 13 | 266 | 12 | 1,959 | 38 | 49 | 32 | 797 | 225 | 583 | 285 | 6 | 0 |
| Oven Cleaners: Detergent Types | 20 | 19 | es ; | 0 | e | 11 | 0 | 7 | 0 | 19 | 0 | 0 | 0 | e | - ; | 9 | - | 0 | 0 |
| Oven Cleaners: Other or Unknown | 420 | 392 | 91 | 13 | 28 | 209 | 0 | 49 | 2 | 369 | 9 | 4 | ω | 138 | 49 | 101 | 33 | - | 0 |
| Rust Removers | | ! | | | | | | | , | | | | , | | | | | | |
| Rust Removers: Acids Other Than | 570 | 486 | 169 | 13 | 10 | 256 | - | 34 | С | 471 | 11 | 7 | 7 | 101 | 116 | 140 | 19 | 0 | 0 |
| Rust Removers: Alkalis | 4 | 4 | _ | 0 | 0 | С | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 |
| Rust Removers: Hydrofluoric | 322 | 311 | 61 | 0 | 8 | 217 | 0 | 21 | 4 | 288 | 7 | 0 | 15 | 132 | 98 | 131 | 40 | 0 | 0 |
| Acid Rust Removers: Other or | 196 | 173 | 33 | S | ∞ | 109 | 0 | 15 | 8 | 158 | 2 | 2 | 11 | 39 | 22 | 41 | 19 | 0 | 0 |
| Unknown | | | | | | | | | | | | | | | | | | | |
| Spot Removers/Dry Cleaning Agents Spot Removers/Dry Cleaning | s 163 | 151 | 127 | - | С | 18 | 0 | 2 | 0 | 148 | - | 0 | 2 | 13 | 32 | 23 | 2 | 0 | 0 |
| Agents: Anionics or Nonionics Spot Removers/Dry Cleaning | 213 | 200 | 133 | 6 | 9 | 40 | 0 | 11 | 1 | 193 | - | 2 | 4 | 32 | 45 | 4 | 7 | 0 | 0 |
| Agents: Glycols | | , | Ş | , | , | \ | (| , | (| i | (| , | | , | ; | · | (| (| (|
| Spot Removers/Dry Cleaning | 61 | 09 | 49 | 2 | 7 | 9 | 0 | - | 0 | 28 | 0 | _ | _ | κ | 21 | 16 | 0 | 0 | 0 |
| Agents: Isopropanor Spot Removers/Dry Cleaning | 20 | 18 | 4 | - | ю | 6 | 0 | - | 0 | 17 | - | 0 | 0 | 4 | ю | 33 | 2 | 0 | 0 |
| Agents: Other Halogenated Hydrocarbon Containing Products | | | | | | | | | | | | | | | | | | | |
| Spot Removers/Dry Cleaning | 452 | 414 | 220 | 19 | 13 | 124 | 0 | 33 | S | 389 | 111 | 4 | 10 | 86 | 104 | 104 | 18 | 3 | 0 |
| Agents: Other Hydrocarbon and/or Non-Halogenated | | | | | | | | | | | | | | | | | | | |
| Containing | , | 9 | i | , | • | ļ | (| • | 4 | | , | | | ì | , | , | • | 4 | (|
| Spot Removers/Dry Cleaning | 109 | 103 | 70 | _ | 7 | 27 | 0 | rs. | 0 | 100 | _ | 0 | 7 | 16 | 21 | 18 | 2 | 0 | 0 |
| Agents: Other of Charlown Spot Removers/Dry Cleaning | 14 | 14 | 10 | 0 | 0 | 4 | 0 | 0 | 0 | 13 | 0 | 0 | - | Т | ю | - | 1 | 0 | 0 |
| Agents: Perchloroethylene | | | | | | | | | | | | | | | | | | | |
| Toilet Bowl Cleaners Toilet Bowl Cleaners, Acide | \$ 100 | 2 207 | 1 272 | 110 | 107 | 1 537 | _ | 235 | 27 | 2 173 | 150 | 9 | 5 | 999 | 107 | 1 150 | 175 | = | 6 |
| Toilet Down Cleaners: Allerie | 2,085 | 7,567 | 1,2,1 | 57 | 167 | 775 | t < | 777 | 5 - | 2,172 | 27 | 27 | 1 0 | 370 | 107 | 517 | 6.7 | 11 | n c |
| Toilet Bowl Cleaners: Other or | 4,530 | 4,286 | 3,731 | 71 | 48 | 333 | † I | 72 | 20 | 4,221 | 47 | 9 | 12 | 353 | 1,148 | 327 | 8 9 | 2 2 | 0 |
| Unknown | | | | | | | | | | | | | | | | | | | |
| Wall/Floor/Tile/All-Purpose | 2,239 | 1,928 | 1,256 | 57 | 55 | 452 | 2 | 102 | 4 | 1,852 | 49 | 10 | 17 | 283 | 530 | 376 | 47 | 2 | 0 |
| Cleaning Agents: Acids | i | 1 | | | 0 | | ; | i | | 1 | 0 | į | (| , | , | | 0 | (| (|
| Wall/Floor/1116/All-Purpose Cleaning Agents: Alkalis | 1,776 | 6,952 | 4,712 | 204 | 198 | 1,513 | 14 | 6/2 | 32 | 6,657 | 180 | 4./ | 63 | 1,106 | 1,646 | 1,372 | 202 | × | 0 |
| , | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| (| | | | ı | | | | | | | 4 | | | | | | | | |
|--|------------------|---------------------|---------|-------|-------|--------|-------------------|------------------------------------|---------------|---------|---------|--------------|---------------------|------------------------|--------|--------|------------|-------------|------|
| | No of | No | | | | Age | | | | | Keason | | ء. - | Treated in Health — | | O | Outcome | | |
| | Case Mentions | Single Exposures | <=> | 6–12 | 13–19 | V_1 | nknown U Child | Unknown Unknown Child Adult Age | ıknown Age | Unint | Int O | A Other R | Adv Rxn F | | None] | Minor | Moderate N | Major Death | eath |
| Wall/Floor/Tile/All-Purpose Cleaning Agents: Anionics or Nonionics | 9,449 | 8,534 | 5,686 | 276 | 252 | 1,974 | 20 | 302 | 24 | 8,128 | 272 | 87 | 35 | 1,419 | 1,938 | 1,353 | 131 | w | 0 |
| Wall/Floor/Tile/All-Purpose | 2,385 | 2,035 | 1,259 | 66 | 83 | 476 | 9 | 101 | Ξ | 1,898 | 93 | 25 | 15 | 298 | 381 | 397 | 34 | 3 | 0 |
| Cleaning Agents: Cationics Wall/Floor/Tile/All-Purpose | 746 | 708 | 584 | 12 | 19 | 72 | 0 | 14 | 7 | 989 | 13 | П | ∞ | 47 | 196 | 93 | 7 | П | 0 |
| Wall/Floor/Tile/All-Purpose | 1,297 | 1,168 | 006 | 29 | 28 | 170 | 3 | 28 | 10 | 1,131 | 25 | 3 | 7 | 103 | 289 | 147 | 14 | 2 | 0 |
| Cleaning Agents: Olycols Wall/Floor/Tile/All-Purpose | 463 | 426 | 326 | 12 | ∞ | 71 | 0 | 6 | 0 | 404 | 9 | 9 | 6 | 36 | 118 | 92 | 3 | 0 | 0 |
| Vall/Floor/Tile/All-Purpose | 2 | 2 | 0 | 0 | - | 1 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | П | 0 | 0 | 0 | 0 |
| Vall/Floor/Tile/All-Purpose Cleaning Agents: Other or Thknown | 1,528 | 1,392 | 886 | 26 | 40 | 290 | П | 43 | 4 | 1,325 | 40 | 14 | 10 | 231 | 318 | 243 | 32 | - | 0 |
| Category Total: Cosmetics/Personal Care Products Dental Care Products | 201,750 | 180,493 111,817 | 111,817 | 660'9 | 6,627 | 46,318 | 380 | 8,348 | 904 | 171,493 | 5,303 1 | 1,833 1 | 1,446 | 26,989 | 36,278 | 34,941 | 4,492 | 194 | 21 |
| False Teeth Cleaning Agents | 1.871 | 1.841 | 301 | 27 | 31 | 1.345 | 2 | 125 | 10 | 1.774 | 34 | 5 | 23 | 91 | 347 | 162 | 6 | 0 | 0 |
| Other Dental Care Products (Excluding Fluoride Supplements) | 4,318 | 4,223 | 2,078 | 409 | 238 | 1,263 | ∞ | 215 | 12 | 3,914 | 83 | 6 | 208 | 306 | 640 | 373 | 41 | - | 0 |
| Toothpastes (with Fluoride) | 22,987 | 22,446 | 20,039 | 612 | 366 | 1,173 | 19 | 219 | 18 | 21,864 | 237 | 53 | 277 | 376 | 4,516 | 1,166 | 45 | 0 | 0 |
| Toothpastes (without Fluoride) Hair Care Products | 2,148 | 2,060 | 1,822 | 43 | 36 | 131 | 2 | 22 | 4 | 1,992 | 13 | ю | 52 | 28 | 374 | 91 | 10 | 0 | 0 |
| Curl Activators | 53 | 53 | 43 | 0 | 1 | S | 0 | 3 | 1 | 49 | 1 | 0 | 2 | 14 | 15 | 7 | 2 | 0 | 0 |
| Hair Coloring Agents (Excluding Peroxides) | 2,376 | 2,313 | 954 | 62 | 156 | 936 | - | 191 | 13 | 1,925 | 29 | 8 | 348 | 439 | 347 | 517 | 133 | 7 | 0 |
| Hair Oils | 344 | 335 | 287 | 6 | S | 31 | 0 | 3 | 0 | 328 | 3 | - | 3 | 47 | 73 | 43 | ∞ | 0 | 0 |
| Hair Relaxers (with Other | 574 | 268 | 415 | 10 | 17 | 116 | 0 | ∞ | 7 | 550 | 2 | 0 | 13 | 275 | 122 | 184 | 92 | 2 | 0 |
| Hair Relaxers (with Other | 88 | 88 | 89 | 2 | 0 | 17 | 0 | _ | 0 | 84 | 0 | C | 4 | 26 | 26 | 17 | 9 | С | 0 |
| Non-Alkalines) | | | | ı | | | | • | | | | | | ì | ì | ; | | | |
| Hair Relaxers (with Sodium Hydroxide) | 764 | 754 | 540 | 15 | 26 | 148 | 1 | 23 | 1 | 725 | 7 | 0 | 22 | 350 | 153 | 222 | 83 | 0 | 0 |
| Hair Rinses, Conditioners, Relaxers | 2,259 | 2,138 | 1,780 | 94 | 49 | 178 | - | 32 | 4 | 2,072 | 31 | 4 | 27 | 171 | 460 | 223 | 26 | 0 | 0 |
| Hair Sprays | 1,795 | 1,617 | 1,119 | 09 | 112 | 280 | П | 41 | 4 | 1,412 | 179 | 13 | 11 | 270 | 353 | 260 | 45 | 1 | 1 |
| Other Hair Care Products | 3,127 | 2,978 | 2,151 | 70 | 110 | 515 | 10 | 105 | 17 | 2,794 | 36 | 9 | 137 | 379 | 562 | 425 | 81 | 2 | 0 |
| (Excluding Peroxides) Permanent Wave Solutions | 302 | 296 | 181 | 4 | 4 | 82 | 0 | 15 | 0 | 279 | 2 | - | 14 | 112 | 55 | 85 | 24 | 0 | 0 |
| Shampoos | 6,321 | 900'9 | 4,680 | 266 | 181 | 739 | 12 | 1111 | 17 | 5,731 | 165 | 20 | 84 | 423 | 833 | 1,002 | 72 | 2 | 0 |
| Hand Sanitizers Hand Sanitizers: Ethanol Based | 191.8 | 3 705 | 2 032 | 307 | 112 | 200 | ٧ | 48 | - | 3.476 | 150 | 22 | c | 23.1 | 087 | 313 | 23 | C | 0 |
| Hand Sanitizers: Isonronanol | 33 | 32 | 2,722 | 20, | 711 | 4 | 0 0 | p = | - C | 30 | 12) | - 6 | 1 C | 2 | 7 / 2 | 2.2 | G C | ۰ - | 0 0 |
| Based | | 1 | 3 | 1 | - | - | | | | 3 | , | , | | 1 | 3 | 1 | | | |
| Hand Sanitizers: Non-Alcohol Based | 330 | 328 | 243 | 34 | 12 | 27 | | 6 | 2 | 316 | 9 | 4 | 0 | Ξ | 46 | 28 | 0 | 0 | 0 |
| Hand Sanitizers: Unknown | 77 | 75 | 48 | 6 | 4 | ∞ | _ | 5 | 0 | 89 | 4 | ж | 0 | 7 | 13 | 10 | 0 | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | Treated | | Õ | Outcome | | |
|--|----------------------------|-------------------------------|----------------|-------|--------|-------------|--------------------------------|-------|----------------|---------|----------------|-------|---------------|---------------------------------|---|--------|------------|---------|----------------|
| | No. of Case Mentions | No. of Single Exposures | > = 5 | 6-12 | 13–19 |)==20 | Unknown Unknown Child Adult | | Unknown Age | Unint | Int | Other | Adv in Exxn F | in Health – Care Facility | None | Minor | Moderate 1 | Major L | Death |
| Miscellaneous Cosmetics/Personal Care Products | Sare Produc | ts | | | | | | | | | | | | | | | | | |
| Baby Oils | 2,012 | | 1,801 | 28 | 28 | 94 | 2 | 15 | 4 | 1,941 | 13 | 4 | 6 | 181 | 524 | 172 | 12 | 2 | 0 |
| Bath Oils and/or Bubble Baths | 3,066 | 2,979 | 2,716 | 102 | 24 | 116 | 7 | 14 | 0 | 2,932 | 26 | 2 | 17 | 130 | 512 | 569 | 11 | 0 | 0 |
| Creams, Lotions, and Make-Up | 27,623 | 26,577 | 22,687 | 645 | 472 | 2,331 | 45 | 349 | 48 | 25,663 | 258 | 99 | 581 | 877 | 4,180 | 1,326 | 105 | - | 1 |
| Deodorants | 23,287 | 23,026 | 21,005 | 466 | 551 | 801 | 38 | 154 | 11 | 22,482 | 279 | 65 | 186 | 969 | 3,605 | 1,407 | 09 | 3 | 0 |
| Depilatories | 995 | 926 | 288 | 45 | 86 | 451 | 2 | 88 | 4 | 199 | 51 | 9 | 256 | 229 | 116 | 250 | 91 | _ | 0 |
| Douches | 173 | 171 | 140 | 0 | - | 26 | 0 | 4 | 0 | 161 | 5 | - | 4 | 6 | 50 | 15 | 2 | 0 | 0 |
| Eye Products | 1,559 | 1,462 | 1,235 | 16 | 32 | 145 | 2 | 24 | ∞ | 1,399 | 9 | 2 | 54 | 75 | 262 | 101 | 19 | 2 | 0 |
| Lipsticks and Lip Balms (with | 196 | 933 | 853 | 25 | 15 | 30 | | ∞ | 1 | 912 | 12 | 1 | ∞ | 26 | 170 | 99 | 3 | 0 | 0 |
| Camphor) | 0 | 000 | 000 | 9 | 1,7 | 9 | | ć | č | 607 | , | c | 9 | 7 | , <u>, , , , , , , , , , , , , , , , , , </u> | 010 | ć | - | c |
| Camphor) | 2,980 | 3,824 | 1,66,6 | 109 | /c | 190 | CI | 30 | 97 | 1,381 | 2/ | c | 199 | | 212 | 738 | C7 | - | 0 |
| Perfumes. Colognes, and Affershaves | 12.559 | 12.234 | 10.302 | 578 | 396 | 808 | ~ | 114 | 28 | 11,758 | 339 | 91 | 17 | 916 | 2.718 | 2.328 | 06 | ٧. | C |
| Peroxides | 9,316 | 8,961 | 3,450 | 386 | 432 | 3,917 | 13 | 712 | 51 | 8,404 | 220 | 56 | 267 | 878 | 1,157 | 1,546 | 167 | 7 | - |
| Powders Made of Material Other | 1,779 | 1,736 | 1,588 | 34 | 18 | 71 | 10 | 15 | 0 | 1,701 | 17 | 8 | 4 | 112 | 315 | 308 | 11 | 0 | 0 |
| Than Talc | | | | | | | | | | | | | | | | | | | |
| Powders Made of Talc | 2,354 | 2,280 | 1,947 | 78 | 54 | 157 | 3 | 37 | 4 | 2,215 | 4 | 10 | 6 | 263 | 473 | 468 | 38 | 0 | 0 |
| Soaps (Bar, Hand or Complexion) | 17,338 | 16,608 | 12,503 | 880 | 497 | 2,277 | 30 | 380 | 41 | 15,824 | 350 | 143 | 270 | 817 | 2,433 | 2,000 | 109 | _ | 0 |
| Suntan and/or Sunscreen Products | 12,846 | 12,646 | 11,447 | 468 | 142 | 478 | 26 | 73 | 12 | 12,419 | 39 | 16 | 162 | 478 | 1,804 | 1,568 | 63 | 0 | 0 |
| Mouthwashes | | | | | | | | | | | | | | | | | | | |
| Mouthwashes: Ethanol Containing | 8,883 | 8,246 | 2,803 | 684 | 617 | 3,547 | 6 | 555 | 31 | 7,075 | 1,080 | 27 | 38 | 1,039 | 1,456 | 762 | 208 | 20 | 1 |
| Mouthwashes: Fluoride Containing | 6,225 | 6,141 | 4,345 | 1,131 | 143 | 451 | ∞ - | 9 9 | т (| 6,039 | 29 | S (| 24 | 84 | 1,130 | 168 | 7 | ۰. | 0 |
| Mouthwashes: Non Ethanol | 1,104 | 1,065 | 514 | 130 | 49 | 317 | _ | 25 | 7 | 1,003 | 40 | 0 | 4 | 09 | 195 | 49 | 4 | _ | 0 |
| Containing | 701 | 001 | Ü | 5 | - | ľ | c | | c | | c | | c | Ų | 6 | 5 | Ų | c | c |
| Mouthwashes: Unknown | 196 | 180 | 8/ | 19 | Ξ | 27 | 0 | CI | 0 | 16/ | × | _ | 33 | CI | 56 | 13 | n | 0 | 0 |
| Nan Froducts Acretic Nail Adhacites | 1 306 | 1 387 | 601 | 390 | 12 | 331 | - | 53 | 7 | 1 3/12 | , | Ξ | _ | 787 | 177 | 262 | 7.7 | c | 0 |
| Acrylic Nail Primare | 055,1 | 1,362 | 222 | CO2 | +71 | 150 23 | | J OX | ` ` | 245,1 | 77 | - | t (| 701 | 1/1 | 202 | 17 | 1 - | 0 |
| Acrylic Nail Removers | 30 | 30 | 777 | † (1 | - c | 3 5 | | 0 - | | 80 | 1 C | | ۱ ح | 8 = | S & | 0 | <u> </u> | | 0 |
| Miscellaneous Nail Products | 1 133 | 1 008 | 27.7 | 30 | 33 | 232 | > - | 50 | > - | 1 073 | ¹ C | 0 0 | <u> </u> | 103 | 070 | , 10 | 5,5 | > - | 0 |
| Nail Polish Removers (Acetone | 2,493 | 2,444 | 1 877 | 75 | 76 | 346 | ٠ ٧ |) « | , 9 | 2,371 | 49 | ~ ~ | J (| 254 | 929 | 350 | 3 4 | - 0 | 0 0 |
| Containing) | 1 | í | 1,0,1 | | ` | 2 | , | | | į | 2 | 2 | 'n | 3 | | | - | | |
| Nail Polishes | 10,356 | 10,133 | 9,243 | 295 | 4 | 347 | 23 | 99 | 15 | 10,013 | 75 | 24 | 15 | 553 | 1,915 | 1,115 | 39 | _ | 0 |
| Other Nail Polish Removers | 1,228 | 1,196 | 920 | 52 | 45 | 159 | 0 | 17 | 3 | 1,151 | 30 | 7 | 7 | 125 | 310 | 184 | 15 | _ | 0 |
| Unknown Nail Polish Removers | 8,169 | 7,902 | 5,784 | 334 | 372 | 1,184 | 13 | 204 | 11 | 7,614 | 204 | | 13 | 857 | 1,851 | 1,124 | 28 | 2 | 0 |
| Category Total: | 214,861 | 208,321 | 162,208 | 8,917 | 5,929 | 26,195 | 336 | 4,321 | 415 | 199,571 | 4,288 | 815 | 3,406 | 12,993 | 36,813 | 21,622 | 1,960 | 99 | 4 |
| Deodorizers | | | | | | | | | | | | | | | | | | | |
| Air Freshener | 7557 | 2 401 | 1 022 | 210 | 110 | 37.0 | v | 23 | V | 7 2 47 | 00 | 30 | 16 | 757 | 737 | 503 | 7 | < | < |
| Air Frachanam: Limide | 10.807 | 107.01 | 0,602 | 205 | 100 | 181 | . 7 | 00 | , = | 10.561 | 99 | 55 | 2 7 | 167 | 7 530 | 200 | ‡ 8 | |) - |
| Air Fresheners: Solids | 5,007 | 4 995 | 2,032 4 540 | 107 | 58 | 7451 744 | C1 4 | 37 | | 10,001 | 45 | 8 4 | <u>†</u> 4 | 300 | 1 104 | 1,7,4 | 980 | | - 0 |
| Air Fresheners: Unknown Form | 2,222 | 2.179 | 1.874 | 82 | % % | 152 | - (1) | 27 | , cc | 2.104 | 50 | - 4 | - 01 | 225 | 542 | 312 | 91 | · C | 0 |
| Miscellaneous Deodorizers | | | | | | | | i | | | | | | | ! | | | |) |
| Diaper Pail Deodorizers | 12 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 2 | _ | 0 | 0 | 0 |
| (Excluding Moth Repellants) | | | | | | | | | | | | | | | | | | | |
| Other Types of Deodorizer | 4,467 | 4,293 | 3,207 | 135 | 83 | 714 | 6 | 135 | 10 | 4,164 | 99 | 24 | 37 | 456 | 995 | 633 | 53 | 7 | 0 |
| Toilet Bowl Deodorizers | 449 | 435 | 385 | œ | ĸ | 28 | - | 6 | - | 432 | c | C | C | 26 | 142 | 4 | 2 | 0 | 0 |
| Unknown Types of Deodorizer | 89 | 65 | 39 | 9 | , | 1 5 | 0 | v. | 0 | 62 | , | 2 | 0 | > ∞ | 1 4 | · ∞ | 1 m | 0 | 0 |
| (Not for Personal Use) | | | | | | | | | | | | | | | | | | | |
| Category Total: | 25,606 | 25,172 | 21,571 | 845 | 411 | 1,908 | 37 | 365 | 35 | 24,620 | 315 | 139 | 81 | 2,170 | 5,766 | 3,721 | 234 | 3 | - |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | , | 2 | | | | Age | | | | | Reason | | ⁻ | Treated | | Outc | Outcome | | |
|--|----------------------------|-------------------------------|-------|------|-------|-------|--------------------|---------------|----------------|-------|------------|-------|----------------|---------------------------------|-------|----------------|------------|----------|-------|
| | No. or Case Mentions | No. or Single Exposures | >= > | 6–12 | 13–19 |)==20 | Unknown U Child | Unknown Adult | Unknown Age | Unint | Int | Other | Adv In | in Health – Care Facility | None | Minor Mc | Moderate M | Major Do | Death |
| Dyes Miscellaneous Dyes | | | | | | | | | | | | | | | | | | | |
| Dues: Esbrics | 308 | 307 | 767 | 27 | 18 | 95 | _ | 17 | < | 373 | 0 | - | 1 | 10 | 0.1 | 90 | C | 0 | 0 |
| Dyes: Foods (Including Easter | 1,107 | 1,063 | 886 | 88 | 26 | 42 | t /- | 1 1 | 2 0 | 1,025 | 24 | 9 | 2 ∞ | 23 | 186 | 40 | 1 ∞ | 0 | 0 |
| Egg) | | | | | | | | | | | | | | | | | | | |
| Dyes: Leathers | 61 | 09 | 54 | 0 | _ | 3 | 0 | 1 | | 27 | - | 0 | - | 2 | 24 | 7 | 0 | 0 | 0 |
| Dyes: Other | 463 | 427 | 154 | 72 | 108 | 70 | - | 17 | 5 | 384 | 21 | 4 | 18 | 53 | 101 | 31 | 7 | _ | 0 |
| Dyes: Unknown | 09 | 55 | 35 | 7 | _ | 10 | 0 | 2 | 0 | 49 | 0 | 1 | 4 | 7 | 11 | 9 | _ | 0 | 0 |
| Category Total: | 2,089 | 1,999 | 1,391 | 205 | 154 | 181 | 12 | 48 | œ | 1,887 | 22 | 12 | 43 | 104 | 403 | 105 | 18 | 1 | 0 |
| Essential Oils | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Essential Oil | | | | | | | | | | | | | | | | | | | |
| Cinnamon Oil | 542 | 494 | 297 | 45 | 61 | 69 | 2 | 19 | - | 386 | 9/ | 4 | 27 | 62 | 47 | 180 | 12 | 0 | 0 |
| Clove Oil | 485 | 455 | 276 | 12 | ∞ | 121 | 0 | 34 | 4 | 410 | 14 | 1 | 30 | 66 | 93 | 136 | 16 | 0 | 0 |
| Eucalyptus Oil | 206 | 471 | 281 | 20 | 9 | 148 | _ | 15 | 0 | 442 | 18 | 0 | 11 | 110 | 137 | 88 | 13 | 3 | _ |
| Miscellaneous Essential Oils | 7,918 | 7,741 | 6,414 | 206 | 100 | 818 | 16 | 170 | 17 | 7,520 | 77 | 24 | 111 | 643 | 1,928 | 1,362 | 73 | 3 | 0 |
| Pennyroyal Oil | 17 | 15 | 2 | 0 | 2 | ∞ | 0 | 3 | 0 | 6 | 4 | 1 | - | 3 | 0 | 4 | 0 | 0 | 0 |
| Tea Tree Oil | 1,235 | 1,157 | 761 | 38 | 28 | 270 | 2 | 53 | 5 | 1,063 | 42 | 4 | 45 | 167 | 325 | 165 | 17 | _ | 0 |
| Category Total: | 10,703 | 10,333 | 8,031 | 321 | 205 | 1,434 | 21 | 294 | 27 | 9,830 | 231 | 34 | 225 | 1,084 | 2,530 | 1,935 | 131 | 7 | 1 |
| Fertilizers | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Fertilizers | | | | | i | | | | | | | | , | | | į | | | |
| Household Plant Foods (Generally | 1,943 | 1,864 | 1,100 | 155 | 71 | 445 | 2 | 88 | m | 1,807 | 30 | 18 | 9 | 09 | 353 | 49 | - | 0 | 0 |
| Tor Indoor Plants) | 1 617 | 1 450 | 010 | 110 | 00 | 010 | c | 1.7 | 7 | 1 201 | 00 | 9 | ţ | 100 | 000 | 5 | 9 | < | < |
| Outdoor Eartilizare | 7,1017 | 2.506 | 1 663 | 111 | 0,7 | 010 | c 7.0 | 10 | 2 = | 1,301 | 3.5 | 10 | 2 5 | 171 | 235 | 171 | 20 | , د | 0 |
| Dlant Hormonas | 2,012 | | 1,000 | | † < | 701 | <u> </u> | 99 | 110 | 7,7 | 7 | 7 6 | <u> </u> | <u> </u> | 0 | 1 (| 07 - | 1 < | 0 |
| Hall Holmones Tubnown Tenas of Bartilizar | 101 | 96 | 53 | > = | † " | ` ; | | יי ר | | 7 0 | > < | n c | > " | t 2 | v 5 | 4 7 | - 6 | 0 0 | > < |
| Catagory Total: | 6 317 | ŭ | 3 745 | 440 | 190 | 1265 | 33 | 245 | ° 6 | 5 743 | † 6 | 9 | . 4 | 331 | 1 197 | 344 | . . | · (| - |
| Category rotat. Fire Extinguishers | 110,0 | | 3,7 | Î | 130 | 1,203 | 35 | 3 | 2 | 3,143 | 3 | Ć | ř | 100 | 1,177 | † | S | 4 | > |
| Miscellaneous Fire Extinguisher | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Fire Extinguishers | 2.882 | 2.812 | 300 | 347 | 425 | 1.261 | 83 | 317 | 79 | 2.486 | 114 | 164 | 7 | 681 | 404 | 801 | 133 | 4 | 0 |
| Category Total: | 2.882 | | 300 | 347 | 425 | 1,261 | % | 317 | 62 | 2.486 | 114 | 4 7 | ; ; | | 404 | 20. | 133 | - 4 | • |
| Food Products/Food Poisoning | 1,00,1 | | | Ì | ì | 10761 | 3 | | | 1,100 | | | 5 | 100 | | 100 | 3 | ٠ | |
| Bacterial Food Poisoning (Documented) | ted) | | | | | | | | | | | | | | | | | | |
| Botulism | | 129 | 13 | 9 | 4 | 87 | _ | 17 | _ | 108 | 4 | 9 | 6 | 56 | 24 | 4 | 4 | 9 | _ |
| Other Types of Bacterial Food | 625 | 909 | 171 | 53 | 38 | 276 | 1 | 61 | 5 | 569 | 0 | 12 | 24 | 83 | 54 | 71 | 25 | С | 0 |
| Poisoning (Salmonella, Shigella, Vibrio, Staphylococcus, | | | | | | | | | | | | | | | | | | | |
| Streptococcus, etc) | | | | | | | | | | | | | | | | | | | |
| Unknown Types of Bacterial Food Poisoning | 8,144 | 8,002 | 1,149 | 287 | 519 | 4,635 | 30 | 1,008 | 74 | 7,433 | 10 | 129 | 412 | 836 | 524 | 1,548 | 417 | 4 | 0 |
| Ichthyosarcotoxins | | | | | | | | | | | | | | | | | | | |
| Ciguatera Poisoning | 182 | 178 | 2 | 2 | 6 | 118 | 5 | 35 | 7 | 157 | 0 | 0 | 19 | 87 | 2 | 37 | 28 | 5 | 0 |
| Clupeotoxic Fish Poisoning | 10 | 10 | 0 | 0 | 2 | 5 | 0 | 3 | 0 | 7 | 0 | 0 | 3 | - | 0 | 2 | 0 | 0 | 0 |
| Other Types of Seafood Poisoning | 177 | 147 | 10 | 9 | 7 | 101 | 0 | 12 | Ξ | 113 | 0 | 7 | 32 | 31 | 10 | 56 | 22 | _ | 9 |
| Paralytic Shellfish Poisoning | 142 | 133 | 3 | 13 | 7 | 6 | 0 | 10 | 3 | 110 | 0 | 7 | 21 | 37 | S | 21 | 18 | _ | 0 |
| Scombroid Fish Poisoning | 151 | 139 | ∞ | 9 | 5 | 26 | 0 | 17 | 9 | 96 | 0 | _ | 42 | 32 | ∞ | 42 | 20 | 0 | 0 |
| Tetrodon Poisoning | 146 | 144 | 18 | 28 | 17 | 59 | 2 | 17 | 3 | 129 | 6 | - | 4 | 36 | 15 | 24 | 11 | _ | 1 |
| Miscellaneous Food Products/Food Poisoning | Poisoning | | | | | | | | | | | | | | | | | | |
| Capsicum Peppers (Exclude | 4,788 | 4,682 | 817 | 393 | 494 | 2,289 | 16 | 628 | 45 | 3,687 | 154 | 41 | 795 | 285 | 53 | 1,955 | 150 | 0 | 0 |
| (1001-1001) | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | , | | | | Age | | | | | Reason | | | Treated | | Ō | Outcome | | |
|--|----------------------------|-------------------------------|--------|--------|-------|--------|----------------|--|----------------|---------|--------|-------|-----------------|---------------------------------|--------|-------|---|-------------|-----------|
| | No. of Case Mentions | No. of Single Exposures | <= > | 6-12 | 3–19 |) ==20 | nknown U | Unknown Unknown Unknown Child Adult Age | Jnknown Age | Unint | Int | Other | Adv ii Rxn l | in Health - Care Facility | None | Minor | Moderate | Major Death | Death |
| | | | | | | | | | , | | | | | | | | | , | |
| Monosodium Glutamate (MSG) | 98 | 78 | 10 | 2 | 3 | 47 | 0 | 16 | 0 | 32 | _ | 0 | 45 | 11 | 4 | 20 | 9 | 0 | 0 |
| Other Adverse Reactions to Food | 2,243 | 2,088 | 572 | 138 | 157 | 935 | 10 | 253 | 23 | 772 | 32 | 115 | 1,153 | 409 | 112 | 482 | 158 | 4 | 1 |
| Unknown Types of Suspected | 8,344 | 8,179 | 991 | 569 | 554 | 5,023 | 4 | 882 | 116 | 7,745 | 12 | 149 | 263 | 861 | 263 | 1,560 | 475 | 6 | 0 |
| Food Poisoning | | | | | | | | | | | | | | | | | | | |
| Category Total: | 25,176 | 24,514 | 3,764 | 1,803 | 1,816 | 13,769 | 109 | 2,959 | 294 | 20,958 | 222 | 458 | 2,822 | 2,735 | 1,074 | 5,795 | 1,394 | 34 | 6 |
| Foreign Bodies/Toys/Miscellaneous | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Foreign Bodies/Toys/Miscellaneous | Miscellane | | | | | | | | | | | | | | | | | | |
| Ashes | 400 | 396 | 304 | 11 | 7 | 33 | 3 | 12 | 1 | 362 | _ | 7 | 0 | 10 | 46 | 35 | 0 | 0 | 0 |
| Bubble Blowing Solutions | 4,056 | 4,010 | 3,736 | 150 | 28 | 72 | 6 | 15 | 0 | 3,971 | 23 | 11 | 4 | 124 | 551 | 979 | 25 | 0 | 0 |
| Charcoals | 511 | 457 | 377 | ∞ | 14 | 42 | 0 | 14 | 2 | 437 | ∞ | 2 | 10 | 25 | 95 | 25 | 3 | 0 | 0 |
| Christmas ornaments | 484 | 479 | 405 | 25 | 5 | 35 | 0 | 6 | 0 | 476 | 33 | 0 | 0 | 39 | 98 | 28 | _ | 0 | 0 |
| Coins | 3.916 | 3.813 | 3.119 | 514 | 53 | 6 | Ξ | 12 | 7 | 3.726 | 49 | 6 | _ | 1.272 | 1.060 | 396 | 41 | 2 | О |
| Desiceants | 33 705 | 33 535 | 20 949 | 1 540 | 412 | 1 087 | 144 | 346 | 57 | 33 205 | 23.1 | 70 | × × | 1 194 | 4 583 | 238 | 1.5 | · C | · C |
| Hace / Irina | 6000 | 5 366 | 7 308 | 17. | 107 | 507 | | 151 | <u> </u> | 5 185 | 2 2 | 115 | . [| 100 | 777 | 107 | 1 | - | 0 0 |
| Clear Chillic | 6,000 | 2,200 | 1,000 | 177 | 707 | 5 5 | 17 4 | 101 | 0.0 | 7,100 | t < | 511 | , , | 27.0 | 100 | 771 | 200 | ٠. | 0 |
| Oldass | 3,440 | 7,547 | 1,300 | 104 | 200 | 2,141 | 99 | 939 | 00 | 3,190 | 040 | , (| 70 | 2/0 | 100 | 457 | 07 | ٠, | O |
| Glow Products | 216,77 | 188,77 | 550,01 | 5,354 | 834 | 3/8 | 83 | 247 | 32 | 615,22 | 309 | 7.7 | 70 | 850 | 2,686 | 4,159 | 19 | 7 - | 0 (|
| Incense (Punk) | | 403 | 279 | 10 | 34 | 89 | _ | 2 | 9 | 332 | 89 | _ | 7 | 88 88 | 71 | 29 | 28 | 0 | 0 |
| Other Types of Foreign Body, Toy, or Miscellaneous Substance | 23,949 | 22,875 | 15,248 | 2,702 | 970 | 2,967 | 61 | 805 | 122 | 21,895 | 505 | 232 | 179 | 2,074 | 4,007 | 1,104 | 132 | 4 | 0 |
| Soil | 2.034 | 1 781 | 1 474 | 117 | ~ | 182 | ιτ | 30 | 7 | 1 743 | 27 | - | 10 | 71 | 275 | 103 | 12 | - | 0 |
| Toyle | 7.027 | 7.833 | 6.037 | 1 310 | 218 | 102 | . . | 8 2 | . [| 7.576 | i S | 153 | 2 4 | 451 | 1 168 | 438 | 2.5 | - | 0 0 |
| IOys | 1.94.1 | 7,033 | 0,007 | 016,1 | 017 | 261 | <u> </u> | , , | | 0,5,0 | 2 5 | 5.5 | o • | 5 5 | 1,100 | 000 | 7 1 | - 0 | 0 0 |
| Unknown Types of Foreign Body, Toy, or Miscellaneous | 6// | /9/ | 155 | 96 | 40 | 65 | 7 | <u>×</u> | - | 124 | 13 | 21 | 4 | | 130 | 20 | | 0 | 0 |
| Substance | | | | | | | | | | | | | | | | | | | |
| Thermometers | | | | | | | | | | | | | | | | | | | |
| Thermometers: Mercury | 2,338 | 2,322 | 629 | 494 | 183 | 604 | 22 | 322 | 18 | 2,263 | 41 | 9 | 7 | 157 | 574 | 39 | | 0 | 0 |
| Thermometers: Other | 1,312 | 1,291 | 517 | 253 | 61 | 284 | 6 | 150 | 17 | 1,252 | 24 | 10 | 4 | 70 | 289 | 45 | 3 | 0 | 0 |
| Thermometers: Unknown | 353 | 351 | 114 | 58 | 21 | 114 | _ | 42 | 1 | 341 | 2 | 7 | 0 | 15 | 33 | _ | 0 | 0 | 0 |
| Category Total: | 116.537 | 113.877 | | 13.245 | 3.306 | 8.862 | 444 | 3.069 | 371 | 111.197 | 1.483 | 745 | 309 | 7.079 | 17.282 | 7.732 | 392 | 12 | • |
| Fumes/Cases/Vanors | | 2621 | | | | | | 6006 | | | , | 2 | | | 1 | | | ł | > |
| Miscellaneous Fumes/Gases/Vanors | - | | | | | | | | | | | | | | | | | | |
| Carbon Dioxide | 368 | 323 | 28 | 58 | 65 | 125 | 0 | 39 | ∞ | 294 | 19 | 0 | 7 | 62 | 54 | 57 | 25 | 0 | 0 |
| Carbon Monoxide | 13.472 | 12,404 | 1.576 | 1.173 | 802 | 6.352 | 161 | 2.075 | 235 | 11.983 | 271 | 25 | 53 | 5.080 | 3.119 | 3.096 | 1.056 | 166 | 37 |
| Chloramine Gas | 777 | 737 | 27 | 23 | 33 | 568 | 0 | 76 | 10 | 714 | 22 | - | 0 | 187 | 78 | 236 | 97 | - | C |
| Chlorine Gas | 4.459 | 4.258 | 300 | 386 | 332 | 2.672 | 32 | 486 | 50 | 4.034 | 143 | 22 | 51 | 1.313 | 249 | 1.690 | 627 | 12 | 2 |
| Chlorine Gas (When Household | 1,353 | 1,316 | 48 | 91 | 75 | 944 | 5 | 141 | 12 | 1.274 | 42 | 0 | 0 | 325 | 119 | 527 | 215 | 2 | _ |
| Acid is Mixed with | | | | | | | | | | | | | | | | | | | |
| Hypochlorite) | | | | | | | | | | | | | | | | | | | |
| Hydrogen Sulfide (Sewer Gas) | 1,169 | 1,054 | 59 | 43 | 51 | 486 | 7 | 386 | 22 | 1,037 | S | _ | 4 | 307 | 321 | 237 | 77 | 12 | 2 |
| Methane and Natural Gas | 5,330 | 4,996 | 885 | 892 | 254 | 2,049 | 26 | 849 | 41 | 4,944 | 20 | 9 | 22 | 754 | 1,847 | 802 | 133 | 1 | 1 |
| Other Types of Fume, Gas or | 1,341 | 1,215 | 111 | 52 | 74 | 289 | 21 | 256 | 14 | 1,103 | 50 | 22 | 37 | 344 | 196 | 285 | 116 | 4 | _ |
| Vapor | | | | | | | | | | | | | | | | | | | |
| Polymer Fume Fever | 7 | 7 | 0 | - | 0 | 9 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 2 | 3 | 3 | 0 | 0 | 0 |
| Simple Asphyxiants | 2,626 | 2,408 | 289 | 283 | 224 | 1,236 | 26 | 318 | 32 | 2,119 | 236 | 13 | 26 | 765 | 363 | 527 | 222 | 15 | В |
| Unknown Types of Fume. | 1.812 | 1,750 | 115 | 62 | 52 | 913 | 21 | 526 | 61 | 1.660 | 18 | 36 | 17 | 354 | 202 | 384 | 126 | 3 | 2 |
| Gas or Vapor | ` | | | | | | | | | ` | | | | | | | | | I |
| Category Total: | 32,714 | 30,468 | 3,438 | 3,064 | 1,962 | 16,038 | 329 | 5,152 | 485 | 29,169 | 826 | 126 | 217 | 9,493 | 6,551 | 7,844 | 2,694 | 218 | 52 |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | (Continued | (pan) |
| | | | | | | | | | | | | | | | | | |) | , |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | , | , | | | | Age | | | | | Reason | | F. | Treated | | Out | Outcome | | |
|--|----------------------------|---------------------|--------------|-------|-------|--------|--------------------------------|-------|----------------|--------|--------|-------|--------------|-----------------------------------|-------|-------------|------------|---------|-------|
| | No. or Case Mentions | Single Exposures | > = \$ | 6–12 | 13–19 |)==20 | Unknown Unknown Child Adult | | Unknown Age | Unint | Int | Other | Adv Rxn F | nn Healtn — Care Facility] | None | Minor M | Moderate N | Major D | Death |
| Heavy Metals | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Heavy Metals | 1 066 | 600 | 301 | 17 | - | 730 | 7 | 31 | 7 | 000 | 7 | 0 | 5 | 10 | 103 | ć | 71 | - | < |
| Arsenic (Excluding Pesticides) | 1,000 | | 204 | 40 | 78 4 | 539 | 9 | 66 | 11 | 603 | 13 | 130 | 13 | 482 | 131 | 53 53 | 45 | t 9 |) K |
| Barium, Soluble Salts | 29 | | 2 | 1 | ∞ | 3 | 0 | 2 | 0 | 11 | - | 0 | 4 | 5 | 2 | - | - | - | 0 |
| Cadmium | 197 | | 41 | 31 | 9 | 99 | - | 16 | 1 | 92 | 0 | 62 | 9 | 46 | 20 | 9 | 10 | 0 | 0 |
| Copper | 735 | | 83 | 59 | 146 | 242 | 2 | 64 | 5 | 533 | 24 | 11 | 17 | 163 | 87 | 164 | 33 | 3 | 0 |
| Fireplace Flame Colors | 32 | 32 | 14 | 4 | - | 9 | 5 | 2 | 0 | 24 | 0 | 0 | ∞ | 1 | 7 | 7 | 0 | 0 | 0 |
| Gold | 5 | 5 | 2 | - | 1 | _ | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lead | 2,390 | 2,2 | 1,120 | 198 | 104 | 613 | 22 | 158 | 19 | 2,068 | 4 | 42 | 16 | 895 | 570 | 137 | 55 | 4 | 0 |
| Manganese | 69 | 34 | 5 | 1 | 5 | 19 | 0 | 3 | | 24 | 0 | 1 | S | 19 | _ | 9 | 7 | 0 | 0 |
| Mercury (Other) | 105 | | 19 | 2 | 9 | 48 | 0 | 22 | 2 | 75 | 2 | 10 | 7 | 28 | 21 | ∞ | 1 | - | 0 |
| Mercury, Elemental (Excluding | 1,700 | 1,622 | 159 | 193 | 261 | 269 | Ś | 269 | 38 | 1,357 | 113 | 52 | 52 | 376 | 442 | 36 | 20 | 0 | 0 |
| Metal Firme Fever | 564 | 512 | 33 | 90 | 5 | 358 | - | 4 | 0 | 448 | 33 | × | 22 | 160 | 22 | 155 | 09 | C | 0 |
| Other Tynes of Heavy Metal | 2 648 | - | 755 | 12.1 | 106 | 709 | - (r | 146 | 1 7 | 1 567 | 76 | 41 | 12.1 | 376 | 322 | 174 | 8 9 | 1 0 | 0 0 |
| Selenium | 7,010 | | | 0 | 901 | - | 0 0 | 0 | CT C | 1,00,1 | ς ο | F C | 171 | 0/0 | 770 | † C | 3 - | \ C | 0 |
| Thallium | 17 | 12 | 0 | 0 | 0 | - ∞ | 0 | 4 | 0 | 9 | 0 | - | 'n | 10 | 0 | - | 2 | 0 | 0 |
| Unknown Types of Heavy Metal | 61 | 58 | 9 | 4 | 9 | 30 | 0 | Ξ | _ | 39 | S | ν. | 3 | 21 | 3 | 7 | ∞ | 0 | - |
| Category Total: | 10,638 | 9,1 | 2,938 | 742 | 770 | 3,582 | 51 | 912 | 146 | 7,781 | 350 | 381 | 291 | 2,660 | 1,810 | 797 | 318 | 30 | 4 |
| Hydrocarbons | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Hydrocarbons | | | | | | | | | | | | | | | | | | | |
| Benzene | 146 | 124 | 25 | 2 | _ | 28 | 0 | 33 | 7 | 117 | 3 | 0 | 3 | 91 | 29 | 18 | 6 | - | 0 |
| Carbon Tetrachloride | 34 | 31 | 2 | - | 0 | 24 | 0 | 4 | 0 | 31 | 0 | 0 | 0 | Ξ | S | ∞ | 2 | _ | 0 |
| Diesel Fuels | 266 | | 166 | 26 | 46 | 553 | 2 | 123 | 22 | 863 | 20 | 15 | 9 | 239 | 156 | 303 | 43 | - | 0 |
| Freon and Other Propellants | 7,288 | | 709 | 469 | 1,022 | 3,787 | 25 | 882 | 77 | 5,400 | 1,367 | 111 | 09 | 2,262 | 1,155 | 1,658 | 638 | 61 | 6 |
| Gasolines | 15,123 | _ | 3,051 | 877 | 1,463 | 7,865 | 26 | 1,318 | 26 | 13,555 | 886 | 73 | 45 | 2,467 | 2,034 | 4,964 | 412 | 14 | _ |
| Kerosenes | 1,204 | | 534 | 28 | 48 | 398 | ∞ | 91 | 7 | 1,079 | 43 | 19 | - | 363 | 212 | 300 | 83 | 12 | 0 |
| Lamp Oils | 1,875 | | 1,350 | 29 | 52 | 339 | 3 | 4 | 7 | 1,797 | 56 | 19 | 3 | 585 | 489 | 450 | 177 | 12 | 7 |
| Lighter Fluids and/or Naphtha | 2,710 | | 1,401 | 78 | 167 | 723 | 12 | 164 | 19 | 2,379 | 87 | 62 | 25 | 830 | 453 | <i>L</i> 69 | 163 | Ξ | 0 |
| Lubricating Oils and/ | 4,365 | 4,070 | 2,535 | 161 | 143 | 826 | 3 | 235 | 15 | 3,933 | 63 | 99 | 10 | 069 | 1,230 | 289 | 65 | 2 | 0 |
| or Motor Oils | 00 | 00 | 01 | < | c | ٥ | < | < | C | °C | < | - | c | v | c | - | - | c | < |
| Mineral Spirite | 1 871 | - | 587 | 0 0 | 103 | 780 | 9 | 147 | 0 2 | 1 557 | 101 | 21 | 2 | 575 | 306 | 480 | 1 = | 0 |) C |
| Other Types of Halogenated | 304 | 268 | 48 | ∞ ∞ | 21 | 170 | 0 | 26 | 7 7 | 241 | 18 | 9 | 3 6 | 104 | 33 | 87 | 26 | \ — | 1 0 |
| Hydrocarbon | | | | | | | | | | | | | | | | | | | |
| Other Types of Hydrocarbon | 4,687 | 4,358 | 2,245 | 158 | 204 | 1,439 | 10 | 277 | 25 | 4,105 | 155 | 54 | 37 | 1,064 | 1,035 | 975 | 192 | 17 | _ |
| Toluene and/or Xylene (Excluding | 844 | 728 | 106 | 17 | 31 | 435 | 0 | 127 | 12 | 899 | 39 | 4 | 12 | 305 | 73 | 229 | 09 | ∞ | 0 |
| Adhesives) | 7 | 0,0 | | c | i | 7 | (| ć | • | 000 | ţ | ć | , | | ` | Ġ | ò | (| c |
| Turpentine | 403 | 362 | | × | 52 | /81 | 0 | 29 | 2 | 309 | 5 | n 1 | 4 | Ξ | 99 | × × | 76 | 0 |) |
| Unknown Types of Hydrocarbon | 724 | 561 | 205 | 20 | 55 | 211 | ∞ | 57 | S | 485 | 59 | 7 | 6 | 180 | | 126 | 55 | 7 | - |
| Category Total: Industrial Cleanors | 42,604 | 40,402 | 13,094 | 2,015 | 3,379 | 17,955 | 103 | 3,557 | 299 | 36,547 | 3,044 | 451 | 234 | 9,883 | 7,453 | 11,074 | 2,066 | 155 | 16 |
| Miscellaneous Industrial Cleaners | | | | | | | | | | | | | | | | | | | |
| Industrial Cleaner: Disinfectants | 2,767 | 2,603 | 279 | 94 | 173 | 1,709 | 4 | 327 | 17 | 2,401 | 157 | 28 | 14 | 794 | 258 | 817 | 273 | 7 | 0 |
| Industrial Cleaner: Other or | 1,417 | 1,295 | 362 | 45 | 103 | 654 | 9 | 114 | 11 | 1,181 | 57 | 38 | 15 | 507 | 182 | 384 | 123 | 5 | 0 |
| Unknown | | | | | | | | | | | | | | | | | | | |
| Industrial Cleaners: Acids | 1,398 | | 345 | 21 | 53 | 655 | 7 | 127 | ∞ ! | 1,140 | 9 6 | 18 | 8 ; | 369 | 203 | 341 | 94 | S 5 | 0 |
| Industrial Cleaners: Alkalis | 7,547 | 7,557 | 664 | 9 | 169 | 1,249 | 9 | 192 | Ι/ | 2,203 | 8/ | 38 | 31 | 1,146 | 720 | 68/ | 344 | 87 | _ |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| (| | | | | | | | | | | , | | | | | | | | |
|--|---------------------|---------------------|---------------------|--------------|-------|---------------------|--|-------------------|----------------|---------------------|--------|------------------|--------------------------|------------------------|-------|---------------------|----------|-------------|-------|
| | No | No of | | | | Age | | | | | Keason | | =. - | Treated in Health — | | n O | Outcome | | |
| 4 | S. | Single Exposures | \ = 5 | 6-12 | 13–19 | U ₁ | Unknown Unknown Unknown Child Adult Age | nknown U Adult | Jnknown Age | Unint | Int | Other | Adv Rxn F | | None | Minor | Moderate | Major Death | Death |
| Industrial Cleaners: Anionics | 687 | 612 | 303 | 22 | 36 | 214 | 0 | 31 | 9 | 578 | 20 | S | S | 131 | 107 | 119 | 22 | 2 | 0 |
| or roundings Industrial Cleaners: Cationics Category Total: | 820 9,636 | 781 8.869 | 123 2,076 | 4 4 86 | 83 | 428 4.909 | 19 | 100 891 | 2 71 | 671 8,174 | 55 | 29 156 | 101 | 312 3,259 | 98 | 262 2.712 | 53 | 3 | 0 |
| Information Calls Food Information Calls | | ` | | | | | | | | | | | | | | | | | |
| Information Calls About Food Products, Additives or | 12,296 | 10,905 | 6,702 | 763 | 537 | 2,276 | 46 | 498 | 83 | 9,094 | 476 | 44 | 852 | 905 | 1,447 | 1,141 | 175 | 10 | 0 |
| Supplements Information Calls About Possibly Spoiled Foods | 17,379 | 16,921 | 4,680 | 1,667 | 1,080 | 7,551 | 91 | 1,699 | 153 | 15,690 | 47 | 462 | 674 | 879 | 2,019 | 1,216 | 208 | 4 | 0 |
| Miscellaneous Information Calls | | | | | | | | | | | | | | | | | | | |
| Medical Information | 3 | ε, | 0 | 0 | 0 | co o | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Poison Information | 20,00 | 1 000 | - 55 | 0 9 | 0 ! | 0 | 0 ! | 0 1 | 0 % | - 101 | 0 5 | 0 8 | 0 } | 0 ; | 0) | 0 ! | 0 6 | 0; | 0 (|
| Category Iotal: Lacrimators | 080,67 | 27,830 | 11,383 | 2,430 | 1,617 | 9,830 | 13/ | 7,197 | 730 | 74,/8/ | 573 | 986 | 075,1 | 1,781 | 3,400 | 7,55,7 | 383 | 4 | • |
| Miscellaneous Lacrimators Lacrimators: Capsicum Defense | 3,783 | 3,748 | 735 | 664 | 572 | 1,274 | 40 | 363 | 100 | 2,889 | 151 | 538 | 57 | 649 | 143 | 1,735 | 179 | _ | 0 |
| Sprays Lacrimators: CN | 1.012 | 993 | 167 | 86 | 161 | 363 | 6 | 105 | 06 | 701 | 51 | 186 | 6 | 176 | 32 | 479 | 49 | 0 | 0 |
| (Chloroacetophenone) | | , | | | • | | ` | | | | | | ` | | 1 | | <u>}</u> | | |
| Lacrimators: CS (O-Chloroben-zylidene Malonitrile) | 41 | 36 | 4 | 2 | 4 | ∞ | 0 | 18 | 0 | 27 | 4 | 3 | 1 | 23 | 2 | 10 | 18 | 0 | 0 |
| Lacrimators: Other | 89 | 43 | 1 | 0 | 3 | 29 | 0 | 7 | 33 | 36 | 1 | 0 | 5 | 16 | 2 | 10 | 8 | 0 | 0 |
| Lacrimators: Unknown | 224 | 205 | 40 | 22 | 39 | 9/ | 0 | 27 | _ | 145 | 7 | 37 | 4 | 20 | ∞ | 88 | 14 | 0 | 0 |
| Category Total: Motobookiiroworke/Evnlosives | 5,128 | 5,025 | 947 | 786 | 622 | 1,750 | 49 | 520 | 194 | 3,798 | 214 | 764 | 92 | 914 | 187 | 2,322 | 268 | 1 | 0 |
| Miscellaneous Matches/Fireworks/Explosives | xplosives | | | | | | | | | | | | | | | | | | |
| Explosives | 213 | 205 | 111 | 24 | 14 | 41 | - | 13 | - | 186 | 10 | 7 | 1 | 4 | 50 | 25 | 9 | 2 | 0 |
| Fireworks | 208 | 790 | 675 | 59 | 18 | 30 | П | 5 | 2 | 992 | 19 | 4 | 0 | 80 | 259 | 64 | 10 | 0 | 0 |
| Matches | 683 | 674 | 609 | 12 | 6 | 29 | 0 | 13 | 2 | 859 | 11 | 33 | 0 | 22 | 146 | 21 | - | 0 | 0 |
| Other Types of Match, Firework, or Explosive | 62 | 09 | 34 | 10 | 9 | 6 | 0 | - | 0 | 55 | c | - | - | Ξ | 12 | 23 | 3 | 0 | 0 |
| Unknown Types of Match, | - | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Firework, or Explosive | , | 1 | , | 1 | ļ | 9 | • | ; | • | , | : | ļ | • | ļ | , | , | • | • | • |
| Category Total: Mushrooms | 1,757 | 1,730 | 1,430 | 105 | 47 | 109 | 7 | 32 | 'n | 1,666 | £3 | 5 | 7 | 157 | 468 | 133 | 70 | 7 | • |
| Miscellaneous Mushrooms | | | | | | | | | | | | | | | | | | | |
| Group 1 Mushrooms: | 51 | 49 | ∞ | _ | 1 | 38 | 0 | - | 0 | 26 | 16 | 0 | 9 | 31 | S | 6 | 6 | 9 | 0 |
| Cyclopepudes Group 1A Mushrooms: Orellanine | 6 | ∞ | - | 2 | - | С | 0 | - | 0 | 9 | 2 | 0 | 0 | 5 | 2 | - | 0 | 0 | 0 |
| Group 2 Mushrooms: Muscimol (Thotenic Acid) | 48 | 42 | \$ | 0 | ∞ | 28 | 0 | П | 0 | 18 | 24 | 0 | 0 | 35 | 3 | ∞ | 20 | 2 | 0 |
| Group 3 Mushrooms: | 17 | 17 | 3 | 2 | 2 | 6 | 0 | 1 | 0 | 15 | 0 | 0 | 2 | 4 | ∞ | 2 | П | 0 | 0 |
| Monomethylhydrazine (MMH) | ć | 5 | - | C | c | 7 | c | c | | 9 | - | c | c | 5 | - | - | , | c | c |
| Group 4 Mushrooms: Muscarine and Histamine | 17 | 77 | - | 0 | 0 | 71 | 0 | 0 | 0 | 18 | 4 | 0 | 0 | 71 | - | 4 | 7 | 0 | 0 |
| Group 5 Mushrooms: Coprine | 11 | 9 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | S | - | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 0 |
| Group 6 Mushrooms: Hallucinogenics (Psilocybin | 643 | 478 | 26 | 4 | 208 | 202 | - | 31 | 9 | 74 | 394 | 7 | 9 | 344 | 23 | 92 | 193 | 9 | 0 |
| and Psilocin) | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | ; | , | | | | Age | | | | | Reason | | Г. | Treated | | Õ | Outcome | | |
|---|----------------------------|-------------------------------|--------|----------------|-------|----------------|------------------------------------|-------------------|----------------|----------|--------|-------|--------------|---------------------------------|-------|-------|----------|-------------|-------|
| | No. of Case Mentions | No. of Single Exposures | >= > | 6–12 | 3–19 | U ₁ | Unknown Unknown Child Adult Age | nknown U Adult | Jnknown Age | Unint | Int | Other | Adv Rxn F | in Health – Care Facility | None | Minor | Moderate | Major Death | Death |
| Group 7 Mushrooms: | 197 | 180 | 45 | 23 | ∞ | 93 | 2 | ∞ | _ | 132 | 31 | 0 | 17 | 66 | 35 | 06 | 25 | - | 0 |
| Mushrooms: Miscellaneous, | 131 | 108 | 53 | ∞ | 7 | 35 | 0 | 5 | 0 | 92 | 4 | 0 | 12 | 21 | 31 | 17 | 3 | 0 | 0 |
| Mushrooms: Other Potentially Toxic | 164 | 158 | 62 | 13 | 9 | 73 | 1 | 2 | П | 119 | 10 | 0 | 24 | 45 | 31 | 36 | 6 | - | 0 |
| Mushrooms: Unknown | 4,977 | 4,844 | 3,180 | 403 | 313 | 811 | 111 | 102 | 24 | 4,176 | 526 | 13 | 106 | 1,559 | 2,168 | 612 | 216 | 7 | 1 |
| Category Total: Other/Unknown Nondrug Substances | 6,275 | 5,912 | 3,389 | 456 | 554 | 1,314 | 15 | 152 | 32 | 4,681 | 1,012 | 15 | 173 | 2,158 | 2,310 | 881 | 478 | 23 | 1 |
| Miscellaneous Other/Unknown Nondrug Substances | drug Subst | ances | | | | | | | | | | | | | | | | | |
| Other Non-Drug Substances | 26,101 | 24,112 | 12,249 | 2,103 | 1,401 | 6,445 | 129 | 1,459 | 326 | 20,723 | 1,621 | 681 | 845 | 4,365 | 4,521 | 4,080 | 1,081 | 62 | 7 |
| Unknown Substances Unlikely | 5,828 | 5,525 | 1,541 | 374 | 290 | 2,405 | 35 | 761 | 119 | 3,682 | 243 | 885 | 285 | 1,694 | 522 | 9// | 288 | 51 | 9 |
| to be Drug Products Category Total: | 31,929 | 29,637 | 13.790 | 7.477 | 1.691 | 8.850 | 164 | 2.220 | 445 | 24.405 | 1.864 | 1.566 | 1.130 | 6.059 | 5.043 | 4.856 | 1.369 | 113 | 7 |
| Paints and Stripping Agents | | 3,5 | 001,00 | í | 1,0,1 | 0,000 | | 1 | Ì | 2 | 1,001 | | 007,1 | 60,0 | 2 | 20,4 | 0041 | 3 | 3 |
| Miscellaneous Paints and Stripping Agents | Agents | | | | | | | | | | | | | | | | | | |
| Other Types of Paint, Varnish or I acquer | 409 | 381 | 157 | 34 | 19 | 127 | 7 | 35 | 7 | 362 | 6 | 0 | ∞ | 65 | 69 | 63 | 18 | 0 | 0 |
| Unknown Types of Paint, | 6,324 | 5,980 | 4,072 | 277 | 194 | 1,098 | 36 | 286 | 17 | 5,777 | 86 | 24 | 74 | 654 | 1,018 | 502 | 101 | 9 | 0 |
| Varnish or Lacquer | | | | | | | | | | | | | | | | | | | |
| Varnishes and Lacquers | 1,103 | 1,021 | 317 | 37 | 48 | 475 | 7 | 126 | 11 | 981 | 19 | 7 | 14 | 189 | 140 | 252 | 41 | 2 | 0 |
| Faints Anti Algos Doints | 10 | 16 | < | - | , | 10 | < | , | - | 7 | - | - | < | v | c | | < | < | < |
| Anti-Corrector Daints | 30 | 10 |) r | > - | n v | 25 | > < | n c | > - | C1 22 | | 0 0 | ۰ د | 0 | n 11 | n o | o v | | |
| Oil-Base Paints | 2,175 | 2.014 | 551 | 27.1 | 182 | 2 2 2 | > × | 180 | 7 | 1 829 | 117 | 0 | 1 05 | 394 | 092 | 489 | 8 | ی د | 0 |
| Water Base Paints (Acrylic. | 3,445 | 3,378 | 2.623 | 154 | 78 | 425 | 2 | 85 | . 9 | 3.318 | 28 | 9 | 26 | 216 | 621 | 200 | 28 | 0 | 0 |
| Latex, etc) | : | | Î | | | | | | | , | | | | | | | | | > |
| Wood stains | 615 | 584 | 269 | 16 | 18 | 222 | 0 | 55 | 4 | 263 | 4 | 9 | 11 | 75 | 101 | 92 | 19 | 1 | 0 |
| Stripping Agents | | į | | | | | , | | | , | | | | | 1 | | i | | |
| Methylene Chloride Stripping | 375 | 354 | 20 | ∞ | 29 | 215 | 2 | 47 | es. | 335 | 6 | - | ∞ | 117 | 32 | 129 | 31 | - | 0 |
| Agents Other Types of Stripping Agent | 547 | 511 | 0.7 | 14 | 30 | 306 | C | 09 | C | 484 | 14 | 4 | 7 | 200 | 43 | 140 | 92 | C | 0 |
| Unknown Types of Stripping | 80 | 71 | 6 | 2 | 2 | 53 | 0 | 3 50 | 0 0 | 89 | - | 0 | . 2 | 30 | Ś | 27 | 7 | 1 0 | 0 |
| Agent | | | | | | | | | | | | | | | | | | | |
| Category Total: Pesticides | 15,130 | 14,345 | 8,148 | 814 | 809 | 3,771 | 2 | 887 | 28 | 13,765 | 300 | 27 | 202 | 1,956 | 2,295 | 1,914 | 412 | 18 | • |
| Fumigants | | | | | | | | | | | | | | | | | | | |
| Aluminum Phosphide | 64 | 20 | 9 | 0 | 4 | 33 | 0 | 9 | _ | 48 | 1 | 0 | - | 33 | 0 | 18 | 9 | 0 | 7 |
| Methyl Bromide | 3 | 3 | 0 | 0 | 0 | - | 0 | 7 | 0 | 3 | 0 | 0 | 0 | 2 | - | 0 | 0 | 0 | 0 |
| Other Fumigants | 23 | 23 | 4 | 0 | 0 | 15 | 0 | 4 | 0 | 21 | 0 | 0 | 7 | 7 | 3 | 2 | 0 | 0 | 0 |
| Sulfuryl Fluoride | 208 | 181 | 28 | 4 4 | 7 0 | 66 | 0 0 | 30 | т С - | 166 | m c | 4 c | r , | 34 | 19 | 15 | 7 1 | - < | 0 0 |
| Cundicides (Non-modicinal) | 2 | 27 | 10 | C | 0 | 6 | > | n | - | 00 | > | 1 | J | CI | • | / 1 | - | | > |
| Carbamate Fungicides | 155 | 122 | 29 | 7 | 4 | 62 | 0 | 19 | _ | 117 | _ | _ | m | 42 | 22 | 28 | 13 | 0 | 0 |
| Copper Compound Fungicides | 89 | 62 | 6 | - | 0 | 4 | 0 | ∞ | 0 | 99 | 3 | 0 | 3 | 11 | 7 | 13 | 3 | 0 | 0 |
| Mercurial Fungicides | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Types of Non-Medicinal | 631 | 525 | 133 | 17 | 17 | 305 | 2 | 46 | 5 | 496 | 12 | 3 | 13 | 66 | 105 | 112 | 17 | 0 | 1 |
| Fungicide | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |

(Continued)

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | F | Treated | | Out | Outcome | | |
|--|----------------------------|-------------------------------|------------|----------------|----------|-------------|--------------------------------|-------|----------------|--------------|----------|---------|--------------|---------------------------------|-------|---------|------------|-------------|-------|
| | No. of Case Mentions | No. of Single Exposures | > = > | 6–12 | 13–19 |)==20 | Unknown Unknown Child Adult | | Unknown Age | Unint | Int | Other F | Adv in Rxn F | in Health — Care Facility | None | Minor M | Moderate M | Major Death | eath |
| Dhthalimide Ennaicides | 50 | 30 | 7 | " | - | 01 | 0 | - | 0 | 90 | 4 | 0 | c | c | × | " | - | c | |
| Unknown Types of Non- | i c | 8 - | 21 | 0 < | ٠ | 2 04 | 0 0 | - | 0 0 | 2 - | + < | 0 0 | 0 0 | 1 C | 0 0 | , u | | 0 0 | 0 |
| Medicinal Fungicide | 77 | CI | 0 | | | 0 | > | - | > | CI | > | > | > | 1 | > | O | - | | > |
| Wood Preservatives | 172 | 161 | 25 | 11 | 5 | 95 | 1 | 22 | 2 | 149 | 4 | 0 | ∞ | 30 | 21 | 22 | 5 | _ | 0 |
| Herbicides (Including Algaecides, Defoliants, Desiccants, Plant Growth Regulators) | efoliants, D | esiccants, F | lant Gro | wth Reg | nlators) | | | | | | | | | | | | | | |
| 2,4-D or 2,4,5-T | 20 | 18 | 9 | _ | _ | ∞ | 0 | 2 | 0 | 18 | 0 | 0 | 0 | 4 | 9 | _ | 0 | 0 | 0 |
| Carbamate Herbicides (Excluding | 19 | 16 | 7 | 0 | c | 11 | 0 | 0 | 0 | 13 | 0 | 0 | 2 | 7 | ж | 3 | -1 | 2 | 0 |
| Chlorophenoxy Herbicides | 2.321 | 2.073 | 525 | 107 | 62 | 1.166 | 2 | 197 | 4 | 1.932 | 20 | 8 | 4 | 362 | 403 | 436 | 63 | - | 0 |
| Digital | 2000 | 177 | 36 | 9 | 1 4 | 114 | ı C | 17 | . 0 | 171 | 6 | - | . " | 35 | 30 | 800 | 9 9 | · C | 0 |
| Glyphosate | 4 238 | 3.963 | 1.030 | 165 | 1 2 | 2.284 | ی د | 332 | 28.0 | 3.711 | 75 | 1 1 | 146 | 62.1 | 854 | 1.065 | × 5 | 0 | 0 0 |
| Other Types of Herbicide | 1.352 | 1.083 | 265 | 42 | 29 | 610 | · ∞ | 122 | 2 | 1.031 | 12 | 4 | 31 | 216 | 210 | 206 | 47 | 4 | 1 0 |
| Paraquat | 76 | 63 | 3 | ! - | - | 45 | 0 | 7 | 0 | 56 | 9 | - | 0 | 46 | 13 | 17 | 6 | 2 | · (*) |
| Triazine Herbicides | 296 | 252 | 75 | 12 | 6 | 134 | 0 | 21 | _ | 231 | 7 | 8 | 14 | 51 | 34 | 4 | S | 0 | 0 |
| Unknown Types of Herbicide | 443 | 374 | 88 | 28 | 12 | 197 | П | 46 | 2 | 340 | 10 | 13 | 7 | 93 | 89 | 69 | 12 | - | 0 |
| Urea Herbicides | 99 | 53 | 22 | 0 | 1 | 24 | 0 | 9 | 0 | 50 | 0 | 0 | 3 | 8 | 10 | 11 | 0 | 0 | 0 |
| Insecticides (Including Insect Growth Regulators, Molluscicides, Nematicides) | h Regulato | rs, Mollusc | icides, No | ematicide | (S; | | | | | | | | | | | | | | |
| Carbamate Insecticides Alone | 2,118 | 1,966 | 746 | 107 | 63 | 871 | 4 | 160 | 15 | 1,818 | 79 | 19 | 39 | 401 | 423 | 279 | 83 | 13 | 4 |
| Carbamate Insecticides in Combination with Other Insecticides | 307 | 288 | 28 | 12 | 20 | 156 | 2 | 37 | æ | 264 | 11 | 6 | С | 4 | 38 | 49 | 10 | 0 | 0 |
| Chlorinated Hydrocarbon | 302 | 256 | 87 | 13 | 6 | 111 | 1 | 33 | 2 | 234 | 10 | 3 | ∞ | 29 | 53 | 41 | 12 | 3 | 0 |
| Insecticides Alone | | | | | | | | | | | | | | | | | | | |
| Chlorinated Hydrocarbon Insecticides in Combination with Other Insecticides | 288 | 274 | 95 | 17 | 9 | 134 | 7 | 18 | 6 | 263 | 4 | 0 | v | 46 | 27 | 79 | 12 | - | 0 |
| Insect Growth Regulators | 175 | 106 | 55 | 7 | 2 | 33 | 0 | 8 | 1 | 102 | - | 0 | 3 | 15 | 29 | 14 | _ | 0 | 0 |
| Metaldehyde | 153 | 148 | 52 | 0 | 2 | 78 | 0 | 14 | 2 | 145 | 0 | - | 2 | 12 | 26 | 13 | _ | 0 | 0 |
| Nicotine (Excluding Tobacco | 20 | 17 | 4 | 3 | 0 | 6 | 0 | - | 0 | 16 | 1 | 0 | 0 | - | П | 3 | 1 | 0 | 0 |
| Products) Organophosphate Insecticides | 2.909 | 2.652 | 722 | 171 | 107 | 1.331 | 10 | 249 | 62 | 2.445 | 103 | 21 | 71 | 652 | 578 | 530 | 109 | 20 | 4 |
| Alone | ì | î | | | | | | ì | } | e Î | | i | | } |) | | | ì | |
| Organophosphate Insecticides in Combination with Carbamate | 83 | 73 | 29 | 9 | 7 | 24 | 0 | 12 | 0 | 89 | 2 | 0 | 7 | Ξ | 18 | 18 | 7 | 0 | 0 |
| Insecticides | | | | | | | | | | | | | | | | | | | |
| Organophosphate Insecticides in Combination with | 812 | 771 | 129 | 41 | 47 | 471 | 8 | 74 | 9 | 723 | 25 | 9 | 17 | 137 | 109 | 185 | 30 | 0 | 0 |
| Non-Carbamate Insecticides | | | | | | | | | | | | | | | | | | | |
| Organophosphate/Carbamate/ Chlorinated Hydrocarbon | - | | 0 | 0 | 0 | - | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| (Fixed-Combo) | 1 | , | | | | | | ; | 1 | ! | | | | | | | , | | |
| Other Types of Insecticide Piperonyl Butoxide & Pyrethrins | 9,590 173 | 9,135 158 | 4,504 | 392 21 | 222 | 3,298 51 | 32 | 602 | 82 | 8,743 147 | 112 3 | 0 0 | 221 8 | 803 24 | 1,830 | 1,168 | 114 | 4 0 | 0 1 |
| (without Carbamate or O.P.) | | | | | | | | | | | | | | | | | | | |
| Pyrethrins | 5,568 | 5,211 | 1,754 | 428 | 202 | 2,277 | 19 | 483 | 48 | 4,754 | 153 | 24 | 267 | 781 | 785 | 1,125 | 178 | 9 | 0 |
| Pyrethrins Only (Alone) | 2 | 5 | 0 | 0 | _ | 3 | 0 | - | 0 | S | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Pyrethroids | 24,063 | 22,856 | 5,897 | 1,223 | 1,013 | 12,469 | 46 | 1,991 | 217 | 21,157 | 633 | 180 | 829 | 3,612 | 3,531 | 5,735 | 773 | 12 | 7 |
| Rotenone | 73 | 71 | 24 | 3 | 3 | 40 | 0 | - | 0 | 69 | 0 | 0 | 7 | 10 | 16 | 14 | 7 | 0 | 0 |
| Unknown Types of Insecticide | 4,381 | 4,028 | 1,022 | 223 | 165 | 1,966 | 17 | 269 | 99 | 3,626 | 106 | 105 | 151 | 1,066 | 495 | 770 | 181 | 6 | _ |
| Veterinary Insecticide/Pesticide Product (For Pets-Flea | 69 | 69 | 21 | S | m | 31 | - | 7 | — | 65 | - | 0 | n | ∞ | ∞ | 7 | 0 | 0 | 0 |
| Collars, Etc.) | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | | | | 1 | | | • | • | | | | | | | | | | | |
|--------------------------------------|------------------|---------------------|--------|-------|-------|--------|--|-------------------|----------------|--------|--------|-------|--------------|---------|--------|---------|------------|---------|-------|
| | No of | No | | | | Age | | | | | Reason | | L | Treated | | Outo | Outcome | | |
| | Case Mentions | Single Exposures | <= > | 6-12 | 13–19 | U >=20 | Unknown Unknown Unknown Child Adult Age | nknown U Adult | Jnknown Age | Unint | Int | Other | Adv Rxn F | | None] | Minor M | Moderate N | Major D | Death |
| Miscellaneous Pesticides | | | | | | | | | | | | | | | | | | | |
| Arsenic Pesticides | 70 | 29 | 43 | 2 | 0 | 19 | 0 | 3 | 0 | 99 | _ | 0 | 0 | 4 | 16 | 2 | 0 | 0 | 0 |
| Borates and/or Boric Acid Pesti- | 5,065 | 5,000 | 4,270 | 92 | 62 | 466 | 7 | 87 | 16 | 4,924 | 37 | 17 | 20 | 338 | 1,281 | 142 | 16 | 0 | 0 |
| cides (Excluding Other Uses) | c | c | < | < | C | - | c | C | - | c | C | C | C | - | C | c | c | c | < |
| Repellents | 7 | 4 | 0 | > | 0 | - | 0 | 0 | 1 | 1 |) | | | - | 0 | 0 | 0 | > |) |
| Animal Repellents | 370 | 359 | 122 | 33 | 19 | 155 | 0 | 29 | 1 | 336 | 10 | ∞ | 4 | 42 | 4 | 94 | 12 | 0 | 0 |
| Insect Repellants (Exclude | 16 | 15 | 9 | П | 1 | 9 | 0 | 0 | - | 15 | 0 | 0 | 0 | - | 1 | 2 | 0 | 0 | 0 |
| Lacrimators) | 1 | 1 | | 1 | į | , | : | , | ; | 1 | ; | ; | | ! | | | ļ | | |
| Insect Repellents with DEET | 5,345 | 5,253 | 3,194 | 685 | 251 | 934 | 10 | 165 | 41 | 4,850 | 89 | 4 | 280 | 486 | 801 | 1,564 | 97 | 4 | 0 |
| Insect Repellents without DEET | 1,453 | 1,407 | 971 | 143 | 41 | 500 | _ | 40 | 7 | 1,327 | 22 | 7 | 20 | 102 | 274 | 276 | 17 | 0 | 0 |
| Naphthalene Moth Repellants | 1,474 | 1,438 | 1,004 | 53 | 23 | 273 | 7 | 72 | 11 | 1,375 | 31 | 17 | 12 | 566 | 480 | 06 | 20 | 0 | 0 |
| (Excluding Deodolizing Products) | | | | | | | | | | | | | | | | | | | |
| Other Types of Moth Repellant | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | _ | 0 | 0 | 0 | 0 |
| Paradichlorobenzene Moth | 110 | 105 | 51 | 9 | 4 | 38 | 0 | S | 1 | 103 | 1 | 0 | 1 | 6 | 18 | 7 | 3 | 0 | 0 |
| Repellants (Excluding | | | | | | | | | | | | | | | | | | | |
| Deodorizing Products) | | | | | | | | | | | | | | | | | | | |
| Unknown Types of Moth | 2,277 | 2,239 | 1,122 | 92 | 42 | 657 | 32 | 274 | 20 | 2,113 | 84 | 12 | 24 | 340 | 570 | 218 | 50 | 7 | 0 |
| Repellant | | | | | | | | | | | | | | | | | | | |
| Rodenticides | | | | | | | | | | | | | | | | | | | |
| ANTU (1-naphthalenylthiourea) | 5 | 5 | 0 | - | 4 | 0 | 0 | 0 | 0 | 33 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bromethalin Rodenticides | 578 | 554 | 407 | 13 | 10 | 87 | S | 21 | 11 | 514 | 21 | 15 | 7 | 185 | 174 | Ξ | 2 | - | 0 |
| Cholecalciferol Rodenticides | 13 | 13 | 5 | 2 | 0 | 9 | 0 | 0 | 0 | 12 | 0 | _ | 0 | 2 | 9 | _ | 0 | 0 | 0 |
| Long-Acting Anticoagulant | 10,488 | 10,227 | 8,966 | 198 | 06 | 765 | 17 | 160 | 31 | 9,796 | 331 | 78 | 7 | 2,774 | 3,151 | 124 | 46 | 17 | 0 |
| Rodenticides | | | | | | | | | | | | | | | | | | | |
| Other Types of Rodenticide | 619 | 602 | 440 | 34 | 16 | 84 | 2 | 19 | 7 | 572 | 19 | 3 | 7 | 99 | 154 | 17 | 9 | 9 | 0 |
| Sodium Monofluoroacetate | 2 | 2 | _ | 0 | 0 | _ | 0 | 0 | 0 | _ | - | 0 | 0 | 7 | 0 | 0 | - | 0 | 0 |
| Strychnine Rodenticides | 70 | 57 | 14 | - | 2 | 32 | 0 | 9 | 7 | 30 | 13 | 10 | - | 30 | 17 | ∞ | 0 | 7 | _ |
| Unknown Types of Rodenticide | 1,397 | 1,291 | 895 | 38 | 32 | 233 | 14 | 09 | 19 | 1,119 | 96 | 54 | 9 | 516 | 370 | 43 | Ξ | 9 | 0 |
| Warfarin Type Anticoagulant | 280 | 269 | 210 | 9 | 5 | 31 | 4 | 11 | 2 | 250 | 12 | 5 | 1 | 73 | 91 | 4 | 2 | 2 | 0 |
| Rodenticides | | | | | | | | | | | | | | | | | | | |
| Zinc Phosphide Rodenticides | 101 | 87 | 28 | _ | _ | 40 | 0 | 15 | 2 | 81 | 5 | - | 0 | 27 | 24 | 12 | 2 | 0 | 0 |
| Category Total: | 91,362 | 86,419 | 39,333 | 4,493 | 2,763 | 32,724 | 251 | 6,137 | 718 | 80,877 | 2,181 | 746 | 2,358 | 14,667 | 17,284 | 14,813 | 2,060 | 129 | 21 |
| Photographic Products | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Photographic Products | | | | | | | | | | | | | | | | | | | |
| Developers, Fixing Baths, Ston Baths | 169 | 148 | 15 | S | 09 | 52 | 2 | 13 | - | 143 | 0 | 0 | S | 40 | 26 | 41 | S | 0 | 0 |
| Other Types of Photographic | 254 | 238 | 143 | 1 | 10 | 54 | 0 | 10 | 0 | 23.1 | ۲, | - | ď | 35 | 33 | 44 | 9 | 0 | 0 |
| Product | ì | | - | 1 | ì | , | | 2 | | i | , | • |) | ì | , | : |) | | |
| Photographic Coating Fluids | 4 | 4 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Unknown Types of Photographic | 7 | 9 | 2 | 0 | - | 2 | 0 | _ | 0 | 9 | 0 | 0 | 0 | 3 | 0 | 2 | 2 | 0 | 0 |
| Product | | | | | | | | | | | | | | | | | | | |
| Category Total: | 434 | 396 | 162 | 17 | 80 | 110 | 7 | 7 | - | 384 | e | 1 | œ | 89 | 61 | 88 | 13 | 0 | 0 |
| Plants | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Plants | | | | | | | ; | | 1 | 1 | | ; | ì | , | , | | , | , | |
| Plants: Amygdalin and/or | 2,910 | 2,833 | 1,744 | 398 | 93 | 473 | 11 | 109 | 2 | 2,653 | 93 | 11 | 71 | 169 | 619 | 139 | 15 | _ | 0 |
| Cyanogenic Glycosides | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| • | | | | • | | | | | | | | | E | - | | | | | |
|--|----------------|---------------------|----------------|------------|------------|--------------|--------------------------------|--------------------|---|--------|------------|--------------|-----------------|------------------------|------------|------------|-------------|----------|-------|
| | No of | No of | | | | Age | | | | | Keason | | Ē. Ē | Treated in Health — | | Outcome | ome | | |
| | | Single Exposures | \ = 5 | 6–12 1 | /3-19 > | =20 | Unknown Unknown Child Adult | nknown Un Adult | Unknown Age | Unint | Int Ot | A Other R | Adv C Rxn Fa | | None | Minor Mc | Moderate Ma | Major De | Death |
| Plants: Anticholinergics Plants: Cardiac Glycosides | 834 1,414 | 754 | 337 739 | 42 185 | 196 42 | 152 326 | 1 5 | 18 | ∞ € | 476 | 262 94 | 1 2 | 8 27 | 328 220 | 165 344 | 71 | 153 32 | 25 | 0 5 |
| (Excluding Drugs) Plants: Colchicine | 19 | 19 | 10 | 9 | П | 2 | 0 | 0 | 0 | 18 | - | 0 | 0 | 4 | 6 | 4 | П | 0 | 0 |
| Plants: Depressants | 198 | 172 | 113 | 11 | 13 | 31 | 0 | 3 | _ | 138 | 24 | - | 7 | 23 | 35 | 13 | 3 | 2 | 0 |
| Plants: Gastrointestinal Irritants (Excluding Oxalate Containing Plants) | 8,573 | 8,237 | 5,896 | 743 | 195 | 1,150 | 26 | 208 | 19 | 7,772 | 281 | 13 | 159 | 718 | 1,687 | 749 | 120 | S | 0 |
| Plants: Hallucinogenics (Code as Street Drug Unless Plant Part Involved) | 469 | 395 | 120 | 19 | 118 | 123 | 1 | 12 | 2 | 184 | 188 | 4 | 17 | 165 | 99 | 53 | 77 | 33 | 0 |
| Plants: Nicotine (Excluding Tobacco Products) | 212 | 195 | 6 | 26 | 11 | 52 | 0 | 6 | 0 | 181 | 12 | 0 | _ | 29 | 99 | 52 | 16 | 2 | 0 |
| Plants: Non-Toxic | 7,561 | 7,090 | 5,194 | 774 | 158 | 734 | 28 | 177 | 25 | 6,533 | 161 | 10 | 379 | 368 | 916 | 457 | 78 | 5 | 0 |
| Plants: Other Toxic Types | 4,939 | 4,677 | 3,250 | 569 | 165 | 527 | <u>8</u> ' | 127 | 21 | 4,277 | 252 | = : | 129 | 504 | 1,129 | 343 | 95 | 6 0 | 0 |
| Plants: Oxalates Plants: Skin Irritants (Excluding Oxalate Containing Plants) | 6,071 6,014 | 5,984 | 4,792 2,794 | 512 530 | 137 282 | 435 1,560 | 28 | 92 383 | 34 | 5,695 | 228 158 | 29 | 44 291 | 307 593 | 1,242 | 983 701 | 188 | 0 4 | 00 |
| Plants: Solanine | 1,428 | 1,392 | 901 | 149 | 31 | 234 | 9 | 63 | ∞ | 1,308 | 27 | 12 | 43 | 130 | 372 | 73 | 10 | 0 | 0 |
| Plants: Stimulants | 181 | 164 | 39 | 26 | 13 | 71 | 0 | 15 | 0 | 114 | 36 | 2 | 7 | 57 | 29 | 30 | 16 | 0 | 0 |
| Plants: Toxalbumins | 177 | 167 | 79 | 12 | 15 | 48 | 0 | 12 | 1 | 139 | 22 | 4 | _ | 57 | 40 | 25 | 5 | 0 | 0 |
| Plants: Unknown Toxic Types or Unknown if Toxic | 12,295 | 11,696 | 8,258 | 1,414 | 320 | 1,312 | 40 | 305 | 47 | 10,941 | 477 | 31 | 226 | 1,072 | 2,634 | 952 | 148 | 2 | 0 |
| Category Total: | 53,295 | 50,759 | 34,363 | 5,416 | 1,790 | 7,230 | 169 | 1,606 | 185 | 46,794 | 2,316 | 142 1, | 1,410 | 4,782 | 10,025 | 4,767 | 1,008 | 61 | 7 |
| Polishes and Waxes Miscellaneous Polishes and Waxes | | | | | | | | | | | | | | | | | | | |
| Floor Waxes, Polishes, or Sealers | 537 | 511 | 302 | 17 | 15 | 138 | 0 | 37 | 2 | 474 | 12 | 21 | 3 | 85 | 140 | 93 | 12 | 0 | 0 |
| Furniture Polishes | 2,145 | 2,090 | 1,786 | 54 | 34 | 176 | 4 | 31 | 5 | 2,027 | 38 | 17 | 7 | 201 | 654 | 253 | 27 | 3 | 0 |
| Miscellaneous Polishes and Waxes (Excluding Mineral Seal Oils) | 2,824 | 2,730 | 2,124 | 69 | 65 | 384 | 4 | 77 | 7 | 2,637 | 4 | 22 | 21 | 326 | 707 | 340 | 45 | 2 | 0 |
| Category Total: | 5,506 | 5,331 | 4,212 | 140 | 114 | 869 | ∞ | 145 | 14 | 5,138 | 94 | 09 | 31 | 612 | 1,501 | 989 | 84 | 5 | 0 |
| Kadiation Miscellaneous Radiation | | | | | | | | | | | | | | | | | | | |
| Nonpharmaceutical Radiation: | 267 | 247 | 17 | 16 | 11 | 138 | 0 | 54 | ======================================= | 197 | 11 | 16 | 17 | 78 | 39 | 20 | 6 | 0 | 0 |
| Category Total: Sporting Equipment Miscellaneous Sporting | 267 | 247 | 17 | 16 | Ξ | 138 | 0 | 54 | 11 | 197 | 11 | 16 | 17 | 78 | 39 | 20 | 6 | 0 | 0 |
| Equipment | | | | | | | | | | | | | | | | | | | |
| Fishing Baits | 09 | 99 | 49 | 7 | 7 | 2 | 0 | - | 0 | 53 | 3 | 0 | 0 | _ | 14 | 3 | 0 | 0 | 0 |
| Fishing Products, Miscellaneous | 18 | 16 | ∞ | e | 0 | 4 | 0 | 0 | _ | 14 | 1 | 0 | - | 7 | 2 | 0 | _ | 0 | 0 |
| Golf Balls (Including Liquid Center of Golf Balls) | 2 | 2 | - | 0 | - | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gun Bluing Compounds | 34 | 31 | 15 | 0 | 0 | 10 | 0 | 5 | 1 | 29 | 1 | 1 | 0 | 17 | 6 | 9 | 4 | 0 | 0 |
| Hunting Products, Miscellaneous | 343 | 330 | 199 | 26 | 15 | 65 | 0 | 21 | 4 | 282 | 12 | 24 | 5 | 100 | 26 | 37 | ∞ | 0 | 0 |
| Other Types of Sporting Fourinment | 17 | 16 | 12 | 0 | - | 2 | 0 | - | 0 | 16 | 0 | 0 | 0 | 0 | S | 4 | 0 | 0 | 0 |
| mondinha | | | | | | | | | | | | | | | | | | | |

| | , | , | | | | Age | | | | | Reason | | F. | Treated | | Õ | Outcome | | |
|--|----------------------------|-------------------------------|-------|----------|-------|----------------|----------|------------------------------------|---------------|------------|--------|--------------|------------------|-----------------------------------|-----------|-------------|----------|-------------|--------------|
| Z | No. of Case Mentions | No. of Single Exposures | > = 5 | 6–12 1 | | U ₁ | nknown U | Unknown Unknown Child Adult Age | nknown Age | Unint | Int O | A Other R | Adv 1n Rxn Fe | in Health — Care Facility] | None | Minor N | Moderate | Major Death |)eath |
| Unknown Types of Sporting | 8 | 3 | - | 0 | 0 | 2 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Equipment Category Total: Swimming Pool/Aquarium | 477 | 454 | 285 | 31 | 19 | 82 | 0 | 28 | 9 | 398 | 18 | 25 | 9 | 120 | 128 | 20 | 13 | 0 | 0 |
| Miscellaneous Swimming Pool/Aquarium | rium | | | | | | | | | | | | | | | | | | |
| Algicides | 2,025 | 1,940 | 572 | 240 | 66 | 872 | 13 | 125 | 19 | 1,859 | 41 | 7 | 32 | 369 | 209 | 609 | 178 | 3 | 0 |
| Aquarium Products, | 1,574 | 1,483 | 1,176 | 61 | 33 | 169 | 1 | 39 | 4 | 1,436 | 23 | 18 | S | 129 | 415 | 117 | ∞ | 0 | 0 |
| Miscellaneous | 601 | - | 2 | o | 7 | ç | < | 0 | | 172 | c | c | c | 0 | ć | , | _ | c | c |
| Dromine Shock Treatments Chlorine Shock Treatments | 3 434 | 3 208 | 573 | 8 401 | 0 251 | 1717 | 0 0 | 220 | 0 71 | 3 158 | 7 5 | 0 % | 2 5 | 010 | 22 186 | 34 1 360 | 4 4 | 0 6 | 0 0 |
| Other Types of Swimming Pool | 1,674 | 1,564 | 427 | 210 | 108 | 721 | 3 % | 88 | 7 | 1,479 | 29 | 7 | 4 9 | 340 | 203 | 519 | 124 | - 61 | 0 |
| or Aquarium Product | | | | | | | | | | | | | | | | | | | |
| Swimming Pool and Aquarium Test Kits | 234 | 201 | 156 | 33 | 7 | 31 | 0 | 3 | 1 | 198 | 7 | _ | 0 | 28 | 49 | 23 | 4 | 0 | 0 |
| Category Total: | 9,064 | 8,603 | 2,957 | 1,013 | 504 | 3,552 | 37 | 492 | 48 | 8,243 | 162 | 46 | 137 | 1,794 | 1,085 | 2,671 | 741 | 12 | 0 |
| Tobacco/Nicotine Products Miscellaneous Tobacco Products | | | | | | | | | | | | | | | | | | | |
| Chewing Tobacco | 883 | 898 | 745 | 18 | 30 | 57 | 4 | 10 | 4 | 827 | 26 | Э | 9 | 227 | 244 | 279 | 17 | 0 | 0 |
| Cigarettes | 5,955 | 5,774 | 5,363 | 46 | 69 | 237 | 11 | 43 | 5 | 5,639 | 75 | 25 | 28 | 972 | 2,006 | 1,088 | 73 | - | 0 |
| Cigars | 96 | 88 | 29 | 2 | 4 | 12 | _ | 2 | 0 | 75 | 3 | 0 | 10 | 16 | 34 | 17 | 2 | 0 | 0 |
| Filter Tips Only (i.e. Butts) | 142 | 136 | 125 | 2 | 2 | 5 | 0 | 2 | 0 | 135 | _ | 0 | 0 | 20 | 54 | 19 | 2 | 0 | 0 |
| Other Types of Tobacco Product | 84 | 9/ | 39 | 2 | 3 | 26 | 0 | 9 | 0 | 61 | 7 | 0 | 7 | 19 | 10 | 18 | 9 | 0 | 0 |
| Snuff | 473 | 455 | 361 | 9 | 24 | 53 | 0 | 11 | 0 | 431 | 13 | 2 | 7 | 129 | 126 | 138 | 11 | 2 | 0 |
| Unknown Types of Tobacco | 1,125 | 1,074 | 728 | 18 | 4 | 219 | 1 | 99 | ∞ | 934 | 49 | 7 | 63 | 280 | 285 | 233 | 42 | 2 | 0 |
| Product | - | 3 | | | | | | | | | | | | | | | | | |
| Nicotine Containing (Excluding Tobacco Products) | icco Produ | | ų | c | - | 5 | • | c | | ć | , | c | , | 5 | - | - | - | c | c |
| and/or Cartridge Containing | 67 | % 7 | n | > | 4 | 61 | 0 | > | 0 | 07 | 7 | 0 | 0 | 01 | 4 | Π | - | 0 | 0 |
| Nicoune Flectronic Cigarettes: Nicotine | - | - | - | C | C | C | 0 | C | 0 | - | C | 0 | C | - | - | C | C | C | 0 |
| Liquid | • | • | • | | | | | | | • | | | | • | • | | | | |
| Category Total: | 8,788 | 8,500 | 7,434 | 94 | 180 | 628 | 17 | 130 | 17 | 8,123 | 191 | 37 | 127 | 1,674 | 2,764 | 1,803 | 154 | w | 0 |
| Waterproofers/Sealants | .5 | | | | | | | | | | | | | | | | | | |
| Waternroofers/sealants: aerosols | 090 | 747 | 116 | 10 | 80 | 70 | 0 | 14 | 0 | 220 | 22 | 0 | v | 71 | 15 | 19 | 13 | 4 | 0 |
| Waterproofers/sealants: liquids | 114 | 110 | 5.4 | , 4 | 9 % | 44 | 0 0 | ţ (* | 0 0 | 100 | 1 4 | - · | v | 25 | 2,5 | 2,5 | CT CT | - ۱ | 0 0 |
| Waterproofers/sealants: solids | | 3 | , , | 0 0 | | - | 0 0 | o C | 0 0 | 6 | | - 0 | o C | G C | G C | - 1 | 0, | - 0 | 0 0 |
| Waterproofers/sealants: unknown | 43 | 42 | 9 | 0 | 2 | 22 | 0 | 2 | 0 | 1 04 | 0 | 0 | · - | _ | 9 | ν. | · v | 0 | · C |
| form | | | | | | | | | | | | | | | | | | | , |
| Category Total: | 420 | 402 | 188 | 25 | 33 | 137 | 0 | 19 | 0 | 362 | 27 | 1 | 11 | 103 | 82 | 92 | 28 | w | 0 |
| Weapons of Mass Destruction | , | | | | | | | | | | | | | | | | | | |
| Miscellaneous Weapons of Mass Destruction | truction | Ţ | c | c | c | | c | . | | - | c | | c | • | • | c | (| c | c |
| Anthrax | ~ ! | - ; | 0 0 | 0 0 | ο , | ٥ , | 0 0 | - (| 0 0 | 4 , | 0 0 | 7 0 | o , | 7 0 | 4 (| 0 (| 0 0 | 0 0 | 0 0 |
| Other Biological Weapons | 17 | 16 | 0 (| 0 , | - (| 13 | 0 | 7 9 | 0 | <u>c</u> | 0 (| 0 (| – (| ∞ (| 7 ; | 7 5 | 0 | ο, | ο, |
| Other Chemical Weapons | 109 | 84 | | 4 | 7 | 61 | 0 | 10 | 4 (| 9/ | m (| 0 | 7 | 42 | Ξ' | 20 | ∞ (| | |
| Other Suspicious Powders | 9 | 9 | 0 | 0 | 0 | 2 | 0 | 4 | 0 | ro. | 0 | rs. | 0 | m | 7 | 0 | 7 | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | \(\text{F}\) |

Table 22A. Demographic profile of SINGLE SUBSTANCE Nonpharmaceuticals exposure cases by generic category

| | J. J. | M | | | | Age | | | | | Reason | 'n | -; | Treated | | 0 | Outcome | | |
|--|---|---|--------------|----------|------------|------------------------|---------------|--|----------------|---|-----------|--------|-----------------------|--------------------------------|---------------|---------------|---------------------------------|------------|----------|
| | No. of No. of Case Single Mentions Exposure | No. 01 No. 01 — Case Single Mentions Exposures | <=5 6-12 | 6–12 | 13-19 >=20 | - | Unknown Child | Unknown Adult | Jnknown Age | Unint | Int Other | Other | Adv Care Rxn Facility | n rieann - Care Facility | None | Minor | None Minor Moderate Major Death | Major | Death |
| Other Suspicious Substances (Non-Powder) | 4 | 4 | 0 | 0 | - | - | 0 | 2 | 0 | 2 | 0 | - | 0 | 2 | 0 | | - | 0 | 0 |
| Suspicious Powders in Envelope | 10 | 10 | | _ | 0 | 9 | 0 | 2 | 0 | 1 | 0 | ∞ | 0 | 0 | 7 | 0 | 0 | 0 | 0 |
| Category Total: Nonpharmaceuticals Total: | 153 1,232,413 | 153 127 4 5 1,232,413 1,125,336 631,401 74,673 5 | 4 631,401 | 5 74,673 | 51,825 | 4 89 51,825 296,815 | 3,576 | $\begin{matrix} 0 & 21 \\ 3,576 & 60,158 \end{matrix}$ | 4 6,888 1 | 4 101 3 14 3 57 26 23 6,888 1,052,278 39,041 12,020 18,135 165,663 194,098 182,012 | 39,041 | 12,020 | 3 18,135 | 57 165,663 | 26 194,098 | 23 182,012 | 11 1 34,678 2,327 | 1 2,327 | 1 243 |

Outcome

(Continued)

3

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| 4 | | 1 | | | | | | | | | | | | 000000 | | | | | |
|--|----------------------|---|--------|-------|-------|-----------|--------------------|--|----------------|--------|-------|-------|--------------|--------------------------------------|-----------------|-------------|------------|-------------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=5 | 6–12 | 13–19 |) >=20 | Jnknown U Child | Unknown Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv I Rxn | reated in Health Care Facility | None | Minor | Moderate | Major Death | Deatl |
| Acetylsalicylic Acid with | 34 | 13 | - | 0 | - | ∞ | 0 | 2 | - | 4 | 7 | 1 | - | 9 | - | 9 | - | 0 | 0 |
| Acetylsalicylic Acid with | 82 | 50 | 6 | 2 | 7 | 31 | 0 | П | 0 | 18 | 30 | 0 | 1 | 30 | ∞ | 12 | 9 | 3 | 0 |
| Acetylsalicylic Acid with Other Narcotics or | 37 | 11 | 7 | 0 | 2 | 9 | 0 | 0 | - | 3 | 9 | 0 | 2 | 5 | 3 | 2 | 1 | 0 | 0 |
| Narcotic Analogs Acetylsalicylic Acid with | 42 | 20 | 33 | 0 | - | 15 | 0 | - | 0 | 11 | ∞ | 0 | 1 | v | 4 | 4 | 0 | 0 | 0 |
| Acetylsalicylic Acid with Propoxyphene | 6 | 9 | 7 | 0 | 0 | 8 | 0 | 1 | 0 | S | - | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Miscellaneous Analgesics Non-Aspirin Salicylates (Excluding Topicals and/or Gastrointestinal | 415 | 328 | 216 | 12 | 25 | 63 | 0 | 12 | 0 | 271 | 40 | 0 | 15 | 98 | 105 | 26 | 15 | П | 0 |
| Other Analoesics | 410 | 323 | 164 | 9 | 17 | 117 | - | ~ | C | 274 | 17 | C | 31 | 46 | 99 | 61 | 12 | - | 0 |
| Phenacetin | 1 | 1 | - | 0 | 0 | 0 | 0 | 0 | 0 | į – | 0 | 0 | 0 | 7 | - 2 | 0 | 0 | 0 | 0 |
| Phenazopyridine | 1,308 | 1,095 | 832 | 21 | 40 | 169 | 0 | 30 | 3 | 626 | 41 | 2 | 89 | 211 | 380 | 105 | 30 | 5 | 0 |
| Salicylamide | 4 | 2 | 0 | 1 | 0 | _ | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Unknown Analgesics 197 | 197 | 84 | 24 | 7 | 19 | 32 | 0 | 7 | 0 | 39 | 40 | 0 | S | 43 | 17 | 16 | 7 | 0 | 0 |
| Onster oldar Amtininaminato Colchicine | nry Drugs | 25.4 | 40 | 7 | v | 173 | - | Ξ | c | 107 | 30 | 0 | 7.0 | 137 | 48 | 52 | 33 | 10 | V |
| Cyclooxygenase-2 | 1,104 | 596 | 257 | 22 | 18 | 260 | 7 | 36 | | 523 | 8 4 | 0 | 32 | 95 | 159 | 23 | 7 | 1 | 0 |
| rs | 67 573 | 009 39 | 17 161 | 2 175 | 2516 | 8 653 | 73 | 970 | 100 | 55 350 | 0 160 | 767 | 730 | 11 240 | 15 100 | 2 124 | 707 | 76 | |
| Ibuprofen with | 64,575 | 660,00 | | | 010,0 | 0,033 | Ç C | 0/6 | 061 | 5 | 7,107 | † O | 06/ | 0+7,11 | 22 + ,C1 | 4,1.74 O | 9 | 9 0 | |
| Diphenhydramine | 0 | 0 | t | 4 | 0 | > | 0 | 0 | 0 | J. | 4 | | | 4 | 4 | 0 | 0 | > | > |
| Ibuprofen with | 155 | 86 | 33 | 12 | 10 | 37 | 1 | 4 | 1 | 28 | 30 | 0 | S | 39 | 25 | 10 | 4 | 1 | 0 |
| Hydrocodone | į | | ć | | , | ļ | ¢ | ; | (| | , | (| | i c | i | : | (| (| (|
| Indomethacin | 551 | 331 | 86 | | ∞ ı | 174 | 0 | 7.7 | 0 (| 234 | 63 | 0 | 34 | 95 | 4, 6 | 42 | · ∞ | 0 0 | 0 |
| u | 101 | 59 | 31 | | 7 | 16 | 0 6 | _ 0,0 | o ; | 48 | ∞ ç | 0 1 | e i | χ (| 22 | S 0 | — <u>Ş</u> |) t | 0 |
| | 12,477 | 7,550 | 2,634 | | 1,302 | 2,952 | 21 17 | 349 | 26 | 4,809 | 2,243 | 'n, | 455 | 2,367 | 1,914 | 859 | 160 | _ (| 0 |
| Other Types of Nonsteroidal | 6,693 | 3,974 | 1,739 | 186 | 226 | 1,553 | _ | 237 | 70 | 3,257 | 203 | 9 | 191 | 196 | 1,056 | 362 | 62 | 6 | 0 |
| Antiinflammatory Drug | | | | | | | | | | | | | | | | | | | |
| Unknown Types of | 10 | 9 | _ | 0 | 2 | _ | 0 | _ | _ | 2 | 2 | 0 | - | 4 | 0 | 2 | _ | 0 | 0 |
| Antiinflammatory Drug | | | | | | | | | | | | | | | | | | | |
| Opioids | | | | | | | | | | | | | | | | | | | |
| Buprenorphine | 771 | 514 | 293 | 4 | 30 | 147 | S | 27 | ∞ | 340 | 121 | 16 | 31 | 381 | 70 | 168 | 98 | 7 | 0 |
| Butorphanol | 21 | 16 | 4 | 0 | 0 | 7 | 0 | 5 | 0 | 10 | 3 | 0 | 2 | 7 | 4 | 5 | 1 | 0 | 0 |
| Codeine | 1,993 | 1,501 | 738 | 200 | 106 | 402 | 0 | 51 | 4 | 1,270 | 152 | _ | 70 | 296 | 409 | 155 | 31 | - | 0 |
| Fentanyl | 300 | 167 | 11 | 3 | 11 | 125 | 0 | 13 | 4 | 36 | 104 | 4 | 19 | 116 | 12 | 25 | 20 | 18 | 2 |
| Hydrocodone Alone | 316 | 193 | 40 | 15 | 24 | 86 | 0 | 13 | 3 | 116 | 59 | 1 | 15 | 64 | 26 | 47 | 14 | 0 | 0 |
| or in Combination | | | | | | | | | | | | | | | | | | | |
| (Excluding Combina- | | | | | | | | | | | | | | | | | | | |
| tion Products with | | | | | | | | | | | | | | | | | | | |
| Acetaminophen, | | | | | | | | | | | | | | | | | | | |
| Acetylsalicylic Acid or | | | | | | | | | | | | | | | | | | | |
| rouproten <i>)</i> | | | | | | | | | | | | | | | | | | | |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| No. of Case No. of Single- | | | | | | | Age | | | | | Reason | | | | | Õ | Outcome | | |
|--|--|-------------------------|----------------------------|---------|-------|------------------|--------|-----|--------------------|----------------|---------|--------|-------|-----|--------------------------------------|-------|---------|------------|---------|---------------|
| 1 | | No. of Case Mentions | No. of Single Exposures | > = 5 | 6–12 | 13–19 | >=20 | | Unknown 1 Adult | Jnknown Age | Unint | Int | Other | 1 | reated in lealth Care Facility | | Minor N | Moderate] | Major 1 | Death |
| 1 | Hydromorphone | 4 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | - | - | 0 | - | - | 0 | 2 | 0 | 0 | 0 |
| 1 | Levorphanol | _ | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | _ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | С |
| 4,000 2,115 2,44 3, 41 1, 14 4, 49 4, 49 4, 41 | Meneridine | 270 | 140 | 8 | 10 | 16 | 84 | 0 | 10 | 2 | 99 | 59 | _ | 13 | 79 | 30 | 25 | 10 | cr. | 0 |
| 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, | Methadone | 4,866 | 2,115 | 284 | 30 | 170 | 1,439 | c | 152 | 37 | 730 | 1,095 | 29 | 128 | 1,482 | 255 | 340 | 477 | 205 | 22 |
| 1,15 | Morphine | 4,102 | 2,108 | 338 | 41 | 118 | 1,374 | 3 | 193 | 41 | 1,065 | 788 | 39 | 168 | 1,188 | 355 | 380 | 293 | 94 | 7 |
| 1,157 1,158 1,158 1,119 1,158 1,158 1,119 1,158 | Nalbuphine | 2 | 7 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | _ | _ | 0 | 0 |
| Maintone | Other or Unknown | 9,001 | 5,032 | 1,561 | 1111 | 306 | 2,574 | 16 | 392 | 72 | 2,549 | 1,789 | 138 | 466 | 3,151 | 734 | 1,188 | 820 | 247 | 13 |
| 150 | Narcotics | 1 | | , | | į | | | : | i | | | ļ | ; | , | | | į | ; | |
| Harmonic | Oxycodone Alone or | 9,157 | 4,278 | 969 | 121 | 372 | 2,597 | ∞ | 412 | 72 | 2,102 | 1,746 | 29 | 262 | 2,160 | 200 | 804 | 478 | 112 | 12 |
| National Part National Par | in Combination | | | | | | | | | | | | | | | | | | | |
| 160 89 11 2 12 25 28 9 1 29 51 3 5 62 14 14 15 15 15 19 19 19 19 19 | (Excluding Combina- | | | | | | | | | | | | | | | | | | | |
| | tion Products with | | | | | | | | | | | | | | | | | | | |
| 160 160 160 170 | Acetaminophen or | | | | | | | | | | | | | | | | | | | |
| 10 10 10 10 10 10 10 10 | Acetylsancync Acid) | , | Ö | ; | • | | l | • | c | • | ć | į | , | ı | (| , | ; | , | 9 | (|
| 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, | Oxymorphone | 169 | 68 | Ξ, | 7 . | 77 | င္က ေ | 0 0 | × | | 67 6 | | η, | n o | 79 | 13 | Ξ ° | 91 9 | 01 | 0 0 |
| 1.57 99 10 0 0 0 0 0 0 0 0 | Pentazocine | 6/ | 4/ | , c | 4 (| က I | 87 ! | 0 | 0 | _ , | 7.7 | C : | _ , | 6 | 52 | 0 ; | × ; | × (| ο . | 0 |
| 11.255 5.817 1.12 1.0 0 0 0 0 0 0 0 0 0 | Propoxyphene | 257 | 66 | 16 | 0 | 7 | 29 | 0 | ∞ | _ | 42 | 45 | _ | 6 | 54 | 4 | 15 | 13 | 4 | 0 |
| nand Acetykalicytic Acid Combinations cn and Acetykalicytic Acid Combinations (Acid Marcial Acid Combinations) (Acid Marcial Acid Marcial | Remifentanil | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,12.55 S817 1,12.2 167 656 3,500 3 323 46 2,450 2,867 36 386 3,551 1,282 4 | Tapentadol | 29 | 40 | _ | 0 | 0 | 37 | 0 | 2 | 0 | 15 | 19 | - | 4 | 21 | 9 | ∞ | 9 | - | 0 |
| Acial man Acetystalicylic Acial Complimations Acial Complexial Continuous Acial Size | Tramadol | 11,225 | 5,817 | 1,122 | 167 | 959 | 3,500 | 33 | 323 | 46 | 2,450 | 2,867 | 36 | 386 | 3,551 | 1,282 | 1,223 | 606 | 181 | \mathcal{C} |
| d s/711 6,071 3,092 10.28 1,679 3 135 32 4,023 1,825 2 200 2,422 1,664 sdeful siders Acidens distants 2 8 2 8 2 8 2 8 2 8 1,679 3 1,83 5 2 1 1 7 3 3 al dAce-sidens 335 214 93 8 2 8 2 8 2 8 1 9 4 2 1 9 6 1 9 6 1 9 6 1 9 6 1 9 1 | Other Acetaminophen and | Acetylsalicyl | ic Acid Combi | nations | | | | | | | | | | | | | | | | |
| cist of the bright stands and bright stands are all stands at the bright stands at the bri | Acetaminophen and Acetylsalicylic Acid | 8,711 | 6,071 | 3,092 | 102 | 1,028 | 1,679 | 3 | 135 | 32 | 4,023 | 1,825 | 2 | 200 | 2,422 | 1,664 | 884 | 328 | 16 | 0 |
| A chebra 3.55 2.14 9.9 8 2.2 81 0 10 0 143 56 1 12 73 39 39 31/535 208,222 106,743 8,790 21,879 62,627 236 6,706 1,241 143,029 55,822 1,521 6,144 72,353 49,146 143,024 1,235 1, | with Other Ingredients | | | | | | | | | | | | | | | | | | | |
| vibout sist print out state out 317,535 208,222 106,743 8,790 21,879 62,627 236 6,706 1,241 143,029 55,822 1,521 6,144 72,333 49,146 cts 159 127 14 21 24 52 0 13 3 55,822 1,521 6,144 72,333 49,146 94 510 13 3 55,822 1,521 6,144 72,333 49,146 94 510 13 3 55,822 1,521 6,144 72,333 49,146 94 510 95 16 17 2 6 17 12 2 6 17 1,17 1,49 14 21 3 9 1,10 9 46 0 7 2 2 1,49 14 236 1,70 1,70 state 37 3,14 36 4,6 3 4 | Acetaminophen and Ace- | 335 | 214 | 93 | ∞ | 22 | 81 | 0 | 10 | 0 | 143 | 99 | _ | 12 | 73 | 39 | 17 | 21 | 9 | 0 |
| S S S S S S S S S S | tylsalicylic Acid without | | | | | | | | | | | | | | | | | | | |
| Strict S | alents | | | | 9 | į | | Š | i | ; | | | | ; | | | į | , | ; | 3 |
| Sample 159 127 14 21 24 52 0 13 3 55 50 1 19 62 10 10 125 10 10 10 13 60 0 15 2 67 21 5 3 59 19 10 10 10 1 10 1 10 1 1 | Total: | 317,535 | | 106,743 | 8,790 | 21,879 | 62,627 | 236 | 902'9 | 1,241 | 143,029 | | | 144 | 72,353 | | 21,270 | 11,423 | 2,311 | 213 |
| Salation 155 127 14 21 24 52 0 13 3 55 50 1 19 62 10 10 10 13 10 10 13 10 15 10 13 10 10 13 10 13 10 13 10 13 13 | nesthetics Inhalation Anasthatics | | | | | | | | | | | | | | | | | | | |
| Alation 1.59 1.67 1.77 1.74 1.74 1.74 | Mitman Origin | 150 | 101 | - | 5 | ć | 63 | c | 5 | c | ¥ | 02 | - | 0 | 2 | 5 | 00 | ć | < | < |
| Anesthetics 1 Anesthetics 1 Anesthetics 2 | Nitrous Oxide | 961 361 | 127 | 4 5 | 77 | 4 7 : | 75 | 0 0 | 51 | n (| S 5 | 2 5 | - u | ر ر | 70 | 0 9 | 67 6 | 77 | o - | O = |
| Anesthetics | Other Types of Inhalation | 571 | 100 | 10 | 0 | 13 | 00 | 0 | 2 | 7 | /0 | 17 | n | 3 | 66 | 19 | 17 | ٥ | _ | _ |
| 1,589 1,398 5,86 114 94 510 5 77 12 1,172 81 7 127 320 347 1,589 1,398 5,86 114 94 510 5 77 12 1,172 81 7 127 320 347 1,589 1,398 5,86 114 94 510 5 77 12 1,172 81 7 127 320 347 1,589 1,398 5,813 3,775 2,22 163 953 6 1,76 18 4,901 149 14 236 730 1,708 1,589 1,398 5,513 3,775 2,22 163 953 6 1,76 18 4,901 149 14 236 730 1,708 1,589 1,589 1,589 1,589 1,589 1,589 1,589 1,147 62 8,686 300 5 134 724 1,409 1,1413 1,384 1,413 1,414 1,413 1,414 | Local and/or Tonical Anestl | hetics | | | | | | | | | | | | | | | | | | |
| 1,899 1,398 586 114 94 510 5 77 12 1,172 81 7 127 320 347 5,575 5,313 3,775 222 163 953 6 176 18 4,901 149 14 236 730 1,708 betics | Dibucaine | 2.1 | 20 | 7 | C | C | v | 0 | 6 | C | 20 | C | 0 | 0 | - | 12 | 0 | C | C | 0 |
| hetics hetics 5,575 5,313 3,775 222 163 953 6 176 18 4,901 149 14 236 730 1,708 | Lidocaine | 1 589 | 1 398 | 286 | 114 | 94 | 510 | · | - 77 | 2 | 1 172 | × -× |) L | 127 | 320 | 347 | 172 | ° 89 | . 4 | - |
| teal hetics 154 | Other or Unknown | 5.575 | 5.313 | 3.775 | 222 | 163 | 953 | ک د | 176 | 2 ~ | 4.901 | 149 | 4 | 236 | 730 | 1.708 | 584 | 06 | = | - 0 |
| hetics lys 154 74 7 3 9 46 0 7 2 21 47 2 4 60 7 sthetic 37 30 10 4 2 10 0 4 0 23 2 0 5 11 4 7,665 7,065 4,415 364 305 1,639 11 294 37 6,261 351 29 394 1,244 2,107 holinergic Drugs lys 11,413 9,148 390 76 115 7,348 10 1,147 62 8,686 300 5 134 724 1,409 had s, and | Local and/or Topical | | | | | | | , | | , | | | | ì | , | , | | | ; | |
| hetics rgs 154 74 7 3 9 46 0 7 2 21 47 2 4 60 7 sthetic 37 30 10 4 2 10 0 4 0 23 2 0 5 11 4 7,665 7,065 4,415 364 305 1,639 11 294 37 6,261 351 29 394 1,244 2,107 holinergic Drugs 11,413 9,148 390 76 115 7,348 10 1,147 62 8,686 300 5 134 724 1,409 s, and 3,5 and 3 3 4 6 1,147 62 8,686 300 5 134 724 1,409 | Anesthetic | | | | | | | | | | | | | | | | | | | |
| sthetic 37 30 10 4 2 10 0 7 2 21 47 2 4 60 7 7 8 sthetic 37 30 10 4 2 10 0 4 0 23 2 0 5 11 4 4 5 11 4 4 5 11 4 1 4 5 11 4 1 4 | Miscellaneous Anesthetics | | | | | | | | | | | | | | | | | | | |
| sthetic 37 30 10 4 2 10 0 4 0 23 2 0 5 11 4 7,665 7,065 4,415 364 305 1,639 11 294 37 6,261 351 29 394 1,244 2,107 by the bulb of the bu | Ketamine and Analogs | 154 | 74 | 7 | 3 | 6 | 46 | 0 | 7 | 2 | 21 | 47 | 2 | 4 | 09 | 7 | 15 | 28 | 4 | 0 |
| 7,665 7,065 4,415 364 305 1,639 11 294 37 6,261 351 29 394 1,244 2,107 holinergic Drugs by and s, and | Other Types of Anesthetic | 37 | 30 | 10 | 4 | 7 | 10 | 0 | 4 | 0 | 23 | 7 | 0 | S | 11 | 4 | 4 | ю | - | 0 |
| 7,665 7,065 4,415 364 305 1,639 11 294 37 6,261 351 29 394 1,244 2,107 holinergic Drugs lgs 11,413 9,148 390 76 115 7,348 10 1,147 62 8,686 300 5 134 724 1,409 s, and | Unknown Types of | 5 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | _ | 0 | 0 | _ | 0 | 0 | 0 | 0 | 0 |
| 7,665 7,065 4,415 364 305 1,639 11 294 37 6,261 351 29 394 1,244 2,107 holinergic Drugs lgs 11,413 9,148 390 76 115 7,348 10 1,147 62 8,686 300 5 134 724 1,409 s, and | Anesthetic | | | | | | | | | | | | | | | | | | | |
| tholinergic Drugs 1988 11,413 9,148 390 76 115 7,348 10 1,147 62 8,686 300 5 134 724 1,409 1), and 5, and | Category Total: | 7,665 | 7,065 | 4,415 | 364 | 305 | 1,639 | 11 | 294 | 37 | 6,261 | 351 | 29 | 394 | 1,244 | 2,107 | 831 | 217 | 31 | 7 |
| 9,148 390 76 115 7,348 10 1,147 62 8,686 300 5 134 724 1,409 | nticholinergic Drugs Miscellancous Anticholiner | oio Denos | | | | | | | | | | | | | | | | | | |
| pu pu | Anticholineraic Drugs | 11 413 | 9 148 | 390 | 92 | 115 | 7 348 | 10 | 1 147 | 69 | 8 686 | 300 | v | 134 | 774 | 1 409 | 251 | 174 | 2.1 | - |
| Cold Preparations, and Plants) | (Excluding Cough and | | | | | 1 | 2 | 2 | | } | | | , | | | | | - | i | • |
| rians) | Cold Preparations, and | | | | | | | | | | | | | | | | | | | |
| | riants) | | | | | | | | | | | | | | | | | | | |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | ı | | : - | | | Outcome | | |
|--|-------------------------|---|----------|-------|-------|--------|------------------------------------|------------------|----------------|--------|--------|-------|-----------|---------------------------------------|-------|-------|----------|-------------|-------------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | > = 5 | 6–12 | 13–19 | >=20 | Unknown Unknown Child Adult Age | Jnknown Adult | Unknown Age | Unint | Int | Other | Adv | Ireated in Health Care Facility | None | Minor | Moderate | Major Death | Death |
| Category Total: | 11,413 | 9,148 | 390 | 92 | 115 | 7,348 | 10 | 1,147 | 62 | 8,686 | 300 | 5 | 134 | 724 | 1,409 | 251 | 174 | 21 | - |
| Anticoagulants Miscellaneous Anticoagulants | | | | | | | | | | | | | | | | | | | |
| Glycoprotein IIIa/IIb Inhibitors | 10 | 6 | 0 | 0 | 0 | S | 0 | 7 | 7 | 5 | 0 | 0 | 4 | ∞ | 7 | 0 | 3 | 0 | 0 |
| Henarins | 301 | 239 | 27 | 9 | 2 | 172 | | 29 | 2 | 173 | 4 | 0 | 48 | 105 | 4 | 31 | 27 | 2 | 2 |
| Other Antiplatelets | 2,887 | 1,075 | 314 | 21 | ı /- | 620 | 0 | 108 | ויא | 1,003 | 36 | 0 | 32 | 158 | 228 | 23 | 13 | 0 | 10 |
| Other Types of | 42 | 35 | 11 | 2 | 0 | 20 | 0 | 1 | 1 | 28 | 0 | 0 | 9 | 20 | 7 | 2 | 2 | 3 | - |
| Anticoagulant Unknown Tynes of | 7.7 | 20 | 12 | - | c | 4 | C | C | - | 15 | 4 | C | C | 7 | 9 | C | O | - | 0 |
| Anticoagulant | ì | 2 | 1 | - | 1 | ٠ | | | - | G | ٠ | | | - | | | | - | |
| Warfarin (Excluding Rodenticides) | 4,295 | 2,590 | 1,054 | 32 | 35 | 1,302 | 7 | 144 | 16 | 2,240 | 246 | 10 | 62 | 824 | 969 | 29 | 140 | 21 | 0 |
| Category Total: | 7,562 | 3,968 | 1,418 | 62 | 46 | 2,123 | œ | 284 | 27 | 3,464 | 300 | 10 | 169 | 1,122 | 883 | 123 | 185 | 27 | 3 |
| Anticonvulsants | 4 | | | | | | | | | | | | | | | | | | |
| Miscellaneous Annconvulsants | ants | 0.00 | | | 5 | | - | 3 | - | | - | • | 5 | 400 | 6 | 9 | į | Ţ | |
| Carbamazepine Other Trines of | 4,282 | 2,248 | 458 | 101 | 213 | 1,3/4 | - c | 91 | 01 % | 1,147 | 811 | 7 % | 214 | 1,489 | 349 | 279 | 1/1 | 122 | _ v |
| Anticonvulsant | 62,070 | 13,230 | 2,0,5 | 660 | 1,507 | 0,323 | 10 | † | 00 | 0,40 | †,00,† | 70 | //0 | 0,6,0 | 2,300 | 2,320 | 1,000 | CCI | J. |
| (Excluding Barbiturates) | | | | | | | | | | | | | | | | | | | |
| Phenytoin | 3,441 | 2,145 | 202 | 25 | 61 | 1,749 | _ | 91 | 16 | 362 | 569 | _ | 496 | 1,596 | 329 | 553 | 519 | 39 | 3 |
| Primidone | 285 | 131 | 17 | _ | 4 | 66 | 0 | ∞ | 2 | 96 | 26 | 0 | 8 | 53 | 20 | 36 | 12 | 1 | 0 |
| Succinimides | 112 | 91 | 53 | 20 | S | 12 | _ | 0 | 0 | 81 | S | 0 | S | 18 | 25 | 14 | 2 | 0 | 0 |
| Unknown Types of Anti- | 21 | ∞ | | П | 2 | 2 | 0 | 1 | | 4 | 2 | 0 | 0 | 4 | 0 | 7 | 0 | 0 | 0 |
| Barbiturates) | | | | | | | | | | | | | | | | | | | |
| Valproic Acid | 8,226 | 3,211 | 530 | 232 | 454 | 1,822 | 2 | 143 | 28 | 1,584 | 1,213 | 1 | 327 | 1,886 | 821 | 989 | 425 | 50 | 2 |
| Category Total: | 46,065 | 21,064 | 4,936 | 1,279 | 2,306 | 11,383 | 15 | 1,008 | 137 | 12,281 | 6,630 | 32 | 1,727 | 11,002 | 4,910 | 4,389 | 2,509 | 290 | 11 |
| Antidepressants | | | | | | | | | | | | | | | | | | | |
| Cyclic Antidepressants | 701.7 | 103.0 | 771 | 0.7 | ,,, | 1 607 | c | 103 | 71 | 3001 | 1 510 | c | 10 | 1 063 | 37.4 | 103 | 307 | 1,10 | c |
| Americaline | 6,104 | 2,684 | 400 | /x < | 323 | 1,68/ | 7 0 | 103 | <u>0</u> | 2,00 | 91C,1 | n (| , s 18 | 1,962 | C/4 | 381 | 689 | 717 | ς Σ |
| Amoxapine Cvolio Antidonnocconto | 67 6 | y 5 |) c | 0 0 | 7 | να | 0 0 | | 0 0 | 7 6 | 0 6 | 0 0 | ۷ < | ~ 0 | - c | o - | 7 V | - c | > |
| Formulated with a | 7 | 01 | 1 | > | , |) | | | | , | ` | | > | 0 | 1 | - | 0 | 1 | |
| Benzodiazepine | | | | | | | | | | | | | | | | | | | |
| Cyclic Antidepressants | 61 | 20 | 4 | - | 2 | 12 | 0 | 1 | 0 | ∞ | 12 | 0 | 0 | 11 | 5 | 5 | 7 | 0 | 0 |
| Formulated with a Phenothiazine | | | | | | | | | | | | | | | | | | | |
| Desipramine | 78 | 29 | 3 | - | 0 | 25 | 0 | 0 | 0 | 19 | 9 | 0 | 4 | 14 | 4 | 7 | 7 | 1 | 0 |
| Doxepin | 1,190 | 476 | 20 | 23 | 45 | 336 | 0 | 16 | 9 | 167 | 284 | 1 | 16 | 350 | 69 | 122 | 114 | 36 | 5 |
| Imipramine | 502 | 226 | 19 | 30 | 24 | 101 | 0 | 6 | - | 139 | 73 | - | 12 | 131 | 09 | 39 | 37 | 12 | 0 |
| Maprotiline | 3 | 1 | 0 | 0 | 0 | _ | 0 | 0 | 0 | 0 | _ | 0 | 0 | 1 | 0 | 0 | _ | 0 | 0 |
| Nortriptyline | 1,076 | 433 | 92 | 15 | 40 | 275 | 0 | 25 | 2 | 210 | 187 | 7 | 32 | 258 | 88 | 61 | 71 | 24 | 3 |
| Other Types of Cyclic | 3,525 | 1,530 | 459 | 47 | 145 | 962 | 2 | 29 | 14 | 929 | 475 | 9 | 91 | 787 | 388 | 246 | 195 | 22 | 4 |
| Antidepressant | 2 | ų | C | - | , | , | c | c | c | c | - | c | c | , | - | c | c | c | c |
| Protriptyline | 13 | n 4 | o - | | 7 0 | 7 0 | 0 0 | 0 0 | 0 0 | 7 - | | 0 0 | ۷ ٥ | 7 4 | | 7 0 | 3 | 0 - | 0 0 |
| Cyclic Antidentessant | CI | 0 | - | - | 4 | 7 | > | 0 | > | - | † | > | > | 0 | - | | C | - |) |
| Miscellaneous Antidepressants | ants | | | | | | | | | | | | | | | | | | |
| Lithium | 6,370 | 3,244 | 184 | 86 | 351 | 2,450 | 2 | 125 | 34 | 928 | 1,179 | 9 | 949 | 2,608 | 545 | 647 | 1,021 | 133 | 1 |
| | | | | | | | | | | | | | | | | | | ; | - |
| | | | | | | | | | | | | | | | | | | (Continued, | ned) |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | и | | .: F | | | Outcome | | |
|---|-------------------------|---|------------|-------|-------|--------|------------------|------------------------------|----------------|--------|--------|-------|------------|---|--------|-------|----------|-------|----------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Adult Age | Unknown Age | Unint | Int | Other | Adv Rxn | Health Care Facility | None | Minor | Moderate | Major | Death |
| Monoamine Oxidase | 228 | 110 | 12 | - | 3 | 80 | 0 | 14 | 0 | 63 | 28 | 2 | 17 | 48 | 21 | 13 | 20 | S | 0 |
| Other Types of | 21,765 | 9,460 | 2,290 | 350 | 1,148 | 5,098 | ∞ | 502 | 49 | 5,563 | 3,383 | 29 | 397 | 5,155 | 2,522 | 1,585 | 1,298 | 255 | 9 |
| Antidepressant Selective Serotonin Remaske Inhibitore | 45,095 | 19,568 | 5,643 | 1,090 | 4,030 | 7,824 | 19 | 813 | 149 | 10,655 | 8,033 | 54 | 717 | 9,756 | 6,105 | 3,197 | 1,382 | 76 | 9 |
| Trazodone | 15,264 | 5,835 | 575 | 195 | 1,008 | 3,725 | 0 | 271 | 61 | 1,766 | 3,868 | 10 | 120 | 4,225 | 1,286 | 1,840 | 815 | 39 | ω |
| Unknown Types of Antidepressant | 68 | 53 | <i>3</i> 0 | 0 | 6 | Ξ | - | 4 | - | n | 21 | _ | 7 | 17 | 7 | .n | 7 | 0 | 0 |
| | 101,430 | 43,675 | 9,829 | 1,940 | 7,135 | 22,438 | 35 | 1,951 | 348 | 21,485 | 19,086 | 115 | 2,442 | 25,346 | 11,575 | 8,352 | 2,665 | 878 | 37 |
| Miscellaneous Antihistamines Cimetidine and Other | es 9,155 | 7,050 | 5,713 | 229 | 158 | 908 | 2 | 131 | 11 | 6,720 | 229 | _ | 88 | 624 | 1,791 | 224 | 30 | 0 | 1 |
| Histamine-2 Blockers Diphenhydramine Alone | 6,723 | 5,618 | 4,347 | 343 | 209 | 638 | 3 | 65 | 13 | 4,917 | 601 | 12 | 89 | 1,414 | 1,477 | 758 | 238 | 15 | 1 |
| (Over the Counter) Diphenhydramine Alone | 17 | 12 | 6 | 2 | 0 | 1 | 0 | 0 | 0 | 11 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| (Prescription) Diphenhydramine Alone (Unknown if Over the | 32,288 | 22,943 | 12,792 | 1,516 | 2,317 | 5,685 | 18 | 510 | 105 | 16,460 | 5,865 | 46 | 447 | 8,043 | 5,155 | 3,346 | 2,186 | 206 | 10 |
| Counter or Prescription) Other Antihistamines Alone (Excluding Cough and Cold | 46,508 | 33,668 | 19,829 | 4,561 | 2,462 | 5,984 | 29 | 737 | 99 | 29,773 | 3,233 | 39 | 527 | 5,846 | 8,790 | 2,386 | 824 | 42 | 0 |
| Preparations) Category Total: Antimicrobials | 94,691 | 69,291 | 42,690 | 6,651 | 5,146 | 13,114 | 52 | 1,443 | 195 | 57,881 | 9,929 | 86 | 1,130 | 15,928 | 17,215 | 6,715 | 3,278 | 263 | 12 |
| Anthelmintics Diethylcarbamazine Other Tymes of | 71 | 69 | 23 | 3 | 1 2 | 36 | 0 % | 9 | 0 | 69 | 33 | 0 « | 0 35 | 2 | 10 | 1 5 | 0 0 | 0 - | 0 |
| Anthelmintic Dinarazina | 317 | 306 | 27.5 | , 0 | £ - | 38 | , , | (4 | - (| 7000 | 5 1 | 0 < | | () F | 171 | 101 | 7 - | | |
| Therazine Unknown Types of Anthelmintic Antibiotics | 5 | 5 | 2 7 7 | 0 | † 0 | 2 2 | 0 0 | o | 7 0 | 267 | 0 | † 0 | 0 0 | 0 | 2 | 0 | 0 | 0 0 | 0 |
| Systemic Antibiotic Preparations (Oral, Intravenous, Intramscular) | 37,645 | 31,074 | 16,833 | 2,698 | 1,546 | 8,376 | 89 | 1,405 | 148 | 26,387 | 1,213 | 15 | 3,378 | 3,747 | 5,414 | 2,245 | 485 | 27 | 0 |
| Topical Antibiotic Preparations (Dermal, Otic, | 7,396 | 7,060 | 5,142 | 310 | 160 | 1,143 | 17 | 263 | 25 | 6,847 | 62 | S | 144 | 193 | 1,231 | 295 | 23 | 0 | 0 |
| Unknown Types of Antibiotic Preparation | 416 | 310 | 149 | 29 | 19 | 98 | 0 | 25 | 2 | 231 | 18 | 7 | 59 | 38 | 29 | 31 | 7 | 0 | 0 |
| Systemic Antifungal Preparations (Oral, Intravenous, Intramecular) | 1,609 | 1,319 | 745 | 81 | 36 | 375 | 8 | 76 | 3 | 1,195 | 28 | 2 | 92 | 170 | 301 | 06 | 21 | 1 | 0 |
| Topical Antifungal Preparations (Dermal, Otic, Ophthalmic, Nasal) | 9,886 | 9,508 | 7,185 | 240 | 122 | 1,604 | 21 | 315 | 21 | 9,233 | 53 | 12 | 200 | 646 | 1,708 | 582 | 62 | 2 | 2 0 |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | ι | | .: - | | | Outcome | | |
|---|-------------------------|---|----------|------------|----------|---------|--------------------|--|----------------|--------|--------|-------|------------|-------------------------|--------|-------|------------|-------------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6-12 | 13–19 | >=20 | Jnknown Child | Unknown Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv Rxn | Health Care Facility | None | Minor | Moderate | Major | Death |
| Unknown Types of Antifungal Preparation | 15 | 14 | 9 | 0 | 0 | 9 | 0 | 2 | 0 | 14 | 0 | 0 | 0 | 2 | - | 8 | 1 | 0 | 0 |
| Antiparasitics | 210 | 313 | 14 | 30 | 53 | 777 | - | oc c | , | 717 | 30 | c | 9 | 100 | 17 | 63 | 9 | c | - |
| Metronidazole | 1 352 | 832 | ¥ 75 | 5,5 5,5 | c 4 | 378 | | 67 76 | 2 | 414 | 49 | ۰ - | 124 | 105 | 133 |) « | ? <u>~</u> | 1 C | - 0 |
| Other Types of | 32 | 255 | 14 | 3 0 | <u> </u> | 0/0 | ٠ ٥ | , c | 0 0 | 35 | , | - C | 77 | 671 | 201 | 3 | 0, 0 | 1 C | 0 0 |
| Antiparasitic | 1 | î | - | 1 | | ` | | 1 | | ì | 1 | | | | | ì | | | |
| Antituberculars | Ī | i i | 9 | c | Ç | (| (| ١ | , | Ö | ì | ¢ | 1 | | (| | (| (| (|
| Isoniazid | 274 | 178 | 04 - | ∞ c | 53 | 69 | 0 0 | v c | mc | 68 | 26 | 0 0 | 27 | 121 | 38 | 12 | 78 | 38 | 0 0 |
| Other Types of Antitubercular | 07 | 0 | - | 0 | 0 | O | 0 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | > | 1 |) |) |
| Rifampin | 91 | 55 | 22 | 4 | ∞ | 19 | 0 | 2 | 0 | 42 | 4 | 0 | 6 | 19 | 11 | 6 | 4 | 0 | 0 |
| Antivirals | | i | | | | | | | | i | | | | | | , | | | |
| Amantadine | 195 | 78 | 19 | ς. | 7 | 40 | 0 | _ | 0 | 51 | 12 | _ | 4 : | 38 | 19 | 9 | ∞ ; | n | 0 |
| Antiretrovirals | 614 | 355 | 100 | 4 2 | 16 | 191 | 0 0 | 0 5 | 0 0 | 277 | 63 | 0 (| 4 : | 116 | 91 | 30 | 18 | 0 0 | _ < |
| Other Anu-Innuenza | 667 | 677 | 130 | 4 | CI. | 37 | 0 | 10 | 0 | 607 | 4 | 7 | 13 | 33 | cc | 1/ | r | 0 | 0 |
| Systemic Antiviral Prepa- | 1,245 | 947 | 362 | 37 | 51 | 420 | - | 71 | S | 815 | 89 | _ | 59 | 158 | 222 | 61 | 23 | 3 | 0 |
| rations (Oral, Intrave- | | | | | | | | | | | | | | | | | | | |
| nous, Intramuscular) | 5 | | ć | 5 | | 7 | , | - | - | 104 | c | c | (| 5 | ć | 4 | • | c | c |
| ropical Antiviral Preparations (Dermal. | 197 | 191 | 78 | 19 | 0 | \$ | 7 | 4 | 4 | 184 | 0 | 0 | 0 | 71 | 30 | CI | 7 | 0 | 0 |
| Otic, Ophthalmic, Nasal) | | | | | | | | | | | | | | | | | | | |
| Unknown Types of | 424 | 293 | 116 | 11 | 13 | 133 | 0 | 20 | 0 | 241 | 24 | 0 | 27 | 50 | 62 | 19 | 4 | 0 | 0 |
| Antiviral Preparations | _ | | | | | | | | | | | | | | | | | | |
| Other Brass of | 105 | 118 | 7.73 | , | v | 33 | < | v | - | 106 | , | - | ٥ | 00 | 27 | 10 | C | < | < |
| Antimicrobial | 571 | 0110 | C/ | n | O. | 32 | 0 | C | 0 | 901 | n | - | 0 | 07 | 2) | 10 | 7 |) |) |
| Unknown Types of | 18 | 13 | 9 | 0 | 1 | 4 | 0 | 2 | 0 | 11 | 0 | 0 | 2 | 2 | _ | ъ | 0 | 0 | 0 |
| lal | | | | | | | | | | | | | | | | | | | |
| | 64,779 | 55,139 | 32,729 | 3,647 | 2,199 | 13,749 | 121 | 2,463 | 231 | 48,958 | 1,734 | 99 | 4,275 | 5,895 | 10,065 | 3,703 | 770 | 76 | 7 |
| Antineoplastics Miscellaneous Antineonlastics | ę | | | | | | | | | | | | | | | | | | |
| Antingon logic Dense | 1 700 | 1 257 | 223 | ć | 30 | 013 | c | 100 | ć | 1 175 | 90 | < | 130 | 116 | 700 | 124 | 04 | 0 | - |
| Antineoplastic Diugs | 1,709 | 1,557 | 325 | 75 | 30 | 013 | ۷ , | 120 | 77 8 | 1,1/2 | 36 | | 130 | 440 | 524 | 124 | 00 | 10 | 1 = |
| Asthma Therapies | 1,707 | 166,1 | 344 | 35 | 90 | CIO | 4 | 071 | 7 | 6/1,1 | 30 | • | 001 | - | † | 134 | 90 | 10 | t |
| Miscellaneous Asthma Therapies | apies | | | | | | | | | | | | | | | | | | |
| Albuterol | 6,547 | 5,908 | 4,569 | 277 | 209 | 452 | ∞ | 06 | 3 | 5,449 | 569 | 18 | 158 | 736 | 1,455 | 546 | 226 | 5 | 0 |
| Aminophylline or | 331 | 213 | 20 | 4 | 14 | 165 | 0 | ∞ | 2 | 136 | 33 | 0 | 37 | 118 | 39 | 18 | 54 | 13 | 1 |
| Theophylline | 1 | 6 | 1 | , | , | | ; | ! | ١ | | 1 | ١ | | i | İ | | • | • | |
| Leukotriene Antagonist | 9,935 | 8,296 | 6,549 | 1,188 | 160 | 326 | Ξ | 27 | S | 8,102 | 154 | 9 | 29 | 719 | 1,971 | 128 | 3 | 0 | 0 |
| Non-Selective Beta | 1.390 | 1.359 | 366 | 381 | 92 | 471 | 0 | 46 | т | 1.299 | 42 | 6 | 11 | 402 | 102 | 809 | 173 | - | 0 |
| Agonists | | | | , , | 1 | | , | | , | ì | ! | ı | | ! | | | | • | > |
| Other Asthma | 300 | 215 | 29 | 18 | 5 | 111 | 2 | 10 | 2 | 170 | 15 | _ | 26 | 92 | 70 | 15 | 23 | 4 | 3 |
| Therapeutic Agents | | 6 | l | 0 | i | ii C | , | 1 | ; | 1 | č | , | č | Č | | | č | , | (|
| Terbutaline and Other Reta-2 Agonists | 2,532 | 2,233 | 705 | 296 | 78 | 985 | m | 155 | Π | 2,056 | 81 | 7 | 91 | 236 | 442 | 138 | 81 | 7 | 0 |
| Unknown Asthma | 10 | 9 | 3 | - | 1 | - | 0 | 0 | 0 | 3 | 2 | 0 | - | 2 | 1 | 0 | 0 | 0 | 0 |
| Therapeutic Agents | | | | | | | | | | | | | | | | | | | |
| Category Total: | 21,045 | 18,230 | 12,279 | 2,465 | 559 | 2,511 | 54 | 366 | 56 | 17,215 | 296 | 30 | 353 | 2,305 | 4,080 | 1,453 | 260 | 25 | 4 |
| | | | | | | | | | | | | | | | | | | (Continued) | (pənı |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | ' | | | | Age | | | | | Reason | | | Teoopto : | | Out | Outcome | | |
|---|-------------------------|---|----------|-----------|---------------|-----------|------------------|--|--|--------|--------|----------|------------|-------------------------|------------|---------|------------|---------|-----------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 | >=20 | Jnknown Child | Unknown Unknown Unknown Child Adult Age | Jnknown Age | Unint | Int | Other | Adv Rxn | Health Care Facility | None | Minor M | Moderate N | Major 1 | Death |
| Cardiovascular Drugs Miscellaneous Cardiovascular Drugs | lar Drugs | | | | | | | | | | | | | | | | | | |
| Alpha Blockers | 2,448 | 1,060 | 227 | 26 | 40 | 269 | 0 | 99 | 4 | 876 | 126 | 0 | 54 | 330 | 308 | 92 | 75 | 4 | 0 |
| Angiotensin Converting Enzyme Inhibitors | 17,345 | 8,118 | 3,667 | 393 | 231 | 3,468 | 9 | 329 | 24 | 7,234 | 969 | 7 | 171 | 2,266 | 3,007 | 298 | 219 | ∞ | 7 |
| Angiotensin Receptor | 6,319 | 3,181 | 878 | 98 | 89 | 1,932 | _ | 208 | ∞ | 2,968 | 149 | 0 | 62 | 899 | 1,088 | 129 | 77 | - | 0 |
| DIOCKETS Antiarrhythmics | 1 563 | 040 | 146 | 0 | 10 | 705 | 0 | 02 | 0 | 898 | 30 | - | 20 | 305 | 325 | 20 | 2 | 0 | v |
| Antihvperlipidemics | 13.023 | 5.854 | 2.698 | 203 | 123 | 2.460 | o v | 349 | 16 | 5.494 | 169 | 9 | 173 | 535 | 1.104 | 123 | 36 | v 5 | o |
| Antihypertensives (Evoluding Dimetics) | 3,613 | 2,091 | 759 | 573 | 174 | 521 | | 09 | 6 | 1,798 | 190 | | 68 | 946 | 730 | 278 | 246 | . ∞ | - |
| Beta Blockers (Including | 23,091 | 10,360 | 3,318 | 372 | 360 | 5,786 | 6 | 484 | 31 | 8,833 | 1,283 | 7 | 186 | 4,141 | 4,131 | 469 | 772 | 70 | 5 |
| All Propranolol Cases) | | 1 | | , | , | 1 | | | ć | | 0 | , | | 6 | 0 | | : | , | , |
| Calcium Antagonists | 11,194 | 4,945 | 1,369 | 126 | 126 | 3,077 | 4 0 | 221 | 22 | 4,297 | 502 | m c | 117 | 2,300 | 2,053 | 301 | 416 | 65 | 13 |
| Clonidine | 7.833 | 4 381 | 1777 | 1 014 | 413 | 1,232 | 9 | 69 | 17 | 3 341 | 906 | <u>~</u> | 79 | 7 917 | 007 826 | 915 | 1 167 | 138 | Ç7 - |
| Hydralazine | 688 | 298 | 93 | 8 | 51. | 165 | 0 | 15 | ; e | 265 | 26 | 0 | 9 | 115 | 117 | 32 | 31 | 2 | 0 |
| Long-Acting Nitrates | 924 | 308 | 87 | 9 | 8 | 191 | 0 | 19 | 2 | 284 | 15 | 0 | ∞ | 72 | 104 | 25 | 16 | - | 0 |
| Nitroglycerin | 1,557 | 1,163 | 790 | 21 | 21 | 287 | 2 | 36 | 9 | 1,027 | 102 | S | 18 | 389 | 530 | 81 | 24 | _ | 0 |
| Nitroprusside | 25 | 23 | 4 | 0 | 0 | 18 | 0 | ! | 0 | 3 | 0 | 0 | 20 | 21 | S | _ | S. | _ | 0 |
| Other Types of | 592 | 281 | 103 | ∞ | ε | 149 | 0 | 17 | - | 259 | 10 | 0 | Ξ | 46 | 74 | 9 | 11 | 0 | 0 |
| Other Types of | 1,258 | 668 | 306 | 23 | 43 | 426 | - | 83 | 17 | 643 | 108 | 12 | 123 | 290 | 220 | 100 | 57 | 5 | 0 |
| vasodnator Unknown Types of | 70 | 28 | 10 | _ | 0 | 13 | 0 | 3 | - | 14 | 41 | 0 | 0 | 15 | 10 | 0 | 2 | 0 | 0 |
| Cardiovascular Drug | | | | | | | | | | | | | | | | | | | |
| Unknown Types of Vasodilator | 18 | 6 | 4 | -1 | 0 | co | 0 | - | 0 | 6 | 0 | 0 | 0 | 2 | ∞ | 1 | 0 | 0 | 0 |
| Vasopressors | 3,322 | 3,003 | 788 | 829 | 244 | 1,099 | 6 | 174 | 11 | 2,895 | 92 | ъ | 27 | 1,005 | 259 | 1,212 | 334 | 2 | 0 |
| Category Total: | 5 | 48,460 | 17,246 | 3,563 | 1,884 | 23,314 | 4 | 2,242 | 167 | 41,943 | 4,487 | 58 1 | 1,719 | 17,443 | 15,257 | 4,227 | 4,083 | 441 | 53 |
| Cold and Cougn Preparations Acetaminophen and Acetylsalicylic Acid Combinations with Decongestant | ; salicylic Acid | Combinations | with Dec | ongestani | t and/or A | ntihistam | ne withou | t Phenylpı | and/or Antihistamine without Phenylpropanolamine | ine | | | | | | | | | |
| Acetaminophen and | . 58 | 38 | 25 | _ | 2 | 33 | 0 | · - | 0 | 28 | 7 | 0 | 3 | 6 | 7 | ν. | 0 | 0 | 0 |
| Acetylsalicylic Acid with Decongestant and/or Antihistamine | | | ì | • | ı |) | | • | | ì | | |) | ` | | , | | | |
| Combinations without | | | | | | | | | | | | | | | | | | | |
| or Opioids | | | | | | | | | | | | | | | | | | | |
| Acetaminophen, | 109 | 84 | 55 | 9 | 8 | 14 | 0 | _ | 0 | 69 | 15 | 0 | 0 | 17 | 18 | 10 | 5 | 0 | 0 |
| Acetylsalicylic Acid, and Dextromethorphan | | | | | | | | | | | | | | | | | | | |
| Combinations with | | | | | | | | | | | | | | | | | | | |
| Decongestant and/or | | | | | | | | | | | | | | | | | | | |
| Antihistamine without Phenylpropanolamine | | | | | | | | | | | | | | | | | | | |
| Acetaminophen. | 10 | 4 | - | 0 | 2 | - | 0 | 0 | 0 | 2 | 2 | 0 | 0 | _ | 0 | - | - | 0 | 0 |
| Acetylsalicylic Acid, | | | | | | | | | | | | | | | | | | |) |
| and Opioid | | | | | | | | | | | | | | | | | | | |
| Combinations with Decongestant and/or | | | | | | | | | | | | | | | | | | | |
| Antihistamine without | | | | | | | | | | | | | | | | | | | |
| Phenylpropanolamine | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | " | Contin | (Ponnitae |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
|---------|---|--|--|---|--|---|--|---|--|
| | Major | 0 | 0 | 0 | 0 | 0 | 12 | 0 | Ξ |
| Outcome | Moderate | c. | 0 | W | 0 | - | 317 | 7 | 200 |
|) | Minor | 6 | 0 | 27 | 0 | 7 | 1,098 | ϵ | 353 |
| | None | 31 | - | 72 | 0 | - | 2,315 | 7 | 718 |
| E | Health Care Facility | 7.2 | 0 | 45 | 0 | e | 2,473 | Ξ | 861 |
| | Adv Rxn | 4 | 0 | ĸ | 0 | 0 | 285 | 0 | 128 |
| u | Other | 0 | 0 | 0 | 0 | 0 | 28 | 0 | ν, |
| Reason | Int | 17 | 0 | 23 | 0 | ю | 1,652 | w | 609 |
| | Unint | 69 | 4 | 233 | 0 | 14 | 7,107 | 78 | 2,369 |
| | Unknown Age | 0 | 0 | 0 | 0 | 0 | 43 | 0 | ∞ |
| | Unknown Unknown Unknown Child Adult Age | - | 0 | 6 | 0 | 0 | 186 | 0 | 72 |
| | Jnknown Child | mine 0 | 0 | 0 | 0 | nolamine 0 | 16 | 0 | 24 |
| Age |)==20 | or Antihista 20 | П | 19 | 0 | henylpropa 3 | 1,708 | L | 542 |
| Ą | 13–19 | tant and/ | 0 | 17 | 0 | without P | 1,051 | 6 | 477 |
| | 6–12 | Seconges 3 | 0 | 15 | 0 | stamine 3 | 651 | - | 196 |
| | <=5 | ions with I | ю | 206 | 0 | Vor Antihis 11 | 5,474 | 23 | 1,807 |
| | No. of Case No. of Single Mentions Exposures | ine Combinat 91 | 4 | 259 | 0 | ongestant and 17 | 9,129 | 33 | 3,126 |
| | No. of Case Mentions | Ipropanolam 134 | 9 | 335 | - | ons with Dec 27 | 14,501 | 47 | 4,557 |
| | | Acetaminophen and Phenylpropanolamine Combinations with Decongestant and/or Antihistamine Acetaminophen and 134 91 58 3 9 20 Phenylpropanolamine Combinations with Decongestant and/or Article Combinations with Combinations C | Acetaminophen, Phenylpropanolamine, and Codeine Combinations | and/or Antihistamine and/or Antihistamine Acetaminophen, Phenyl- propanolamine, and Dextromethorphan Combinations with | Antihistamine Acetaminophen, Phenylpropanolamine, and Other Opioid Combinations with | Antinistamine Acetaminophen Combinations with Decongestant and/or Antihistamine without Phenylpropanolamine Acetaminophen and 27 17 11 3 0 3 0 Codeine Combinations with Decongestant and/or Antihistamine without Phenylpropa- | Acetaminophen and Dextromethorphan Combinations with Decongestant and/or Antihistamine without | Artenyphopanonannie Acetaminophen and Other Opioid Combinations with Decongestant and/or Antihistamine without | A cetaminophen with Decongestant and/ or Antihistamine Combinations without Phenylpropanolamine or Opioids |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | ı | | E. Postour | | | Outcome | | |
|---|-------------------------|---|--------------------|---------------|---------------|------------------|--|--------------------------------|----------------|-------|--------|-------|--------------|-------------------------|----------|-------|----------------------|-------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 | U)>=20 | Unknown Unknown Unknown Child Adult Age | ^í nknown U Adult | Jnknown Age | Unint | Int | Other | Adv I Rxn | Health Care Facility | None | Minor | Moderate Major Death | Major | Death |
| | cylic Acid, an | d Phenylpropai | nolamine C | Combinat 2 | tions with | Decongest 3 | tant and/or | Antihista 0 | amine 0 | 16 | 6 | 0 | 0 | 7 | 9 | - | - | 0 | 0 |
| and/or Antihistamine without Opioid Acetaminophen, Acetylsalicylic Acid, Phenylpropanolamine, and Dextromethorphan Combinations with Decongestant and/or | 95 | 08 | 57 | 10 | 4 | W | 0 | 4 | 0 | 73 | 9 | 0 | = | 15 | 17 | ∞ | - | 0 | 0 |
| Antihistamine Acetaminophen, Acetyl- salicylic Acid, Phenyl- propanolamine, and Opioid Combinations with Decongestant | ∞ | v. | W | 0 | 0 | - | 0 | | 0 | 4 | - | 0 | 0 | - | 71 | 2 | 0 | 0 | 0 |
| Acetylsalicylic Acid and Phenylpropanolamine Combinations with Decongestant and/or Antihistamine Acetylsalicylic Acid and Phenylpropanolamine 26 14 2 2 8 0 Phenylpropanolamine Combinations with Decongestant and/or Antihistamine without | enylpropanol 31 | lamine Combin 26 | nations with 14 | h Decong 2 | sestant and 2 | d/or Antihi 8 | istamine 0 | 0 | 0 | 23 | 7 | 0 | П | ю | 9 | ю | - | 0 | 0 |
| Opioid Acetylsalicylic Acid, Phenylpropanolamine, and Dextromethorphan Combinations with Decongestant and/or Antihistamine | 10 | 7 | 4 | 2 | 0 | 1 | 0 | 0 | 0 | 9 | - | 0 | 0 | 2 | 64 | 7 | 0 | 0 | 0 |
| Acetylsalicylic Acid Combinations with Decongestant and/or Antihistamine without Phenylpropanolamine Acetylsalicylic Acid and 2 2 0 0 0 2 0 Codeine Combinations with Decongestant and/or Antihistamine without Phenylpropa- | nations with] | Decongestant a 2 | ind/or Antil 0 | histamin 0 | e without | Phenylpro 2 | ppanolamin 0 | 0 e | 0 | 0 | 7 | 0 | 0 | - | П | 0 | 0 | 0 | 0 |
| Acetylsalicylic Acid and Dextromethorphan Combinations with Decongestant and/or Antihistanine without | 51 | 39 | 24 | 8 | 2 | 6 | 0 | - | 0 | 30 | 7 | 0 | 6 | 9 | L | ∞ | - | 0 | 0 |
| Arenylaphopanoanme Acetylsalicylic Acid and Other Opioid Combinations with Decongestant and/or Antihistamine without Phenylpropanolamine | 6 | 61 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | _ | | : | | | Outcome | | |
|---|-------------------------|---|------------------|-----------|-------|-------|--|--------------------|----------------|--------|--------|-------|--------------|---------------------------------------|-------|-------|------------|-------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 |)==20 | Unknown Unknown Unknown Child Adult Age | Unknown 1 Adult | Unknown Age | Unint | Int | Other | Adv F Rxn | Treated in Health Care Facility | None | Minor | Moderate | Major | Death |
| Acetylsalicylic Acid with Decongestant and/or Antihistamine Combinations without Phenylpropanolamine or Onioids | 68 | 51 | 26 | w | 6 | Ξ | 0 | 7 | 0 | 38 | = | 0 | _ | 19 | 41 | co. | N | 0 | 0 |
| Antihistamine and/or Decongestant with Phenylpropanolamine Antihistamine and/or 15 12 3 Decongestant with Phenylpropanolamine Phenylpropanolamine | ngestant wit 15 | th Phenylpropa 12 | nolamine 3 | 0 | 0 | 3 | 0 | w | | 10 | 1 | 0 | - | - | 7 | С | 0 | 0 | 0 |
| Antihistamine and/or Decongestant with Phenylpropanolamine | 539 | 455 | 314 | 99 | 34 | 4 | 0 | L | 0 | 391 | 55 | 0 | 6 | 120 | 150 | 55 | 32 | 0 | 0 |
| Antihistamine and/or Decongestant with Phenylpropanolamine | 25 | 19 | 12 | ю | 0 | 4 | 0 | 0 | 0 | 17 | 0 | 0 | - | 4 | 6 | | ϵ | 0 | 0 |
| and Other Optoid Antihistamine and/or Decongestant with Phenylpropanolamine without Opioid | 382 | 301 | 236 | 35 | 41 | 13 | 0 | 6 | | 274 | 21 | 0 | 'n | 78 | 95 | 23 | 6 | - | 0 |
| Antihistamine and/or Decongestant without Phenylpropanolamine Antihistamine and/or 1,370 1,103 529 1 Decongestant with Codeine without | ngestant wit 1,370 | thout Phenylprd 1,103 | opanolami 529 | ne 165 | 95 | 282 | 1 | 27 | 4 | 934 | 124 | - | 28 | 243 | 295 | 165 | 32 | 9 | 0 |
| Phenypropanolamine Antihistamine and/or Decongestant with Dextromethorphan without Phenylpropa- | 13,547 | 11,267 | 6,926 | 1,002 | 2,006 | 1,219 | 12 | 83 | 19 | 8,428 | 2,635 | v | 170 | 3,625 | 2,639 | 1,626 | 1,194 | 42 | _ |
| Antihistamine and/or Decongestant with Other Opioid without | 1,062 | 878 | 323 | 116 | 62 | 336 | 0 | 37 | 4 | 708 | 116 | | 43 | 241 | 201 | 181 | 45 | - | ε |
| Phenylpropanolamine Antihistamine and/or Decongestant without Phenylpropanolamine and Opioid | 17,900 | 13,951 | 9,748 | 1,225 | 738 | 1,980 | æ | 227 | 30 | 12,888 | 723 | 7 | 300 | 2,301 | 3,964 | 1,257 | 271 | 11 | 2 |
| Miscellaneous Cold and Cough Preparations Acetaminophen in 391 3 Combination with Dextromethorphan (Without Deconges- tants or Antihista- | ough Prepara 391 | ations 316 | 258 | 33 | ٢ | 15 | 0 | к | 0 | 299 | 13 | 0 | 4 | 59 | 86 | 24 | v | 0 | 0 |
| mines) Acetylsalicylic Acid in Combination with Dextromethorphan | 4 | ю | 7 | 0 | - | 0 | 0 | 0 | 0 | 71 | 1 | 0 | 0 | - | 2 | | 0 | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | u | | | | - | Outcome | | |
|--|-------------------------|---|------------|-----------|------------|-----------|------------------|--|----------------|-------|--------|-------|------------|--------------------------------------|-------|-------|----------|-------|---------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv Rxn | reated in Health Care Facility | None | Minor | Moderate | Major | . Death |
| Expectorants or Antitussives (Without Narcotics or Narcotic | 3,252 | 2,297 | 1,175 | 156 | 169 | 655 | 2 | 126 | 14 | 2,012 | 187 | 0 | 87 | 395 | 500 | 151 | 44 | 2 | |
| Non-Acetylsalicylic Acid Salicylates in Combination with | Ξ | 9 | ю | 0 | 0 | 7 | 0 | 1 | 0 | S | П | 0 | 0 | 1 | 1 | 0 | П | 0 | 0 |
| Dextromethorphan Other Dextromethorphan | 14,037 | 11,059 | 5,334 | 1,457 | 1,828 | 2,179 | 7 | 216 | 38 | 8,343 | 2,397 | 15 | 255 | 3,023 | 2,140 | 1,601 | 848 | 22 | 2 |
| Other Phenylpropanolamine Preparations | 246 | 211 | 85 | S | 0 | 106 | 0 | 13 | 2 | 209 | 2 | 0 | 0 | ∞ | 56 | 6 | 0 | 0 | 0 |
| Excluding Street Drugs and Diet Aids) Other Types of Cough and Cold Preparation (Excluding Phenyl- propanolamine, | 2,585 | 2,200 | 1,799 | 112 | 81 | 183 | H | 23 | H | 2,081 | 80 | 8 | 34 | 259 | 610 | 132 | 33 | | 0 |
| Dextromethorphan, Acetaminophen, and Acetylsalicylic Acid) | | | | | | | | | | | | | | | | | | | |
| Unknown Types of Cough and Cold Preparation | 1,245 | 289 | 308 | 39 | 161 | 152 | S | 15 | 7 | 378 | 265 | П | 24 | 379 | 132 | 127 | 80 | 2 | 0 |
| Non-Acetylsalicylic Acid Salicylates and Phenylpropanolamine Combinations with Decongestant and/or Antihistamine | licylates and | Phenylpropar | olamine (| Combina | tions with | Deconges | tant and/o | r Antihist | | | | | | | | | | | |
| Non-Acetylsalicylic Acid Salicylates and Phenylpropanolamine Combinations with Decongestant and/or Antihistamine without | - | - | 0 | 1 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Acetylsalicylic Acid Salicylates, Phenylpropanolamine, and Dextromethorphan Combinations with Decongestant and/or | 9 | ю | 7 | 0 | 0 | - | 0 | 0 | 0 | т | 0 | 0 | 0 | - | 7 | 0 | 0 | 0 | 0 |
| Antrinstatine Non-Acetylsalicylic Acid Salicylates with Decongestant and/or Antihistamine without Phenylpropanolamine | licylates witl | n Decongestant | t and/or A | ntihistan | nine witho | ut Phenyl | propanola | mine | | | | | | | | | | | |
| Non-Acetylsalicylic Acid Salicylates and Dextromethorphan Combinations with Decongestant and/or Antihistamine without | 9 | 4 | 8 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 2 | П | 0 | 0 | 0 |
| Phenylpropanolamine Non-Acetylsalicylic Acid Salicylates and Opioid Combinations with Decongestant and/or Antibistamine without | | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phenylpropanolamine | | | | | | | | | | | | | | | | | | | |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | | | | | | | | | TESTED IN | | | | | |
|---|-------------------------|---|---|-------|--|-------|------------------|--|----------------|--------|-------|-------|------------|-------------------------|--------|-------|--------------|-------------|------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | >= > | 6–12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv Rxn | Health Care Facility | None | Minor | Moderate | Major Death | Deat |
| Non-Acetylsalicylic Acid Salicylates with Decongestant and/or Antihistamine without Phenylpropanolamine | 4 | 4 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| and Optoid Category Total: Diagnostic Agents | 76,724 | 57,793 | 34,865 | 5,312 | 6,782 | 9,537 | 71 | 1,054 | 172 | 47,106 | 8,986 | 99 | 1,390 | 14,235 | 14,124 | 6,892 | 3,140 | 111 | 10 |
| Miscellaneous Diagnostic Agents | gents | c | - | C | C | - | C | C | C | c | C | C | c | C | C | c | | | |
| Glucose or Ketones | N ! | ۷ : | - ; |) |) | - ; | 0 ' |) | • | ٧ | 0 ' | 0 |) | | | | | 0 | |
| Other Types of Diagnostic Agent | 483 | 439 | 109 | 24 | 12 | 222 | 3 | 65 | 4 | 370 | c | 0 | 49 | 170 | 70 | 75 | 25 | 7 | 0 |
| Unknown Types of Diag- | 12 | 9 | - | 0 | 0 | 3 | 0 | 2 | 0 | S | 0 | 0 | 1 | 0 | 0 | | 0 | 0 | 0 |
| Category Total: Dietary Supplements/ Herbals/Homeopathic | 497 | 447 | ======================================= | 24 | 12 | 226 | ю | 67 | 4 | 377 | ю | 0 | 65 | 170 | 70 | 92 | 25 | 7 | 0 |
| Amino Acius | 000 | 000 | 00 | 7 | 00 | - | < | - | < | 110 | 71 | - | ć | 77 | ć | 70 | | c | |
| Orbon Amino Agid | 543 | 308 | 216 | 0 0 | 22 | 1 - 1 |) (| - 1 | o - | 000 | 27 | - 6 | 4 v | ¥ 2 | 200 | 27 | y - | ۷ < | 0 0 |
| Dietary Supplements Botanical Products | 545 | 990 | 210 | 13 | C | 711 | 4 | CI | - | 667 | 3) | n | Ç | 70 | 6 | 6 | 1 | | > |
| Blue Cohosh | 1 | 1 | _ | 0 | 0 | 0 | 0 | 0 | 0 | _ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Citrus Aurantium (Single | 10 | ∞ | 4 | 0 | 0 | 4 | 0 | 0 | 0 | 5 | 0 | 0 | 3 | 0 | 3 | 1 | 0 | 0 | 0 |
| Echinacea | 797 | 235 | 186 | 10 | ĸ | 2 | - | 4 | 0 | 219 | 4 | 0 | 12 | 16 | 40 | 6 | - | - | 0 |
| Ginkgo Biloba | 120 | 74 | 46 | ; - | 'n | 23 | 0 | 0 | ı — | 09 | . 4 | 2 | | 6 | 16 | 9 | 2 | 0 | 0 |
| Ginseng | 118 | 92 | 40 | 9 | 4 | 23 | 0 | 33 | 0 | 54 | 7 | 0 | 15 | 15 | 13 | ∞ | 7 | 0 | 0 |
| Kava Kava | 42 | 21 | 4 | 0 | 0 | 16 | 0 | - | 0 | ∞ | 9 | 0 | 7 | 11 | 4 | 4 | 4 | 0 | 0 |
| Ma Huang/Ephedra (Single Ingredient) | 63 | 37 | 14 | - | 7 | 14 | 0 | 0 | - | 16 | 13 | 0 | ∞ | 20 | ∞ | Ξ | 4 | 0 | 0 |
| Multi-Botanicals with | 124 | 103 | 57 | 2 | 6 | 33 | 0 | 2 | 0 | 71 | 20 | 0 | 12 | 40 | 28 | 11 | 10 | 0 | 0 |
| Citrus Aurantium | | | | | | | | | | | | | | | | | | | |
| Multi-Botanicals with | 285 | 202 | 26 | 12 | 31 | 53 | 0 | 6 | 0 | 123 | 48 | - | 27 | 78 | 46 | 34 | 26 | - | 0 |
| Multi-Botanicals without | 2,417 | 1,942 | 1,036 | 72 | 173 | 869 | 0 | 61 | 2 | 1,319 | 296 | 3 | 313 | 531 | 377 | 279 | 143 | S | 0 |
| Ma Huang or Citrus | | | | | | | | | | | | | | | | | | | |
| Other Single Ingredient | 2,212 | 1,708 | 1,015 | 71 | 50 | 464 | 4 | 94 | 10 | 1,414 | 102 | 6 | 170 | 222 | 314 | 155 | 35 | 4 | 1 |
| Botanicals | | | | | | | | | | | | | | | | | | | |
| St. John's Wort | 231 | 140 | 77 | 4 | 12 | 4 | 0 | α | 0 | 66 | 29 | 0 | 12 | 23 | 33 | 17 | 3 | 0 | 0 |
| Valerian | 274 | 148 | 74 | n c | <u> - </u> | 81 | 0 0 | - 5 | | 5.5 | 4 8 | - 0 | 23 | 28 | 7.8 | 25 | y | 0 0 | 0 |
| Cultural Medicines | 607 | 0/1 | , | 1 | 71 | 66 | 0 | CI | - | † | 30 | 0 | CO | 66 | cc | 31 | 1 | > | ⊃ |
| Asian Medicines | 125 | 101 | 42 | 4 | S | 40 | 0 | 6 | - | 70 | 11 | 0 | 17 | 36 | 22 | 20 | 2 | - | 0 |
| Ayurvedic Medicines | 13 | 6 | 2 | 0 | - | 5 | 0 | - | 0 | 9 | - | 2 | 0 | 5 | 4 | - | 2 | 0 | 0 |
| Hispanic Medicines | 11 | ∞ | 4 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 4 | 3 | - | 7 | 1 | 0 | 0 |
| Other Cultural Medicines | 28 | 38 | 18 | 1 | 4 | 11 | 1 | 3 | 0 | 21 | 11 | 0 | V. | 20 | 11 | 7 | 7 | C | 0 |

| | | , | | | | Age | | | | | Reason | | | Tractod | | On | Outcome | | |
|---|-------------------------|---|--------|-------|-------|-------|--------------------|--|----------------|--------|--------|-------|--------------|-------------------------|-------|-------|------------|-------------|------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=5 | 6–12 | 13–19 | >=20 | Unknown 1 Child | Unknown Unknown Unknown Child Adult Age | Jnknown Age | Unint | Int | Other | Adv F Rxn | Health Care Facility | None | Minor | Moderate N | Major Death | eath |
| Energy Products | | | | | | | | | | | | | | | | | | | |
| Energy Drinks: Caffeine | 183 | 139 | 29 | 21 | 23 | 30 | 0 | 9 | 0 | 87 | 31 | _ | 19 | 26 | 25 | 24 | ∞ | 0 | 0 |
| Containing (From | | | | | | | | | | | | | | | | | | | |
| Guarana, Kola Nut, | | | | | | | | | | | | | | | | | | | |
| Tea, Yerba Mate, | | | | | | | | | | | | | | | | | | | |
| Cocoa, etc) | | | | | | | | | | | | | | | | | | | |
| Energy Drinks: | 242 | 169 | 74 | 4 | 35 | 40 | 0 | 2 | _ | 102 | 45 | _ | 21 | 34 | 31 | 31 | 17 | 7 | 0 |
| Caffeine Only | | | | | | | | | | | | | | | | | | | |
| Vole Nut Tee Verbe | | | | | | | | | | | | | | | | | | | |
| Mote Cocos etc) | | | | | | | | | | | | | | | | | | | |
| France, Cocoa, cit.) | 101 | 71 | ¥ | c | ć | 20 | c | - | C | 5 | ¥ | - | r | ¥ | c | 00 | ć | c | C |
| and Coffeine Contain | 151 | 0/ | 0 | 1 | 25 | 20 | > | - | 0 | 71 | CC | - | - | CC | 1 | 67 | 07 | n |) |
| ing (Erom Any Course | | | | | | | | | | | | | | | | | | | |
| Ing (riom Any Source Including Guarana | | | | | | | | | | | | | | | | | | | |
| Vole Nint Tee Verbe | | | | | | | | | | | | | | | | | | | |
| Mote Constant | | | | | | | | | | | | | | | | | | | |
| Mate, Cocoa, etc) | , | • | (| c | | • | (| (| (| (| , | , | 0 | , | | | (| (| (|
| Energy Drinks: Ethanol | 4 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | _ | _ | 0 | - | 0 | 0 | 0 | 0 | 0 |
| and Caffeine Only | | | | | | | | | | | | | | | | | | | |
| (Without Guarana, | | | | | | | | | | | | | | | | | | | |
| Kola Nut, Tea, Yerba | | | | | | | | | | | | | | | | | | | |
| Mate, Cocoa, etc) | | | | | | | | | | | | | | | | | | | |
| Energy Drinks: No | 9 | 5 | 3 | 0 | _ | 1 | 0 | 0 | 0 | c | 0 | 0 | 1 | 1 | 0 | _ | 0 | 0 | 0 |
| Caffeine (From Any | | | | | | | | | | | | | | | | | | | |
| Source) | | | | | | | | | | | | | | | | | | | |
| Energy Drinks: Unknown | 115 | 69 | 21 | 7 | 18 | 20 | _ | 2 | 0 | 34 | 17 | _ | 17 | 29 | Ξ | 19 | 6 | 0 | 0 |
| Energy Products: Other | | 34 | 6 | 0 | 5 | 19 | 0 | - | 0 | 15 | 10 | 0 | 6 | 13 | 4 | 10 | 9 | 0 | 0 |
| Hormonal Products | | | | | | | | | | | | | | | | | | | |
| Androgen or Androgen | 147 | 101 | 60 | , | v | 73 | < | c | C | 02 | ٥ | < | - | ć | 00 | - | , | - | 0 |
| Precure Distant | ÷ | 101 | 60 | 1 | 0 | C7 | > | 1 |) | 61 | 0 | > | <u>+</u> | † | 07 | = | O | - |) |
| Cumplements | | | | | | | | | | | | | | | | | | | |
| Supplements | , | ç | ć | c | | | (| , | c | ţ | (| c | , | • | • | | c | c | (|
| Glandular Dietary | 63 | 20 | 38 | 0 | 3 | 9 | 0 | 30 | 0 | 4./ | 0 | 0 | 3 | 9 | 6 | 4 | 0 | 0 | 0 |
| Supplements | | 1 | , | | ; | 1 | , | į | į | 1 | 1 | | i | | | ; | , | | |
| Melatonin | 6,409 | 5,105 | 3,626 | 647 | 365 | 395 | 7 | 61 | 14 | 4,356 | 650 | ∞ | 1/ | /49 | 1,207 | 521 | 16 | 0 | 0 |
| Phytoestrogen Dietary | 71 | 43 | 24 | 0 | m | 14 | 0 | 2 | 0 | 33 | 2 | 0 | S | 10 | 10 | 9 | - | 0 | 0 |
| Supplements | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Dietary Supplements/Herbals/Homeopathic | plements/He. | rbals/Homeopa | ıthic | | | | | | | | | | | | | | | | |
| Homeopathic Agents | 12,181 | 11,627 | 10,875 | 179 | 78 | 415 | 19 | 55 | 9 | 11,248 | 117 | 46 | 205 | 630 | 2,576 | 286 | 52 | 7 | _ |
| Unknown Dietary | 2,581 | 2,167 | 1,411 | 120 | 118 | 454 | 7 | 49 | ∞ | 1,711 | 167 | 11 | 267 | 496 | 443 | 190 | 128 | Ξ | 7 |
| Supplements or | | | | | | | | | | | | | | | | | | | |
| Homeopathic Agents | | | | | | | | | | | | | | | | | | | |
| Other Dietary Supplements | s | | | | | | | | | | | | | | | | | | |
| Blue-Green Algae | 179 | 167 | 57 | 22 | 6 | 53 | 0 | 23 | 33 | 155 | _ | 4 | 7 | 32 | 21 | 40 | 7 | 0 | 0 |
| Glucosamine (with or | 899 | 413 | 295 | 17 | v | 84 | _ | 11 | С | 385 | v | 2 | 2.1 | 19 | 77 | 12 | _ | 0 | 0 |
| without Chondroitin) | | | ì | ; | , | - | • | | | | , | ı | i | | : | ! | | | |
| Other Single Ingredient | 1,415 | 865 | 638 | 55 | 18 | 127 | 0 | 24 | 3 | 192 | 29 | 0 | 29 | 83 | 156 | 39 | ∞ | 0 | 0 |
| Non-Botanical Dietary | | | | | | | | | | | | | | | | | | | |
| Supplements | | | | | | | | | | | | | | | | | | | |
| Category Total: | 31,820 | 26,621 | 20,240 | 1,308 | 1,111 | 3,398 | 38 | 471 | 55 | 23,082 | 1,820 | 98 1 | 1,531 | 3,534 | 5,701 | 1,907 | 296 | 33 | 4 |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | , | | 1 |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| Numerican Directory of Chemical Disease (No. Chemical Disease) Numerican Disease (No. Chemical Disease) Nume | | | | | | | Age | | | | | TOPPON | 1 | | | | | Outcome | | |
|--|---|-------------------------|----------------------------|-----------|-------|-------|-------|------------------|------------------|----------------|--------|--------|-------|-----|---------------------------------------|-------|-------|----------|----------|-------|
| Hard 1,275 1,584 144 256 250 1 1 1 2 2 2 2 2 2 2 | | No. of Case Mentions | No. of Single Exposures | >=> =5 | 6–12 | 13–19 | | Unknown Child | Unknown Adult | Unknown Age | Unint | Int | Other | i . | Treated in Health Care Facility | None | Minor | Moderate | | Death |
| 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, | Diuretics Miscellaneous Diuretics | | | | | | | | | | | | | | | | | | | |
| 1 | Furosemide | 3,451 | 1,237 | 594 | 4 | 56 | 520 | - | 52 | 0 | 1,132 | 73 | - | 24 | 306 | 315 | 132 | 54 | 5 | 0 |
| Mineral Mine | Other Types of Diuretic | 2,054 | 935 | 401 | 41 | 46 | 400 | 8 | 35 | 9 | 800 | 82 | 0 | 52 | 228 | 261 | 57 | 39 | 2 | 0 |
| Minch Minc | Thiazide | 4,912 | 1,960 | 905 | 123 | 89 | 780 | 0 | 98 | _ | 1,740 | 185 | _ | 31 | 435 | 531 | 66 | 39 | m · | 0 |
| 1 | Unknown Types of Diuretic | 274 | 116 | 49 | m | m | 42 | - | m | 0 | 103 | 6 | 0 | 4 | 28 | 30 | m | - | - | 0 |
| Hutchist | Category Total: | 10,691 | 4,248 | 1,961 | 211 | 146 | 1,742 | w | 176 | 7 | 3,775 | 349 | 2 | 111 | 266 | 1,137 | 291 | 133 | ∞ | 0 |
| National Part 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4,4 1,4,4,4,4 1,4,4,4,4 1,4,4,4,4 1,4,4,4,4 1,4,4,4 1,4,4,4,4 1,4,4,4,4 1,4,4,4 1,4,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4 1,4,4,4,4 1,4,4,4,4 1,4,4,4,4,4 1,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4 | Electrolytes and Minerals | | 1 | | | | | | | | | | | | | | | | | |
| 1. 1. 1. 1. 1. 1. 1. 1. | Miscellaneous Electrolytes | s and Mineral | | 13 070 | 470 | 161 | 445 | 10 | 99 | 7 | 14 002 | 150 | 0 | 71 | 356 | 2351 | 200 | 31 | 0 | 0 |
| 1. 1. 1. 1. 1. 1. 1. 1. | Salts | 10,01 | C+7,+1 | 0.0,01 | È | | È | 7 | 3 | CT | 700,41 | (61 | | 1/ | | 1,77 | 64 | 10 | | > |
| 1, | Chromium, Trivalent | 337 | 293 | 128 | 14 | 6 | 103 | 9 | 32 | _ | 272 | ∞ | 0 | 11 | 51 | 62 | 17 | 4 | 0 | 0 |
| 1. | Colloidal Silver | 87 | 75 | 34 | 4 6 | 4 5 | 25 | 0 (| ∞ ; | 0 • | 51 | r : | m + | Ξ ; | 30 | 13 | 13 | 7 1 | 0 | 0 |
| 3,431 2,273 116 277 1,074 8 158 25 3,285 418 7 203 1,084 1,069 390 107 8 8 8 8 8 8 8 8 8 | Fluoride (Excluding Vitamins, Hydrofluoric | | 2,480 | 2,105 | 877 | 47 | I | 7 | 77 | 4 | 2,380 | 17 | - | C | 104 | 211 | 158 | n | 0 | 0 |
| 88 3.931 2.273 116 277 1,074 8 158 25 3.285 418 7 203 1,084 1,084 1,069 390 107 8 86 36 36 4 514 100 1 74 245 191 106 390 107 8 6 172 432 19 60 159 2 15 4 514 100 1 74 245 191 106 45 1 77 44 16 3 1 26 0 7 1 45 2 0 7 1 45 2 0 7 1 45 2 2 1 45 2 2 1 45 1 4 36 1 4 36 1 1 4 36 1 4 36 1 4 36 36 36 36 36 </td <td>Acid & Mouthwashes)</td> <td>_</td> <td></td> | Acid & Mouthwashes) | _ | | | | | | | | | | | | | | | | | | |
| 84 865 866 867 868 86 86 86 86 86 86 86 86 86 86 86 86 | Iron and Iron Salts | 5,148 | 3,931 | 2,273 | 116 | 277 | 1,074 | ∞ | 158 | 25 | 3,285 | 418 | 7 | 203 | 1,084 | 1,069 | 390 | 107 | ∞ | — |
| Secondary Seco | (Excluding vitalinis with Iron) | | | | | | | | | | | | | | | | | | | |
| 1, 1, 1, 1, 1, 1, 1, 1, | Magnesium and Magne- | 1,083 | 865 | 368 | 40 | 34 | 383 | 2 | 36 | 2 | 693 | 84 | 7 | 80 | 127 | 147 | 104 | 19 | 0 | 0 |
| National Line 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, | sium Salts | 0 | .00 | 0 | - | (| | • | ļ | • | į | • | | ī | | 5 | | į | ٠ | (|
| | Multi-Mineral and Multi-Herbal Dietary | 8/8 | 1691 | 432 | 19 | 09 | 159 | 7 | cı | 4 | 514 | 100 | - | 4/ | 242 | 191 | 106 | 45 | - | 0 |
| National Column National C | Supplement | | | | | | | | | | | | | | | | | | | |
| 1 | Multi-Mineral Dietary | 236 | 172 | 128 | 7 | 1 | 30 | 0 | 9 | 0 | 150 | ∞ | 1 | 13 | 22 | 35 | 12 | 2 | 0 | 0 |
| 13 15 15 15 15 15 15 15 | Supplements Other Types of Fleetro- | 27 | 2 | 16 | 'n | - | 36 | 0 | 7 | - | 75 | c | 0 | 1 | 7 | o | 01 | C | - | 0 |
| 1 | lyte or Mineral | õ | † | 01 | 'n | - | 2 | | - | - | 7 | 1 | | | 71 | | 01 | 1 | - | |
| 1. 2.725 1.540 2.98 1.38 6.01 8 1.27 1.3 2.369 249 34 60 360 357 377 56 1.540 2.98 1.38 6.01 8 1.27 1.3 2.369 249 34 60 360 357 377 36 1.540 2.04, 3.540 3.589 | Potassium and Potassium | | 289 | 268 | 22 | 17 | 313 | 0 | 64 | 3 | 580 | 74 | 2 | 25 | 144 | 166 | 27 | 24 | _ | 0 |
| 7. 2,725 1,540 298 138 601 8 127 13 2,369 249 34 60 360 557 377 56 1 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 | Salts Selenium and Selenium | 123 | 90 | 7.0 | 0 | C | 50 | 0 | 7 | - | 83 | 7 | - | A | 30 | 7 | 17 | × | 0 | 0 |
| 1, 2,725 1,540 298 138 601 8 127 13 2,369 249 34 60 360 557 377 56 1 1 | Salts | (71 | 8 | 1 | > | 1 | ò | | - | - | 70 | ` | - | r | 3 | CI | 1 | 0 | > | > |
| 4 13 5 0 0 8 0 0 13 0 0 13 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 | Sodium and Sodium Salts | | 2,725 | 1,540 | 298 | 138 | 601 | ∞ | 127 | 13 | 2,369 | 249 | 34 | 09 | 360 | 557 | 377 | 99 | - | 2 |
| 1 838 459 35 41 252 1 44 6 712 38 4 79 92 113 97 13 2 34 73 20,854 1,256 769 3,589 48 581 75 25,149 1,181 70 713 2,662 5,240 1,540 321 14 34 759 35 | Unknown Types of Elec- | 14 | 13 | S | 0 | 0 | 8 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | S | 3 | 3 | 3 | 0 | 0 |
| 1 838 459 35 41 252 1 44 6 712 38 4 79 92 113 97 13 2 10 27,172 20,854 1,256 769 3,589 48 581 75 25,149 1,181 70 713 2,662 5,240 1,540 321 14 10 27,172 20,854 1,256 769 3,589 48 581 75 25,149 1,181 70 713 2,662 5,240 1,540 321 14 13 2,190 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 14 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | trolyte or Mineral | - | - | - | c | c | C | c | C | < | - | c | c | c | c | c | C | c | c | c |
| 1 838 459 35 41 252 1 44 6 712 38 4 79 92 113 97 13 2 10 27,172 20,854 1,256 769 3,589 48 581 75 25,149 1,181 70 713 2,662 5,240 1,540 321 14 13 2,190 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 14 595 387 15 11 150 0 29 3 569 11 1 13 15 11 13 8 8 8 8 9 9 9 8 9 8 9 8 9 9 9 9 9 9 9 | vanadılım and vanadılım Salts | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |) |
| 40 27,172 20,854 1,256 769 3,589 48 581 75 25,149 1,181 70 713 2,662 5,240 1,540 321 14 13 Legarations 1,133 271 38 368 5 63 4 1,779 31 6 63 65 331 159 12 0 13 2,190 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 14 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Zinc and Zinc Salts | 1,011 | 838 | 459 | 35 | 41 | 252 | _ | 4 | 9 | 712 | 38 | 4 | 79 | 92 | 113 | 76 | 13 | 2 | 0 |
| at Preparations 1,133 271 38 368 5 63 4 1,779 31 6 63 65 331 159 12 0 3 2,190 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 44 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Category Total: | 32,430 | 27,172 | 20,854 | 1,256 | 692 | 3,589 | 48 | 581 | 75 | 25,149 | 1,181 | 70 | 713 | 2,662 | 5,240 | 1,540 | 321 | 14 | 3 |
| 1,133 271 38 368 5 63 4 1,779 31 6 63 65 331 159 12 0 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Eye/Ear/Nose/Throat Prepar | ations | , | | | | | | | | | | | | | | | | | |
| or Eye/ 2,335 1,882 1,135 2/1 38 368 5 63 4 1,779 31 6 63 65 351 159 12 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Miscellaneous Eye/Ear/No | se/Throat Pro | eparations | | į | ć | 0 | ι | (| • | | č | • | (| , | ć | | - | (| (|
| ges- 2,313 2,190 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 homi- ng e) sal 624 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Iopical Steroids For Eye, Nose/Throat | | 1,882 | 1,133 | 7/1 | 38 | 208 | n | 03 | 4 | 1,779 | 31 | 0 | 60 | 60 | 331 | 661 | 71 | 0 | 0 |
| ges- 2,313 2,190 962 108 140 809 1 159 11 1,981 50 4 151 253 575 249 28 3 homi- homi- ng e) sal 624 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Nasal Preparations | | | | | | | | | | | | | | | | | | | |
| mi- 624 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Other Nasal Deconges- | 2,313 | 2,190 | 962 | 108 | 140 | 608 | П | 159 | 11 | 1,981 | 50 | 4 | 151 | 253 | 575 | 249 | 28 | 3 | 0 |
| 624 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | tants or Sympathomi- | | | | | | | | | | | | | | | | | | | |
| 624 595 387 15 11 150 0 29 3 569 11 1 13 29 92 69 8 0 | Tetrahydrazoline) | | | | | | | | | | | | | | | | | | | |
| Preparation | Other Types of Nasal | 624 | 595 | 387 | 15 | 11 | 150 | 0 | 29 | 3 | 269 | 11 | 1 | 13 | 29 | 92 | 69 | ∞ | 0 | 0 |
| | Preparation | | | | | | | | | | | | | | | | | | | |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| No. of Case No. of Single 24 23 24 23 6 4 4 6 4 4 3,726 3,620 3,3726 3,620 1,864 1,960 1,864 1,746 1,689 2,191 2,152 65 63 65 63 65 64 2,197 2,165 2,197 2,165 2,191 2,152 65 63 1,264 6 6 21,114 19,909 1 8,169 7,748 10,748 6,159 2,734 2,433 | | 6–12 | : | | nknown U | Unknown Unknown Unknown | Jnknown | | | | | reated in | | | | | |
|---|------------------------------------|------------|-------|-------|----------|-------------------------|---------|--------|-----|-------|------------|-------------------------|------------|-------|----------|-------------|------|
| 24 23 3,726 3,620 3,726 3,620 3,726 3,620 1,316 1,264 1,960 1,864 1,746 1,689 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 | 15 0 0 1,878 98 735 | | 13–19 | >=20 | Child | Adult | Age | Unint | Int | Other | Adv Rxn | Health Care Facility | None | Minor | Moderate | Major Death | Deat |
| 3,726 3,620 3,37 292 1,316 1,264 1,960 1,864 1,746 1,689 59 54 2,197 2,165 2,197 2,165 2,197 2,165 495 457 495 63 65 63 61,264 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 0 1,878 98 735 | - | - | 3 | 0 | 3 | 0 | 21 | 0 | 2 | 0 | 7 | 12 | 3 | 0 | 0 | 0 |
| 3,726 3,620 3,37 292 1,316 1,264 1,960 1,864 1,746 1,689 59 54 2,197 2,165 2,197 2,165 2,197 2,165 495 457 495 63 65 63 67 457 347 325 1,369 1,264 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 1,878 98 735 | - | 0 | 2 | 0 | - | 0 | 4 | 0 | 0 | 0 | 1 | - | - | 0 | 0 | 0 |
| 3,726 3,620 3,37 292 1,316 1,264 1,960 1,864 1,746 1,689 59 54 59 54 495 457 495 457 347 325 1,369 1,264 6 6 6 6 1,689 1,264 8,169 7,748 10,743 6,159 2,734 2,433 | 1,878 98 735 | | | ! | , | | , | | | | | ; | | | | | |
| 337 292 1,316 1,264 1,960 1,864 1,746 1,689 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 735 | 65 | 219 | 1,218 | m (| 229 | ∞ (| 3,535 | 39 | 50 | 25 | 615 | 391 | 710 | 152 | · | 0 |
| 1,316 1,204 1,960 1,864 1,746 1,689 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 735 | | 4 6 | 157 | 7 0 | 50 | 7 ; | 265 | 7 2 | 7 ; | <u>×</u> | 55 | 78 | 22 | 13 | - (| 0 (|
| 1,960 1,864 1,746 1,689 59 54 2,197 2,165 2,191 2,152 65 63 457 347 325 1,369 1,264 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | | /4 | 102 | 283 | 'n | 83 | Ξ | 1,035 | 6/ | 101 | 43 | 284 | 458 | 80 | 25 | 7 | 0 |
| 1,746 1,689 59 54 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 1,064 | 68 | 69 | 524 | S | 103 | 10 | 1,718 | 40 | 34 | 70 | 188 | 340 | 123 | 33 | 2 | 0 |
| 59 54 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 1,264 8,169 7,748 10,743 6,159 2,734 2,433 | 1,169 | 4 | 103 | 301 | 9 | 58 | ∞ | 1,463 | 73 | 125 | 18 | 406 | 753 | 112 | 36 | 2 | 0 |
| 59 54 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | | | | | | | | | | | | | | | | | |
| 2,197 2,165 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 15 | П | ∞ | 18 | 0 | 12 | 0 | 37 | 4 | 6 | 4 | 14 | 6 | S | 3 | 0 | 0 |
| 2,197 2,103 2,191 2,152 65 63 495 457 347 325 1,369 1,264 6 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | | | 2 | Ç | c | 8 | 5 | 6 | c | c | ć | 7 | , | C | Ċ | • | • |
| 65 63 495 457 347 325 1,369 1,264 6 6 6 6 6 7,748 8,169 7,748 10,743 6,159 2,734 2,433 | 1,083 936 | 18/ 110 | 79 | 852 | n vo | 162 | 2 8 | 2,137 | 0 9 | 0 | 21 | 233 | 452 252 | 573 | 55 41 | 7 0 | 00 |
| 65 63 495 457 347 325 1,369 1,264 6 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | | | | | | | | | | | | | | | | | |
| 495 457 347 325 1,369 1,264 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 19 | ю | 4 | 53 | 0 | ∞ | 0 | 61 | 0 | 0 | 7 | 10 | S | 24 | ю | 0 | 0 |
| 347 325 1,369 1,264 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 202 | 50 | 51 | 128 | 0 | 25 | П | 416 | 32 | 0 | ∞ | 50 | 128 | 33 | S | 0 | 0 |
| 1,369 1,264 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 174 | 42 | 25 | 61 | - | 21 | - | 296 | 21 | - | 7 | 16 | 06 | 13 | 2 | 0 | 0 |
| 6 6 6 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | 1,083 | 65 | 30 | 69 | 0 | 15 | 2 | 1,219 | 30 | 0 | 14 | 46 | 261 | 42 | 3 | 0 | 0 |
| 8,169 7,748 10,743 6,159 2,734 2,433 | 2 | 0 | 0 | - | - | 2 | 0 | 3 | - | 0 | 2 | | 0 | 2 | 0 | 0 | 0 |
| 21,114 19,909 1 8,169 7,748 10,743 6,159 2,734 2,433 | | | | | | | | | | | | | | | | | |
| rer Types 8,169 7,748 ton Pump 10,743 6,159 icylate- 2,734 2,433 | 10,955 1, | 1,108 | 896 | 5,670 | 32 | 1,092 | 81 | 18,663 | 432 | 305 | 479 | 2,446 | 4,208 | 2,759 | 399 | 13 | • |
| ton Pump 10,743 6,159 icylate- 2,734 2,433 | 7,105 | 253 | 46 | 278 | 10 | 48 | ∞ | 7,595 | 79 | 24 | 47 | 155 | 1,199 | 110 | 6 | 0 | 0 |
| icylate- 2,734 | | 226 | 155 | 1,827 | 9 | 272 | 11 | 5,744 | 212 | 11 | 179 | 470 | 1,414 | 197 | 21 | 0 | 0 |
| | 1,998 | 151 | 38 | 212 | 0 | 31 | в | 2,244 | 66 | | 82 | 228 | 624 | 84 | 12 | 0 | 0 |
| Antidiarrheals: Diphe- 351 198 noxylate and Atropine | 88 | 6 | 6 | 82 | _ | 7 | _ | 153 | 27 | 0 | 15 | 110 | <i>L</i> 9 | 36 | 17 | 0 | 0 |
| Antidimentals: 1,413 1,102 Ioneramide | 711 | 41 | 27 | 284 | 1 | 35 | ю | 940 | 87 | - | 99 | 280 | 403 | 6 | 18 | 4 | 0 |
| Antidiarrheals: Non- 28 19 Narcotic Containing (Fechalias Calicul | 12 | 1 | 2 | 4 | 0 | 0 | 0 | 16 | 2 | - | 0 | ϵ | С | - | - | 0 | 0 |
| Containing) Antidiarrheals: Paregoric 12 9 | 9 | 0 | 1 | 2 | 0 | 0 | 0 | ∞ | - | 0 | 0 | v | 5 | _ | 0 | 0 | 0 |
| Containing | | | | | | | | | | | | | | | | | |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | u | | | |) | Outcome | | |
|--|-------------------------|---|-------------|-----------|-------|--------------|------------------|------------------------------------|----------------|--------|--------|-------|------------------|---------------------------------------|-------|-------|----------|-------------|-------------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | > \$ = 5 | 6-12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv 1 Rxn | Ireated in Health Care Facility | None | Minor | Moderate | Major | Death |
| Antispasmodics | 2 130 | 1 663 | 000 | 2 | 50 | 537 | c | 13 | 0 | 1 361 | 107 | - | 2 | 533 | 531 | 001 | 5 | c | |
| Antispasmodics: Anti- cholinergic Containing | 3,170 | 1,003 | 679 | 110 | 701 | 166 | 7 | 0 | o | 1,301 | 191 | - | 2 | ccc | 166 | 199 | 4, | 7 | 0 |
| Antispasmodics: Other | 35 | 20 | S | 0 | 2 | 10 | 0 | 3 | 0 | 13 | S | 0 | 2 | ∞ | 3 | 4 | 2 | 0 | 0 |
| Types Miscellaneous Gastrointestinal Prenarations | inal Prenara | fions | | | | | | | | | | | | | | | | | |
| Laxatives | 16.540 | 14.799 | 10.975 | 629 | 413 | 2.331 | 22 | 391 | 38 | 13.754 | 530 | 95 | 401 | 1.266 | 2.296 | 1.472 | 159 | 4 | С |
| Other Types of Gastroin- | 608,6 | 8,632 | 7,343 | 205 | 66 | 816 | 15 | 144 | 10 | 8,204 | 162 | 9 | 246 | 538 | 1,513 | 218 | 92 | 9 | 0 |
| testinal Preparation | 7 | <u>,</u> | 7 | 0 | - | 0 | 0 | 0 | <u> </u> | 7 | C | C | C | - | C | - | 0 | 0 | C |
| Gastrointestinal | 17 | CI | <u>+</u> | > | - | > | > | 0 | > | CI | 0 | > | > | - | 1 | - | | > | > |
| Preparation | | | | | | | | | | ! | | | | | | | | | |
| Category Total: Hormones and Hormone | 52,983 | 42,797 | 32,749 | 1,633 | 895 | 6,383 | 27 | 866 | 82 | 40,047 | 1,401 | 140 | 1,132 | 3,597 | 8,060 | 2,420 | 425 | 16 | 0 |
| Antagonists | | | | | | | | | | | | | | | | | | | |
| Miscellaneous Hormones and Hormone Antagonists | nd Hormone | Antagonists | | | | | | | | | | | | | | | | | |
| Androgens | 425 | 343 | 102 | 11 | 21 | 164 | 1 | 41 | 3 | 243 | 20 | 2 | 45 | 88 | 52 | 48 | 16 | 9 | 0 |
| Corticosteroids | 10,482 | 8,606 | 4,489 | 269 | 278 | 2,664 | 16 | 425 | 37 | 7,977 | 135 | 8 | 467 | 553 | 1,289 | 352 | 54 | 0 | 0 |
| Estrogens | 1,877 | 1,194 | 669 | 35 | 62 | 324 | 3 | 62 | 6 | 666 | 46 | 3 | 144 | 144 | 236 | 112 | 14 | 0 | 7 |
| Insulin | 6,080 | 5,297 | 141 | 99 | 92 | 4,468 | 4 | 494 | 32 | 4,822 | 385 | 7 | 99 | 1,901 | 2,176 | 286 | 298 | 34 | 9 |
| oral Contraceptives | 7,911 | 899'9 | 5,280 | 215 | 438 | 561 | 15 | 137 | 22 | 6,124 | 436 | 7 | 93 | 457 | 1,130 | 177 | 14 | 0 | 0 |
| Other Hormone | 544 | 424 | 145 | 24 | 13 | 221 | - | 20 | 0 | 396 | 15 | - | 12 | 44 | 77 | 11 | - | 0 | 0 |
| Antagonists | 000 | - | 000 | 30 | - | 100 | - | 7 | r | | 9 | , | ¥ | 170 | 901 | 27 | 7 | c | c |
| Other Hormones | 90/ | 1.461 | 022 | ر د بر | 14.1 | /87 | - 6 | 4 c | υ <u>-</u> | 1217 | S 6 | ه د | 6 6 | 8/1 | 198 | 60 1 | 10 | O 4 | > |
| Flogestins | 1,710 | 1,461 | 040 | £ , | 102 | 404 | n (| 000 | <u> </u> | 1,214 | 1 - | 0 0 | - 704 | 200 | 552 | 011 | 77 | 4 < | > 0 |
| Selective Estrogen Receptor Modulators | 4/6 | 204 | 0/ | n | 11 | 7 | 0 | 10 | 0 | 190 | 4 | 0 | - | 97 | 20 | 4 | - | |) |
| Thyroid Preparations | 13.452 | 9.382 | 4.888 | 457 | 229 | 3.337 | œ | 438 | 25 | 9.036 | 246 | ν. | 85 | 1.145 | 1.889 | 4 | 40 | - | С |
| (Including Synthetics | | | | | ì | | |) | ì | | 2 | , | 3 | | | | 2 | • | |
| allu Extracts) | | Ģ. | < | - | · | ų | C | c | c | 5 | c | < | · | ų | c | - | · | c | c |
| Hormone Antagonists | 7 | 18 | 7 | - | n | n | 0 | Þ | 0 | 71 | n | 0 | n | n | n | - | n | 0 | 0 |
| Oral Hypoglycemic | | ; | | | | į | | | | | | | | | | | | | , |
| Oral Hypoglycemics: Biguanides | 7,503 | 3,464 | 821 | 96 | 233 | 2,071 | - | 227 | 15 | 2,884 | 459 | 7 | 97 | 834 | 086 | 233 | 112 | 32 | 9 |
| Oral Hypoglycemics: | 1,235 | 518 | 204 | 13 | 17 | 253 | 0 | 30 | П | 471 | 30 | 0 | 13 | 213 | 221 | 29 | 51 | 2 | 0 |
| Oral Hypoglycemics: | 3 998 | 1 712 | 868 | 35 | 4 | 999 | 6 | 85 | 6 | 1 453 | 163 | C | 71 | 1 222 | 712 | 9 | 401 | 4 | C |
| Sulfonylureas | | 1 | | , | : | | 1 | 2 | ` | | , | 1 | | 1 | 1 | , | | : | |
| Oral Hypoglycemics: | 1,101 | 408 | 186 | 10 | 5 | 189 | 0 | 18 | 0 | 361 | 28 | - | 17 | 132 | 169 | 16 | 11 | 1 | 0 |
| Thiazolidinediones | | | | | | | | | | | | | | | | | | | |
| Category Total: | 57,632 | 40,410 | 19,013 | 1,803 | 1,589 | 15,708 | 55 | 2,072 | 170 | 36,807 | 2,072 | 49 | 1,373 | 7,144 | 9,441 | 1,638 | 1,524 | 124 | 14 |
| Miscellaneous Drugs Other Miscellaneous Drugs | *** | | | | | | | | | | | | | | | | | | |
| Allopurinol | 764 | 298 | 162 | 9 | 7 | 107 | 0 | 14 | 2 | 275 | 15 | 0 | ∞ | 49 | 87 | 9 | 2 | 8 | 0 |
| Disulfiram | 257 | 75 | 16 | _ | 0 | 49 | 0 | ∞ | | 45 | 14 | - | 15 | 23 | 15 | 11 | 7 | 0 | 0 |
| Ergot Alkaloids | 186 | 138 | 74 | 2 | 9 | 50 | _ | 4 | | 104 | 14 | 0 | 20 | 78 | 48 | 22 | 14 | 2 | 0 |
| Levo-Dopa and Related | 1,051 | 559 | 166 | 10 | 5 | 339 | 1 | 35 | 3 | 504 | 32 | 0 | 16 | 147 | 146 | 79 | 26 | 1 | 0 |
| Drugs | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | (Continued) | ued |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | ı | | | | | Outcome | | |
|--|-------------------------|---|------------|----------|------------|--------|--|------------------|----------------|------------|------------|-------|-------|---------------------------------------|------------|--------|----------|-------------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | >=> =5 | 6–12 | 13–19 | >=20 | Unknown Unknown Unknown Child Adult Age | Unknown Adult | Unknown Age | Unint | Int | Other | Adv | Treated in Health Care Facility | None | Minor | Moderate | Major Death | Death |
| Phenothiazines Sleep Aids, Over the | 4,829 1,392 | 1,999 | 284 158 | 66 14 | 205 116 | 1,313 | 1 1 | 110 | 20 | 840 251 | 890 551 | 12 | 232 | 1,353 | 392 169 | 419 | 471 | 35 19 | 9 0 |
| Counter Only (Excluding Diphenhydramine) | | | | | | | | | | | | | | | | | | | , |
| Unknown Types of Sedative/Hynnotic/ | 266 | 102 | S | 1 | 10 | 65 | 0 | 17 | 4 | 10 | 80 | - | 9 | 77 | 12 | 16 | 18 | 0 | 0 |
| Anti-Anxiety or Anti- Descebatio Deng | | | | | | | | | | | | | | | | | | | |
| inec | 161,196 | 26,897 | 12,314 | 2,864 | 8,358 | 38,949 | 49 | 3,591 | 772 | 26,343 | 37,045 | 451 | 2,038 | 44,516 | 12,724 | 19,934 | 9,172 | 686 | 33 |
| Miscellaneous Serums, Toxoids, Vaccines | ids, Vaccine | Ş | | | | | | | | | | | | | | | | | |
| Miscellaneous Serums, | 2,353 | 2,131 | 425 | 167 | 149 | 1,061 | 18 | 276 | 35 | 1,544 | 10 | 2 | 562 | 286 | 191 | 383 | 98 | - | 0 |
| Category Total: Stimulants and Street | 2,353 | 2,131 | 425 | 167 | 149 | 1,061 | 18 | 276 | 35 | 1,544 | 10 | 7 | 562 | 286 | 191 | 383 | 98 | 1 | 0 |
| Drugs Connectingide and Angloss | | | | | | | | | | | | | | | | | | | |
| Marijijana | 5 250 | 1 966 | 190 | 37 | 790 | \$15 | 0 | 97 | 20 | 3998 | 1 444 | 63 | 09 | 1 413 | 130 | 226 | 528 | 96 | C |
| Tetrahydrocannabinol | 1,206 | 987 | 3 | 5 | 456 | 473 | 0 | 35 | 13 | 67 | 906 | 2 8 | 8 - | 839 | 30 | 333 | 395 | 22 | |
| (THC) Homologs Tetrahydrocannabinol | 16 | 10 | 2 | - | 4 | 3 | 0 | 0 | 0 | 4 | 5 | 0 | _ | ∞ | 0 | - | 4 | 0 | 0 |
| (THC) Pharmaceuticals | | | | | | | | | | | | | | | | | | | |
| Diet Aids: Phenylpropa- nolamise and Caffeine | 24 | 22 | 6 | 0 | 4 | 6 | 0 | 0 | 0 | 12 | v | 0 | ν. | 7 | ю | 2 | ĸ | 0 | 0 |
| Combinations Diet Aids: Phenylpropa- | 18 | 16 | 10 | П | 0 | 5 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 0 | 0 |
| Other Types of Diet Aid, | 242 | 201 | 116 | 3 | 15 | 58 | 0 | 9 | 8 | 135 | 28 | 0 | 36 | 85 | 50 | 27 | 23 | 0 | 0 |
| Other Types of Diet Aid, | 100 | 92 | 37 | 0 | 4 | 28 | 0 | 4 | 33 | 51 | 15 | - | 7 | 43 | 19 | 15 | 5 | 0 | 0 |
| Unknown Types of Diet | 1111 | 81 | 40 | 7 | 6 | 20 | 1 | 2 | 2 | 53 | 15 | 0 | 11 | 39 | 20 | ∞ | 6 | 2 | 1 |
| Ald Miscellaneous Stimulants and Street Drugs | nd Street Dr | săn. | | | | | | | | | | | | | | | | | |
| Amphetamines and Related Compounds | 14,614 | 9,834 | 3,591 | 1,827 | 1,796 | 2,316 | 6 | 230 | 65 | 6,902 | 2,363 | 63 | 405 | 4,757 | 2,632 | 1,648 | 1,374 | 75 | 2 |
| Amyl or Butyl Nitrites | 86 | 73 | 7 | _ | 3 | 51 | 0 | 13 | 8 | 27 | 44 | 0 | - | 44 | 5 | 16 | 11 | 9 | 0 |
| (Succ. Dugs.) Caffeine | 4,429 | 3,328 | 1,284 | 163 | 620 | 1,074 | _ | 159 | 27 | 1,908 | 931 | 29 | 424 | 1,020 | 533 | 637 | 379 | ∞ | 0 |
| Cocaine | 5,130 | 1,582 | 62 | 9 | 124 | 1,222 | - | 135 | 32 | 162 | 1,329 | 50 | 15 | 1,331 | 234 | 248 | 426 | 06 | 10 |
| Ephedrine | 245 546 | 191 | 105 | ν - | 12 | 56 | 0 0 | 11 | 2 4 | 147 | 33 | - 5 | 10 | 43 | 4 5 | 14 | 130 | - 0 | 00 |
| Acid including | 2 | 7+5 | Ci | ٦ | 3 | † | > | C 7 | 0 | 10 | 107 | † | - | 1 | 17 | Č. | 771 | ř | > |
| Hallucinogenic Amphetamines | 2,054 | 1,222 | 28 | 12 | 523 | 557 | 2 | 75 | 25 | 1117 | 1,020 | 53 | 41 | 926 | 82 | 230 | 335 | 54 | ∞ |
| Heroin | 2,365 | 1,171 | 18 | - | 125 | 968 | 1 | 06 | 40 | 69 | 1,015 | 47 | 13 | 1,028 | 139 | 181 | 317 | 138 | 8 |
| Lysergic acid diethylamide (LSD) | 301 | 174 | - | 0 | 92 | 81 | 0 | 11 | S | 15 | 146 | 7 | С | 139 | 9 | 38 | 61 | 7 | 0 |
| | | | | | | | | | | | | | | | | | | (Continued) | (pənı |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | | | Õ | Outcome | | |
|---|-------------------------|---|--------|----------|-------|--------|------------------|------------------------------------|----------------|--------|--------|-------|--------------|---------------------------------------|-----------|---------|------------|---------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6-12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Child Adult Age | Jnknown Age | Unint | Int | Other | Adv F Rxn | Treated in Health Care Facility | None | Minor N | Moderate N | Major I | Death |
| Mescaline/Peyote | 77 | 99 | 15 | 2 | ∞ | 33 | 0 | 9 | 2 | 41 | 24 | 0 | - | 29 | 1 | 20 | 9 | 4 | 0 |
| Methamphetamines | 3,012 | 1,738 | 188 | 73 | 140 | 1,053 | ∞ | 227 | 49 | 536 | 1,066 | 09 | 32 | 1,361 | 257 | 270 | 400 | 105 | 4 |
| Methylphenidate | 9,315 | 6,503 | 1,530 | 2,478 | 1,330 | 1,040 | 9 | 103 | 16 | 5,105 | 1,155 | 17 | 186 | 2,103 | 1,557 | 897 | 624 | 13 | _ |
| Other Hallucinogens | 83 | 61 | 0 | 0 | 24 | 37 | 0 | 0 | 0 | _ | 99 | 2 | - | 20 | 33 | 13 | 21 | 4 | - |
| Other Stimulants (Eveluding Amphet. | 244 | 152 | 19 | 4 | 25 | 68 | 0 | 12 | т | 81 | 54 | 0 | 16 | 69 | 15 | 20 | 33 | 7 | 0 |
| amines) | | | | | | | | | | | | | | | | | | | |
| Other Street Drugs | 363 | 301 | 3 | 2 | 53 | 226 | 2 | 14 | - | 16 | 279 | 2 | 2 | 247 | 12 | 88 | 125 | ∞ | 0 |
| Phenylcyclohexylpiperi- | 747 | 350 | 16 | 2 | 48 | 250 | 0 | 25 | 6 | 72 | 250 | ∞ | - | 291 | 23 | 70 | 123 | 27 | 0 |
| une (FCF) Unknown Hallucinogens | 00 | 16 | 0 | C | v | 6 | C | - | - | C | 41 | - | - | 7 | C | v | 9 | 0 | 0 |
| Unknown Stimulants or | 264 | 191 | o m | o en | , % | 66 | 0 | . 5 | ı m | 17 | 143 | 4 | 6 | 147 | <u> 4</u> | . 43 | 70 | o vo | - |
| Street Drugs | 3 | | | , | 8 | | | 2 | , | | 2 | | ` | | | 2 | | , | • |
| Category Total: | 50,874 | 30,654 | 7,285 | 4,636 | 6,296 | 10,774 | 33 | 1,291 | 339 | 15,981 | 12,544 | 474 1 | 1,272 | 16,338 | 5,839 | 5,409 | 5,428 | 645 | 4 |
| 10pical Freparations Miscellaneous Tonical Prenarations | parations | | | | | | | | | | | | | | | | | | |
| Acne Preparations | 3.437 | 3.314 | 1.948 | 165 | 432 | 629 | 4 | 118 | 18 | 3.081 | 70 | ю | 159 | 238 | 613 | 392 | 33 | 0 | 0 |
| Boric Acid or Borates | 88 | 87 | 38 | 2 | 4 | 39 | 0 | 3 | - | 84 | - | 0 | 2 | Ξ | 18 | 6 | - | 0 | 0 |
| (As Antiseptics, Excluding Insecticides) | | | | | | | | | | | | | | | | | | | |
| Calamine (Including | 3,188 | 3,098 | 2,344 | 75 | 30 | 555 | ∞ | 77 | 6 | 3,065 | 19 | 3 | 9 | 146 | 504 | 159 | 9 | 0 | 0 |
| All Caladryl Type | | | | | | | | | | | | | | | | | | | |
| Camphor Camphor | 10,814 | 10,621 | 8,733 | 246 | 239 | 1,185 | 14 | 186 | 18 | 10,376 | 152 | 13 | 74 | 1,080 | 3,015 | 1,222 | 82 | 16 | 0 |
| Camphor and Methyl | 1,881 | 1,861 | 1,623 | 55 | 18 | 141 | 2 | 21 | 1 | 1,823 | 12 | 1 | 25 | 194 | 615 | 235 | 7 | - | 0 |
| Salicylate | | | | | | | | | | | | | | | | | | | |
| Diaper Care and Rash | 43,625 | 43,119 | 41,353 | 374 | 248 | 879 | 78 | 168 | 19 | 43,036 | 38 | 9 | 35 | 629 | 6,208 | 857 | 25 | - | 0 |
| Products | | | | | | | | | | ` | | | | | | | | | |
| Hexachlorophene | 15 | 14 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 13 | 0 | 0 | - | 1 | 4 | 2 | 0 | 0 | 0 |
| Containing Antiseptics Hydrogen Peroxide 3% | 12,554 | 12,270 | 4,796 | 535 | 541 | 5,452 | 21 | 688 | 36 | 11,926 | 227 | 45 | 51 | 643 | 1,553 | 1,739 | 52 | 4 | 0 |
| Iodine or Iodide | | 866 | 317 | 69 | 84 | 439 | 2 | 85 | 2 | 837 | 95 | ∞ | 49 | 207 | 215 | 171 | 34 | 2 | 0 |
| Containing Antiseptics | | | | | | | | | | i | | | | | | | | | |
| Mercury Containing Antisentics | 82 | 77 | 45 | κ | 2 | 23 | 0 | 4 | 0 | 71 | 2 | _ | 2 | 15 | 25 | С | 2 | 0 | 0 |
| Methyl Salicylate | 8,925 | 8,828 | 6,807 | 351 | 225 | 1,169 | 17 | 237 | 22 | 8,575 | 89 | 22 | 152 | 724 | 1,997 | 1,409 | 48 | 2 | 0 |
| Minoxidil, Topical | 164 | 155 | 99 | 6 | 0 | 99 | 0 | 13 | 1 | 146 | 5 | 0 | 4 | 33 | 38 | 22 | 5 | 0 | 0 |
| Other Types of Rube- | 3,424 | 3,334 | 2,230 | 83 | 81 | 783 | 7 | 139 | 16 | 3,026 | 19 | 4 | 284 | 213 | 267 | 603 | 40 | - | 0 |
| Excluding Camphor | | | | | | | | | | | | | | | | | | | |
| and Methyl Salicylate) | | | | | | | | | | | | | | | | | | | |
| Other Types of Topical Antiseptic | 6,280 | 6,154 | 4,569 | 475 | 257 | 705 | 6 | 133 | 9 | 5,800 | 224 | 93 | 32 | 394 | 1,541 | 583 | 38 | 7 | 0 |
| Podophyllin | 52 | 48 | 11 | 3 | 3 | 26 | 0 | 5 | 0 | 30 | 3 | 0 | 15 | 13 | 11 | 5 | 9 | 0 | 0 |
| Silver Nitrate | 123 | 103 | 15 | 1 | 38 | 31 | 2 | 15 | 1 | 80 | 7 | 1 | 14 | 26 | 12 | 27 | 7 | 0 | 0 |
| Topical Steroids | 11,291 | 10,991 | 7,561 | 570 | 174 | 2,215 | 11 | 428 | 32 | 10,808 | 99 | S | 116 | 218 | 1,627 | 343 | 21 | - | 0 |
| (Including Otic, | | | | | | | | | | | | | | | | | | | |
| Dermal Preparations) | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | 100 |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | : - | | 0 | Outcome | | |
|--|-------------------------|---|------------|-------|----------|--------|------------------|------------------------------------|----------------|------------|----------|---|--------------|-------------------------|--------|----------|------------|-------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv F Rxn | Health Care Facility | None | Minor | Moderate | Major | Death |
| Topical Steroids in Combination with Antibiotics (Including Otic, Ophthalmic, and | 1,291 | 1,258 | 638 | 82 | 41 | 392 | 6 | 76 | 7 | 1,230 | c. | - | 24 | 83 | 183 | 221 | 16 | 0 | 0 |
| Dermal Preparations) Wart Preparations and | 1,561 | 1,544 | 1,030 | 135 | 58 | 246 | 3 | 63 | 7 | 1,460 | 20 | 4 | 59 | 226 | 314 | 248 | 50 | 1 | 0 |
| Other Keratolytics Category Total: Unknown Drug | 109,918 | 107,874 | 84,129 | 3,236 | 2,477 | 14,980 | 178 | 2,683 | 191 | 105,467 | 1,021 | 210 1 | 1,104 | 5,094 | 19,060 | 8,250 | 473 | 31 | 0 |
| Miscellaneous Unknown Drug Miscellaneous Unknown 20,370 | r ug 20,370 | 15,154 | 5,235 | 721 | 1,859 | 5,748 | 66 | 1,078 | 414 | 7,574 | 4,391 | 821 | 935 | 9,243 | 2,800 | 2,077 | 2,124 | 646 | 57 |
| Drugs Category Total: Veterinary Drugs | 20,370 | 15,154 | 5,235 | 721 | 1,859 | 5,748 | 66 | 1,078 | 414 | 7,574 | 4,391 | 821 | 935 | 9,243 | 2,800 | 2,077 | 2,124 | 646 | 57 |
| Miscellaneous Veterinary Drugs Miscellaneous Veterinary 3,2 Drugs without Human |)rugs 3,239 | 3,057 | 929 | 98 | 98 | 1,642 | ∞ | 279 | 27 | 2,915 | 31 | ======================================= | 76 | 356 | 708 | 909 | <i>L</i> 9 | 8 | - |
| Category Total: Vitamins | 3,239 | 3,057 | 929 | 98 | 98 | 1,642 | œ | 279 | 27 | 2,915 | 31 | 11 | 97 | 356 | 708 | 206 | 29 | ю | 1 |
| Miscellaneous Vitamins Other Types of Vitamin Unknown Types of Vitamin | 828 738 | 624 555 | 452 402 | 41 | 22 27 | 91 45 | 3 | 16 | 2 4 | 562 507 | 26 24 | 3 | 32 | 80 42 | 138 | 32 25 | 5 2 | | 0 0 |
| Multiple Vitamin Liquids: Adult Formulations Multiple Vitamin Liquids: Adult | Adult Formu 5 | ulations 5 | 4 | 0 | - | 0 | 0 | 0 | 0 | ĸ | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 |
| Formulations with Fluoride (No Iron) Multiple Vitamin Liquids: Adult | 172 | 136 | 81 | 4 | 7 | 39 | 0 | 'n | 0 | 121 | 10 | 0 | 5 | 19 | 27 | 6 | 7 | 0 | 0 |
| No Fluoride) Multiple Vitamin Liquids: Adult Formulations | 6 | -1 | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| with Iron and Fluoride Multiple Vitamin Liquids: Adult Formulations without Iron or Fluoride | 274 | 194 | 119 | 16 | 11 | 43 | 0 | v | 0 | 156 | 25 | 0 | 13 | 24 | 32 | 19 | 10 | 0 | 0 |
| Multiple Vitamin Liquids: Pediatric Formulations Multiple Vitamin 300 280 Liquids: Pediatric Formulations with | Pediatric Fo | rmulations 280 | 277 | 2 | - | 0 | 0 | 0 | 0 | 278 | | - | 0 | 7 | 59 | 9 | 0 | 0 | 0 |
| Fluoride (No 1101) Multiple Vitamin Liquids: Pediatric Formulations with Iron (No Fluoride) | 577 | 536 | 516 | 11 | Ŋ | С | - | 0 | 0 | 518 | 7 | 0 | 10 | 32 | 126 | 21 | κ | 0 | 0 |
| | | | | | | | | | | | | | | | | | | | - |

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | - | | Õ | Outcome | | |
|---|-------------------------|---|--------|----------|-------|------|------------------|--|----------------|--------|--------|-------|--------------|-------------------------|-------|----------|----------|----------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=5 | 6–12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Unknown Child Adult Age | Jnknown Age | Unint | Int | Other | Adv F Rxn | Health Care Facility | None | Minor | Moderate | Major | Death |
| Multiple Vitamin Liquids: Pediatric Formulations with Iron | 69 | 99 | 64 | - | - | 0 | 0 | 0 | 0 | 65 | 0 | 0 | - | 2 | 20 | 2 | 0 | 0 | 0 |
| Maltiple Vitamin Liquids: Pediatric Formulations without Iron or Fluoride | 504 | 470 | 434 | 29 | 4 | П | П | 0 | 1 | 459 | 9 | 0 | Ŋ | 17 | 70 | 18 | - | 0 | 0 |
| Multiple Vitamin Tablets: Adult Formulations Multiple Vitamin Tablets: 43 3 Adult Formulations with Fluoride (No | dult Formu 43 | lations 32 | 28 | К | 0 | - | 0 | 0 | 0 | 31 | 0 | 0 | - | 2 | S | 0 | | 0 | 0 |
| Multiple Vitamin Tablets: Adult Formula- tions with Iron (No Fluoride) | 6,912 | 5,666 | 4,254 | 107 | 203 | 962 | 8 | 126 | == | 5,327 | 230 | - | 100 | 550 | 1,427 | 222 | 23 | ω | 0 |
| Multiple Vitamin Tablets: Adult Formulations with Iron and Fluoride | 43 | 35 | 26 | - | 3 | ß | 0 | 0 | 0 | 33 | 2 | 0 | 0 | 8 | 9 | - | 0 | 0 | 0 |
| Multiple Vitamin Tablets: Adult Formulations with Iron Carbonyl (No Fluoride) | 87 | 75 | 59 | 9 | 7 | ∞ | 0 | 0 | 0 | 70 | 4 | 0 | - | 10 | 19 | ω | 7 | 0 | 0 |
| Multiple Vitamin Tablets: Adult Formula- tions without Iron or Fluoride | 4,037 | 3,029 | 2,100 | 216 | 129 | 495 | 10 | 71 | ∞ | 2,718 | 175 | 60 | 127 | 291 | 689 | 143 | 23 | - | 0 |
| Multiple Vitamin Tablets: Pediatric Formulations Multiple Vitamin Tablets: 713 668 Pediatric Formulations with Fluoride (No Iron) | ediatric For 713 | mulations 668 | 623 | 39 | 61 | П | 21 | 0 | 1 | 099 | ∞ | 0 | 0 | 22 | 149 | 12 | | 0 | 0 |
| Multiple Vitamin Tablets: Pediatric Formula- tions with Iron (No | 8,945 | 8,526 | 7,600 | 745 | 66 | 63 | Ξ | 'n | ε | 8,336 | 158 | 4 | 21 | 597 | 2,053 | 367 | 41 | 0 | 0 |
| Multiple Vitamin Tablets: Pediatric Formulations with Iron and Fluoride | 09 | 55 | 50 | κ | П | 0 | 0 | П | 0 | 52 | 2 | 0 | - | 'n | 14 | - | 0 | 0 | 0 |
| Multiple Vitamin Tablets: Pediatric Formulations with Iron Carbonyl (No Flunde) | 28 | 26 | 23 | | 2 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 | 10 | 12 | 7 | 0 | 0 | 0 |
| Tablets: ulations Fluoride | 27,479 | | 21,117 | 4,768 | 541 | 223 | 91 | 30 | 12 | 25,718 | 1,014 | 10 | 13 | 873 | 4,947 | 477 | 6 | 0 | 0 |
| Multiple Vitamins, Cuspect Multiple Vitamins, Unspecified Adult Formulations with Iron (No Fluoride) | 1,842 | 1,294 | 941 | 47 | 43 | 215 | - | 4 | ю | 1,208 | 56 | 6 | 26 | 140 | 274 | 50 | ю | 1 | 0 |

9,747 764

 $12,111 \quad 1,847,220 \quad 219,404 \quad 16,805 \quad 52,650 \quad 446,296 \quad 419,418 \quad 295,169 \quad 90,595$

96,180

5,007

1,173,168 136,028 128,268 596,486

2,759,287 2,147,248

GRAND TOTAL
(Nonpharmacueticals +
Pharmaceuticals):

Table 22B. Demographic profile of SINGLE SUBSTANCE nonpharmaceuticals exposure cases by generic category

| | | | | | | Age | | | | | Reason | | | Tracted | |) | Outcome | | |
|---|-------------------------|---|--------------|--------|----------|--------------|------------------|--|----------------|--------------|----------|--------------|--------------|-------------------------|---------|--------------|--------------|-------------|-------|
| | No. of Case Mentions | No. of Case No. of Single Mentions Exposures | <=> | 6–12 | 13–19 | >=20 | Unknown Child | Unknown Unknown Unknown Child Adult Age | Unknown Age | Unint | Int | Other | Adv F Rxn | Health Care Facility | None | Minor | Moderate | Major Death | Deat |
| Multiple Vitamins, Unspecified Adult Formulations with Iron and Fluoride | 2 | | 0 | 0 | - | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Multiple Vitamins, Unspecified Adult Formulations without Iron or Fluoride | 103 | 98 | 61 | ∞ | ω | 12 | 0 | 7 | 0 | 79 | ω | 0 | 4 | ς. | 13 | 2 | 0 | 0 | 0 |
| Multiple Vitamins, Unspecified Pediatric Formulations Multiple Vitamins, 44 43 Unspecified Pediatric Formulations with Fluoride (No Iron) | ified Pediatri 44 | ic Formulatio 43 | ns 41 | П | 0 | - | 0 | 0 | 0 | 43 | 0 | 0 | 0 | ϵ | 10 | 0 | 0 | 0 | 0 |
| Multiple Vitamins, Unspecified Pediatric Formulations with Iron (No Fluoride) | 91 | 98 | 73 | 12 | -1 | 0 | 0 | 0 | 0 | 84 | 7 | 0 | 0 | 6 | 21 | ю | 0 | 0 | 0 |
| Multiple Vitamins, Unspecified Pediatric Formulations with Iron and Fluoride | 6 | ∞ | 7 | - | 0 | 0 | 0 | 0 | 0 | 7 | 1 | 0 | 0 | - | - | 0 | 0 | 0 | 0 |
| Multiple Vitamins, Unspecified Pediatric Formulations without Iron or Fluoride Other Vitamins | 795 | 773 | 649 | 109 | 6 | 4 | 2 | 0 | 0 | 745 | 24 | 0 | 6 | 22 | 153 | 9 | 0 | 0 | 0 |
| Other B Complex Vitamins | 4,846 | 3,567 | 3,003 | 78 | 47 | 349 | 7 | 74 | 6 | 3,409 | 89 | 0 | 87 | 207 | 723 | 63 | 2 | 0 | 0 |
| Vitamin A | 533 | 435 | 306 | 17 | 6 | 68 | 0 | 12 | 2 | 397 | 17 | 0 | 18 | 39 | 69 | 14 | 9 | _ | 0 |
| Vitamin B3 (Niacin) | 2,923 | 2,400 | 829 | 29 | 253 | 1,260 | 4 | 167 | 6 | 1,122 | 380 | 9 | 882 | 477 | 140 | 703 | 126 | 5 | 0 |
| Vitamin B6 (Pyridoxine) | 394 | 232 | 167 | ∞ | ∞ | 43 | 0 | 9 | 0 | 205 | 14 | 0 | 13 | 29 | 20 | ∞ | 3 | 0 | 0 |
| Vitamin C | 2,035 | 1,484 | 1,193 | 92 | 46 | 114 | 3 | 32 | 4 | 1,365 | 79 | ж | 36 | 75 | 253 | 78 | 7 | 0 | 0 |
| Vitamin D | 4,836 | 3,877 | 1,876 | 185 | 89 | 1,514 | 7 | 215 | 12 | 3,644 | 9/ | 0 | 148 | 405 | 7111 | 142 | 27 | 2 | 0 |
| Vitamin E | 982 | 969 | 533 | 35 | 7 | 100 | 3 | 18 | 0 | 651 | 27 | | 17 | 28 | 132 | 28 | 1 | 0 | 0 |
| Category Total: | 71,252 | 62,743 | 47,758 | 6,677 | 1,556 | 5,681 | 149 | 841 | 81 | 58,603 | 2,439 | 33 1 | 1,581 | 4,026 | 12,461 | 2,458 | 271 | 12 | • |
| Pharmaceuticals Total: | 1,526,870 | 1,021,909 | 541,765 | 61,355 | 76,443 | 299,671 | 1,431 | 36,021 | 5,223 | 794,940 | 180,362 | 4,785 | 34,515 | 280,632 | 225,319 | 113,157 | 55,917 | 7,420 | 521 |
| Invalid\Missing Invalid\Missing Category Total: Invalid\Missing Total: | 4 4 4 | დ ო ო | 0 0 0 | 0 0 0 | 0 0 0 | o e e | 0 0 | | o o o | 8 8 8 | | o o o | 0 • • | | | o o o | o o o | 0 0 0 | 0 0 0 |
| | | | | | | | | | | | | | | | | | | | |

Four exposure cases (3 single exposure cases) did not include a valid pharmaceutical or nonpharmaceutical product code (invalid generic codes).

Appendix A – Acknowledgments

The compilation of the data presented in this report was supported in part through the US Centers for Disease Control AAPCC Contract 200-2006-19121.

The authors wish to express their appreciation to the following individuals who assisted in the preparation of the manuscript: Katherine W. Worthen, Laura J. Rivers, Carol L. Hesse, and Regina R. Padilla.

The authors express their sincere gratitude to the staff at AAPCC Central Office Staff: J. Elise Bailey, MSPH, Acting Executive Director, Julie Tufts, and the entire staff for their support during the preparation of the manuscript.

NPDS Toxicology Quote of the Day

For the toxicology trivia aficionado, NPDS added the Toxicology Quote of the Day to the NPDS home page. We are indebted to John H. Trestrail III, BS Pharm, FAACT, DABAT for this historical and folkloric data.

Poison Centers (PCs)

We gratefully acknowledge the extensive contributions of each participating PC and the assistance of the many health care providers who provided comprehensive data to the PCs for inclusion in this database. We especially acknowledge the dedicated efforts of the Specialists in Poison Information (SPIs) who meticulously coded 3,952,772 calls made to US PCs in 2010.

As in previous years, the initial review of reported fatalities and development of the abstracts and case data for NPDS was the responsibility of the staff at the 60 participating PCs. Many individuals at each center participated in the fatality case reviews. These toxicology professionals and their centers are:

Alabama Poison Center

Perry Lovely, MD, ACMT

John Fisher, PharmD, DABAT, FAACT

Lois Dorough, BSN, RN, CSPI

Arizona Poison and Drug Information Center

Keith Boesen, PharmD, CSPI

F. Mazda Shirazi, MS, MD, PhD, FACEP

Arkansas Poison & Drug Information Center

Henry F. Simmons, Jr., MD

Pamala R. Rossi, PharmD

Howell Foster, PharmD

Banner Good Samaritan Poison and Drug

Information Center

Daniel Brooks, MD

Mary-Ann Calley, RN, CSPI

Jane Klemens, RN, CSPI

Sharyn Welch, RN

Blue Ridge Poison Center

Christopher Holstege, MD

Nathan Charlton, MD

David Lawrence, MD

Sue Kell, PhD

California Poison Control System,

Fresno/Madera Division

Richard J. Geller, MD, MPH

California Poison Control System,

Sacramento Division

Timothy Albertson, MD, PhD

Judith Alsop, PharmD

California Poison Control System,

San Diego Division

Richard F. Clark, MD

Lee Cantrell, PharmD

Jean Lo, MD

Stephen Thornton, MD

Joshua Nogar, MD

California Poison Control System, San Francisco

Kent R. Olson, MD

Susan Kim-Katz, PharmD

Raymond Ho, PharmD

Kathryn Meier, PharmD

Sandra Hayashi, PharmD

Derrick Lung, MD

Patil Armenian, MD

Thomas Kearney, PharmD

Freda Rowley, PharmD

Ilene Anderson, PharmD

Jo Ellen Dyer, PharmD

Craig Smollin, MD

Elizabeth Birdsall, PharmD

Worapant Kriengsoontornkij, MD

Beth Manning, PharmD

Ben Tsutaoka, PharmD

Carolinas Poison Center

Michael C. Beuhler, MD

Marsha Ford, MD

Anna Rouse Dulaney, PharmD

William Kerns II, MD

Christine M. Murphy, MD

Central Ohio Poison Center

Marcel J. Casavant, MD. FACEP, FACMT

Heath Jolliff, DO, FACEP, FAAEM

S. David Baker, PharmD, DABAT

Julee Fuller-Pyle

Julie Lecky, BA

Central Texas Poison Center

Ryan Morrissey, MD

Vikhyat Bebarta, MD

Douglas J. Borys, PharmD, DABAT

Children's Hospital of MI Regional

Poison Center

Cynthia Aaron, MD

Lydia Baltarowich, MD

Jeffrey Bargeon, MD

Keenan Bora, MD

Susan C. Smolinske, PharmD

Brandon Warrick, MD

Cincinnati Drug and Poison Information Center

G. Randall Bond, MD

Rachel Sweeney, RN

Connecticut Poison Center

Charles McKay, MD Kathy Hart, MD

Bernard C. Sangalli, MS

Florida/USVI Poison Information Center, Jacksonville

Thomas Kunisaki, MD, FACEP, ACMT

Florida Poison Information Center, Miami

Jeffrey N. Bernstein, MD Richard S. Weisman, PharmD

Florida Poison Information Center, Tampa

Cynthia R. Lewis-Younger, MD, MPH

Pam Eubank, RN, CSPI Shirley Rendon, MD, CSPI Judy Turner, RN, CSPI

Georgia Poison Center

Robert Geller, MD Brent W. Morgan, MD Arthur Chang, MD Ziad Kazzi, MD

Gaylord P. Lopez, PharmD Stephanie Hon, PharmD Andre Matthews, MD Soumya Pandalai, MD Sarah Jane Reedy, MD Rizwan Riyaz, MD Sophia Sheikh, MD

Rachel Gorodetsky, PhamD

David J. Roberts, MD

Hennepin Regional Poison Center

Elisabeth F. Bilden, MD Deborah L. Anderson, PharmD Jon B. Cole, MD Heather Ellsworth, MD Laurie Willhite, PharmD, CSPI

Illinois Poison Center

Michael Wahl, MD Sean Bryant, MD

Indiana Poison Center

James B. Mowry, PharmD R. Brent Furbee, MD

Iowa Statewide Poison Control Center

Sue Ringling, RN Edward Bottei, MD

Kentucky Regional Poison Center

George M. Bosse, MD

Henry A. Spiller, MS, RN, DABAT, FAACT

Long Island Regional Poison and Drug

Information Center

Thomas R. Caraccio, PharmD, DABAT Michael McGuigan, MDCM, MBA

Louisiana Poison Center

Mark Ryan, PharmD Thomas Arnold, MD Karen Mullins, RN

Maryland Poison Center

Suzanne Doyon, MD, FACMT Samantha Lee, PharmD

Mississippi Poison Control Center

Robert Cox MD, PhD, DABT, FACMT

Tanya Calcote, RN, CSPI

Missouri Poison Center at SSM Cardinal Glennon

Children's Medical Center

Anthony Scalzo, MD

Shelly Enders, PharmD, CSPI

National Capital Poison Center

Cathleen Clancy, MD, FACMT

Nicole Whitaker, RN, BA, BSN, MEd, CSPI

Nebraska Regional Poison Center

Claudia Barthold, MD Ronald I. Kirschner, MD

New Jersey Poison Information and

Education System

Steven M. Marcus, MD Bruce Ruck, PharmD

New Mexico Poison and Drug Information Center

Steven A. Seifert, MD, FAACT, FACMT Blaine E. (Jess) Benson, PharmD, DABAT

New York City Poison Control Center

Maria Mercurio-Zappala, MS, RPh

Robert S. Hoffman, MD Lewis Nelson, MD Zhanna Livshits, MD David Jang, MD Fiona Garlich, MD Jeff Lapoint, DO Colleen Rivers, MD

North Texas Poison Center

Brett Roth, MD, ACMT, FACMT Melody Gardner, RN, MSN, CCRN

Northern Ohio Poison Center

Lawrence S. Quang, MD Alfred Aleguas, PharmD

Northern New England Poison Center

Jane Clark

Tamas Peredy, MD

Oklahoma Poison Control Center

William Banner, Jr., MD, PhD, ABMT Lee McGoodwin, PharmD, MS, DABAT

Scott Schaeffer, RPh, DABAT

Oregon Poison Center

Zane Horowitz, MD Sandra L. Giffin, RN, MS

Palmetto Poison Center

William H. Richardson, MD Jill E. Michels, PharmD

Pittsburgh Poison Center

Kenneth D. Katz, MD Rita Mrvos, BSN

Edward P. Krenzelok, PharmD

Puerto Rico Poison Center

José Eric Dîaz-Alcalá, MD

Andrés Britt, MD Ingrid Mercedes, MD Elba Hernández, RN

Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island

Michele Burns Ewald, MD David Kemmerer, RN Kishan Kapadia, MD Russ Berger, MD

Regional Poison Control Center, Children's

Hospital of Alabama

Erica Liebelt, MD, FACMT Michele Nichols, MD Ann Slattery, DrPH DABAT Diane Smith, RN, CSPI Valoree Stanley, RN, CSPI

Rocky Mountain Poison & Drug Center

Carol L. Hesse, RN, CSPI Shireen Banerji, PharmD, DABAT

Alvin C. Bronstein, MD, FACEP, FACMT

Christopher Hoyte, MD Jeena Jacob, MD Andrew Monte, MD Regina R. Padilla

South Texas Poison Center

Douglas Cobb, RPh Cynthia Abbott-Teter, PharmD Miguel C. Fernandez, MD George Layton, MD C. Lizette Villarreal, MA

Southeast Texas Poison Center

Wayne R. Snodgrass, MD, PhD, FACMT Jon D. Thompson, MS, DABAT Jean L. Cleary, PharmD, CSPI

Tennessee Poison Center

John G. Benitez, MD, MPH Saralyn Williams, MD Donna Seger, MD

Texas Panhandle Poison Center

Shu Shum, MD

Jeanie E. Jaramillo, PharmD Cristie Johnston, RN, CSPI

The Poison Control Center at the Children's Hospital of Philadelphia

Allison A. Muller, PharmD Kevin Osterhoudt, MD

The Ruth A. Lawrence Poison and Drug Information Center

Ruth A. Lawrence, MD Norma Barton, BS Pharm, CSPI

Timothy J. Wiegand, MD

University of Kansas Hospital Poison Control Center

Tama Sawyer, PharmD

Upstate NY Poison Center

Jeanna M. Marraffa, PharmD

Jamie Nelsen, PharmD

Christine M. Stork, PharmD Utah Poison Control Center

Martin Caravati, MD, MPH

Virginia Poison Center

Rutherfoord Rose, PharmD Kirk Cumpston, DO

Brandon Wills, DO

Washington Poison Center

William T. Hurley, MD, FACEP

David Serafin, CPIP

West Texas Regional Poison Center

John F. Haynes, Jr., MD, ABEM, ABMT

Stephen W. Borron, MD, MS, FACEP, FACMT

Leo Artalejo III, PharmD Hector L. Rivera, RPh

West Virginia Poison Center

Elizabeth J. Scharman, PharmD, DABAT, BCPS, FAACT

Lynn F. Durback-Morris RN, BSN, MBA, DABAT (Posthumous Recognition)

Anthony F. Pizon, MD, ABMT

Western New York Poison Center

Prashant Joshi, MD

Ashley N. Webb, PharmD, MSc

Wisconsin Poison Center

David D. Gummin, MD Lori Rohde, RN, CSPI

Fatality Review Team

The Lead and Peer review of the 2010 fatalities was carried out by the 33 individuals listed here. The authors and the AAPCC wish to express our appreciation for their volunteerism, dedication, hard work and good will in completing this task in a limited time.

Alfred Aleguas Jr., PharmD, DABAT, Managing Director, Northern Ohio Poison Center

Anna Rouse Dulaney*, PharmD, DABAT, Carolinas Poison

Ann-Jeannette Geib*, MD, FACEP, Assistant Professor of Emergency Medicine UMDNJ-Robert Wood Johnson Medical School New Brunswick, NJ

Bernard C. Sangalli*, MS, DABAT, Director, Connecticut Poison Center

Charles McKay, MD, Associate Medical Director, Connecticut Poison Control Center, University of Connecticut School of Medicine

Curtis Elko, CSOI, Washington Poison Center

Cynthia Lewis-Younger, MD, MPH, Florida Poison Information Center, Tampa

Daniel Brooks, MD, Banner Good Samaritan Medical Center, Phoenix

Diane Calello, MD, NJPIES

Elizabeth J. Scharman, PharmD, DABAT, BCPS, FAACT, Director, West Virginia Poison Center

Henry Spiller, MS, DABAT, FAACT Kentucky Regional Poison Center, Louisville, KY

Howell Foster, PharmD, DABAT, Arkansas Poison & Drug Information Center

Jan Scaglione, PharmD, DABAT, Cincinnati Drug and Poison Information Center

Jennifer Lowry, MD, Division of Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO

Jill E. Michels, PharmD, DABAT, Managing Director, Palmetto Poison Center, SC

Judith A. Alsop, PharmD, DABAT, California Poison Control System, Sacramento Division

Karen E. Simone, PharmD, DABAT, Director, Northern New England Poison Center, Maine Medical Center

Kathryn Meier, PharmD, DABAT, Senior Toxicology Management Specialist, California Poison Control System, San Francisco Division

Maria Mercurio-Zappala*, RPh, MS, DABAT, FAACT Managing Director, NYC Poison Control Center

Mark Su, MD, FACEP, FACMT, Assistant Professor of Emergency Medicine, Director, Fellowship in Medical Toxicology, Department of Emergency Medicine, North Shore University Hospital, Manhasset, NY

Mike Levine, MD, Banner Good Samaritan Medical Center,

Nathanael McKeown*, DO, Oregon Poison Center

Rais Vohra*, MD, California Poison Control System, Fresno/ Madera

Richard J. Geller, MD, MPH, Medical and Managing Director, California Poison Control System, Fresno/Madera

Robert B. Palmer, PhD, DABAT, Toxicology Associates, Denver, CO; Rocky Mountain Poison and Drug Center, Denver, CO

Robert Goetz, PharmD, DABAT, Cincinnati Drug and Poison Information Center

S. David Baker, PharmD, DABAT, Managing Director, Central Ohio Poison Center

Steven M. Marcus, MD, NJ Poison Information and Education System, Departments of Preventive Medicine and Community Health and Pediatrics, NJ Medical School, University of Medicine and Dentistry of NJ.

Susan Smolinske, PharmD, Children's Hospital of Michigan RPCC. Detroit

Tammi Schaeffer, DO, Rocky Mountain Poison and Drug Center-Denver Health, Denver, CO

Thomas Martin, MD, Washington Poison Center

Timothy J. Wiegand, MD, Department of Emergency Medicine at Strong Memorial Hospital and the University of Rochester Medical Center, Rochester, NY

William T. Hurley, MD, Medical Director, Washington Poison Center

*These reviewers further volunteered to read the top ranked 200 abstracts and judged to publish or omit.

AAPCC Micromedex Joint Coding Group

Chair: Elizabeth J. Scharman, PharmD, DABAT, BCPS, **FAACT**

Alvin C. Bronstein, MD, FACEP, FACMT Christina Davis, PharmD

Sandy Giffin, RN, MS Kendra Grande, RPh Amy Hinton Katherine M. Hurlbut, MD Wendy Klein-Schwartz, PharmD, MPH Fiona McNaughton Susan C. Smolinske, PharmD

AAPCC Rapid Coding Team

Chair: Alvin C. Bronstein, MD, FACEP, FACMT Elizabeth J. Scharman, PharmD, DABAT, BCPS, FAACT Jay L. Schauben, PharmD, DABAT, FAACT Susan C. Smolinske, PharmD

AAPCC Surveillance Team

NPDS surveillance anomalies are analyzed daily by a team of 10 medical and clinical toxicologists working across the country in a distributed system. These dedicated professionals interface with the Health Studies Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC) and the PCs on a regular basis to identify anomalies of public health significance and improve NPDS surveillance systems:

Alfred Aleguas, Pharm D, DABAT S. David Baker, PharmD, DABAT Director, Alvin C. Bronstein, MD, FACEP, FACMT Blaine (Jess) Benson, PharmD, DABAT Douglas J. Borys, PharmD, DABAT John Fisher, PharmD, DABAT, FAACT Jeanna M. Marraffa, PharmD, DABAT Maria Mercurio-Zappala, RPH, MS, DABAT, FAACT Henry A. Spiller, MS, DABAT, FAACT Richard G. Thomas, Pharm D, DABAT

Regional Poison Center (PC) Fatality Awards

Each year the AAPCC and the Fatality Review team recognized several regional PCs for their extra effort in their preparation of fatality reports and prompt responses to reviewer queries during the review process. The awards were presented at the September 2011, North American Congress of Clinical Toxicology meeting in Washington, DC

First Center to Complete all Cases, West Virginia Poison Center, all 16 reports closed 16-Dec-2010

Highest Percentage with Autopsy Reports, Oklahoma Poison Control Center, 100% of 10 cases

Honorable mention: Northern New England Poison Center (Portland), 83% of 24 cases

Largest Number Autopsy Reports, 31 autopsies of 43 fatalities, Kentucky Regional Poison Center (Louisville)

Highest Overall Quality of Reports, Western New York Poison Center (Buffalo), 10.4 of possible 13 for their 11 fatalities

Honorable mention: Florida Poison Information Center (Tampa), 9.72 of possible 13 for their 36 fatalities Carolinas Poison Center, 8.96 of possible 13 for their 54 fatalities

Most Abstracts Published in 2009 Annual report, a 3-way tie California Poison Control System (Sacramento) California Poison Control System (San Francisco) Florida Poison Information Center (Tampa)

Outstanding Case Preparation, California Poison Control System, Fresno/Madera Division West Virginia Poison Center

Most Helpful Regional Poison Center Staff, a tie Rocky Mountain Poison & Drug Center, Carol Hesse Utah Poison Control Center, Martin Caravati

Appendix B – Data Definitions

Reason for Exposure

NPDS classifies all calls as either EXPOSURE (concern about an exposure to a substance) or INFORMATION (no exposed human or animal). A call may provide information about one or more exposed person or animal (receptors). Specialists in Poison Information (SPIs) coded the reasons for exposure reported by callers to PCs according to the following definitions:

Unintentional general: All unintentional exposures not otherwise defined below.

Environmental: Any passive, non-occupational exposure that results from contamination of air, water, or soil. Environmental exposures are usually caused by manmade contaminants

Occupational: An exposure that occurs as a direct result of the person being on the job or in the workplace.

Therapeutic error: An unintentional deviation from a proper therapeutic regimen that results in the wrong dose, incorrect route of administration, administration to the wrong person, or administration of the wrong substance. Only exposures to medications or products used as medications are included. Drug interactions resulting from unintentional administration of drugs or foods which are known to interact are also included.

Unintentional misuse: Unintentional improper or incorrect use of a nonpharmaceutical substance. Unintentional misuse differs from intentional misuse in that the exposure was unplanned or not foreseen by the patient.

Bite/sting: All animal bites and stings, with or without envenomation, are included.

Food poisoning: Suspected or confirmed food poisoning; ingestion of food contaminated with microorganisms is included

Unintentional unknown: An exposure determined to be unintentional, but the exact reason is unknown.

Suspected suicidal: An exposure resulting from the inappropriate use of a substance for reasons that are suspected to be self-destructive or manipulative.

Intentional misuse: An exposure resulting from the intentional improper or incorrect use.

Medical Outcome

No effect: The patient did not develop any signs or symptoms as a result of the exposure.

Minor effect: The patient developed some signs or symptoms as a result of the exposure, but they were minimally bothersome and generally resolved rapidly with no residual disability or disfigurement. A minor effect is often limited to the skin or mucus membranes (e.g., self-limited gastrointestinal symptoms, drowsiness, skin irritation, first-degree dermal burn, sinus tachycardia without hypotension, and transient cough).

Moderate effect: The patient exhibited signs or symptoms as a result of the exposure that were more pronounced, more prolonged, or more systemic in nature than minor symptoms. Usually, some form of treatment is indicated. Symptoms were not life-threatening, and the patient had no residual disability or disfigurement (e.g., corneal abrasion, acid-base disturbance, high fever, disorientation, hypotension that is rapidly responsive to treatment, and isolated brief seizures that respond readily to treatment).

Major effect: The patient exhibited signs or symptoms as a result of the exposure that were life-threatening or resulted in significant residual disability or disfigurement (e.g., repeated seizures or status epilepticus, respiratory compromise requiring intubation, ventricular tachycardia with hypotension, cardiac or respiratory arrest, esophageal stricture, and disseminated intravascular coagulation).

Death: The patient died as a result of the exposure or as a direct complication of the exposure.

Not followed, judged as nontoxic exposure: No follow-up calls were made to determine the outcome of the exposure because the substance implicated was nontoxic, the amount implicated was insignificant, or the route of exposure was unlikely to result in a clinical effect.

Not followed, minimal clinical effects possible: No follow-up calls were made to determine the patient's outcome because the exposure was likely to result in only minimal toxicity of a trivial nature. (The patient was expected to experience no more than a minor effect.).

Unable to follow, judged as a potentially toxic exposure: The patient was lost to follow-up, refused follow-up, or was not followed, but the exposure was significant and may have resulted in a moderate, major, or fatal outcome. Unrelated effect: The exposure was probably not responsible for the effect.

Confirmed nonexposure: This outcome option was coded to designate cases where there was reliable and objective evidence that an exposure initially believed to have occurred actually never occurred (e.g., all missing pills are later located). All cases coded as confirmed nonexposure are excluded from this report.

Death, indirect report: Death, indirect report are deaths that the poison center acquired from medical examiner or media, but did not manage nor answer any questions about the death.

Relative Contribution to Fatality (RCF)

The definitions used for the Relative Contribution to Fatality (RCF) classification were as follows:

- 1. Undoubtedly responsible: In the opinion of the CRT the Clinical Case Evidence establishes beyond a reasonable doubt that the SUBSTANCES actually caused the
- 2. Probably responsible: In the opinion of the CRT the Clinical Case Evidence suggests that the SUB-STANCES caused the death, but some reasonable doubt remained.
- **3. Contributory:** In the opinion of the CRT the Clinical Case Evidence establishes that the SUBSTANCES contributed to the death, but did not solely cause the death. That is, the SUBSTANCES alone would not have caused the death, but combined with other factors, were partially responsible for the death.
- **4. Probably not responsible:** In the opinion of the CRT the Clinical Case Evidence establishes to a reasonable probability, but not conclusively, that the SUB-STANCES associated with the death did not cause the death
- **5.** Clearly not responsible: In the opinion of the CRT the Clinical Case Evidence establishes beyond a reasonable doubt that the SUBSTANCES did not cause this
- 6. Unknown: In the opinion of the CRT the Clinical Case Evidence is insufficient to impute or refute a causative relationship for the SUBSTANCES in this death.

Appendix C – Abstracts of Selected Cases

Selection of Abstracts for Publication

The abstracts included in Appendix C were selected for publication in a three-stage process consisting of qualifying, ranking and reading. Qualifying was based on the RCF – only RCF = 1-Undoubtedly Responsible, 2-Probably Responsible or 3-Contributory were eligible for publication. Fatalities by Indirect report were excluded beginning with the 2008 annual report. Ranking was based on the number of substances (1/N) and weighted case score. The case weighting factors were the averages chosen based on review team recommendations in 2006. Each case score was multiplied by the respective factors to obtain a weighted publication score: Hospital records *4.4 + Postmortem *7.6 + Blood levels *6.9 + Quality/Completeness *6.4 + Novelty/Educational value *6.0. Scores were normalized (z-score) within each reviewer before the final weighting: 33% for 1/N and 67% for weighted case scores.

The top ranked abstracts (200 + ties) were each read by 6 individual reviewers (See Appendix A) and the 2 managers (Cantilena and Spyker). Each reader judged each abstract as "publish" or "omit" and all abstracts receiving 5 or more of 8 publish votes were selected, further edited and crossreviewed by the 2 managers.

Abstracts

A structured format for abstracts was required in the PC preparation of the abstracts and was used in the abstracts presented. Abbreviations, units and normal ranges omitted from the abstracts are given at the end of this appendix.

Case 14. Acute methanol ingestion: undoubtedly responsible.

Scenario/Substances: 39 y/o male ingested an unknown amount of windshield washing fluid that contained methanol. The patient walked into the ED with the sole complaint of abdominal pain. The ingestion at this time was unknown. Past Medical History: Spanish speaking, unable to obtain any specific medical history.

Physical Exam: Awake and alert. BP 120/61, HR 107, RR 30, T normal, O₂ sat 98% on FIO₂ of 50%.

Laboratory Data: ABG-pH 6.77/pCO₂ 28.8/pO₂ 445

| Na 134 | Cl 100 | BUN 22 | Cl., 174 |
|--------|--------------------|--------|----------|
| K 3.9 | HCO ₃ 7 | Cr 1.0 | Glu 174 |

Osmolar gap of 124, anion gap of 27. Lactate level was normal. Urine was negative for crystals. ECG QRS 110 ms, QTc 444 ms; Chest x-ray was normal. Head and abdominal CT scans were normal. Ethanol was negative. The following day the patient had a BUN of 14 mg/dL, Cr 0.98, K, and Na 141.

Clinical Course: The patient developed chest pain, became obtunded and required intubation within 2 hr after ED presentation. Metabolic acidosis, seizures, and posturing followed and he was given propofol, sodium bicarbonate, levetiracetam, phenobarbital, and alprazolam. Toxic alcohol was suspected and fomepizole was started while labs were obtained. Pt was also placed on hemodialysis, then CVVHD. Day 2 he showed no signs of improvement and became hypotensive (BP 70) requiring pressors. Methanol level 12 hr post ingestion was 98 mg/dL. Day 3 the patient was declared brain dead, comfort measures were instituted and he expired that day.

Autopsy Findings: The cause of death is methanol intoxication. Methanol level was 191 mg/dL which was obtained through hospital sample of blood.

Case 21. Acute methanol ingestion: undoubtedly

Scenario/Substances: A 42 y/o female ingested homemade moonshine at a party. About 12 hr after she left the party, she became ill with nausea and vomiting. Her condition worsened throughout the following day and she developed blindness that evening and she was taken to the ED.

Physical Exam: Heart rate 92, BP 100/49, she was comatose, pupils fixed and dilated, lungs clear.

Laboratory Data: ABG-pH 6.93/pCO₂ 29/pO₂ 159, HCO₃ 5.1, CK 202, acetaminophen, ethanol, salicylate and

ethylene glycol not detected, methanol 154 mg/dL.

Clinical Course: In the ED naloxone was given without response, she was intubated and given IV bicarbonate to treat the metabolic acidosis. The patient was then transferred to the ICU at a tertiary care hospital. Head CT: unremarkable, EKG: QT 521 ms, QRS of 108 ms. She became progressively tachycardic and hypotensive and was started on IV fluid resuscitation and vasopressors. Hemodialysis and fomepizole were initiated for presumed ethylene glycol toxicity. She remained comatose with unreactive pupils. Based on a neurology consult, nuclear brain scan and EEG she was pronounced brain dead.

Autopsy Findings: Methanol detected in small amounts at autopsy. No methanol detected in the moonshine and no other people at the party became ill. Source of methanol remains unclear.

Case 62. Acute methanol ingestion: undoubtedly responsible.

Scenario/Substances: 36 y/o female found unresponsive by friend, brought to the ED 4 days after ingestion of automotive antifreeze containing methanol. At the time of the exposure, at a different ED, she gave a history of being assaulted by 1 or more men who forced her to drink the product. She was brought to the ED by friends and had several episodes of vomiting, was observed and released.

Past Medical History: Fibromyalgia, Wolff-Parkinson-White syndrome s/p ablation, prior suicide attempt with pills 20 years prior. No current mental health issues.

Physical Exam: Unresponsive female. BP 153/36, HR 76, RR 16, T 34°C. Pupils fixed and dilated.

Laboratory Data: pH 6.82/pO $_2$ 468; O $_2$ sat 99 on a ventilator at 100% O $_2$

$$\begin{array}{c|cccc} Na & 142 & & Cl & 107 & & BUN & 9 \\ \hline K & 3.7 & & HCO_3 < 5 & & Cr & 2.1.6 & & Glu & 224 \\ \end{array}$$

Ca 9.0, lactate 12.5, serum osmolality 378 mOsm/kg, INR 1.6. UDS negative; acetaminophen, ethanol and salicylate not detected. Phenytoin 10 mcg/mL, methanol 116 mg/dL (toxic alcohols not tested during original ED evaluation 4 days prior).

Clinical Course: The patient was intubated, ventilated, and treated with IV HCO₃, fomepizole and hemodialysis. Hypotension (BP 40s) was treated with pressors; EEG showed no brain activity. Cr peaked at 2.0. Day 2 showed labile BP and T; Day 3 low Hgb and platelets were treated with transfusion of RBCs and platelets and CK increased to 5496 with troponin 0.73; On Day 4 CK 3670 with CKMB 26.1 and troponin 0.36; AST and ALT were 178 and 60 respectively; MRI showed diffuse cerebral and cerebellar swelling with evidence of ischemic injury and transtentorial herniation and compression of the brain stem. After ice water and apnea testing, she was declared brain dead and her organs were harvested for transplantation.

Autopsy Findings: Cause of death: Acute methanol toxicity, hypertrophic cardiomyopathy and atherosclerotic coronary artery disease. Death was listed as accidental but a homicide

investigation was initiated. Pathological diagnosis include: Acute methanol toxicity, hypoxic encephalopathy, acute respiratory and renal failure, hypertrophic cardiomyopathy, atherosclerotic coronary artery disease, obesity, Wolff–Parkinson–White syndrome, bilateral pulmonary congestion and edema, liver steatosis and ovarian cyst. Toxicology results (hospital blood): methanol 140 mg/dL, second measurement (unknown time) methanol 45 mg/dL.

Case 66. Acute ethylene glycol ingestion: undoubtedly responsible.

Scenario/Substances: 49 y/o male ingested a gallon of antifreeze in a suicide attempt. EMS transported him to the ED. **Laboratory Data:** In the ED: methanol 0, ABG-pH 7.05/pCO₂ 26/pO₂ 313, BE 24,

| Na 150 | Cl 110 | BUN 13 | Glu 100 |
|--------|--------------------|--------|---------|
| K 4.7 | HCO ₃ 5 | Cr 1.4 | Giù 100 |

| Time (hours after arrival) | Ethylene glycol (mg/dL) | Osmolar gap |
|----------------------------|-------------------------|-------------|
| 0.5 | 1282 | 235 |
| 12 | 770 | 157 |
| 18 | 554 | 122 |

Clinical Course: He was intubated and sedated, gastric lavaged returned 1200 ml of fluid with the appearance of antifreeze. Fomepizole and CVVHD were initiated. Bicarb bolus given in ER. HR 73, BP 133/71, normal sinus rhythm on the monitor. He was able to follow commands. On Day 2, he became unresponsive. Head CT showed bilateral subarachnoid hemorrhaging. Family decided to institute comfort measures and he expired on Day 4.

Autopsy Findings: Many polarizable crystals were present in the kidneys consistent with calcium oxalate. Cause of death: ethylene glycol intoxication; manner of death: suicide.

Case 72. Acute hymenoptera stings: contributory.

Scenario/Substances: 82 y/o male stung ~90 times during an encounter with a swarm of bees.

Past Medical History: COPD, right sided heart disease. **Laboratory Data:** ABG-pH 7.25/pCO₂ 61.2/pO₂ 235/HCO₃ 25.2/BE 2.3, FIO₂ 100%. WBC 21.9, Platelets 94,

$$\begin{array}{c|cccc} Na & 123 & Cl & BUN & 30 \\ \hline K & HCO_3 & Cr & 1.57 & Glu & 141 \\ \end{array}$$

PT 17.3, FSP > 20, Ca 7.1, AST 273, ALT 508, lactate 2.6, CK 481, CKMB 7.7, troponin 1.74.

Clinical Course: In the ED he was initially intubated treated with albuterol, steroids, and antihistamines. He stabilized, was extubated and admitted to the medicine floor. At ~24 hr after envenomation he developed respiratory distress and evidence of an acute cardiac event based on ECG and enzymes. He was re-intubated, and transferred to a tertiary care facility. There he required norepinephrine and neosynephrine for hypotension, developed acute renal injury. He was treated

with heparin for bilateral pulmonary emboli. Developed a fever, received antibiotics for suspected pneumonia, bicarb for acidosis, and insulin for hyperglycemia. Was weaned off pressors but showed no improvement in neurologic status. He had a cardiac arrest and died on Day 6.

Autopsy Findings: Not done.

Case 74. Acute crotalid envenomation: undoubtedly responsible.

Scenario/Substances: 23-month-old female screamed while playing on a slide near her family's vacation home; she was found crying with blood on her ankle with a small rattlesnake nearby. EMS was notified. She began vomiting, became somnolent, and had a generalized tonic-clonic seizure. She was given O₂ via non rebreather mask, and IV fluids enroute.

Physical Exam: BP 106/85, HR 224, RR 46, O₂ sat 100% on NRB. The patient was vomiting blood and had generalized petechiae. There were 4 puncture marks anterior to her medial left ankle with mild ecchymosis and little to no swelling.

Laboratory Data: ABG-pH 7.09/pCO₂ 31/pO₂ 116 after intubation. WBC 33, Hct 22, platelets 10 with hemolysis on peripheral smear. INR 19, PTT > 300 sec, fibrinogen < 70 mcg/mL; D-dimer > 22 mcg/mL, FDP 320 mcg/mL. Initial $C \times R$ revealed right main bronchus intubation. Repeat $C \times R$ revealed appropriate positioning with pronounced pulmonary edema.

Clinical Course: Two-hour post bite the patient arrived at the ED, was promptly intubated after premedication with atropine, etomidate, and rocuronium and received 6 vials of crotalidae polyvalent immune Fab. The patient was transferred to ICU and at 3 hr became hypotensive and was resuscitated with CPR, epinephrine, Ca gluconate, and HCO₃, and maintained on pressors. She received a total of 4 units PRBC, 5 units FFP, 2 units platelets, 10 units cryoprecipitate and 1 dose of factor VII. Poison control was consulted 4.5 hr after exposure and recommended additional crotaline Fab. Prior to repeat Fab administration the patient became pulseless, and could not be resuscitated. She expired less than 5 hr after the bite.

Autopsy Findings: Postmortem findings included: 4 fang marks anterior to the left medial malleolus; cutaneous and serous petechiae; and acute hemorrhagic pancreatitis and gastritis. The cause of death was listed as hemorrhagic diathesis due to snake bites.

Case 80. Acute cyanide ingestion: undoubtedly responsible.

Scenario/Substances: 19 y/o male walked out of his bedroom holding a bag of white powder and informed his family they should call an ambulance and then collapsed. EMS found him hypertensive, tachycardic, and agitated. While en route to the ED he was intubated, then became bradycardic without a pulse. He was successfully treated with atropine with return of pulse.

Past Medical History: Depression and suicide ideation since age nine; No prescribed medications.

Physical Exam: Unresponsive, comatose male; BP 60, HR 100, afebrile.

Laboratory Data: ABG-pH 6.99, Glu 300, UDS positive for cannabinoids. Follow up ABG-pH 7.15; cyanide levels: admission 5,806 ng/mL; 7 hr 11,300 ng/mL; 20 hr 82.8 ng/mL; Day 2 45.5 ng/mL, <30 ng/mL, and 31.6 ng/mL.

Clinical Course: Hyperkalemia was treated per standard protocol. He then had bradycardia and hypotension, followed by a cardiac arrest from which he was resuscitated within 5 min. Persistent hypotension and bradycardia were treated with pressors; 2 mg of naloxone and glucagon up to 8 mg were tried. Bolus doses of sodium bicarbonate were administered with some improvement of QRS complex; magnesium sulfate infusion was started. BP was supported to BP 50s (MAP 20) with insulin 75 units/hr, intralipid infusion, and maximum infusion doses of norepinephrine, phenylephrine and vasopressin. Five-hour post-presentation BP was stable at 100 on continuous intralipid infusion and maximum infusion doses of epinephrine, norepinephrine, phenylephrine, and vasopressin. Insulin was discontinued for hypoglycemia and D10W infusion was added. Additional history from the patient's friend was provided that the patient may have ordered sodium cyanide over the internet. Sodium thiosulfate and hydroxocobalamin were recommended but the patient required transfer since hydroxocobalamin was not available in the treating hospital. Sodium thiosulfate (12.5 g) was administered; sodium nitrate was not administered due to hypotension. At 7 hr following sodium thiosulfate and hydroxocobalamin, vasopressors were off. Pupils were fixed and dilated, no responses could be elicited, neurology examined the patient and suspected brain death. Comfort measures were instituted and he expired on Day 2.

Autopsy Findings: Autopsy was not performed.

Case 84. Acute cyanide, venlafaxine, and lorazepam ingestion: undoubtedly responsible.

Scenario/Substances: 33 y/o female found unresponsive in a hotel room with a white powdery substance chopped on a cutting board. The substance was initially believed to be methamphetamine. The patient collapsed at the scene, and EMS found her in an agonal rhythm and deteriorated into cardiac arrest. ACLS with intubation in the field occurred before being transported to the ED.

Past Medical History: The patient had a history of cholecystectomy and depression. She was prescribed buspirone 100 mg and lorazepam 0.5 mg.

Physical Exam: Intubated patient in cardiac arrest with CPR in progress and pulseless electrical activity noted. Pupils fixed and dilated, cyanotic with cool skin.

Laboratory Data: ABG-pH 6.95/pCO₂ 11.8/pO₂ 25, O₂ saturation 22%; Hgb 14.3, Hct 42.0.

| Na 141 | Cl 105 | BUN 8 | Cl., 171 |
|--------|---------------------|--------|----------|
| K 4.2 | HCO ₃ 25 | Cr 0.2 | Glu 171 |

Ionized calcium 1.10, troponin 0.04.

Clinical Course: The patient's husband advised ED staff that the patient had ingested potassium cyanide. CPR continued with ACLS but was unsuccessful and the patient expired in the ED.

Autopsy Findings: The oral mucosa was severely congested and partially denuded with coagulative necrosis consistent with alkaline chemical burns. The esophageal mucosa was also partially denuded distally, just proximal to the gastroesophageal junction. Cyanide was 15 mg/L in antemortem blood. Cause of Death: Cyanide poisoning. Manner of Death: Suicide (ingestion).

Case 98. Acute cyanide ingestion: undoubtedly responsible.

Scenario/Substances: 59 y/o male brought to ED after spouse called EMS to report he ingested potassium cyanide in a suicide attempt. He was found comatose, bradycardic with agonal respirations and was intubated.

Past Medical History: Depression, alcoholism, and chronic back pain. Medications escitalopram, disulfiram, and eye drops. Seen the day earlier for chest pain for which he received meperidine and was found to have uncontrolled hypertension.

Physical Exam: Unresponsive, with fixed and dilated pupils. No heart sounds detected, breath sounds were equal on both sides with bag ventilation. His skin was noted to be pink and warm.

Laboratory Data: No labs were assessed during resuscitation.

Clinical Course: The patient was given multiple doses of epinephrine and atropine, 300 mg of sodium nitrite was followed by 50 ml of 25% sodium thiosulfate. A brief return of a weak pulse with HR followed; CPR was continued and sodium nitrite and sodium thiosulfate were repeated 15 min later. Asystole with cyanosis continued and the patient expired in the ED 25 min after arrival.

Autopsy Findings: Scleral hemorrhage in the right eye, areas of petechiae in both the right and left eye, extensive amount of dark brownish red discoloration of the entire body of stomach and lower esophagus and congestion of the spleen were found. Premortem blood cyanide 4.7 mg/L, citalopram 0.061 mg/L (average therapeutic level of 0.5 mg/L). Post mortem blood cyanide 13.3 mg/L. Death was ruled as successful suicide with potassium cyanide.

Case 103. Acute hydrochloric acid ingestion: undoubtedly responsible.

Scenario/Substances: A 46 y/o male was brought in by EMS after a witnessed intentional ingestion of 38% hydrochloric acid in a suicide attempt.

Past Medical History: Depression and previous suicidality. **Physical Exam:** In the ED he was unresponsive and had oral lesions consistent with chemical burns.

Laboratory Data: He was acidotic, EKG showed an acute MI, C×R was clear and a distended abdomen was also noted. **Diagnostics:** A CT of the abdomen was ordered but the patient was not stable enough to leave the department to undergo the study.

Clinical Course: On arrival to the ED, the patient had multiple episodes of emesis, he was intubated for airway

protection, an NG tube was placed, and a large amount of fluid was recovered. Despite aggressive supportive care and early surgical consultation the patient expired a few hours after admission.

Autopsy Findings: Not performed.

Case 104. Acute ethylene glycol ingestion: undoubtedly responsible.

Scenario/Substances: A 63 y/o male was found unresponsive at home more than 12 hr after being seen awake by his partner. EMS found him apneic, but with a pulse and intubated him prior to transport to ED.

Physical Exam: On arrival in the ED he was hypotensive, hypothermic, in 3rd degree heart block. Pupils were oval, fixed and dilated. Copious bright blue-green emesis and stool were noted.

Laboratory Data: ABG-pH 6.4/pCO $_2$ 24/pO $_2$ 594/HCO $_3$ 1.6, lactate 8, ethylene glycol 474 mg/dL, methanol, ethanol, isopropanol, phenobarbital, tricyclics, acetaminophen, and salicylate not detected.

Clinical Course: In the ED he was unresponsive with Cheyne-Stokes respirations requiring no sedation. The appearance of the vomitus/stool and profound acidemia raised suspicion for ingestion of antifreeze, so he was given fomepizole, thiamine, pyridoxine, and hemodialysis was initiated. Dopamine and norepinephrine were given for continued hypotension with oliguria. After warming, his T normalized. Adequate BP maintained on vasopressors and he began to spontaneously open his eyes and move his extremities, but did not respond to verbal stimuli. He continued to vomit despite gastric suction. His ABG improved to pH 7.41/ pCO₂ 30/pO₂ 166/HCO₃ 18.3. Vancomycin and ampicillin/ sulbactam were started for suspected aspiration pneumonia. After 16 hr of hemodialysis, his ethylene glycol level was 42 mg/dL, lactate 8.1. He tolerated weaning of vasopressor support, but was only minimally responsive to painful stimuli. He developed decerebrate posturing and multiple seizures without status epilepticus. He maintained adequate BP and sinus rhythm with no ectopy but SBP spiked into 200s during seizure activity. He was given lorazepam for the seizures and labetalol for the hypertensive episodes. He continued oliguric, so hemodialysis was continued. Despite maximal support and he never regained meaningful response to stimuli. Goals of care were changed to comfort only; he died on Day 10.

Autopsy Findings: Autopsy revealed cardiomegaly, pulmonary edema, and swollen kidneys with oxalate crystals visible on touch prep. Cause of death was ruled ethylene glycol toxicity with manner of death suicide.

Case 108. Acute ethylene glycol ingestion: undoubtedly responsible.

Scenario/Substances: A 65 y/o female did not answer phone calls or the door. She had last been seen 16 hr earlier. EMS broke down the door and found her comatose with no gag reflex and dilated pupils, HR 94, BP 60 by palpation, Kussmal respirations with RR 30, O_2 sat 69%, Glu (finger

stick) 130. She was endotracheally intubated and transported to the ED.

Past Medical History: Anxiety, depression, myasthenia gravis, biliary cirrhosis, COPD, asthma, degenerative disc disease of lumbar spine, diverticulosis, gastric hypomobility syndrome, melanosis coli, suicidal overdose on her medications 1 month prior. Medications (N = 14).

Physical Exam: She was unresponsive to painful stimuli, pupils 6 mm and sluggishly reactive lungs clear. After IV fluids: BP 165/79, HR 112, RR 21, O₂ sat 100% on FiO₂ 60%, T 37°C.

Laboratory Data: ABG-pH 7.08/pCO₂ 16.2/pO₂ 341, FiO₂ 100%, WBC 9.0, platelets 596, Ca 8.8, AST 34, ALT 32,

| Na 149 | Cl 119 | BUN 11 | Cl., 140 |
|--------|--------------------|---------|----------|
| K 4.2 | HCO ₃ 9 | Cr 0.65 | Glu 148 |

lactate 3.4 mmol/L, anion gap of 42, osmolal gap of 147, CK 63, UDS positive for benzodiazepines only. Serum acetaminophen, ethanol, ketones and salicylate not detected. ECG: sinus rhythm, normal intervals, nonspecific ST segment changes; C×R was unremarkable, CT scan without contrast showed a questionable small subdural bleed, and an abnormal appearance to the brain stem.

Clinical Course: She was given IV fluids, started on methylprednisolone and admitted to the ICU. The metabolic acidosis did not respond to sodium bicarbonate, her renal function continued to deteriorate and she developed seizures. Blood was sent to an outside laboratory for ethylene glycol and volatiles screen. Crystals resembling oxalate were observed in the urine. Hemodialysis, fomepizole, folate, pyridoxine, thiamine were started. The patient remained comatose on the ventilator, and developed status epilepticus which was treated with phenytoin, lorazepam, and midazolam infusions. She became hypotensive and her status continued to deteriorate, the family opted for institution of comfort measures, and she expired 2.5 days after being found by EMS. Further history was obtained, and it was suspected that she ingested antifreeze and fertilizer (bat guano). Ethylene glycol level was later reported as 646 mg/dL, other volatiles (methanol, ethanol, isopropanol, acetone, acetaldehyde) were negative. **Autopsy Findings:** Not available.

Case 122. Acute hypochlorite ingestion: undoubtedly responsible.

Scenario/Substances: 32 y/o male brought to the ED by EMS after drinking an unknown amount of a cleaning solution (hypochlorites 5.25%) some time that morning.

Past Medical History: Bipolar, morbid obesity, and sleep

Physical Exam: Awake and alert with vomiting, coughing, and wheezing. BP 157/70, HR 119, RR 28, T 36°C; O₂ sat 94% on 3 L of O_2NC .

Laboratory Data: Acetaminophen, ethanol and salicylate not detected; UDS negative.

Clinical Course: O₂ increased to 6 L NC. GI consult was requested for endoscopic evaluation but never completed. BP 148/53, HR 92. He was given lorazepam and ondansetron for agitation and vomiting and normal saline at 75 ml/hr. In the ICU he became combative and had respiratory distress. Intubation was attempted about 5.5 hr after presentation; the larynx was noted to be very edematous and swollen, and he was successfully intubated but the balloon of the endotracheal tube subsequently ruptured, he developed bradycardia and cardiopulmonary arrest and expired ~8 hr after arrival in the ED.

Autopsy Findings: (performed after embalming). Significant respiratory tract injury (wrinkled tan-pink to tan gray mucosa at the larynx and trachea) was noted along with cardiomegaly. Cause of death: respiratory insufficiency due to ingestion of bleach with contribution of bipolar disorder. Post mortem heart blood clot was significant only for isopropanol at 60 mg/dL and methanol, consistent with being embalmed; no drugs of abuse (benzodiazepines, cocaine, fentanyl, opiates) were detected.

Case 125. Acute toilet bowl cleaner (acid): undoubtedly responsible.

Scenario/Substances: 44 y/o female brought to the ED by family and stated that she had intentionally ingested 3/4 of a bottle of a toilet bowl cleaner containing 15-25% hydrochloric acid ~45 min prior to arrival. The patient's complained of severe abdominal pain and sore throat.

Past Medical History: Multiple previous suicide attempts, schizoaffective disorder, major depression, hypertension, GERD, and a cholecystectomy.

Physical Exam: Awake, alert, oriented, drooling patient. BP 126/72, HR 79, 37°C, O₂ sat 99% on 3L NC. Oropharynx had coagulative necrosis with large amount of exudate and secretions. Stridor was audible over the neck area. Her abdomen was soft, nondistended, with bowel sounds.

Laboratory Findings: ABG-pH 7.24/pCO₂ 27/HCO₃ 12. WBC 13.2, platelets 91K, PTT 46.7, d-dimer > 20 mcg/mL, fibrinogen 232 mg/dL; Cr 1.1, lactate 3.2, myoglobin 192 ng/mL, UA large amount of blood, protein 30 mg/dL, UDS unable to perform due to black color or urine sample. Acetaminophen not detected, salicylate < 1.7 mg/dL.

Clinical Course: The patient was sent directly to the OR for possible tracheostomy but the stridor and oral swelling stabilized as she developed DIC, so the tracheostomy was not performed. She was admitted to the ICU, given pantoprazole, IV fluids with sodium bicarbonate and antibiotics. Hemodialysis was initiated for the metabolic acidosis. Stridor, oral edema and tachypnea increased requiring intubation. She became hypotensive and febrile T 39°C 3 and required pressor support. CT scan indicated perforation of her esophagus, stomach and small intestine then septic shock, lactateosis and multi organ failure. Her family declined surgical intervention, comfort measures were instituted and she expired on Day 2. **Autopsy Findings:** Bilateral pleural effusions of 500 mL of brown-black fluid and 2700 mL of similar fluid in the peritoneal cavity. The proximal esophagus was white, the distal esophagus was brown-black with focal perforation posteriorly. The stomach had diffusely thick and black necrotic mucosa, full thickness at the fundus, with a large

perforation. The trachea showed sloughed epithelium with

extensive necrosis of the epiglottis. The cause of death was the sequelae of hydrochloric acid ingestion. The manner of death was suicide.

Case 126. Acute alkali drain cleaner ingestion with aspiration: undoubtedly responsible.

Scenario/Substances: A 46 y/o male reportedly ingested "3 gulps" of an alkali drain cleaner in a suicide attempt. EMS noted burns to his tongue, oropharynx, and wrist but no respiratory distress. He vomited once, was diaphoretic, complained of abdominal pain and had bradycardia of 54 during transport.

Physical Exam: In the ED the patient's "whole oropharynx" was white without erythema. BP 204/104, HR 52, RR 16, O_2 sat 97%.

Laboratory Data: WBC was "elevated", serum pH 7.09, UDS positive for THC only. Serum acetaminophen and salicylate were not detected.

Clinical Course: In the ED he was electively intubated and given hydromorphone for pain. Insertion of an NG tube was attempted but was unsuccessful and the patient was taken to surgery. Exploratory laparotomy revealed full thickness necrosis and perforation of the esophagus, stomach and entire small intestine through the transverse colon with necrotic lesions of the gallbladder and mesentery were also reported. The patient's condition was deemed not survivable, the laporotomy was closed, and he was returned to the ICU. The patient's family asked for comfort measures and he died on Day 2.

Autopsy Findings: Cause of death: internal bleeding secondary to perforation of the esophagus, stomach, and intestine secondary to ingestion of caustic alkali. The manner of death was suicide.

Case 129. Acute cleaner (acid), ethylene glycol, and hydrocarbons ingestion: undoubtedly responsible.

Scenario/Substances: 54 y/o male in ED with a history of ingesting 4 cups of an unknown "wood conditioner."

Past Medical History: Bi-polar disease. Medications included aripiprazole, quetiapine, bupropion, zolpidem, and simvastatin for home meds. Five months previously he had a negative work up to rule out a myocardial infarct.

Physical Exam: Altered mental status. BP 87/49, HR 40–156, O₂ sat 97% on 100% oxygen.

Laboratory Data: ABG-pH 7.21;

Ca 5.5, albumin 3.7, lipase 452, lactate 6.9, anion gap 17, troponin 1.25. Acetaminophen, ethanol and salicylate were not detected. A volatile screen was negative but an ethylene glycol level was never ordered. ECG showed a widened QRS and atrial fibrillation. A urine sample fluoresced under an ultraviolet lamp.

Clinical Course: The patient was intubated and given 3 amps Ca and admitted to ICU. Acidosis worsened to pH 7.08 with serum bicarb 7.7 and lactate 6.1 with the anion

gap 23. SVT, bigeminy, widened QRS, and wide complex bradycardia with 3–5 sec pauses were seen; hypotension was refractory to pressors. Fomepizole was started for suspected ethylene glycol ingestion. Hours later the patient had a junctional rhythm, became pulseless and was not able to be resuscitated.

Autopsy Findings: Caustic fluid with severe metabolic acidosis; polarizable, birefringent calcium oxalate crystals in renal tubules. Insufficient sample for ethylene glycol and formic acid testing. Cause of death: Severe metabolic acidosis due to ingestion of caustic fluids.

Case 139. Acute hydrogen peroxide ingestion with aspiration: undoubtedly responsible.

Scenario/Substances: An 82 y/o female ingested up to 2 tablespoons of 32% hydrogen peroxide given to her by her husband, a self-claimed homeopath.

Past Medical History: Atrial fibrillation, dementia.

Physical Exam: Trismus was present on arrival. BP 100s; HR 50s; afebrile, O_2 sat 98% on 60% FiO_2 ; No oral burns seen.

Laboratory Data: WBC 11.3, Hgb 15.2, Hct 45.4, platelets 120, Troponin < 0.5, electrolytes reported normal except Ca 7.0; ECG atrial fibrillation, C×R diffuse increased lung marking and plural fluid.

Clinical Course: The patient reported vomiting at home, developed respiratory distress thought due to aspiration pneumonitis, was intubated, sedated, and given antibiotics. Day 2 she had bloody return on suctioning of gastric contents. No endoscopy was performed. Sedation was weaned periodically but the patient was unable to breath over the ventilator. The patient was extubated on Day and was unable to verbalize discomfort. On Day 10 a MRI of the head showed multiple bilateral areas of restricted diffusion consistent with ischemia due to emboli. Comfort measures were instituted and she expired on Day 15.

Autopsy Findings: Not performed.

Case 157. Acute nitrogen oxide inhalation: probably responsible.

Scenario/Substances: 26 y/o healthy male farm-worker entered a silo and collapsed after 5–10 min. He arrived at the ED after ~15 min down time.

Physical Exam: BP 143/102, HR 99, RR 14, O₂ sat 99% after intubation, pupils equal at 3 mm with no corneal reflex, no gag reflex; withdraws to pain, comatose.

Laboratory Data: ABG-pH 7.08/pCO₂ 59/pO₂ 506,

$$\begin{array}{c|cccc} Na & 140 & & Cl & 103 & & BUN & 11 \\ \hline K & 3.5 & & HCO_3 & 20 & & Cr & 1.5 & & \\ \end{array} \qquad \qquad Glu & 270$$

Lactate 13.8, troponin 0.87, INR 1.41, acetaminophen and salicylate not detected, UDS, negative, COHb 1.5 at 1 hr after exposure, CT showed extensive bilateral pulmonary infiltrates.

Clinical Course: The patient arrived at the ED in cardiovascular arrest. Spontaneous circulation returned after epinephrine, atropine, and dopamine infusion, but he remained unresponsive.

The patient underwent post-arrest hypothermia for cardiac arrest and cleared his lactate. He developed pneumonia on Day 6 and persistent diffuse cerebral edema on Day 7. Due to poor prognosis, comfort measures were instituted and he expired.

OHSA Findings: Occupational health authorities reported normal oxygen levels in the silo on the day of exposure. They investigated the silo 3 days later and found carbon dioxide levels of 880 ppm (OSHA limit is 10,000 ppm). The levels of nitrogen and sulfur containing species were undetectable.

Autopsy Findings: Autopsy revealed pneumonia and cerebral edema. Postmortem toxicology tests were negative.

Case 192. Acute carbon monoxide exposure: undoubtedly responsible. Unintentional Environmental, Carbon Monoxide.

Scenario/Substances: 64 y/o female was found at home during a house fire. EMS resuscitated her after suppressing the fire to get to her.

Past Medical History: Bipolar disease, hypertension, rheumatoid arthritis, tobacco use, and alcohol abuse. Medications included methotrexate, folic acid, prednisone, lisinopril, propoxyphene with acetaminophen, and amitriptyline.

Physical Exam: Unresponsive female, covered with soot with singed nose hairs and with pulseless VT; full thickness burns on the dorsum of the right hand.

Laboratory Data: Lactate 8.9 mmol/L, ABG-pH 6.97/ pCO₂ 51/pO₂ 468, bicarbonate 11.6, COHb 45.9%, met Hgb

Clinical Course: The patient's rhythm converted to sinus with epinephrine and atropine. She was intubated and given hydroxocobalamin for suspected cyanide poisoning. The patient was stabilized and transferred to another hospital for emergent hyperbaric oxygen treatment. At the second hospital she developed multiple episodes of seizure-like activity. Lorazepam was administered during and after hyperbaric treatment, then transferred to the ICU where she remained on the ventilator, sedated and unresponsive to pain. On Day 3, the patient developed a fever to T 39°C and became hypertensive with BP 177/101 on Day 5. Pupils were fixed with an upper gaze; tonic-clonic seizure activity continued with occasional posturing and no reflexes were present. Empiric bronchodilator therapy and antibiotics were started for course breath sounds and infiltrates on $C \times R$. The patient remained on a ventilator, unconscious and unresponsive. An EEG showed a burst suppression pattern suggestive of poor prognosis. CT of the brain without contrast showed no intracranial hemorrhage or herniation. Comfort measures were instituted and he expired on Day 6.

Autopsy Findings: Not performed. The ME concluded that the cause of death was anoxic encephalopathy, and the manner of death was accidental.

Case 221. Acute fluorochlorocarbon inhalation: undoubtedly responsible.

Scenario/Substances: 28 y/o male found slumped over his computer in asystole after inhaling a compressed gas duster. Estimated time he was apneic was 30 min. He was defibrillated, then given epinephrine and vasopressin

Past Medical History: Substance abuse.

Physical Exam: Obtunded, intubated and ventilated. BP 183/68, HR 164, O₂ sats 94% on ventilator.

Laboratory Data: ABG-pH 6.96; K 2.9. At 12 hr ABG-pH 7.28/pCO₂ 42/pO₂ 156. WBC, Hgb 18, platelets 293, INR 1.1.

| Na 139 | Cl 103 | BUN 9 | Glu 304 |
|--------|---------------------|--------|---------|
| K 3.2 | HCO ₃ 21 | Cr 1.6 | Giu 304 |

Clinical Course: The patient received epinephrine 2 vials, naloxone 2 vials, sodium bicarbonate 2 vials, and atropine 3 vials. Postresuscitation, ECG showed atrial fibrillation, head CT demonstrated evidence of severe hypoxic injury. He was hypertensive (BP 153/113) and tachycardic (HR 170) treated with a diltiazem infusion. Seizures were treated with diazepam and midazolam. At 12 hr pupils were fixed and dilated, lower extremities were rigid, the upper extremities had tremors and T was 106.9 despite cooling blankets. At 24 hr he became hypotensive (BP 50-60). Comfort measures were instituted and he expired on Day 2.

Autopsy Findings: Autopsy not performed, the patient was embalmed prior to ME notification; the cause of death was determined to be cerebral hypoxia and cardiac arrhythmia, secondary to toxicity from an inhaled aerosol. Manner of death was accidental.

Case 226 Fluorochlorocarbon inhalation: undoubtedly responsible.

Scenario/Substances: A 50 y/o female was found unresponsive by her daughter who initiated CPR and called 911. The patient had reportedly been "huffing" a keyboard cleaner aerosol. EMS intubated the patient continued CPR. Initial rhythm was PEA, and she arrived at the ED with CPR in progress. Estimated downtime was 30 min.

Past Medical History: Breast cancer with bilateral mastectomy and chemotherapy 4 years ago. History of polysubstance abuse including tobacco, alcohol, marijuana, cocaine, methamphetamine, and huffing.

Physical Exam: Intubated unresponsive female, BP 101/83, HR 113, RR 20 with bagging. Normocephalic and atraumatic, pupils equal and reactive to light, mucous membranes pink and moist.

Laboratory Data: ABG-pH 7.15/pCO₂ 58/pO₂ 366 EKG: SR at 92, QRS 124 ms, QTc 556 ms, RBBB, ST depression with biphasic T waves leads II, II, aVF, and V4–6. WBC 5.1, Hgb 11.9, Hct 37.7, platelets 198, PT 11.9, INR 1.1.

| Na 139 | Cl 104 | BUN 9 | Glu 365 |
|--------|---------------------|--------|---------|
| K 3.5 | HCO ₃ 16 | Cr 1.7 | G1u 303 |

Ca 8.0, total bilirubin 0.3, Alk phos 170, AST 343, ALT 267, CK 136, troponin I < 0.04 ng/mL. Salicylate, ethanol, acetaminophen were not detected. UDS negative, CXR: bilateral lower lobe infiltrates, echocardiogram: no pericardial effusion, EEG: diffuse generalized slow wave activity consistent with metabolic encephalopathy.

Clinical Course: In the ED, spontaneous circulation was restored with administration of normal saline bolus, epinephrine, and sodium bicarbonate. The patient was given a single dose of amiodarone and started on dopamine and norepinephrine infusions. She was admitted to the ICU and started on antibiotics for presumed aspiration pneumonia. Despite multiple vasopressor infusions, she became hypotensive and pulseless and expired on Day 2.

Autopsy Findings: Fractures of left ribs 2–5 (anterolateral) and right ribs 2–7 (anterior). Postmortem blood 1,1-difluoroethane 32 mcg/mL.

Case 228. Acute mineral spirits ingestion: undoubtedly responsible.

Scenario/Substances: 18-month-old female was carried into the ED unresponsive by her father ~15 min after an unwitnessed ingestion. Father reported that the child ingested "paint thinner" that had been stored in a water bottle. Soon after the ingestion the patient became unresponsive, had convulsions, and vomited.

Physical Exam: Seizing patient with agonal respirations with an organic solvent odor. BP 98/71, HR 166, O₂ sat, 78% on room air. Mouth had copious secretions. Face, neck and torso skin had well demarcated erythema with overlying, oily emesis.

Laboratory Data: ABG (after 40 min resuscitation) pH 6.83/pCO₂ 85/pO₂ 20; COHb and metHgb were negative. Capillary blood Glu 88, K 5.6. Hgb 13.

Clinical Course: The patient seized for 1 min and was resuscitated for 60 min with airway suctioning, bag valve mask RR with 100% FiO₂, chest compressions, seven rounds of epinephrine and atropine, endotracheal intubation, sodium bicarbonate, NS bolus, and 500 mg pralidoxime. Spontaneous circulation was never regained. The patient expired when resuscitation was concluded. The father later clarified that the chemical was used to clean surfaces prior to applying paint.

Autopsy Findings: Postmortem revealed acute lung injury and alveolar hemorrhage. Cause of death was due to aspiration of aromatic and aliphatic hydrocarbons.

Case 236. Acute alkyldimethylbenzyl ammonium chloride/nonionic disinfectant ingestion: probably responsible. Scenario/Substances: 55 y/o female accidentally ingested 1 mouthful of a disinfectant containing non-ionic surfactant (1%–5%), cationic detergents (5%), and sodium carbonate (1%–5%)/pH 11.7. She reportedly immediately spit it out, was given yogurt, milk and fluids at home, but she was unable to drink due to vomiting.

Past Medical History: Renal failure, dialysis, legally blind, diabetes, hypertension, hyperlipidemia, and bilateral below the knee amputations.

Physical Exam: She was alert and oriented without respiratory distress. BP 207/85, HR 100, RR 18, O_2 sat 96% on 2L O_2 . She only complained of a sore throat. C×R was clear on Day 1.

Laboratory Data: Glu 454, C×R "clear", blood cultures positive.

Clinical Course: BP was treated with labetalol, insulin given for hyperglycemia; she had no difficulty swallowing and was able to eat and drink later on Day 1. Day 2 she vomited after an oral fluid challenge and complained of throat irritation upper endoscopy later that day was negative. She received scheduled dialysis and developed an axillary T 40°C and became hypotensive with diminished lung sounds. A blood culture was positive and she received vancomycin and gentamycin. Patient expired unexpectedly on Day 3.

Autopsy Findings: No autopsy was performed. ME review stated the cause of death was complications of erosive esophagitis secondary to ingestion of cleaning fluid. Manner of death was accidental.

Case 238. Acute phosphine inhalation: undoubtedly responsible (see also Case 257).

Scenario/Substances: A 4 y/o female developed nausea, vomiting and lethargy at home after the family yard had been treated with up to 1.2 pounds of aluminum phosphide pellets for pest control.

Past Medical History: Healthy female.

Laboratory Data: COHb was 0.8% at the ED.

Clinical Course: She was taken to the ED and died shortly after arrival.

Environmental Findings: Phosphine gas concentrations were measured at the home the next day: Front door 25 ppm, garage 48 ppm, and top of stairs 25 ppm.

Autopsy Findings: Pulmonary edema, pleural petechiae, hepatic congestion. Postmortem toxicology blood phosphorus 0.69 mg/mL (ICP/MS, normal 0.31–0.44 mg/mL). Cause of death: Phosphine gas toxicity. Phosphine gas concentrations were measured at the home the next day: Front door 25 ppm, garage 48 ppm, and top of stairs 25 ppm.

Case 241. Acute chlorfenapyr ingestion: undoubtedly responsible.

Scenario/Substances: A 46 y/o male reportedly took a drink of a commercial insecticide that he mistook for water after it had been transferred from its original container into an unlabeled container. He spit it out, but ingested a small quantity described as "drops." He developed nausea and vomiting ~1 hr (post ingestion). EMS was called at 10 hr when he had abdominal pain, back pain, and diaphoresis with normal lung sounds and no diarrhea or increased salivation. EMS transported the patient to the ED. The type of insecticide was initially unknown.

Past Medical History: Patient reported as "health conscious" with no significant pre-existing medical problems.

Physical Exam: Generalized mild weakness, abdominal pain and back pain, diaphoretic, but mouth was dry. BP 104/59, HR 89, RR 16, T 37°C, O₂ sat 100%, lungs clear. He reported no further GI symptoms, but he was periodically restless, wanting to get up and walk around.

Laboratory Data: HCO₃ 25, renal and hepatic tests WNL.

Clinical Course: The product was identified as a chlorfenapyr containing pesticide. The manufacturer reported that the other ingredients were surfactants and emulsifiers. At 16 hr the patient was still diaphoretic, but wished to leave the hospital against medical advice. He was convinced to stay for further observation and treatment. At 21 hr, the patient developed tachypnea (RR 28–30) and hypoxia (O₂ sat 80%) if nasal cannula oxygen was removed. He was still alert and oriented but requiring oxygen with slightly labored respirations. BP 110/62, HR 113, T 37.1°C and O₂ sat 99% on nasal cannula oxygen. He developed increasing respiratory distress, and he was transferred to the ICU. He died on Day 2.

Autopsy Findings: Marked pulmonary congestion, generalized visceral congestion, and mild bilateral apical emphysema. Blood ethanol was not detected, blood lorazepam 170 ng/mL, and the remainder of the benzodiazepine, drugs of abuse, and alcohols testing was negative. The lab was not able to test for chlorfenapyr. The cause of death was cardiorespiratory arrest secondary to toxic effects of insecticide ingestion (chlorfenapyr).

Case 242. Methomyl ingestion: probably responsible. Scenario/Substances: A 47 y/o male ingested an unknown white powder. He initially presented to the ED with complaints of "shakiness" was given 2 doses of lorazepam and discharged home. The next morning he returned to the ED with complaints of feeling shaky and could barely walk. He then went into full arrest/asystole.

Past Medical History: Depression for the past week.

Physical Exam: In the ED: Unresponsive, fixed pupils with miosis. HR 70s, BP 89/45, T 31°C.

Laboratory Data: Prior to resuscitation: ABG-pH 6.7/pCO₂ 127/pO₂ 68, BE 23. After resuscitation: pH 7.05/pCO₂ 61/ pO₂ 94/BE 15. Hgb 15, Hct 46, platelets 162, Ca 9.1,

Serum osmol 311, CK 1080, AST 147, ALT 108. UA: 3 + sediment, protein > 3000, RBC 5–10, pH 6.0. Acetaminophen, ethanol and salicylate not detected. UDS negative.

Clinical Course: He was intubated and placed on a ventilator. He was treated with epinephrine, atropine, bicarbonate, calcium, naloxone and vasopressin. Norepinephrine was started. He was admitted to ICU on max doses of norepinephrine, epinephrine and vasopressin drips were started. He had foul-smelling diarrhea that was described as clear red with mucoid chunks. Warming was attempted with warm IV fluids. He was drooling significantly but had no oral lesions. The next day the white powder was sent to an analytical lab for testing. The patient remained on norepinephrine, epinephrine, and vasopressin drips as his HR dropped to the 30s. Based on the prognosis the family opted for institution of comfort measures and he expired of respiratory failure.

Toxin Findings: The white powder was thought to be a "fish stunning powder" which is placed in the water to stupefy the fish and make them easier to catch. Two weeks later, the results of the lab testing revealed that the white powder was methomyl.

Autopsy Findings: No drugs or substances were found on the toxicology screening. They were unable to locate a laboratory that could test body fluids for methomyl. Cause of death was "undetermined."

Case 244. Acute paraquat ingestion: undoubtedly responsible.

Scenario/Substances: 50 y/o homeless male was brought to a hospital vomiting blood. Approximately 5 days earlier, he ingested a substance he believed to be fruit juice in an agricultural field. Since that time he has had throat pain and been hoarse. On the day of presentation he was dyspneic. A bystander told responding EMS that he believed that the substance ingested was paraquat.

Past Medical History: Not available.

Physical Exam: Awake, alert jaundiced male in mild respiratory distress. Vital signs described as "stable." The oropharynx was erythematous consistent with a corrosive insult.

Laboratory Data: ABG-pH 7.45/pCO₂ 30/pO₂ 59 on 2L NC. BUN 146, Cr 12.2, AST 259, ALT 189, Alk phos 1252, total bilirubin 9.4, albumin 2.5. C×R showed pulmonary fibrosis. Clinical Course: Bi-PAP and hemodialysis was initiated. Over days his liver and renal function improved. Oxygenation declined steadily through Day 10 when the patient expired from respiratory failure.

Autopsy Findings: No autopsy was performed. A Day 4 urine specimen (~9 days post ingestion) found urine paraquat to be 1.03 mcg/mL.

Case 248. Acute chlorpyrifos ingestion: contributory.

Scenario/Substances: 56 y/o male inadvertently ingested a mouthful of chlorpyrifos insecticide mistaking it for his water after drinking 10-12 beers. He drank water to dilute it but started vomiting immediately and was brought to the ED by a family member.

Past Medical History: The patient had a history of hypertension, osteoarthritis, chronic ethanol abuse and was a heavy smoker.

Physical Exam: Alert and followed commands; diaphoretic, with vomiting, diarrhea, fasciculations and increased oral secretions. BP 150/90, HR 80, 37°C with O₂ sat 100%. He was given atropine and pralidoxime, sedated, intubated and mechanically ventilated for airway protection. Exam showed rhonchi bilaterally, moist skin, soft abdomen with active bowel sounds. He had good urine output from his Foley catheter.

Laboratory Findings: Na 140, K 3.4, BUN 9, Cr 0.8; AST 30, ALT 40, CK 135; RBC cholinesterase level was 1585 IU/L (reference 5300-10,000 IU/L). Triglyceride level was 397 mg/dL, blood alcohol 0.23 g/L.

Clinical Course: He patient was admitted to the ICU and given atropine for diarrhea stools and increased oral secretions. He developed tremors and agitation which was thought to be symptoms of alcohol withdrawal. His C×R showed bilateral infiltrates and aspiration pneumonia was

suspected. After Day 5, his level of consciousness decreased and he became unresponsive even without sedation. Later he became hemodynamically unstable and required vasopressors. On Day 8 he had 2 cardiac arrests and expired.

Autopsy Findings: Evidence of arteriosclerotic and hypertensive heart disease, chronic ethanol abuse, arteriole nephrosclerosis, bronchopneumonia and alveolar damage were noted. The cause of death was deemed organophosphate poisoning. The manner of death was undetermined.

Case 251. Acute organophosphate ingestion: undoubtedly responsible.

Scenario/Substances: 64 y/o male was found in cardio-pulmonary arrest by his wife after ingestion of 16 ounces of 50% malathion. She performed CPR until EMS arrived on scene. EMS intubated him. He was revived following a single 1 mg dose of atropine IV.

Past Medical History: Not provided.

Physical Exam: Unresponsive male with bradycardia, miosis and mild hypotension. Lung fields clear to auscultation; odor of malathion present.

Laboratory Data: RBC AChE 1057 IU/L [reference range: 9572–15031] (2 hr postingestion and pre-2-PAM dosing); 3254 IU/L (one day with continuous 2-PAM infusion). 19 H postingestion: pH 7.31; HCO₃13.

Clinical Course: The patient was treated with bolus doses of 1 mg atropine and a norepinephrine infusion was titrated successfully to MAP > 60. His lung sounds were clear and he was easy to ventilate. A persistent smell of malathion including from the ventilator circuit was described. A Mark 1 2-PAM injector was administered followed by a loading dose and continuous infusion at 8 mg/kg/H. Bolus doses of midazolam infusion were administered for neuro-protection. At 3 hr he developed mild fasciculations which resolved 5 hr later. At 17 hr he remained unresponsive without any sedation or midazolam with fasciculations resuming. Lungs remained clear, continuous 2-PAM infusion was in place and he was restarted on a norepinephrine infusion due to hypotension with HR 58. At 25 hr re-warming from therapeutic hypothermia began without sedation. Neurologically he was unresponsive except for occasional eye-opening without tracking. ECG showed QTc 501 ms; pH 7.31, HCO₃ 3 for which he received 2 amps of sodium bicarbonate IVP. At 34 hr EEG showed no brain activity, comfort measures were instituted and he expired on Day 5.

Autopsy Findings: Autopsy was not performed.

Case 257. Acute phosphine inhalation: undoubtedly responsible. (see also Case 238)

Scenario/Substances: A 15 m/o female presented to the ED with difficulty breathing, nausea and vomiting for several hr after the family's yard had been treated with up to 1.2 pounds of aluminum phosphide pellets for pest control.

Past Medical History: Healthy female.

Physical Exam: Cyanotic, BP 98/76, HR 164, RR 40.

Laboratory Data: ECG: RBBB, lactate 3.4, UDS negative for cocaine, amphetamines, benzodiazepines, barbiturates, and opiates. COHb 2.4%. C×R: mild pulmonary edema.

Clinical Course: She received low dose dopamine for hypotension 1 hr after presentation. Heart rhythm deteriorated to wide complex tachycardia and cardiac arrest 10–12 hr after presentation. The patient was intubated and placed on ECMO for ~36 hr before she expired.

Environmental Findings: Phosphine gas concentrations were measured at the home the next day: Front door 25 ppm, garage 48 ppm, and top of stairs 25 ppm.

Autopsy Findings: Pulmonary edema, cerebral edema, hepatic congestion, bilateral pulmonary effusions. Postmortem toxicology blood phosphorus 0.50 mg/mL (ICP/MS, normal 0.31–0.44 mg/mL). Cause of death: Phosphine toxicity.

Case 262. Acute phosgene inhalation and dermal exposure: undoubtedly responsible.

Scenario/Substances: A 58 y/o employee at a chemical plant was sprayed in the face with phosgene while servicing a transfer hose. EMS transported him to the ED.

Physical Exam: HR 80, BP 98/65, RR 26, T 35.6°C.

Clinical Course: In the ED he complained of a sore throat. He was decontaminated and started on IV fluids. About 2.5 hr later he developed shortness of breath, tachypnea, and his O_2 sat dropped to 80%. His condition continued to worsen, he was intubated, he developed pulmonary edema and hypotension. Despite norepinephrine, steroids, nebulizations, and oxygen, lorazepam and fentanyl his condition rapidly deteriorated and he died the following day.

OHSA Findings: Later investigations of the chemical plant confirmed the phosgene leak.

Autopsy Findings: Not performed.

Case 264. Acute methadone ingestion: undoubtedly responsible.

Scenario/Substances: A 2 y/o male was found in cardiopulmonary arrest on the couch while being watched by family friends. A bottle of methadone was found near the child. The owner of the methadone tablets stated he had recently spilled his methadone prescription, but believed he had recovered all the spilled tablets. EMS was called and transported the child to the ED.

Past Medical History: Recent respiratory tract infection. **Laboratory Data: Clinical Course:** Resuscitation efforts by EMS and ED staff were not successful.

Autopsy Findings: Autopsy showed findings suggestive of positional asphyxia, including being found unresponsive on pillows on a couch with an adult, bilateral conjunctival hemorrhages, multifocal visceral petechial hemorrhages, tardieu spots and diffuse cerebral edema with early acute hypoxic neuronal changes. Additional findings were miltifocal areas of bronchopneumonia with edema and congestion. Postmortem blood methadone 514 ng/mL, EDDP 33.5 ng/mL. Cause of death: methadone intoxication with bronchopneumonia as a significant contributing factor.

Case 267. Acute fentanyl transdermal exposure: undoubtedly responsible.

Scenario/Substances: A 5 y/o male was found to be minimally responsive. Over the next hr he remained obtunded,

appeared to be gasping for breath and became cyanotic. He was brought to the ED by the family and rescue breathing was initiated enroute. On arrival at the ED he was pulseless, was intubated and received epinephrine and dopamine with return of circulation. He was then transported via helicopter to an HCF with a pediatric ICU. He did not receive further sedation or analgesia. The cause of illness was uncertain, although the patient was exposed to lindane the previous evening.

Physical Exam: After resuscitation, ECG showed sinus rhythm with a QRS of 86 ms, and a slightly prolonged QTc. HR was 120, gag and corneal reflexes were absent and he did not respond to noxious stimuli, pupils were fixed and dilated with bilateral retinal hemorrhages.

Laboratory Data: During cardiac arrest ABG-pH was 6.0. Following resuscitation venous blood gas: pH 7.28/pCO₂ 46/pO₂ 26, O₂ sat of 39, lactate 7.7, anion gap 25

Acetaminophen and salicylate were not detected, UDS was negative ALT 574, AST 760, CK 4472.

Clinical Course: Head CT: diffuse cerebral edema with effacement of basal cisterns and sulci. CT angiography: no intracranial blood flow. He was given comfort care and expired shortly thereafter.

Autopsy Findings: Antemortem blood (on ED arrival) fentanyl 5 ng/mL. The manner of death was an accident, cause of death was anoxic brain injury. Lindane was not detected postmortem and judged not contributory. Further history: the patient's grandmother used transdermal fentanyl, which the child had been observed playing with on previous occasions. Fentanyl patches were not recovered however, specific efforts to recover material from the GI tract were not made as this history was unavailable at the time of autopsy.

Case 268. Acute oxycodone ingestion: undoubtedly responsible.

Scenario/Substances: A 7 y/o 48 kg previously healthy male experienced severe dental pain while visiting relatives out of state. Administration of 400 mg of ibuprofen orally at home failed to control the pain, so the child was given 1 oxycodone 30 mg immediate-release tablet prescribed for an adult relative. At 30 min (after ingestion) the child complained of dizziness and was instructed to sit down. At 1 hr he was unarousable. CPR was initiated by an adult relative and EMS was summoned. The child was immediately intubated by EMS, IV access was established; 5 doses of epinephrine were required to achieve a pulse and detectable BP. One dose of naloxone was administered with no response.

Clinical Course: Resuscitation in the ED included dopamine at 20 mcg/kg/min, epinephrine at 3 mg/kg/min with return of circulation. Initial ABG-pH 6.9, neuro exam revealed fixed, irregular, and dilated pupils with no spontaneous movement, breathing, T 32°C. Once HR had been maintained for 30 min, the child was transported via helicopter to a tertiary

care HCF. An additional dose of naloxone was administered with no effect. On arrival at the second HCF: WBC 12.2, Hgb 14.7, PT 20.5, INR 1.7, PTT 65.7, Ca 8.3 Ca (ionized) 1.63, PO4 7.5

| Na 142 | Cl 109 | BUN 18 | Glu 388 |
|--------|---------------------|---------|---------|
| K | HCO ₃ 13 | Cr 1.37 | Giu 300 |

AST 955, ALT 496, Alk phos 283, bilirubin 0.4, HCO₃ 12, BE -16, lactate 13 mmol/L. The patient was admitted to a pediatric ICU where, despite continued care, his condition continued to deteriorate. Because irreversible neurologic and organ damage had occurred heroic measures were not initiated; the patient expired 12 hr postadmission.

Autopsy Findings: Pulmonary congestion and edema/pulmonary aspiration with acute pneumonia; history suspicious for a drug related death. Silver colored metal cap on the third tooth to the left of the midline in the lower jaw; its counter-part on the right is behind its neighboring teeth, history of tooth ache. Antemortem blood: oxycodone 0.39 mcg/mL, oxymorphone 17 ng/mL, ethanol not detected. Cause of death: oxycodone drug toxicity, manner of death: accident.

Case 257. Acute oxycodone ingestion: probably responsible.

Scenario/Substances: A 15 y/o male texted his mother to inform her that he was "getting high" on oxycodone. He ingested an unknown amount that evening and was found by his mother the next morning hypoxic. EMS found the patient in cardiac arrest, resuscitated him, and transported him to the ED.

Past Medical History: Tourette's Syndrome.

Physical Exam: Non-responsive, pupils fixed and dilated. **Laboratory Data:** UDS was positive for synthetic opioids

and negative for barbiturates, benzodiazepines, cocaine. Serum acetaminophen and salicylate were not detected. Cr 4.21, CK 17,435, ALT 4222, AST 1954, lactate 4.1 mmol/L, troponin 10.03.

Clinical Course: In the ED he was intubated and placed on a naloxone drip, and later was transferred to a tertiary care pediatric hospital. He remained unresponsive without movement. He was placed on vasopressors to maintain BP. Trial doses of naloxone 6 mg and flumazenil 2 mg were given and brain exams were conducted. The patient was declared brain dead on Day 3. Comfort measures were instituted and he expired on Day 4.

Autopsy Findings: Cerebral edema, liver congestion, pulmonary edema, obesity. Antemortem blood oxycodone 0.14 mcg/mL. Blood negative for cocaine, methamphetamine, morphine. Cause of Death: drug toxicity (oxycodone).

Case 280. unknown acetaminophen/diphenhydramine ingestion: undoubtedly responsible.

Scenario/Substances: 17 y/o female was brought to the ED for slurred speech and picking at things in the air. EMS reported a pre-hospital seizure. Time of ingestion unknown. Empty bottle containing acetaminophen/diphenhydramine found under patient's bed.

Past Medical History: Bipolar disorder, anxiety. Medications: alprazolam, hydrocodone/acetaminophen, ziprasidone **Physical Exam:** BP 117/58, HR 167, RR 16 (intubated, ventilator) T 39°C, O₂ sat 100%. Pupils dilated; skin red and dry, no rigidity noted.

Laboratory Data: WBC 19.3, Hgb 12.0, Hct 36, platelets 147; PT 17.5, INR 1.7, PTT 27.3, fibrinogen 152, Ddimer >5800 (normal < 500)

| Na 148 | Cl 120 | BUN 11 | Glu 75 |
|--------|---------------------|--------|--------|
| K 3.6 | HCO ₃ 18 | Cr 1.4 | Giu 73 |

Acetaminophen 100 mcg/mL (unknown time), AST 125, ALT 53; UDS positive for benzodiazepines and diphenhydramine; Head CT negative.

Clinical Course: Delirium was present and she developed seizures which were difficult to control with alprazolam and phenobarbital. Core T increased to 107 within hr and she was transferred to a tertiary care center without complete control of the hyperthermia. Hypotension was treated with dopamine. The patient remained unresponsive on a ventilator without sedation. N-acetylcysteine was given. Maximum AST 659, ALT 886. MRI of brain showed multiple areas of ischemic/hypoxic injury. LP results was negative; CK 10,645. C×R showed bilateral pulmonary atelectasis. Patient was sedated, paralyzed, actively cooled; the pupils became unequal and nonreactive. Neurological status continued to deteriorate; cerebral herniation occurred, comfort measures were instituted and she expired on Day 9.

Autopsy Findings: An autopsy was not performed. ME determined the cause of death was hypoxic-ischemic encephalopathy due to probable anticholinergic (diphenhydramine) and acetaminophen toxicity, ruled accidental.

Case 282. Acute salicylate and loratadine ingestion: undoubtedly responsible.

Scenario/Substances: 18 y/o male presented 6 hr after ingesting an entire bottle of aspirin, and 24 hr after ingesting 120 tablets of loratadine 10 mg.

Past Medical History: healthy male.

Physical Exam: In the ED (6 hr) BP 114/68; HR 120; RR 17; T 37°C; O₂ sat, 97% on room air; alert and oriented.

Laboratory Data: ABG-pH 7.55/pCO₂ 23/pO₂ 128, WBC 12.2, AST 20, ALT 16, UDS negative; urine pH 6.5,

| Na 141 | Cl 106 | | |
|--------|---------------------|--------|--|
| K 4.1 | HCO ₃ 21 | Cr 1.1 | |

salicylate 85.5 mg/dL (6 hr).

Clinical Course: 2 hr after arrival (8 hr postingestion), the patient began to have seizures and was hyperthermic. He was treated with lorazepam, and intubated. Just prior to this, he developed VT. After intubation he was given 2 boluses of sodium bicarbonate then a continuous infusion. However, he continued to have seizures and phenobarbital was added. Serum pH dropped to 7.22 and urine pH dropped to 6.1 despite alkalinization and hyperventilation. He was transferred to a tertiary care hospital for hemodialysis and expired shortly after arrival.

Autopsy Findings: Pulmonary edema (severe), no pill fragments or residue in the stomach. Postmortem serum salicylate, 98.2 mg/dL; serum acetaminophen 5.2 mcg/mL. Cause of death: was acute salicylate poisoning, Manner cause of death: suicide.

Case 289. Acute ibuprofen, salicylate, acetaminophen and hydrocodone ingestion: undoubtedly responsible.

Scenario/Substances: A 19 y/o female took acute oral overdose of ibuprofen 200 mg (max 500 tablets), aspirin 325 mg (max 100 tablets), and hydrocodone/acetaminophen (max 30 tablets). Family found her unresponsive and attempted to revive her in cold shower. EMS found her unresponsive and administered naloxone. She had a seizure en route to hospital and underwent rapid sequence intubation.

Past Medical History: Depression, alcohol abuse.

Physical Exam: BP 88/40–71/36, HR 124, T 35°C, lungs clear, pupils pinpoint and unreactive,, moving all extremities unresponsive to voice, withdraws to pain.

Laboratory Data: ABG-pH 7.20, HCO₃ 11, base excess –15 mMol/L, lactate 6.5 mMol/L (peaked at 9.8), acetaminophen 10.3 mcg/mL, peak salicylate 29 mg/dL. Urine tox screen positive for opiates, benzodiazepines (administered therapeutically), and barbiturates thought to be false positive secondary to ibuprofen as confirmatory testing was negative). Patient had no history of barbiturate use. Peak values for anion gap 22, K 6.1, INR 2.5, Cr 2.3, CK 51,381. Blood ibuprofen 410 mcg/mL on Day 4. Admission urine: hydrocodone 1576 ng/mL, hydromorphone 298 ng/mL.

Clinical Course: Lorazepam and vecuronium were administered in ED for agitation. Orogastric tube was placed, stomach aspirated of pill fragments, and 50 grams activated charcoal instilled. She remained hypotensive in ED despite 4 L fluid resuscitation and initiation of pressors. Head CT was normal. She was alkalinized for suspected salicylate intoxication. She remained hypotensive throughout hospital course despite infusions of dopamine, norepinephrine, neosynephrine, and vasopressin. She was dialyzed on Day 2 for acidosis, hyperkalemia, and suspected salicylate intoxication. BP improved briefly, but fell again and remained low. Propofol infusion was begun for agitation. Transvenous pacemaker inserted for slow, idioventricular rhythm on Day 3. She arrested and died on day 4.

Autopsy Findings: Death was due to multiorgan system failure due to polydrug overdose of ibuprofen, opiates, and salicylate.

Case 295. Acute colchicine ingestion: undoubtedly responsible.

Scenario/Substances: A 20 y/o male ingested an unknown number of his mother's 0.6 mg. colchicine tablets. He had one episode of emesis and diarrhea at home.

Physical Exam: Alert and oriented.

Laboratory Data: UDS positive for cocaine and THC metabolites.

Clinical Course: and presented to the ED 8 hr after ingestion. In the ED he complained of nausea only. Initial HR 75, BP 136/78, ECG: normal sinus rhythm. He was admitted

to a medical floor, given an antiemetic, and had no further episodes of emesis or diarrhea. At 35 hr postingestion he developed the sudden onset of vomiting, abdominal pain and bloody diarrhea, systolic BP 90, HR 110-120, and he was transferred to the ICU. He continued to be alert and oriented despite watery, bloody rectal discharge and diminished urine output despite 3 L of IV fluids. ABG-pH 7.13/pCO₂ 15/pO₂ 66 on a nonrebreather mask with FiO₂ 100%. WBC 29.0, Hgb of 18.2, CK 1845 IU/L, HCO₃ 15, BUN 37, Cr 2.9, amylase 233 IU/L, lipase 106 IU/L, lactate 12.2, Ca 6.9L, AST 386, ALT 175, total protein 5.5 g/dL, PT 41.9, aPTT 74.2, INR 11.8. Patient was transferred to another facility for ECMO support. His O₂ sat remained in the 40% range despite intubation and was bleeding from multiple sites. ABG-pH 6.94, T 36.4°C, HR 110, BP 96/50 with multiple vasopressors. The patient expired at ~46 hr post ingestion. **Autopsy Findings:** Not performed.

Case 392. Acute fentanyl ingestion with aspiration: undoubtedly responsible.

Scenario/Substances: 31 y/o male was found unresponsive lying supine in pool of emesis. The night before he told his girlfriend he was suicidal and intended to use a fentanyl patch. He reportedly had been buying his drugs on the street and would frequently chew on fentanyl 25 mcg patches. He was believed to have been chewing on a 100 mcg patch that

Past Medical History: Depression, recreational drug

Physical Exam: Unresponsive, labored breathing with periods of apnea, B/P 120/71, HR 114, T 38°C. Pinpoint pupils, coarse lungs sounds.

Laboratory Data: ABG-pH, 7.15/pCO₂ 75/pO₂ 145.

| Na 143 | Cl 102 | BUN 29 | Glu 88 |
|--------|---------------------|--------|--------|
| K 6.1 | HCO ₃ 29 | Cr 3.5 | Giu 88 |

AST 246, ALT 134; CK, 6871, acetaminophen and ethanol not detected; Urine was tea colored, UDS negative. C×R positive for aspiration. ECG QRS 72 ms, QT 459 ms, peaked T waves.

Clinical Course: Post-fluid resuscitation and intubation: B/ P101/54, HR 120, RR 34, ECG: normal QRS and QT with sinus tachycardia. Urine output ~50 cc/hr. Day 2 CK 49,763 IU/L, AST 1288. The patient was sedated with propofol. Day 5 pancreatitis found (lipase 4727); EEG showed no seizure activity but dampened alpha waves. The patient was unresponsive with posturing; comfort measures were instituted and she expired on Day 14.

Autopsy Findings: Not performed. ME's report attributed the cause of death as cerebral anoxia secondary to fentanyl overdose, but determined the manner of death to be accidental.

Case 468. Acute acetaminophen/diphenhydramine ingestion: undoubtedly responsible.

Scenario/Substances: A 38 y/o female ingested 90 acetaminophen/diphenhydramine tablets in an intentional overdose. She presented to the ED 2 days after the ingestion.

Physical Exam: Initially patient was alert and oriented, tachycardic, but hemodynamically stable. Pupils were dilated and icteric.

Laboratory Data: In the ED acetaminophen was 107 mcg/ mL, AST 9162, ALT 6888, INR 9.4, CK 1534, total bilirubin 4.29, Cr 1.3 mg/dL, WBC 20.

Clinical Course: Patient was started on IV N-acetylcysteine, received Glu for initial hypoglycemia, IVFS and vitamin K. AST increased to 12,341, ammonia to 101, lactate 4.9, repeat Cr to 1.81. She was treated with antibiotics and transferred to a tertiary care facility. She became encephalopathic and was intubated and ventilated. She was placed in phenobarbital-induced coma and hypothermia. She received a liver transplant and had a partial small bowel resection secondary to necrotic bowel. She developed hypotension and was started on pressors, then became hypertensive. Patient didn't improve clinically following the transplant, CT scan of her abdomen suggested bowel perforation and she died from a cardiac arrest on Day 15; 9 days after the transplant.

Autopsy Findings: Cause of death: acute acetaminophen toxicity.

Case **506**. Acute tramadol ingestion: probably responsible.

Scenario/Substances: 41 y/o female found by her husband unresponsive and cyanotic after complaints of nausea and vomiting followed by an episode of syncope at home. She was on tramadol and pregabalin for fibromyalgia. The tramadol was recently filled but the medication bottle could not be found. EMS found her to be apneic, unresponsive, and in PEA. Intubation was performed in the field and she was given naloxone, epinephrine, and atropine resulting in sinus rhythm but remaining unresponsive.

Past Medical History: Chronic pain, and fibromyalgia. Medications included tramadol, pregabalin, and acetaminophen/ hydrocodone.

Physical Exam: Unresponsive with pupils were fixed and dilated at 8 mm. BP 78/38, HR 117, RR 20 (ventilator), T 37°C. There were no localizing movements of any extremity; breath sounds was coarse bilaterally, and she had no spontaneous breaths.

Laboratory Data: ABG-pH 6.62/pCO₂ 118 AST 142, ALT 125, acetaminophen 5 mg/L, salicylate 5.4 mg/dL, ethanol not detected. ECG showed sinus tachycardia with inferior ST depression consistent with ischemia secondary to prolonged CPR.

Clinical Course: Shortly after arrival to the ED, she had 2 additional episodes of PEA and bradycardia treated with additional atropine and epinephrine. Dopamine was used for her hypotension and acidemia was treated with sodium bicarbonate and ventilation. Repeat ABG-pH of 7.2/pCO₂ 38.8. A CT scan of the head showed loss of grey/white differentiation and diffuse cerebral edema suggestive of diffuse

anoxic brain injury. Comfort measures were instituted and he expired on Day 1.

Autopsy Findings: Cardiomegaly with biventricular dilatation and obesity (body mass index 34.3). Postmortem peripheral blood was positive for tramadol (2500 ng/mL) and o-desmethyltramadol (400 ng/mL). The cause of death was reported as acute tramadol toxicity.

Case 552. Acute salicylate ingestion: undoubtedly responsible.

Scenario/Substances: A 45 y/o female ingested 800 aspirin tablets (325 mg) in a self-harm attempt and presented to the ED 1 hr later.

Past Medical History: Multiple sclerosis, seizure disorder, renal insufficiency; medications: clonazepam, lorazepam, carbamazepine, and phenytoin.

Physical Exam: In the ED, altered mental status "staring into space".

Laboratory Data: Serum K 4.3, Cr 0.9, BUN 19, salicylate 53.4 mg/dL, ABG-pH 7.56/pCO₂ 16/pO₂ 98/HCO₃ 14, phenytoin 9 mg/L, carbamazepine 4.5 mg/L, acetaminophen not detected.

Clinical Course: She was started on bicarbonate IV drip. At 5–6 hr after admission she was tachypneic, vomiting, T 42.8°C, treated with cooling blankets, salicylate 121 mg/dL. At 8 hr after admission the patient was intubated and placed on ventilator. One hr after intubation she suffered a cardiac arrest and expired.

Autopsy Findings: Pulmonary edema, charcoal liquid in the stomach; Postmortem blood salicylate 650 mcg/mL; blood screen: alcohol, cocaine, methamphetamine and morphine not detected. Cause of Death: Acute salicylate toxicity.

Case 588. Acute-on-chronic colchicine and ethanol ingestion: undoubtedly responsible.

Scenario/Substances: A 48 y/o male ingested 60 colchicine tablets (unknown strength) with alcohol.

Past Medical History: Gout, diabetes, coronary artery disease, alcoholism, depression, previous suicide attempts.

Physical Exam: Initial vital signs and ECG in the ED were "normal." Later that day he became tachycardic to 120, BP 123/79, T (oral) 37°C, RR 15, O_2 sat 98% on 2 L O_2 .

Laboratory Data: Serum HCO₃ 19, pH 7.5. Salicylate and acetaminophen were undetected, UDS was negative. WBC 14.4, hepatic enzymes were WNL, ECG: sinus tachycardia 155. QRS and Q-T WNL.

Clinical Course: Gastric lavage was performed and he was given activated charcoal in the ED. He received IV NS. On Day 2, he developed a tremor, vomited and appeared to be in alcohol withdrawal. He was started on benzodiazepines for ethanol withdrawal per the CIWA protocol. His systolic BP 130 and his HR 100–120. On Day 3 he was agitated and in sinus tachycardia, BUN 40, Cr 3.55 with normal urine output. He was started on sodium polystyrene sulfonate for hyperkalemia. On Day 4 he became hypotensive, bradycardic and suffered cardiac arrest during hemodialysis. He was pronounced dead on Day 4.

Autopsy Findings: Toxicology: postmortem blood ethanol 0.08 g%, caffeine was present, venlafaxine and norvenlafaxine were not detected. Ante-mortem serum colchicine 15 ng/mL, delta-9-tetra-hydrocannabinol and 11-hydroxy-delta-9-THC were not detected, but 11-nor-delta-9 THC 10 ng/mL. Norvenlafaxine was present in the urine. The cause of death was intoxicating effects of colchicine overdose, the manner of death was suicide.

Case 602. Acute salicylate ingestion: undoubtedly responsible.

Scenario/Substances: 49 y/o male presented to the ED with signs of salicylate poisoning. He was severely agitated and confused, had tachypnea and the initial salicylate level was 102 mg/dL.

Past Medical History: Not reported.

Physical Exam: Agitated and confused male. BP 140/90, HR 140, RR 32, T38.2°C.

Laboratory Data: K 3.9, salicylate 105 mg/dL; at 2 hr salicylate 126 mg/dL. Serum pH 7.55 while on IV bicarbonate infusion.

Clinical Course: The patient remained agitated and aggressive but was not intubated until dialysis access was to be placed. Dialysis was delayed and he expired before dialysis could be initiated on Day 1.

Autopsy Findings: Not available.

Case 612. Acute-on-chronic colchicine, alprazolam ingestion: undoubtedly responsible.

Scenario/Substances: 50 y/male ingested 30 colchicine tablets, 0.6 mg each, and 60 alprazolam, 0.25 mg each. Ingestion was witnessed by two older sons.

Past Medical History: Arthritis and gout.

Physical Exam: Ataxic and confused male. BP 129/81, HR 97, RR 18.

Laboratory Data:

| Na 139 | Cl 100 | BUN 8 | Glu 70 |
|--------|---------------------|--------|--------|
| K 4.1 | HCO ₃ 29 | Cr 0.9 | Giu 70 |

Calcium 9.3 mg/dL, albumin 4.1, total protein 7.3, total bilirubin 0.8, Alk phos 86, AST 30, ALT 23, lipase 22, acetaminophen and ethanol not detected; CK 82, troponin not detected, UDS was positive for benzodiazepines.

Clinical Course: The patient presented within 1 hr of ingestion. He was ambulating in ED and was able to drink activated charcoal. At 12 hr he had tachypnea, tachycardia and worsened mental status. He was intubated and sedated with propofol and given additional activated charcoal given via NGT. BP 94/73, HR 109, RR 26, T 37°C, O₂ sat 100% on 30% FiO₂ via ventilator. At 36 hr urine output was less than 5 ml/hr and he had hypoactive bowel sounds. Cr 2.92, HCO₃ 16. Bicarbonate IV infusion and antibiotics were started. At 60 hr: BP 133/100, HCO3 16, BUN 41, Cr 5.4, CK, 5806, Glu 216 and hemodialysis was started. At 80 hr he had bleeding from IV site, eyes, nose, mouth, blood in urine (dark color) and found to have platelets 34 and AST of 380. Bleeding continued and he expired 108 hr after exposure.

Autopsy: Not performed.

Case 616. Fentanyl transdermal, ethanol: undoubtedly responsible.

Scenario/Substances: 51 y/o female found unresponsive several hours after she was witnessed cutting open and eating the contents of a fentanyl patch. EMS found the patient in asystole and hypoglycemic. CPR was initiated, she was intubated, given oxygen and an IV was started. Three doses of epinephrine, 1 dose of atropine, naloxone 2 mg, and dextrose 50% in route were given enroute to the ED. No significant change the patient's condition occurred.

Past Medical History: The patient had a history of herniated disk surgery, back pain, hypertension, tobacco and alcohol use. Medications found at the home included an empty container of metoprolol and the cut open fentanyl

Physical Exam: The patient was in asystole with CPR in progress. Her breath smelled of alcohol, pupils were dilated, and she appeared to be posturing.

Laboratory Data: WBC 6.3, Hgb 11.1, Hct 38, platelet

Ca 23.8, Mg 2.8, anion gap18, ALT 2722, AST 3440, CK 112, CKMB 2.4, troponin 0.29, ethanol 176 mg/dL.

| Na 135 | Cl 111 | BUN 9 | Glu 729 |
|--------|---------------------|--------|---------|
| K 10.2 | HCO ₃ 16 | Cr 1.0 | Glu 729 |

Clinical Course: The patient received multiple doses of epinephrine, atropine, and naloxone as well as sodium bicarbonate and calcium chloride and was defibrillated several times without success. ACLS was discontinued after 30 min and the patient expired in the ED.

Autopsy Findings: There were no significant gross or microscopic findings. Blood fentanyl was 7.3 ng/mL, and was positive in the urine. Ethanol was 206 mg/dL in the blood and 248 mg/dL in the urine. The blood drug screen was positive for citalopram (trace) and alprazolam at less than 5 ng/mL. The UDS was positive for citalogram and metoprolol.

Cause of Death: Intoxication with Ethanol and Fentanyl. Manner of Death: Accidental ingestion of alcohol and Fentanyl patch contents.

Case 658. Acute-on-chronic acetaminophen/propoxyphene, lorazepam ingestion: undoubtedly responsible.

Scenario/Substances: 54 y/o male found unresponsive by his mother at home with empty bottles of acetaminophen/ propoxyphene and lorazepam; was last seen "normal" the previous day.

Past Medical History: Depression with previous suicide attempts, anxiety, polysubstance abuse, seizures, bipolar disorder, and ethanol abuse. Medications included acetaminophen/propoxyphene, 120 tablets filled 11 days previously and lorazepam.

Physical Exam: Unresponsive. BP 90/52, HR 85, RR 16 (ventilator), T 33.5°C. Lungs clear.

Laboratory Data: ABG-pH 7.12/pCO₂ 47/pO₂ 80.

| Na 139 | Cl 102 | BUN 11 | Glu 172 | |
|--------|---------------------|--------|---------|--|
| K 3.8 | HCO ₃ 12 | Cr 3.9 | Glu 172 | |

AST 153, ALT 53, Alk phos 63, INR 1.9, platelets 117; ammonia 64, lactate 19, acetaminophen 735 mcg/mL; UDS positive for benzodiazepines and cocaine. At 1 hr ABG-pH 7.0/pCO₂ 31/pO₂ 134; at 6 hr ABG-pH 6.9/pCO₂ 31/pO₂ 105; CPK 16,202, troponin 0.08; ammonia 95, AST 842, ALT 183; acetaminophen 530 mcg/mL. At 9 hr ABG-pH 6.86/pCO₂ 36/pO₂ 95; ammonia 149, AST 983, ALT 242, PT, 29.3 sec; INR 2.7, PTT 64 sec; acetaminophen 500 mcg/ mL. At 20 hr acetaminophen 444 mcg/mL; INR 4.1, Cr 3.1. HCO3 8.

Clinical Course: The patient was intubated, hypothermic and hypotensive, did not respond to 1 dose of naloxone or IV fluids, and was started on vasopressors, norepinepherine and dopamine. He was started on N-acetylcysteine via nasogastric tube. Due to worsening acidosis, he patient was started on fomepizole and given 100 mg of thiamine and folic acid 50 mg every 4 hr. N-acetylcysteine was switched to IV at 2.5 hr due to loss of bowel sounds; alkalinzation therapy was started at 4.5 hr. At 6.5 hr, activated charcoal was given via nasogastric tube. He remained acidotic with significantly elevated acetaminophen levels (500 mcg/mL at 9 hr) and hemodialysis was recommended. A 3rd pressor was added to maintain BP, pupils were fixed and dilated, no gag or cough reflex were present. Comfort measures were instituted and he expired on Day 2.

Autopsy Findings: No autopsy was performed. Antemortem serum contained norpropoxyphene 1.3 mg/L, propoxyphene 2.0 mg/L. Cause of death was acute hepatic failure due to acetaminophen toxicity with contributions from propoxyphene toxicity. However, the clinical course is not consistent with typical acetaminophen hepatotoxicity but more with an acute acidosis from a highly elevated serum acetaminophen level.

Case 784. Acute morphine ingestion: undoubtedly responsible.

Scenario/Substances: 84 y/o female was found by nursing home staff to have altered mental status, uneven breathing, and "gurgling" in her chest. She was transported to a tertiary care hospital.

Past Medical History: Dementia, hypertension, anemia, osteoporosis, and osteoarthritis.

Physical Exam: C×R: consistent with pneumonia

Laboratory Data: UDS positive for opioids. Confirmatory testing resulted in a morphine level > 50,000 ng/mL.

Clinical Course: The patient expired on Day 2.

Autopsy Findings: No autopsy was performed. An ME review determined the cause of death to be aspiration pneumonia due to acute morphine toxicity. Six other patients at the same nursing home unit also tested positive for morphine; none (including this patient) had been prescribed morphine. A nurse at the facility was later charged with second degree murder and 6 counts of felony patient abuse.

Case 792. Acute opioid ingestion: probably responsible. Scenario/Substances: A 15-month-old, was noted to be "congested" with wheezing when the mother came home from her work. The mother did not attempt to awaken the child. 5 hr later, the child was unresponsive. EMS found the child in respiratory arrest.

Past Medical History: previously healthy child, on no medications.

Physical Exam: Unresponsive in respiratory arrest of unknown duration. Post resuscitation on ventilator BP 114/66, HR 144, O₂ Sat 100%, lung sounds were coarse.

Laboratory Data: Glu 40, UDS positive for opiates by GS/MS confirmed morphine. Serum drug screen drawn 12 hr post admission was negative for opiates barbiturate, benzodiazepines, cannabinoids, cocaine, fentanyl, methadone, phencyclidine, propoxyphene, alcohols analgesics, anesthetics antihistamines and antipsychotics.

Clinical Course: Resuscitation by EMS and ED staff was successful, but there was no response to naloxone. Therapies included intubation, mechanical ventilation, dextrose, antibiotics and sedation with midazolam. The child displayed no purposeful movements. An MRI showed anoxic brain injury. The child suffered subsequent brain herniation and expired on Day 4. After an investigation, it was believed the child had ingested morphine belonging to one of the several adults in the home, as more than one adult had pain medications available to them. It was unknown if the child found a tablet that had been dropped or had possibly been given the morphine by one of the adults.

Autopsy Findings: Diffuse hypoxic-ischemic encephalopathy, cerebral edema and central brain herniation. There was no evidence of inflicted trauma. Cause of death: complication of morphine intoxication.

Case 803. Acute-on-chronic valproic acid (extended release), ziprasidone ingestion: undoubtedly responsible.

Scenario/Substances: 28 y/o female was found obtunded in bed. She had taken ~260 valproic acid 500 and possibly 40 tablets of ziprasidone. CPR was performed by EMS.

Past Medical History: Bipolar disorder, PTSD, substance abuse, including cocaine, tobacco, and ethanol; schizoaffective disorder, and multiple suicide attempts.

Physical Exam: Obtunded female, BP 91/50, HR 95, RR 15, O_2 sat 100% on 40% Fi O_2 .

Laboratory Data: ABG-pH 7.31/pCO₂ 35/pO₂ 138; Cr 1.5; UDS positive for cocaine. Valproic acid level was 1000 mcg/mL; acetaminophen and ethanol were not detected.

Clinical Course: She was intubated and put on the ventilator, given a normal saline fluid bolus and activated charcoal. A second valproic acid level was 1072 mcg/mL, 2 additional doses of activated charcoal of 0.5 gm/kg were given. BP decreased to 67/30 and required dopamine 10 mcg/min. A 3rd valproic acid level was 987.1 mcg/mL.

| Na 152 | Cl 120 | |
|--------|---------------------|--|
| K 4.6 | HCO ₃ 14 | |

 $\frac{\text{BUN 8}}{\text{Cr 1.7}}$

ABG-pH 7.26/pCO₂ 31/pO₂ 111; AST 16, ALT 20. She was started on a sodium bicarbonate drip and dopamine was increased. Ammonia level was 298; lactulose started. Day 2 sedation was discontinued, her pupils reacted sluggishly. Ammonia 505 mmol/L

| Na 154 | Cl 116 | BUN 8 | |
|--------|---------------------|--------|--|
| K 2.7 | HCO ₃ 20 | Cr 1.7 | |

Sodium bicarbonate was stopped; IV fluids and dopamine were continued. Lactulose was stopped and L-carnitine IV infusion was started; valproic acid 1073.1 mcg/mL. The patient had respiratory decompensation and worsened hypotension. Propofol was started. Comfort measures were instituted and she expired on Day 5.

Autopsy Findings: An autopsy was not performed. ME review determined the cause of death to be drug overdose due to polysubstance abuse, severe mental illness and bipolar disease.

Manner of death was suicide.

Case 809. Acute valproic acid and methamphetamine ingestion: undoubtedly responsible.

Scenario/Substances: 37 y/o male ingested an unknown amount of valproic acid at some unknown time. He was found unresponsive outside, wet and hypothermic and was transported to the ED. A suicide note was found in his clothing. He was intubated in the field.

Past Medical History: Bi-polar disorder, chronic hepatitis C, chronic alcoholism, hypertension, history of drug abuse. He had been hospitalized 3 times in the past 30 days with previous suicide attempts.

Physical Exam: Heart rate 125, BP 102/51, HR 125, RR 18 on the ventilator, T 35°C. O₂ sat 100% on FIO₂ 30%. **Laboratory Data:** ABG-pH 6.93/pCO₂ 25/pO₂ 143,

| Na 150 | Cl 110 | BUN 12 |
|--------|---------------------|--------|
| K 4.1 | HCO ₃ 20 | Cr 0.8 |

UDS positive for methamphetamine, amphetamine and THC. Initial valproic acid level on arrival was 1286 mcg/mL which increased to 1399 mcg/mL when repeated.

Clinical Course: After admission to the ICU, the patient was started on lactulose and oral L-carnitine and remained unresponsive. Day 2 labs: valproic acid 1548 mcg/mL, NH₃ 827, ABG-pH 7.41/pCO₂ 33/pO₂ 80,

| Na 161 | Cl 120 | BUN 12 | Glu 70 |
|--------|---------------------|--------|--------|
| K 4.2 | HCO ₃ 19 | Cr 1.4 | Giu 70 |

Ca 6.2, Mg 2.3, AST 203, ALT 168. The patient was made DNR. On Day 3 he was unresponsive, intubated, hypotensive (82/31) and having runs of SVT in the 200 range.

| Na 158 | Cl 125 | BUN 18 |
|--------|---------------------|--------|
| K 2.6 | HCO ₃ 18 | Cr 3.5 |

Glu 31

valproic acid 532 mcg/mL, NH₃ 345. Comfort measures were instituted and he expired on Day 3.

Autopsy Findings: Cause of death was listed as multiorgan system failure due to acute valproic acid poisoning. Other significant conditions: Bi-polar disorder, chronic hepatitis C, chronic alcoholism, hypertension, hypothermia, history of drug abuse, recent methamphetamine use. Serum concentrations from hospital samples showed valproic acid 414 mg/L (potentially toxic at 150-200 mg/L); d-Methamphetamine 0.11 mg/L (potentially toxic at 0.2–5 mg/L); d-Amphetamine 0.11 mg/L (potentially toxic at 0.2 mg/L).

Case 818. Acute-on-chronic oxcabazepine, bupropion (extended release), diltiazem (extended release) ingestion: undoubtedly responsible.

Scenario/Substances: 50 y/o male brought himself to the ED 2.5 hr after reported ingestion of 0.8 grams of diltiazem extended release, 3.6 grams of oxcarbazepine, and 4.5 grams of bupropion XL as a suicide gesture to escape impending legal trouble.

Past Medical History: depression, sexual perversion (with previous incarceration), antisocial personality disorder, alcohol abuse, tobacco use, hypertension.

Physical Exam: 3.5 hr postingestion: awake, alert and oriented. BP, 173/73, HR, 92, RR 18, T 37°C, O₂ sat, 99% on RA. No remarkable physical findings.

Laboratory Data: WBC 17.9, PT 13.4, INR 1.0.

Anion gap 21, lactate 182, AST 21; and ALT 26; Acetaminophen and salicylate were not detected; Serum tox screen was positive for benzodiazepines; toxic alcohol levels returned later negative for both methanol and ethylene glycol.

Clinical Course: The patient complained of "lightheadedness" and mild epigastric pain, became diaphoretic and tachypneic and at 2 hr was given oral activated charcoal and had a witnessed aspiration. At 6 hr the patient became hypotensive and bradycardic, hyperglycemic (Glu 353) and was incubated. ECG showed a junctional rhythm, first degree block, with a QRS of nearly 120 ms. IV fluid, 5 mg glucagon, 2 amps Calcium Chloride, and 2 amps Calcium gluconate were given with minimal response. 1 mg of atropine was given and the patient was transvenously paced at a rate of 81 bpm and transferred to the ICU and sedated with benzodiazepines. High dose insulin, 100 units/hr (1 unit/kg/hr) was started and he also received 20% lipid emulsion (150 ml bolus, then infusion of 25 ml/kg/hr). Bilateral lung rhonchi were noted; ABG-pH 6.96/pCO₂ 55/pO₂ 109. Glu continued to rise despite insulin increased to 200 units per hour. At 12.5 hr pressors were required to keep systolic BP in the 50s with transvenous pacing. Day 2 Ph 7.2, Glu 723 mg/dL, C×R showed bilateral pleural effusions and pulmonary edema; ECMO was started, Despite insulin infusion (300 units/hr), the patient remained hyperglycemic and acidotic with BP's in the 90s. The lipid infusion was discontinued and fentanyl infusion started. Day 3 Hyperkalemia developed with low K 2.5 the day prior. Hemodialysis started, insulin infusion decreased to 250 units/hr, pressors continued with BP 75. HR 90-100, and cardiac output recorded at 16 L/min. Day 4 the patient had a L leg fasciotomy for a compartment syndrome below the ECMO catheter site. Day 4 a fasciotomy was performed on the left leg with anticipated future amputation. Insulin infusion stopped and D10W infusion started for Glu 85; no activity seen on EEG. Day 5 ECMO stopped; pressors continued to keep BP 70–90, eyes opened, responded to touch, AST increased 4101, ALT 1711. Day 6 a necrotic scrotum, thought secondary to prolong pressors was diagnosed; due to ongoing poor brain activity and significant heart damage, the patient was transferred to palliative care and expired 1 hr after pressors were discontinued.

Autopsy: Not performed.

Case 833. Acute-on-chronic citralopram and ethanol ingestion: undoubtedly responsible.

Scenario/Substances: A 19 y/o female ingested an unknown number of her citalogram 40 mg tablets and ethanol in a suicide attempt.

Physical Exam: In the ED her HR 120, systolic BP 117; alert and oriented.

Laboratory Data: Ethanol 0.16 g/dL, citalopram: 6,600 ng/ mL, acetaminophen not detected, UDS: negative;

Clinical Course: Patient quickly developed twitching activity treated with lorazepam. Minutes later she developed a VT, which deteriorated to VF. CPR was initiated and she was defibrillated twice. IV fat emulsion 1.5 ml/kg was administered. She developed PEA and expired.

Autopsy Findings: No significant natural disease process, injury or trauma was identified. Cause of death was citalopram toxicity.

Case 899. Doxepin ingestion: undoubtedly responsible. Scenario/Substances: 49 y/o female presented to the ED after ingesting ~60 doxepin tablets witnessed by her husband in an apparent suicide attempt.

Past Medical History: Depression, anxiety, insomnia, Hepatitis C

Physical Exam: Somnolent; BP 85/51, HR 90, RR 16, T 37°C, O₂ sat 100% on 100% FIO₂ on mechanical ventilation. Pupils 4 mm, sluggishly reactive to light; unable to follow commands.

Laboratory Data:

| Na 142 | Cl 108 | BUN 14 | Glu 105 |
|--------|---------------------|--------|---------|
| K 3.6 | HCO ₃ 27 | Cr 0.9 | Giu 103 |

AST 36, ALT 36; ethanol, acetaminophen, salicylate not detected; UDS negative. ECG: QRS 160 ms, QTC 649 ms. Clinical Course: Upon arrival to the ED generalized seizures occurred. The patient was intubated, given 12 mg lorazepam and 1 gm phenobarbital which controlled the seizure activity. 30 amps of sodium bicarbonate and oral activated charcoal were given. ECG intervals decreased to QRS 126 and QTc 600. Follow up Na was 170, pH 7.75. EEG showed encephalopathy consistent with phenobarbital

and TCA overdose. Day 2 head CT showed abnormal focal hypodensities in the frontal lobes bilaterally, as well as possibly in the bilateral basal ganglia, which represent ischemia or edema, or possibly nonhemorrhagic contusion in the frontal lobes. The patient was unresponsive to pain without sedation; pupils were slightly reactive. Na decreased to 150, pH normalized, QRS was 104, QTc in the mid 500s with ongoing K and Mg replacement. Phenobarbital 6 mcg/mL. On Day 3, pupils became fixed and dilated, head CT showed cerebral edema with brain stem herniation, cerebral perfusion study did not show evidence of cerebral blood flow. Comfort measures were instituted and she expired on Day 5. Blood concentrations from Day 2 showed doxepin 1,133 ng/mL, n-desmethyl-doxepin at 514 ng/mL.

Autopsy Findings: Not performed. Cause of death was acute doxepin intoxication. Manner of death was suicide.

Case 906. unknown doxepin ingestion: undoubtedly responsible.

Scenario/Substances: A 51 y/o male was admitted for detoxification/alcohol withdrawal. He was discharged 2 days later and started to drink again. The day after discharge, he presented to the ED at and requested readmission for detoxification. He was released but returned 3 hr later stating that 15 min prior to his return he had ingested 60 tablets of doxepin 100 mg in the parking lot so that he would have to be admitted. He was not suicidal, but stated that he was looking for a place to stay.

Past Medical History: Homelessness, alcohol dependence, poly-substance abuse, GERD, tobacco abuse, hypertension, IV drug abuse, and COPD. Medications included doxepin.

Clinical Course: In the ED was ambulatory and conversant. He refused interventions, pulled out his IV catheter, and refused to drink activated charcoal. He then became unresponsive, requiring endotracheal intubation for airway management. An orogastric tube was inserted and activated charcoal was administered. He seized and became hypotensive with a systolic BP of 30. He was given 4 mg of IV lorazepam for the seizure and was placed on a high-dose norepinephrine infusion for the hypotension. He continued to have intermittent seizures. His HR decreased to 26 with a narrow QRS complex and he then developed cardiac arrest. CPR was initiated including 5 ampules each of epinephrine, atropine and calcium chloride IV. Resuscitation was unsuccessful and he expired 2 hr after the ingestion.

Autopsy Findings: Cause of death was drug overdose with the primary drugs being ethanol and doxepin, manner undetermined.

Case 907. Acute venlafaxine and paroxetine ingestion: undoubtedly responsible.

Scenario/Substances: A 52 y/o took a "bunch of pills" and cut his wrists. A venlafaxine capsule was found in his throat.

Past Medical History: Depression.

Physical Exam: In the ED, HR 109, BP 91/66, T 36.6°C; O₂ sat 100% on room air. Patient was rigid, exhibited myoclonus, hyper-reflexive, altered mental status, and seizures.

Laboratory Data: ABG- pH 7.3/pCO₂ 45/pO₂ 149/HCO₃ 22; CK 888, acetaminophen and salicylate not detected, blood venlafaxine 28 mg/L, ECG: QRS 162 ms.

Clinical Course: Patient was intubated and admitted to the ICU. He was placed on a lorazepam infusion for seizures and required dopamine and vasopressin to support his BP. He received multiple doses of sodium bicarbonate during cardiopulmonary arrests, but ultimately could not be resuscitated.

Autopsy Findings: Cause of death: acute venlafaxine and paroxetine intoxication.

Case 932. Acute amitriptyline ingestion: undoubtedly responsible.

Scenario/Substances: 62 y/o male ingested 60 tablets of his 10 mg amitriptyline at an unknown time.

Past Medical History: Diabetes Mellitus.

Physical Exam: Initially responsive with rapid deterioration; ECG showed QRS 140 ms. Vital signs on day 2: HR, 92, BP, 110/50, T, 35.7°C.

Laboratory Data: ABG-pH 7.45/pCO₂ 40; bicarbonate 27.4.

Clinical Course: The patient rapidly deteriorated, seized in the ED and required intubation. HCO₃ was given for the wide QRS. He was admitted to the ICU, given phenytoin for seizures and norepinephrine/dopamine for hypotension without BP response. Vasopressin and epinephrine were added and he was placed on a bicarbonate infusion. The patient had a cardiopulmonary arrest in the ICU, was given epinephrine, bicarbonate boluses and atropine. Phenytoin was stopped, lorazepam started and fat emulsion (20% 100 ml IV, then 25 ml/hr IV infusion) initiated. After brief improvement in BP (systolic BP 130s), epinephrine, dopamine, and norepinephrine were weaned off prior to the patient becoming hypotensive again and widening his QRS again to 160 ms. Therapy with norepinephrine, epinephrine, dopamine and intralipid was restarted, 2 sodium bicarbonate boluses given without response. Comfort measures were instituted and he expired on Day 1.

Autopsy Findings: The Coroner's stated cause of death was amitriptyline toxicity.

Case 964. Acute quetiapine, quinine, acetaminophen/diphenhydramine, and carprofen ingestion: probably responsible.

Scenario/Substances: A 38 y/o female was found unresponsive at home with a suicide note. Family had last spoken to her by phone 3 hr earlier. EMS intubated the patient and placed intraosseous access, Glu was normal, and there was no response to intraosseous naloxone in the field. EMS noted wide QRS that narrowed with 1 amp sodium bicarbonate en route to the ED.

Past Medical History: Mitral insufficiency, idiopathic pulmonary insufficiency, asthma, hypothyroidism, diabetes, GERD, depression with prior suicide attempts. She was on 25 medications including quetiapine, escitalopram, hydromorphone, not including quinine or quinidine.

Physical Exam: BP 72/41, HR100, on ventilator, T 36.3°C no evidence of trauma, course ronchi bilaterally, GCS 3, pupils fixed and 6 mm.

Laboratory Data: At 4 hr in the ED, ABG-pH 7.31/pCO₂ 54/pO₂ 159, WBC 11.3, Hct 34.9, platelets 377, Glu 79, electrolytes, BUN, Cr, ALT, AST, bilirubin, CK, troponin, and UA unremarkable, acetaminophen 29 mg/L, salicylate not detected. UDS positive for benzodiazepines, opiates, and amphetamines; negative for alcohol, barbiturate, cannabinoid, cocaine, and phencyclidine; urine HCG negative. C×R and head CT were noncontributory. ECG: sinus tachycardia 105, a new LBBB, QRS 174 ms, QTc 520 ms.

Clinical Course: In the ED, the patient was given additional sodium bicarbonate push, and infusion was started. Saline boluses were given, dopamine and norepinephrine infusions were begun for hypotension. A generalized seizure responded to lorazepam. The patient developed VT followed by VF, she was cardioverted multiple times, and initially responded to Ca, magnesium, and epinephrine, but the patient again became pulseless. CPR per ACLS was unsuccessful and she died at 7 hr.

Autopsy Findings: Acquired aortic valve stenosis with fusion or right and left coronary artery valve cusps; cardiac hypertrophy, pulmonary congestion, congestion of abdominal viscera. Postmortem UDS positive for opiates, benzodiazepines, quinine, citalopram + metabolite, quetiapine metabolites, and promethazine + metabolite. Postmortem blood screen positive for opiates. Postmortem (cardiac blood) serum quinine 49 mcg/mL (toxic > 6), serum hydromorphone 33 ng/mL.

Case 965. Acute levamisole and cocaine inhalation/nasal: probably responsible.

Scenario/Substances: A 57 y/o female presented to the ED with altered mental status, fever and neutropenia.

Past Medical History: Mild mental retardation, obesity, peptic ulcer disease, B cell lymphoma, low back pain, Castleman's disease, lymphadenopathies, hypertension, asthma, depression, diabetes, hepatitis B and C, polysubstance abuse including crack cocaine, methadone maintenance. He had anemia, neutropenia and thrombocytopenia due to 3 cycles of antineoplastic therapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for the lymphoma. Ten days prior to presentation, her WBC 1.2.

Physical Exam: Appeared toxic and ill, HR 129, BP 142/83, RR 29, T (rectal) 41°C, lungs clear, mild bilateral lower extremity edema, GCS 7, ECG: sinus tachycardia with nonspecific T wave changes.

Laboratory Data: WBC: 0.6, Hgb 9.0, platelets 86, INR $1.6, {\rm PTT}\ 17.6, {\rm ABG-\ pH}\ 7.49/{\rm pCO}_2\ 28/{\rm pO}_2\ 76/{\rm HCO}_3.\ 22,$

$$\begin{array}{c|cccc} Na \ 139 & Cl \ 109 & BUN \ 12 \\ \hline K \ 3.2 & HCO_3 \ 22 & Cr \ 1.9 & Glu \ 104 \\ \end{array}$$

AST 23, ALT 19, Alk phos 75, bilirubin 2.1, lactate 1.3 mmol/L, troponin < 0.04 ng/mL, UDS positive for cocaine, cocaine metabolites, levamisole, opiate, methadone and methadone metabolites, acetaminophen, lidocaine, propofol, fluconazole and citalopram, blood volatile screen negative, serum methadone 0.13 mg/L, benzoylecgonine 0.26 mg/L, citalopram 170 ng/mL.

Clinical Course: Patient was sedated, intubated, and received IV fluids and antibiotics for bilateral pneumonia. On Day 2 she became increasingly hypotensive and acidotic, developed oliguric renal failure and CVVHD was initiated. She suffered 2 VT arrests which responded to electric cardioversion and amiodarone. Levofloxacin was discontinued for the long QT. Norepinephrine and vasopressin were started. On Day 3 dobutamine was started, additional broad spectrum antibiotics were initiated and filgrastim was started for neutropenia. Her INR and bilirubin increased, albumin and platelets decreased. Platelets and packed red blood cells were infused. On Day 4 prognosis was poor, comfort measures were instituted, and she expired.

Autopsy Findings: Bone marrow showed microscopic neutropenia and increased megakaryocytes consistent with levamisole exposure. Immediate cause of death was ruled as neutropenia due to recent levamisole exposure.

Case 970. Chronic methotrexate ingestion: undoubtedly responsible.

Scenario/Substances: A 69 y/o, 91 kg male mistakenly took 30 methotrexate tablets over 10 days.

Laboratory Data: WBC 0.2, Hgb 11.2, Hct 32.6, platelets 30,

| Na 133 | Cl 99 | BUN 21 | Glu 115 |
|--------|---------------------|---------|---------|
| K 4.2 | HCO ₃ 26 | Cr 0.97 | Giu 113 |

Ca 7.8, AST 25, ALT 34, Alk phos 53, total protein 5.4 g/dL, albumin 2.6 g/dL

Clinical Course: He presented to the ED with complaints of sores in his mouth, congestion in the lungs, incontinence, confusion, and drowsiness. A normal saline bolus and IV leucovorin were administered while in the ED; the patient was intubated and placed on a ventilator. After brief admission to a medical floor, he was transferred to an ICU. Blood cultures were positive for Enterobacter aerogenes, Morganella morganii, and Streptococcus pneumoniae; respiratory cultures were positive for Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. A CT scan revealed a left-sided pleural effusion with consolidation within the left lower lobe of the lungs and atelectasis and/or consolidation within the right lower lobe. Multiple C×Rs revealed a progressive pneumonia. Medications administered included albuterol, vancomycin, ciprofloxacin, and piperacillin/tazobactam. Despite aggressive care, the patient expired ~24 hr postadmission.

Autopsy Findings: An autopsy was not performed. ME: Elderly white male with no evidence of trauma. Cause of death: sepsis due to pancytopenia, due to methotrexate intoxication. Manner of death: accident.

Case 986. Acute-on-chronic diltiazem, amiodarone, metoprolol and lisinopril ingestion: undoubtedly responsible. Scenario/Substances: A 31 y/o ingested 20 tabs of 120 mg diltiazem, 10 tabs of 200 mg amiodarone, 10 tabs

of 50 mg metoprolol, and 10 tabs of 2.5 mg lisinopril 5–8 hr prior.

Past Medical History: Hypertrophic cardiomyopathy, AICD, previous overdose of diltiazem.

Physical Exam: On arrival to the ED (5–8 hr after ingestion) she was drowsy and globally weak. HR 70, systolic BP 80–90.

Laboratory Data: UDS positive for benzodiazepines, caffeine, lidocaine, and theobromine. Ethanol, acetone, ispropranol, methanol, acetaminophen blood levels not detected.

Clinical Course: The patient was treated initially with IV fluids. She became more hypotensive and was admitted to the ICU. She became dyspneic and was intubated. Shortly thereafter she suffered a cardiac arrest that was treated with glucagon and vasopressors without response. IV fat emulsion therapy was given with return of spontaneous circulation. She was treated with insulin at 100 units/hr and a calcium infusion as well as dopamine, phenylephrine and vasopressin. She improved clinically, was alert and able to follow commands. Shortly thereafter, 13 hr postingestion, she suffered a second cardiac arrest and could not be resuscitated.

Autopsy Findings: Amiodarone: 1916 ng/mL (ref range 500–2500), desmethylamiodarone 801 ng/mL (ref range 500–2500), Metoprolol 162 ng/mL (ref range 30–280), 7-amino clonazepam 3.4 ng/mL, Diltiazem 4500 ng/mL (ref range 130–190). Cause of death was diltiazem toxicity.

Case 1055. Acute-on-chronic propafenone (extended release): undoubtedly responsible.

Scenario/Substances: 65 y/o male found by his spouse to be incoherent \sim 10 hr after intentionally ingesting 18.2 gm of propafenone (56×325 mg extended release tablets).

Physical Exam: BP 70, HR 50; Semi conscious male with muscle fasciculations and brief, intermittent seizures.

Laboratory Data: pH 7.33, Glu normal; acetaminophen or salicylate not detected. ECG QRS 150–200 ms, junctional rhythm. A transthoracic echocardiogram showed low LV function and asynchronous contractions.

Clinical Course: The patient was intubated and given benzodiazepines for seizures, propofol for sedation, sodium bicarbonate for widened QRS and IV fluids, dopamine, and epinephrine for low BP. IV fat emulsion therapy was given at 2 hr (~12 hr post exposure; bolus then infusion). BP 96/61, HR 69; QRS 240 ms. BP support over next 24 hr with dopamine and epinephrine; QRS normalized ~20 hr post exposure. Transthoracic echocardiogram on Day 2 demonstrated normal myocardial function. He developed intermittent first degree heart block, myoclonus, and fever; antibiotics were given. At 40 hr post ingestion, the patient improved, pressors and sedation were being weaned, spontaneous RR 20, QRS duration normalized, and he was successfully extubated. Several hours later QRS widening redeveloped with seizures and hypotension (BP 50-60), refractory to vasopressors and bicarbonate therapy. The patient expired 57 hr post exposure.

Autopsy Findings: Unavailable.

Case 1095. Acute-on-chronic flecainide ingestion: undoubtedly responsible.

Scenario/Substances: 21 month-old male with a history of supraventricular tachycardia (SVT) drank an unknown amount of flecainide and became unconscious and unresponsive within 5 min. When EMS arrived, he was in cardiac arrest

Past Medical History: Permanent junctional reciprocating tachycardia form of SVT controlled with oral flecainide at 0.8 mL (16 mg) orally 3 times a day (~4.4 mg/kg/day).

Laboratory Data: ABG-pH 6,75/pCO₂ 102, Na 129, K 5.6 **Physical Exam:** Unresponsive infant in asystole.

Clinical Course: Cardiopulmonary resuscitation with compressions and epinephrine were started and 20% intralipid infusion was initiated which resulted in return of spontaneous circulation. He received maximum doses of epinephrine and atropine which increased BP to 135/92 transiently. The patient was intubated, IV fluids and sodium bicarbonate were administered. The patient arrived to the second HCF about 5 hr post ingestion via the transport team. Chest compressions continued throughout the transport. Atropine, 20% intralipid infusion, dopamine infusion and IV NS were continued. At the second HCF he was still in asystole, pupils were fixed and dilated at 5 mm; additional epinephrine, atropine, sodium bicarbonate, and calcium were administered without effect. He expired when resuscitation was concluded.

Autopsy Findings: Left ventricular wall measured 8 mm and right ventricular wall 2 mm and the size and contours of the heart were normal. There was patchy congestion particularly in both lower lobes, pulmonary arteries were free of emboli. No brain injury was detectable and the unfixed brain weight was 1150 grams. Body weight was 11.8 kg. Postmortem blood flecainide 54 mcg/mL and liver 104 mcg/gm.

Case 1108. Acute selenium and citric acid ingestion/inhalation: probably responsible.

Scenario/Substances: A 30 y/o male was exposed to l-selenomethione powder at work. He reportedly inhaled and ingested some powder after opening a box containing the compound. He developed nausea and vomiting for 4 hr before going to the ED. He also reportedly took 3 teaspoons of citric acid during the day, but the exact time is unknown.

Past Medical History: opioid dependence.

Physical Exam: HR 80–120, BP 110/50, RR 30–40, normal pupils. Lungs clear bilaterally. Heart: irregular rhythm, abdomen nontender, extremities cyanotic, skin pale, no rash or burns. Neuro: confused and lethargic. Smelled strongly of chemical odor.

Laboratory Data: ECG: atrial fibrillation. ABG-pH 7.01/pCO₂ 17/pO₂ 329, UDS negative for benzodiazepine, amphetamine, barbiturates, and cocaine; Serum salicylate, TCA, acetaminophen, ethanol were not detected.

| Na 146 | Cl 107 | BUN 14 | Glu 29 |
|--------|---------------------|--------|--------|
| K 3.2 | HCO ₃ 12 | Cr 1.5 | Giu 29 |

Lactate 20.0 mmol/L, AST 444, ALT 545. C×R: peribronchial cuffing without infiltrates.

Clinical Course: The patient was intubated on ED arrival and placed on 100% oxygen. He became hypotensive (70/40), the atrial fibrillation deteriorated to bradycardia then asystole. He was given naloxone, and multiple doses of epinephrine and atropine without response. He received IV D50W, bicarbonate IV, butt was unable to be resuscitated and died in the ED.

Autopsy Findings: Coagulative necrosis of esophagus, stomach and duodenum, acute hepatic necrosis, and hypoxic ischemic encephalopathy. Postmortem toxicology: blood selenium 11,000 mcg/mL (normal range, 60–230 mcg/mL), urine selenium 25,000 mcg/L (normal < 200 mcg/mL); whole blood cyanide 0.14 µg/mL, methadone 0.10 µg/mL. Cause of death: Acute selenium toxicity.

1113. Case Metformin ingestion: undoubtedly responsible.

Scenario/Substances: A 24 y/o female inmate presented to the prison infirmary with severe GI distress, vomiting and dehydration. She reported taking metformin prior to presentation.

Past Medical History: Unknown.

Physical Exam: BP 106/38, HR 70–113, T 31.9°C. Mental status quickly deteriorated, the patient was intubated and mechanical ventilated.

Laboratory Data: pH 6.82; lactate 41 mmol/L,

| Na 145 | Cl 116 | BUN 17 | Glu 20 |
|--------|--------------------|--------|--------|
| K 4.0 | HCO ₃ 5 | Cr 1.3 | GIU 20 |

acetaminophen and salicylate were not detected.

Clinical Course: The patient received 24 ampules (44 mEq each) of sodium bicarbonate, aggressive fluid resuscitation, and dextrose therapy prior to transfer to a tertiary hospital for hemodialysis. At the receiving hospital, she received another 18 ampules of sodium bicarbonate and underwent hemodialysis with additional bicarbonate in the dialysate. Hypotension and acidosis continued. The patient expired 22 hr after presenting to the hospital.

Autopsy Findings: Not performed.

Case 1118. Acute metformin ingestion: undoubtedly responsible. Bilirubin 0.83, ALT 33, AST 26L, Alk phos 37. Scenario/Substances: 39 y/o male presented after ingestion of 40–60 1,000 mg tablets of metformin with 4 10 mg tranylcypromine ~3–4 hr prior to arrival.

Past Medical History: Depression, diabetes, multiple previous suicidal attempts, MRSA abscesses with several incision and drainage procedures.

Physical Exam: Heart Rate 122, Respiratory Rate 14, BP 127/84, HR 122, RR 14, T 37°C, SaO₂ 98% on room air. PE showed tachycardia; remainder reported as normal.

Laboratory Data: ABG- pH 7.341/pCO₂ 37.4/pO₂ 70.4; WBC 11.3, Hgb 13.9,

| Na 140 | Cl 105 | BUN 14 | |
|--------|---------------------|--------|--|
| K 4.2 | HCO ₃ 23 | Cr 1.7 | |

Platelets 184, Ca 8.8, Mg 1.7, Phos 4.3, Lactate 4.3 mmol/L, ethanol, acetaminophen and salicylate were not detected.

Clinical Course: The patient was admitted to the stepdown ICU, IV fluids were given with one amp of sodium bicarbonate (50 mEq of sodium). Ten hr later pH was 7.169, anion gap increased to 22, Cr to 3.0, and lactate to 20.1 mmol/L. HCO₃ infusion was started and nephrology consulted for hemodialysis. Dialysis initially ran for only 30 min due to poor flow in the catheter. Oxygenation worsened and the patient was intubated at 24 hr. A new dialysis catheter was placed and hemodialysis ran for 12 hr followed by continuous veno-venous hemodialysis for the duration of the patient's course. A THAM infusion was also initiated. At 36 hr, refractory hypotension emerged followed by acute respiratory distress syndrome, hepatic failure and renal failure. Antibiotics were given for a possible ventilator-associated pneumonia; cisatracurium was given IV to maximize ventilation; Intralipid (20% fat emulsion) was also started by bolus, followed by a 2 hr infusion) without clinical change. At 43 hr the patient went into a PEA arrest and could not be resuscitated. Metformin levels predialysis and 26 hr later were 66 mcg/ mL and 21 mcg/mL respectively. The patient's nadir pH was 6.72 immediately after intubation; lactate was >30mmol/L after intubation and ranged from 18 mmol/L to >30 mmol/L for the duration of the hospitalization.

Autopsy Findings: Not performed.

Case 1134. Acute epinephrine subcutaneously: undoubtedly responsible.

Scenario/Substances: A 57 y/o male experienced an allergic reaction to shellfish and went to the ED.

Past Medical History: Seafood allergy, hyperlipidemia, hypertension. coronary disease status post coronary stenting × 3, GERD. Medications including: valsartan, atorvastatin, metoprolol, and esomeprazole.

Clinical Course: In the ED he received an initial 0.3 mg 1:1000 epinephrine subcutaneously and IV solumedrol. He developed recurrence of his symptoms and was inadvertently given 3 mg subcutaneously instead of the intended 0.3 mg. The patient experienced immediate chest pain, tachycardia, ventricular ectopy and vomiting. The patient was given amiodarone with slowing of the HR. He was intubated with a great deal of difficulty due to airway edema. The patient expired after a resuscitation lasting 1 hr during which he received aspirin, fentanyl, nitroglycerin and morphine.

Autopsy Findings: Cause of death: global myocardial necrosis due to iatrogenic overdose of epinephrine administered for anaphylaxis.

Case 1135. Acute baclofen parenteral: undoubtedly responsible.

Scenario/Substances: This 19 y/o male had an intrathecal catheter for baclofen infusion.

Past Medical History: Transverse myelitis with neurogenic quadriparesis thought due to immunization for H flu type B in infancy. He underwent elective spinal fusion for scoliosis and revision of his intrathecal catheter for baclofen infusion which had been initiated many years ago.

Clinical Course: One day after surgery, he developed increased muscle tone and agitation which were attributed to baclofen or benzodiazepine withdrawal, so he was returned to surgery for revision of the intrathecal access placement. He did well and was transferred out of ICU Day 2 after initial surgery, but 1 day later he developed fever to 41.7°C with agitation, hallucinations, muscle rigidity and clonus. His baclofen infusion rate was adjusted, cooling and acetaminophen were provided. On Day 3 he was given haloperidol for agitation and hallucinations without significant improvement. Treatment with dantrolene was begun on Day 4 and he improved somewhat with T 39.4°C and HR 120s, and was well-sedated on lorazepam with no breakthrough agitation. However on Day 5 he developed respiratory depression and hypotension and rhabodmyolysis with a CK > 300,000, increased AST, GI bleeding and thrombocytopenia. The findings were thought to represent baclofen withdrawal so the baclofen infusion rate was increased and the concentrations in the reservoir and CSF (120 mcg/mL) were confirmed. Daily hemodialysis was begun. He continued to require vasopressor support and external cooling, antibiotic therapy was initiated empirically. Levetiracetam and phenytoin were added for seizure activity which continued despite the addition of propofol, midazolam and fentanyl and he became anuric. Midazolam and propofol were discontinued after seizure activity resolved. He maintained papillary and gag reflexes but was responsive only to painful stimuli. Goals of care were changed to comfort only, and he died on Day 27. **Autopsy Findings:** Not performed.

Case 1136. Acute-on-chronic carisoprodol and acetamin-ophen: undoubtedly responsible.

Scenario/Substances: 27 y/o female found lethargic on the floor with a bottle of carisoprodol, was moved to a couch then found unresponsive several hr later when EMS was called. EMS reported BP 70/40 and Glu 20. An IV was inserted and glucagon and 1 amp of 50% dextrose were administered. The prescription for carisoprodol had just been filled for 96 tablets, and only 6 remained.

Past Medical History: Major depressive disorder; previous suicide attempt.

Physical Exam: Unresponsive female. BP 113/61, HR 120, RR 20, T 37°C, O_2 sat on 2 L of oxygen 100%.

Laboratory Data:

| Na 143 | Cl 110 | BUN 14 | Glu 196 |
|--------|--------------------|--------|---------|
| K 4.8 | HCO ₂ 6 | Cr 0.9 | Giu 190 |

WBC 24, PT 35.1, INR 2.91, PTT 45.7. AST 1426, ALT 1240, total bilirubin 1.9, direct bilirubin 1.3; acetaminophen 43 mcg/mL, salicylate and ethanol not detected. UDS was positive for opiates.

Clinical Course: The patient was intubated and placed on a ventilator in the ED, sedated with propofol and antibiotics were administered. The 21 hr N-acetyl-cysteine protocol was started. At 5 hr the PT was 88.8 sec, INR 7.23, ABG-pH

6.965/pCO₂ 19.8/pO₂ 173.5. Sodium bicarbonate was given and she was admitted to the ICU. At 16 hr AST 10,654, ALT 6228 which increased to >10,000 for both on Day 2 with WBC 25.5, PT 140.2 and INR >9. NAC was restarted and FFP given. Day 3 the patient was completely unresponsive, urinary output decreased to 10–15 cc/hr, NH₃167, Cr 2.5, AST 9219, ALT 7581, total bilirubin 3.3, direct bilirubin 1.5, PT 63.8, INR 5.23, PTT 37.7, WBC 26.7, Hgb 9.6 g/dL, Hct 27.3, platelets 103. Brain herniation occurred, and the patient was extubated and expired on Day 4.

Autopsy Findings: Severe pulmonary congestion and edema, and cerebral edema were noted. Carisoprodol was measured at 4.4 mcg/mL and meprobamate at 36 mcg/mL in premortem hospital serum from the ED. The cause of death was determined to be complications of drug toxicity and the manner of death was undetermined.

Case 1156. Acute-on-chronic tizanidine and ethanol ingestion: undoubtedly responsible.

Scenario/Substances: A 63 y/o female ingested 160 of her tizanidine 160 tablets with vodka. A hand written suicide note to her children was found with the patient. The patient was found unresponsive by the family and EMS was called. EMS found the patient hypotensive and obtunded.

Laboratory Data: Chemistry panel was unremarkable except for a Glu of 161 and lipase of 300 U/L. Ethanol 219 mg/dL, acetaminophen 2.2 mcg/mL, salicylate 3.9 mg/dL, UDS negative for barbiturate, amphetamines, benzodiazepines, methadone, opiates, PCP and TCA.

Clinical Course: The patient arrived unresponsive and rapidly deteriorated to respiratory arrest and then full cardiopulmonary arrest. Resuscitation efforts by ED staff including intubation and full ACLS protocol were not successful.

Autopsy Findings: Post mortem blood: tizanidine 440 ng/mL (therapeutic ~2 ng/mL), ethanol 0.184 g%, hydrocodone 10.7 ng/mL, rocuronium 5499 ng/mL, venlafaxine 379 ng/mL, norvenlafaxine 581 ng/mL (~2 × therapeutic).

Case 1159. Acute haloperidol ingestion: undoubtedly responsible.

Scenario/Substances: 2 y/o female was found in the bedroom with a pill container and tablets in her hand. A shelf had fallen down causing a container of haloperidol and zolpidem to fall. The mother tried to make her vomit by sticking fingers in her mouth, which was not successful so the child was given a glass of milk and put to bed. The family believed they could account for all tablets, and did not consult the poison center or a physician. Later in the afternoon the child was found unresponsive and presumed dead.

Laboratory Data: In the ED: Postmortem labs upon arrival

| Na 141 | Cl 115 | BUN 16 | Glu 24 |
|--------|--------------------|--------|--------|
| K 14.8 | HCO ₃ 9 | Cr 0.2 | Glu 24 |

Clinical Course: The child was pronounced dead on arrival.

Autopsy Findings: Pulmonary edema. Post-mortem haloperidol (subclavian blood) 90 ng/mL (normal 5–15).

Haloperidol was the only substance detected. ME cause of death: acute haloperidol toxicity.

Case 1259. Acute latrodectus envenomation: undoubtedly responsible.

Scenario/Substances: 37 y/o male presented to the ED after sustaining a suspected black widow spider bite on his right

Past Medical History: Asthma. Medications; included cyclobenzaprine, albuterol meter dose inhaler, and fluticasone propionate diskus.

Physical Exam: Male in moderate distress. BP 159/74, HR 103, RR 22, O2 sat, 96% on room air; T 37°C. He had a small area of raised erythema on right anterior mid-shin, no diaphoresis, soft, non-tender abdomen without peritoneal signs.

Laboratory Data: WBC 6.5, Hgb 15.1, platelets 195,

| Na 136 | Cl 105 | BUN 12 | Cl., 125 |
|--------|---------------------|--------|----------|
| K 3.8 | HCO ₃ 26 | Cr 0.9 | Glu 135 |

ALT 19, AST 21.

Clinical Course: At 1 hr after the envenomation he developed tightening in his shoulders and neck with nausea, diaphoresis, back pain and chest pain, treated with 30 mg ketorolac, 2 mg lorazepam and 2 mg hydromorphone unsuccessfully. He received a test dose of normal horse serum in saline per the package insert with no reaction prior to an infusion of 2.5 mL antivenin in 50 mL of 0.9% normal saline. At 15 min into the antivenin infusion, after reporting facial tingling and dyspnea, he had HR 135, RR 36 and developed anaphylactic shock with respiratory then cardiac arrest. He was resuscitated, given IV steroids, epinephrine, diphenhydramine and naloxone but suffered another cardiac arrest 30 min later and again was prior to transfer to a tertiary care center on multiple pressors and a ventilator. He remained pressor-dependent, displayed myoclonic jerking of shoulders, neck and arms, had oliguria with fixed and dilated pupils. He received a bolus dose of 1 mg/kg of methylene blue was given IV. Within 30 min pressors were discontinued and he improved significantly over the next 12 hr becoming able to follow commands and attempting to get out of bed. The patient developed acute tubular necrosis and a HCO₂ infusion was started. On Day 2 T rose to 39°C, BP dropped to 54/35, O₂ sat abruptly decreased to 80%. He was given pressor therapy but had another cardiac arrest and expired 36 hr after presentation.

Autopsy Findings: An autopsy was not performed. The ME viewed the body and listed the cause of death to be anaphylactic shock.

Case 1275. Acute methylenedioxymethamphetamine (MDMA) ingestion: undoubtedly responsible.

Scenario/Substances: A 23 y/o male was running at a rave (electronic dance party), when he fell down 5 steps and began to have generalized tonic-clonic seizure activity. EMS administered midazolam 4 mg IV without cessation of seizures and transported him to the ED. After a 15 min transport time, he arrived at the ED unresponsive and actively seizing. The poison center was consulted on 11 other similar cases from the same event.

Physical Exam: Seizing male patient, BP normal, HR 168–179, core T 42.2°C; A 3 cm scalp laceration was represent, pupils 5 mm and nonreactive, eyes deviated upward. Tonic-clonic seizure activity continued in bilateral lower extremities.

Laboratory Data: K 6.1, BUN 19, Cr 1.7, Lactate 8.9, AST 918, ALT 202, CK 1592, (reaching 54,000), venous blood: pH 7.21 and pCO₂ 58. UDS positive for MDMA.

Clinical Course: The patient was intubated, had ice packs applied to his groin and axilla and received normal saline fluid boluses, phosphenytoin, acetaminophen, Ca gluconate, insulin and dextrose. In the ICU he received more cool IV fluids and was placed on a surface cooling blanket. Three hours after arrival his core T 38.7°C and he developed disseminated intravascular coagulopathy and bleeding with an elevated troponin of 9.7 ng/mL. He received dantrolene at 6 hr, paralytic therapy with vecuronium at 8 hr, and levetiracetam was started. A massive transfusion protocol was started with administration of packed RBC, platelets, fresh frozen plasma, DDAVP, Factor 7, cryoprecipitate and prothrombin complex concentrate. Hypotension was treated with 3 pressors; CVVH was started for hyperkalemia and anuric renal failure. Comfort measures were instituted at 18 hr and he expired at 20 hr.

Autopsy Findings: Multiple ecchymoses were present on the skin. Both lungs were essentially airless and diffusely wet, heavy with diffuse red-black coloration and red fluid filling the bronchi. Laboratory analysis from the time of admission showed: MDMA 0.83 mg/L, MDA 0.04 mg/L, L-methamphetamine 0.04 mg/L. Post mortem heart blood analysis showed MDMA 1.42 mg/L, MDA 0.43 mg/L. The cause of death was reported as multiple system failure due to sequelae of methylenedioxymethamphetamine (MDMA) intoxication.

Case 1280. Methylenedioxymethamphetamine (MDMA) ingestion: undoubtedly responsible.

Scenario/Substances: 23 y/o female was found unresponsive by her husband, who brought her to the ED and reported she ingested MDMA the previous night and that she may have had a seizure prior to presentation to the ED.

Past Medical History: Not provided.

Physical Exam: Intubated female. BP 123/84, HR 111. Pupils were mydriatic and nonreactive; muscle tone supple. **Laboratory Data:**

AST 21, ALT 16, CK 425; acetaminophen, ethanol, and salicylate, ethanol were not detected. ECG: QRS 90 ms, QTc 453 ms. CT scan showed cerebral edema.

Clinical Course: The patient's clinical condition deteriorated upon arrival to the ED. She required norepinephrine and phenylephrine for hemodynamic support. She expired Day 2.

Autopsy Findings: Autopsy was not performed. Cause of death was methlenedioxy methamphetamine (MDMA) toxicity. Hospital urine was positive for methylenedioxymethamphetamine, methylene dioxyamphetamine, benzyl piperazine, caffeine, and lidocaine and metabolites. Hospital blood showed methylenedioxymethamphetamine 0.22 mg/L, methylene dioxyamphetamine was trace, less than 0.05 mg/L, and positive for benzylpiperazine.

Case 1283. Acute methylenedioxymethamphetamine (MDMA) ingestion: probably responsible.

Scenario/Substances: A 25 y/o male took 2 pills of "ecstasy" at a party. He began feeling unwell and called friends who picked him up. En route to the hospital he became unresponsive. They were seen by a police officer who recognized the patient was in distress and the patient was brought directly into the ED.

Physical Exam: In the ED the patient was somewhat cyanotic, unresponsive, warm, and rigid, T 39°C, pupils fixed and dilated, mouth clamped, did not withdraw to pain. He was apneic, had a weak and thready pulse with a HR in the 20s, then developed PEA.

Laboratory Data: ABG-pH $7.09/pCO_2$ 38/p O_2 352 on 70% FiO₂, WBC 15.7, Hct 51, platelets 207, Mg 4.8, free Ca 0.6,

CK 4214, troponin 0.8, CKMB 4.7, AST 160, ALT 113, Alk phos 51, bilirubin 0.3, UDS positive for amphetamines, negative for tricyclics. Acetaminophen, ethanol and salicylate not detected. EKG (post resuscitation): tachycardia, ST elevations in inferior leads, nonspecific QRS widening, normal QTc. The initial CT scan was unremarkable.

Clinical Course: CPR was initiated, he was intubated, and IV access obtained. He received atropine, calcium and bicarbonate. He regained a palpable pulse with a HR in the 130s, BP in the 60s, QRS 90 ms. He was started on a bicarbonate infusion along with aggressive fluid resuscitation. An NG tube was inserted and activated charcoal was administered. A norepinephrine infusion was necessary to support his BP. Additional IV bicarbonate was administered for QRS 146 ms. A dopamine infusion was started for bradycardia and hypotension. Cooling measures were initiated for hyperthermia. Sequential CTs showed progressive bilateral cerebral edema treated with mannitol and dexamethasone. Pressor support was gradually reduced. He developed rhabdomyolysis and central diabetes insipidus. His family opted for comfort measures on Day 8 and he died shortly afterward. Cause of death: cerebral edema secondary to drug overdose, possibly methylenedioxymethamphetamine (MDMA).

Autopsy Findings: Not performed.

Case 1287. Acute heroin, alprazolam, and THC homolog ingestion: undoubtedly responsible.

Scenario/Substances: 26 y/o male y/o was found unresponsive by his girlfriend in her home the day after being released from incarceration the day before and given 2 doses of amitriptyline before leaving the jail facility. He reportedly had altered mental status for ~12 hr prior to "passing out" early the next morning after possibly taking K2 and alprazolam bars. Rescue breathing was performed prior to EMS arrival. Intubation was performed in the field and naloxone 0.4 mg was administered.

Past Medical History: Bipolar disorder/schizophrenia. **Physical Exam:** BP 120/69, HR 105, RR 14. GCS 11, intu-

bated on mechanical ventilation.

Laboratory Data: Ca 8.7, ALT 37, AST 56, INR 1.1,

| Na 141 | Cl 105 | BUN 8 | Glu 216 |
|--------|---------------------|--------|---------|
| K 3.5 | HCO ₃ 25 | Cr 1.1 | Giu 210 |

ethanol, acetaminophen and salicylate were undetectable. UDS positive for benzodiazepines, opiates, and cannabinoids. ECG: QRS 94, QTc 462.

Clinical Course: In the ED, 2 episodes of hypotension were treated with fluid boluses. The patient was extubated on Day 2 and left the hospital against medical advice. One day later, he was found at home breathing heavily with foam around the mouth by his girlfriend. EMS performed CPR and ALS, cardiac rhythm converted to VT and he was transported to the ED. Upon arrival resuscitation efforts continued but were unsuccessful. Quantitation of the UDS from the previous day showed morphine 16,560 ng/mL and codeine 193 ng/mL.

Autopsy Findings: Anatomical findings included pulmonary edema, dilated myocardium and acute vesicular and visceral congestion. Blood toxicology showed alprazolam 31.3 ng/mL, morphine 35.5 ng/mL, 6-monoacetylmorphine 3.9 ng/mL, nortriptyline 27.5 ng/mL, and amiodarone (not quantitated).

Urine toxicology showed alprazolam 315 ng/mL, a-OH-alprazolam 757 ng/mL, morphine >10,000 ng/mL, 6-monoacetylmorphine 854 ng/mL, and codeine 641 ng/mL. Cause of death was listed as acute heroin intoxication.

Case 1303. Acute methylenedioxymethamphetamine (MDMA) ingestion: undoubtedly responsible.

Scenario/Substances: 31 y/o female witnessed to have ingested a white powdery substance at a concert became unresponsive and was transported to the hospital by EMS.

Physical Exam: Unresponsive female. BP 70, HR 160, T 43°C, O_2 sat 100% Fi O_2 100%.

Clinical Course: Patient was intubated in ED, IV access obtained and cooling measures were initiated. She remained hypotensive and developed cardiac arrest and was unable to be resuscitated.

Autopsy Findings: Peripheral blood toxicology; 3, 4-methylenedioxyamphetamines 1.8 mg/L. Pulmonary congestion and edema, minor blunt trauma of lower legs and cholelithiasis.

Case 1325. Acute-on-chronic cocaine parenteral: undoubtedly responsible.

Scenario/Substances: A 44 y/o female was abusing cocaine, became agitated, and developed violent erratic behavior. She hit her head and then ran out of the home and collapsed. EMS found her unresponsive, with shallow, tachypneic breathing. Electrical cardioversion failed \times 2 and she was subsequently given adenosine with return of a HR of 190, T 39.5°C and rising.

Laboratory Data: In the ED: ABG-pH 7.22/pCO₂ 38/pO₂ 271, WBC 16.8, Hgb 9.3, platelets 67,

| Na 139 | Cl 112 | | Glu 205 |
|--------|--------------------|--------|---------|
| K 6.5 | HCO ₃ 6 | Cr 3.5 | Giu 203 |

AST 393; ALT 88, CK 6158, troponin 32, myoglobin > 1000 ng/mL; lactate 18.2 mmol/L. Serum acetaminophen, salicylates, and ethanol were not detected.

Clinical Course: In the ICU, the patient became hypotensive and was treated with phenylephrine, vasopressin, norepinephrine, dopamine, IV fluids, and sodium bicarbonate. She then developed DIC with bleeding from multiple sites and was treated with FFP. INR > 10, fibrinogen < 60 mg/ dL, and d-dimer > 10,000 ng/mL. Subsequent Cr was 3.5, BUN 20. Hgb declined to 1.8 with a pH as low as 6.99, and lactate as high as 18.2 mmol/L. Her pupils were fixed and dilated and she expired on Day 1.

Autopsy Findings: ME cause of death: cocaine toxicity, with DIC, rhabdomyolysis and excited delirium. Postmortem blood benzoylecgonine 830 ng/mL, liver benzoylecgonine 1000 ng/ mL. There was evidence of trauma and hemorrhage in periorbital, frontal scalp, larynx, breast, thigh, abdomen, and around a recent needle puncture in the right antecubital fossa.

Case 1344. Acute unknown drug ingestion: probably responsible.

Scenario/Substances: A previously healthy 3 y/o female went to a pharmacy with her mother the day prior to hospital presentation. There were multiple tablets on the floor, which the child reportedly "picked up and placed in her mouth." She vomited once in the pharmacy and once at home in the evening. She was last seen the night before hospital presentation. The next morning she was noted to be sleepy but was left at home. A few hours later, the parents could not wake her and called EMS who found her to be near apneic. She presented to the ED actively ventilated via bag-valve mask.

Past Medical History: Unremarkable.

Physical Exam: BP 119/57, HR 119; O₂ sat normal, pupils miotic, a sticky substance on the child's eyelids, a "bump" on the forehead, and the child was only responsive to pain. Laboratory Data: Acetaminophen and salicylate not detected.

| Na 142 | Cl 113 | BUN 59 | Cl., 02 |
|--------|------------------|--------|---------|
| K 5.6 | HCO ₃ | Cr 2.7 | Glu 93 |

ABG (post-intubation)-pH 7.05/pCO₂ 63/p O₂ 73/HCO₃ 17. Ca 8, anion gap of 18, INR 2.6, PT 28, serum iron 49 mg/dL.

ECG: sinus tachycardia with normal intervals, head CT: bilateral cerebellar infarcts with herniation.

Clinical Course: Upon arrival to the ED, the child was intubated, sodium bicarbonate infusion was started for metabolic acidemia and ventilator was adjusted to correct respiratory acidemia. Neurosurgery admitted her to the PICU.

Administration for Children's Services was involved due to heightened suspicion of child abuse. The child was declared brain-dead late in Day 1 and died on Day 2.

Autopsy Findings: The ME determined the cause of death to be cerebellar infarction and manner of death to be natural. They reported antemortem blood norbuprenorphine 1.2 ng/mL.

Abbreviations & Normal ranges for Abstracts

Disclaimer – all laboratories are different and provide their own normal ranges. Units and normal ranges are provided here for general guidance only. These values were taken from Harrison's¹², Goldfrank¹³ or Dart¹⁴.

Serum electrolyte summary table

| Sodium | Chloride | BUN | |
|-------------------|---------------------|----------------------------|----------------|
| [136–146] | [102–109] | [7-20] mg/dL | Glucose |
| Potassium [3.5–5] | Bicarbonate [22–26] | Creatinine [0.5–1.2] mg/dL | [75–110] mg/dL |

serum electrolytes have units of mEq/L = mmol/L \sim = approximately

ABG-pH/pCO₂/pO₂/HCO₃/BE

| = arterial blood gases | |
|--|--|
| = partial pressure of carbon dioxide [38–42] | |
| = hydrogen ion concentration [7.38–7.42] | |
| = partial pressure of oxygen [90–100] | |
| = advanced cardiac life support, pro- | |
| tocol for the provision of cardiac | |
| resuscitation | |
| 10000010011 | |
| = alkaline phosphatase [13–100] U/L | |
| = ampoule | |
| = Alanine aminotransferase [7–41] U/L = | |
| (SGPT) | |
| = against medical advice | |
| = [25-80] mcg/dL = [15-47] mcmol/L | |
| = acute respiratory distress syndrome | |
| = Aspartate aminotransferase [12–38] U/L | |
| = (SGOT) | |
| = atrio-ventricular block | |
| = British anti-Lewisite | |
| = base excess, mmol/L | |
| = [22-26] mEq/L | |
| = total [0.3–1.3] mg/dL, direct [0.1, 0.4] | |
| mg/dL, indirect [0.2, 0.9] mg/dL | |
| = below the limit of quantitation | |
| = body mass index | |
| = Blood Pressure, systolic/diastolic, (Torr) | |
| = see Urea nitrogen | |
| | |

= degrees Centigrade

| Ca | = calcium, $[8.7-10.2]$ mg/dL | Hgb | = Hgb [12.0–15.8] g/dL females, [13.3– |
|-------------------|--|-------------------|--|
| CABG | = coronary artery bypass graft | | 16.2] g/dL males |
| CAD | = coronary artery disease | HIV | = human immunodefficiency virus |
| CIWA | = Clinical Institute Withdrawal Assess- | HR | = HR, beats per min |
| | ment for Alcohol | hr | = hour(s) |
| CK | = creatinine kinase (CPK), total: [39–238] | ICU | = intensive care unit |
| CK | U/L females, [51–294] U/L males | IgE | = immunoglobulin E |
| CKMB | = MB fraction of CK [0.0–5.5 mcg/L | IM | = intramuscular |
| CKMD | | | |
| | = 0.0-5.5 ng/mL | INR | = international normalized ratio (PT to |
| E | CW | | control) [0.8–1–2] |
| Fraction of total | CK activity $[0-0.04 = 0-4.0\%]$ | IU/L | = international units per Liter |
| Cl | - ablasida [102, 100] mFa/I | IV | = intravenous |
| Cl | = chloride [102–109] mEq/L | K | = potassium, [3.5–5] mEq/L |
| CNS | = central nervous system | kg | = kilogram |
| COHb | = carboxyhemoglobin | L | = Liter |
| COPD | = chronic obstructive pulmonary disease | Lactate | = lactic acid [4.5–14.4] mg/dL arterial, |
| CPR | = cardio pulmonary resuscitation | | [4.5–19.8] mg/dL venous |
| Cr | = creatinine [0.5–0.9] mg/dL females, | LBBB | = left bundle branch block on ECG |
| | [0.6–1.2] males, | Leukocyte | - left buildle brailen block on Leg |
| CRRT | = continuous renal replacement therapy | • | - white blood count [2.54, 0.06] 103/mm3 |
| CSF | = cerebrospinal fluid | count | = white blood count $[3.54-9.06] 10^3 / \text{mm}^3$ |
| CT | = computed tomography (CAT scan) | m/o | = months old |
| CVA | = cerebrovascular accident | mcg/dL | = micrograms per deciliter |
| | | mcg/L | = micrograms per Liter |
| CVVHD | = continuous venovenous hemodiafiltration | mcg/min | = micrograms per minute |
| $C \times R$ | = chest radiograph, chest xray | mcg/mL | = micrograms per milliliter |
| D10W | = 10% dextrose in water | mcmol/L | = micromoles per liter |
| D5W | = 5% dextrose in water | MDA | = 3,4-methylenedioxyamphetamine |
| Day | = when capitalized, Day = hospital day, | MDMA | = methylenedioxymethamphetamine |
| | i.e., days since admission | 1,121,111 | (ecstasy) |
| DIC | = disseminated Intravascualar coagulation | ME | = medical examiner |
| Dx | = diagnosis | | |
| ECMO | = extracorporeal membrane oxygenation | mEq | = milliequivalents |
| ECG | = electrocardiogram (EKG), leads = I, II, III, | mEq/L | = milliequivalents per Liter |
| LCG | aVR, aVL, aVF, V1, V2, V3, V4, V5, V6 | Mg | = magnesium [1.5–2.3] mg/dL |
| ED | | mg | = milligrams |
| ED | = emergency department, in these abstracts | mg/dL | = milligrams per deciliter |
| EDDD | refers to the initial health care facility | mg/kg | = milligrams per kilogram |
| EDDP | = principal methadone metabolite, 2- | mg/L | = milligrams per Liter |
| | ethylidene-1,5-dimethyl-3,3-diphenyl- | min | = minutes |
| | pyrrolidine | mmol/L | = millmoles per Liter |
| EEG | = electroencephalogram | mosm/kg | = milliosmoles per kilogram |
| ELISA | = enzyme-linked immunosorbent assay | mosm/kg mosm/L | = milliosmoles per Liter |
| EMS | = emergency medical services, paramed- | MRI | = Magnetic Resonance Imaging |
| | ics, the first responders | | = milliseconds |
| ER | = extended release (sustained release) | ms | - mmseconds |
| FFP | = fresh frozen plasma | | |
| FiO ₂ | = fraction of inspired oxygen | | |
| | = grams per deciliter | Narrative Head | arc. |
| g/dL | | | |
| GCS | = Glasgow Coma Score, ranges from 3 to 15 | | ances: concise narrative of EMS & pre-HCF |
| GERD | = gastroesophageal reflux disease | events | TT' 4 P. 1. |
| GI | = gastrointestinal | | History: available relevant past medical |
| Glu | = glucose, fasting [75–110] mg/dL | history | |
| HCF | = health care facility | | initial physical exam if available |
| HCG | = human chorionic gonadotropin test for | Clinical Course | e: concise narrative of HCF & beyond with |
| | pregnancy | outcome | |
| HCO ₃ | = bicarbonate | Laboratory Dat | a: initial results, give units except for units |
| HCP | = health care provider | given in abbre | - |
| Hct | = hematocrit [35.4–44.4] females, [38.8– | • | ngs: = medical examiner and/or autopsy |
| | 46.4]% males | results | 5 |
| | 10.TJ/0 maios | 100100 | |

| NG ng/mL not detected | = nasogastric = nanograms per milliliter = analyte below the level of quantitation, negative = normal saline | QTc | = QT interval corrected for HR, usually QTcB = QT/RR ^{1/2} (Bazett correction) 1–15 y-o [<440] msec, adult male [<430] msec, adult female [<450] msec |
|-----------------------------|---|---------------|--|
| O ₂ sat | = oxygen percent saturation [94–100]% at | RBBB | = right bundle branch block on ECG |
| | sea level | RBC | = red blood cell(s) |
| OR | = operating room | RR | = RR, breaths per minute |
| Osm | = osmole | s/p | = status post |
| PALS | = pediatric advanced life support | sec | = seconds |
| PC | = poison center (= PCC, or Poison Con- | SVT | = supraventricular tachycardia |
| | trol Center) | T (oral) | = Temperature (oral) $[36.4, 37.2]$ °C or |
| PCP | = primary care provider | T (rectal) | = Temperature (rectal) [36.4, 37.2]°C or |
| PEA | = pulseless electrical activity | T (tympanic) | = Temperature (tympanic) [36.4, 37.2]°C |
| PEEP | = positive end expiratory pressure | THC | = tetrahydrocannabinol |
| Platelets | = platelet count $[150-400] \times 10^9/L$ | Tprot | = total protein |
| PO | = per os ("by mouth" in Latin) | Troponin I | = normal range [0–0.08] ng/mL, Cut-off |
| Potassium | = [3.5-5] mEq/L | | for MI > 0.04 ng/mL |
| Ppm | = parts per million | U/dL | = units per deciliter |
| PR | = P-R interval [120–200] msec on the ECG | U/L | = units per liter |
| PT | = prothrombin time, INR is preferred, | U/mL | = units per milliliter |
| | but PT may be used if INR is not | UA | = urinalysis |
| | available | UDS | = urine drug screen |
| PTA | = Prior to admission | Urea nitrogen | _ |
| PTT | = partial thromboplastin time [26.3–39.4] | (BUN) | = [6-17] mg/dL |
| | sec | VF | = Ventricular fibrillation |
| QRS | = ECG QRS complex duration [60–100] | VT | = Ventricular tachycardia |
| | msec | WBC | = white blood count, see leukocyte count |
| QT | = Q to T interval on the ECG waveform, | WNL | = within normal limits |
| | varies with HR | y/o | = years old |
| | | | |